PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ALIPERTI, G; EDMUNDOWICZ, SA; SOPER, NJ; ASHLEY, SW				ALIPERTI, G; EDMUNDOWICZ, SA; SOPER, NJ; ASHLEY, SW			COMBINED ENDOSCOPIC SPHINCTEROTOMY AND LAPAROSCOPIC CHOLECYSTECTOMY IN PATIENTS WITH CHOLEDOCHOLITHIASIS AND CHOLECYSTOLITHIASIS	ANNALS OF INTERNAL MEDICINE			English	Note							COMMON BILE-DUCT; EXPLORATION	Eighteen symptomatic patients with cholecystolithiasis and choledocholithiasis were prospectively evaluated to assess the efficacy of endoscopic sphincterotomy combined with laparoscopic cholecystectomy as definitive management of simultaneous gallbladder and bile duct stones. The endoscopic management of bile duct stones was successful in all 18 patients. Seventeen patients later had laparoscopic cholecystectomy, and one required conventional cholecystectomy (5.6%; 95% CI, 0.1% to 27.3%). Mean (+/- SE) duration of postoperative hospitalization (1.6 +/- 1.0 days), total hospital stay (5.0 +/- 3.5 days), and length of convalescence (9.3 +/- 6.6 days) were significantly reduced (P < 0.01 for each) compared with similar measures from a group of 12 consecutive patients treated with conventional cholecystectomy and bile duct exploration (8.3 +/- 4.3, 14.1 +/- 12.6, and 41.7 +/- 10.9 days, respectively). Outcomes in our patients compared favorably with those in patients described in published series of cholecystectomy and bile duct exploration. We found that endoscopic sphincterotomy combined with laparoscopic cholecystectomy is effective in the treatment of patients with simultaneous gallbladder and bile duct stones. Length of hospital stay and degree of postoperative disability were significantly reduced among our patients compared with those having standard cholecystectomy and bile duct exploration.			ALIPERTI, G (corresponding author), WASHINGTON UNIV, SCH MED, GASTROENTEROL CLIN SECT, 1 BARNES HOSP PLAZA, ST LOUIS, MO 63110 USA.			Edmundowicz, Steven/0000-0002-6541-3485				COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P94, DOI 10.1016/S0016-5107(91)70637-8; CRANLEY B, 1980, BRIT J SURG, V67, P869, DOI 10.1002/bjs.1800671210; FRAZEE RC, 1989, SURG GYNECOL OBSTET, V168, P513; NORRBY S, 1988, ACTA CHIR SCAND, V154, P113; REDDICK E J, 1989, Surgical Endoscopy, V3, P131, DOI 10.1007/BF00591357; SHERIDAN WG, 1987, BRIT J SURG, V74, P1095, DOI 10.1002/bjs.1800741208; SIVAK MV, 1989, AM J SURG, V158, P228, DOI 10.1016/0002-9610(89)90256-0; SMITH PC, IN PRESS SURGERY; SOPER NJ, 1991, SURGERY, V109, P342; VELLACOTT KD, 1979, BRIT J SURG, V66, P389, DOI 10.1002/bjs.1800660605	10	60	60	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					783	785		10.7326/0003-4819-115-10-783	http://dx.doi.org/10.7326/0003-4819-115-10-783			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1834001				2022-12-28	WOS:A1991GP80000007
J	OGAS, J; ANDREWS, BJ; HERSKOWITZ, I				OGAS, J; ANDREWS, BJ; HERSKOWITZ, I			TRANSCRIPTIONAL ACTIVATION OF CLN1, CLN2, AND A PUTATIVE NEW G1-CYCLIN (HCS26) BY SWI4, A POSITIVE REGULATOR OF G1-SPECIFIC TRANSCRIPTION	CELL			English	Article							YEAST HO GENE; CELL-CYCLE CONTROL; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; EXPRESSION; PROTEIN; INTERCONVERSION; SEQUENCE	SWI4 of budding yeast codes for a component of a transcription factor (cell cycle box factor, or CCBF) necessary for G1-specific expression of HO. We show that SWI4 is essential for haploid cell viability at high temperature and in a/alpha-cells at all temperatures: SWI4-deficient cells arrest as large unbudded cells. Eight high copy number plasmids were identified that allow swi4- strains to grow under nonpermissive conditions. Two carry G1 cyclin genes, CLN1 and CLN2; another carries HCS26, coding for a putative cyclin. a/alpha-swi4- mutants exhibit 3- to 20-fold reductions in the levels of CLN1, CLN2, and HCS26 transcripts. The requirement of SWI4 for transcription appears to be direct: each gene contains sites similar to the CCBF-binding site; CCBF binds to the upstream region of HCS26. We propose that SWI4 participates in a positive feedback loop by which CLN1, CLN2, and possibly HCS26 promote their own transcription in G1.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM GENET, SAN FRANCISCO, CA 94143 USA; UNIV TORONTO, DEPT MED & MOLEC GENET, TORONTO M5S 1A8, ONTARIO, CANADA	University of California System; University of California San Francisco; University of Toronto	OGAS, J (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM CELL BIOL, SAN FRANCISCO, CA 94143 USA.			Ogas, Joe/0000-0002-1332-7729	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018738, R37AI018738] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18738] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; Ausubel FM, 1988, MOL REPROD DEV; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GUARENTE L, 1984, P NATL ACAD SCI-BIOL, V81, P7860, DOI 10.1073/pnas.81.24.7860; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HICKS JB, 1976, GENETICS, V83, P245; HUISMAN O, 1987, GENETICS, V116, P191; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENSEN R, 1983, P NATL ACAD SCI-BIOL, V80, P3035, DOI 10.1073/pnas.80.10.3035; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; Sherman F., 1982, METHODS YEAST GENETI; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; VAI M, 1987, EXP CELL RES, V171, P448, DOI 10.1016/0014-4827(87)90176-5; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	34	282	284	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					1015	1026		10.1016/0092-8674(91)90445-5	http://dx.doi.org/10.1016/0092-8674(91)90445-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1832336				2022-12-28	WOS:A1991GE46000018
J	ANASTOS, K; CHARNEY, P; CHARON, RA; COHEN, E; JONES, CY; MARTE, C; SWIDERSKI, DM; WHEAT, ME; WILLIAMS, S				ANASTOS, K; CHARNEY, P; CHARON, RA; COHEN, E; JONES, CY; MARTE, C; SWIDERSKI, DM; WHEAT, ME; WILLIAMS, S			HYPERTENSION IN WOMEN - WHAT IS REALLY KNOWN - THE WOMENS CAUCUS, WORKING GROUP ON WOMENS HEALTH OF THE SOCIETY-OF-GENERAL-INTERNAL-MEDICINE	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY HEART-DISEASE; HIGH-DENSITY LIPOPROTEIN; METABOLIC RISK-FACTORS; FOLLOW-UP; MILD HYPERTENSION; BLOOD-PRESSURE; DRUG-USE; FRAMINGHAM; TRIAL; SEX	Purpose: To determine whether there is sufficient information in the medical literature to guide appropriate treatment of hypertensive women. Data Identification: Epidemiologic surveys of hypertension, clinical trials of antihypertensive therapy, and studies of selected adverse effects of antihypertensive agents were identified through a computerized search using MEDLINE and by identifying all studies cited in current medical textbooks as supporting evidence for the guidelines for the treatment of hypertensive individuals. All epidemiologic studies selected were cross-sectional or longitudinal, multicenter, population-based surveys. All clinical trials were large, randomized studies comparing one or more antihypertensive agents with a placebo or nonplacebo control group. Epidemiologic studies and clinical trials were reviewed to assess the quantity and quality of information available regarding important aspects of hypertension in women. Data pertaining to epidemiology, natural history, results of treatment, and two significant side effects of antihypertensive treatment were examined. Results of Data Analysis: The prevalence of hypertension is greater in black women than in black men and is about equal in white women and men. Because women outnumber men in the population, there are more hypertensive women than men. The attributable risk percent (the proportion of end points that could be eliminated by removing hypertension) for cardiovascular complications of hypertension is higher for women than men. Clinical trials show clear benefit of therapy for black women but no clear benefit for white women; some studies suggest that treatment of white women is harmful. Lipid profiles and their relation to ischemic heart disease differ for women and men; there is currently no information on the effects of antihypertensive agents on serum lipids in women. Few data have been published on the frequency of sexual dysfunction in treated hypertensive women. Conclusions: Hypertension in women and its related cardiovascular outcomes are a major public health problem. Clinical trials of antihypertensive therapy do not fully support current guidelines for the treatment of hypertensive women. Research concerning adverse effects of antihypertensive agents has largely excluded women from consideration; further studies are required to guide appropriate treatment.	MONTEFIORE MED CTR, DEPT MED, 111 E 210TH ST, BRONX, NY 10467 USA; BRONX LEBANON HOSP CTR, BRONX, NY 10456 USA; BRONX MUNICIPAL HOSP CTR, BRONX, NY 10461 USA; COLUMBIA PRESBYTERIAN MED CTR, NEW YORK, NY 10032 USA; N CENT BRONX HOSP, BRONX, NY USA; NYU MED CTR, NEW YORK, NY 10016 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; BronxCare Health System; Columbia University; NewYork-Presbyterian Hospital; New York University								AMERY A, 1985, LANCET, V1, P1349; AMERY A, 1986, LANCET, V2, P589; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; [Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; [Anonymous], 1980, LANCET, V1, P1261; APPLEGATE WB, 1989, ANN INTERN MED, V110, P901, DOI 10.7326/0003-4819-110-11-901; BAUM C, 1988, MED CARE, V26, P105, DOI 10.1097/00005650-198802000-00002; BAUM C, 1985, JAMA-J AM MED ASSOC, V253, P382, DOI 10.1001/jama.253.3.382; BENGTSSON C, 1986, MYOCARDIAL INFARCTIO, P93; BOEHRINGER K, 1982, ANN INTERN MED, V97, P206, DOI 10.7326/0003-4819-97-2-206; BRECKENRIDGE A, 1985, BRIT MED J, V291, P89, DOI 10.1136/bmj.291.6488.89; BRUNNER D, 1987, AM J CARDIOL, V59, P1271, DOI 10.1016/0002-9149(87)90903-9; BRUSH TL, 1986, CORONARY HEART DISEA, P106; BUSH T, 1984, AM J EPIDEMIOL, V120, P489; BUSH TL, 1988, CLIN CHEM, V34, pB60; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; GODSLAND IF, 1987, AM HEART J, V114, P1467, DOI 10.1016/0002-8703(87)90552-7; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HALLBERG L, 1967, ACTA MED SCAND, V181, P185; HELGELAND A, 1980, AM J MED, V69, P725, DOI 10.1016/0002-9343(80)90438-6; KANNEL WB, 1987, AM HEART J, V114, P413, DOI 10.1016/0002-8703(87)90511-4; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LARDINOIS CK, 1988, ARCH INTERN MED, V148, P1280, DOI 10.1001/archinte.148.6.1280; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; READER R, 1984, CIRCULATION, V69, P668; RIFKIND BM, 1979, LIPIDS, V14, P105, DOI 10.1007/BF02533578; ROCCELLA EJ, 1991, ANN INTERN MED, V114, P224, DOI 10.7326/0003-4819-114-3-224; SCHNALL PL, 1984, NEW YORK STATE J MED, V84, P299; SCHOENBERGER JA, 1990, ARCH INTERN MED, V150, P301; STAMLER J, 1976, JAMA-J AM MED ASSOC, V235, P2299, DOI 10.1001/jama.235.21.2299; TRUSWELL AS, 1985, BRIT MED J, V291, P197, DOI 10.1136/bmj.291.6489.197; Wassertheilsmoller S, 1991, ANN INTERN MED, V114, P613, DOI 10.7326/0003-4819-114-8-613; WITTENBERG CK, 1985, JAMA-J AM MED ASSOC, V253, P1700; ZHOU HH, 1989, NEW ENGL J MED, V320, P565, DOI 10.1056/NEJM198903023200905; 1987, MED LETT DRUGS THER, V29, P65; 1979, JAMA-J AM MED ASSOC, V242, P2572; 1981, MED J AUSTRALIA, V2, P398; 1970, JAMA-J AM MED ASSOC, V213, P1145; 1982, ADV DATA VITAL HLTH, V84; 1977, JAMA-J AM MED ASSOC, V237, P2385	41	164	165	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					287	293		10.7326/0003-4819-115-4-287	http://dx.doi.org/10.7326/0003-4819-115-4-287			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854113				2022-12-28	WOS:A1991GA76400009
J	HAYWARD, RA; KRAVITZ, RL; SHAPIRO, MF				HAYWARD, RA; KRAVITZ, RL; SHAPIRO, MF			THE UNITED-STATES AND CANADIAN HEALTH-CARE SYSTEMS - VIEWS OF RESIDENT PHYSICIANS	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICAL-CARE; INSURANCE; SATISFACTION; EXPENDITURES; SERVICES; ONTARIO; ACCESS; POOR; COST; PLAN	Objective: To evaluate U.S. and Canadian resident physicians' views about their health care systems. Design: Self-administered questionnaire survey in 1989. Participants: Senior family medicine and internal medicine residents in Canada and in ten geographically representative American states. Main Results: American and Canadian residents had similar levels of professional satisfaction and almost universally agreed on the ethical obligation to provide care to persons of all social circumstances, but U.S. residents were more likely to perceive a serious access problem in their country (75% compared with 18%) and to think that current controls on the medical profession interfere with patient care (81% compared with 58%; P < 0.001). In addition, U.S. residents were more likely than Canadian residents to believe that primary care salaries were too low (78% compared with 38%) and that salaries of medical subspecialists (57% compared with 17%) and surgeons (85% compared with 28%) were too high. In general, residents preferred their own country's predominant health care system. Whereas 87% of U.S. physicians supported private fee-for-service health care, 85% of Canadian physicians supported government-funded national health insurance. Nonetheless, 42% of U.S. physicians supported and only 17% strongly opposed national health insurance as an alternative approach. About two thirds of respondents from both countries opposed a salaried national health service. Conclusions: American residents perceived greater problems with access, overall intrusions into medical practice, and fee disparities than did their Canadian counterparts. They preferred private fee-for-service health care, but few strongly opposed government-funded national health insurance as an alternative approach to the health care needs of the United States.	UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	HAYWARD, RA (corresponding author), UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, DIV GEN MED, 3116 TAUBMAN CTR, ANN ARBOR, MI 48109 USA.		Kravitz, Richard/AAF-7425-2021	Kravitz, Richard/0000-0001-5575-529X				American College of Physicians, 1990, ANN INTERN MED, V112, P641; BALDWIN MF, 1986, MODERN HEALTHCARE, V16, P30; BEAUCHAMP DE, 1990, NEW ENGL J MED, V323, P640, DOI 10.1056/NEJM199009063231005; BELKIN K, 1990, NY TIMES        0219, pA1; Blendon R J, 1989, Health Manage Q, V11, P2; BLENDON RJ, 1990, HEALTH AFFAIR, V9, P185, DOI 10.1377/hlthaff.9.2.185; BLENDON RJ, 1990, NEW ENGL J MED, V323, P208, DOI 10.1056/NEJM199007193230329; BLENDON RJ, 1989, HLTH AFFAIRS     SPR, P149; BOVBJERG RR, 1986, INQUIRY-J HEALTH CAR, V23, P403; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; GONZALEZ ML, 1988, SOCIOECONOMIC CHARAC; HAYWARD RA, 1988, NEW ENGL J MED, V318, P1507, DOI 10.1056/NEJM198806093182305; HIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441, DOI 10.1056/NEJM198602133140710; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; IGLEHART JK, 1989, NEW ENGL J MED, V321, P1767, DOI 10.1056/NEJM198912213212527; IGLEHART JK, 1985, NEW ENGL J MED, V313, P59, DOI 10.1056/NEJM198507043130134; IGLEHART JK, 1986, NEW ENGL J MED, V315, P778, DOI 10.1056/NEJM198609183151238; IGLEHART JK, 1986, NEW ENGL J MED, V315, P202, DOI 10.1056/NEJM198607173150330; KRAVITZ RL, 1990, MED CARE, V28, P502, DOI 10.1097/00005650-199006000-00003; KRAVITZ RL, 1989, AM J PUBLIC HEALTH, V79, P1227, DOI 10.2105/AJPH.79.9.1227; LEVIT KR, 1990, HEALTH AFFAIR, V9, P171, DOI 10.1377/hlthaff.9.2.171; LEWIS CE, 1991, ANN INTERN MED, V114, P1, DOI 10.7326/0003-4819-114-1-1; MIZES JS, 1984, PUBLIC OPIN QUART, V48, P794, DOI 10.1086/268885; MUNDINGER MO, 1985, NEW ENGL J MED, V313, P44, DOI 10.1056/NEJM198507043130110; RELMAN AS, 1989, NEW ENGL J MED, V320, P590, DOI 10.1056/NEJM198903023200910; SCHWARTZ MD, 1991, ANN INTERN MED, V114, P6, DOI 10.7326/0003-4819-114-1-6; TAYLOR MG, 1984, MED PERSPECTIVES CAN; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; 1990, MED SCH ADM REQUIREM; 1990, RECOMMENDATIONS C PE; 1989, ANN REPORT C WASHING, P27; 1990, 1987 PHYSICIAN INCOM	34	7	7	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					308	314		10.7326/0003-4819-115-4-308	http://dx.doi.org/10.7326/0003-4819-115-4-308			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854115				2022-12-28	WOS:A1991GA76400011
J	SCHOLER, HR; CIESIOLKA, T; GRUSS, P				SCHOLER, HR; CIESIOLKA, T; GRUSS, P			A NEXUS BETWEEN OCT-4 AND E1A - IMPLICATIONS FOR GENE-REGULATION IN EMBRYONIC STEM-CELLS	CELL			English	Article							EUKARYOTIC TRANSCRIPTIONAL ACTIVATORS; EARLY MOUSE EMBRYOGENESIS; F9 TERATOCARCINOMA CELLS; OCTAMER BINDING-PROTEINS; HEAVY-CHAIN ENHANCER; REGION 1A PROTEINS; CARCINOMA-CELLS; ADENOVIRUS INFECTION; CELLULAR PROTEINS; ESCHERICHIA-COLI	Oct-4 is a transcription factor expressed in the pluripotent progenitor cells of the early mouse embryo. Additional factors are required for the distal activation of genes in differentiated cells containing ectopically expressed Oct-4. Here we show that Oct-4 and E1A are sufficient for distance-independent activation of the basal transcription machinery. The ratio of Oct-4 to E1A is critical for transcriptional activation, because higher levels of either factor are less efficient. Activation depends on a transactivation domain linked to the POU domain of Oct-4 and also on the conserved domain 3 of the 289R E1A protein. This domain is required for binding to the C-terminal part of Oct-4 including the POU domain. Our results indicate that E1A can serve as a bridging factor between Oct-4 and the basal initiation complex, and we postulate that an E1A-like factor acts as a cellular bridging factor of Oct-4 in pluripotent cells.			SCHOLER, HR (corresponding author), MAX PLANCK INST BIOPHYS CHEM, DEPT MOLEC CELL BIOL, W-3400 GOTTINGEN, GERMANY.			Scholer, Hans/0000-0003-2643-5136				BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BORRELLI E, 1986, P NATL ACAD SCI USA, V83, P2846, DOI 10.1073/pnas.83.9.2846; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHELLAPPAN SP, 1990, P NATL ACAD SCI USA, V87, P5878, DOI 10.1073/pnas.87.15.5878; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CROCE CM, 1981, P NATL ACAD SCI-BIOL, V78, P5754, DOI 10.1073/pnas.78.9.5754; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; GULP JS, 1988, P NATL ACAD SCI USA, V85, P6450; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1988, ANTIBODIES LABORATOR; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HEN R, 1986, NATURE, V321, P249, DOI 10.1038/321249a0; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KELLY F, 1982, BIOCHIM BIOPHYS ACTA, V651, P105, DOI 10.1016/0304-419X(82)90009-9; KEMLER I, 1990, FASEB J, V4, P1444, DOI 10.1096/fasebj.4.5.2407588; KO JL, 1986, EMBO J, V5, P1645, DOI 10.1002/j.1460-2075.1986.tb04407.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORELLO D, 1982, NATURE, V296, P260, DOI 10.1038/296260a0; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; NELSON CC, 1990, P NATL ACAD SCI USA, V87, P8041, DOI 10.1073/pnas.87.20.8041; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOLER HR, 1984, CELL, V36, P403, DOI 10.1016/0092-8674(84)90233-2; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SCHOLER HR, 1991, IN PRESS TRENDS GENE; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber E., 1989, TISSUE SPECIFIC GENE, P33; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SLEIGH MJ, 1985, TRENDS GENET, V1, P17, DOI 10.1016/0168-9525(85)90009-5; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; SVENSSON C, 1984, EMBO J, V3, P789, DOI 10.1002/j.1460-2075.1984.tb01886.x; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VELCICH A, 1989, ONCOGENE, V4, P707; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	77	175	176	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 26	1991	66	2					291	304		10.1016/0092-8674(91)90619-A	http://dx.doi.org/10.1016/0092-8674(91)90619-A			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1830243	hybrid			2022-12-28	WOS:A1991FY71200010
J	ZEMEL, G; KATZEN, BT; BECKER, GJ; BENENATI, JF; SALLEE, DS				ZEMEL, G; KATZEN, BT; BECKER, GJ; BENENATI, JF; SALLEE, DS			PERCUTANEOUS TRANSJUGULAR PORTOSYSTEMIC SHUNT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPEUTIC PORTACAVAL-SHUNT; ENDOSCOPIC SCLEROTHERAPY; RANDOMIZED TRIAL; VARICEAL HEMORRHAGE; PORTAL-HYPERTENSION; BLEEDING VARICES; CIRRHOSIS; DISEASE; STENTS	Objective. - To determine the effectiveness of the Palmaz balloon expandable stent for the creation of a transjugular intrahepatic portosystemic shunt. The device is designed to achieve portal decompression in patients with variceal hemorrhage secondary to portal hypertension. Design. - Transjugular intrahepatic portosystemic shunting was performed in eight patients during a 9-month period. Mean follow-up was 5 months. Patients. - All patients had cirrhosis with portal hypertension and varices. Bleeding occurred in seven patients from esophageal varices and in one patient from hemorrhoids. Main Outcome Measures. - Shunt patency and recurrent variceal hemorrhage. Results. - Shunts created from a transjugular approach between a hepatic and a portal vein (diameters of 8 to 12 mm) lowered the average portosystemic pressure gradient from 36 to 11 mm Hg. Mean postoperative hospital stay was 7.7 days. Complete variceal decompression after transjugular intrahepatic portosystemic shunt placement was identified endoscopically in all eight patients. The patient treated for hemorrhoids rebled and was treated successfully by transfemoral balloon expansion of the shunt diameter from 8 to 12 mm. All shunts were patent at 1 to 9 months (mean, 5 months) of follow-up. Conclusion. - Initial results suggest that transjugular intrahepatic portosystemic shunt is a safe and effective method of portal decompression for the treatment of variceal hemorrhage.			ZEMEL, G (corresponding author), BAPTIST HOSP MIAMI,MIAMI VASC INST,8900 N KENDALL DR,MIAMI,FL 33176, USA.							CASTANEDAZUNIGA WR, 1988, INTERVENTIONAL RADIO, P167; CELLO JP, 1987, NEW ENGL J MED, V316, P11, DOI 10.1056/NEJM198701013160103; COLAPINTO RF, 1982, CAN MED ASSOC J, V126, P267; COLDWELL DM, 1991, RADIOLOGY, V178, P249, DOI 10.1148/radiology.178.1.1984312; JACKSON FC, 1971, ANN SURG, V174, P672, DOI 10.1097/00000658-197110000-00012; JOHANSEN K, 1989, AM J SURG, V157, P479, DOI 10.1016/0002-9610(89)90639-9; PALMAZ JC, 1986, AM J ROENTGENOL, V147, P1251, DOI 10.2214/ajr.147.6.1251; PALMAZ JC, 1985, AJR, V145, P820; RESNICK RH, 1974, GASTROENTEROLOGY, V67, P843; REYNOLDS TB, 1981, GASTROENTEROLOGY, V80, P1005; RICHTER GM, 1990, RADIOLOGY, V174, P1027, DOI 10.1148/radiology.174.3.174-3-1027; RIKKERS LF, 1987, ANN SURG, V206, P261, DOI 10.1097/00000658-198709000-00004; RIKKERS LF, 1983, SURGERY, V94, P126; ROSCH J, 1987, RADIOLOGY, V162, P481; ROSCH J, 1969, RADIOLOGY, V92, P1112; RUEFF B, 1976, LANCET, V1, P655; RUTHERFORD RB, 1991, CIRCULATION, V83, P6; VIALLET A, 1975, GASTROENTEROLOGY, V69, P1297; WARREN WD, 1986, ANN SURG, V203, P454, DOI 10.1097/00000658-198605000-00002; WARREN WD, 1983, AM J SURG, V145, P8, DOI 10.1016/0002-9610(83)90159-9	20	169	186	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1991	266	3					390	393		10.1001/jama.266.3.390	http://dx.doi.org/10.1001/jama.266.3.390			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV960	1829120				2022-12-28	WOS:A1991FV96000029
J	SCHOLTEN, JD; CHANG, KH; BABBITT, PC; CHAREST, H; SYLVESTRE, M; DUNAWAYMARIANO, D				SCHOLTEN, JD; CHANG, KH; BABBITT, PC; CHAREST, H; SYLVESTRE, M; DUNAWAYMARIANO, D			NOVEL ENZYMATIC HYDROLYTIC DEHALOGENATION OF A CHLORINATED AROMATIC	SCIENCE			English	Article							ESCHERICHIA-COLI K-12; 4-CHLOROBENZOIC ACID; NUCLEOTIDE-SEQUENCE; BACILLUS-BREVIS; PSEUDOMONAS SP; TYROCIDINE BIOSYNTHESIS; ENZYMATIC-SYNTHESIS; ARTHROBACTER SP; GENE; DEGRADATION	Microbial enzyme systems may be used in the biodegradation of persistent environmental pollutants. The three polypeptide components of one such system, the 4-chlorobenzoate dehalogenase system, have been isolated, and the chemical steps of the 4-hydroxybenzoate-forming reaction that they catalyze have been identified. The genes contained within a 4.5-kilobase Pseudomonas sp. strain CBS3 chromosomal DNA fragment that encode dehalogenase activity were selectively expressed in transformed Escherichia coli. Oligonucleotide sequencing revealed a stretch of homology between the 57-kilodalton (kD) polypeptide and several magnesium adenosine triphosphate (MgATP)-cleaving enzymes that allowed MgATP and coenzyme A (CoA) to be identified as the dehalogenase cosubstrate and cofactor, respectively. The dehalogenase activity arises from two components, a 4-chlorobenzoate:CoA ligase-dehalogenase (an alpha-beta-dimer of the 57- and 30-kD polypeptides) and a thioesterase (the 16-kD polypeptide).	UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLLEGE PK,MD 20742; UNIV QUEBEC,INST NATL RECH SCI SANTE,POINTE CLAIRE H9R 1G6,QUEBEC,CANADA; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94145	University System of Maryland; University of Maryland College Park; University of Quebec; University of California System; University of California San Francisco				Sylvestre, Michel/0000-0002-6942-3373	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028688] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28688] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOWICZ DA, 1990, CRIT REV BIOTECHNOL, V10, P241, DOI 10.3109/07388559009038210; BRYCE GF, 1972, BIOCHEMISTRY-US, V11, P1708, DOI 10.1021/bi00759a028; CHAREST H, UNPUB; Commandeur LCM, 1990, BIODEGRADATION, V1, P207, DOI 10.1007/BF00058837; DeLuca M., 1978, METHOD ENZYMOL, V57, P3, DOI DOI 10.1016/0076-6879(78)57003-1; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELSNER A, 1991, APPL ENVIRON MICROB, V57, P324, DOI 10.1128/AEM.57.1.324-326.1991; FARRELL DH, 1990, GENE, V86, P45, DOI 10.1016/0378-1119(90)90112-5; GREENWOOD KT, 1976, BIOCHIM BIOPHYS ACTA, V454, P285, DOI 10.1016/0005-2787(76)90231-8; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HORI K, 1989, J BIOCHEM-TOKYO, V106, P639, DOI 10.1093/oxfordjournals.jbchem.a122909; KANDA M, 1989, J BIOCHEM-TOKYO, V105, P653, DOI 10.1093/oxfordjournals.jbchem.a122720; KLAGES U, 1980, ZBL BAKT MIK HYG I C, V1, P215, DOI 10.1016/S0172-5564(80)80002-9; KLAGES U, 1979, FEMS MICROBIOL LETT, V6, P201, DOI 10.1111/j.1574-6968.1979.tb03703.x; KNOBLOCH KH, 1977, ARCH BIOCHEM BIOPHYS, V184, P237, DOI 10.1016/0003-9861(77)90347-2; LAWRENCE CB, 1988, COMPUT APPL BIOSCI, V4, P25; LOZOYA E, 1988, EUR J BIOCHEM, V176, P661, DOI 10.1111/j.1432-1033.1988.tb14328.x; MARKS TS, 1984, APPL ENVIRON MICROB, V48, P1020, DOI 10.1128/AEM.48.5.1020-1025.1984; MARKS TS, 1984, BIOCHEM BIOPH RES CO, V124, P669, DOI 10.1016/0006-291X(84)91607-3; MERKEL SM, 1989, J BACTERIOL, V171, P1; MULLER R, 1988, BIOL CHEM H-S, V369, P567, DOI 10.1515/bchm3.1988.369.2.567; MULLER R, 1984, BIOCHEM BIOPH RES CO, V124, P178, DOI 10.1016/0006-291X(84)90933-1; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSKOSKI R, 1970, BIOCHEMISTRY-US, V9, P4839; ROSKOSKI R, 1970, BIOCHEMISTRY-US, V9, P4846; RUSNAK F, 1989, BIOCHEMISTRY-US, V28, P6827, DOI 10.1021/bi00443a008; SAVARD P, 1986, J BACTERIOL, V168, P81, DOI 10.1128/jb.168.1.81-85.1986; STAAB JF, 1989, FEMS MICROBIOL LETT, V59, P15; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THIELE J, 1987, FEMS MICROBIOL LETT, V41, P115, DOI 10.1016/0378-1097(87)90222-9; VANDENTWEEL WJJ, 1986, APPL MICROBIOL BIOT, V25, P289, DOI 10.1007/BF00253665; WECKERMANN R, 1988, NUCLEIC ACIDS RES, V16, P11841, DOI 10.1093/nar/16.24.11841; WOODROW GC, 1979, BIOCHIM BIOPHYS ACTA, V582, P145, DOI 10.1016/0304-4165(79)90297-6	34	127	134	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					182	185		10.1126/science.1853203	http://dx.doi.org/10.1126/science.1853203			4	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1853203				2022-12-28	WOS:A1991FW16000032
J	DIRICK, L; NASMYTH, K				DIRICK, L; NASMYTH, K			POSITIVE FEEDBACK IN THE ACTIVATION OF G1 CYCLINS IN YEAST	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; HO GENE; MATING-PHEROMONE; CELL; ARREST; SIZE	YEAST cells become committed to the mitotic cell cycle at a stage during G1 called Start 1. To enter Start, cells must grow to a critical size. They also require the CDC28 protein kinase and at least one of three G1-specific cyclins encoded by CLN1, 2, and 3 (refs 2-4). It is thought that Start is triggered by the accumulation of G1 cyclins that bind to the CDC28 kinase and activate it. So what determines the accumulation of G1 cyclins? For CLN1 and CLN2, transcriptional activation could be involved because their RNAs appear transiently during the cell cycle as cells undergo Start 5. Here we report that the appearance of CLN1 and CLN2 RNAs depends on an active CDC28 kinase and is stimulated by CLN3 activity. We propose that CDC28 kinase activity due to CLN1 and CLN2 proteins arises through a positive feedback loop which allows CLN proteins to promote their own synthesis.			DIRICK, L (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403				ANDREWS BJ, 1989, NATURE, V342, P803; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; NASMYTH KA, IN PRESS CELL; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	19	173	176	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					754	757		10.1038/351754a0	http://dx.doi.org/10.1038/351754a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1829507				2022-12-28	WOS:A1991FU20100067
J	HAVRAN, WL; CHIEN, YH; ALLISON, JP				HAVRAN, WL; CHIEN, YH; ALLISON, JP			RECOGNITION OF SELF ANTIGENS BY SKIN-DERIVED T-CELLS WITH INVARIANT GAMMA-DELTA-ANTIGEN RECEPTORS	SCIENCE			English	Article							DENDRITIC EPIDERMAL-CELLS; MYCOBACTERIUM-TUBERCULOSIS; MURINE EPIDERMIS; PRECURSORS; PROTEINS; PRODUCT; SUBSET; MICE	Thy-1+ dendritic epidermal T cells (dECs) express invariant gamma-delta-antigen receptors and are found in intimate contact with keratinocytes in murine epidermis - thus raising the possibility that keratinocytes express a ligand for the antigen receptor of these T cells. Thy-1+ dECs were stimulated to produce lymphokines by interaction with keratinocytes in vitro. This stimulation was mediated through the dEC antigen receptor and did not appear to be restricted by the major histocompatibility complex. Thus, dECs can recognize self antigens and may participate in immune surveillance for cellular damage rather than for foreign antigens.	UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720; STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	University of California System; University of California Berkeley; Stanford University	HAVRAN, WL (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Allison, James/0000-0001-8980-5697	NATIONAL CANCER INSTITUTE [R37CA040041, R01CA040041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026942] Funding Source: NIH RePORTER; NCI NIH HHS [CA40041] Funding Source: Medline; NIAID NIH HHS [AI26942] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allison J P, 1990, Semin Immunol, V2, P59; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; ASARNOW DM, 1989, NATURE, V341, P60, DOI 10.1038/341060a0; BERGSTRESSER PR, 1984, J INVEST DERMATOL, V83, P83, DOI 10.1111/1523-1747.ep12262587; BERGSTRESSER PR, 1983, J INVEST DERMATOL, V81, P286, DOI 10.1111/1523-1747.ep12518332; BONNEVILLE M, 1989, P NATL ACAD SCI USA, V86, P5928, DOI 10.1073/pnas.86.15.5928; BORN W, 1990, IMMUNOL TODAY, V11, P40; GILLIS S, 1978, J IMMUNOL, V120, P2027; HAVRAN WL, 1989, J IMMUNOL, V142, P1422; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HAVRAN WL, UNPUB; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; JANIS EM, 1989, SCIENCE, V244, P713, DOI 10.1126/science.2524098; KORMAN AJ, 1988, J EXP MED, V168, P1021, DOI 10.1084/jem.168.3.1021; KUPPER TS, 1987, J INVEST DERMATOL, V88, P501; KUZIEL WA, 1987, NATURE, V328, P263, DOI 10.1038/328263a0; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; OBRIEN RL, 1989, CELL, V57, P667, DOI 10.1016/0092-8674(89)90135-9; STINGL G, 1987, P NATL ACAD SCI USA, V84, P2430, DOI 10.1073/pnas.84.8.2430; SULLIVAN S, 1985, J INVEST DERMATOL, V84, P491, DOI 10.1111/1523-1747.ep12273454; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0; YOUNG RA, 1989, CELL, V59, P5, DOI 10.1016/0092-8674(89)90861-1	24	338	340	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1991	252	5011					1430	1432		10.1126/science.1828619	http://dx.doi.org/10.1126/science.1828619			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP868	1828619				2022-12-28	WOS:A1991FP86800036
J	JAP, BK; WALIAN, PJ; GEHRING, K				JAP, BK; WALIAN, PJ; GEHRING, K			STRUCTURAL ARCHITECTURE OF AN OUTER-MEMBRANE CHANNEL AS DETERMINED BY ELECTRON CRYSTALLOGRAPHY	NATURE			English	Article							ESCHERICHIA-COLI; RHODOBACTER-CAPSULATUS; SENSITIVE SPECIMENS; LIPID BILAYERS; PHOE PROTEIN; PORIN; RESOLUTION; BEAM	PORINS are a family of membrane channels commonly found in the outer membranes of Gram-negative bacteria where they serve as diffusional pathways for waste products, nutrients and antibiotics, and can also be receptors for bacteriophages 1,2. Porin channels have been shown in vitro to be voltage-gated 3-6. They can exhibit slight selectivities for certain solutes; for example PhoE porin has some selectivity for anionic and phosphate-containing compounds 1,7. Unlike many known membrane proteins which often contain long stretches of hydrophobic segments that are believed to traverse the membrane in a helical conformation, porins are found to have charged residues distributed almost uniformly along their primary sequences and have most of their secondary structure in a beta-sheet conformation 8-10. We have made crystalline patches of PhoE porin embedded in a lipid bilayer and have used these to determine the structure of PhoE porin by electron crystallography to a resolution of 6 angstrom. The basic structure consists of a trimer of elliptically shaped, cylindrical walls of beta-sheet. Each cylinder has an inner lining, formed by parts of the polypeptide, that defines the channel size. The structure provides a clue as to how deletions of segments of polypeptide, which are found in certain mutants, can result in an actual increase in the channel size.			JAP, BK (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,DONNER LAB,BERKELEY,CA 94720, USA.		Gehring, Kalle/I-4403-2013; Gehring, Kalle/N-2945-2019	Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184				AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BULLOUGH P, 1987, ULTRAMICROSCOPY, V21, P223, DOI 10.1016/0304-3991(87)90147-1; DARGENT B, 1986, EMBO J, V5, P773, DOI 10.1002/j.1460-2075.1986.tb04280.x; DOWNING KH, 1986, ULTRAMICROSCOPY, V20, P269, DOI 10.1016/0304-3991(86)90191-9; HOENGER A, 1990, J STRUCT BIOL, V103, P185, DOI 10.1016/1047-8477(90)90022-5; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; JAP BK, 1989, J MOL BIOL, V205, P407, DOI 10.1016/0022-2836(89)90351-3; JAP BK, 1990, J STRUCT BIOL, V103, P57, DOI 10.1016/1047-8477(90)90086-R; KLEFFEL B, 1985, EMBO J, V4, P1589, DOI 10.1002/j.1460-2075.1985.tb03821.x; KORTELAND J, 1982, BIOCHIM BIOPHYS ACTA, V690, P282, DOI 10.1016/0005-2736(82)90332-7; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; MAURO A, 1988, P NATL ACAD SCI USA, V85, P1071, DOI 10.1073/pnas.85.4.1071; MISRA R, 1988, J BACTERIOL, V170, P3611, DOI 10.1128/jb.170.8.3611-3617.1988; NESTEL U, 1989, FEBS LETT, V242, P405, DOI 10.1016/0014-5793(89)80511-3; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; SASS HJ, 1989, J MOL BIOL, V209, P171, DOI 10.1016/0022-2836(89)90180-0; SCHINDLER H, 1978, P NATL ACAD SCI USA, V75, P3751, DOI 10.1073/pnas.75.8.3751; SHAW PJ, 1981, MICRON, V12, P279, DOI 10.1016/0047-7206(81)90081-9; TOMMASSEN J, 1988, NATO ASI SER, V16, P351; WALIAN PJ, 1990, J MOL BIOL, V215, P429, DOI 10.1016/S0022-2836(05)80362-6; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WEISS MS, 1989, FEBS LETT, V256, P143, DOI 10.1016/0014-5793(89)81735-1; XU GZ, 1986, BIOCHIM BIOPHYS ACTA, V862, P57, DOI 10.1016/0005-2736(86)90468-2	26	132	134	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					167	170		10.1038/350167a0	http://dx.doi.org/10.1038/350167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	1848682				2022-12-28	WOS:A1991FB64500064
J	KUO, HC; NASIM, FUH; GRABOWSKI, PJ				KUO, HC; NASIM, FUH; GRABOWSKI, PJ			CONTROL OF ALTERNATIVE SPLICING BY THE DIFFERENTIAL BINDING OF U1 SMALL NUCLEAR RIBONUCLEOPROTEIN PARTICLE	SCIENCE			English	Article							PRE-MESSENGER RNA; SITE SELECTION; SNRNP PROTEIN; AFFINITY-CHROMATOGRAPHY; COMPLEX; SPLICEOSOME; GENE; IDENTIFICATION; SEQUENCES; INVITRO	Cellular factors controlling alternative splicing of precursor messenger RNA are largely unknown, even though this process plays a central role in specifying the diversity of proteins in the eukaryotic cell. For the identification of such factors, a segment of the rat preprotachykinin gene was used in which differential expression of neuropeptides-gamma and K is dependent on alternative splicing of the fourth exon (E4). Sequence variants of the three-exon segment, (E3-E4-E5) were created, resulting in a sensitive assay for factors mediating the splicing switch between E4-skipping and E4-inclusion. A dinucleotide mutation in the 5' splice site of E4 that increases base-pairing of this site to U1 small nuclear RNA resulted in uniform selection of E4, whereas a control mutation that destroyed base-pairing resulted in uniform E4-skipping. Affinity selection of spliceosomes formed on these functionally distinct substrates revealed that the extreme difference in splicing was mediated by differential binding of the U1 small nuclear ribonucleoprotein particle (snRNP) to the 5' splice site of E4. These data show that, apart from its established role in selecting 5' splice sites, U1 snRNP plays a fundamental role in 3' exon selection and provides insight into possible mechanisms of alternative splicing.	BROWN UNIV, BIOCHEM SECT, PROVIDENCE, RI 02912 USA	Brown University			Nasim, Faiz/F-6397-2015; Nasim, Faiz-ul Hassan/G-5799-2010	Nasim, Faiz-ul Hassan/0000-0001-9107-7449	NIGMS NIH HHS [GM-39695] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039695] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BONADIO J, 1990, J BIOL CHEM, V265, P2262; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; CHABOT B, 1987, MOL CELL BIOL, V7, P281, DOI 10.1128/MCB.7.1.281; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; COOPER TA, 1989, NUCLEIC ACIDS RES, V17, P7905, DOI 10.1093/nar/17.19.7905; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; ETZERODT M, 1988, EMBO J, V7, P4311, DOI 10.1002/j.1460-2075.1988.tb03330.x; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FREYER GA, 1989, J BIOL CHEM, V264, P14631; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XY, 1988, EMBO J, V7, P809, DOI 10.1002/j.1460-2075.1988.tb02879.x; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GARCIABLANCO MA, 1990, P NATL ACAD SCI USA, V87, P3082, DOI 10.1073/pnas.87.8.3082; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; GRABOWSKI PJ, 1986, SCIENCE, V233, P1294, DOI 10.1126/science.3638792; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HELFMAN DM, 1989, NUCLEIC ACIDS RES, V17, P5633, DOI 10.1093/nar/17.14.5633; KASHER MS, 1986, MOL CELL BIOL, V6, P3117, DOI 10.1128/MCB.6.9.3117; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KRAUSE JE, 1987, P NATL ACAD SCI USA, V84, P881, DOI 10.1073/pnas.84.3.881; KUIVANIEMI H, 1988, J BIOL CHEM, V263, P11407; KUO HC, UNPUB; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; NASIM FH, 1990, GENE DEV, V4, P1172, DOI 10.1101/gad.4.7.1172; NASIM FH, UNPUB; NOBLE JCS, 1987, CELL, V50, P227, DOI 10.1016/0092-8674(87)90218-2; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10373, DOI 10.1093/nar/15.24.10373; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; TALERICO M, 1990, MOL CELL BIOL, V10, P6299, DOI 10.1128/MCB.10.12.6299; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; WEIL D, 1988, J BIOL CHEM, V263, P8561; YUAN ZA, 1987, MOL CELL BIOL, V7, P3018, DOI 10.1128/MCB.7.8.3018; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	63	159	159	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 1	1991	251	4997					1045	1050		10.1126/science.1825520	http://dx.doi.org/10.1126/science.1825520			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1825520				2022-12-28	WOS:A1991EZ66500041
J	LUKETIC, VA; SHIFFMAN, ML; MCCALL, JB; POSNER, MP; MILLS, AS; CARITHERS, RL				LUKETIC, VA; SHIFFMAN, ML; MCCALL, JB; POSNER, MP; MILLS, AS; CARITHERS, RL			PRIMARY HEPATOCELLULAR-CARCINOMA AFTER ORTHOTOPIC LIVER-TRANSPLANTATION FOR CHRONIC HEPATITIS-B INFECTION	ANNALS OF INTERNAL MEDICINE			English	Note							VIRUS	Nearly all patients having hepatic transplantation for chronic hepatitis B infection re-acquire this virus in their new liver. Chronic hepatitis B is a risk factor for developing hepatocellular carcinoma. Thus, liver transplant recipients with chronic hepatitis B may be at an increased risk for developing this tumor in their hepatic allograft. The patient described in this report had hepatic transplantation for progressive liver failure due to chronic hepatitis B infection. The donor had no serologic evidence of hepatitis B, and no evidence of hepatocellular carcinoma was present on pre-transplant evaluation or after careful examination of the explanted liver. Serologic and histologic evidence of hepatitis B infection developed within 4 to 6 months after transplantation. By 30 months, progressive liver dysfunction developed. A computed tomographic scan done at 47 months showed several intrahepatic masses, which at autopsy were found to represent multifocal hepatocellular carcinoma. This is the first documented case of primary hepatocellular carcinoma in the hepatic allograft of a patient with recurrent chronic hepatitis B infection. The carcinoma developed after only 4 years in this immunosuppressed patient, compared with more than 20 years for the average patient with chronic hepatitis B infection. We recommend that patients with chronic hepatitis B who need hepatic transplantation be counseled about the risk for hepatocellular carcinoma and screened for this tumor after transplantation.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, HEPATOL SECT, BOX 711, MCV STN, RICHMOND, VA 23298 USA; UNIV WASHINGTON, MED CTR, SEATTLE, WA 98195 USA; JOHNS HOPKINS UNIV HOSP, BALTIMORE, MD 21205 USA	Virginia Commonwealth University; University of Washington; University of Washington Seattle; Johns Hopkins University; Johns Hopkins Medicine								ANDERSON MG, 1985, GUT, V26, P847; BEASLEY RP, 1984, SEMIN LIVER DIS, V4, P113, DOI 10.1055/s-2008-1040651; CARITHERS RL, 1990, CURRENT HEPATOLOGY, P221; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; DINDZANS VJ, 1988, GASTROENTEROL CLIN N, V17, P19; HEYWARD WL, 1985, JAMA-J AM MED ASSOC, V254, P3052, DOI 10.1001/jama.254.21.3052; PAFREY PS, 1985, TRANSPLANTATION, V39, P610; POPPER H, 1987, HEPATOLOGY, V7, P764, DOI 10.1002/hep.1840070425; STARZL TE, 1989, NEW ENGL J MED, V321, P1092, DOI 10.1056/NEJM198910193211606; WU PC, 1982, HEPATOLOGY, V2, P777, DOI 10.1002/hep.1840020605	10	20	20	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1991	114	3					212	213		10.7326/0003-4819-114-3-212	http://dx.doi.org/10.7326/0003-4819-114-3-212			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV339	1845838				2022-12-28	WOS:A1991EV33900008
J	SZCZEPURA, AK; FLETCHER, J; FITZPATRICK, JD				SZCZEPURA, AK; FLETCHER, J; FITZPATRICK, JD			COST-EFFECTIVENESS OF MAGNETIC-RESONANCE-IMAGING IN THE NEUROSCIENCES	BRITISH MEDICAL JOURNAL			English	Article							TECHNOLOGY	Objectives - To measure, in a service setting, the effect of magnetic resonance imaging on diagnosis, diagnostic certainty, and patient management in the neurosciences; to measure the cost per patient scanned; to estimate the marginal cost of imaging and compare this with its diagnostic impact; to measure changes in patients' quality of life; and to record the diagnostic pathway leading to magnetic resonance imaging. Design - Controlled observational study using questionnaires on diagnosis and patient management before and after imaging. Detailed costing study. Quality of life questionnaires at the time of imaging and six months later. Diagnostic pathways extracted from medical records for a representative sample. Setting - Regional superconducting 1.5 T magnetic resonance service. Subjects - 782 consecutive neuroscience patients referred by consultants for magnetic resonance imaging during June 1988-9; diagnostic pathways recorded for 158 cases. Main outcome measures - Costs of magnetic resonance imaging and preliminary investigations; changes in planned management and resulting savings; changes in principal diagnosis and diagnostic certainty; changes in patients' quality of life. Results - Average cost of magnetic resonance imaging was estimated at 206.20 pounds/patient (throughput 2250 patients/year, 1989-90 prices including contrast and upgrading). Before magnetic resonance imaging diagnostic procedures cost 164.40 pounds/patient (including inpatient stays). Management changed after imaging in 208 (27%) cases; saving an estimated 80.90 pounds/patient. Confidence in planned management increased in a further 226 (29%) referrals. Consultants' principal diagnosis changed in 159 of 782 (20%) referrals; marginal cost Per diagnostic change was 626 pounds. Confidence in diagnosis increased in 236 (30%) referrals. No improvement in patients' quality of life at six month assessment. Conclusions - Any improvement in diagnosis with magnetic resonance imaging is achieved at a higher cost. Techniques for monitoring the cost effectiveness of this technology need to be developed.	WALSGRAVE GEN HOSP,COVENTRY CV2 2DX,ENGLAND		SZCZEPURA, AK (corresponding author), UNIV WARWICK,WARWICK BUSINESS SCH RES BUREAU,HLTH SERV RES UNIT,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.			Szczepura, Ala/0000-0001-6244-9872				BOGATAY LM, 1987, HOSP TOP, V39, P12; BYDDER GM, 1988, BRIT J RADIOL, V61, P889, DOI 10.1259/0007-1285-61-730-889; CHERRYMAN GR, 1985, BRIT MED J, V291, P1437, DOI 10.1136/bmj.291.6506.1437; COOPER LS, 1988, JAMA-J AM MED ASSOC, V259, P3277, DOI 10.1001/jama.259.22.3277; DIXON AK, 1991, BMJ, V3302, P78; DURICK AA, 1988, RADIOL TECHNOL, V59, P239; EVENS RG, 1988, RADIOLOGY, V166, P27, DOI 10.1148/radiology.166.1.3336692; EVENS RG, 1991, AM J ROENTGENOL, V157, P603, DOI 10.2214/ajr.157.3.1872246; FINEBERG HV, 1977, JAMA-J AM MED ASSOC, V238, P224, DOI 10.1001/jama.238.3.224; GUDEX C, 1988, 38 U YORK CTR HLTH E; KENT DL, 1988, ANN INTERN MED, V108, P759, DOI 10.7326/0003-4819-108-5-759; KENT DL, 1988, ANN INTERN MED, V108, P402, DOI 10.7326/0003-4819-108-3-402; Larson E B, 1989, Int J Technol Assess Health Care, V5, P195; Pribyl S, 1988, Appl Radiol, V17, P29; ROBERTS H, 1990, 33 PUBL FIN F DISC P; ROSSER R, 1983, HLTH INDICATORS; SCHERSTEN T, 1985, INT J TECHNOL ASSESS, V1; SCHUMAN WP, 1988, AJR, V151, P857; STILWELL JA, 1984, BRIT J RADIOL, V57, P647, DOI 10.1259/0007-1285-57-679-647; SZCZEPURA AK, 1988, SOC SCI MED, V26, P715, DOI 10.1016/0277-9536(88)90063-9; SZCZEPURA AK, 1991, 1 BUS SCH HLTH SERV; SZCZEPURA AK, 1990, VALUE USE BACTERIOLO; 1990, MRI ASSESSMENT PROGR; 1988, HLTH TECHNOLOGY, V2, P3; 1990, EC EVALUATION CLIN A; 1988, MRI ASSESSMENT PROGR; 1989, HLTH PERSONAL SOCIAL; 1986, MAGNET RESON MED, V6, P1; 1990, MAGNETIC RESONANCE I; 1989, MRI ASSESSMENT PROGR; 1988, ANN INTERN MED, V108, P474; 1985, DHSS141 DEP HLTH SOC	32	30	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1435	1439		10.1136/bmj.303.6815.1435	http://dx.doi.org/10.1136/bmj.303.6815.1435			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1819260	Bronze, Green Published			2022-12-28	WOS:A1991GU38500022
J	HUNTER, T; PINES, J				HUNTER, T; PINES, J			CYCLINS AND CANCER	CELL			English	Review							MATURATION; PHOSPHORYLATION; ACTIVATION; MITOSIS; P34CDC2; KINASE; CELLS; YEAST; P53				HUNTER, T (corresponding author), SALK INST BIOL STUDIES, LA JOLLA, CA 92037 USA.			Pines, Jonathon/0000-0002-5227-6004				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PINES J, 1991, IN PRESS J CELL BIOL; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TSAI LH, 1991, IN PRESS NATURE; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	32	494	511	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1071	1074		10.1016/0092-8674(91)90028-W	http://dx.doi.org/10.1016/0092-8674(91)90028-W			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1833062				2022-12-28	WOS:A1991GG55200002
J	HAMPTON, RY; GOLENBOCK, DT; PENMAN, M; KRIEGER, M; RAETZ, CRH				HAMPTON, RY; GOLENBOCK, DT; PENMAN, M; KRIEGER, M; RAETZ, CRH			RECOGNITION AND PLASMA-CLEARANCE OF ENDOTOXIN BY SCAVENGER RECEPTORS	NATURE			English	Article							LOW-DENSITY-LIPOPROTEIN; ESCHERICHIA-COLI LIPOPOLYSACCHARIDE; A-BINDING-SITES; CHOLESTEROL DEPOSITION; PERITONEAL-MACROPHAGES; RAT-LIVER; CELLS; PROTEIN; DEGRADATION; METABOLISM	LIPID A is the active moiety of lipopolysaccharide (LPS, also referred to as endotoxin), a surface component of Gram-negative bacteria that stimulates macrophage activation and causes endotoxic shock 1,2. Macrophages can bind, internalize and partially degrade LPS, lipid A and its bioactive precursor, lipid IV(A) (refs 3-7). We report here that lipid IV(A) binding and subsequent metabolism to a less active form by macrophage-like RAW 264.7 cells is mediated by the macrophage scavenger receptor. Scavenger-receptor ligands inhibit lipid IV(A) binding to, and metabolism by, RAW cells, and lipid IV(A) binds to type I and type II bovine scavenger receptors on transfected Chinese hamster ovary cells. Although in vitro competition studies with RAW cells indicate that scavenger receptor binding is not involved in LPS or lipid IV(A)-induced stimulation of macrophages, in vivo studies show that scavenger-receptor ligands greatly inhibit hepatic uptake of lipid IV(A) in mice. Thus, scavenger receptors expressed on macrophages may have an important role in the clearance and detoxification of endotoxin in animals.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM,RAHWAY,NJ 07065; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Merck & Company; Massachusetts Institute of Technology (MIT)	HAMPTON, RY (corresponding author), UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706, USA.							BEUTLER B, 1988, BIOCHEMISTRY-US, V27, P7575, DOI 10.1021/bi00420a001; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; DRESEL HA, 1987, EMBO J, V6, P319, DOI 10.1002/j.1460-2075.1987.tb04757.x; DUNCAN RL, 1984, J IMMUNOL, V132, P1416; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; FREUDENBERG MA, 1984, REV INFECT DIS, V6, P483; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOLENBOCK DT, 1990, INFECT IMMUN, V58, P4069, DOI 10.1128/IAI.58.12.4069-4075.1990; HAMILTON TA, 1990, J IMMUNOL, V144, P2343; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HARA H, 1987, BIOCHEM BIOPH RES CO, V146, P802, DOI 10.1016/0006-291X(87)90601-2; KAPLAN HM, 1983, MOUSE BIOMEDICAL RES, V3, P248; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; PETERSON AA, 1987, INFECT IMMUN, V55, P974, DOI 10.1128/IAI.55.4.974-978.1987; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; PITAS RE, 1990, J BIOL CHEM, V265, P12722; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1988, COLD SPRING HARB SYM, V53, P973, DOI 10.1101/SQB.1988.053.01.112; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	30	474	491	2	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					342	344		10.1038/352342a0	http://dx.doi.org/10.1038/352342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852209				2022-12-28	WOS:A1991FY28900073
J	RANSOHOFF, DF				RANSOHOFF, DF			SCREENING FOR COLORECTAL-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FECAL OCCULT BLOOD; COLONIC POLYPS; CONTROLLED TRIAL; UNITED-STATES; SIGMOIDOSCOPY; CARCINOMA; PATTERNS; ADENOMAS; HISTORY; HEALTH		YALE UNIV,DEPT MED,NEW HAVEN,CT 06520; UNIV COLORADO,DEPT MED,DENVER,CO 80202	Yale University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								AHLQUIST DA, 1985, NEW ENGL J MED, V312, P1422, DOI 10.1056/NEJM198505303122204; AHLQUIST DA, 1989, CANCER, V63, P1826; ARMINSKI T. C., 1964, DIS COLON RECTUM, V7, P249, DOI 10.1007/BF02630528; ATKIN W S, 1990, Gastroenterology, V98, pA650; Blatt LJ., 1961, DIS COLON RECTUM, V4, P277; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CHAPMAN I, 1963, ANN SURG, V157, P223, DOI 10.1097/00000658-196302000-00007; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; FRIEDMAN G D, 1990, Journal of General Internal Medicine, V5, pS23, DOI 10.1007/BF02600836; GILBERTSEN VA, 1980, CANCER, V45, P2899, DOI 10.1002/1097-0142(19800601)45:11<2899::AID-CNCR2820451132>3.0.CO;2-M; GNAUCK R, 1980, PROGR CANCER RES THE, V13, P175; GOLDMAN B, 1989, AM COLL PHYSICIANS O, V9, P1; GOLDMAN B, 1989, AM COLL PHYS OBS, V9, P10; GROSSMAN S, 1988, GASTROENTEROLOGY, V94, P395, DOI 10.1016/0016-5085(88)90427-1; HARDCASTLE JD, 1989, LANCET, V1, P1160; HERZOG P, 1982, GASTROENTEROLOGY, V83, P957; KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-#; KINZLERKW, 1991, SCIENCE, V251, P1366; KNIGHT KK, 1989, JAMA-J AM MED ASSOC, V261, P587; KRONBORG O, 1987, SCAND J GASTROENTERO, V22, P677, DOI 10.3109/00365528709011142; MACKLIN MT, 1960, J NATL CANCER I, V24, P551, DOI 10.1093/jnci/24.3.551; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; NEUGUT AI, 1988, AM J GASTROENTEROL, V83, P295; RANSOHOFF DF, 1990, JAMA-J AM MED ASSOC, V264, P76, DOI 10.1001/jama.264.1.76; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; RICKERT RR, 1979, CANCER-AM CANCER SOC, V43, P1847, DOI 10.1002/1097-0142(197905)43:5<1847::AID-CNCR2820430538>3.0.CO;2-L; SEIDMAN H, 1985, CA-CANCER J CLIN, V35, P36, DOI 10.3322/canjclin.35.1.36; SELBY JV, 1989, JAMA-J AM MED ASSOC, V261, P595; SELBY JV, 1988, J CLIN EPIDEMIOL, V41, P427, DOI 10.1016/0895-4356(88)90043-1; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; SIMON JB, 1990, JAMA-J AM MED ASSOC, V264, P84, DOI 10.1001/jama.264.1.84; SMART CR, 1990, MAYO CLIN PROC, V65, P892, DOI 10.1016/S0025-6196(12)62581-6; SONGSTER CL, 1980, CANCER, V45, P1099, DOI 10.1002/1097-0142(19800315)45:5+<1099::AID-CNCR2820451312>3.0.CO;2-T; SPENCER RJ, 1984, MAYO CLIN PROC, V59, P305, DOI 10.1016/S0025-6196(12)61425-6; STJOHN DJB, 1990, GASTROENTEROLOGY, V98, pA312; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; WAYE J, 1990, GASTROINTEST ENDOS S, V36, pA226; WINAWER SJ, 1985, SCREENING CANCER, P347; WOOLF CM, 1958, AM J HUM GENET, V10, P42; ZINKIN LD, 1983, DIS COLON RECTUM, V26, P37, DOI 10.1007/BF02554677; 1990, OTABPH74 OFF TECHN A; 1989, CAN MED ASSOC J, V141, P209; 1990, CLIN EFFICACY ASSESS; 1989, SUMMARY CURRENT GUID; 1989, NCI NIH892789 PUBL; 1987, WORKING GUIDELINES E; 1989, CAN MED ASSOC J, V141, P1126	54	161	166	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1991	325	1					37	41						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU342	1810273				2022-12-28	WOS:A1991FU34200007
J	HASKILL, S; BEG, AA; TOMPKINS, SM; MORRIS, JS; YUROCHKO, AD; SAMPSONJOHANNES, A; MONDAL, K; RALPH, P; BALDWIN, AS				HASKILL, S; BEG, AA; TOMPKINS, SM; MORRIS, JS; YUROCHKO, AD; SAMPSONJOHANNES, A; MONDAL, K; RALPH, P; BALDWIN, AS			CHARACTERIZATION OF AN IMMEDIATE-EARLY GENE INDUCED IN ADHERENT MONOCYTES THAT ENCODES I-KAPPA-B-LIKE ACTIVITY	CELL			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; CYCLE CONTROL PROTEINS; NECROSIS FACTOR-ALPHA; DNA-BINDING PROTEINS; TRANSCRIPTION FACTOR; NUCLEAR FACTOR; REL ONCOGENE; REGULATORY SEQUENCE; NUCLEOTIDE-SEQUENCE; NEUROGENIC LOCUS	We have cloned a group of cDNAs representing mRNAs that are rapidly induced following adherence of human monocytes. One of the induced transcripts (MAD-3) encodes a protein of 317 amino acids with one domain containing five tandem repeats of the cdc 10/ankyrin motif, which is 60% similar (46% identical) to the ankyrin repeat region of the precursor of NF-kappa-B/KBF1 p50. The C-terminus has a putative protein kinase C phosphorylation site. In vitro translated MAD-3 protein was found to specifically inhibit the DNA-binding activity of the p50/p65 NF-kappa-B complex but not that of the p50/p50 KBF1 factor or of other DNA-binding proteins. The MAD-3 cDNA encodes an I-kappa-B-like protein that is likely to be involved in regulation of transcriptional responses to NF-kappa-B, including adhesion-dependent pathways of monocyte activation.	UNIV N CAROLINA,DEPT OBSTET & GYNECOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET,CHAPEL HILL,NC 27599; CETUS CORP,DEPT CELL BIOL,EMERYVILLE,CA 94608	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	HASKILL, S (corresponding author), UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599, USA.		Tompkins, Stephen/A-3317-2008	Tompkins, Stephen/0000-0002-1523-5588	NCI NIH HHS [1 R01 CA52515, 5 T32 CA09156] Funding Source: Medline; NIAID NIH HHS [1 R01 AI26774] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052515, T32CA009156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026774] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BALDWIN AS, 1990, DNA PROTEIN ENG TECH, V2, P73; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLANAR MA, 1989, MOL CELL BIOL, V9, P844, DOI 10.1128/MCB.9.2.844; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; EIERMAN DF, 1989, J IMMUNOL, V142, P1970; EIERMAN DF, 1991, IN PRESS INT C LEUKO; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; HASKILL S, 1988, J IMMUNOL, V140, P1690; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIEBERMANN T, 1990, MOL CELL BIOL, V10, P2317; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NOLAND TA, 1989, J BIOL CHEM, V264, P20778; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; SPORN SA, 1990, J IMMUNOL, V144, P4434; SPRINGER TA, 1989, CURRENT PROTOCOLS MO; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	57	711	728	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1281	1289		10.1016/0092-8674(91)90022-Q	http://dx.doi.org/10.1016/0092-8674(91)90022-Q			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1829648	Green Submitted			2022-12-28	WOS:A1991FU89900019
J	GOODWIN, FK				GOODWIN, FK			CONTINGENT INEFFICACY AND TOLERANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note																		WEISS SRB, 1991, EPILEPSIA, V322, P140	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2657	2657						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	1850809				2022-12-28	WOS:A1991FL98900006
J	MATSUSHIME, H; ROUSSEL, MF; ASHMUN, RA; SHERR, CJ				MATSUSHIME, H; ROUSSEL, MF; ASHMUN, RA; SHERR, CJ			COLONY-STIMULATING FACTOR-I REGULATES NOVEL CYCLINS DURING THE G1 PHASE OF THE CELL-CYCLE	CELL			English	Article							MATURATION-PROMOTING FACTOR; CDC2 PROTEIN-KINASE; FACTOR-I RECEPTOR; CONTROL GENE CDC2+; SEA-URCHIN EGGS; C-FMS GENE; FISSION YEAST; MESSENGER-RNA; GROWTH-FACTOR; SACCHAROMYCES-CEREVISIAE	Three mouse cyclin-like (CYL) genes were isolated, two of which are regulated by colony-stimulating factor 1 (CSF-1) during the G1 phase of the macrophage cell cycle. CSF-1 deprivation during G1 leads to rapid degradation of CYL proteins (p36CYL) and correlates with failure to initiate DNA synthesis. However, after entering S phase, macrophages no longer require CSF-1 and can complete cell division without expressing CYL genes. During G1, p36CYL is phosphorylated and associates with a polypeptide antigenically related to p34cdc2. The timing of p36CYL expression, its rapid turnover in the absence of CSF-1, and its phosphorylation and transient binding to a cdc2-related polypeptide suggest that CYL genes may function during S phase commitment.	ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	MATSUSHIME, H (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA.		Roussel, Martine F/F-1469-2016; Sherr, Charles J/N-8074-2018	Roussel, Martine F/0000-0002-1740-8139; Sherr, Charles J/0000-0002-5516-6206	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA7064, P01-CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; BRITTEN RJ, 1968, SCIENCE, V161, P529, DOI 10.1126/science.161.3841.529; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DEAN PN, 1980, CELL TISSUE KINET, V13, P672; DEAN PN, 1980, CELL TISSUE KINET, V13, P299, DOI 10.1111/j.1365-2184.1980.tb00468.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FURMAN WL, 1986, VIROLOGY, V152, P432, DOI 10.1016/0042-6822(86)90145-5; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL M, 1988, CELL, V54, P739; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; JACKOWSKI S, 1990, J BIOL CHEM, V265, P6611; JIMENEZ J, 1990, EMBO J, V9, P3565, DOI 10.1002/j.1460-2075.1990.tb07567.x; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; ORLOFSKY A, 1987, EMBO J, V6, P2947, DOI 10.1002/j.1460-2075.1987.tb02599.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; POLLARD JW, 1991, P NATL ACAD SCI USA, V88, P1474, DOI 10.1073/pnas.88.4.1474; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHERR CJ, 1979, J VIROL, V32, P860, DOI 10.1128/JVI.32.3.860-875.1979; SHERR CJ, 1991, IN PRESS ORIGINS HUM; SHERR CJ, 1990, PEPTIDE GROWTH FACTO, P667; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANLEY ER, 1978, NATURE, V274, P168, DOI 10.1038/274168a0; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WHEELER EF, 1986, NATURE, V324, P377, DOI 10.1038/324377a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	90	1195	1225	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1991	65	4					701	713		10.1016/0092-8674(91)90101-4	http://dx.doi.org/10.1016/0092-8674(91)90101-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1827757				2022-12-28	WOS:A1991FM03700019
J	CHAPMAN, KB; BOEKE, JD				CHAPMAN, KB; BOEKE, JD			ISOLATION AND CHARACTERIZATION OF THE GENE ENCODING YEAST DEBRANCHING ENZYME	CELL			English	Article							PRE-MESSENGER RNA; SACCHAROMYCES-CEREVISIAE; REVERSE-TRANSCRIPTASE; SPLICING INVITRO; TY ELEMENTS; INTRON; DNA; INTERMEDIATE; SEQUENCES; MUTANTS	Using a genetic screen aimed at identifying cellular factors involved in Ty1 transposition, we have identified a mutation in a host gene that reduces Ty1 transposition frequency. The mutant, dbr1, is also defective in the process of intron turnover. In dbr1 cells, excised introns derived from a variety of pre-mRNAs are remarkably stable and accumulate to levels exceeding that of the corresponding mRNA. The stable excised introns accumulate in the form of a lariat that is missing the linear sequences 3' of the branchpoint. The DBR1 gene has been isolated by complementation of the transposition phenotype. DBR1 is shown to encode debranching enzyme, an RNA processing activity that hydrolyzes the 2'-5' phosphodiester linkage at the branchpoint of excised intron lariats. In Saccharomyces cerevisiae, debranching enzyme plays a requisite role in the rapid turnover of excised introns, yet its function is not essential for viability.			CHAPMAN, KB (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,725 N WOLFE ST,BALTIMORE,MD 21205, USA.				NCI NIH HHS [ET32 CA09139] Funding Source: Medline; NIGMS NIH HHS [GM-36481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENAS J, 1987, J BIOL CHEM, V262, P4274; AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BOEKE JD, 1988, SCIENCE, V239, P280, DOI 10.1126/science.2827308; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOEKE JD, 1989, MOBILE DNA; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; FLAVELL A, 1985, NATURE, V316, P574, DOI 10.1038/316574a0; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FURUICHI T, 1987, CELL, V48, P47, DOI 10.1016/0092-8674(87)90354-0; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; HWANG PK, 1986, NATURE, V324, P80, DOI 10.1038/324080a0; JACQUIER A, 1986, P NATL ACAD SCI USA, V83, P5835, DOI 10.1073/pnas.83.16.5835; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LAMPSON BC, 1989, CELL, V56, P701, DOI 10.1016/0092-8674(89)90592-8; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; RODRIGUEZ JR, 1984, CELL, V39, P603, DOI 10.1016/0092-8674(84)90467-7; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSKIN B, 1990, METHOD ENZYMOL, V181, P180; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SCHWINDINGER WF, 1987, J BIOL CHEM, V262, P5690; SHARP PA, 1987, COLD SPRING HARB SYM, V52, P277, DOI 10.1101/SQB.1987.052.01.033; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; WESSLER SR, 1989, GENE, V82, P127, DOI 10.1016/0378-1119(89)90037-1; XU H, 1990, MOL CELL BIOL, V10, P2695, DOI 10.1128/MCB.10.6.2695; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553	34	184	188	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					483	492		10.1016/0092-8674(91)90466-C	http://dx.doi.org/10.1016/0092-8674(91)90466-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1850323				2022-12-28	WOS:A1991FK18200015
J	NEBREDA, AR; MARTINZANCA, D; KAPLAN, DR; PARADA, LF; SANTOS, E				NEBREDA, AR; MARTINZANCA, D; KAPLAN, DR; PARADA, LF; SANTOS, E			INDUCTION BY NGF OF MEIOTIC MATURATION OF XENOPUS OOCYTES EXPRESSING THE TRK PROTOONCOGENE PRODUCT	SCIENCE			English	Article							BIOCHEMICAL-CHARACTERIZATION; RECEPTOR; PROTEINS; ACTIVATION; SEQUENCES	The effect of nerve growth factor (NGF) was assessed in Xenopus oocytes expressing the human trk proto-oncogene product, p140prototrk. Oocytes injected with trk messenger RNA expressed polypeptides recognized by antibodies to the trk gene product. Exposure of these oocytes to nanomolar amounts of NGF resulted in specific surface binding of I-125-labeled NGF, tyrosine phosphorylation of p140prototrk, and meiotic maturation, as determined by germinal vesicle breakdown and maturation promoting factor (p34cdc2) kinase activation. Thus the trk proto-oncogene product can act as a receptor for NGF in a functionally productive manner.	NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ADV BIOSCI LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Parada, luis F/B-9400-2014; Nebreda, Angel Rodriguez/R-9594-2019					ALLENDE CC, 1988, FEBS LETT, V234, P426, DOI 10.1016/0014-5793(88)80130-3; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BONGARZONE I, 1989, ONCOGENE, V4, P1457; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OPRESKO LK, 1990, J CELL BIOL, V111, P1661, DOI 10.1083/jcb.111.4.1661; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SEHGAL A, 1988, MOL CELL BIOL, V8, P2242, DOI 10.1128/MCB.8.5.2242; SMITH LD, 1989, DEVELOPMENT, V107, P685; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x	27	119	122	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					558	560		10.1126/science.1850550	http://dx.doi.org/10.1126/science.1850550			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850550				2022-12-28	WOS:A1991FJ12700044
J	VANTOL, HHM; BUNZOW, JR; GUAN, HC; SUNAHARA, RK; SEEMAN, P; NIZNIK, HB; CIVELLI, O				VANTOL, HHM; BUNZOW, JR; GUAN, HC; SUNAHARA, RK; SEEMAN, P; NIZNIK, HB; CIVELLI, O			CLONING OF THE GENE FOR A HUMAN DOPAMINE D4-RECEPTOR WITH HIGH-AFFINITY FOR THE ANTIPSYCHOTIC CLOZAPINE	NATURE			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; EXPRESSION; CDNA; PHOSPHORYLATION	DOPAMINE receptors belong to the family of G protein-coupled receptors. On the basis of the homology between these receptors, three different dopamine receptors (D1, D2, D3) have been cloned 1-7. Dopamine receptors are primary targets for drugs used in the treatment of psychomotor disorders such as Parkinson's disease and schizophrenia 8,9. In the management of socially withdrawn and treatment-resistant schizophrenics, clozapine 10 is one of the most favoured antipsychotics because it does not cause tardive dyskinesia 11. Clozapine, however, has dissociation constants for binding to D2 and D3 that are 4 to 30 times the therapeutic free concentration of clozapine in plasma water 12, 13. This observation suggests the existence of other types of dopamine receptors which are more sensitive to clozapine. Here we report the cloning of a gene that encodes such a receptor (D4). The D4 receptor gene has high homology to the human dopamine D2 and D3 receptor genes. The pharmacological characteristics of this receptor resembles that of the D2 and D3 receptors, but its affinity for clozapine is one order of magnitude higher. Recognition and characterization of this clozapine neuroleptic site may prove useful in the design of new types of drugs.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201; UNIV TORONTO,DEPT PSYCHIAT,TORONTO M5S 1A8,ONTARIO,CANADA; CLARKE INST PSYCHIAT,MOLEC NEUROBIOL LAB,TORONTO M5T 1R8,ONTARIO,CANADA	Oregon Health & Science University; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	VANTOL, HHM (corresponding author), UNIV TORONTO,DEPT PHARMACOL,MED SCI BLDG,TORONTO M5S 1A8,ONTARIO,CANADA.		Civelli, Olivier/A-8392-2012; Sunahara, Roger/AAJ-8667-2020					ACKENHEIL M, 1976, ARZNEIMITTEL-FORSCH, V26, P1156; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CASEY DE, 1989, PSYCHOPHARMACOLOGY, V99, pS47, DOI 10.1007/BF00442559; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GRAY PW, 1983, P NATL ACAD SCI-BIOL, V80, P5842, DOI 10.1073/pnas.80.19.5842; HAMER DH, 1979, CELL, V18, P1299, DOI 10.1016/0092-8674(79)90240-X; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P461; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; SANCHEZROA PM, 1989, LIFE SCI, V45, P1821, DOI 10.1016/0024-3205(89)90523-7; SEEMAN P, 1988, ISI ATLAS-PHARMACOL, V2, P161; SEEMAN P, 1979, EUR J PHARMACOL, V56, P247, DOI 10.1016/0014-2999(79)90177-8; SEEMAN P, 1987, NEUROPSYCHOPHARMACOL, V1, P5, DOI 10.1016/0893-133X(87)90004-2; SEEMAN P, 1990, ACTA PSYCHIAT SCAND, V82, P14, DOI 10.1111/j.1600-0447.1990.tb05280.x; SEEMAN P, 1987, SYNAPSE, V1, P152; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STORMANN TM, 1990, MOL PHARMACOL, V37, P1; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0; 1990, CLOZARIL SUMMARY PRE	32	1951	2000	2	101	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					610	614		10.1038/350610a0	http://dx.doi.org/10.1038/350610a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	1840645				2022-12-28	WOS:A1991FH11200060
J	FITZPATRICK, R				FITZPATRICK, R			SURVEYS OF PATIENT SATISFACTION .1. IMPORTANT GENERAL-CONSIDERATIONS	BRITISH MEDICAL JOURNAL			English	Article							DIMENSIONS				FITZPATRICK, R (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND.							BAKER R, 1990, BRIT J GEN PRACT, V40, P487; BOLLAM MJ, 1988, BRIT MED J, V296, P829, DOI 10.1136/bmj.296.6625.829; DIMATTEO MR, 1980, MED CARE, V18, P376, DOI 10.1097/00005650-198004000-00003; DIXON P, 1989, NHS ITS CUSTOMERS, V3; FEINSTEIN AR, 1977, CLIN PHARMACOL THER, V22, P485; Fitzpatrick R, 1983, Sociol Health Illn, V5, P297, DOI 10.1111/1467-9566.ep10491836; Fitzpatrick R., 1984, EXPERIENCE ILLNESS, P154; Fitzpatrick R M, 1987, Int Disabil Stud, V9, P161; FITZPATRICK RM, 1983, SOC SCI MED, V17, P501, DOI 10.1016/0277-9536(83)90057-6; HALL JA, 1988, SOC SCI MED, V27, P935, DOI 10.1016/0277-9536(88)90284-5; Hopkins A., 1990, MEASURING QUALITY ME; HOPKINS A, 1990, MEASURING OUTCOMES M; Kincey J, 1975, J R Coll Gen Pract, V25, P558; KORSCH BM, 1968, PEDIATRICS, V42, P855; MAXWELL RJ, 1984, BRIT MED J, V288, P1470, DOI 10.1136/bmj.288.6428.1470; RASHID A, 1990, BRIT MED J, V299, P1015; ROGHMANN KJ, 1979, MED CARE, V17, P461, DOI 10.1097/00005650-197905000-00002; ROTER DL, 1987, MED CARE, V25, P437, DOI 10.1097/00005650-198705000-00007; SAVAGE R, 1990, BRIT MED J, V301, P968, DOI 10.1136/bmj.301.6758.968; SIRA ZB, 1980, J HEALTH SOC BEHAV, V21, P170; STILES WB, 1979, MED CARE, V17, P667, DOI 10.1097/00005650-197906000-00010; WARE JE, 1975, MED CARE, V13, P669, DOI 10.1097/00005650-197508000-00006; WEISS BD, 1990, MED CARE, V28, P434, DOI 10.1097/00005650-199005000-00003; 1985, QUALITY GENERAL PRAC; 1983, NHS MANAGEMENT INQUI; 1989, CMND555	26	412	434	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					887	889		10.1136/bmj.302.6781.887	http://dx.doi.org/10.1136/bmj.302.6781.887			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FG421	1821624	Green Published, Bronze			2022-12-28	WOS:A1991FG42100026
J	SELIKOFF, IJ; GREENBERG, M				SELIKOFF, IJ; GREENBERG, M			A LANDMARK CASE IN ASBESTOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The first published account of disease attributed to occupational asbestos exposure was that of Nellie Kershaw, who died in 1924. The circumstances relating to that case are described and explanations are given for its not having a greater impact on policy at that time. This case, starting in 1898, is set in the context of missed opportunities for preventing a major public health hazard. The effects of this hazard are still being witnessed today.	CUNY MT SINAI SCH MED, DEPT COMMUNITY MED, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								AURIBAULT M, 1906, B INSPECTION TRAVAIL, V14, P120; Cooke WE, 1927, BRIT MED J, V1927, P1024, DOI 10.1136/bmj.2.3491.1024; Cooke WE, 1924, BMJ-BRIT MED J, V1924, P147, DOI 10.1136/bmj.2.3317.147; Doll R, 1955, BRIT J IND MED, V12, P81; Haddow AC, 1929, BRIT MED J, V1929, P580, DOI 10.1136/bmj.2.3586.580; Hoffman FI, 1918, B US BUREAU LABOR ST, V231, P176; KNOX JF, 1968, BRIT J IND MED, V25, P293; KNOX JF, 1965, ANN NY ACAD SCI, V132, P526, DOI 10.1111/j.1749-6632.1965.tb41133.x; LEE DHK, 1979, ENVIRON RES, V18, P300, DOI 10.1016/0013-9351(79)90107-5; Legge T, 1934, IND MALADIES, P190; LEWINSOHN HC, 1972, J ROY SOC HEALTH, V12, P69; Merewether E. R. A., 1930, REPORT EFFECTS ASBES; Pancoast HK, 1918, AM J ROENTGENOL, V5, P129; PETO J, 1977, BRIT J IND MED, V34, P169; 1902, ANN REPORT 1901; 1976, LANCET, V1, P944; 1907, 3946 DEP COMM COMP I; 1911, ANN REPORT YEAR 1910; 1931, 1140 HM STAT OFF COM; 1899, ANN REPORT YEAR 1898	20	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					898	901		10.1001/jama.265.7.898	http://dx.doi.org/10.1001/jama.265.7.898			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1825122				2022-12-28	WOS:A1991EX58700043
J	GIRARD, F; STRAUSFELD, U; FERNANDEZ, A; LAMB, NJC				GIRARD, F; STRAUSFELD, U; FERNANDEZ, A; LAMB, NJC			CYCLIN-A IS REQUIRED FOR THE ONSET OF DNA-REPLICATION IN MAMMALIAN FIBROBLASTS	CELL			English	Article							DEPENDENT PROTEIN-KINASE; EMBRYONIC-CELL CYCLE; SEA-URCHIN EGGS; MESSENGER-RNA; TYROSINE PHOSPHORYLATION; M-PHASE; P34CDC2; CDC2; DROSOPHILA; EXTRACTS	Cyclin A protein is synthesized and localized into the nucleus at the onset of S phase in nontransformed mammalian fibroblasts. Inhibition of cyclin A synthesis or activity through microinjection of plasmids encoding antisense cyclin A cDNA or affinity-purified anti-cyclin A antibodies during G1 phase was shown to abolish the nuclear staining for cyclin A in plasmid-injected cells, and both procedures led to inhibition of DNA synthesis. No similar effect was observed with injection of other antisense vectors including antisense cyclin B, and reinjection of purified human cyclin A protein into cyclin A antisense-injected cells effectively relieved this inhibition of DNA synthesis. Taken together, these data suggest that cyclin A plays a major role in the control of DNA replication in mammalian cells.			GIRARD, F (corresponding author), CNRS, CRBM, CELL BIOL UNIT, INSERM, BP 5051, F-34033 MONTPELLIER, FRANCE.			Girard, Franck/0000-0003-2587-4495				BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FORSBURG SL, 1991, NATURE, V351, P245, DOI 10.1038/351245a0; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McClure DB, 1982, COLD SPRING HARBOR C, V9, P345; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	47	863	876	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1169	1179		10.1016/0092-8674(91)90293-8	http://dx.doi.org/10.1016/0092-8674(91)90293-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1836977				2022-12-28	WOS:A1991GX16400015
J	ALBERS, GW; ATWOOD, JE; HIRSH, J; SHERMAN, DG; HUGHES, RA; CONNOLLY, SJ				ALBERS, GW; ATWOOD, JE; HIRSH, J; SHERMAN, DG; HUGHES, RA; CONNOLLY, SJ			STROKE PREVENTION IN NONVALVULAR ATRIAL-FIBRILLATION	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							THROMBOEMBOLIC COMPLICATIONS; RISK-FACTORS; ANTICOAGULANT-THERAPY; EXERCISE PERFORMANCE; NATURAL-HISTORY; SINUS RHYTHM; FRAMINGHAM; STANDARDIZATION; CARDIOVERSION; MAINTENANCE	There has been considerable uncertainty about the best way to prevent stroke in patients with nonvalvular atrial fibrillation. Recent studies have suggested that low-dose warfarin therapy, in addition to producing fewer bleeding complications, may be as effective as higher-dose therapy in preventing thromboembolic events. Four large, prospective, randomized trials have examined the risks and benefits of warfarin therapy for stroke prophylaxis in patients with nonvalvular atrial fibrillation. All four studies showed a substantially reduced incidence of stroke and a low incidence of significant bleeding in patients treated with warfarin. One of these studies also showed that aspirin reduced the incidence of stroke. The benefits associated with long-term low-dose warfarin therapy appear to exceed the risks for serious bleeding in most patients with atrial fibrillation. Aspirin may be a viable therapeutic option for patients who are unable to take warfarin or for those in subgroups at a low risk for stroke.	STANFORD UNIV, MED CTR, DEPT NEUROL & NEUROL SCI, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, DIV CARDIOL, STANFORD, CA 94305 USA; MCMASTER UNIV, FAC HLTH SCI, HAMILTON L8L 2X2, ONTARIO, CANADA; HAMILTON CIV HOSP, RES CTR, HAMILTON L8V 1C3, ONTARIO, CANADA; UNIV TEXAS, HLTH SCI CTR, DIV NEUROL, SAN ANTONIO, TX 78284 USA	Stanford University; Stanford University; McMaster University; McMaster University; University of Texas System; University of Texas Health San Antonio	ALBERS, GW (corresponding author), PALO ALTO VET AFFAIRS MED CTR, PALO ALTO, CA 94304 USA.			Albers, Gregory/0000-0003-0263-4632				ALBERS GW, 1991, ANN NEUROL, V30, P511, DOI 10.1002/ana.410300402; [Anonymous], 1989, Arch Neurol, V46, P727; ARONOW WS, 1989, AM J CARDIOL, V63, P366, DOI 10.1016/0002-9149(89)90349-4; ATWOOD JE, 1988, CHEST, V93, P20, DOI 10.1378/chest.93.1.20; ATWOOD JE, 1987, J AM COLL CARDIOL, V10, P314; BJERKELUND CJ, 1969, AM J CARDIOL, V23, P208, DOI 10.1016/0002-9149(69)90068-X; BRAND FN, 1985, JAMA-J AM MED ASSOC, V254, P3449, DOI 10.1001/jama.254.24.3449; BRECKENRIDGE AM, 1977, DRUGS, V14, P367, DOI 10.2165/00003495-197714050-00003; BRODSKY MA, 1989, AM J CARDIOL, V63, P1065, DOI 10.1016/0002-9149(89)90079-9; BROZOVIC M, 1978, SEMIN HEMATOL, V15, P27; Close J B, 1979, J R Coll Gen Pract, V29, P547; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; DEBELDER MA, 1989, CIRCULATION, V80, pS1; DEYKIN D, 1970, NEW ENGL J MED, V283, P801, DOI 10.1056/NEJM197010082831508; DITTRICH HC, 1989, AM J CARDIOL, V63, P193, DOI 10.1016/0002-9149(89)90284-1; DOLHABERRIAGUE L, 1989, STROKE, V20, P1648, DOI 10.1161/01.STR.20.12.1648; DUNN M, 1989, CHEST, V95, pS118, DOI 10.1378/chest.95.2_Supplement.118S; FLEGEL KM, 1989, STROKE, V20, P1000, DOI 10.1161/01.STR.20.8.1000; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; GLANCY DL, 1970, BRIT HEART J, V32, P652; HART RG, 1986, ARCH NEUROL-CHICAGO, V43, P71; HELLEMANS J, 1963, BRIT J HAEMATOL, V9, P506, DOI 10.1111/j.1365-2141.1963.tb05475.x; HIRSH J, 1989, CHEST, V95, pS5, DOI 10.1378/chest.95.2.5S; HIRSH J, 1987, ARCH INTERN MED, V147, P769, DOI 10.1001/archinte.147.4.769; HIRSH J, 1988, THROMB HAEMOSTASIS, V59, P129; HURST JW, 1990, DM-DIS MON, V36, P247; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KIRKWOOD TBL, 1983, THROMB HAEMOSTASIS, V49, P238; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KITCHENS JM, 1986, J GEN INTERN MED, V1, P126, DOI 10.1007/BF02599816; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KULBERTUS HE, 1982, ATRIAL FIBRILLATION; LEVINE HJ, 1989, CHEST, V95, pS98, DOI 10.1378/chest.95.2.98S; MALONE SA, 1989, CIRCULATION, V80, pS1; MATSUZAKI M, 1990, CIRCULATION, V82, P709, DOI 10.1161/01.CIR.82.3.709; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MEIJLER FL, 1983, J AM COLL CARDIOL, V2, P391, DOI 10.1016/S0735-1097(83)80182-X; OREILLY RA, 1968, ANN NY ACAD SCI, V151, P913, DOI 10.1111/j.1749-6632.1968.tb11950.x; PETERSEN P, 1990, ARCH INTERN MED, V150, P819, DOI 10.1001/archinte.150.4.819; PETERSEN P, 1989, LANCET, V1, P175; PETERSEN P, 1990, STROKE, V21, P4, DOI 10.1161/01.STR.21.1.4; PLATIA EV, 1989, AM J CARDIOL, V63, P925, DOI 10.1016/0002-9149(89)90141-0; POLLER L, 1987, HEMATOL REV, V225, P41; PRESTI CF, 1989, AM HEART J, V117, P976, DOI 10.1016/0002-8703(89)90642-X; Quick AJ, 1935, J BIOL CHEM, V110, P107; ROY D, 1986, AM HEART J, V112, P1039, DOI 10.1016/0002-8703(86)90318-2; SHERMAN DG, 1984, ARCH NEUROL-CHICAGO, V41, P708, DOI 10.1001/archneur.1984.04050180030011; TEGELER CH, 1987, ANN NEUROL, V21, P315, DOI 10.1002/ana.410210323; VIGANO S, 1983, THROMB HAEMOSTASIS, V50, P310; WIENER I, 1987, AM J CARDIOL, V59, P177, DOI 10.1016/S0002-9149(87)80102-9; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; WRIGHT IS, 1954, LANCET, V1, P92; ZUCKER S, 1970, AM J CLIN PATHOL, V53, P348	55	65	65	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					727	736		10.7326/0003-4819-115-9-727	http://dx.doi.org/10.7326/0003-4819-115-9-727			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1834004				2022-12-28	WOS:A1991GL69700012
J	BOR, R; MILLER, R; JOHNSON, M				BOR, R; MILLER, R; JOHNSON, M			A TESTING TIME FOR DOCTORS - COUNSELING PATIENTS BEFORE AN HIV TEST	BRITISH MEDICAL JOURNAL			English	Article											BOR, R (corresponding author), ROYAL FREE HAMPSTEAD NHS TRUST,HIV & AIDS COUNSELLING UNIT,LONDON NW3 2QG,ENGLAND.							APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; LAFORET EG, 1976, JAMA-J AM MED ASSOC, V235, P1579, DOI 10.1001/jama.235.15.1579; MILLER R, 1988, AIDS GUIDE CLIN COUN; 1990, GUIDELINES COUNSELLI; 1988, HIV INFECTION AIDS E	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1991	303	6807					905	907		10.1136/bmj.303.6807.905	http://dx.doi.org/10.1136/bmj.303.6807.905			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK221	1809265	Green Published, Bronze			2022-12-28	WOS:A1991GK22100026
J	BELLACOSA, A; TESTA, JR; STAAL, SP; TSICHLIS, PN				BELLACOSA, A; TESTA, JR; STAAL, SP; TSICHLIS, PN			A RETROVIRAL ONCOGENE, AKT, ENCODING A SERINE-THREONINE KINASE CONTAINING AN SH2-LIKE REGION	SCIENCE			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; TYROSINE KINASES; CATALYTIC DOMAINS; PHOSPHOLIPASE-C; SRC; GENE; MUTAGENESIS; EXPRESSION; SIMILARITY; ACTIVATION	The v-akt oncogene codes for a 105-kilodalton fusion phosphoprotein containing Gag sequences at its amino terminus. Sequence analysis of v-akt and biochemical characterization of its product revealed that it codes for a protein kinase C-related serine-threonine kinase whose cellular homolog is expressed in most tissues, with the highest amount found in thymus. Although Akt is a serine-threonine kinase, part of its regulatory region is similar to the Src homology-2 domain, a structural motif characteristic of cytoplasmic tyrosine kinases that functions in protein-protein interactions. This suggests that Akt may form a functional link between tyrosine and serine-threonine phosphorylation pathways.	FOX CHASE CANC INST,DEPT MED ONCOL,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA-06927, CA-38047] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA038047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, UNPUB; BERTNESS VL, 1990, CANCER GENET CYTOGEN, V44, P47, DOI 10.1016/0165-4608(90)90196-H; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; ONO Y, 1988, J BIOL CHEM, V263, P6927; PAWSON T, 1988, ONCOGENE, V3, P491; REDDY EP, 1983, P NATL ACAD SCI USA, V80, P2623; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Staal SP, 1988, GENOMICS, V2, P96, DOI 10.1016/0888-7543(88)90114-0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TSICHLIS PN, IN PRESS CURR TOP MI; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEISS R, 1985, RNA TUMOR VIRUSES, V2, P139	32	777	820	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					274	277		10.1126/science.1833819	http://dx.doi.org/10.1126/science.1833819			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1833819				2022-12-28	WOS:A1991GJ64200035
J	CARRHILL, RA; MORRIS, J				CARRHILL, RA; MORRIS, J			CURRENT PRACTICE IN OBTAINING THE Q IN QALYS - A CAUTIONARY NOTE	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-STATUS				CARRHILL, RA (corresponding author), UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND.							BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; CARRHILL RA, 1989, SOC SCI MED, V29, P469, DOI 10.1016/0277-9536(89)90296-7; DEAN M, 1991, LANCET, V337, P480, DOI 10.1016/0140-6736(91)93408-2; DIXON AK, 1991, BRIT MED J, V302, P79, DOI 10.1136/bmj.302.6768.79; Goldberg DP., 1972, DETECTION PSYCHIATRI; Gudex C, 1988, QALY TOOLKIT; HUNT SM, 1980, J EPIDEMIOL COMMUN H, V34, P281, DOI 10.1136/jech.34.4.281; KAPLAN RM, 1988, HEALTH SERV RES, V23, P203; LEESE B, 1990, COSTS BENEFITS USE E; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; ROSSER RM, 1972, INT J EPIDEMIOL, V1, P361, DOI 10.1093/ije/1.4.361	11	41	41	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					699	701		10.1136/bmj.303.6804.699	http://dx.doi.org/10.1136/bmj.303.6804.699			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG980	1833014	Bronze, Green Published			2022-12-28	WOS:A1991GG98000026
J	WIKLER, KC; RAKIC, P				WIKLER, KC; RAKIC, P			RELATION OF AN ARRAY OF EARLY-DIFFERENTIATING CONES TO THE PHOTORECEPTOR MOSAIC IN THE PRIMATE RETINA	NATURE			English	Article							RHESUS-MONKEY RETINA; LINEAGE; GREEN; BLUE	THE retina of diurnal primates, including humans, contains a reiterative mosaic of red-, green- and blue-sensitive cones whose visual pigments are maximally sensitive to long, middle or short wavelengths, respectively 1. Although the distribution of the cone subtypes in the adult rhesus monkey has been quantified using opsin-specific antisera 2, the mechanism for the phenotypic specification of the cone subtypes and the establishment of their ratios in the retinal mosaic remain unknown. Here we present immunocytochemical evidence that a subset of cones (about 10%) express their cell-specific opsin two to three weeks before the surrounding cones. Remarkably, these precocious cones are evenly stationed throughout undifferentiated regions of the retinal surface from several weeks after their last mitotic division 3, and at least one month before the formation of their synapses with bipolar and horizontal cells 4. Use of confocal laser microscopy reveals that the inner segments of immunolabelled and surrounding unlabelled cones are transiently in apposition with one another, enabling surface mediated interactions to occur during this period. We suggest that the early maturing cones induce neighbouring undifferentiated cones to express an appropriate opsin phenotype, and therefore constitute a 'protomap' for the emergence of the species-specific retinal mosaic.			WIKLER, KC (corresponding author), YALE UNIV,SCH MED,NEUROBIOL SECT,POB 3333,NEW HAVEN,CT 06510, USA.							ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; CURCIO C A, 1989, Society for Neuroscience Abstracts, V15, P1206; FINLAY BL, 1989, DEV VERTEBRATE RETIN; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; Jacobs GH, 1981, COMP COLOR VISION; JOHNSON LV, 1988, INVEST OPHTH VIS SCI, V29, P550; LAVAIL M, 1983, INVEST OPHTHALMOL, V24, P7; LAVAIL MM, IN PRESS J COMP NEUR; LEREA CL, 1989, NEURON, V3, P367, DOI 10.1016/0896-6273(89)90261-4; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NISHIMURA Y, 1985, J COMP NEUROL, V241, P420, DOI 10.1002/cne.902410403; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAPAPORT DH, 1982, DEV BRAIN RES, V5, P273, DOI 10.1016/0165-3806(82)90126-2; REH TA, 1989, J NEUROSCI, V9, P417; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WATANABE T, 1990, NEURON, V2, P461; WETTS R, 1989, DEV BIOL, V136, P254, DOI 10.1016/0012-1606(89)90146-2; WIKLER KC, 1990, J COMP NEUROL, V297, P499, DOI 10.1002/cne.902970404; WIKLER KC, 1990, J NEUROSCI, V10, P3390	20	77	77	1	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					397	400		10.1038/351397a0	http://dx.doi.org/10.1038/351397a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	1827876				2022-12-28	WOS:A1991FN85600055
J	SHARMA, HM; TRIGUNA, BD; MARTAND, AV; CHOPRA, D				SHARMA, HM; TRIGUNA, BD; MARTAND, AV; CHOPRA, D			MAHARISHI AYUR-VEDA - MODERN INSIGHTS INTO ANCIENT-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANSCENDENTAL MEDITATION; ANTINEOPLASTIC PROPERTIES; CARE		ALL INDIA AYUR VEDA CONGRESS,NEW DELHI,INDIA; AMER ASSOC AYURVED MED,LANCASTER,MA		SHARMA, HM (corresponding author), OHIO STATE UNIV,COLL MED,DEPT PATHOL,ROOM M3685L,320 W 10TH AVE,COLUMBUS,OH 43210, USA.							ALEXANDER CN, 1989, J PERS SOC PSYCHOL, V57, P950, DOI 10.1037/0022-3514.57.6.950; CHOPRA D, 1990, PERFECT HLTH; Chopra Deepak, 1989, QUANTUM HEALING EXPL; Chopra R., 1982, INDIGENOUS DRUGS IND; DILEEPAN KN, 1990, BIOCHEM ARCH, V6, P267; GHISAGRANTNE KL, 1963, SUSHRUTA SAMHITA; Janssen G., 1989, NED TIJDSCHR GENEES, V5, P586; NIWA Y, 1991, INDIAN J CLIN PRACT, V1, P23; ORMEJOHNSON D, 1987, PSYCHOSOM MED, V49, P493, DOI 10.1097/00006842-198709000-00006; ORMEJOHNSON DW, 1988, J CONFLICT RESOLUT, V32, P776, DOI 10.1177/0022002788032004009; PATEL V, 1990, FASEB Journal, V4, pA637; PRASAD KN, 1990, 8TH BIENN M INT SOC; SCHNEIDER RH, 1990, J SOC BEHAV PERS, V5, P1; SHARMA HM, 1990, EUR J PHARMACOL, V183, P193, DOI 10.1016/0014-2999(90)93027-N; SHARMA HM, 1990, PHARMACOL BIOCHEM BE, V35, P767, DOI 10.1016/0091-3057(90)90356-M; SHARMA HM, 1989, CLIN TER CARDIOVAS, V8, P227; SHARMA RK, 1977, CHARAKA SAMHITA; THYAGARAJAN SP, 1988, LANCET, V2, P764; VASISHTA SD, 1983, ESSENCE PULSE DIAGNO; WALLACE RK, 1970, SCIENCE, V167, P1751, DOI 10.1126/science.167.3926.1751; Zaman H, 1974, TRADITIONAL MED, P231	21	29	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2633	&						0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	1817464				2022-12-28	WOS:A1991FL98900001
J	LI, R; KNIGHT, JD; JACKSON, SP; TJIAN, R; BOTCHAN, MR				LI, R; KNIGHT, JD; JACKSON, SP; TJIAN, R; BOTCHAN, MR			DIRECT INTERACTION BETWEEN SP1 AND THE BPV ENHANCER E2-PROTEIN MEDIATES SYNERGISTIC ACTIVATION OF TRANSCRIPTION	CELL			English	Article							BOVINE PAPILLOMAVIRUS TYPE-1; DNA-BINDING PROTEINS; CARBOXY-TERMINAL DOMAIN; LONG CONTROL REGION; TRANS-ACTIVATOR; MUTATIONAL ANALYSIS; GENE-EXPRESSION; MAMMALIAN-CELLS; E2 PROTEIN; PROMOTER	The physical interaction of heterologous site-specific DNA-binding proteins is an important theme in eukaryotic transcriptional regulation. In this paper, we show that the cellular transcription factor Sp1 and the BPV-1 (bovine papillomavirus type 1) enhancer protein E2 activate transcription synergistically from two papilloma viral promoters and a series of synthetic promoter constructs in transient transfection experiments. Furthermore, Sp1 can target E2 to a promoter region even in the absence of a specific E2 DNA-binding motif. Biochemical experiments establish that Sp1 enhances E2 binding to its sites and that the two proteins form a specific complex. Sp1 sequesters distally bound E2 to the promoter region by formation of stable DNA loops, visualized by electron microscopy. These experiments substantiate the notion that enhancer binding proteins are targeted to promoter regions by direct interaction with proteins that bind proximal to the transcriptional start site.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley	LI, R (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELLULAR BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.		Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Jackson, Stephen Philip/0000-0001-9317-7937				ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BAKER CC, 1987, EMBO J, V6, P1027, DOI 10.1002/j.1460-2075.1987.tb04855.x; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOSTATNI N, 1988, EMBO J, V7, P3807, DOI 10.1002/j.1460-2075.1988.tb03265.x; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAUGEN TH, 1987, EMBO J, V6, P145, DOI 10.1002/j.1460-2075.1987.tb04732.x; HAUGEN TH, 1988, EMBO J, V7, P4245, DOI 10.1002/j.1460-2075.1988.tb03322.x; HEIKE T, 1989, EMBO J, V8, P1411, DOI 10.1002/j.1460-2075.1989.tb03522.x; HERMONAT PL, 1987, J VIROL, V61, P3889, DOI 10.1128/JVI.61.12.3889-3895.1987; HERMONAT PL, 1988, EMBO J, V7, P2815, DOI 10.1002/j.1460-2075.1988.tb03137.x; HIROCHIKA H, 1988, GENE DEV, V2, P54, DOI 10.1101/gad.2.1.54; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KIM CH, 1987, P NATL ACAD SCI USA, V84, P6025, DOI 10.1073/pnas.84.17.6025; KNIGHT J, 1981, IN PRESS P NATL ACAD; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MCBRIDE AA, 1988, EMBO J, V7, P533, DOI 10.1002/j.1460-2075.1988.tb02842.x; MCBRIDE AA, 1989, P NATL ACAD SCI USA, V86, P510, DOI 10.1073/pnas.86.2.510; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MOSKALUK C, 1987, P NATL ACAD SCI USA, V84, P1215, DOI 10.1073/pnas.84.5.1215; MULLER HP, 1990, TRENDS GENET, V6, P300, DOI 10.1016/0168-9525(90)90236-Y; PRAKASH SS, 1988, J VIROL, V62, P3608, DOI 10.1128/JVI.62.10.3608-3613.1988; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROBBINS P, 1985, EUKARYOTIC TRANSCRIP, P41; ROBBINS PD, 1986, MOL CELL BIOL, V6, P1283, DOI 10.1128/MCB.6.4.1283; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SPALHOLZ BA, 1987, J VIROL, V61, P2128, DOI 10.1128/JVI.61.7.2128-2137.1987; SPALHOLZ BA, 1991, J VIROL, V65, P743, DOI 10.1128/JVI.65.2.743-753.1991; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; SPALHOLZ BA, 1988, J VIROL, V62, P2128; STENLUND A, 1985, J MOL BIOL, V182, P541, DOI 10.1016/0022-2836(85)90240-2; STENLUND A, 1990, GENE DEV, V4, P123, DOI 10.1101/gad.4.1.123; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; SU W, 1991, IN PRESS GENES DEV; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; THEVENY B, 1987, NATURE, V329, P79, DOI 10.1038/329079a0; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VAILLANCOURT P, 1990, J VIROL, V64, P3927, DOI 10.1128/JVI.64.8.3927-3937.1990; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0	70	301	304	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					493	505		10.1016/0092-8674(91)90467-D	http://dx.doi.org/10.1016/0092-8674(91)90467-D			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1850324				2022-12-28	WOS:A1991FK18200016
J	ACHAORBEA, H; SHAKHOV, AN; SCARPELLINO, L; KOLB, E; MULLER, V; VESSAZSHAW, A; FUCHS, R; BLOCHLINGER, K; ROLLINI, P; BILLOTTE, J; SARAFIDOU, M; MACDONALD, HR; DIGGELMANN, H				ACHAORBEA, H; SHAKHOV, AN; SCARPELLINO, L; KOLB, E; MULLER, V; VESSAZSHAW, A; FUCHS, R; BLOCHLINGER, K; ROLLINI, P; BILLOTTE, J; SARAFIDOU, M; MACDONALD, HR; DIGGELMANN, H			CLONAL DELETION OF V-BETA 14-BEARING T-CELLS IN MICE TRANSGENIC FOR MAMMARY-TUMOR VIRUS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LONG TERMINAL REPEAT; POSITIVE SELECTION; PROVIRAL DNA; MOUSE; RECEPTOR; TOLERANCE; REGION; MLSA; DETERMINANTS	Autoreactive T lymphocytes are clonally deleted during maturation in the thymus. Deletion of T cells expressing particular receptor V-beta elements is controlled by poorly defined autosomal dominant genes. A gene has now been identified by expression of transgenes in mice which causes deletion of V-beta-14+ T cells. The gene lies in the open reading frame of the long terminal repeat of the mouse mammary tumour virus.	UNIV ZURICH,INST IMMUNOL & VIROL,CH-8051 ZURICH,SWITZERLAND; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of Zurich; Swiss Institute Experimental Cancer Research	ACHAORBEA, H (corresponding author), LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND.							ABE R, 1989, J EXP MED, V170, P1059, DOI 10.1084/jem.170.4.1059; BEHLKE MA, 1986, P NATL ACAD SCI USA, V83, P767, DOI 10.1073/pnas.83.3.767; BERUMEN L, 1983, EUR J IMMUNOL, V13, P292, DOI 10.1002/eji.1830130405; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BLOCHLINGER K, 1986, THESIS U LAUSANNE; BUETTI E, 1981, CELL, V23, P335, DOI 10.1016/0092-8674(81)90129-X; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; EICHER EM, 1990, GENETICS, V125, P431; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; KUO WL, 1988, J VIROL, V62, P2394, DOI 10.1128/JVI.62.7.2394-2402.1988; LEE BK, 1990, J VIROL, V64, P4568, DOI 10.1128/JVI.64.9.4568-4572.1990; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; MACDONALD HR, 1988, NATURE, V336, P471, DOI 10.1038/336471a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MACDONALD HR, 1989, PROGR IMMUNOLOGY, V7, P561; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHALIDES R, 1981, CELL, V23, P165, DOI 10.1016/0092-8674(81)90281-6; MOLINA IJ, 1989, J IMMUNOL, V143, P39; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PULLEN AM, 1989, J IMMUNOL, V142, P3033; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; SALMONS B, 1990, J VIROL, V64, P6355, DOI 10.1128/JVI.64.12.6355-6359.1990; SCHNEIDER R, 1989, J EXP MED, V169, P2149, DOI 10.1084/jem.169.6.2149; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SINGER PA, 1990, EMBO J, V9, P3641, DOI 10.1002/j.1460-2075.1990.tb07575.x; SPEISER DE, 1989, J EXP MED, V170, P595, DOI 10.1084/jem.170.2.595; TSUBURA A, 1988, CANCER RES, V48, P6555; VACCHIO MS, 1990, J EXP MED, V172, P807, DOI 10.1084/jem.172.3.807; VANKLAVERENP, 1988, J VIROL, V62, P4410; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEBB SR, 1989, J EXP MED, V169, P1, DOI 10.1084/jem.169.1.1; WELLINGER RJ, 1986, J VIROL, V60, P1; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0	51	317	323	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					207	211		10.1038/350207a0	http://dx.doi.org/10.1038/350207a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1848685				2022-12-28	WOS:A1991FC77900047
J	CATTERALL, WA				CATTERALL, WA			EXCITATION CONTRACTION COUPLING IN VERTEBRATE SKELETAL-MUSCLE - A TALE OF 2 CALCIUM CHANNELS	CELL			English	Review							SARCOPLASMIC-RETICULUM; DIHYDROPYRIDINE RECEPTORS; RYANODINE RECEPTOR; COMPLEMENTARY-DNA; RELEASE CHANNEL; BETA-SUBUNIT; PHOSPHORYLATION; EXPRESSION; ALPHA-1-SUBUNIT; RECONSTITUTION				CATTERALL, WA (corresponding author), UNIV WASHINGTON,DEPT ANAT,SEATTLE,WA 98195, USA.							ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; ARREOLA J, 1987, J PHYSIOL-LONDON, V393, P307, DOI 10.1113/jphysiol.1987.sp016825; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CURTIS BM, 1986, BIOCHEMISTRY-US, V25, P3077, DOI 10.1021/bi00359a002; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; FLUCHER BE, 1990, NEURON, V5, P339, DOI 10.1016/0896-6273(90)90170-K; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P4290, DOI 10.1073/pnas.85.12.4290; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LAI FA, 1990, J BIOL CHEM, V265, P20839; NUNOKI K, 1989, P NATL ACAD SCI USA, V86, P6816, DOI 10.1073/pnas.86.17.6816; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHWARTZ LM, 1985, NATURE, V314, P747, DOI 10.1038/314747a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0	27	179	180	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					871	874		10.1016/0092-8674(91)90309-M	http://dx.doi.org/10.1016/0092-8674(91)90309-M			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1848157				2022-12-28	WOS:A1991FA94000002
J	GERARD, NP; GERARD, C				GERARD, NP; GERARD, C			THE CHEMOTACTIC RECEPTOR FOR HUMAN-C5A ANAPHYLATOXIN	NATURE			English	Article							BETA-ADRENERGIC-RECEPTOR; C5A RECEPTOR; CLONING; CDNA; C3A	HOST defence and inflammatory responses are controlled and amplified by receptor-mediated events often initiated by a chemotactic factor that directs the approach of phagocytic cells 1. Complement receptors CR1 and CR3 are responsible for the phagocytic and adhesive properties of neutrophils 2,3, whereas the C5a receptor mediates the pro-inflammatory and chemotactic actions of the complement anaphylatoxin C5a 4-6. In addition stimulating chemotaxis, granule enzyme release and superoxide anion production, this receptor stimulates upregulation of expression and activity of the adhesion molecule MAC-1, and of CR1, and a decrease in cell-surface glycoprotein 100MEL-14 on neutrophils 7-9. In vivo, the C5a receptor may participate in anaphylactoid and septic shock. The human C5a receptor was cloned from U937 and HL-60 cells and identified by high affinity binding when expressed in COS-7 cells. The deduced amino-acid sequence of the receptor reveals the expected motifs befitting its interaction with cellular GTP-binding proteins.	BETH ISRAEL HOSP, DIV PULM, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	GERARD, NP (corresponding author), CHILDRENS HOSP MED CTR, INA SUE PERLMUTTER RES LAB, BOSTON, MA 02115 USA.							AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; ARUFFO A, 1990, P NATL ACAD SCI USA, V265, P20455; BIRNBAUMER L, 1990, AM REV RESPIR DIS, V141, pS106, DOI 10.1164/ajrccm/141.3_Pt_2.S106; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; COTECCHIA S, 1985, LIFE SCI, V37, P2389, DOI 10.1016/0024-3205(85)90106-7; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DELBALZO U, 1989, CIRC RES, V65, P847, DOI 10.1161/01.RES.65.3.847; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; FELTNER DE, 1986, J IMMUNOL, V137, P1961; GERARD NP, 1990, BIOCHEMISTRY-US, V29, P9274, DOI 10.1021/bi00491a024; GERARD NP, 1990, J BIOL CHEM, V265, P20455; HACK CE, 1989, AM J MED, V86, P20, DOI 10.1016/0002-9343(89)90224-6; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; JOHNSON RJ, 1985, J BIOL CHEM, V260, P7161; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; ROLLINS TE, 1985, J BIOL CHEM, V260, P7157; SNYDERMAN R, 1986, MED CLIN N AM, V70, P217, DOI 10.1016/S0025-7125(16)30951-8; STIMLERGERARD NP, 1980, AM J PATHOL, V100, P1057; WARD PA, 1974, AM J PATHOL, V77, P519	23	628	662	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 14	1991	349	6310					614	617		10.1038/349614a0	http://dx.doi.org/10.1038/349614a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	1847994				2022-12-28	WOS:A1991EX57000061
J	MURPH, JR; BARON, JC; BROWN, CK; EBELHACK, CL; BALE, JF				MURPH, JR; BARON, JC; BROWN, CK; EBELHACK, CL; BALE, JF			THE OCCUPATIONAL RISK OF CYTOMEGALOVIRUS-INFECTION AMONG DAY-CARE PROVIDERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIRUS INFECTION; MOLECULAR EPIDEMIOLOGY; CHILDREN; TRANSMISSION; PREGNANCY; CENTERS; PARENTS	We prospectively studied day-care providers at six day-care centers in southeastern Iowa to determine their occupational risk for primary cytomegalovirus infection and to define epidemiologic risk factors. Ninety-six (38%) of 252 day-care providers were seropositive for cytomegalovirus by latex agglutination at entry into the study. Among 82 seronegative providers available for follow-up, seven seroconversions occurred at only two of the six participating centers, yielding an annualized seroconversion rate of 7.9%. Median time to seroconversion among these providers was 13 months. Using Kaplan-Meier estimates of risk, we determined that the overall risk of seroconversion among providers at various centers ranged from 0% to 22% by 12 months and from 0% to 40% by 16 months. Risk of cytomegalovirus acquisition by providers was independent of race, age, education, the presence of a child at home, or caring for children younger than 2 or 3 years in the day-care center. However, the risk of seroconversion among day-care providers appeared to parallel rates of cytomegalovirus excretion and acquisition among children at each center.	UNIV IOWA,COLL MED,DIV GEN PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DIV PEDIAT NEUROL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PREVENT MED & ENVIRONM HLTH,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa	MURPH, JR (corresponding author), UNIV IOWA HOSP & CLIN,DIV GEN PEDIAT,2474 JCP,IOWA CITY,IA 52242, USA.				NICHD NIH HHS [HD 22136] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022136] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADLER SP, 1985, J INFECT DIS, V152, P760, DOI 10.1093/infdis/152.4.760; ADLER SP, 1988, J PEDIATR-US, V112, P366, DOI 10.1016/S0022-3476(88)80314-7; ADLER SP, 1989, NEW ENGL J MED, V321, P1290, DOI 10.1056/NEJM198911093211903; AHLFORS K, 1982, ACTA PAEDIATR SCAND, V71, P109, DOI 10.1111/j.1651-2227.1982.tb09380.x; BALCAREK KB, 1990, JAMA-J AM MED ASSOC, V263, P840, DOI 10.1001/jama.263.6.840; BALFOUR CL, 1986, JAMA-J AM MED ASSOC, V256, P1909, DOI 10.1001/jama.256.14.1909; BLACKMAN JA, 1987, PEDIATR INFECT DIS J, V6, P725, DOI 10.1097/00006454-198708000-00006; GRIFFITHS PD, 1984, BRIT J OBSTET GYNAEC, V91, P307, DOI 10.1111/j.1471-0528.1984.tb05915.x; HUTTO C, 1985, PEDIATR INFECT DIS J, V4, P149, DOI 10.1097/00006454-198503000-00008; JONES LA, 1985, J INFECT DIS, V151, P953, DOI 10.1093/infdis/151.5.953; KALBFLEISH JD, 1980, STATISTICAL ANAL FAI, P143; MCHUGH TM, 1985, J CLIN MICROBIOL, V22, P1014, DOI 10.1128/JCM.22.6.1014-1019.1985; MURPH JR, 1988, AM J DIS CHILD, V142, P843, DOI 10.1001/archpedi.1988.02150080049020; MURPH JR, 1986, J PEDIATR-US, V109, P35, DOI 10.1016/S0022-3476(86)80568-6; PASS RF, 1990, PEDIATR INFECT DIS J, V9, P465, DOI 10.1097/00006454-199007000-00003; PASS RF, 1984, PEDIATRICS, V74, P121; PASS RF, 1986, NEW ENGL J MED, V314, P1414, DOI 10.1056/NEJM198605293142204; PASS RF, 1982, NEW ENGL J MED, V307, P477, DOI 10.1056/NEJM198208193070804; STAGNO S, 1986, JAMA-J AM MED ASSOC, V256, P1904, DOI 10.1001/jama.256.14.1904; 1987, USERS MANUAL STAT LI, P371	20	78	78	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	1991	265	5					603	608		10.1001/jama.265.5.603	http://dx.doi.org/10.1001/jama.265.5.603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV718	1846215				2022-12-28	WOS:A1991EV71800016
J	MILLER, NA; CARMICHAEL, HA; CALDER, BD; BEHAN, PO; BELL, EJ; MCCARTNEY, RA; HALL, FC				MILLER, NA; CARMICHAEL, HA; CALDER, BD; BEHAN, PO; BELL, EJ; MCCARTNEY, RA; HALL, FC			ANTIBODY TO COXSACKIE-B VIRUS IN DIAGNOSING POSTVIRAL FATIGUE SYNDROME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYALGIC ENCEPHALOMYELITIS; INFECTIOUS-MONONUCLEOSIS; GENERAL-PRACTICE; PERSISTENT; EPIDEMIC; ILLNESS; DISEASE; MUSCLE	Objective-To study the association between coxsackie B virus infection and the postviral fatigue syndrome and to assess the immunological abnormalities associated with the syndrome. Design - Case-control study of patients with the postviral fatigue syndrome referred by local general practitioners over one year. Setting - General practioner referrals in Dunbartonshire, Scotland. Patients - 254 Patients referred with the postviral fatigue syndrome (exhaustion, myalgia, and other symptoms referable to postviral fatigue syndrome of fairly recent onset - that is, several months) and age and sex matched controls obtained from same general practitioner; 11 patients were rejected because of wrong diagnoses, resolution of symptoms, and refusal to participate, leaving 243 patients and matched controls. Main outcome measures - Detailed questionnaire (patients and controls) and clinical examination (patients) and blind analysis of blood sample at entry and after six months for determination of coxsackie B virus IgM and IgG antibodies and other variables (including lymphocyte protein synthesis, lymphocyte subsets, and immune complexes). Results - Percentage positive rates for coxsackie B virus IgM at entry were 24.4% for patients and 22.6% for controls and for coxsackie B virus IgG 56.2% and 55.3% respectively; there were no significant differences between different categories of patients according to clinical likelihood of the syndrome nor any predictive value in a fourfold rise or fall in the coxsackie B virus IgG titre in patients between entry and review at six months. The rates of positive antibody test results in patients and controls showed a strong seasonal variation. Of the numerous immunological tests performed, only a few detected significant abnormalities; in particular the mean value for immune complex concentration was much higher in 35 patients and 35 controls compared with the normal range and mean value for total IgM was also raised in 227 patients and 35 controls compared with the normal range. Conclusions - Serological tests available for detecting coxsackie B virus antibodies do not help diagnose the postviral fatigue syndrome. Percentage positive rates of the antibodies in patients simply reflect the background in the population as probably do the raised concentrations of total IgM and immune complexes.	VALE LEVEN HOSP, ALEXANDRIA G83 0UA, DUNBARTON, SCOTLAND; UNIV GLASGOW, NEUROL, GLASGOW G12 8QQ, SCOTLAND; RUCHILL HOSP, REG VIRUS LAB, GLASGOW G20 9NB, SCOTLAND	University of Glasgow								ACHESON ED, 1959, AM J MED, V26, P569, DOI 10.1016/0002-9343(59)90280-3; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; ARCHARD LC, 1988, J EXP CLIN CANC RES, V7, P3; ARNOLD DL, 1984, LANCET, V1, P1367; BARNES DM, 1986, SCIENCE, V234, P541, DOI 10.1126/science.3020689; BEHAN PO, 1985, J INFECTION, V10, P211, DOI 10.1016/S0163-4453(85)92488-0; BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157; BELL EJ, 1983, SCOT MED J, V28, P157, DOI 10.1177/003693308302800212; BORYSIEWICZ LK, 1986, Q J MED, V58, P111; CALDER BD, 1984, J ROY COLL GEN PRACT, V34, P15; CALDER BD, 1987, J ROY COLL GEN PRACT, V37, P11; DILLON MJ, 1974, BRIT MED J, V1, P301, DOI 10.1136/bmj.1.5903.301; DUBOIS RE, 1984, SOUTHERN MED J, V77, P1376, DOI 10.1097/00007611-198411000-00007; FEGAN KG, 1983, J ROY COLL GEN PRACT, V33, P335; Grist N. R., 1979, DIAGNOSTIC METHODS C; HAMBLIN TJ, 1983, BRIT MED J, V287, P85, DOI 10.1136/bmj.287.6385.85; HENDERSON DA, 1959, NEW ENGL J MED, V260, P814, DOI 10.1056/NEJM195904162601606; HENDERSON DA, 1959, NEW ENGL J MED, V260, P757, DOI 10.1056/NEJM195904092601506; JAMAL GA, 1985, J NEUROL NEUROSUR PS, V48, P691, DOI 10.1136/jnnp.48.7.691; JONES JF, 1985, ANN INTERN MED, V102, P1, DOI 10.7326/0003-4819-102-1; KADIRY WA, 1983, PROG BRAIN RES, V59, P61; KEIGHLEY BD, 1983, J ROY COLL GEN PRACT, V33, P339; MCCARTNEY RA, 1986, J MED VIROL, V19, P205, DOI 10.1002/jmv.1890190302; POOLE M, 1984, NZ MED J, V97, P351; Ramsay AM, 1986, POSTVIRAL FATIGUE SY, V1st; RICE GPA, 1984, J NEUROIMMUNOL, V6, P75, DOI 10.1016/0165-5728(84)90028-6; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; TOBI M, 1982, LANCET, V1, P61; YOUSEF GE, 1988, LANCET, V1, P146	29	70	71	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 19	1991	302	6769					140	143		10.1136/bmj.302.6769.140	http://dx.doi.org/10.1136/bmj.302.6769.140			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU020	1847316	Green Published, Bronze			2022-12-28	WOS:A1991EU02000019
J	MAZUMDER, RN; NATH, SK; ASHRAF, H; PATRA, FC; ALAM, AN				MAZUMDER, RN; NATH, SK; ASHRAF, H; PATRA, FC; ALAM, AN			ORAL REHYDRATION SOLUTION CONTAINING TRISODIUM CITRATE FOR TREATING SEVERE DIARRHEA - CONTROLLED CLINICAL-TRIAL	BRITISH MEDICAL JOURNAL			English	Article							SODIUM-CITRATE; BICARBONATE; THERAPY				MAZUMDER, RN (corresponding author), INT CTR DIARRHOEL DIS RES,CLIN RES CTR,POB 128,DHAKA 1000,BANGLADESH.							HOFFMAN SL, 1985, J INFECT DIS, V152, P1159, DOI 10.1093/infdis/152.6.1159; ISLAM MR, 1984, GUT, V25, P900, DOI 10.1136/gut.25.8.900; NEWSOME PM, 1983, SCAND J GASTROENTERO, V18, P119; PATRA FC, 1989, BMJ-BRIT MED J, V298, P1353, DOI 10.1136/bmj.298.6684.1353; SIEWERT M, 1983, PHARMAZEUTISCHE ZEIT, V128, P1169	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					88	89		10.1136/bmj.302.6768.88	http://dx.doi.org/10.1136/bmj.302.6768.88			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1847315	Green Published, Bronze			2022-12-28	WOS:A1991ER95100019
J	SENTMAN, CL; SHUTTER, JR; HOCKENBERY, D; KANAGAWA, O; KORSMEYER, SJ				SENTMAN, CL; SHUTTER, JR; HOCKENBERY, D; KANAGAWA, O; KORSMEYER, SJ			BCL-2 INHIBITS MULTIPLE FORMS OF APOPTOSIS BUT NOT NEGATIVE SELECTION IN THYMOCYTES	CELL			English	Article							T-CELL-RECEPTOR; TRANSGENIC MICE; ANTIGEN RECEPTOR; THYMUS; GENE; INVIVO; EXPRESSION; SURVIVAL; PROTEIN; DEATH	The vast majority of cortical thymocytes die during T cell development while those that survive this selective process accumulate in the medulla. bcl-2, an inner mitochondrial membrane protein, has been shown to inhibit apoptosis in certain cell lines. In the thymus, bcl-2 is regionally localized to the mature T cells of the medulla. To assess the role of bcl-2 in the programmed death of thymocytes, we generated transgenic mice that redirected bcl-2 expression to cortical thymocytes. bcl-2 protected immature CD4+8+ thymocytes from glucocorticoid, radiation, and anti-CD3-induced apoptosis. Moreover, bcl-2 altered T cell maturation, resulting in increased percentages of CD3hi and CD4-8+ thymocytes. Despite this, clonal deletion of T cells that recognize endogenous superantigens still occurred. This transgenic model indicates that multiple death pathways operate within the thymus that can be distinguished by their dependence on bcl-2.	WASHINGTON UNIV, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	SENTMAN, CL (corresponding author), WASHINGTON UNIV, HOWARD HUGHES MED INST, DEPT MED, ST LOUIS, MO 63110 USA.				NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA49712-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; Blomgren H, 1970, Cell Immunol, V1, P545, DOI 10.1016/0008-8749(70)90041-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COHEN JJ, 1984, J IMMUNOL, V132, P38; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FINKEL TH, 1989, CELL, V58, P1047, DOI 10.1016/0092-8674(89)90503-5; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LUCKEHUHLE C, 1979, RADIAT RES, V79, P97, DOI 10.2307/3575025; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NETA R, 1988, J IMMUNOL, V140, P108; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PENIT C, 1986, J IMMUNOL, V137, P2115; PETRIE HT, 1990, J EXP MED, V172, P1583, DOI 10.1084/jem.172.6.1583; PEZZELLA F, 1990, AM J PATHOL, V137, P225; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHI YF, 1991, J IMMUNOL, V146, P3340; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TURKA LA, 1991, J IMMUNOL, V146, P1428; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	56	1259	1313	1	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					879	888		10.1016/0092-8674(91)90361-2	http://dx.doi.org/10.1016/0092-8674(91)90361-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1835668				2022-12-28	WOS:A1991GT75500007
J	LITTLE, JR				LITTLE, JR			STAPHYLOCOCCUS-AUREUS CARRIAGE IN THE NURSING-HOME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											LITTLE, JR (corresponding author), WASHINGTON UNIV, MED CTR, ST LOUIS, MO 63130 USA.							CEDERNA JE, 1990, INFECT CONT HOSP EP, V11, P13, DOI 10.1086/646072; MUDER RR, 1991, ANN INTERN MED, V114, P107, DOI 10.7326/0003-4819-114-2-1-107; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; STORCH GA, 1987, INFECT CONT HOSP EP, V8, P24, DOI 10.1017/S0195941700066947; STRAUSBAUGH LJ, 1991, INFECT CONT HOSP EP, V12, P36, DOI 10.2307/30147087	5	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1999	2000		10.1001/jama.266.14.1999	http://dx.doi.org/10.1001/jama.266.14.1999			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1823539				2022-12-28	WOS:A1991GH40600030
J	BRUNK, BP; MARTIN, EC; ADLER, PN				BRUNK, BP; MARTIN, EC; ADLER, PN			DROSOPHILA GENES POSTERIOR SEX COMBS AND SUPPRESSOR 2 OF ZESTE ENCODE PROTEINS WITH HOMOLOGY TO THE MURINE BMI-1 ONCOGENE	NATURE			English	Article							VIRUS TYPE-1; EXPRESSION; DOMAINS; SEQUENCE; BINDING; FINGER	THE Polycomb group (Pc-G) genes are needed to maintain expression patterns of the homeotic selector genes of the Antennapedia (Antp-C) and bithorax (bx-C) complexes, and hence for the maintenance of segmental determination 1-3. We report the predicted protein sequence of the Pc-G gene Posterior Sex Combs (Psc), and of the neighbouring and related gene Suppressor two of zeste (Su(z)2). Both genes encode large proteins that contain a 200 amino-acid domain identical over 37.4% that is also conserved in the murine oncogene bmi-1 (refs 4, 5). At the amino terminus of this domain is a cysteine-rich sequence that has been proposed as a novel type of zinc finger 6.	UNIV VIRGINIA, INST MOLEC BIOL, DEPT BIOL, CHARLOTTESVILLE, VA 22901 USA; UNIV VIRGINIA, CTR CANC, CHARLOTTESVILLE, VA 22901 USA	University of Virginia; University of Virginia								ADLER PN, IN PRESS DEV GENET; BRUNK BP, 1990, GENETICS, V124, P145; BRUNK BP, 1991, GENETICS, V128, P119; BRUNK BP, 1989, THESIS U VIRGINIA; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; EVERETT RD, 1988, J MOL BIOL, V202, P87, DOI 10.1016/0022-2836(88)90521-9; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; HAUPT Y, 1991, J CELL, V65, P753; ITOH K, 1991, J CLIN INVEST, V87, P177, DOI 10.1172/JCI114968; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; PARO R, 1990, TRENDS GENET, V5, P131; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SMILEY BL, 1990, MOL CELL BIOL, V10, P6436, DOI 10.1128/MCB.10.12.6436; STRUHL G, 1985, EMBO J, V4, P3259, DOI 10.1002/j.1460-2075.1985.tb04075.x; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; THEIM S, 1989, J VIROL, V63, P4489; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; WEDEEN C, 1986, CELL, V44, P739, DOI 10.1016/0092-8674(86)90840-8; WU CT, 1989, MOL GEN GENET, V218, P559, DOI 10.1007/BF00332424	25	190	197	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 26	1991	353	6342					351	353		10.1038/353351a0	http://dx.doi.org/10.1038/353351a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1833647				2022-12-28	WOS:A1991GG65400060
J	HOLMES, WE; LEE, J; KUANG, WJ; RICE, GC; WOOD, WI				HOLMES, WE; LEE, J; KUANG, WJ; RICE, GC; WOOD, WI			STRUCTURE AND FUNCTIONAL EXPRESSION OF A HUMAN INTERLEUKIN-8 RECEPTOR	SCIENCE			English	Article							NEUTROPHIL-ACTIVATING FACTOR; GROWTH-HORMONE; CDNA LIBRARIES; CLONING; ERYTHROPOIETIN; PROLACTIN; BINDING; FAMILY; DOMAIN	Interleukin-8 (IL-8) is a member of a family of pro-inflammatory cytokines. Although the best characterized activities of IL-8 include the chemoattraction and activation of neutrophils, other members of this family have a wide range of specific actions including the chemotaxis and activation of monocytes, the selective chemotaxis of memory T cells, the inhibition of hematopoietic stem cell proliferation, and the induction of neutrophil infiltration in vivo. A complementary DNA encoding the IL-8 receptor from human neutrophils has now been isolated. The amino acid sequence shows that the receptor is a member of the superfamily of receptors that couple to guanine nucleotide binding proteins (G proteins). The sequence is 29% identical to that of receptors for the other neutrophil chemoattractants, fMet-Leu-Phe and C5a. Mammalian cells transfected with the IL-8 receptor cDNA clone bind IL-8 with high affinity and respond specifically to IL-8 by transiently mobilizing calcium. The IL-8 receptor may be part of a subfamily of related G protein-coupled receptors that transduce signals for the IL-8 family of pro-inflammatory cytokines.	GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CELL BIOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech								BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BESEMER J, 1989, J BIOL CHEM, V264, P17409; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLORE GM, 1989, J BIOL CHEM, V264, P18907; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GROB PM, 1990, J BIOL CHEM, V265, P8311; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HOLMES WE, UNPUB; KORCHAK HM, 1984, J BIOL CHEM, V259, P4076; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lee J.-S., UNPUB; Maniatis T., 1982, MOL CLONING; MORRISON M, 1970, BIOCHEMISTRY-US, V9, P2995, DOI 10.1021/bi00817a010; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PACHOLCZYK T, 1990, BIOTECHNIQUES, V9, P556; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RAMACHANDRAN J, 1989, BIOESSAYS, V10, P54, DOI 10.1002/bies.950100205; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TENNENBERG SD, 1988, J IMMUNOL, V141, P3937; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; THOMAS KM, 1990, J BIOL CHEM, V265, P20061; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	38	992	1095	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1991	253	5025					1278	1280		10.1126/science.1840701	http://dx.doi.org/10.1126/science.1840701			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1840701				2022-12-28	WOS:A1991GE68900040
J	LIGHT, DW				LIGHT, DW			OBSERVATIONS ON THE NHS REFORMS - AN AMERICAN PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article											LIGHT, DW (corresponding author), UNIV MED & DENT NEW JERSEY,DIV SOCIAL & BEHAV MED,NEWARK,NJ 07103, USA.							FERRIMAN A, 1991, OBSERVER        0707, P3; GERNEY C, 1991, COMMUNICATIONS, P10; Griffiths R, 1991, AUDIT COMMISSION MAN, V3; KUZNIK F, 1990, SPECIAL REPORT HLTH, P23; LIGHT DW, 1990, HLTH SERVICE J  1025, P1604; LIGHT DW, 1990, HLTH SERVICE J  1004, P1470; LIGHT DW, 1990, HLTH SERVICE J  1101, P1648; LIGHT DW, 1991, HLTH SERVICE J  1011, P1513; LIGHT DW, IN PRESS LANCET; POPE C, 1991, SOCIOL HEALTH ILL, V13, P193, DOI 10.1111/1467-9566.ep11340798; Schieber G J, 1991, Health Aff (Millwood), V10, P106, DOI 10.1377/hlthaff.10.1.106; WARNER J, 1991, INDEPENDENT     0707; 1991, 191 BRIT MED ASS EC; 1991, JOINT GUIDANCE NHSME	14	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					568	570		10.1136/bmj.303.6802.568	http://dx.doi.org/10.1136/bmj.303.6802.568			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1812855	Bronze, Green Published			2022-12-28	WOS:A1991GE94800028
J	TURKA, LA; SCHATZ, DG; OETTINGER, MA; CHUN, JJM; GORKA, C; LEE, K; MCCORMACK, WT; THOMPSON, CB				TURKA, LA; SCHATZ, DG; OETTINGER, MA; CHUN, JJM; GORKA, C; LEE, K; MCCORMACK, WT; THOMPSON, CB			THYMOCYTE EXPRESSION OF RAG-1 AND RAG-2 - TERMINATION BY T-CELL RECEPTOR CROSS-LINKING	SCIENCE			English	Article							RECOMBINATION ACTIVATING GENE; V(D)J RECOMBINATION; DEVELOPMENTAL BIOLOGY; ANTIGEN RECEPTOR; MATURE THYMOCYTES; CHAIN TRANSCRIPTS; SURFACE-ANTIGEN; ADJACENT GENES; LYMPHOCYTES-T; THYMUS	The expression of the V(D)J [variable (diversity) joining elements] recombination activating genes, RAG-1 and RAG-2, has been examined during T cell development in the thymus. In situ hybridization to intact thymus and RNA blot analysis of isolated thymic subpopulations separated on the basis of T cell receptor (TCR) expression demonstrated that both TCR- and TCR+ cortical thymocytes express RAG-1 and RAG-2 messenger RNA's. Within the TCR+ population, RAG expression was observed in immature CD4+CD8+ (double positive) cells, but not in the more mature CD4+CD8- or CD4-CD8+ (single positive) subpopulations. Thus, although cortical thymocytes that bear TCR on their surface continue to express RAG-1 and RAG-2, it appears that the expression of both genes is normally terminated during subsequent thymic maturation. Since thymocyte maturation in vivo is thought to be regulated through the interaction of the TCR complex with self major histocompatibility complex (MHC) antigens, these data suggest that signals transduced by the TCR complex might result in the termination of RAG expression. Consistent with this hypothesis, thymocyte TCR cross-linking in vitro led to rapid termination of RAG-1 and RAG-2 expression, whereas cross-linking of other T cell surface antigens such as CD4, CD8, or HLA class I had no effect.	UNIV MICHIGAN,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	TURKA, LA (corresponding author), UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109, USA.		Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176; McCormack, Wayne/0000-0002-2117-8727	NIDDK NIH HHS [DK-01899] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001899] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON JP, 1987, ANNU REV IMMUNOL, V5, P503, DOI 10.1146/annurev.iy.05.040187.002443; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; FINKEL TH, 1989, CELL, V58, P1047, DOI 10.1016/0092-8674(89)90503-5; FINKEL TH, 1989, J IMMUNOL, V142, P3006; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; MARCHE PN, 1986, P NATL ACAD SCI USA, V83, P2190, DOI 10.1073/pnas.83.7.2190; MARRACK P, 1987, SCIENCE, V238, P1047; MATHIESON BJ, 1984, IMMUNOL REV, V82, P141, DOI 10.1111/j.1600-065X.1984.tb01121.x; MATIS LA, 1988, J EXP MED, V168, P2379, DOI 10.1084/jem.168.6.2379; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCGHEE D, 1979, THYMUS, V1, P151; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P9324, DOI 10.1073/pnas.87.23.9324; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; NIETO MA, 1990, J IMMUNOL, V145, P1364; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; SAMUELSON LE, 1991, CELL, V64, P875; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCOLLAY R, 1983, THYMUS, V5, P245; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; SHORTMAN K, 1987, J IMMUNOL, V138, P342; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; SPRENT J, 1989, FUNDAMENTAL IMMUNOLO, P69; STROMINGER JL, 1989, SCIENCE, V244, P943, DOI 10.1126/science.2658058; TOYONAGA B, 1987, ANNU REV IMMUNOL, V5, P585, DOI 10.1146/annurev.immunol.5.1.585; TRIEBEL F, 1988, J IMMUNOL, V140, P300; TURKA LA, 1990, J IMMUNOL, V144, P1646; TURKA LA, 1991, J IMMUNOL, V146, P1428; TURKA LA, UNPUB; VANEWIJK W, 1981, J IMMUNOL, V127, P2594; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEISSMAN IL, 1973, J EXP MED, V137, P504, DOI 10.1084/jem.137.2.504; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0	42	234	243	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					778	781		10.1126/science.1831564	http://dx.doi.org/10.1126/science.1831564			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1831564				2022-12-28	WOS:A1991GB29500034
J	BUENO, A; RICHARDSON, H; REED, SI; RUSSELL, P				BUENO, A; RICHARDSON, H; REED, SI; RUSSELL, P			A FISSION YEAST B-TYPE CYCLIN FUNCTIONING EARLY IN THE CELL-CYCLE	CELL			English	Article							MATURATION-PROMOTING FACTOR; P34CDC2 PROTEIN-KINASE; H-1 HISTONE KINASE; M-PHASE; SACCHAROMYCES-CEREVISIAE; CDC2 KINASE; SCHIZOSACCHAROMYCES-POMBE; MATING-PHEROMONE; DNA-REPLICATION; MITOTIC INDUCER	We have cloned a fission yeast gene, cig1+, encoding a 48 kd product that is most similar to cyclin B proteins. The cig1+ protein has a "cyclin box" approximately 40% identical to B-type cyclins of other species, but lacks the "destruction box" required for proteolysis of mitotic cyclins. Deletion of cig1+ had no observable effect on cell viability or progression through G2 or M phase, but instead caused a marked lag in the progression from G1 to S phase. G1 constituted approximately 70% of the cell cycle in cig1 deletion strains, as compared with < 10% in cig1+ strains. Constitutive cig1+ overexpression was lethal, causing cessation of growth and arrest in G1. Expression of cig1+ failed to rescue an S. cerevisiae strain lacking CLN Start cyclins. Thus, cig1+ identifies a new class of B-type cyclin acting in G1 or S phase that appears to be functionally distinct from all previously described cyclin proteins.			BUENO, A (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Bueno, Avelino/A-9505-2016; Richardson, Helena E/A-8080-2013	Bueno, Avelino/0000-0002-0362-4391; Richardson, Helena E/0000-0003-3852-4953	NIGMS NIH HHS [GM38328, GM41281] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038328, R01GM041281, R37GM038328] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; DESSEV G, 1991, J CELL BIOL, V112, P523, DOI 10.1083/jcb.112.4.523; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FANTES PA, 1977, J CELL SCI, V24, P51; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGAN I, 1988, J CELL SCI, V91, P587; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUNT T, 1991, NATURE, V349, P100, DOI 10.1038/349100a0; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, J CELL SCI, P77; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	57	75	76	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1991	66	1					149	159		10.1016/0092-8674(91)90147-Q	http://dx.doi.org/10.1016/0092-8674(91)90147-Q			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1829983				2022-12-28	WOS:A1991FW91300017
J	ROSNER, MH; VIGANO, MA; RIGBY, PWJ; ARNHEITER, H; STAUDT, LM				ROSNER, MH; VIGANO, MA; RIGBY, PWJ; ARNHEITER, H; STAUDT, LM			OCT-3 AND THE BEGINNING OF MAMMALIAN DEVELOPMENT	SCIENCE			English	Editorial Material							EMBRYONAL CARCINOMA-CELLS; DNA-BINDING DOMAIN; TRANSCRIPTION FACTOR; POU-DOMAIN; IMMUNOGLOBULIN GENES; NUCLEAR FACTOR; STEM-CELLS; MOUSE EMBRYOGENESIS; PROTEIN-BINDING; LEUKEMIA-VIRUS		NCI, METAB BRANCH, BETHESDA, MD 20892 USA; NATL INST MED RES, EUKARYOT MOLEC GENET LAB, LONDON NW7 1AA, ENGLAND; NINCDS, VIRAL & MOLEC PATHOGENESIS LAB, BETHESDA, MD 20892 USA; GEORGETOWN UNIV, SCH MED, DEPT PATHOL, WASHINGTON, DC 20057 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); MRC National Institute for Medical Research; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Georgetown University			Staudt, Louis/AAC-5324-2019	vigano, maria alessandra/0000-0003-2009-0384				BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DWORKIN MB, 1990, MOL REPROD DEV, V26, P261, DOI 10.1002/mrd.1080260310; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; HAAS MW, 1991, VIROLOGY, V180, P41, DOI 10.1016/0042-6822(91)90007-X; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JOHNSON MH, 1981, BIOL REV, V56, P463, DOI 10.1111/j.1469-185X.1981.tb00356.x; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LOH TP, 1990, MOL CELL BIOL, V10, P4045, DOI 10.1128/MCB.10.8.4045; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; ROSNER MH, 1991, CELL, V64, P1103, DOI 10.1016/0092-8674(91)90265-Z; ROSNER MH, UNPUB; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TSUKIYAMA T, 1989, MOL CELL BIOL, V9, P4670, DOI 10.1128/MCB.9.11.4670; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	48	11	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1991	253	5016					144	145		10.1126/science.1853199	http://dx.doi.org/10.1126/science.1853199			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1853199				2022-12-28	WOS:A1991FW16000023
J	KISS, T; MARSHALLSAY, C; FILIPOWICZ, W				KISS, T; MARSHALLSAY, C; FILIPOWICZ, W			ALTERATION OF THE RNA-POLYMERASE SPECIFICITY OF U3 SNRNA GENES DURING EVOLUTION AND INVITRO	CELL			English	Article							SMALL NUCLEAR RNAS; C-MYC GENE; III PROMOTER; TATA BOX; TRANSCRIPTION; COMPONENTS; SEQUENCES; BINDING; PLANTS; VIRUS	We present evidence that the genes encoding U3 snRNA in plants are transcribed by RNA polymerase III (pol III) and not by RNA polymerase II (pol II) as in vertebrates or lower eukaryotes. The U3 gene is the only known example of a gene transcribed by different polymerases in different organisms. It is possible to convert the plant U3 gene into a functional pol II-transcribed gene by manipulating the spacing between the promoter elements and inserting a pol II-specific termination signal. Pol II-transcribed U3 RNA, containing the 5'-terminal cap different from that present in the wild-type counterpart, is packaged in transfected protoplasts into U3 snRNP precipitable with anti-fibrillarin antibodies. These findings provide further evidence for the common ancestry of the pol II and pol III transcription systems, and indicate that promoter diversification in some genes has occurred relatively recently.			KISS, T (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.			Kiss, Tamas/0000-0003-0293-3093				BARBOSA E, 1978, J BIOL CHEM, V253, P7698; BENTLEY DL, 1989, GENE DEV, V3, P1179, DOI 10.1101/gad.3.8.1179; BOCHNIG P, 1987, EUR J BIOCHEM, V168, P461, DOI 10.1111/j.1432-1033.1987.tb13439.x; CHANDRASEKHARAPPA SC, 1983, J CELL PHYSIOL, V117, P169, DOI 10.1002/jcp.1041170206; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; England T E, 1980, Methods Enzymol, V65, P65; EPSTEIN P, 1984, BIOCHEMISTRY-US, V23, P5421, DOI 10.1021/bi00318a007; FILIPOWICZ W, 1990, MOL BIOL REP, V14, P125, DOI 10.1007/BF00360443; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; GOUY M, 1989, MOL BIOL EVOL, V6, P109; GUILTINAN MJ, 1988, EUR J CELL BIOL, V46, P547; GUPTA S, 1990, J BIOL CHEM, V265, P19137; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HELLUNGLARSEN P, 1980, BIOCHIM BIOPHYS ACTA, V609, P201, DOI 10.1016/0005-2787(80)90213-0; HELLUNGLARSEN P, 1981, BIOCHEM BIOPH RES CO, V99, P1303, DOI 10.1016/0006-291X(81)90761-0; HOWE JG, 1989, CELL, V57, P825, DOI 10.1016/0092-8674(89)90797-6; HUGHES JMX, 1987, EMBO J, V6, P2145, DOI 10.1002/j.1460-2075.1987.tb02482.x; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KISS T, 1985, EUR J BIOCHEM, V152, P259, DOI 10.1111/j.1432-1033.1985.tb09192.x; KISS T, 1990, NUCLEIC ACIDS RES, V18, P1941, DOI 10.1093/nar/18.8.1941; KROL A, 1983, NUCLEIC ACIDS RES, V11, P8583, DOI 10.1093/nar/11.24.8583; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LUHRMANN R, 1982, NUCLEIC ACIDS RES, V10, P7103, DOI 10.1093/nar/10.22.7103; MARSHALLSAY C, 1990, NUCLEIC ACIDS RES, V18, P3451; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MEMET S, 1988, J BIOL CHEM, V263, P10048; MUHLBACH HP, 1979, NATURE, V278, P185, DOI 10.1038/278185a0; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; PARRY HD, 1989, TRENDS BIOCHEM SCI, V14, P15, DOI 10.1016/0968-0004(89)90083-2; PORTER GL, 1988, NUCLEIC ACIDS RES, V16, P10131, DOI 10.1093/nar/16.21.10131; REDDY R, 1990, NUCLEIC ACIDS RES, V18, P2231, DOI 10.1093/nar/18.suppl.2231; REDDY R, 1988, NUCLEIC ACIDS RES, V16, pR71, DOI 10.1093/nar/16.suppl.r71; REDDY R, 1981, J BIOL CHEM, V16, P8452; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.ge.19.120185.002035; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; SZKUKALEK A, 1990, NUCLEIC ACIDS RES, V18, P1295, DOI 10.1093/nar/18.5.1295; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; VANKAN P, 1989, EMBO J, V8, P3875, DOI 10.1002/j.1460-2075.1989.tb08566.x; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; WAIBEL F, 1990, NUCLEIC ACIDS RES, V18, P3459; WISE JA, 1981, J BIOL CHEM, V256, P956	52	98	104	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					517	526		10.1016/0092-8674(91)90469-F	http://dx.doi.org/10.1016/0092-8674(91)90469-F			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1826860				2022-12-28	WOS:A1991FK18200018
J	MALINOW, R				MALINOW, R			TRANSMISSION BETWEEN PAIRS OF HIPPOCAMPAL SLICE NEURONS - QUANTAL LEVELS, OSCILLATIONS, AND LTP	SCIENCE			English	Article							LONG-TERM POTENTIATION; PYRAMIDAL CELLS; RELEASE; INDUCTION; EFFICACY; INVITRO	Long-term potentiation (LTP) of synaptic transmission after coincident pre- and postsynaptic activity is considered a cellular model of changes underlying learning and memory. In intact tissue, LTP has been observed only between populations of neurons, making analysis of mechanisms difficult. Transmission between individual pre- and postsynaptic hippocampal cells was studied, suggesting quantal amplitude distributions with little variability in quantal size. LTP between such pairs is manifested by large, persistent, and synapse-specific potentiation with a shift in amplitude distribution that suggests presynaptic changes. Oscillations in amplitude of transmission, apparently of presynaptic origin, are common and can be triggered by LTP.	STANFORD UNIV, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Stanford University	MALINOW, R (corresponding author), UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA.							ALGER BE, 1982, J PHYSIOL-LONDON, V328, P105, DOI 10.1113/jphysiol.1982.sp014255; AMARAL DG, 1990, PROG BRAIN RES, V83, P1; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS T, 1988, LONG TERM POTENTIATI; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; BROWN TH, 1976, P NATL ACAD SCI USA, V73, P2913, DOI 10.1073/pnas.73.8.2913; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; FRIEDLANDER MJ, 1990, J NEUROSCI, V10, P814; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESS G, 1987, NEUROSCI LETT, V77, P187, DOI 10.1016/0304-3940(87)90584-2; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MCNAUGHTON BL, 1981, J NEUROPHYSIOL, V46, P952, DOI 10.1152/jn.1981.46.5.952; MEIRI H, 1978, J PHYSIOL-LONDON, V278, P513, DOI 10.1113/jphysiol.1978.sp012321; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; PAWSON PA, 1989, PROC R SOC SER B-BIO, V237, P489, DOI 10.1098/rspb.1989.0061; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SASTRY BR, 1986, SCIENCE, V232, P988, DOI 10.1126/science.3010459; SAYER RJ, 1989, J NEUROSCI, V9, P840; SAYER RJ, 1990, J NEUROSCI, V10, P826; SILVERMAN V, 1986, DENSITY ESTIMATE STA; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	30	197	199	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1991	252	5006					722	724		10.1126/science.1850871	http://dx.doi.org/10.1126/science.1850871			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1850871				2022-12-28	WOS:A1991FK18500054
J	LAW, MR; FROST, CD; WALD, NJ				LAW, MR; FROST, CD; WALD, NJ			BY HOW MUCH DOES DIETARY SALT REDUCTION LOWER BLOOD-PRESSURE .3. ANALYSIS OF DATA FROM TRIALS OF SALT REDUCTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MODERATE SODIUM RESTRICTION; MILD ESSENTIAL-HYPERTENSION; POTASSIUM SUPPLEMENTATION; BORDERLINE HYPERTENSION; PLASMA-CATECHOLAMINES; RANDOMIZED CROSSOVER; NORMOTENSIVE ADULTS; WEIGHT-REDUCTION; RENIN SYSTEM; MEN	Objective-To determine whether the reduction in blood pressure achieved in trials of dietary salt reduction is quantitatively consistent with estimates derived from blood pressure and sodium intake in different populations, and, if so, to estimate the impact of reducing dietary salt on mortality from stroke and ischaemic heart disease. Design-Analysis of the results of 68 crossover trials and 10 randomised controlled trials of dietary salt reduction. Main outcome measure-Comparison of observed reductions in systolic blood pressure for each trail with predicted values calculated from between population analysis. Results-In the 45 trials in which salt reduction lasted four weeks or less the observed reductions in blood pressure were less than those predicted, with the difference between observed and predicted reductions being greatest in the trials of shortest duration. In the 33 trials lasting five weeks or longer the predicted reductions in individual trials closely matched a wide range of observed reductions. This applied for all age groups and for people with both high and normal levels of blood pressure. In people aged 50-59 years a reduction in daily sodium intake of 50 mmol (about 3 g of salt), attainable by moderate dietary salt reduction would, after a few weeks, lower systolic blood pressure by an average of 5 mm Hg, and by 7 mm Hg in those with high blood pressure (170 mm Hg); diastolic blood pressure would be lowered by about half as much. It is estimated that such a reduction in salt intake by a whole Western population would reduce the incidence of stroke by 26% and of ischaemic heart disease by 15%. Conclusions-The results from the trials support the estimates from the observational data in the accompanying two papers. The effect of universal moderate dietary salt reduction on mortality from stroke and ischaemic heart disease would be substantial-larger, indeed, than could be achieved by fully implementing recommended policy for treating high blood pressure with drugs. However, reduction also in the amount of salt added to processed foods would lower blood pressure by at least twice as much and prevent some 70 000 deaths a year in Britain as well as much disability.			LAW, MR (corresponding author), ST BARTHOLOMEWS HOSP, COLL MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021					AMBROSIONI E, 1982, HYPERTENSION, V4, P789, DOI 10.1161/01.HYP.4.6.789; ASHIDA T, 1985, HYPERTENSION, V7, P972, DOI 10.1161/01.HYP.7.6.972; BUCKNALL CA, 1986, BRIT MED J, V293, P739, DOI 10.1136/bmj.293.6549.739; CAPPUCCIO FP, 1985, J HYPERTENS, V3, P243, DOI 10.1097/00004872-198506000-00008; CARNEY S, 1975, MED J AUSTRALIA, V1, P803, DOI 10.5694/j.1326-5377.1975.tb82051.x; CHALMERS J, 1986, J HYPERTENS, V4, pS629; CHALMERS JP, 1989, LANCET, V1, P399; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Cooper R, 1984, J Hypertens, V2, P361; CORCORAN AC, 1951, CIRCULATION, V3, P1; DAHL LK, 1954, J CLIN INVEST, V33, P1397, DOI 10.1172/JCI103017; DAHL LK, 1958, NEW ENGL J MED, V258, P1186, DOI 10.1056/NEJM195806122582402; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DODSON PM, 1989, BMJ-BRIT MED J, V298, P227, DOI 10.1136/bmj.298.6668.227; DOLE VP, 1951, J CLIN INVEST, V30, P584, DOI 10.1172/JCI102476; ELASHRY A, 1987, J HUM HYPERTENS, V1, P105; ERWTEMAN TM, 1984, BMJ-BRIT MED J, V289, P406, DOI 10.1136/bmj.289.6442.406; FAGERBERG B, 1984, BRIT MED J, V288, P11, DOI 10.1136/bmj.288.6410.11; FROST CD, 1991, BRIT MED J, V302, P815, DOI 10.1136/bmj.302.6780.815; FUJITA T, 1980, AM J MED, V69, P334, DOI 10.1016/0002-9343(80)90002-9; GILLUM RF, 1983, AM HEART J, V105, P128, DOI 10.1016/0002-8703(83)90289-2; GROBBEE DE, 1987, J HYPERTENS, V5, P115, DOI 10.1097/00004872-198702000-00016; HARGREAVES M, 1989, CLIN SCI, V76, P553, DOI 10.1042/cs0760553; JAMES WPT, 1987, LANCET, V1, P426; JEST P, 1986, ACTA MED SCAND, P75; KAWASAKI T, 1978, AM J MED, V64, P193, DOI 10.1016/0002-9343(78)90045-1; KIRKENDALL WM, 1976, J LAB CLIN MED, V87, P418; KJELDSEN SE, 1988, HYPERTENSION, V11, P477, DOI 10.1161/01.HYP.11.5.477; KOBAYASHI Y, 1983, JPN CIRC J, V47, P268, DOI 10.1253/jcj.47.268; KOGA Y, 1985, JPN HEART J, V26, P197; KOJIMA S, 1987, CLIN EXP HYPERTENS A, V9, P1243, DOI 10.3109/10641968709160047; Koolen M I, 1984, J Hypertens, V2, P55, DOI 10.1097/00004872-198402000-00010; KURTZ TW, 1987, NEW ENGL J MED, V317, P1043, DOI 10.1056/NEJM198710223171702; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LIJNEN P, 1986, POSTGRAD MED J, V62, P3; LINARES OA, 1988, AM J PHYSIOL, V254, pE222, DOI 10.1152/ajpendo.1988.254.2.E222; LONGWORTH DL, 1980, CLIN PHARMACOL THER, V27, P544, DOI 10.1038/clpt.1980.76; MACGREGOR GA, 1982, LANCET, V1, P351, DOI 10.1016/S0140-6736(82)91389-7; MACGREGOR GA, 1989, LANCET, V2, P1244, DOI 10.1016/S0140-6736(89)91852-7; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Mancini M, 1986, J CLIN HYPERTENS, V4, P315; MASUGI F, 1988, J HUM HYPERTENS, V1, P293; MILLER JZ, 1983, HYPERTENSION, V5, P790, DOI 10.1161/01.HYP.5.5.790; MILLER JZ, 1987, J CHRON DIS, V40, P245, DOI 10.1016/0021-9681(87)90160-3; MORGAN T, 1988, J HUM HYPERTENS, V1, P311; MORGAN T, 1987, CAN J PHYSIOL PHARM, V65, P1752, DOI 10.1139/y87-274; MORGAN T, 1978, LANCET, V1, P227; MORGAN TO, 1981, MED J AUSTRALIA, V2, P396, DOI 10.5694/j.1326-5377.1981.tb101026.x; MYERS J, 1982, CLIN EXP PHARMACOL P, V9, P287, DOI 10.1111/j.1440-1681.1982.tb00808.x; NIARCHOS AP, 1984, AM J MED, V77, P1061, DOI 10.1016/0002-9343(84)90189-X; OMVIK P, 1986, J HYPERTENS, V4, P535, DOI 10.1097/00004872-198610000-00004; OS I, 1986, ACTA MED SCAND, V220, P195; PARFREY PS, 1981, BRIT MED J, V283, P94, DOI 10.1136/bmj.283.6284.94; PARIJS J, 1973, AM HEART J, V85, P22, DOI 10.1016/0002-8703(73)90522-X; PERERA GA, 1947, J CLIN INVEST, V26, P1109, DOI 10.1172/JCI101903; PETRIE A, 1978, LECTURE NOTES MED ST; Poston L, 1985, Klin Wochenschr, V63 Suppl 3, P136; PRIDDLE WW, 1962, CAN MED ASSOC J, V86, P1; PUSKA P, 1983, LANCET, V1, P1; Resnick L M, 1985, Trans Assoc Am Physicians, V98, P313; RICHARDS AM, 1984, LANCET, V1, P757, DOI 10.1016/S0140-6736(84)91276-5; ROMOFF MS, 1979, J CLIN ENDOCR METAB, V48, P26, DOI 10.1210/jcem-48-1-26; RUTAN GH, 1989, J CLIN EPIDEMIOL, V42, P663, DOI 10.1016/0895-4356(89)90010-3; SHORE AC, 1988, J HYPERTENS, V6, P613, DOI 10.1097/00004872-198808000-00003; SILMAN AJ, 1983, LANCET, V1, P1179; SKRABAL F, 1984, HYPERTENSION, V6, P152, DOI 10.1161/01.HYP.6.2_Pt_1.152; SKRABAL F, 1984, KLIN WOCHENSCHR, V62, P124, DOI 10.1007/BF01738702; SMITH SJ, 1985, BMJ-BRIT MED J, V290, P110, DOI 10.1136/bmj.290.6462.110; STOKES GS, 1986, J HYPERTENS, V4, P35, DOI 10.1097/00004872-198602000-00006; SULLIVAN JM, 1980, HYPERTENSION, V2, P506, DOI 10.1161/01.HYP.2.4.506; SWALES JD, 1989, BMJ-BRIT MED J, V298, P694; TEOW BH, 1985, CLIN EXP HYPERTENS A, V7, P1681, DOI 10.3109/10641968509073618; THALER BI, 1982, NEW ZEAL MED J, V95, P839; VANBRUMMELEN P, 1978, ACTA MED SCAND, V204, P151; VANBRUMMELEN P, 1987, CLIN INVEST MED, V10, P581; VOLPE M, 1985, CIRCULATION, V72, P47, DOI 10.1161/01.CIR.72.1.47; WARREN S E, 1980, Clinical Cardiology, V3, P348; WATT GCM, 1983, BMJ-BRIT MED J, V286, P432, DOI 10.1136/bmj.286.6363.432; WATT GCM, 1985, BMJ-BRIT MED J, V291, P1525, DOI 10.1136/bmj.291.6508.1525; WEINBERGER MH, 1988, JAMA-J AM MED ASSOC, V259, P2561, DOI 10.1001/jama.259.17.2561; WEISSBERG PL, 1985, J HYPERTENS, V3, P475; 1989, LANCET, V1, P1301	82	420	426	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	1991	302	6780					819	824		10.1136/bmj.302.6780.819	http://dx.doi.org/10.1136/bmj.302.6780.819			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF377	1827353	Green Published, Bronze			2022-12-28	WOS:A1991FF37700024
J	BOOY, FP; NEWCOMB, WW; TRUS, BL; BROWN, JC; BAKER, TS; STEVEN, AC				BOOY, FP; NEWCOMB, WW; TRUS, BL; BROWN, JC; BAKER, TS; STEVEN, AC			LIQUID-CRYSTALLINE, PHAGE-LIKE PACKING OF ENCAPSIDATED DNA IN HERPES-SIMPLEX VIRUS	CELL			English	Article							CRYO-ELECTRON-MICROSCOPY; DOUBLE-STRANDED DNA; 3-DIMENSIONAL STRUCTURE; DEOXYRIBONUCLEIC ACID; SIMIAN VIRUS-40; RECONSTRUCTION; TYPE-1; CORE; BACTERIOPHAGES; HERPESVIRUSES	The organization of DNA within the HSV-1 capsid has been determined by cryoelectron microscopy and image reconstruction. Purified C-capsids, which are fully packaged, were compared with A-capsids, which are empty. Unlike A-capsids, C-capsids show fine striations and punctate arrays with a spacing of approximately 2.6 nm. The packaged DNA forms a uniformly dense ball, extending radially as far as the inner surface of the icosahedral (T = 16) capsid shell, whose structure is essentially identical in A-capsids and C-capsids. Thus we find no evidence for the inner T = 4 shell previously reported by Schrag et al. to be present in C-capsids. Encapsidated HSV-1 DNA closely resembles that previously visualized in bacteriophages T4 and lambda, thus supporting the idea of a close parallelism between the respective assembly pathways of a major family of animal viruses (the herpesviruses) and a major family of bacterial viruses.	UNIV VIRGINIA,HLTH SCI CTR,CTR CANC,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; NIH,DIV COMP RES & TECHNOL,BETHESDA,MD 20892; PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	University of Virginia; University of Virginia; National Institutes of Health (NIH) - USA; Purdue University System; Purdue University; Purdue University West Lafayette Campus	BOOY, FP (corresponding author), NIAMSD,STRUCT BIOL RES LAB,BLDG 6,ROOM 114,BETHESDA,MD 20892, USA.			, Timothy/0000-0001-6543-8968	NIGMS NIH HHS [R01 GM033050, GM34036, GM33050, R37 GM033050] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034036, R37GM033050, R01GM033050] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TS, 1989, BIOPHYS J, V55, P243, DOI 10.1016/S0006-3495(89)82799-7; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; BAKER TS, 1990, J VIROL, V64, P563, DOI 10.1128/JVI.64.2.563-573.1990; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; BLACK LW, 1985, P NATL ACAD SCI USA, V82, P7960, DOI 10.1073/pnas.82.23.7960; BOOY FP, 1985, J MOL BIOL, V184, P667, DOI 10.1016/0022-2836(85)90312-2; BOOY FP, 1988, 46TH P ANN M EL MICR, P164; CARRASCOSA JL, 1978, MICRON, V9, P199, DOI 10.1016/0047-7206(78)90021-3; Casjens S., 1988, BACTERIOPHAGES, V1, P16; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; EARNSHAW W, 1976, J MOL BIOL, V104, P387, DOI 10.1016/0022-2836(76)90278-3; FRIEDMANN A, 1975, J GEN VIROL, V26, P171, DOI 10.1099/0022-1317-26-2-171; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; FURLONG D, 1978, P NATL ACAD SCI USA, V75, P2764, DOI 10.1073/pnas.75.6.2764; FURLONG D, 1972, J VIROL, V10, P1071, DOI 10.1128/JVI.10.5.1071-1074.1972; HAY J, 1987, ANIMAL VIRUS STRUCTU, P391; KIEFF ED, 1971, J VIROL, V8, P125, DOI 10.1128/JVI.8.2.125-132.1971; KLUG A, 1972, NATURE, V238, P435, DOI 10.1038/238435a0; LEE JY, 1988, VIROLOGY, V167, P87, DOI 10.1016/0042-6822(88)90057-8; LEPAULT J, 1987, EMBO J, V6, P1507, DOI 10.1002/j.1460-2075.1987.tb02393.x; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; NAZERIAN K, 1974, J VIROL, V13, P1148, DOI 10.1128/JVI.13.5.1148-1150.1974; NERMUT MV, 1987, ANIMAL VIRUS STRUCTU, P373; NEWCOMB WW, 1989, J VIROL, V63, P3777, DOI 10.1128/JVI.63.9.3777-3783.1989; NEWCOMB WW, 1989, J VIROL, V63, P4397; NII S, 1975, BIKEN J, V18, P41; OCALLAGHAN DJ, 1976, PROG MED VIROL, V22, P152; OKADA K, 1980, J ELECTRON MICROSC, V29, P401; OLSON NH, 1989, ULTRAMICROSCOPY, V30, P281, DOI 10.1016/0304-3991(89)90057-0; PERDUE ML, 1975, VIROLOGY, V64, P187, DOI 10.1016/0042-6822(75)90091-4; PUVIONDUTILLEUL F, 1987, J HISTOCHEM CYTOCHEM, V35, P635, DOI 10.1177/35.6.3033063; RAU DC, 1984, P NATL ACAD SCI-BIOL, V81, P2621, DOI 10.1073/pnas.81.9.2621; RICHARDS KE, 1979, J MOL BIOL, V78, P255; RICHTER K, 1990, 13TH P INT C EL MICR, V1, P488; RIXON FJ, 1988, J GEN VIROL, V69, P2879, DOI 10.1099/0022-1317-69-11-2879; SCHRAG JD, 1989, CELL, V56, P651, DOI 10.1016/0092-8674(89)90587-4; SERWER P, 1986, J MOL BIOL, V190, P509, DOI 10.1016/0022-2836(86)90019-7; SHERMAN G, 1988, VIROLOGY, V163, P461; STEVEN AC, 1986, J VIROL, V57, P578, DOI 10.1128/JVI.57.2.578-584.1986; TRUS BL, 1981, ULTRAMICROSCOPY, V6, P383, DOI 10.1016/S0304-3991(81)80240-9; WILDY P, 1960, VIROLOGY, V12, P204, DOI 10.1016/0042-6822(60)90195-1	41	233	235	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					1007	1015		10.1016/0092-8674(91)90324-R	http://dx.doi.org/10.1016/0092-8674(91)90324-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1848156	Green Published, Green Accepted			2022-12-28	WOS:A1991FA94000017
J	FOULKES, NS; BORRELLI, E; SASSONECORSI, P				FOULKES, NS; BORRELLI, E; SASSONECORSI, P			CREM GENE - USE OF ALTERNATIVE DNA-BINDING DOMAINS GENERATES MULTIPLE ANTAGONISTS OF CAMP-INDUCED TRANSCRIPTION	CELL			English	Article							DEPENDENT PROTEIN-KINASE; NUCLEAR FACTOR CREB; C-FOS PROMOTER; CYCLIC-AMP; RESPONSE ELEMENT; SEQUENCE ELEMENTS; LEUCINE ZIPPER; ONCOGENE FOS; PHOSPHORYLATION; RNA	We isolated a gene from a mouse pituitary cDNA library that encodes a protein highly homologous to nuclear factor CREB, an activator of cAMP-responsive promoter elements (CREs). We demonstrate that while CREB is expressed uniformly in several cell types, this gene, termed CREM, shows cell-specific expression. CREM has a remarkable organization, since downstream of the stop codon there is a second, out-of-frame DNA-binding domain. Using PCR and RNAase protection analysis, we have identified three mRNA isoforms that appear to be obtained by differential cell-specific splicing. Sequencing of the isoforms demonstrated alternative usage of the two DNA-binding domains. CREM proteins reveal the same efficiency and specificity of binding to CRE sequences as CREB, but in contrast to CREB, CREM acts as a down-regulator of cAMP-induced transcription.			FOULKES, NS (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE.		Foulkes, Nicholas S/K-7003-2013; Sassone-Corsi, Paolo/H-6182-2011; Borrelli, Emiliana/M-8994-2018	Foulkes, Nicholas S/0000-0002-1794-9891; 				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HABENER J, 1990, MOL ENDOCRINOL, V1, P1087; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARDY S, 1988, P NATL ACAD SCI USA, V85, P4171, DOI 10.1073/pnas.85.12.4171; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Maniatis T, 1989, DECONTAMINATION DILU; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MERINO A, 1989, J BIOL CHEM, V264, P21266; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONEIL TK, 1990, SCIENCE, V249, P774; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RAYMOND V, 1989, ONCOGENE RES, V5, P1; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMONSEN CC, 1983, MOL CELL BIOL, V3, P2250, DOI 10.1128/MCB.3.12.2250; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	51	626	637	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					739	749		10.1016/0092-8674(91)90503-Q	http://dx.doi.org/10.1016/0092-8674(91)90503-Q			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1847666				2022-12-28	WOS:A1991EZ47800009
J	ADACHI, Y; LUKE, M; LAEMMLI, UK				ADACHI, Y; LUKE, M; LAEMMLI, UK			CHROMOSOME ASSEMBLY INVITRO - TOPOISOMERASE-II IS REQUIRED FOR CONDENSATION	CELL			English	Article							XENOPUS-LAEVIS; SACCHAROMYCES-CEREVISIAE; MITOTIC CHROMOSOMES; DNA TOPOISOMERASES; NUCLEAR SCAFFOLD; CELL-CYCLE; YEAST; LOCALIZATION; CHROMATIN; ORGANIZATION	The role of topoisomerase II (topo II) in chromosome condensation was studied in a mitotic extract derived from Xenopus eggs by specific immunodepletion. HeLa nuclei, which have a high complement of endogenous topo II, are converted to mitotic chromosomes in the topo II-depleted extract equally well as in the control. Chicken erythrocyte nuclei, however, which have a very low content of topo II, do not convert to condensed chromosomes in the depleted extract, although their condensation is normal upon addition of purified topo II. Dosage experiments support the possible notion of a structural involvement of topo II in chromosome condensation. In the topo II-depleted extract the erythrocyte nuclei progress to precondensation chromosomes, which lack the nuclear membrane-lamina complex and consist of a cluster of swollen chromatids.	UNIV GENEVA, DEPT MOLEC BIOL, CH-1211 GENEVA 4, SWITZERLAND; SUNY STONY BROOK, DEPT PHARMACOL SCI, STONY BROOK, NY 11794 USA	University of Geneva; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	ADACHI, Y (corresponding author), UNIV GENEVA, DEPT BIOCHEM, CH-1211 GENEVA 4, SWITZERLAND.		Adachi, Yasuhisa/GYA-3190-2022	Galora De Mora, Raul Pavlov/0000-0001-8342-9782; Adachi, Yasuhisa/0000-0003-4197-092X				ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; CHEN GL, 1984, J BIOL CHEM, V259, P3560; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DUNPHY WG, 1988, J CELL BIOL, V106, P2047, DOI 10.1083/jcb.106.6.2047; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GIAEVER GN, 1988, BIOPHYS CHEM, V29, P7, DOI 10.1016/0301-4622(88)87020-0; HARLOW E, 1988, ANTIBODIES; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; KROHNE G, 1980, P NATL ACAD SCI-BIOL, V77, P1034, DOI 10.1073/pnas.77.2.1034; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNER CF, 1986, J BIOL CHEM, V261, P3293; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LUKE M, 1989, DEV BIOL, V136, P459, DOI 10.1016/0012-1606(89)90271-6; MARSDEN MPF, 1979, CELL, V17, P849, DOI 10.1016/0092-8674(79)90325-8; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NAKAGAWA J, 1989, J CELL SCI, V94, P449; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; REITMAN M, 1990, CELL BIOL, V10, P2774; Sambrook J, 1989, MOL CLONING LABORATO; SHIMAMURA A, 1989, METHOD ENZYMOL, V170, P603; Sternglanz R, 1989, CURR OPIN CELL BIOL, V1, P533, DOI 10.1016/0955-0674(89)90016-1; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WOODLAND HR, 1977, DEV BIOL, V57, P118, DOI 10.1016/0012-1606(77)90359-1; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; ZIERLER MK, 1985, J BIOL CHEM, V260, P974	48	388	397	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					137	148		10.1016/0092-8674(91)90215-K	http://dx.doi.org/10.1016/0092-8674(91)90215-K			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846085				2022-12-28	WOS:A1991ET17500015
J	LEWONTIN, RC; HARTL, DL				LEWONTIN, RC; HARTL, DL			POPULATION-GENETICS IN FORENSIC DNA TYPING	SCIENCE			English	Article								Variable number of tandem repeat (VNTR) sequences are used to link defendants with crimes by matching DNA patterns. The probative value of a match is often calculated by multiplying together the estimated frequencies with which each particular VNTR pattern occurs in a reference database. However, this method is liable to potential serious errors because ethnic subgroups within major racial categories exhibit genetic differences that are maintained by endogamy. The multiplication procedure currently in use can be made scientifically valid only by extensive sampling of VNTR frequency distributions m a variety of ethnic groups, similar to the ethnic studies of various blood groups done m the past. Alternative approaches for dealing with subpopulation heterogeneity are discussed.	WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL)	LEWONTIN, RC (corresponding author), HARVARD UNIV,MUSEUM COMPARAT ZOOL,CAMBRIDGE,MA 02138, USA.		Schneider, Peter M./A-6661-2011					ACTON RT, 1990, 1ST P ANN INT S HUM, P5; BALAZS I, 1989, AM J HUM GENET, V44, P182; BUDOWLE B, 1991, CRIME LAB DIGEST, V18, P9; BUDOWLE B, 1991, AM J HUM GENET, V48, P841; CASKEY CT, 1991, AM J HUM GENET, V49, P893; CHAKRABORTY R, 1991, HUM BIOL, V63, P571; CHAKRABORTY R, 1991, AM J HUM GENET, V49, P895; HOOVER JE, 1982, ENCY AM, P215; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; Kennedy RJR, 1944, AM J SOCIOL, V49, P331, DOI 10.1086/219427; Kennedy RJR, 1952, AM J SOCIOL, V58, P56, DOI 10.1086/221073; KIDD JR, 1991, HUMAN BIOL; LANDER ES, 1989, NATURE, V339, P501, DOI 10.1038/339501a0; LANDER ES, 1991, AM J HUM GENET, V49, P899; Lewontin R.C., 1972, EVOL BIOL, P381, DOI [10.1007/978-1-4684-9063-3_14, DOI 10.1007/978-1-4684-9063-3_14]; LIEBERSON S, 1962, ETHNIC PATTERNS AM C; MOURANT A. E, 1954, DISTRIBUTION HUMAN B; Mourant AE., 1976, DISTRIBUTION HUMAN B; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; Nelson L, 1943, AM J SOCIOL, V48, P585, DOI 10.1086/219247; Peach C., 1981, ETHNIC SEGREGATION C; SPUHLER JN, 1961, HUM BIOL, V33, P223; 1990, GENETIC WITNESS FORE	23	225	248	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1745	1750		10.1126/science.1845040	http://dx.doi.org/10.1126/science.1845040			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1845040				2022-12-28	WOS:A1991GW31600031
J	VANARSDEL, PP				VANARSDEL, PP			PSEUDOALLERGIC REACTIONS TO NONSTEROIDAL ANTIINFLAMMATORY DRUGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ASPIRIN				VANARSDEL, PP (corresponding author), UNIV WASHINGTON,MED CTR,SEATTLE,WA 98195, USA.							ASAD SI, 1984, BRIT MED J, V288, P745, DOI 10.1136/bmj.288.6419.745; STEVENSON DD, 1988, ALLERGY PRINCIPLES P, P1537; VANARSDEL PP, 1984, J ALLERGY CLIN IMMUN, V73, P431, DOI 10.1016/0091-6749(84)90351-8	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	1991	266	23					3343	3344						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU964	1835738				2022-12-28	WOS:A1991GU96400039
J	KEMENY, N; SEITER, K; MARTIN, D; URMACHER, C; NIEDZWIECKI, D; KURTZ, RC; COSTA, P; MURRAY, M				KEMENY, N; SEITER, K; MARTIN, D; URMACHER, C; NIEDZWIECKI, D; KURTZ, RC; COSTA, P; MURRAY, M			A NEW SYNDROME - ASCITES, HYPERBILIRUBINEMIA, AND HYPOALBUMINEMIA AFTER BIOCHEMICAL MODULATION OF FLUOROURACIL WITH N-PHOSPHONACETYL-L-ASPARTATE (PALA)	ANNALS OF INTERNAL MEDICINE			English	Article							N-(PHOSPHONACETYL)-L-ASPARTIC ACID PALA; PHASE-I TRIAL; COLORECTAL-CANCER; L-ASPARAGINASE; 5-FLUOROURACIL INCORPORATION; CARCINOMA; INFUSION; THERAPY; ENHANCEMENT; COMBINATION	Objective: To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer. Design: Retrospective analysis. Setting: Regional cancer treatment center. Patients: Forty-four previously untreated patients with metastatic colorectal cancer in a phase I-II trial of PALA-fluorouracil. Measurements and Main Results: One or more transient hepatic abnormalities frequently occurred in 15 of the 17 responding patients. Within the first 10 weeks of treatment, 5 patients developed ascites, 12 had a decrease in the serum albumin level, 6 developed bilirubin elevations, and 7 had transaminase elevations, all in the presence of a complete or partial tumor response. Prolongations of the prothrombin time and elevations of serum glucose levels were also seen. Conclusions: An unusual syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia is associated with a PALA-fluorouracil regimen. These abnormalities, which may be related to decreased hepatic protein synthesis, occurred more often in patients whose tumor was responding to chemotherapy. Clinicians must recognize that in patients undergoing chemotherapy with these agents, ascites and elevated liver function tests may be secondary to drug administration and are not necessarily due to disease progression.	CATHOLIC MED CTR BROOKLYN & QUEENS INC, DEPT SURG, JAMAICA, NY 11432 USA		KEMENY, N (corresponding author), MEM SLOAN KETTERING CANC CTR, 1275 YORK AVE, NEW YORK, NY 10021 USA.			Niedzwiecki, Donna/0000-0002-3566-0450	NCI NIH HHS [P01-CA-25842] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA025842] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANSFIELD F, 1977, CANCER-AM CANCER SOC, V39, P34, DOI 10.1002/1097-0142(197701)39:1<34::AID-CNCR2820390107>3.0.CO;2-2; ARBUCK SG, 1989, CANCER, V63, P1036, DOI 10.1002/1097-0142(19890315)63:6+<1036::AID-CNCR2820631309>3.0.CO;2-K; ARDALAN B, 1988, J CLIN ONCOL, V6, P1053, DOI 10.1200/JCO.1988.6.6.1053; BORHANMANESH F, 1989, ARCH INTERN MED, V149, P2127, DOI 10.1001/archinte.149.9.2127; BUROKER TR, 1985, J CLIN ONCOL, V3, P1624, DOI 10.1200/JCO.1985.3.12.1624; CAPIZZI RL, 1970, ANNU REV MED, V21, P433, DOI 10.1146/annurev.me.21.020170.002245; CHABNER B, 1982, PHARM PRINCIPLES CAN, P397; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; Cooney D A, 1975, Adv Pharmacol Chemother, V12, P185, DOI 10.1016/S1054-3589(08)60222-7; ERLICHMAN C, 1980, RECENT RES CANCER, V74, P65; ERVIN TJ, 1980, CANCER TREAT REP, V64, P1067; GRALLA RJ, 1980, CANCER TREAT REP, V64, P1301; GRALNICK HR, 1971, CANCER, V27, P1313, DOI 10.1002/1097-0142(197106)27:6<1313::AID-CNCR2820270606>3.0.CO;2-W; HANSEN RM, 1989, ONCOLOGY, V46, P245; HOLCENBERG JS, 1977, ANNU REV PHARMACOL, V17, P97, DOI 10.1146/annurev.pa.17.040177.000525; KEMENY N, 1987, SEMIN SURG ONCOL, V3, P190, DOI 10.1002/ssu.2980030312; KOVACH JS, 1979, CANCER TREAT REP, V63, P1909; KUFE DW, 1981, J BIOL CHEM, V256, P9802; KUFE DW, 1981, BIOCHEM PHARMACOL, V30, P129, DOI 10.1016/0006-2952(81)90183-0; MADDREY WC, 1985, GASTROENTEROLOGY, P2922; MARSH JC, 1991, J CLIN ONCOL, V9, P371, DOI 10.1200/JCO.1991.9.3.371; MARTIN DS, 1983, CANCER RES, V43, P2317; MENARD DB, 1980, GASTROENTEROLOGY, V78, P142; MOYER JD, 1979, CANCER RES, V39, P3089; MUGGIA FM, 1987, CANCER TREAT REP, V71, P253; OCONNELL MJ, 1982, CANCER TREAT REP, V66, P77; ODWYER PJ, 1990, J CLIN ONCOL, V8, P1497, DOI 10.1200/JCO.1990.8.9.1497; OHNUMA T, 1970, CANCER RES, V30, P2297; PETERS GJ, 1990, EUR J CANCER, V26, P516, DOI 10.1016/0277-5379(90)90029-S; PRATT CB, 1971, CANCER, V28, P361, DOI 10.1002/1097-0142(197108)28:2<361::AID-CNCR2820280215>3.0.CO;2-3; PRESANT CA, 1983, MED PEDIATR ONCOL, V11, P162, DOI 10.1002/mpo.2950110305; RUBIN J, 1981, CANCER TREAT REP, V65, P335; SILLS RH, 1978, MED PEDIATR ONCOL, V4, P311, DOI 10.1002/mpo.2950040406; VANECHO DA, 1980, CANCER TREAT REP, V64, P339; WEISS GR, 1982, CANCER CHEMOTH PHARM, V8, P301; WINDSCHITL HE, 1990, CANCER, V66, P853, DOI 10.1002/1097-0142(19900901)66:5<853::AID-CNCR2820660507>3.0.CO;2-V	36	20	20	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1991	115	12					946	951		10.7326/0003-4819-115-12-946	http://dx.doi.org/10.7326/0003-4819-115-12-946			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU417	1824554				2022-12-28	WOS:A1991GU41700006
J	MARSH, GN				MARSH, GN			CARING FOR LARGER LISTS	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; PRIMARY CARE; TELEPHONE; PRACTITIONER; MANAGEMENT; COMPUTER; ENGLAND; NORTH; SIZE				MARSH, GN (corresponding author), NORTON MED CTR,STOCKTON ON TEES TS20 1AN,ENGLAND.							AYLETT M, 1985, BRIT MED J, V290, P1115, DOI 10.1136/bmj.290.6475.1115; Balint M., 1970, TREATMENT DIAGNOSIS; BOWLING A, 1988, NURSE FAMILY PRACTIC; BROWN C, 1990, BRIT MED J, V300, P829, DOI 10.1136/bmj.300.6728.829; BUTLER JR, 1987, BMJ-BRIT MED J, V295, P1383, DOI 10.1136/bmj.295.6610.1383; CATER L, 1988, NURSE FAMILY PRACTIC; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; CORNEY RH, 1985, J ROY COLL GEN PRACT, V35, P291; CURTIS P, 1989, CAN FAM PHYSICIAN, V35, P123; DIFFORD F, 1984, J ROY COLL GEN PRACT, V34, P658; DRURY M, 1988, J ROY COLL GEN PRACT, V38, P503; DRURY M, 1990, NEW PRACTICE MANAGER; DRURY M, 1986, MED SECRETARYS RECEP; FLEMING DM, 1985, BRIT MED J, V291, P869, DOI 10.1136/bmj.291.6499.869; FOWLER G, 1988, NURSE FAMILY PRACTIC; GARVIIE D, 1990, HORIZONS         OCT, P10; GRANT GB, 1987, BASIC FORMULARY GENE; Gray D J, 1979, J R Coll Gen Pract, V29, P666; HACETT GI, 1987, BMJ, V294, P24; Hart JT, 1988, PREVENTION CORONARY; JEWELL D, 1988, PRACTITIONER, V232, P474; KNIGHT R, 1987, J ROY COLL GEN PRACT, V37, P19; MARKS I, 1985, BMJ-BRIT MED J, V290, P1181, DOI 10.1136/bmj.290.6476.1181; MARSH G, 1976, TEAM CARE GENERAL PR; MARSH GN, 1987, J ROY COLL GEN PRACT, V37, P301; MARSH GN, 1977, BRIT MED J, V2, P1267, DOI 10.1136/bmj.2.6097.1267; MARSH GN, 1988, BRIT MED J, V296, P173, DOI 10.1136/bmj.296.6616.173; MARSH GN, 1982, LANCET, V1, P669; MARSH GN, 1989, J ROY COLL GEN PRACT, V39, P201; MARSH GN, 1984, BRIT MED J, V288, P200, DOI 10.1136/bmj.288.6412.200; MARSH GN, 1981, BRIT MED J, V283, P1159, DOI 10.1136/bmj.283.6300.1159; MARSH GN, 1980, BRIT MED J, V281, P730, DOI 10.1136/bmj.281.6242.730; MASSEYLYNCH M, 1985, PRACTICE TEAM, P8; MCINTOSH IB, 1988, SCOT MED J, V33, P332, DOI 10.1177/003693308803300507; MCLEOD J, 1989, 37 ROYAL COLL GEN PR; MCLEOD J, 1987, 35 ROYAL COLL GEN PR; MEAD M, 1990, UPDATE, V40, P137; PERRIN EC, 1978, NEW ENGL J MED, V298, P130, DOI 10.1056/NEJM197801192980304; PREECE J, 1990, USE COMPUTERS GENERA; PREECE JF, 1986, J ROY COLL GEN PRACT, V36, P564; PRITCHARD P, 1984, MANAGEMENT GENERAL P; RADECKI SE, 1989, MED CARE, V27, P817, DOI 10.1097/00005650-198908000-00005; RAWLINS MD, 1991, BRIT MED J, V302, P427, DOI 10.1136/bmj.302.6774.427; ROBERTSON H, 1985, J ROY COLL GEN PRACT, V35, P130; ROLAND M, 1987, J ROY COLL GEN PRACT, V37, P481; SINGH BM, 1984, BRIT MED J, V289, P726, DOI 10.1136/bmj.289.6447.726; SPILLING R, 1986, TERMINAL CARE HOME; STILWELL B, 1987, J ROY COLL GEN PRACT, V37, P154; STOTT NCH, 1979, BRIT MED J, V1, P29, DOI 10.1136/bmj.1.6155.29; TANT D, 1985, J ROY COLL GEN PRACT, V35, P507; WHEWELL J, 1983, BRIT MED J, V286, P1259, DOI 10.1136/bmj.286.6373.1259; WILKIN D, 1987, J ROY COLL GEN PRACT, V37, P350; ZANDER L, 1978, 5 ROYAL COLL GEN PRA; 1987, REPORT ROLE ED FUTUR; 1965, CHARTER FAMILY DOCTO; 1988, PRACTICE FORMULARY 1; 1986, GENERAL PRACTITIONER; 1987, PHARM CHARTER EXTEND; 1990, STATISTICAL B, V4, P9; 1990, J PRACTICE MANAG FEB	60	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1312	1316		10.1136/bmj.303.6813.1312	http://dx.doi.org/10.1136/bmj.303.6813.1312			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1815559	Green Published, Bronze			2022-12-28	WOS:A1991GT01100025
J	GYOEVA, FK; GELFAND, VI				GYOEVA, FK; GELFAND, VI			COALIGNMENT OF VIMENTIN INTERMEDIATE FILAMENTS WITH MICROTUBULES DEPENDS ON KINESIN	NATURE			English	Article							MONOCLONAL-ANTIBODY; MICRO-INJECTION; COLLAPSE; CELLS; MOVEMENT; TUBULIN	INTERMEDIATE filaments in most types of cultured cells coalign with microtubules. Depolymerization of microtubules results in collapse of vimentin and desmin intermediate filaments to the nucleus where they form a perinuclear cap (reviewed in ref. 1). Collapse can also be induced by microinjection of antibodies against intermediate filament or microtubule proteins 2-7. Thus, two filament systems interact with each other. But the molecules mediating this interaction are unknown. One of the candidates for this role is a microtubule motor kinesin 8. Recent data showed that kinesin is involved in the plus end-directed movement of the membranous organelles along microtubules such as radial extension of lysosomes in macrophages 9 and centrifugal movement of pigment in melanophores 10. Here we report that injection of the anti-kinesin antibody into human fibroblasts results in the redistribution of intermediate filaments to a tight perinuclear aggregate but had no effect on the distribution of microtubules. Thus, kinesin is involved not only in organelle movement but also in interaction of the two major cytoskeletal systems, intermediate filaments and microtubules.	ACAD SCI USSR,INST PROT RES,PUSHCHINO 142292,USSR	Russian Academy of Sciences			Gelfand, Vladimir/M-1974-2019; Gelfand, Vladimir I/D-2545-2013	Gelfand, Vladimir/0000-0002-6361-2798; Gelfand, Vladimir I/0000-0002-6361-2798				BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; GAWLITTA W, 1981, EUR J CELL BIOL, V26, P83; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOLLENBECK PJ, 1989, J CELL SCI, V92, P621; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; KATSUMOTO T, 1990, BIOL CELL, V68, P139, DOI 10.1016/0248-4900(90)90299-I; KLYMKOWSKY MW, 1989, CELL MOTIL CYTOSKEL, V14, P309, DOI 10.1002/cm.970140302; KLYMKOWSKY MW, 1981, NATURE, V291, P249, DOI 10.1038/291249a0; LIN JJC, 1981, CELL, V24, P185, DOI 10.1016/0092-8674(81)90514-6; PERIDES G, 1987, J BIOL CHEM, V262, P13742; RODONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956; STACEY DW, 1977, P NATL ACAD SCI USA, V74, P1514; TOLLE HG, 1986, EXP CELL RES, V162, P462, DOI 10.1016/0014-4827(86)90350-2; TRAUB P, 1987, EUR J CELL BIOL, V43, P55; TROYANOVSKII SN, 1985, IMMUNOLOGIYA, V6, P70; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VALE RD, 1988, J CELL BIOL, V107, P2233, DOI 10.1083/jcb.107.6.2233; WEHLAND J, 1983, J CELL BIOL, V97, P1476, DOI 10.1083/jcb.97.5.1476	20	198	201	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					445	448		10.1038/353445a0	http://dx.doi.org/10.1038/353445a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1832745				2022-12-28	WOS:A1991GH60600062
J	ENGEBRECHT, J; VOELKELMEIMAN, K; ROEDER, GS				ENGEBRECHT, J; VOELKELMEIMAN, K; ROEDER, GS			MEIOSIS-SPECIFIC RNA SPLICING IN YEAST	CELL			English	Article							MEIOTIC GENE CONVERSION; SACCHAROMYCES-CEREVISIAE; SEXUAL-DIFFERENTIATION; DROSOPHILA-MELANOGASTER; CHROMOSOME SEGREGATION; BETA-GALACTOSIDASE; TRANSFORMER GENE; ESCHERICHIA-COLI; DNA-SEQUENCE; RECOMBINATION	Previous studies have suggested that the differentiated state of meiosis in yeast is regulated primarily at the transcriptional level. This study reports a case of posttranscriptional regulation of a gene whose product is essential for meiosis. The MER2 gene is transcribed in mitosis as well as meiosis; however, the transcript is spliced efficiently to generate a functional gene product only in meiosis. Meiotic levels of splicing depend on the MER1 gene product, which is also essential for meiosis and which is produced only in meiotic cells. Therefore, at least one of the functions of the MER1 protein is to mediate splicing of the MER2 transcript. Genetic data suggest that the MER1 gene may also be responsible for splicing the transcript of at least one other gene.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511	Yale University			Engebrecht, JoAnne/K-3355-2019	Engebrecht, JoAnne/0000-0002-2733-7506	NIGMS NIH HHS [GM28904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMERER G, 1983, METHOD ENZYMOL, V101, P192; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; ATCHESON CL, 1987, P NATL ACAD SCI USA, V84, P8035, DOI 10.1073/pnas.84.22.8035; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; COLE GM, 1989, MOL CELL BIOL, V9, P3101, DOI 10.1128/MCB.9.7.3101; CONEY LR, 1988, MOL CELL BIOL, V8, P4009, DOI 10.1128/MCB.8.10.4009; DABEVA MD, 1987, J BIOL CHEM, V262, P16055; DABEVA MD, 1986, P NATL ACAD SCI USA, V83, P5854, DOI 10.1073/pnas.83.16.5854; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; ENGEBRECHT JA, 1989, GENETICS, V121, P237; FARNET C, 1988, MECHANISMS CONSEQUEN, P201; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; Game J., 1983, YEAST GENETICS FUNDA, P109; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KASSIR Y, 1988, CELL, V52, P853, DOI 10.1016/0092-8674(88)90427-8; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KLAPHOLZ S, 1980, GENETICS, V96, P589; KLAPHOLZ S, 1985, GENETICS, V110, P187; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAMBIE EJ, 1988, CELL, V52, P863, DOI 10.1016/0092-8674(88)90428-X; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; Maniatis T., 1982, MOL CLONING; MENEES TM, 1989, GENETICS, V123, P675; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; PERCIVALSMITH A, 1984, MOL CELL BIOL, V4, P142, DOI 10.1128/MCB.4.1.142; PERKINS DD, 1949, GENETICS, V34, P607; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; ROCKMILL B, 1988, P NATL ACAD SCI USA, V85, P6057, DOI 10.1073/pnas.85.16.6057; ROCKMILL B, 1990, GENETICS, V126, P563; RODRIGUEZ JR, 1984, CELL, V39, P603, DOI 10.1016/0092-8674(84)90467-7; ROSE M, 1983, METHOD ENZYMOL, V101, P167; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sherman F., 1986, METHODS YEAST GENETI; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SMITH HE, 1989, MOL CELL BIOL, V9, P2142, DOI 10.1128/MCB.9.5.2142; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; STEWART SE, 1989, MOL CELL BIOL, V9, P3464, DOI 10.1128/MCB.9.8.3464; THOMPSON EA, 1989, MOL GEN GENET, V218, P293, DOI 10.1007/BF00331281; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WANG HT, 1987, MOL CELL BIOL, V7, P1425, DOI 10.1128/MCB.7.4.1425; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604	64	166	171	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1257	1268		10.1016/0092-8674(91)90047-3	http://dx.doi.org/10.1016/0092-8674(91)90047-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1840507				2022-12-28	WOS:A1991GG55200019
J	COX, LS; LASKEY, RA				COX, LS; LASKEY, RA			DNA-REPLICATION OCCURS AT DISCRETE SITES IN PSEUDONUCLEI ASSEMBLED FROM PURIFIED DNA INVITRO	CELL			English	Article							CELL NUCLEAR ANTIGEN; XENOPUS EGGS; POLYMERASE-ALPHA; FREE-EXTRACT; CYCLE; INITIATION; PHASE	Bacteriophage-lambda DNA is assembled into pseudonuclei in Xenopus egg extract and replicated semiconservatively under temporal cell cycle control. Here, replication is shown to be regulated spatially and to occur at discrete sites that represent clustered replication forks. Clustered forks are visualized by incorporation of biotin-19-dUTP into nascent DNA. Pulse-label experiments show that discrete replication foci persist throughout S phase. We conclude that the organization of replication forks into discrete clusters, previously described in eukaryotic nuclei, is not dependent on specific eukaryotic DNA sequences or on a preexisting inherited chromosomal or nuclear structure.			COX, LS (corresponding author), WELLCOME CANC RES CAMPAIGN INST,CANC RES CAMPAIGN MOLEC EMBRYOL GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Cox, Lynne/AAT-2047-2021	Cox, Lynne/0000-0002-5306-285X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLOW JJ, 1990, J CELL SCI, V95, P383; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1987, EMBO J, V6, P1997, DOI 10.1002/j.1460-2075.1987.tb02463.x; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; COOK PR, 1988, J CELL SCI, V90, P1; FORBES DJ, 1983, CELL, V34, P13, DOI 10.1016/0092-8674(83)90132-0; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; HUTCHISON C, 1989, J CELL SCI, V93, P605; LENO GH, 1991, J CELL BIOL, V112, P557, DOI 10.1083/jcb.112.4.557; MECHALI M, 1983, CELL, V35, P63, DOI 10.1016/0092-8674(83)90208-8; MECHALI M, 1984, CELL, V38, P55, DOI 10.1016/0092-8674(84)90526-9; MILLS AD, 1989, J CELL SCI, V94, P471; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAMURA H, 1984, EXP CELL RES, V151, P123, DOI 10.1016/0014-4827(84)90362-8; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; Sambrook J, 1989, MOL CLONING LABORATO; VERHEIJEN R, 1988, J CELL SCI, V90, P11	21	70	71	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					271	275		10.1016/0092-8674(91)90617-8	http://dx.doi.org/10.1016/0092-8674(91)90617-8			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1830242				2022-12-28	WOS:A1991FY71200008
J	BAGCHI, S; WEINMANN, R; RAYCHAUDHURI, P				BAGCHI, S; WEINMANN, R; RAYCHAUDHURI, P			THE RETINOBLASTOMA PROTEIN COPURIFIES WITH E2F-I, AN E1A-REGULATED INHIBITOR OF THE TRANSCRIPTION FACTOR E2F	CELL			English	Article								Recently, we identified an inhibitory protein, E2F-I, that blocks the DNA-binding activity of the transcription factor E2F. We also showed that the adenovirus ElA protein reverses this inhibitory activity of E2F-I, thereby restoring the DNA-binding activity of E2F. We have now further purified this inhibitory activity and show that the most purified preparation of E2F-I contains a 105 kd E1A-binding protein. This 105 kd E1A-binding protein cross-reacts with two different antibodies against the retinoblastoma (RB) gene product. Moreover, the RB gene product copurifies with E2F-I activity. Taken together, we conclude that the product of the RB gene is a part of E2F-I and is involved in the regulation of E2F activity.	UNIV ILLINOIS, COLL DENT MC860, CTR RES PERIODONTAL DIS & ORAL MOLEC BIOL, CHICAGO, IL 60680 USA; WISTAR INST, PHILADELPHIA, PA 19104 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; The Wistar Institute	BAGCHI, S (corresponding author), UNIV ILLINOIS, DEPT BIOCHEM MC536, CHICAGO, IL 60680 USA.				NCI NIH HHS [CA 44466, CA 10815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815, R01CA044466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BABISS LE, 1989, J VIROL, V63, P2709, DOI 10.1128/JVI.63.6.2709-2717.1989; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RAYCHAUDHURI P, 1991, IN PRESS GENES DEV; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; REISSMANN PT, 1989, ONCOGENE, V4, P839; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	54	424	435	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1991	65	6					1063	1072		10.1016/0092-8674(91)90558-G	http://dx.doi.org/10.1016/0092-8674(91)90558-G			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1828393				2022-12-28	WOS:A1991FR04700017
J	WULCZYN, FG; KAHMANN, R				WULCZYN, FG; KAHMANN, R			TRANSLATIONAL STIMULATION - RNA SEQUENCE AND STRUCTURE REQUIREMENTS FOR BINDING OF COM PROTEIN	CELL			English	Article								Translation of the bacteriophage Mu mom gene is positively regulated by the phage Com protein. We report here that purified Com protein specifically stimulates mom gene expression in vitro. Furthermore, Com is shown to bind a site in the mom translational initiation region (TIR) in a sequence-specific manner. In vitro RNA footprint experiments have been used to define the Com-binding site and to study mRNA secondary structure in the mom TIR. Com binding is shown to correlate with a conformational change in the mom TIR both in vivo and in vitro. The role of secondary structure was further examined by testing the effects of mutations in the TIR on translation and stimulation. The results support a model for translational stimulation in which Com binding induces a conformational change in the mom mRNA, thereby enhancing ribosome binding.			WULCZYN, FG (corresponding author), BERLIN GMBH, INST GENBIOL FORSCH, IHNESTR 63, W-1000 BERLIN 33, GERMANY.							AIBA H, 1981, J BIOL CHEM, V256, P1905; ALTUVIA S, 1989, J MOL BIOL, V210, P265, DOI 10.1016/0022-2836(89)90329-X; ALTUVIA S, 1987, P NATL ACAD SCI USA, V84, P6511, DOI 10.1073/pnas.84.18.6511; BETZ JL, 1976, J MOL BIOL, V105, P293, DOI 10.1016/0022-2836(76)90113-3; CAREY J, 1983, BIOCHEMISTRY-US, V22, P4723, DOI 10.1021/bi00289a017; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DESMIT MH, 1990, P NATL ACAD SCI USA, V87, P7668, DOI 10.1073/pnas.87.19.7668; GOLD L, 1981, ANNU REV MICROBIOL, V35, P365, DOI 10.1146/annurev.mi.35.100181.002053; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GRALLA J, 1974, NATURE, V248, P204, DOI 10.1038/248204a0; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HATTMAN S, 1987, GENE, V55, P345, DOI 10.1016/0378-1119(87)90295-2; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; KAHMANN R, 1985, GENE, V39, P61, DOI 10.1016/0378-1119(85)90108-8; KAHMANN R, 1982, COLD SPRING HARB SYM, V47, P639; LEACH D, 1979, MOL GEN GENET, V172, P179, DOI 10.1007/BF00268280; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MAYFORD M, 1989, EMBO J, V8, P4307, DOI 10.1002/j.1460-2075.1989.tb08617.x; MCMULLIN TW, 1990, MOL CELL BIOL, V10, P4590, DOI 10.1128/MCB.10.9.4590; MCPHEETERS DS, 1988, J MOL BIOL, V201, P517, DOI 10.1016/0022-2836(88)90634-1; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOINE H, 1988, P NATL ACAD SCI USA, V85, P7892, DOI 10.1073/pnas.85.21.7892; ROMANIUK PJ, 1987, BIOCHEMISTRY-US, V26, P1563, DOI 10.1021/bi00380a011; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; STERN S, 1988, METHOD ENZYMOL, V164, P481; STORMO GD, 1986, MAXIMIZING GENE EXPR, P195; TANG CK, 1989, CELL, V57, P531, DOI 10.1016/0092-8674(89)90123-2; TOUSSAINT A, 1976, VIROLOGY, V70, P17, DOI 10.1016/0042-6822(76)90232-4; WINTER RB, 1987, P NATL ACAD SCI USA, V84, P7822, DOI 10.1073/pnas.84.22.7822; WULCZYN FG, 1989, CELL, V57, P1201, DOI 10.1016/0092-8674(89)90057-3; WULCZYN FG, 1987, GENE, V51, P139, DOI 10.1016/0378-1119(87)90302-7; WULCZYN FG, 1990, NATO ASI SERIES H, V49, P285; WYCKOFF E, 1986, GENE, V43, P281, DOI 10.1016/0378-1119(86)90217-9; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	38	56	58	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1991	65	2					259	269		10.1016/0092-8674(91)90160-Z	http://dx.doi.org/10.1016/0092-8674(91)90160-Z			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1826635				2022-12-28	WOS:A1991FH09200009
J	GHIARA, JB; RICHARDSON, HE; SUGIMOTO, K; HENZE, M; LEW, DJ; WITTENBERG, C; REED, SI				GHIARA, JB; RICHARDSON, HE; SUGIMOTO, K; HENZE, M; LEW, DJ; WITTENBERG, C; REED, SI			A CYCLIN-B HOMOLOG IN SACCHAROMYCES-CEREVISIAE - CHRONIC ACTIVATION OF THE CDC28 PROTEIN-KINASE BY CYCLIN PREVENTS EXIT FROM MITOSIS	CELL			English	Article							CELL-DIVISION CYCLE; CONTROL GENE CDC2+; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; M-PHASE; SCHIZOSACCHAROMYCES-POMBE; COMPONENT; PRODUCT; MPF	A cyclin B homolog was identified in Saccharomyces cerevisiae using degenerate oligonucleotides and the polymerase chain reaction. The protein, designated Scb1, has a high degree of similarity with B-type cyclins from organisms ranging from fission yeast to human. Levels of SCB1 mRNA and protein were found to be periodic through the cell cycle, with maximum accumulation late, most likely in the G2 interval. Deletion of the gene was found not to be lethal, and subsequently other B-type cyclins have been found in yeast functionally redundant with Scb1. A mutant allele of SCB1 that removes an amino-terminal fragment of the encoded protein thought to be required for efficient degradation during mitosis confers a mitotic arrest phenotype. This arrest can be reversed by inactivation of the Cdc28 protein kinase, suggesting that cyclin-mediated arrest results from persistent protein kinase activation.			GHIARA, JB (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC BIOL, MB-7, LA JOLLA, CA 92037 USA.		Richardson, Helena E/A-8080-2013	Richardson, Helena E/0000-0003-3852-4953	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038328, R37GM038328, R01GM043487] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38328, GM43487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GLOTZER M, 1991, NATURE, V349, P32; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGAN I, 1988, J CELL SCI, V91, P587; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1973, GENETICS, V74, P267; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; LORINCZ AT, 1986, MOL CELL BIOL, V6, P4099; Maniatis T., 1982, MOL CLONING; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; REED SI, 1980, GENETICS, V95, P561; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; RICHARDSON HE, 1989, CELL, V59, P127; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1982, METHODS YEAST GENETI; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WHITFIELD WGF, 1989, NATURE, V338, P337, DOI 10.1038/338337a0; WITTENBERG C, 1987, J CELL BIOL, V105, P1527, DOI 10.1083/jcb.105.4.1527; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	72	277	280	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					163	174		10.1016/0092-8674(91)90417-W	http://dx.doi.org/10.1016/0092-8674(91)90417-W			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1849458	Bronze			2022-12-28	WOS:A1991FF77300018
J	HSU, IC; METCALF, RA; SUN, T; WELSH, JA; WANG, NJ; HARRIS, CC				HSU, IC; METCALF, RA; SUN, T; WELSH, JA; WANG, NJ; HARRIS, CC			MUTATIONAL HOTSPOT IN THE P53 GENE IN HUMAN HEPATOCELLULAR CARCINOMAS	NATURE			English	Article							DNA; EXPOSURE	HUMAN hepatocellular carcinomas (HCC) from patients in Qidong, an area of high incidence in China, in which both hepatitis B virus and aflatoxin B1 are risk factors 1, were analysed for mutations in p53, a putative tumour-suppressor gene. Eight of the 16 HCC had a point mutation at the third base position of codon 249. The G --> T transversion in seven HCC DNA samples and the G --> C transversion in the other HCC are consistent with mutations caused by aflatoxin B1 in mutagenesis experiments 2,3. No mutations were found in exons 5, 6, 8 or the remainder of exon 7. These results contrast with p53 mutations previously reported in carcinomas and sarcomas of human lung, colon, oesophagus and breast; these are primarily scattered over four of the five evolutionarily conserved domains, which include codon 249 (refs 4-9). We suggest that the mutant p53 protein may be responsible for a selective clonal expansion of hepatocytes during carcinogenesis.	NCI,DIV CANC ETIOL,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892; UNIV MARYLAND,SCH MED,DEPT PATHOL,BALTIMORE,MD 21201; CHINESE ACAD MED SCI,INST CANC,BEIJING,PEOPLES R CHINA; QIDONG LIVER CANC INST,JIANGSU,PEOPLES R CHINA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; Chinese Academy of Medical Sciences - Peking Union Medical College								AUTRUP H, 1984, CHEM-BIOL INTERACT, V50, P15, DOI 10.1016/0009-2797(84)90128-5; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; HARRIS CC, 1990, CANCER CELL-MON REV, V2, P146; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1978, P NATL ACAD SCI USA, V75, P2003, DOI 10.1073/pnas.75.4.2003; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; LECHNER JF, 1989, CANCER DETECT PREV, V14, P239; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCMAHON G, 1990, P NATL ACAD SCI USA, V87, P1104, DOI 10.1073/pnas.87.3.1104; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; SAMBAMURTI K, 1988, GENETICS, V120, P863; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUSSI T, 1987, ONCOGENE, V1, P71; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SUKUMAR S, 1988, SCIENCE, V240, P524, DOI 10.1126/science.3282307; Sun T., 1986, DIET NUTRITION CANCE, P225; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WINBERG G, 1980, NUCLEIC ACIDS RES, V8, P253, DOI 10.1093/nar/8.2.253; WOGAN GN, 1989, ENVIRON HEALTH PERSP, V81, P9, DOI 10.2307/3430797; WOGAN GN, 1985, ENVIRON HEALTH PERSP, V62, P5, DOI 10.2307/3430088	25	1455	1520	1	67	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					427	428		10.1038/350427a0	http://dx.doi.org/10.1038/350427a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	1849234				2022-12-28	WOS:A1991FF04200051
J	MORI, Y; FRIEDRICH, T; KIM, MS; MIKAMI, A; NAKAI, J; RUTH, P; BOSSE, E; HOFMANN, F; FLOCKERZI, V; FURUICHI, T; MIKOSHIBA, K; IMOTO, K; TANABE, T; NUMA, S				MORI, Y; FRIEDRICH, T; KIM, MS; MIKAMI, A; NAKAI, J; RUTH, P; BOSSE, E; HOFMANN, F; FLOCKERZI, V; FURUICHI, T; MIKOSHIBA, K; IMOTO, K; TANABE, T; NUMA, S			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION FROM COMPLEMENTARY-DNA OF A BRAIN CALCIUM-CHANNEL	NATURE			English	Article							SKELETAL-MUSCLE; DIHYDROPYRIDINE RECEPTOR; CEREBELLAR SLICES; MESSENGER-RNAS; MUTANT MICE; ALPHA-1-SUBUNIT; MODULATION; CURRENTS; SEQUENCE; NEURONS	The primary structure of a voltage-dependent calcium channel from rabbit brain has been deduced by cloning and sequencing the complementary DNA. Calcium channel activity expressed from the cDNA is dramatically increased by coexpression of the alpha-2 and beta-subunits, known to be associated with the dihydropyridine receptor. This channel is a high voltage-activated calcium channel that is insensitive both to nifedipine and to omega-conotoxin. We suggest that it is expressed predominantly in cerebellar Purkinje cells and granule cells.	KYOTO UNIV, FAC MED, DEPT MED CHEM, KYOTO 606, JAPAN; KYOTO UNIV, FAC MED, DEPT MOLEC GENET, KYOTO 606, JAPAN; UNIV SAARLAND, FAK MED, INST MED BIOCHEM, W-6650 HOMBURG, GERMANY; NATL INST BASIC BIOL, DIV BEHAV & NEUROBIOL, OKAZAKI, AICHI 444, JAPAN; OSAKA UNIV, INST PROT RES, DIV REGULAT MACROMOLEC FUNCT, SUITA, OSAKA 565, JAPAN	Kyoto University; Kyoto University; Saarland University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Osaka University			Mikoshiba, Katsuhiko/N-7943-2015; Nakai, Junichi/GQZ-6415-2022; Furuichi, Teiichi/B-5086-2014	Furuichi, Teiichi/0000-0002-9676-1888; Imoto, Keiji/0000-0002-2861-5985				AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BERTOLINO M, 1990, FASEB J, V4, pA1202; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BOLL W, 1985, NEUROSCI LETT, V56, P335, DOI 10.1016/0304-3940(85)90265-4; BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; BRADLEY P, 1978, BRAIN RES, V142, P135, DOI 10.1016/0006-8993(78)90182-8; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CREPEL F, 1984, J PHYSIOL-LONDON, V346, P111, DOI 10.1113/jphysiol.1984.sp015010; DASCAL N, 1986, SCIENCE, V231, P1147, DOI 10.1126/science.2418503; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HIRANO A, 1975, J NEUROPATH EXP NEUR, V34, P1, DOI 10.1097/00005072-197501000-00001; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KASAI H, 1987, Neuroscience Research, V4, P228, DOI 10.1016/0168-0102(87)90014-9; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LIN JW, 1990, P NATL ACAD SCI USA, V87, P4538, DOI 10.1073/pnas.87.12.4538; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; NUMA S, 1986, ANN NY ACAD SCI, V479, P338, DOI 10.1111/j.1749-6632.1986.tb15580.x; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; Purves, 1985, PRINCIPLES NEURAL DE; RAKIC P, 1973, J COMP NEUROL, V152, P103, DOI 10.1002/cne.901520202; REGAN LJ, 1989, ANN NY ACAD SCI, V560, P121, DOI 10.1111/j.1749-6632.1989.tb24088.x; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SAH D W Y, 1989, Society for Neuroscience Abstracts, V15, P823; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4	37	766	792	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	1991	350	6317					398	402		10.1038/350398a0	http://dx.doi.org/10.1038/350398a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	1849233				2022-12-28	WOS:A1991FF04200040
J	KINZLER, KW; NILBERT, MC; VOGELSTEIN, B; BRYAN, TM; LEVY, DB; SMITH, KJ; PREISINGER, AC; HAMILTON, SR; HEDGE, P; MARKHAM, A; CARLSON, M; JOSLYN, G; GRODEN, J; WHITE, R; MIKI, Y; MIYOSHI, Y; NISHISHO, I; NAKAMURA, Y				KINZLER, KW; NILBERT, MC; VOGELSTEIN, B; BRYAN, TM; LEVY, DB; SMITH, KJ; PREISINGER, AC; HAMILTON, SR; HEDGE, P; MARKHAM, A; CARLSON, M; JOSLYN, G; GRODEN, J; WHITE, R; MIKI, Y; MIYOSHI, Y; NISHISHO, I; NAKAMURA, Y			IDENTIFICATION OF A GENE LOCATED AT CHROMOSOME-5Q21 THAT IS MUTATED IN COLORECTAL CANCERS	SCIENCE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; MUTATIONS; ONCOGENES; COLON; ANTIONCOGENES; LOCALIZATION; CARCINOMAS; SULINDAC; ALLELE; TUMORS	Recent studies have suggested the existence of a tumor suppressor gene located at chromosome region 5q21. DNA probes from this region were used to study a panel of sporadic colorectal carcinomas. One of these probes, cosmid 5.71, detected a somatically rearranged restriction fragment in the DNA from a single tumor. Further analysis of the 5.71 cosmid revealed two regions that were highly conserved in rodent DNA. These sequences were used to identify a gene, MCC (mutated in colorectal cancer), which encodes an 829-amino acid protein with a short region of similarity to the G protein-coupled m3 muscarinic acetylcholine receptor. The rearrangement in the tumor disrupted the coding region of the MCC gene. Moreover, two colorectal tumors were found with somatically acquired point mutations in MCC that resulted in amino acid substitutions. MCC is thus a candidate for the putative colorectal tumor suppressor gene located at 5q21. Further studies will be required to determine whether the gene is mutated in other sporadic tumors or in the germ line of patients with an inherited predisposition to colonic tumorigenesis.	JOHNS HOPKINS ONCOL CTR,MOLEC GENET LAB,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV HOSP,CTR ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,DEPT PATHOL,BALTIMORE,MD 21205; UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84132; JAPANESE FDN CANC RES,INST CANC,TOKYO 170,JAPAN	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Japanese Foundation for Cancer Research			Bryan, Tracy M/B-8468-2014	Nilbert, Mef/0000-0003-2717-1937; Bryan, Tracy/0000-0002-7990-5501	NATIONAL CANCER INSTITUTE [P30CA006973, T32CA009243] Funding Source: NIH RePORTER; NCI NIH HHS [CA 06973, CA 09243] Funding Source: Medline; PHS HHS [6M 07184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHARNEAU J, 1990, GASTROEN CLIN BIOL, V14, P153; DELATTRE O, 1989, LANCET, V2, P353; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; KINZLER KD, UNPUB; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MONOCO AP, 1986, NATURE, V323, P646; MYERS RM, 1986, COLD SPRING HARB SYM, V51, P275, DOI 10.1101/SQB.1986.051.01.033; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; ROLE C, 1987, P NATL ACAD SCI USA, V84, P3623; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SASAKI M, 1989, CANCER RES, V49, P4402; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; TU G, 1990, CELL, V63, P835; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEINBERG RA, 1989, CANCER RES, V49, P3713; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575	43	684	726	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1991	251	4999					1366	1370		10.1126/science.1848370	http://dx.doi.org/10.1126/science.1848370			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	1848370				2022-12-28	WOS:A1991FB73300047
J	NOREL, R; AGUR, Z				NOREL, R; AGUR, Z			A MODEL FOR THE ADJUSTMENT OF THE MITOTIC CLOCK BY CYCLIN AND MPF LEVELS	SCIENCE			English	Article							CELL-CYCLE; BIOLOGY	A mathematical model of cell cycle progression is presented, which integrates recent biochemical information on the interaction of the maturation promotion factor (MPF) and cyclin. The model retrieves the dynamics observed in early embryos and explains how multiple cycles of MPF activity can be produced and how the internal clock that determines durations and number of cycles can be adjusted by modulating the rate of change in MPF or cyclin concentrations. Experiments are suggested for verifying the role of MPF activity in determining the length of the somatic cell cycle.	WEIZMANN INST SCI,DEPT APPL MATH & COMP SCI,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Norel, Raquel/ABB-3422-2021	Norel, Raquel/0000-0001-7737-4172				CONTE SD, 1965, ELEMENTARY NUMERICAL; LIN CC, 1988, MATH APPLIED DETERMI; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NORTH G, 1989, NATURE, V339, P97, DOI 10.1038/339097a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086	11	80	83	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1076	1078		10.1126/science.1825521	http://dx.doi.org/10.1126/science.1825521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1825521				2022-12-28	WOS:A1991EZ66500052
J	ROBINE, JM; RITCHIE, K				ROBINE, JM; RITCHIE, K			HEALTHY LIFE EXPECTANCY - EVALUATION OF GLOBAL INDICATOR OF CHANGE IN POPULATION HEALTH	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DISABILITY; MORBIDITY	Objective-To review and evaluate the usefulness of healthy life expectancy as a global indicator of changes in a population's health. Design-Review of all known studies to date from the United States, mainland Europe, Canada, and the United Kingdom that have used Sullivan's method of calculating disability free life expectancy. Main outcome measures-Life expectancy and disability free life expectancy. Results-Over the past decade the average healthy life expectancy was 60 years for men and 64 for women, with the proportion of years of disability ranging from 11% to 21% in men and from 14% to 24% in women. At the age of 65 men could expect eight years of disability free life and women 10, with the life expectancy being respectively 14 and 19 years. The difference between the wealthiest and poorest income quintiles was 6.3 years in life expectancy and 14.3 in disability free life expectancy for men and 2.8 and 7.6 respectively for women. These results suggest that disparities in health are greater between social groups than between the sexes. Diseases affect mortality and morbidity differently. The order of importance for affecting life expectancy was circulatory disease, cancer, and accidents and for disability free life expectancy, circulatory disease, locomotor disorders, and respiratory disorders. Conclusions-Healthy life expectancy is a valuable index for the appreciation of changes in both the physical and the mental health states of the general population, for allocating resources, and for measuring the success of political programmes. Future calculations should also take into account the probability of recovery and thus extend the applicability of the indicator to populations in poor health rather than focusing on the well population.			ROBINE, JM (corresponding author), CTR HOSP REG UNIV LAPEYRONIE, EPIDEMIOL VIEILLISSEMENT & INCAPAC, INSERM, F-34059 MONTPELLIER, FRANCE.		Robine, Jean-Marie/F-5439-2011; Ritchie, Karen/G-3571-2013	Robine, Jean-Marie/0000-0002-4111-6195; Ritchie, Karen/0000-0002-0688-8982				[Anonymous], 1980, INT CLASSIFICATION I; BEBBINGTON AC, 1988, SOC SCI MED, V27, P321, DOI 10.1016/0277-9536(88)90265-1; Colvez A, 1986, Int Rehabil Med, V8, P18; COLVEZ A, 1983, INT J EPIDEMIOL, V12, P224, DOI 10.1093/ije/12.2.224; CRIMMINS EM, 1989, POPUL DEV REV, V15, P235, DOI 10.2307/1973704; DAVIES AM, 1985, INT J EPIDEMIOL, V14, P9, DOI 10.1093/ije/14.1.9; FRIES JF, 1989, MILBANK Q, V67, P208, DOI 10.2307/3350138; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FUCHS VR, 1984, MILBANK FUND Q, V62, P143; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; KATZ S, 1976, INT J HEALTH SERV, V6, P493, DOI 10.2190/UURL-2RYU-WRYD-EY3K; KOIZUMI A, 1985, HEALTH POLICY, V4, P307, DOI 10.1016/0168-8510(85)90012-0; KRAMER M, 1980, ACTA PSYCHIAT SCAND, V62, P382, DOI 10.1111/j.1600-0447.1980.tb07714.x; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; RITCHIE K, 1988, J CLIN EPIDEMIOL, V41, P635, DOI 10.1016/0895-4356(88)90115-1; ROBICHAUD JB, 1985, SANTE FRANCOPHOMES; ROBINE JM, 1987, REV EPIDEMIOL SANTE, V35, P206; ROBINE JM, 1986, POPULATION, V41, P1025, DOI 10.2307/1532928; ROGERS A, 1989, PUBLIC HEALTH REP, V104, P222; SANDERS BS, 1964, AM J PUBLIC HEALTH N, V54, P1063, DOI 10.2105/AJPH.54.7.1063; STURT E, 1986, PSYCHOL MED, V16, P583, DOI 10.1017/S0033291700010345; SULLIVAN DF, 1971, HSMHA HEALTH REP, V86, P347, DOI 10.2307/4594169; WILKINS R, 1983, AM J PUBLIC HEALTH, V73, P1073, DOI 10.2105/AJPH.73.9.1073; WILKINS R, 1988, SANTE CA VA RAPPORT, V1, P175; Wood Ph.H.N., 1980, CHRONIQUE OMS, V34, P400; 1984, TECH REP SER WHO, P706; 1983, DUREE QUALITE VIE; 1969, SOCIAL REPORT	30	163	166	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 23	1991	302	6774					457	460		10.1136/bmj.302.6774.457	http://dx.doi.org/10.1136/bmj.302.6774.457			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	1825931	Green Published, Bronze			2022-12-28	WOS:A1991EZ03300027
J	LEAPE, LL; BRENNAN, TA; LAIRD, N; LAWTHERS, AG; LOCALIO, AR; BARNES, BA; HEBERT, L; NEWHOUSE, JP; WEILER, PC; HIATT, H				LEAPE, LL; BRENNAN, TA; LAIRD, N; LAWTHERS, AG; LOCALIO, AR; BARNES, BA; HEBERT, L; NEWHOUSE, JP; WEILER, PC; HIATT, H			THE NATURE OF ADVERSE EVENTS IN HOSPITALIZED-PATIENTS - RESULTS OF THE HARVARD MEDICAL-PRACTICE STUDY-II	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE; PREVENTION; MANAGEMENT; QUALITY	Background. In a sample of 30,195 randomly selected hospital records, we identified 1133 patients (3.7 percent) with disabling injuries caused by medical treatment. We report here an analysis of these adverse events and their relation to error, negligence, and disability. Methods. Two physician-reviewers independently identified the adverse events and evaluated them with respect to negligence, errors in management, and extent of disability. One of the authors classified each event according to type of injury. We tested the significance of differences in rates of negligence and disability among categories with at least 30 adverse events. Results. Drug complications were the most common type of adverse event (19 percent), followed by wound infections (14 percent) and technical complications (13 percent). Nearly half the adverse events (48 percent) were associated with an operation. Adverse events during surgery were less likely to be caused by negligence (17 percent) than nonsurgical ones (37 percent). The proportion of adverse events due to negligence was highest for diagnostic mishaps (75 percent), noninvasive therapeutic mishaps ("errors of omission") (77 percent), and events occurring in the emergency room (70 percent). Errors in management were identified for 58 percent of the adverse events, among which nearly half were attributed to negligence. Conclusions. Although the prevention of many adverse events must await improvements in medical knowledge, the high proportion that are due to management errors suggests that many others are potentially preventable now. Reducing the incidence of these events will require identifying their causes and developing methods to prevent error or reduce its effects.	HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH LAW,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard Medical School	LEAPE, LL (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Newhouse, Joseph/AAD-9763-2019; Newhouse, Joseph/AGJ-5632-2022					BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1990, ANN INTERN MED, V112, P221, DOI 10.7326/0003-4819-112-3-221; BRENNAN TA, 1989, MED CARE, V27, P1148, DOI 10.1097/00005650-198912000-00006; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; DEARDEN CH, 1985, INJURY, V16, P249, DOI 10.1016/S0020-1383(85)80013-9; HIATT HH, 1989, NEW ENGL J MED, V321, P480, DOI 10.1056/NEJM198908173210725; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; Miller R.G., 1981, SIMULTANEOUS STAT IN, Ved 2nd, DOI DOI 10.1007/s11263-015-0816-y; PERROW C, 1984, NORMAL ACCIDENTS LIV; RICKETSON DS, 1980, AVIAT SPACE ENVIR MD, V51, P1036; SHAH BV, 1981, SESUDAAN STANDARD ER; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; VINCENT CA, 1989, BMJ-BRIT MED J, V299, P1150, DOI 10.1136/bmj.299.6708.1150; 1977, REPORT MED INSURANCE	16	2452	2534	1	106	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 7	1991	324	6					377	384		10.1056/NEJM199102073240605	http://dx.doi.org/10.1056/NEJM199102073240605			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW296	1824793	Green Submitted, Green Published			2022-12-28	WOS:A1991EW29600005
J	ENNALS, S				ENNALS, S			UNDERSTANDING BENEFITS - BENEFITS FOR PEOPLE INCAPABLE OF WORK	BRITISH MEDICAL JOURNAL			English	Article											ENNALS, S (corresponding author), ESSENTIAL RIGHTS,94 CHAWORTH RD,NOTTINGHAM NG2 7AD,ENGLAND.							POVERTY ACTION GROUP	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					160	162		10.1136/bmj.302.6769.160	http://dx.doi.org/10.1136/bmj.302.6769.160			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU020	1825292	Green Published, Bronze			2022-12-28	WOS:A1991EU02000026
J	SCHRIJVERS, AJP				SCHRIJVERS, AJP			THE NETHERLANDS INTRODUCES SOME COMPETITION INTO THE HEALTH-SERVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									STATE UNIV UTRECHT,UTRECHT,NETHERLANDS	Utrecht University								KIRKMANLIFF BL, 1991, JAMA-J AM MED ASSOC, V265, P2496; 1987, CHANGING HLTH CARE N; 1990, FINANCIEEL OVERZICHT, P1; 1990, GEZONDHEIDSZORG CIJF; 1990, JB LIZ 1989; 1989, VADEMECUM HLTH STATI	6	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2215	2217		10.1001/jama.266.16.2215	http://dx.doi.org/10.1001/jama.266.16.2215			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK661	1823541				2022-12-28	WOS:A1991GK66100014
J	KOFF, A; CROSS, F; FISHER, A; SCHUMACHER, J; LEGUELLEC, K; PHILIPPE, M; ROBERTS, JM				KOFF, A; CROSS, F; FISHER, A; SCHUMACHER, J; LEGUELLEC, K; PHILIPPE, M; ROBERTS, JM			HUMAN CYCLIN-E, A NEW CYCLIN THAT INTERACTS WITH 2 MEMBERS OF THE CDC2 GENE FAMILY	CELL			English	Article							MATURATION-PROMOTING FACTOR; P34CDC2 PROTEIN-KINASE; MAMMALIAN-CELL-CYCLE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; M-PHASE; DNA-REPLICATION; MESSENGER-RNA; SCHIZOSACCHAROMYCES-POMBE; MATING-PHEROMONE	A new human cyclin, named cyclin E, was isolated by complementation of a triple cln deletion in S. cerevisiae. Cyclin E showed genetic interactions with the CDC28 gene, suggesting that it functioned at START by interacting with the CDC28 protein. Two human genes were identified that could interact with cyclin E to perform START in yeast containing a cdc28 mutation. One was CDC2-HS, and the second was the human homolog of Xenopus CDK2. Cyclin E produced in E. coli bound and activated the CDC2 protein in extracts from human G1 cells, and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells. The interactions between cyclin E and CDC2, or CDK2, may be important at the G1 to S transition in human cells.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; UNIV RENNES 1, BIOL & GENET DEV LAB, CNRS, UNITE 256, F-35042 RENNES, FRANCE	Rockefeller University; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	KOFF, A (corresponding author), FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Schumacher, Jill/B-2932-2012; Fisher, Alfred/H-3031-2012	Fisher, Alfred/0000-0001-6451-2644				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURKACZ B, 1986, EMBO J, V5, P369, DOI 10.1002/j.1460-2075.1986.tb04221.x; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGAN I, 1988, J CELL SCI, V91, P587; HARTWELL LH, 1973, GENETICS, V74, P267; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MARSHAK DR, 1991, J CELL BIOCHEM, V45, P391, DOI 10.1002/jcb.240450413; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROBERTS JM, 1988, SCIENCE, V241, P1486, DOI 10.1126/science.2843984; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WITTENBERG C, 1989, MOL CELL BIOL, V9, P4064, DOI 10.1128/MCB.9.9.4064; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zetterberg A, 1990, CURR OPIN CELL BIOL, V2, P296, DOI 10.1016/0955-0674(90)90022-7; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	77	627	683	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1217	1228		10.1016/0092-8674(91)90044-Y	http://dx.doi.org/10.1016/0092-8674(91)90044-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1833068				2022-12-28	WOS:A1991GG55200016
J	TAVERNIER, J; DEVOS, R; CORNELIS, S; TUYPENS, T; VANDERHEYDEN, J; FIERS, W; PLAETINCK, G				TAVERNIER, J; DEVOS, R; CORNELIS, S; TUYPENS, T; VANDERHEYDEN, J; FIERS, W; PLAETINCK, G			A HUMAN HIGH-AFFINITY INTERLEUKIN-5 RECEPTOR (IL5R) IS COMPOSED OF AN IL5-SPECIFIC ALPHA-CHAIN AND A BETA-CHAIN SHARED WITH THE RECEPTOR FOR GM-CSF	CELL			English	Article							COLONY-STIMULATING FACTOR; EOSINOPHIL DIFFERENTIATION FACTOR; MOLECULAR-CLONING; HISTAMINE-RELEASE; SOLUBLE FORM; GENE FAMILY; HUMAN-URINE; EXPRESSION; BINDING; CELLS	cDNA clones encoding two receptor proteins involved in the binding of human interleukin 5 (hIL5) have been isolated. A first class codes for an IL5-specific chain (hIL5R-alpha). The major transcript of this receptor gene, as analyzed in both HL-60 eosinophilic cells and eosinophilic myelocytes grown from cord blood, encodes a secreted form of this receptor. This soluble hIL5R-alpha has antagonistic properties. A second component of the hIL5R is found to be identical to the beta-chain of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) high affinity receptor. The finding that IL5 and GM-CSF share a receptor subunit provides a molecular basis for the observation that these cytokines can partially interfere with each other's binding and have highly overlapping biological activities on eosinophils.	STATE UNIV GHENT, MOLEC BIOL LAB, B-9000 GHENT, BELGIUM	Ghent University	TAVERNIER, J (corresponding author), ROCHE RES GENT, PLATEAUST 22, B-9000 GHENT, BELGIUM.							ASHWORTH A, 1990, NUCLEIC ACIDS RES, V18, P7178, DOI 10.1093/nar/18.23.7178; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BISCHOFF SC, 1990, J EXP MED, V172, P1577, DOI 10.1084/jem.172.6.1577; CLUTTERBUCK E, 1987, EUR J IMMUNOL, V17, P1743, DOI 10.1002/eji.1830171210; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; DEVOS R, 1991, EUR J IMMUNOL, V21, P1315, DOI 10.1002/eji.1830210533; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENOKIHARA H, 1989, BLOOD, V73, P1809; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FISCHKOFF SA, 1988, LEUKEMIA RES, V12, P679, DOI 10.1016/0145-2126(88)90103-8; GAMBLE JR, 1990, SCIENCE, V249, P414; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIRAI K, 1990, J EXP MED, V172, P1525, DOI 10.1084/jem.172.5.1525; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1990, BLOOD, V76, P706; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LIMAYE AP, 1990, J EXP MED, V172, P399, DOI 10.1084/jem.172.1.399; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOPEZ AF, 1990, J CELL PHYSIOL, V145, P69, DOI 10.1002/jcp.1041450111; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; MARCON L, 1988, CLIN EXP IMMUNOL, V73, P29; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MITA S, 1989, P NATL ACAD SCI USA, V86, P2311, DOI 10.1073/pnas.86.7.2311; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; OWEN WF, 1990, P NATL ACAD SCI USA, V87, P8647, DOI 10.1073/pnas.87.21.8647; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; ROLINK AG, 1989, J EXP MED, V169, P1693, DOI 10.1084/jem.169.5.1693; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; Sambrook J, 1989, MOL CLONING LABORATO; SANDERSON CJ, 1986, P NATL ACAD SCI USA, V83, P437, DOI 10.1073/pnas.83.2.437; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SANDERSON CJ, 1990, INT J CELL CLONING, V8, P147, DOI 10.1002/stem.5530080713; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKATSU K, 1988, IMMUNOL REV, V102, P107, DOI 10.1111/j.1600-065X.1988.tb00743.x; TAVERNIER J, 1989, DNA-J MOLEC CELL BIO, V8, P491, DOI 10.1089/dna.1.1989.8.491; TAVERNIER J, 1983, NATURE, V301, P634, DOI 10.1038/301634a0; TOMINAGA A, 1991, J EXP MED, V173, P429, DOI 10.1084/jem.173.2.429; VANDERHEYDEN J, 1991, IN PRESS J IMMUNOL; VANLEEUWEN BH, 1989, BLOOD, V73, P1142; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMAGUCHI Y, 1990, EXP HEMATOL, V18, P1152; YOKOTA T, 1987, P NATL ACAD SCI USA, V84, P7388, DOI 10.1073/pnas.84.21.7388; ZUPAN AA, 1989, J BIOL CHEM, V264, P11714	56	580	592	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1175	1184		10.1016/0092-8674(91)90040-6	http://dx.doi.org/10.1016/0092-8674(91)90040-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1833065				2022-12-28	WOS:A1991GG55200012
J	DIETZ, HC; CUTTING, GR; PYERITZ, RE; MASLEN, CL; SAKAI, LY; CORSON, GM; PUFFENBERGER, EG; HAMOSH, A; NANTHAKUMAR, EJ; CURRISTIN, SM; STETTEN, G; MEYERS, DA; FRANCOMANO, CA				DIETZ, HC; CUTTING, GR; PYERITZ, RE; MASLEN, CL; SAKAI, LY; CORSON, GM; PUFFENBERGER, EG; HAMOSH, A; NANTHAKUMAR, EJ; CURRISTIN, SM; STETTEN, G; MEYERS, DA; FRANCOMANO, CA			MARFAN-SYNDROME CAUSED BY A RECURRENT DENOVO MISSENSE MUTATION IN THE FIBRILLIN GENE	NATURE			English	Article							DINUCLEOTIDE REPEAT POLYMORPHISM; POLYMERASE CHAIN-REACTION; DNA POLYMORPHISMS; CHROMOSOME-15; DUCHENNE; LOCUS	MARFAN syndrome is an inherited disorder of connective tissue manifested in the ocular, skeletal and cardiovascular systems. It is inherited as an autosomal dominant with high penetrance, but has great clinical variability 1. Linkage studies have mapped the Marfan locus to chromosome 15q15-21.3 (refs 2, 3). There have been no reports of genetic heterogeneity in the syndrome. Following the identification of fibrillin (a glycoprotein component of the extracellular microfibril 4), immunohistopathological quantification of the protein in skin and fibroblast culture 5, and examination of fibrillin synthesis, extracellular transport, and incorporation into the extracellular matrix (D. M. Milewicz, R.E.P., E. S. Crawford and P.H. Byers, manuscript in preparation) have demonstrated abnormalities of fibrillin metabolism in most patients. A portion of the complementary DNA encoding fibrillin has been cloned 6 and mapped by in situ hybridization to chromosome 15 (ref. 7). Here we report that the fibrillin gene is linked to the Marfan phenotYPe (theta = 0.00; logarithm of the odds (lod) = (3.9) and describe a de novo missense mutation in the fibrillin gene in two patients with sporadic disease. We thus implicate fibrillin as the protein defective in patients with the Marfan syndrome.	OREGON HLTH SCI UNIV, SHRINERS HOSP CRIPPLED CHILDREN, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, CTR MED GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, CTR MED GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT GYNECOL & OBSTET, CTR MED GENET, BALTIMORE, MD 21205 USA	Oregon Health & Science University; Oregon Health & Science University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	DIETZ, HC (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, DIV PEDIAT CARDIOL, BALTIMORE, MD 21205 USA.		Pyeritz, Reed/A-1364-2010	Puffenberger, Erik/0000-0002-6388-9148				BOUDOULAS H, 1988, MITRAL VALVE PROLAPS, P161; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; DENDUNNEN JT, 1987, NATURE, V329, P640, DOI 10.1038/329640a0; DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; FORREST SM, 1987, NATURE, V329, P638, DOI 10.1038/329638a0; HIGUCHI M, IN PRESS P NATN ACAD; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; MAGENIS RE, IN PRESS GENOMICS; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; NAKAMURA Y, 1988, GENOMICS, V3, P342, DOI 10.1016/0888-7543(88)90125-5; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PYERITZ RE, 1979, NEW ENGL J MED, V300, P772, DOI 10.1056/NEJM197904053001406; SAIKI RK, 1988, NEW ENGL J MED, V319, P537, DOI 10.1056/NEJM198809013190903; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sambrook J., 1989, MOL CLONING; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4637, DOI 10.1093/nar/18.15.4637; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P2202	22	1481	1535	3	134	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					337	339		10.1038/352337a0	http://dx.doi.org/10.1038/352337a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852208				2022-12-28	WOS:A1991FY28900071
J	TUBMAN, TRJ; SHIELDS, MD; CRAIG, BG; MULHOLLAND, HC; NEVIN, NC				TUBMAN, TRJ; SHIELDS, MD; CRAIG, BG; MULHOLLAND, HC; NEVIN, NC			CONGENITAL HEART-DISEASE IN DOWNS-SYNDROME - 2-YEAR PROSPECTIVE EARLY SCREENING STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine the effectiveness of clinical examination, chest radiography, and electrocardiography compared with echocardiography in detecting congenital heart disease early in the life of children with Down's syndrome. Design - Prospective two year screening survey. Setting - Regional paediatric cardiology service, Northern Ireland. Patients - 81 newborn infants with Down's syndrome born in Northern Ireland between November 1987 and November 1989. Interventions - Clinical examination, chest radiography, and electrocardiography soon after birth followed by cross sectional Doppler echocardiography. Main outcome measures - Diagnostic ability of clinical examination, radiography, and electrocardiography compared with echocardiographic findings. Results - 34 babies had congenital heart disease detected by echocardiography (13 had atrioventricular septal defects, seven secundum atrial septal defects, six a solitary patent ductus arteriosus, five isolated ventricular septal defects, and three combinations of heart defects). Individual examination methods were insensitive (the sensitivity of clinical examination was 0.53, of radiography 0.44, and of electrocardiography 0.41) but highly specific (the specificity of clinical examination was 0.94, of radiography 0.98, and of electrocardiography 1.0), although sensitivity improved when the three techniques were combined (the sensitivity was 0.71, the specificity 0.91). Conclusion - Echocardiography performed early in life can detect congenital heart disease that might otherwise be missed. Early detection may help prevent complications such as pulmonary vascular disease that may adversely affect the outcome of cardiac surgery.	ROYAL BELFAST HOSP SICK CHILDREN, CARDIAC UNIT, BELFAST, NORTH IRELAND; BELFAST CITY HOSP, NO IRELAND GENET SERV, BELFAST, NORTH IRELAND	Belfast City Hospital								ADES AE, 1990, ARCH DIS CHILD, V65, P792, DOI 10.1136/adc.65.7.792; BULL C, 1985, LANCET, V1, P1147; CULLUM L, 1969, AM J CARDIOL, V24, P354, DOI 10.1016/0002-9149(69)90428-7; ELWOOD JH, 1981, J MENT DEFIC RES, V25, P147; FRONTERAIZQUIERDO P, 1990, ARCH DIS CHILD, V65, P964, DOI 10.1136/adc.65.9.964; GREENWOOD RD, 1976, PEDIATRICS, V58, P893; GUSSENHOVEN EJ, 1986, PAEDIATRIC CARDIOLOG, V6, P156; JOHNSON AM, 1978, DEV MED CHILD NEUROL, V20, P220; MORRAY JP, 1986, ANESTHESIOLOGY, V65, P221, DOI 10.1097/00000542-198608000-00020; NEWFELD EA, 1977, AM J CARDIOL, V39, P721, DOI 10.1016/S0002-9149(77)80135-5; PARK SC, 1977, AM J DIS CHILD, V131, P29, DOI 10.1001/archpedi.1977.02120140031003; ROWE RD, 1961, AM J MED, V31, P726, DOI 10.1016/0002-9343(61)90157-7; SHAHER RM, 1972, AM J CARDIOL, V29, P497, DOI 10.1016/0002-9149(72)90439-0; SONDON P, 1975, EUROPEAN J CARDIOLOG, V2, P473; TANDON R, 1973, CIRCULATION, V47, P1349, DOI 10.1161/01.CIR.47.6.1349; WILSON NJ, 1985, LANCET, V2, P834, DOI 10.1016/S0140-6736(85)90819-0	16	74	76	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 15	1991	302	6790					1425	1427		10.1136/bmj.302.6790.1425	http://dx.doi.org/10.1136/bmj.302.6790.1425			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR403	1829969	Green Published, Bronze			2022-12-28	WOS:A1991FR40300019
J	COSSON, P; LANKFORD, SP; BONIFACINO, JS; KLAUSNER, RD				COSSON, P; LANKFORD, SP; BONIFACINO, JS; KLAUSNER, RD			MEMBRANE-PROTEIN ASSOCIATION BY POTENTIAL INTRAMEMBRANE CHARGE PAIRS	NATURE			English	Article							ANTIGEN RECEPTOR COMPLEX; T-CELL RECEPTOR; MOLECULAR-COMPONENTS; ANTIBODY; DEGRADATION; IGM	THE transmembrane domain of the alpha-chain of the T-cell receptor is responsible both for its assembly with the CD3 delta-chain 1 and for rapid degradation of the unassembled chain within the endoplasmic reticulum 2, 3. The determinant for both assembly and degradation is located in a segment of eight residues containing two basic amino acids (Fig. 1). We show here that placement of a single basic residue in the transmembrane domain of the Tac antigen can induce interaction with the CD3 chain, through its transmembrane acidic residue. This interaction is most favoured when the interacting residues are located at the same level in the membrane. The ability to induce protein-protein interaction by placing charge pairs within transmembrane domains suggests an approach to producing artificial dimers.			COSSON, P (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.			Bonifacino, Juan S./0000-0002-5673-6370				BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HONIG BH, 1984, P NATL ACAD SCI-BIOL, V81, P5412, DOI 10.1073/pnas.81.17.5412; KINET JP, 1989, CELL, V57, P351, DOI 10.1016/0092-8674(89)90910-0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; PARSEGIAN A, 1969, NATURE, V221, P844, DOI 10.1038/221844a0; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; VANDENELSEN P, 1985, NATURE, V314, P542, DOI 10.1038/314542a0; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x	16	233	234	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					414	416		10.1038/351414a0	http://dx.doi.org/10.1038/351414a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	1827877				2022-12-28	WOS:A1991FN85600061
J	SCHMIDT, GM; HORAK, DA; NILAND, JC; DUNCAN, SR; FORMAN, SJ; ZAIA, JA				SCHMIDT, GM; HORAK, DA; NILAND, JC; DUNCAN, SR; FORMAN, SJ; ZAIA, JA			A RANDOMIZED, CONTROLLED TRIAL OF PROPHYLACTIC GANCICLOVIR FOR CYTOMEGALOVIRUS PULMONARY INFECTION IN RECIPIENTS OF ALLOGENEIC BONE-MARROW TRANSPLANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS PNEUMONIA; INTERSTITIAL PNEUMONIA; BRONCHOALVEOLAR LAVAGE; MONOCLONAL-ANTIBODY; IMMUNE GLOBULIN; RAPID DETECTION; EARLY ANTIGEN; IMMUNOGLOBULIN; ACYCLOVIR; COMBINATION	Background. Cytomegalovirus (CMV)-associated interstitial pneumonia is a major cause of death after allogeneic bone marrow transplantation. We conducted a controlled trial of ganciclovir in recipients of bone marrow transplants who had asymptomatic pulmonary CMV infection. We also sought to identify risk factors for the development of CMV interstitial pneumonia. Methods. After bone marrow transplantation, 104 patients who had no evidence of respiratory disease underwent routine bronchoalveolar lavage on day 35. The 40 patients who had positive cultures for CMV were randomly assigned to either prophylactic ganciclovir or observation alone. Ganciclovir (5 mg per kilogram of body weight intravenously) was given twice daily for two weeks and then five times per week until day 120. Results. Of the 20 culture-positive patients who received prophylactic ganciclovir, 5 (25 percent) died or had CMV pneumonia before day 120, as compared with 14 of the 20 culture-positive control patients (70 percent) who were not treated prophylactically (relative risk, 0.36; P = 0.01). No patient who received the full course of ganciclovir prophylaxis went on to have CMV interstitial pneumonia. Four patients treated with ganciclovir had maximal serum creatinine levels greater-than-or-equal-to 221-mu-mol per liter (2.5 mg per deciliter), as compared with none of the controls (P = 0.029). Of the 55 CMV-negative patients who could be evaluated, 12 (22 percent) had CMV pneumonia - a significantly lower rate than in the untreated CMV-positive control patients (relative risk, 0.33; P = 0.003). The strongest predictors of CMV pneumonia were a lavage-fluid culture that was positive for CMV and a CMV-positive blood culture, both from specimens obtained on day 35. Conclusions. In recipients of allogeneic bone marrow, asymptomatic CMV infection of the lung is a major risk factor for subsequent CMV interstitial pneumonia. Prophylactic ganciclovir is effective in preventing the development of CMV interstitial pneumonia in patients with asymptomatic infection.	CITY HOPE NATL MED CTR,DEPT RESP DIS,DUARTE,CA 91010; CITY HOPE NATL MED CTR,DEPT BIOSTAT,DUARTE,CA 91010; CITY HOPE NATL MED CTR,DEPT VIROL & PEDIAT INFECT DIS,DUARTE,CA 91010; STANFORD UNIV,MED CTR,DEPT MED,DIV RESP DIS,STANFORD,CA 94305	City of Hope; City of Hope; City of Hope; Stanford University	SCHMIDT, GM (corresponding author), CITY HOPE NATL MED CTR,DEPT HEMATOL & BONE MARROW TRANSPLANTAT,1500 E DUARTE RD,DUARTE,CA 91010, USA.				NCI NIH HHS [2PO1-CA-30206, 1PO1-CA-49605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA030206, P01CA049605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLUME KG, 1987, BLOOD, V69, P1015; BLUME KG, 1987, BLOOD, V69, P1789; BOWDEN RA, 1986, NEW ENGL J MED, V314, P1006, DOI 10.1056/NEJM198604173141602; CARDOZO BL, 1985, EUR J CANCER CLIN ON, V21, P43, DOI 10.1016/0277-5379(85)90199-3; EMANUEL D, 1988, ANN INTERN MED, V109, P777, DOI 10.7326/0003-4819-109-10-777; FAULDS D, 1990, DRUGS, V39, P597, DOI 10.2165/00003495-199039040-00008; GLEAVES CA, 1984, J CLIN MICROBIOL, V19, P917, DOI 10.1128/JCM.19.6.917-919.1984; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P299; KROWKA MJ, 1985, CHEST, V87, P237, DOI 10.1378/chest.87.2.237; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; MEYERS JD, 1980, J INFECT DIS, V141, P555, DOI 10.1093/infdis/141.5.555; MEYERS JD, 1982, REV INFECT DIS, V4, P1119; NEIMAN PE, 1977, J INFECT DIS, V136, P754, DOI 10.1093/infdis/136.6.754; OREILLY RJ, 1983, TRANSPLANT P, V15, P1405; PECEGO R, 1986, TRANSPLANTATION, V42, P515, DOI 10.1097/00007890-198611000-00015; REED EC, 1988, ANN INTERN MED, V109, P783, DOI 10.7326/0003-4819-109-10-783; REED EC, 1986, ANN INTERN MED, V105, P214, DOI 10.7326/0003-4819-105-2-214; REED EC, 1987, J INFECT DIS, V156, P641, DOI 10.1093/infdis/156.4.641; REVELLO MG, 1989, J MED VIROL, V29, P88; REYNOLDS HY, 1987, AM REV RESPIR DIS, V135, P250; SCHMIDT GM, 1988, TRANSPLANTATION, V46, P905; SCHMIDT GM, 1989, BLUT, V59, P299; SHEPP DH, 1984, J INFECT DIS, V150, P776, DOI 10.1093/infdis/150.5.776; SHEPP DH, 1985, ANN INTERN MED, V103, P368, DOI 10.7326/0003-4819-103-3-368; SPECTOR SA, 1990, SEMIN HEMATOL, V27, P11; STOVER DE, 1984, ANN INTERN MED, V101, P1, DOI 10.7326/0003-4819-101-1-1; SWENSON PD, 1985, J CLIN MICROBIOL, V21, P669, DOI 10.1128/JCM.21.5.669-673.1985; TUTSCHKA PJ, 1987, BLOOD, V70, P1382; WADE JC, 1982, AM J MED, V73, P249, DOI 10.1016/0002-9343(82)90100-0; WHITEHEAD J, 1983, DESIGN ANAL SEQUENTI, P47; 1986, NEW ENGL J MED, V314, P801	31	592	600	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1991	324	15					1005	1011		10.1056/NEJM199104113241501	http://dx.doi.org/10.1056/NEJM199104113241501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF771	1848679				2022-12-28	WOS:A1991FF77100001
J	MIGNARD, M; MALPELI, JG				MIGNARD, M; MALPELI, JG			PATHS OF INFORMATION-FLOW THROUGH VISUAL-CORTEX	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; STRIATE CORTEX; CORTICAL CONNECTIONS; LAMINAR ORIGINS; AREA 17; CAT; MONKEY; CELLS; PROJECTIONS; NEURONS	The main route of information flow in the cerebral cortex is from the middle layers of cortex to upper and lower layers. However, upper layers of the cat primary visual cortex can be directly driven by inputs from secondary visual cortex when activity in middle layers is disrupted. Upper-layer activity can be driven either by middle layers or by direct corticocortical inputs. One consequence of this result is that areas of cortex thought to be carrying out low-order analysis may be able to extract considerable information from higher order areas.	UNIV ILLINOIS,DEPT PSYCHOL,603 E DANIEL ST,CHAMPAIGN,IL 61820	University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL EYE INSTITUTE [R01EY002695] Funding Source: NIH RePORTER; NEI NIH HHS [EY02695] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BULLIER J, 1988, EXP BRAIN RES, V70, P90; BULLIER J, 1984, J COMP NEUROL, V228, P329, DOI 10.1002/cne.902280304; FISKEN RA, 1975, PHILOS T ROY SOC B, V272, P487, DOI 10.1098/rstb.1975.0099; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; HENRY GH, 1991, EUR J NEUROSCI, V3, P186, DOI 10.1111/j.1460-9568.1991.tb00079.x; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Lee C., UNPUB; LEE CK, 1986, BRAIN RES, V364, P396, DOI 10.1016/0006-8993(86)90855-3; LEVAY S, 1976, BRAIN RES, V113, P1, DOI 10.1016/0006-8993(76)90002-0; LEVENTHAL AG, 1979, EXP BRAIN RES, V37, P349; MALPELI JG, 1983, J NEUROPHYSIOL, V49, P595, DOI 10.1152/jn.1983.49.3.595; MALPELI JG, 1986, J NEUROPHYSIOL, V56, P1062, DOI 10.1152/jn.1986.56.4.1062; MALPELI JG, 1979, J NEUROSCI METH, V1, P143, DOI 10.1016/0165-0270(79)90011-6; MALPELI JG, 1982, NEUROSCI LETT, V32, P29, DOI 10.1016/0304-3940(82)90224-5; MAUNSELL JHR, 1983, J NEUROSCI, V3, P2563; MITZDORF U, 1978, EXP BRAIN RES, V33, P371; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; NAULT B, 1990, Society for Neuroscience Abstracts, V16, P1219; ORBAN GA, 1984, NEURONAL OPERATIONS, P47; OTSUKA R, 1962, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V203, P212, DOI 10.1007/BF00352744; ROCKLAND KS, 1979, BRAIN RES, V179, P3, DOI 10.1016/0006-8993(79)90485-2; ROSENQUIST AC, 1975, BRAIN RES, V80, P71; SANDELL JH, 1982, J NEUROPHYSIOL, V48, P38, DOI 10.1152/jn.1982.48.1.38; SYMONDS LL, 1984, J COMP NEUROL, V229, P39, DOI 10.1002/cne.902290104; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	25	136	137	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1249	1251		10.1126/science.1848727	http://dx.doi.org/10.1126/science.1848727			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FA691	1848727				2022-12-28	WOS:A1991FA69100047
J	BOTTARO, DP; RUBIN, JS; FALETTO, DL; CHAN, AML; KMIECIK, TE; VANDEWOUDE, GF; AARONSON, SA				BOTTARO, DP; RUBIN, JS; FALETTO, DL; CHAN, AML; KMIECIK, TE; VANDEWOUDE, GF; AARONSON, SA			IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT	SCIENCE			English	Article							MOLECULAR-CLONING; TYROSINE KINASE; CELL-LINE; PURIFICATION; GENE; PHOSPHORYLATION; ACTIVATION; SEQUENCE; SUBUNIT; CDNA	Hepatocyte growth factor (HGF) is a plasminogen-like protein thought to be a humoral mediator of liver regeneration. A 145-kilodalton tyrosyl phosphoprotein observed in rapid response to HGF treatment of intact target cells was identified by immunoblot analysis as the beta-subunit of the c-met proto-oncogene product, a membrane-spanning tyrosine kinase. Covalent cross-linking of I-125-labeled ligand to cellular proteins of appropriate size that were recognized by antibodies to c-met directly established the c-met product as the cell-surface receptor for HGF.	NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	BOTTARO, DP (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		Chan, Andrew/AAC-1145-2020; Bottaro, Donald P/AAF-3853-2020; Chan, Andrew Man-Lok/J-9497-2013; Bottaro, Donald P/F-8550-2010	Chan, Andrew/0000-0001-9923-5464; Bottaro, Donald P/0000-0002-5057-5334; Chan, Andrew Man-Lok/0000-0001-9923-5464; Bottaro, Donald P/0000-0002-5057-5334; Kmiecik, Thomas/0000-0002-1367-443X				BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOTTARO DP, UNPUB; Chan A. H. Y., UNPUB; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FALETTO DL, UNPUB; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HORJUP P, 1985, FEBS LETT, V184, P333; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; KUROSKY A, 1980, P NATL ACAD SCI-BIOL, V77, P3388, DOI 10.1073/pnas.77.6.3388; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RUBIN J, UNPUB; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; WHITE MF, 1988, INSULIN RECEPTORS A, P125; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZARNEGAR R, 1989, CANCER RES, V49, P3314	35	2166	2309	0	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					802	804		10.1126/science.1846706	http://dx.doi.org/10.1126/science.1846706			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1846706				2022-12-28	WOS:A1991EX57500047
J	BURBULYS, D; TRACH, KA; HOCH, JA				BURBULYS, D; TRACH, KA; HOCH, JA			INITIATION OF SPORULATION IN BACILLUS-SUBTILIS IS CONTROLLED BY A MULTICOMPONENT PHOSPHORELAY	CELL			English	Article							GTP-BINDING PROTEIN; BACILLUS-SUBTILIS; REGULATORY PROTEINS; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; RESPONSE REGULATOR; DEDUCED PRODUCT; GENE; PHOSPHORYLATION; SPO0A	Stage 0 sporulation (spo0) mutants of Bacillus subtilis are defective in the signal transduction system initiating sporulation. Two of the products of these genes, Spo0A and Spo0F, are related to response regulator components of two-component regulatory systems used to control environmental responses in bacteria. The Spo0F response regulator was found to be the primary substrate for phosphorylation by the sporulation-specific protein kinase, KinA. Phosphorylated Spo0F was the phosphodonor for a phosphotransferase, Spo0B, which transferred the phosphate group to the second response regulator, the transcription regulatory protein Spo0A. This phosphorelay provides a mechanism for signal gathering from several protein kinases using Spo0F as a secondary messenger. These divergent signals are integrated through Spo0B phosphotransferase to activate the Spo0A transcription factor. This system provides for many levels of control to prevent capricious induction of sporulation.			BURBULYS, D (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, DIV CELLULAR BIOL, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039442, R37GM019416, R01GM019416] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39442, GM19416] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHNN J, 1986, P NATL ACAD SCI USA, V83, P8849, DOI 10.1073/pnas.83.23.8849; ANTONIEWSKI C, 1990, J BACTERIOL, V172, P86, DOI 10.1128/JB.172.1.86-93.1990; BOUVIER J, 1984, P NATL ACAD SCI-BIOL, V81, P7012, DOI 10.1073/pnas.81.22.7012; FERRARI FA, 1985, P NATL ACAD SCI USA, V82, P2647, DOI 10.1073/pnas.82.9.2647; FERRARI FA, 1985, J BACTERIOL, V161, P556, DOI 10.1128/JB.161.2.556-562.1985; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HOCH JA, 1985, J BACTERIOL, V161, P552, DOI 10.1128/JB.161.2.552-555.1985; HOCH JA, 1976, ADV GENET, V18, P69, DOI 10.1016/S0065-2660(08)60437-X; HULTQUIS.DE, 1968, BIOCHIM BIOPHYS ACTA, V153, P329, DOI 10.1016/0005-2728(68)90078-9; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KOSHLAND DE, 1952, J AM CHEM SOC, V74, P2286, DOI 10.1021/ja01129a035; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANDELSTAM J, 1974, J BACTERIOL, V120, P38, DOI 10.1128/JB.120.1.38-42.1974; MARCH PE, 1988, ONCOGENE, V2, P539; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; PEREGO M, 1989, J BACTERIOL, V171, P6187, DOI 10.1128/jb.171.11.6187-6196.1989; PEREGO M, 1988, MOL MICROBIOL, V2, P689, DOI 10.1111/j.1365-2958.1988.tb00079.x; PEREGO M, 1987, MOL MICROBIOL, V1, P125, DOI 10.1111/j.1365-2958.1987.tb00536.x; RONSON CW, 1987, CELL, V49, P579, DOI 10.1016/0092-8674(87)90530-7; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SPIEGELMAN G, 1990, J BACTERIOL, V172, P5011, DOI 10.1128/jb.172.9.5011-5019.1990; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; STRAUCH MA, 1989, EMBO J, V8, P1615, DOI 10.1002/j.1460-2075.1989.tb03546.x; SUN DX, 1989, GENE DEV, V3, P141, DOI 10.1101/gad.3.2.141; TRACH K, 1989, J BACTERIOL, V171, P1362, DOI 10.1128/jb.171.3.1362-1371.1989; TRACH KA, 1985, P NATL ACAD SCI USA, V82, P7260, DOI 10.1073/pnas.82.21.7260; WEINRAUCH Y, 1990, GENE DEV, V4, P860, DOI 10.1101/gad.4.5.860; ZAIN-UL-ABEDIN, 1983, Nucleosides and Nucleotides, V2, P257, DOI 10.1080/07328318308078860; ZUBER P, 1987, J BACTERIOL, V169, P2223, DOI 10.1128/jb.169.5.2223-2230.1987	35	728	746	2	58	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					545	552		10.1016/0092-8674(91)90238-T	http://dx.doi.org/10.1016/0092-8674(91)90238-T			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1846779				2022-12-28	WOS:A1991EX36100010
J	CANTLEY, LC; AUGER, KR; CARPENTER, C; DUCKWORTH, B; GRAZIANI, A; KAPELLER, R; SOLTOFF, S				CANTLEY, LC; AUGER, KR; CARPENTER, C; DUCKWORTH, B; GRAZIANI, A; KAPELLER, R; SOLTOFF, S			ONCOGENES AND SIGNAL TRANSDUCTION	CELL			English	Review							PROTEIN-TYROSINE KINASE; ROUS-SARCOMA VIRUS; MIDDLE-T-ANTIGEN; MULTIPLE SEQUENCE ELEMENTS; TRANSFORMING GENE-PRODUCT; GTPASE ACTIVATING PROTEIN; SERUM RESPONSE ELEMENT; PHOSPHOLIPASE-C-GAMMA; AMINO-TERMINAL DOMAIN; PHOSPHATIDYLINOSITOL KINASE				CANTLEY, LC (corresponding author), TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA.		graziani, andrea/B-2554-2009; Graziani, Andrea/AAB-6301-2022; Cantley, Lewis C/D-1800-2014	graziani, andrea/0000-0002-6302-2317; Graziani, Andrea/0000-0002-6302-2317; Cantley, Lewis C/0000-0002-1298-7653	NIGMS NIH HHS [R01 GM041890, GM41890, GM36624] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R37GM041890, R01GM036624] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; Ballou L M, 1988, Adv Exp Med Biol, V231, P445; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BARSAGI D, 1988, J CELL BIOL, V106, P1649, DOI 10.1083/jcb.106.5.1649; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BAZENET CE, 1990, J BIOL CHEM, V265, P7369; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BOYLE WJ, 1991, IN PRESS CELL, V64; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; BUCHKOVICH K, 1990, CIBA F SYMP, V150, P262; BULL P, 1989, MOL CELL BIOL, V9, P5239, DOI 10.1128/MCB.9.11.5239; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER CL, 1990, IN PRESS BIOCHEMISTR; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHAN TO, 1990, MOL CELL BIOL, V10, P3280, DOI 10.1128/MCB.10.6.3280; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CHENG SH, 1989, CURR TOP MICROBIOL, V144, P109; CHOUDHURY GG, 1990, BIOCHEM BIOPH RES CO, V172, P154, DOI 10.1016/S0006-291X(05)80186-X; COCHET C, 1991, IN PRESS J BIOL CHEM, V266; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COOK DN, 1990, J VIROL, V64, P1879, DOI 10.1128/JVI.64.5.1879-1887.1990; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CUADRADO A, 1990, BIOCHEM BIOPH RES CO, V170, P526, DOI 10.1016/0006-291X(90)92123-H; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, IN PRESS MOL CELL BI; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUKUI Y, 1989, ONCOGENE RES, V4, P283; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLEN A, 1989, P NATL ACAD SCI USA, V86, P901; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; GRAZIANI Y, 1983, J BIOL CHEM, V258, P2126; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAN JW, 1990, ONCOGENE, V5, P467; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HELDIN CH, 1990, J CELL SCI, V96, P193; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HUNTER T, 1988, COLD SPRING HARB SYM, V53, P131, DOI 10.1101/SQB.1988.053.01.019; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; LUO K, 1990, ONCOGENE, V5, P803; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MACARA IG, 1989, PHYSIOL REV, V69, P797, DOI 10.1152/physrev.1989.69.3.797; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MAYER BJ, 1991, IN PRESS P NATL ACAD; MCCARLEY DJ, 1987, J VIROL, V61, P1927, DOI 10.1128/JVI.61.6.1927-1937.1987; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEHMET H, 1990, CELL GROWTH DIFFER, V1, P293; MEIER KE, 1990, J BIOL CHEM, V265, P4635; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MUSTELIN T, 1990, ONCOGENE, V5, P809; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OKADA M, 1989, J BIOL CHEM, V264, P20886; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PATSCHINSKY T, 1986, J VIROL, V59, P73, DOI 10.1128/JVI.59.1.73-81.1986; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; POLAKIS P, 1990, INT CANCER C SUMMARI; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; RAO A, 1991, IN PRESS CRIT REV IM; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RENDU F, 1989, BLOOD, V73, P1545; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RIABOWOL KT, 1988, COLD SPRING HARB SYM, V53, P85, DOI 10.1101/SQB.1988.053.01.013; ROBERTS RM, 1991, IN PRESS CELL, V64; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; RUDD CE, 1989, IMMUNOL REV, V111, P225, DOI 10.1111/j.1600-065X.1989.tb00548.x; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SEVERINSSON L, 1990, MOL CELL BIOL, V10, P801, DOI 10.1128/MCB.10.2.801; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VARTICOVSKI L, 1991, IN PRESS MOL CELL BI, V11; VEGA MA, 1990, EUR J IMMUNOL, V20, P453, DOI 10.1002/eji.1830200235; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WENDLER PA, 1989, ONCOGENE, V4, P231; WHITMAN M, 1989, BIOCHIM BIOPHYS ACTA, V948, P327, DOI 10.1016/0304-419X(89)90005-X; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WIGLER MH, 1990, NATURE, V346, P696, DOI 10.1038/346696a0; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	225	2891	3010	1	90	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 25	1991	64	2					281	302		10.1016/0092-8674(91)90639-G	http://dx.doi.org/10.1016/0092-8674(91)90639-G			22	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV336	1846320				2022-12-28	WOS:A1991EV33600007
J	DOWNING, KH				DOWNING, KH			SPOT-SCAN IMAGING IN TRANSMISSION ELECTRON-MICROSCOPY	SCIENCE			English	Article							TOBACCO MOSAIC-VIRUS; SENSITIVE SPECIMENS; PURPLE MEMBRANE; RESOLUTION; MICROGRAPHS; BEAM; CRYSTALS; CRYSTALLOGRAPHY; IMAGES	The determination of the structure of proteins and other organic materials by transmission electron microscopy is a rapidly developing field. Obtaining high-resolution images of these radiation-sensitive specimens has, until recently, been problematic. The development of spot-scan imaging, in which the electron beam is focused to a spot with a diameter of about 1000 angstroms and moved over the specimen to record the image, has overcome some of the most severe problems, which result from beam-induced motion of the specimen and its image. Elimination of this motion greatly enhances the contrast of high-resolution features of the image and promises a significant increase in the speed with which future structural work can be accomplished.			DOWNING, KH (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,DONNER LAB,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM036884] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01-GM36884] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN JM, 1988, J MOL BIOL, V202, P585, DOI 10.1016/0022-2836(88)90288-4; BRILLINGER DR, 1989, J APPL STAT, V16, P165; BULLOUGH P, 1987, ULTRAMICROSCOPY, V21, P223, DOI 10.1016/0304-3991(87)90147-1; BULLOUGH PA, 1990, ELECTRON MICROSC REV, V3, P249, DOI 10.1016/0892-0354(90)90004-C; Bunn CW, 1939, T FARADAY SOC, V35, P0482, DOI 10.1039/tf9393500482; DOWNING KH, 1986, ULTRAMICROSCOPY, V20, P269, DOI 10.1016/0304-3991(86)90191-9; DOWNING KH, 1988, ULTRAMICROSCOPY, V24, P387, DOI 10.1016/0304-3991(88)90129-5; DOWNING KM, UNPUB; FRANK J, 1973, OPTIK, V38, P519; GLAESER RM, 1985, ANNU REV PHYS CHEM, V36, P243, DOI 10.1146/annurev.physchem.36.1.243; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HENDERSON R, 1985, ULTRAMICROSCOPY, V16, P139, DOI 10.1016/0304-3991(85)90069-5; HOLMES KC, 1975, NATURE, V254, P192, DOI 10.1038/254192a0; HOPPE W, 1970, ACTA CRYSTALL A-CRYS, VA 26, P414, DOI 10.1107/S0567739470001080; JAP BK, 1989, J MOL BIOL, V205, P407, DOI 10.1016/0022-2836(89)90351-3; JAP BK, 1990, J STRUCT BIOL, V103, P57, DOI 10.1016/1047-8477(90)90086-R; JENG TW, 1989, J MOL BIOL, V205, P251, DOI 10.1016/0022-2836(89)90379-3; KUHLBRANDT W, 1989, J MOL BIOL, V207, P823, DOI 10.1016/0022-2836(89)90247-7; MCBRIDE JM, 1986, SCIENCE, V234, P830, DOI 10.1126/science.234.4778.830; ORTH H, 1965, MAKROMOL CHEM, V88, P118; PATIL AO, 1988, CHEM REV, V88, P183, DOI 10.1021/cr00083a009; REVOL JF, 1986, J MATER SCI LETT, V5, P249, DOI 10.1007/BF01748066; ROSE AA, 1973, VISION HUMAN ELECTRO, P18; ZEMLIN F, 1989, J ELECTRON MICR TECH, V11, P251, DOI 10.1002/jemt.1060110404; ZEMLIN F, 1985, SCIENCE, V229, P461, DOI 10.1126/science.4012326	26	91	93	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					53	59		10.1126/science.1846047	http://dx.doi.org/10.1126/science.1846047			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1846047				2022-12-28	WOS:A1991EQ60300025
J	BARLOW, DP; STOGER, R; HERRMANN, BG; SAITO, K; SCHWEIFER, N				BARLOW, DP; STOGER, R; HERRMANN, BG; SAITO, K; SCHWEIFER, N			THE MOUSE INSULIN-LIKE GROWTH-FACTOR TYPE-2 RECEPTOR IS IMPRINTED AND CLOSELY LINKED TO THE TME LOCUS	NATURE			English	Article							T-COMPLEX; CHROMOSOME-17; HAPLOTYPE; GENE	T-ASSOCIATED maternal effect (Tme) is the only known maternal-effect mutation in the mouse1,2. The defect is nuclear-encoded3 and embryos that inherit a deletion of the Tme locus from their mother die at day 15 of gestation4. There are many genomically imprinted regions known in the mouse genome5,6, but so far no imprinted genes have been cloned. The Tme locus is absent in two chromosome-17 deletion mutants, T(hp) and the t(Lub2), and its position has been localized using these deletions to a 1-cM region7-10. We report here that the genes for insulin-like growth factor type-2 receptor (Igf2r) and mitochondrial superoxide dismutase-2 (Sod-2) are absent from both deletions. Probes for these genes and for plasminogen (Plg) and T-complex peptide 1 (Tcp-1) were used in pulsed-field gel mapping to show that Tme must lie within a region of 800-1,100 kb. We also demonstrate that embryos express Igf2r only from the maternal chromosome, and that Tcp-1, Plg and Sod-2 are expressed from both chromosomes. Therefore Igf2r is imprinted and closely linked or identical to Tme.	MAX PLANCK INST ENTWICKLUNGSBIOL,W-7400 TUBINGEN,GERMANY; VANDERBILT UNIV,NASHVILLE,TN 37232	Max Planck Society; Vanderbilt University	BARLOW, DP (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Reik, Wolf/I-6794-2012; allen, nick d/A-4336-2010	Stoger, Reinhard/0000-0002-2301-0805				BEECHEY CV, 1990, MOUSE GENOME, V87, P64; BIBBINS KB, 1989, GENOMICS, V5, P139, DOI 10.1016/0888-7543(89)90098-0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DEGAN SJF, IN PRESS GENOMICS; FAN JB, 1988, NUCLEIC ACIDS RES, V17, P2801; FIGUEROA F, 1988, IMMUNOGENETICS, V28, P260, DOI 10.1007/BF00345503; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HOLIDAY R, 1990, PHIL T R SOC B, V236, P177; JOHNSON DR, 1974, GENETICS, V76, P795; JOHNSON DR, 1975, GENET RES CAMB, V24, P207; LATON AK, 1982, THESIS CORNELL U MED; LAUREYS G, 1988, GENOMICS, V3, P224, DOI 10.1016/0888-7543(88)90083-3; Maniatis T, 1989, DECONTAMINATION DILU; MANN EA, 1986, GENETICS, V114, P993; MCGRATH J, 1984, NATURE, V308, P550, DOI 10.1038/308550a0; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; SARVETNICK N, 1986, GENETICS, V113, P723; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SILVER LM, 1985, ANNU REV GENET, V19, P179, DOI 10.1146/annurev.ge.19.120185.001143; SOLTER D, 1988, ANNU REV GENET, V22, P127; SPENCE MA, 1989, CYTOGENET CELL GENET, V51, P149, DOI 10.1159/000132790; SURANI MA, 1988, TRENDS GENET, V4, P59, DOI 10.1016/0168-9525(88)90040-6; SURANI MA, 1990, PHIL T R SOC B, V326, P179; WILLISON K, 1987, EMBO J, V44, P469; WINKING H, 1984, GENETICS, V108, P1013	25	739	760	4	58	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					84	87		10.1038/349084a0	http://dx.doi.org/10.1038/349084a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1845916				2022-12-28	WOS:A1991EQ60100059
J	VANSCHAYCK, CP; DOMPELING, E; VANHERWAARDEN, CLA; FOLGERING, H; VERBEEK, ALM; VANDERHOOGEN, HJM; VANWEEL, C				VANSCHAYCK, CP; DOMPELING, E; VANHERWAARDEN, CLA; FOLGERING, H; VERBEEK, ALM; VANDERHOOGEN, HJM; VANWEEL, C			BRONCHODILATOR TREATMENT IN MODERATE ASTHMA OR CHRONIC-BRONCHITIS - CONTINUOUS OR ON DEMAND - A RANDOMIZED CONTROLLED-STUDY	BRITISH MEDICAL JOURNAL			English	Article							AIR-FLOW OBSTRUCTION; HYPERRESPONSIVENESS; MORTALITY; ADULTS	Objective - To examine the effect of bronchodilator treatment given continuously versus on demand on the progression of asthma and chronic bronchitis and to compare the long term effects of a (beta-2 adrenergic drug (salbutamol) and an anticholinergic drug (ipratropium bromide). Design - Two year randomised controlled prospective crossover study in which patients were assigned to one of two parallel treatment groups receiving continuous treatment or treatment on demand. Setting - 29 general practices in the catchment area of the University of Nijmegen. Patients - 223 patients aged greater-than-or-equal-to 30 with moderate airway obstruction due to asthma or chronic bronchitis, selected by their general practitioners. Interventions - 1600-mu-g salbutamol or 160-mu-g ipratropium bromide daily (113 patients) or salbutamol or ipratropium bromide only during exacerbations or periods of dyspnoea (110). No other pulmonary treatment was permitted. Main outcome measures - Decline in ventilatory function and change in bronchial responsiveness, respiratory symptoms, number of exacerbations, and quality of life. Results - Among 144 patients completing the study, after correction for possible confounding factors the decline in forced expiratory volume in one second was -0.072 1/year in continuously treated patients and -0.020 1/year in those treated on demand (p < 0.05), irrespective of the drug. The difference in the decline in patients with asthma was comparable with that in patients with chronic bronchitis (asthma: 0.092 v -0.025 1/year; chronic bronchitis: -0.082 v 0.031 1/year). Bronchial responsiveness increased slightly (0.4 doubling dose) with continuous treatment in chronic bronchitis, but exacerbations, symptoms, and quality of life were unchanged. Salbutamol and ipratropium bromide had comparable effects on all variables investigated. Conclusions - Continuous bronchodilator treatment without anti-inflammatory treatment accelerates decline in ventilatory function. Bronchodilators should be used only on demand, with additional corticosteroid treatment, if necessary.	CATHOLIC UNIV NIJMEGEN,PULM FUNCT LAB,6500 HB NIJMEGEN,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,DEPT ENDOCRINOL,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen	VANSCHAYCK, CP (corresponding author), CATHOLIC UNIV NIJMEGEN,DEPT GEN PRACTICE,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		Verbeek, A.L.M./H-8103-2014; van Weel, Chris/D-4375-2009	Verbeek, A.L.M./0000-0002-2319-5002; van Weel, Chris/0000-0003-3653-4701				[Anonymous], 1990, BMJ, V301, P651; BARNES PJ, 1990, AM REV RESPIR DIS, V141, pS70; BOMAN G, 1983, EUR J RESPIR DIS, V64, P405; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P237; CROMPTON GK, 1991, LANCET, P43; DOMPELING E, 1991, EUR RESPIR J, V4, P612; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; MITCHELL EA, 1989, THORAX, V44, P81, DOI 10.1136/thx.44.2.81; PETO R, 1983, AM REV RESPIR DIS, V128, P491, DOI 10.1164/arrd.1983.128.3.491; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P114; POSTMA DS, 1986, AM REV RESPIR DIS, V134, P276; QUANJER PLH, 1983, B EUROP PHYSIOPAT S5, V19, P7; REBUCK AS, 1987, CAN MED ASSOC J, V136, P483; SANJAR S, 1988, LANCET, V2, P160; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SEARS MR, 1987, BRIT MED J, V294, P477, DOI 10.1136/bmj.294.6570.477; SINCLAIR BL, 1987, THORAX, V42, P670, DOI 10.1136/thx.42.9.670; STRACHAN DP, 1988, BMJ-BRIT MED J, V296, P890, DOI 10.1136/bmj.296.6626.890; van Schayck C P, 1989, Scand J Prim Health Care, V7, P137, DOI 10.3109/02813438909087230; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VANSCHAYCK CP, 1991, THORAX, V46, P355, DOI 10.1136/thx.46.5.355; WEIR D C, 1990, Thorax, V45, P791; 1987, AM REV RESPIR DIS, V136, P225	24	223	224	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1426	1431		10.1136/bmj.303.6815.1426	http://dx.doi.org/10.1136/bmj.303.6815.1426			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1837744	Bronze, Green Published			2022-12-28	WOS:A1991GU38500020
J	BUCHOLTZ, GA; LOCKEY, RF				BUCHOLTZ, GA; LOCKEY, RF			SEAWATER-INDUCED ITCHING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BUCHOLTZ, GA (corresponding author), UNIV S FLORIDA,COLL MED,JAMES A HALEY VET HOSP,TAMPA,FL 33612, USA.							MANDOJANA RM, 1987, CLIN DERMATOLOGY AQU, V5; SHIMODA T, 1988, J ALLERGY CLIN IMMUN, V81, P1187, DOI 10.1016/0091-6749(88)90889-5; WARIN RP, 1974, MAJOR PROBLEMS DERMA, V1, P136	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3040	3040						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820481				2022-12-28	WOS:A1991GR77500041
J	DERRY, J; LAWRENCE, M; GRIEW, K; ANDERSON, J; HUMPHREYS, J; PANDHER, KS				DERRY, J; LAWRENCE, M; GRIEW, K; ANDERSON, J; HUMPHREYS, J; PANDHER, KS			AUDITING AUDITS - THE METHOD OF OXFORDSHIRE-MEDICAL-AUDIT-ADVISORY-GROUP	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE	Objectives - To develop a systematic method for both summative and formative audit of practice audits, and to use the method to review Oxfordshire practice audits and to plan improvement. Design - Development of a coding system for the audit cycle subsequently used prospectively to assess audits reported to medical audit advisory group coordinators on practice visits. Setting - All 85 general practices in Oxfordshire, of which 80 were visited by Oxfordshire Medical Audit Advisory Group coordinators. Main outcome measures - Satisfaction of criteria for different levels of audit (full, partial, potential, planning or no audit) according to coding scores for practice audits. Results - 46 (58%) practices were classified as doing audit, the remainder doing no audit or only collecting data for family health services authority returns. Of audits being undertaken, 55/102 (54%) included planning care or the setting of targets. Conclusions - The coding system offers the prospect of formative assessment for practices to help them improve their audits, and summative assessment for the family health services authority to satisfy the needs for professional accountability. Its use in Oxfordshire disclosed considerable deficiencies in the process of practice audit. Implications and action - Practices in Oxfordshire should improve their audits. The advisory groups target to March 1992 is for 50% of practices to be doing full or partial and 25% potential audit and half of the remainder planning audit. Practices are encouraged to include in their audit implementing change, planning care, and agreeing criteria for further assessment.	RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORDSHIRE MED AUDIT ADVISORY GRP,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary								BAKER R, 1990, BRIT MED J, V300, P378, DOI 10.1136/bmj.300.6721.378; Crombie D, 1988, 41 ROYAL COLL GEN PR; Donabedian A., 1982, EXPLORATIONS QUALITY, VII; FLEMING DM, 1983, BRIT MED J, V287, P1852, DOI 10.1136/bmj.287.6408.1852; GROL R, 1988, J ROY COLL GEN PRACT, V38, P10; JEWELL D, 1988, J ROY COLL GEN PRACT, V38, P506; MARSH GN, 1988, BRIT MED J, V296, P173, DOI 10.1136/bmj.296.6616.173; NEEDHAM A, 1988, J ROY COLL GEN PRACT, V38, P166; WILSON A, 1990, BRIT MED J, V300, P376, DOI 10.1136/bmj.300.6721.376; 1989, MED AUDIT 1ST REPORT; 1984, 28 ROYAL COLL GEN PR; 1990, MED AUDIT FAMILY PRA; 1991, N ENGLAND STUDY STAN, V3	13	27	27	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1247	1249		10.1136/bmj.303.6812.1247	http://dx.doi.org/10.1136/bmj.303.6812.1247			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1836150	Bronze, Green Published			2022-12-28	WOS:A1991GQ34200030
J	LERNER, BH				LERNER, BH			SCIENTIFIC EVIDENCE VERSUS THERAPEUTIC DEMAND - THE INTRODUCTION OF THE SULFONAMIDES REVISITED	ANNALS OF INTERNAL MEDICINE			English	Article							AIDS TRIALS; DRUGS; FEVER	Because of recent changes in Federal Food and Drug Administration (FDA) regulations, new medications may now be marketed before completion of rigorous controlled testing. In order to understand the ramifications of this development, it is instructive to recall the introduction of the sulfonamides in the 1930s. The sulfonamides, the first effective antibacterial agents, were marketed in an era of relatively few regulations. Although investigators at times designed controlled trials to evaluate use of the drugs, both researchers and practitioners generally prescribed them for severe infections, despite a lack of conclusive data as to their efficacy. The clinical usefulness of sulfonamides for a given condition often became known through uncontrolled case studies and comparisons with historical control groups. Given the relaxation of FDA regulations, this method of drug evaluation may again become more commonplace.	COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA	Columbia University								[Anonymous], 1989, GUIDE CLIN PREVENTIV; ANWYLDAVIES T, 1937, BRIT MED J, V2, P553; Bigler JA, 1938, J AMER MED ASSOC, V110, P343, DOI 10.1001/jama.1938.02790050021006; BORST JGG, 1937, LANCET, V1, P1519; Brown WH, 1940, J AMER MED ASSOC, V114, P1605; BYAR DP, 1976, NEW ENGL J MED, V295, P74, DOI 10.1056/NEJM197607082950204; BYAR DP, 1990, NEW ENGL J MED, V323, P1343, DOI 10.1056/NEJM199011083231912; Colebrook L, 1936, LANCET, V2, P1319; Crean TF, 1937, LANCET, V2, P895; Danziger L, 1938, B JOHNS HOPKINS HOSP, V63, P340; Dees JE, 1937, J AMER MED ASSOC, V108, P1855, DOI 10.1001/jama.1937.02780220013003; DELANEY M, 1989, J INFECT DIS, V159, P416, DOI 10.1093/infdis/159.3.416; Domagk G, 1935, DEUT MED WOCHENSCHR, V61, P829, DOI 10.1055/s-0028-1129654; DOUTHWAITE AH, 1937, PRACTITIONER, V139, P661; DOWLING HF, 1977, FIGHTING INFECTION, P23; DOWLING HF, 1970, MED MAN, P187; EDGAR H, 1990, MILBANK Q, V68, P111, DOI 10.2307/3350178; EISENBERG L, 1977, SCIENCE, V198, P1105, DOI 10.1126/science.337491; Evans GM, 1938, LANCET, V2, P14; Gibberd GF, 1937, BRIT MED J, V1937, P695, DOI 10.1136/bmj.2.4005.695; HARE R, 1970, BIRTH PENICILLIN DIS, V10, P138; Heintzelman JHL, 1937, AM J MED SCI, V193, P759, DOI 10.1097/00000441-193706000-00004; HILL A. M., 1940, Medical Journal of Australia, V1, P293; HOERLEIN H, 1936, PRACTITIONER, V1, P1279; HOGAN B, 1983, US NAVAL MED B, V36, P60; KAEMPFFERT W, 1937, NY TIMES        1024, V12, P21; KAEMPFFERT W, 1937, NY TIMES        1024, V12, P6; KESSLER DA, 1989, NEW ENGL J MED, V320, P281, DOI 10.1056/NEJM198902023200504; KOLATA G, 1990, NY TIMES        0102, pC3; Kolmer JA, 1940, ARCH INTERN MED, V65, P671, DOI 10.1001/archinte.1940.00190100012002; KORNBLITH BA, 1938, JAMA-J AM MED ASSOC, V111, P523; LICH R, 1939, AM J SYPH GON VD, V23, P323; Long PH, 1937, J AMER MED ASSOC, V108, P32, DOI 10.1001/jama.1937.02780010034008; LONG PH, 1939, CLIN EXPT USE SULFAN, P266; Marshall EK, 1939, J AMER MED ASSOC, V112, P352, DOI 10.1001/jama.1939.02800040070025; MASSELL BF, 1988, NEW ENGL J MED, V318, P280, DOI 10.1056/NEJM198802043180504; MASSELL BF, 1937, NEW ENGL J MED, V216, P487; MERIGAN TC, 1990, NEW ENGL J MED, V323, P1341, DOI 10.1056/NEJM199011083231911; Nettle P, 1937, NEW ENGL J MED, V216, P711; OATES JA, 1989, NEW ENGL J MED, V320, P311, DOI 10.1056/NEJM198902023200509; Praino G, 1937, NEW ENGL J MED, V216, P1142; Sappington SW, 1939, ANN INTERN MED, V13, P576, DOI 10.7326/0003-4819-13-4-576; Snodgrass WR, 1937, BMJ-BRIT MED J, V1937, P101; STARR P, 1982, SOCIAL TRANSFORMATIO, P131; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; Taylor FW, 1942, J AMER MED ASSOC, V118, P959, DOI 10.1001/jama.1942.02830120023006; Telling M, 1938, LANCET, V1, P1391; WEINSTEIN MC, 1974, NEW ENGL J MED, V291, P1278, DOI 10.1056/NEJM197412122912405; WERTH B, 1990, NY TIMES MAGAZI 0930, P35; WERTH B, 1990, NY TIMES MAGAZI 0930, P58; Whitby LEH, 1938, LANCET, V1, P1210; WHITBY LEH, 1937, PRACTITIONER, V139, P650; Whorton James C., 1980, HIST ANTIBIOTICS, P125; Young James Harvey, 1958, EMORY U Q, V14, P230; 1937, NY TIMES        0729, P17; 1941, SULFAPYRIDINE ANNOTA; 1936, LANCET, V2, P1339; 1937, NY TIMES        1025, P21; 1938, LANCET, V2, P28; 1937, NEW ENGL J MED, V217, P960; 1979, CAN MED ASS J, V121, P1193; 1943, TIMES           0614, P46; 1937, JAMA-J AM MED ASSOC, V109, P1367; 1938, PRONTOSIL PRONTYLIN; 1937, NEW ENGL J MED, V216, P1138; 1937, NEW ENGL J MED, V216, P706; 1936, NY TIMES        1217, P1	67	13	13	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					315	320		10.7326/0003-4819-115-4-315	http://dx.doi.org/10.7326/0003-4819-115-4-315			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854116				2022-12-28	WOS:A1991GA76400012
J	[Anonymous]				[Anonymous]			MISSING - A STRATEGY FOR HEALTH OF THE NATION	BRITISH MEDICAL JOURNAL			English	Article							INCOME-DISTRIBUTION; MORTALITY; REHABILITATION; OPPORTUNITIES; INEQUALITIES; DISABILITY; BRITAIN; NEEDS; CARE											Bowe F., 1978, HANDICAPPING AM; Clark A, 1989, DISABILITY HANDICAP, V4, P271, DOI DOI 10.1080/02674648966780291; CONNELLY J, 1991, HOUSING HOMELESSNESS; GLOAG D, 1984, BRIT MED J, V289, P211, DOI 10.1136/bmj.289.6439.211; GLOAG D, 1985, BRIT MED J, V290, P368, DOI 10.1136/bmj.290.6465.368; GLOAG D, 1985, BRIT MED J, V290, P43, DOI 10.1136/bmj.290.6461.43; GODFREY C, 1990, PREVENTING ALCOHOL T, V1; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; HIRST M, 1990, QUALITY LIFE PERSPEC; Lowry S., 1991, HOUSING HLTH; LUNDBERG O, 1986, SOC SCI MED, V23, P511, DOI 10.1016/0277-9536(86)90011-0; MACFARLANE A, 1988, J ROY STAT SOC A STA, V151, P342, DOI 10.2307/2982762; MACFARLANE A, 1984, BIRTH COUNTS STATIST; MANT DC, 1986, BUILDING REGULATIONS; MARMOT MG, 1986, LANCET, V2, P274; RUSH D, 1983, J EPIDEMIOL COMMUN H, V37, P249, DOI 10.1136/jech.37.4.249; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; STRACHAN DP, 1991, P ROY COLL PHYS EDIN, V21, P140; THUNHURST C, IN PRESS J ROYAL S A; VAGERO D, 1989, LANCET, V2, P35, DOI 10.1016/S0140-6736(89)90266-3; WHITEHEAD M, 1988, HLTH DIVIDE INEQUALI; WILKINSON RG, 1990, SOCIOL HEALTH ILL, V12, P391, DOI 10.1111/1467-9566.ep11340405; WILKINSON RG, 1989, J SOC POLICY, V18, P307, DOI 10.1017/S0047279400017591; 1990, NATIONAL OPINION POL; 1986, OCCUPATIONAL MORTALI; 1989, CHANGING PUBLIC HLTH; UK MONITORING REPORT; 1989, WORKING PATIENTS; 1980, INEQUALITIES HLTH; 1944, CMND6502; 1989, STRATEGIC PLAN 1990; 1988, OPCS2 OFF POP CENS S; 1978, WHO HLTH SERIES, V1; 1990, HLTH SERVICE ADULTS; 1990, STATE PUBLIC HLTH YE; 1990, ORZ1297 DEP HLTH; 1989, SMOKING HABITS NTION; 1980, UNOFFICIAL GUIDE OFF; 1981, EURRC308; 1985, TARGETS HLTH ALL; 1991, NETWORK NEWS     SPR; 1990, LANCET, V336, P1547; 1989, CARING PEOPLE COMMUN; 1991, CM1523; 1981, DEV INDICATORS MONIT; 1981, WHO HLTH SERIES, V3; 1991, MORTALITY STATISTICS; HEART DISEASE 1990S; 1989, YOUNG PEOPLES HLTH L	49	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					299	302						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FZ721	1823130				2022-12-28	WOS:A1991FZ72100028
J	KRAINER, AR; MAYEDA, A; KOZAK, D; BINNS, G				KRAINER, AR; MAYEDA, A; KOZAK, D; BINNS, G			FUNCTIONAL EXPRESSION OF CLONED HUMAN SPLICING FACTOR SF2 - HOMOLOGY TO RNA-BINDING PROTEINS, U1-70K, AND DROSOPHILA SPLICING REGULATORS	CELL			English	Article							NUCLEAR RIBONUCLEOPROTEIN PARTICLE; ESCHERICHIA-COLI; GENE-EXPRESSION; SNRNP PROTEIN; SITE SELECTION; 70K PROTEIN; U1 SNRNA; SEQUENCE; SEX; PURIFICATION	SF2 is a protein factor essential for constitutive pre-mRNA splicing in HeLa cell extracts and also activates proximal alternative 5' splice sites in a concentration-dependent manner. This latter property suggests a role for SF2 in preventing exon skipping, ensuring the accuracy of splicing, and regulating alternative splicing. Human SF2 cDNAs have been isolated and overexpressed in bacteria. Recombinant SF2 is active in splicing and stimulates proximal 5' splice sites. SF2 has a C-terminal region rich in arginine-serine dipeptides, similar to the RS domains of the U1 snRNP 70K polypeptide and the Drosophila alternative splicing regulators transformer, transformer-2, and suppressor-of-white-apricot. Like transformer-2 and 70K, SF2 contains an RNP-type RNA recognition motif.			KRAINER, AR (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.		Mayeda, Akila/ABC-1134-2020	Mayeda, Akila/0000-0002-9562-550X; Krainer, Adrian/0000-0001-9024-9501	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042699] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline; NIGMS NIH HHS [GM42699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JM, 1966, P NATL ACAD SCI USA, V55, P147, DOI 10.1073/pnas.55.1.147; AEBI M, 1987, TRENDS GENET, V3, P102, DOI 10.1016/0168-9525(87)90193-4; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BROWN JL, 1976, J BIOL CHEM, V251, P1009; CHEN GFT, 1990, NUCLEIC ACIDS RES, V18, P1465, DOI 10.1093/nar/18.6.1465; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ETZERODT M, 1988, EMBO J, V7, P4311, DOI 10.1002/j.1460-2075.1988.tb03330.x; FUCHS PG, 1986, J VIROL, V58, P626, DOI 10.1128/JVI.58.2.626-634.1986; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; JOHNSON KE, 1987, J BIOL CHEM, V262, P8636; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P7125; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KRAINER AR, 1988, FRONTIERS MOL BIOL T, P131; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MANCEBO R, 1990, MOL CELL BIOL, V10, P2492, DOI 10.1128/MCB.10.6.2492; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10373, DOI 10.1093/nar/15.24.10373; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; WADA KN, 1990, NUCLEIC ACIDS RES, V18, P2367, DOI 10.1093/nar/18.suppl.2367; WEBSTER RE, 1966, P NATL ACAD SCI USA, V55, P155, DOI 10.1073/pnas.55.1.155; YUO CY, 1989, MOL CELL BIOL, V9, P3429, DOI 10.1128/MCB.9.8.3429; ZACHOW KR, 1987, VIROLOGY, V158, P251, DOI 10.1016/0042-6822(87)90263-7; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	54	456	470	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					383	394		10.1016/0092-8674(91)90627-B	http://dx.doi.org/10.1016/0092-8674(91)90627-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1830244				2022-12-28	WOS:A1991FY71200018
J	WATANABE, N; HUNT, T; IKAWA, Y; SAGATA, N				WATANABE, N; HUNT, T; IKAWA, Y; SAGATA, N			INDEPENDENT INACTIVATION OF MPF AND CYTOSTATIC FACTOR (MOS) UPON FERTILIZATION OF XENOPUS EGGS	NATURE			English	Article							MATURATION-PROMOTING FACTOR; PROTO-ONCOGENE PRODUCT; CELL-CYCLE; OOCYTES; ARREST; METAPHASE; COMPONENT	IN vertebrates, mature eggs are arrested at the second meiotic metaphase by the cytostatic factor (CSF) 1, now known to be the c-mos proto-oncogene product (Mos) 2,3. Fertilization or egg activation triggers a transient increase in the cytoplasmic free calcium 4,5 and releases the meiotic arrest by inactivating maturation/mitosis-promoting factor (MPF) 6,7. CSF or Mos, which is also inactivated by the calcium transient 8,9, seems to stabilize MPF in mature eggs and CSF-injected embryos. Thus, it was assumed that CSF inactivation is the primary cause of MPF inactivation on meiotic release 2,6,8,10-14. We have directly compared the degradation kinetics of CSF (Mos) and MPF during meiotic release, using the same batch of Xenopus eggs. We report here that, at the molecular level, cyclin subunits of MPF are degraded before Mos is degraded and, at the physiological level, that MPF activity is inactivated before CSF activity during activation of Xenopus eggs. These results, in conjunction with circumstantial evidence, support the novel view that a calcium transient on fertilization induces a CSF-independent pathway for MPF inactivation, whereas CSF inactivation during meiotic release serves only to allow the fertilized egg to enter mitosis.	KURUME UNIV,INST LIFE SCI,DIV MOLEC GENET,2432-3 AIKAWA,KURUME,FUKUOKA 830,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; TOKYO MED & DENT UNIV,BUNKYO KU,TOKYO 113,JAPAN	Kurume University; RIKEN; Tokyo Medical & Dental University (TMDU)			Hunt, Tim/O-8544-2019; Watanabe, Nobumoto/N-6959-2015	Hunt, Tim/0000-0001-5174-6038; Watanabe, Nobumoto/0000-0002-2130-1334				BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HUNT T, 1989, NATURE, V342, P483, DOI 10.1038/342483a0; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; LORCA T, 1991, MOL CELL BIOL, V11, P1171, DOI 10.1128/MCB.11.2.1171; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEYERHOF PG, 1977, DEV BIOL, V61, P214, DOI 10.1016/0012-1606(77)90293-7; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P319; SHIBUYA EK, 1988, DEV BIOL, V129, P253, DOI 10.1016/0012-1606(88)90179-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604	24	159	164	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					247	248		10.1038/352247a0	http://dx.doi.org/10.1038/352247a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1830371				2022-12-28	WOS:A1991FX18500068
J	PONS, TP; GARRAGHTY, PE; OMMAYA, AK; KAAS, JH; TAUB, E; MISHKIN, M				PONS, TP; GARRAGHTY, PE; OMMAYA, AK; KAAS, JH; TAUB, E; MISHKIN, M			MASSIVE CORTICAL REORGANIZATION AFTER SENSORY DEAFFERENTATION IN ADULT MACAQUES	SCIENCE			English	Article							SOMATOSENSORY CORTEX; OWL MONKEYS; AREA 3B; ORGANIZATION; REPRESENTATIONS; CONNECTIONS; MAMMALS; LESIONS; HAND; BODY	After limited sensory deafferentations in adult primates, somatosensory cortical maps reorganize over a distance of 1 to 2 millimeters mediolaterally, that is, in the dimension along which different body parts are represented. This amount of reorganization was considered to be an upper limit imposed by the size of the projection zones of individual thalamocortical axons, which typically also extend a mediolateral distance of 1 to 2 millimeters. However, after extensive long-term deafferentations in adult primates, changes in cortical maps were found to be an order of magnitude greater than those previously described. These results show the need for a reevaluation of both the upper limit of cortical reorganization in adult primates and the mechanisms responsible for it.	UNIV ALABAMA,DEPT PSYCHOL,BIRMINGHAM,AL 35294; VANDERBILT UNIV,DEPT PSYCHOL,NASHVILLE,TN 37240	University of Alabama System; University of Alabama Birmingham; Vanderbilt University	PONS, TP (corresponding author), NIMH,NEUROPSYCHOL LAB,BLDG 9,ROOM 1N107,BETHESDA,MD 20892, USA.							CONLEY M, 1984, Society for Neuroscience Abstracts, V10, P495; Darian-Smith, 1984, HDB PHYSL 2 1, V3, P789; EL-BOHY A, 1990, Society for Neuroscience Abstracts, V16, P1162; FRIEDMAN DP, 1986, J COMP NEUROL, V252, P323, DOI 10.1002/cne.902520304; GARRAGHTY PE, 1989, SOMATOSENS MOT RES, V6, P401, DOI 10.3109/08990228909144683; GARRAGHTY PE, 1990, J COMP NEUROL, V294, P583, DOI 10.1002/cne.902940406; GARRAGHTY PE, IN PRESS P NATL ACAD; GOLDBERGER ME, 1988, PHYSL BASIS FUNCTION, P361; HEINEN S J, 1988, Investigative Ophthalmology and Visual Science, V29, P23; JONES EG, 1978, J COMP NEUROL, V181, P297; Kaas J.H., 1988, P421; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; KAAS JH, 1983, PHYSIOL REV, V63, P206, DOI 10.1152/physrev.1983.63.1.206; KAAS JH, 1979, SCIENCE, V204, P521, DOI 10.1126/science.107591; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; Killackey H P, 1989, J Cogn Neurosci, V1, P3, DOI 10.1162/jocn.1989.1.1.3; MERZENICH MM, 1983, NEUROSCIENCE, V10, P639, DOI 10.1016/0306-4522(83)90208-7; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; MERZENICH MM, 1982, TRENDS NEUROSCI, V5, P434, DOI 10.1016/0166-2236(82)90235-1; MERZENICH MM, 1988, NEUROBIOLOGY NEOCORT, P41; NELSON RJ, 1980, J COMP NEUROL, V192, P611, DOI 10.1002/cne.901920402; PONS TP, 1986, J COMP NEUROL, V248, P313, DOI 10.1002/cne.902480303; PONS TP, 1985, J COMP NEUROL, V241, P445, DOI 10.1002/cne.902410405; PONS TP, 1987, SOMATOSENS MOT RES, V4, P309, DOI 10.3109/07367228709144612; RHOADES RW, 1987, J NEUROPHYSIOL, V57, P1577, DOI 10.1152/jn.1987.57.5.1577; ROE AW, 1990, SCIENCE, V250, P818, DOI 10.1126/science.2237432; SHERMAN SM, 1982, PHYSIOL REV, V62, P738, DOI 10.1152/physrev.1982.62.2.738; SUR M, 1980, J NEUROPHYSIOL, V44, P295, DOI 10.1152/jn.1980.44.2.295; Taub E, 1980, BEHAV PSYCHOL REHABI, P371; WERNER G, 1968, J NEUROPHYSIOL, V31, P856, DOI 10.1152/jn.1968.31.6.856; WOOLSEY CN, 1942, B J HOPKINS HOSP, V70, P339	31	825	856	1	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1857	1860		10.1126/science.1843843	http://dx.doi.org/10.1126/science.1843843			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	1843843				2022-12-28	WOS:A1991FU06100043
J	NICCHITTA, CV; MIGLIACCIO, G; BLOBEL, G				NICCHITTA, CV; MIGLIACCIO, G; BLOBEL, G			BIOCHEMICAL FRACTIONATION AND ASSEMBLY OF THE MEMBRANE-COMPONENTS THAT MEDIATE NASCENT CHAIN TARGETING AND TRANSLOCATION	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; SECRETORY PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM; MICROSOMAL-MEMBRANES; RIBOSOME BINDING; ROUGH MICROSOMES; BOUND RIBOSOMES; RECEPTOR; COMPLEX; SEQUENCE	Fractionation of a microsomal detergent extract with ammonium sulfate allows separation of the signal recognition particle receptor (SR-alpha), which is required for targeting of the nascent chain, from other microsomal proteins, such as signal peptidase, whose activity is displayed during subsequent translocation. The reconstituted SR-alpha-enriched fraction is functional in assays of precursor targeting and elongation arrest release but lacks translocation activity. This defect can be complemented by addition, prior to reconstitution, of a separate protein subfraction. In addition, protein components necessary for translocation can be reversibly depleted from the complementary fraction, under conditions where precursor targeting is retained, by sulfhydryl-directed chromatography. Thus, precursor binding and translocation can be biochemically uncoupled, indicating that they are sequential reactions mediated by distinct components.			NICCHITTA, CV (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012899] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM12899] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; KOCH GLE, 1987, J CELL SCI, V87, P491; KREIBICH G, 1983, METHOD ENZYMOL, V96, P520; KREIBICH G, 1978, J CELL BIOL, V77, P488, DOI 10.1083/jcb.77.2.488; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1015, DOI 10.1073/pnas.84.4.1015; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; TRUMBLE WR, 1984, BIOCHEM BIOPH RES CO, V119, P860, DOI 10.1016/0006-291X(84)90853-2; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WICKNER W, 1980, SCIENCE, V210, P861, DOI 10.1126/science.7001628; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0	41	43	44	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1991	65	4					587	598		10.1016/0092-8674(91)90091-C	http://dx.doi.org/10.1016/0092-8674(91)90091-C			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1851670				2022-12-28	WOS:A1991FM03700009
J	FEATHERSTONE, C; RUSSELL, P				FEATHERSTONE, C; RUSSELL, P			FISSION YEAST P107WEE1 MITOTIC INHIBITOR IS A TYROSINE SERINE KINASE	NATURE			English	Article							EXPRESSION; PROTEINS; MITOSIS	THE fission yeast wee1+ gene product is a dose-dependent, negative regulator of entry into mitosis 1,2. wee1+ encodes a protein of relative molecular mass 107,000 (M(r) 107K), the C-terminal third of which has strong similarities with the serine/threonine protein kinase family 2,3. Here we report that p107wee1 immune complexes phosphorylate p107wee1 equally on serine and tyrosine residues, and also phosphorylate an exogenous substrate, angiotensin II, on tyrosine. Both kinase activities are attributable to p107wee1 because they are also observed when wee1+ is expressed in heterologous systems; both are abolished by a point mutation in the ATP-binding domain, and both behave like an asymmetric monomer of M(r) 114K on gel filtration and density-gradient centrifugation. Thus the wee1+ gene product is representative of a novel class of protein kinase that phosphorylates both serine and tyrosine residues.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Featherstone, Carol/0000-0002-7881-7235				BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MAIZEL JV, 1969, FUNDAMENTAL TECHNIQU, P334; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; Summers MD, 1987, TEXAS AGR EXPT STATI	13	328	340	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 28	1991	349	6312					808	811		10.1038/349808a0	http://dx.doi.org/10.1038/349808a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	1825699				2022-12-28	WOS:A1991EZ66600062
J	MASU, M; TANABE, Y; TSUCHIDA, K; SHIGEMOTO, R; NAKANISHI, S				MASU, M; TANABE, Y; TSUCHIDA, K; SHIGEMOTO, R; NAKANISHI, S			SEQUENCE AND EXPRESSION OF A METABOTROPIC GLUTAMATE RECEPTOR	NATURE			English	Article							LONG-TERM POTENTIATION; INOSITOL PHOSPHOLIPID-METABOLISM; FUNCTIONAL EXPRESSION; XENOPUS OOCYTES; G-PROTEIN; CLONING; MEMBER; FAMILY; SITES; CDNA	The complementary DNA of a metabotropic glutamate receptor coupled to inositol phosphate/Ca2+ signal transduction has been cloned and characterized. This receptor shows no sequence similarity to conventional G protein-coupled receptors and has a unique structure with large hydrophilic sequences at both sides of seven putative membrane-spanning domains. Abundant expression of this messenger RNA is observed in neuronal cells in hippocampal dentate gyrus and CA2-3 and in cerebellar Purkinje cells, suggesting the importance of this receptor in specific hippocampal and cerebellar functions.	KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT MORPHOL BRAIN SCI,KYOTO 606,JAPAN	Kyoto University; Kyoto University			Tsuchida, Kunihiro/A-4501-2012; Shigemoto, Ryuichi/E-3628-2013	Tsuchida, Kunihiro/0000-0002-3983-5756; Shigemoto, Ryuichi/0000-0001-8761-9444				ANGERER LM, 1987, METHOD ENZYMOL, V152, P649; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GOH JW, 1989, SCIENCE, V244, P980, DOI 10.1126/science.2543072; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HWANG PM, 1990, SCIENCE, V249, P802, DOI 10.1126/science.1975122; ITO I, 1988, NEUROSCI LETT, V90, P181, DOI 10.1016/0304-3940(88)90808-7; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KITAMURA N, 1985, J BIOL CHEM, V260, P8610; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; Nakanishi S, 1990, Recent Prog Horm Res, V46, P59; NICOLETTI F, 1986, P NATL ACAD SCI USA, V83, P1931, DOI 10.1073/pnas.83.6.1931; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; ROSS CA, 1990, TRENDS NEUROSCI, V13, P216, DOI 10.1016/0166-2236(90)90163-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLADECZEK F, 1988, TRENDS NEUROSCI, V11, P545, DOI 10.1016/0166-2236(88)90183-X; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; SUGIYAMA H, 1989, NEURON, V3, P129, DOI 10.1016/0896-6273(89)90121-9; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; VARNOLD RL, 1990, DEVELOPMENT, V109, P597; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	36	1074	1130	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					760	765		10.1038/349760a0	http://dx.doi.org/10.1038/349760a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	1847995				2022-12-28	WOS:A1991EZ66600045
J	TREMOLADA, F; CASARIN, C; TAGGER, A; RIBERO, ML; REALDI, G; ALBERTI, A; RUOL, A				TREMOLADA, F; CASARIN, C; TAGGER, A; RIBERO, ML; REALDI, G; ALBERTI, A; RUOL, A			ANTIBODY TO HEPATITIS-C VIRUS IN POSTTRANSFUSION HEPATITIS	ANNALS OF INTERNAL MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; BLOOD	Objective: To evaluate the prevalence of antibodies to hepatitis C virus (anti-HCV), their relation to outcome, and the seroconversion rate in patients with post-transfusion non-A, non-B hepatitis. Design: Retrospective analysis of prospectively collected serum specimens. Setting: A referral-based university hospital. Patients: Sixty-three consecutive patients who developed non-A, non-B post-transfusion hepatitis after open-heart surgery. All patients had follow-up with serial serum testing and clinical evaluation. The mean ( +/- SD) duration of follow-up after hepatitis onset was 81 +/- 33 months (range, 13 to 132 months). Seventeen patients recovered after acute-phase illness, whereas 46 developed chronic disease which, in 30 cases, was confirmed histologically. Main Results: Of 32 patients tested before transfusion, 1 (3.1%) had anti-HCV. Fifty-nine (93%) patients were anti-HCV positive during acute-phase hepatitis: Patients with "early" seroconversion ( < 15 days after hepatitis onset) did not differ from those with "late" seroconversion ( > 60 days after onset) in epidemiologic, clinical, and biochemical features. The rate of anti-HCV positivity during acute-phase illness was not significantly different among patients who recovered (76%) compared with those who developed chronic disease (95%). At 6 to 12 months, patients whose disease resolved had lower antibody activity than those with progressive disease. Further, during long-term follow-up (1 to 9 years), 53% of patients whose disease resolved but only 6.9% of patients who had progressive disease became anti-HCV negative. Conclusions: Hepatitis C virus is the major cause of post-transfusion hepatitis in Italy. The time to anti-HCV seroconversion varies widely after hepatitis onset and is not significantly associated with acute-phase features or outcome of disease.	UNIV PADUA, I-35100 PADUA, ITALY; UNIV MILAN, I-20122 MILAN, ITALY	University of Padua; University of Milan				ALBERTI, ALFREDO/0000-0001-9926-2382				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1975, LANCET, V2, P838, DOI 10.1016/S0140-6736(75)90234-2; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DIENSTAG JL, 1986, SEMIN LIVER DIS, V6, P67, DOI 10.1055/s-2008-1040795; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; SEEFF LB, 1988, GASTROENTEROLOGY, V95, P530; TREMOLADA F, 1988, J CLIN GASTROENTEROL, V10, P413, DOI 10.1097/00004836-198808000-00014; TREMOLADA F, 1983, VOX SANG, V44, P25, DOI 10.1111/j.1423-0410.1983.tb04099.x	8	117	117	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1991	114	4					277	281		10.7326/0003-4819-114-4-277	http://dx.doi.org/10.7326/0003-4819-114-4-277			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX521	1846277				2022-12-28	WOS:A1991EX52100004
J	HABER, DA; HOUSMAN, DE				HABER, DA; HOUSMAN, DE			RATE-LIMITING STEPS - THE GENETICS OF PEDIATRIC CANCERS	CELL			English	Review							WILMS TUMOR; RETINOBLASTOMA GENE; MUTATIONS; ONCOGENE; ALLELES		HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital	HABER, DA (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.							CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, IN PRESS AM J HUM GE; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	20	46	48	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					5	8		10.1016/0092-8674(91)90200-I	http://dx.doi.org/10.1016/0092-8674(91)90200-I			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846091				2022-12-28	WOS:A1991ET17500002
J	HANIFORD, DB; BENJAMIN, HW; KLECKNER, N				HANIFORD, DB; BENJAMIN, HW; KLECKNER, N			KINETIC AND STRUCTURAL-ANALYSIS OF A CLEAVED DONOR INTERMEDIATE AND A STRAND TRANSFER INTERMEDIATE IN TN10 TRANSPOSITION	CELL			English	Article							BACTERIOPHAGE-MU-DNA; RETROVIRAL INTEGRATION; TRANSPOSABLE ELEMENTS; INVITRO TRANSPOSITION; PROTEIN; SEQUENCES; MECHANISM; REARRANGEMENTS; ORGANIZATION; REPLICATION	Tn10 transposes by a nonreplicative "cut and paste" mechanism. We describe here two protein-DNA complexes that are reaction intermediates in the Tn10 transposition process: a cleaved donor complex whose DNA component consists of transposon sequences cleanly excised from flanking donor DNA, and a strand transfer complex whose DNA component contains transposon termini specifically joined to a target site. The kinetic behavior of the first species suggests that it is an early intermediate in the transposition reaction. These two Tn10 complexes are closely analogous to complexes identified in the pathway for replicative "cointegrate" formation by bacteriophage Mu and thus represent intermediates that may be common to both nonreplicative and replicative transposition. These and other results suggest that the Tn10 and Mu reactions are fundamentally very similar despite their very different biological outcomes. The critical difference between the two reactions is the fate of the DNA strand that is not joined to target DNA.			HANIFORD, DB (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							ARCISZEWSKA LK, 1989, J MOL BIOL, V207, P35, DOI 10.1016/0022-2836(89)90439-7; BENDER J, 1986, CELL, V45, P801, DOI 10.1016/0092-8674(86)90555-6; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; BENJAMIN HW, 1988, EMBO J, V7, P1897, DOI 10.1002/j.1460-2075.1988.tb03023.x; BERG DE, 1983, P NATL ACAD SCI-BIOL, V80, P792, DOI 10.1073/pnas.80.3.792; BOEKE JD, 1989, MOBILE DNA, P335; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; CHACONAS G, 1981, J MOL BIOL, V150, P341, DOI 10.1016/0022-2836(81)90551-9; COEN ES, 1989, MOBILE DNA, P413; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FAELEN M, 1978, NATURE, V271, P580, DOI 10.1038/271580a0; FEDOROFF NV, 1989, MOBILE DNA, P375; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINNEGAN DJ, 1989, TRENDS GENET, V5, P103, DOI 10.1016/0168-9525(89)90039-5; FOSTER TJ, 1981, CELL, V23, P201, DOI 10.1016/0092-8674(81)90285-3; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; HALLING SM, 1982, P NATL ACAD SCI-BIOL, V79, P2608, DOI 10.1073/pnas.79.8.2608; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; HARSHEY RM, 1983, P NATL ACAD SCI-BIOL, V80, P2012, DOI 10.1073/pnas.80.7.2012; HARSHEY RM, 1985, P NATL ACAD SCI USA, V82, P7676, DOI 10.1073/pnas.82.22.7676; HUISMAN O, 1989, EMBO J, V8, P2101, DOI 10.1002/j.1460-2075.1989.tb03619.x; ISBERG RR, 1985, J MOL BIOL, V182, P69, DOI 10.1016/0022-2836(85)90028-2; JENCKS WP, 1990, BIOCH MOL BIOL, V1, P1; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KLECKNER N, 1989, MOBILE DNA, P225; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LIEBART JC, 1982, P NATL ACAD SCI-BIOL, V79, P4362, DOI 10.1073/pnas.79.14.4362; LJUNGQUIST E, 1977, P NATL ACAD SCI USA, V74, P3143, DOI 10.1073/pnas.74.8.3143; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; Miller J.H., 1972, EXPT MOL GENETICS; MIZUUCHI K, 1984, CELL, V39, P395, DOI 10.1016/0092-8674(84)90018-7; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; MORISATO D, 1984, CELL, V39, P181, DOI 10.1016/0092-8674(84)90204-6; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; SHEN MM, 1987, GENETICS, V116, P359; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SZATMARI GB, 1986, GENE, V41, P315, DOI 10.1016/0378-1119(86)90113-7; VARMUS H, 1989, MOBILE DNA, P53; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WEINERT TA, 1984, COLD SPRING HARB SYM, V49, P251, DOI 10.1101/SQB.1984.049.01.029	47	78	79	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					171	179						9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846088				2022-12-28	WOS:A1991ET17500018
J	TRENT, JD; NIMMESGERN, E; WALL, JS; HARTL, FU; HORWICH, AL				TRENT, JD; NIMMESGERN, E; WALL, JS; HARTL, FU; HORWICH, AL			A MOLECULAR CHAPERONE FROM A THERMOPHILIC ARCHAEBACTERIUM IS RELATED TO THE EUKARYOTIC PROTEIN T-COMPLEX POLYPEPTIDE-1	NATURE			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; HEAT-SHOCK; RIBULOSEBISPHOSPHATE-CARBOXYLASE; MITOCHONDRIAL PROTEIN; ATP HYDROLYSIS; GENE; CLONING; PURIFICATION; SEQUENCE	THERE is evidence to suggest that components of archaebacteria are evolutionarily related to cognates in the eukaryotic cytosol 1-7. We postulated that the major heat-shock protein of the thermophilic archaebacterium, Sulfolobus shibatae, is a molecular chaperone and that it is related to an as-yet unidentified chaperone component in the eukaryotic cytosol. Acquired thermotolerance in S. shibatae correlates with the predominant synthesis of this already abundant protein, referred to as thermophilic factor 55 (TF55; ref. 8). TF55 is a homo-oligomeric complex of two stacked 9-membered rings, closely resembling the 7-membered-ring complexes of the chaperonins, groEL, hsp60 and Rubisco-binding protein 9-15. The TF55 complex binds unfolded polypeptides in vitro and has ATPase activity-features consistent with its being a molecular chaperone 16,17. The primary structure of TF55, however, is not significantly related to the chaperonins. On the other hand, it is highly homologous (36-40% identity) to a ubiquitous eukaryotic protein, t-complex polypeptide-1 (TCP1; refs 18-20). In Saccharomyces cerevisiae, TCP1 is an essential protein that may play a part in mitotic spindle formation 21. We suggest that TF55 in archaebacteria and TCP1 in the eukaryotic cytosol are members of a new class of molecular chaperones.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; SLOAN KETTERING MEM CANC CTR,ROCKEFELLER RES LAB,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	Yale University; Memorial Sloan Kettering Cancer Center; United States Department of Energy (DOE); Brookhaven National Laboratory	TRENT, JD (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,333 CEDAR ST,NEW HAVEN,CT 06510, USA.		Hartl, F. Ulrich/Y-8206-2019					AHMAD S, 1990, BIOCHIM BIOPHYS ACTA, V1087, P253, DOI 10.1016/0167-4781(90)90214-M; AUER J, 1989, CAN J MICROBIOL, V35, P200, DOI 10.1139/m89-031; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; CARAZO JM, 1991, J STRUCT BIOL, V106, P211, DOI 10.1016/1047-8477(91)90071-4; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P17, DOI 10.1111/j.1749-6632.1987.tb40596.x; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1991, REV BIOCH, V60, P327; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RJW, 1979, J MOL BIOL, V129, P359; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HORWICH A, 1980, J VIROL, V36, P125, DOI 10.1128/JVI.36.1.125-132.1980; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; LECHNER K, 1987, MOL GEN GENET, V208, P523, DOI 10.1007/BF00328150; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; REITER WD, 1990, P NATL ACAD SCI USA, V87, P9509, DOI 10.1073/pnas.87.24.9509; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SEARCY DG, 1991, BIOSYSTEMS, V25, P1, DOI 10.1016/0303-2647(91)90008-9; SHINNICK TM, 1987, J BACTERIOL, V169, P1080, DOI 10.1128/jb.169.3.1080-1088.1987; SILVER LM, 1979, CELL, V17, P275, DOI 10.1016/0092-8674(79)90153-3; SILVER LM, 1987, DEV BIOL, V119, P605, DOI 10.1016/0012-1606(87)90063-7; TRENT JD, 1990, J BACTERIOL, V172, P1478, DOI 10.1128/jb.172.3.1478-1484.1990; URSIC D, 1988, GENE, V68, P267, DOI 10.1016/0378-1119(88)90029-7; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WILLISON K, 1987, EMBO J, V6, P1967, DOI 10.1002/j.1460-2075.1987.tb02459.x; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WILLISON KR, 1986, CELL, V44, P727, DOI 10.1016/0092-8674(86)90839-1; ZILLIG W, 1989, ENDOCYT CELL RES, V6, P1; ZILLIG W, 1987, ANN NY ACAD SCI, V503, P78, DOI 10.1111/j.1749-6632.1987.tb40599.x	43	293	302	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1991	354	6353					490	493		10.1038/354490a0	http://dx.doi.org/10.1038/354490a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1836250				2022-12-28	WOS:A1991GV07800064
J	PATERSONBROWN, S				PATERSONBROWN, S			STRATEGIES FOR REDUCING INAPPROPRIATE LAPAROTOMY RATE IN THE ACUTE ABDOMEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article											PATERSONBROWN, S (corresponding author), UNIV EDINBURGH, ROYAL INFIRM, DEPT SURG, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND.							ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; ANDERSON JL, 1981, AUST NZ J SURG, V51, P462, DOI 10.1111/j.1445-2197.1981.tb05986.x; ANTEBY SO, 1975, ANN SURG, V181, P484, DOI 10.1097/00000658-197504000-00022; BAIGRIE RJ, 1991, BRIT J SURG, V78, P167, DOI 10.1002/bjs.1800780211; BAKER WNW, 1967, BRIT MED J, V3, P146, DOI 10.1136/bmj.3.5558.146; BALLA JI, 1989, BRIT MED J, V298, P579, DOI 10.1136/bmj.298.6673.579; Blacklock A R, 1976, J R Coll Surg Edinb, V21, P165; BROLIN RE, 1987, ANN SURG, V206, P126, DOI 10.1097/00000658-198708000-00002; Buck N, 1987, REPORT CONFIDENTIAL; CAMPBELL JPM, 1988, BRIT J SURG, V75, P554, DOI 10.1002/bjs.1800750616; CHAMBERLAIN GVP, 1978, REPORT WORKING PARTY; CHANG FC, 1973, AM J SURG, V126, P752, DOI 10.1016/S0002-9610(73)80063-7; CLARKE PJ, 1986, ANN ROY COLL SURG, V68, P68; COPE VZ, 1947, DIAGNOSIS ACUTE ABDO, P88; CRICHTON D, 1988, BRIT MED J, V297, P857, DOI 10.1136/bmj.297.6652.857; CROFTS TJ, 1989, NEW ENGL J MED, V320, P970, DOI 10.1056/NEJM198904133201504; CUSCHIERI A, 1988, ANN ROY COLL SURG, V70, P153; DEDOMBAL FT, 1972, BMJ-BRIT MED J, V2, P9, DOI 10.1136/bmj.2.5804.9; DEDOMBAL FT, 1984, SCAND J GASTROENTERO, V19, P28; DEUTSCH AA, 1982, BRIT J SURG, V69, P336, DOI 10.1002/bjs.1800690615; DOMBAL FTD, 1974, BRIT MED J, V1, P376, DOI 10.1136/bmj.1.5904.376; DONOVAN AJ, 1979, ANN SURG, V189, P627, DOI 10.1097/00000658-197905000-00013; DUBOIS F, 1990, ANN SURG, V211, P60, DOI 10.1097/00000658-199001000-00010; DUDLEY HAF, 1986, BRIT MED J, V292, P1157, DOI 10.1136/bmj.292.6529.1157; DUNN JT, 1984, ARCH SURG-CHICAGO, V119, P1305; ELLIS BW, 1990, BRIT MED J, V301, P159, DOI 10.1136/bmj.301.6744.159; FIELD S, 1985, BRIT MED J, V290, P1934, DOI 10.1136/bmj.290.6486.1934; FOSTER HM, 1988, BRIT MED J, V297, P489, DOI 10.1136/bmj.297.6646.489-e; FOWKES FGR, 1980, BRIT J SURG, V67, P613, DOI 10.1002/bjs.1800670903; GOUGH MH, 1980, BRIT MED J, V281, P913, DOI 10.1136/bmj.281.6245.913; GRUER R, 1986, LANCET, V1, P23; Gunn A A, 1976, J R Coll Surg Edinb, V21, P170; GUNN AA, 1989, BRIT J SURG, V76, P422, DOI 10.1002/bjs.1800760440; HALL TJ, 1980, BRIT J SURG, V67, P751, DOI 10.1002/bjs.1800671019; HOFFMANN J, 1987, ACTA CHIR SCAND, V153, P561; Howie C R, 1984, J R Coll Surg Edinb, V29, P249; KANG WM, 1989, SURGERY, V105, P154; KORUTH N M, 1985, Journal of the Royal College of Surgeons of Edinburgh, V30, P258; KOURTESIS GJ, 1988, AUST NZ J SURG, V58, P801, DOI 10.1111/j.1445-2197.1988.tb00983.x; LAWRENCE PC, 1987, ANN ROY COLL SURG, V69, P233; LEAPE LL, 1980, ANN SURG, V191, P410, DOI 10.1097/00000658-198004000-00004; LEE PWR, 1976, BRIT J SURG, V63, P763, DOI 10.1002/bjs.1800631009; MACARTNEY FJ, 1987, BMJ-BRIT MED J, V295, P1325, DOI 10.1136/bmj.295.6609.1325; MCADAM WAF, 1990, ANN ROY COLL SURG, V72, P140; MCARTHUR P, 1975, BRIT J SURG, V62, P850, DOI 10.1002/bjs.1800621025; MILLER RE, 1971, AMER J ROENTGENOL RA, V112, P574, DOI 10.2214/ajr.112.3.574; Moore A T, 1987, Health Trends, V19, P8; NAGY AG, 1989, AM J SURG, V157, P490, DOI 10.1016/0002-9610(89)90642-9; Neutra R., 1977, COSTS RISKS BENEFITS, P277; OLDHAM JFM, 1972, MED J AUSTRALIA, V1, P483, DOI 10.5694/j.1326-5377.1972.tb46881.x; OOMS HWA, 1991, BRIT J SURG, V78, P315, DOI 10.1002/bjs.1800780316; OTT DJ, 1983, JAMA-J AM MED ASSOC, V249, P2380, DOI 10.1001/jama.249.17.2380; PATERSONBROWN S, 1990, BRIT J SURG, V77, P13, DOI 10.1002/bjs.1800770105; PATERSONBROWN S, 1988, BRIT MED J, V296, P1363, DOI 10.1136/bmj.296.6633.1363-a; PATERSONBROWN S, 1989, BRIT J SURG, V76, P1011, DOI 10.1002/bjs.1800761007; PATERSONBROWN S, 1986, BRIT J SURG, V73, P1022, DOI 10.1002/bjs.1800731230; PATERSONBROWN S, 1986, J R COLL SURG EDINB, V31, P16; PEARSON RH, 1988, BRIT MED J, V297, P309, DOI 10.1136/bmj.297.6644.309; PUYLAERT JBCM, 1987, NEW ENGL J MED, V317, P666, DOI 10.1056/NEJM198709103171103; RALLS PW, 1985, RADIOLOGY, V155, P767, DOI 10.1148/radiology.155.3.3890007; SAMUELS BI, 1983, RADIOLOGY, V147, P207, DOI 10.1148/radiology.147.1.6828731; SCARLETT PY, 1986, ANN ROY COLL SURG, V68, P179; SIMPSON A, 1985, CLIN RADIOL, V36, P41, DOI 10.1016/S0009-9260(85)80016-7; SPIRTOS NM, 1987, AM J OBSTET GYNECOL, V156, P90, DOI 10.1016/0002-9378(87)90212-2; STEWART J, 1984, BRIT J SURG, V71, P799, DOI 10.1002/bjs.1800711021; STEWART RJ, 1986, LANCET, V2, P1414; STEWART RJ, 1988, AUST NZ J SURG, V58, P965, DOI 10.1111/j.1445-2197.1988.tb00102.x; STOWER MJ, 1985, J ROY SOC MED, V78, P630, DOI 10.1177/014107688507800806; SUGARBAKER PH, 1975, LANCET, V1, P442; SUTTON GC, 1989, BRIT J SURG, V76, P82, DOI 10.1002/bjs.1800760126; VELANOVICH V, 1990, SURG GYNECOL OBSTET, V170, P7; VIPOND MN, 1990, BRIT J SURG, V77, P86, DOI 10.1002/bjs.1800770130; WHITWORTH CM, 1988, SURG GYNECOL OBSTET, V167, P187; Wilkins R A, 1986, Health Trends, V18, P25; WOODWARD A, 1988, BRIT MED J, V296, P1740, DOI 10.1136/bmj.296.6638.1740; WORTHEN NJ, 1981, AM J ROENTGENOL, V137, P973, DOI 10.2214/ajr.137.5.973	76	15	16	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	1991	303	6810					1115	1118		10.1136/bmj.303.6810.1115	http://dx.doi.org/10.1136/bmj.303.6810.1115			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1836146	Green Published, Bronze			2022-12-28	WOS:A1991GN20900027
J	EWEN, ME; XING, YG; LAWRENCE, JB; LIVINGSTON, DM				EWEN, ME; XING, YG; LAWRENCE, JB; LIVINGSTON, DM			MOLECULAR-CLONING, CHROMOSOMAL MAPPING, AND EXPRESSION OF THE CDNA FOR P107, A RETINOBLASTOMA GENE PRODUCT-RELATED PROTEIN	CELL			English	Article							LARGE T-ANTIGEN; SV40 LARGE-T; SUSCEPTIBILITY GENE; SEQUENCE; BINDING; TRANSFORMATION; REGION; NITROCELLULOSE; IDENTIFICATION; INACTIVATION	p107 is a cellular protein that forms specific complexes with adenovirus E1A and SV40 large T antigen (T). The genetics of the p107-T/E1A interaction as well as other features of this protein suggests that p107 shares functional properties with the tumor suppressor product, RB. A partial cDNA for human p107 has been cloned. Its sequences map to 20q11.2 and encode a 936 residue protein. Comparison analysis of the p107 protein sequence reveals a major region of RB homology extending over 564 residues. This region in RB is essential to its growth-controlling function. Sequences outside of these two regions are largely unique to each protein. The p107 and RB homology regions can independently bind to T and E1A. Thus, these two proteins display similarities of structure that may, at least in part, explain their known functional similarities and suggest a generic function for p107 in cell cycle regulation.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; UNIV MASSACHUSETTS,SCH MED,DEPT CELL BIOL,WORCESTER,MA 01655	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	EWEN, ME (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.			Lawrence, Jeanne/0000-0001-6572-3128				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; DAVIS MP, 1984, CANCER GENET CYTOGEN, V12, P63, DOI 10.1016/0165-4608(84)90009-8; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1988, ANTIBODIES LABORATOR; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JOHNSON CV, 1991, GENET ANAL TECH APPL, V8, P41; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LAWRENCE JB, 1988, CELL, V52, P51; LEBEAU MM, 1985, P NATL ACAD SCI USA, V82, P6692; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Maniatis T., 1982, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YUNIS JJ, 1988, BRIT J HAEMATOL, V68, P189, DOI 10.1111/j.1365-2141.1988.tb06188.x	38	440	449	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1155	1164		10.1016/0092-8674(91)90038-Z	http://dx.doi.org/10.1016/0092-8674(91)90038-Z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1833063				2022-12-28	WOS:A1991GG55200010
J	LEOPOLD, P; OFARRELL, PH				LEOPOLD, P; OFARRELL, PH			AN EVOLUTIONARILY CONSERVED CYCLIN HOMOLOG FROM DROSOPHILA RESCUES YEAST DEFICIENT IN G1 CYCLINS	CELL			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; MESSENGER-RNA; M-PHASE; MOLECULAR-CLONING; FISSION YEAST; GENE; TRANSFORMATION; MITOSIS	We have isolated two Drosophila cDNA clones that rescue Saccharomyces cerevisiae deficient in CLN functions. One of these clones is the Drosophila homolog of the cdc2 gene. The second encodes a distant and new member of the cyclin family of proteins, cyclin C. It is highly homologous (72% identity) to a human clone isolated in a similar screen. Yeast cells rescued by a plasmid constitutively expressing this Drosophila cyclin C are unusually small, consistent with an unregulated high level of G1 cyclin function. Sequence comparisons identified regions conserved among the more distantly related cyclins. Based on these conserved elements, we identified homology between cyclins and the ras oncogene.			LEOPOLD, P (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			O'Farrell, Patrick/0000-0003-0011-2734	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037193] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL43821] Funding Source: Medline; NIGMS NIH HHS [R01 GM037193-10, R01 GM037193] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Guthrie C, 1991, METHODS ENZYMOLOGY; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JIMENEZ J, 1990, EMBO J, V9, P3565, DOI 10.1002/j.1460-2075.1990.tb07567.x; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MOTAKURA T, 1991, NATURE, V350, P512; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WANG J, 1990, NATURE, V342, P942; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041	46	162	174	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1207	1216		10.1016/0092-8674(91)90043-X	http://dx.doi.org/10.1016/0092-8674(91)90043-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1833067	Green Accepted			2022-12-28	WOS:A1991GG55200015
J	IRIE, K; NOMOTO, S; MIYAJIMA, I; MATSUMOTO, K				IRIE, K; NOMOTO, S; MIYAJIMA, I; MATSUMOTO, K			SGV1 ENCODES A CDC28/CDC2-RELATED KINASE REQUIRED FOR A G-ALPHA-SUBUNIT MEDIATED ADAPTIVE RESPONSE TO PHEROMONE IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							FACTOR SIGNALING PATHWAY; CELL-DIVISION CONTROL; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; MATING PHEROMONE; FACTOR RECEPTOR; GENE CDC2; A-FACTOR; YEAST; SEQUENCE	The GPA1 gene of S. cerevisiae encodes a G-alpha-subunit that plays a positive role in the transduction of signals stimulating recovery from pheromone-induced cell cycle arrest. The GPA1Val50 mutation, in which Gly-50 is replaced by valine, causes hyperadaptation to pheromone. However, GPA1Val50 cells do not recover from division arrest in the absence of both CLN1 and CLN3, which encode G1 cyclins, indicating that the recovery-promoting activity of GPA1Val50 requires the function of G1 cyclins. An sgv1 mutation suppresses the hyperadaptive response caused by GPA1Val50 and also confers cold- and temperature-sensitive growth. The SGV1 gene encodes an apparent protein kinase homologous to CDC28/cdc2 kinase: SGV1 is 42% identical to CDC28. The activated mutation, CLN3-2, partially suppresses the growth defect of sgv1, suggesting that the SGV1 and CLN3 proteins may act in the same growth control pathway.			IRIE, K (corresponding author), NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CARR AM, 1989, MOL GEN GENET, V218, P41, DOI 10.1007/BF00330563; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CLEJEK E, 1979, Cell, V18, P623; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; CROSS F, 1988, MOL CELL BIOL, V8, P4657; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTWELL LH, 1980, J CELL BIOL, V85, P811, DOI 10.1083/jcb.85.3.811; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; ITOH H, 1983, J BACTERIOL, V153, P163; JAHNG KY, 1988, MOL CELL BIOL, V8, P2484, DOI 10.1128/MCB.8.6.2484; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MIYAJIMA I, 1989, MOL CELL BIOL, V9, P2289, DOI 10.1128/MCB.9.6.2289; MOORE SA, 1984, J BIOL CHEM, V259, P1004; NAKAFUKU M, 1987, P NATL ACAD SCI USA, V84, P2140, DOI 10.1073/pnas.84.8.2140; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P3777, DOI 10.1128/MCB.8.9.3777; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NASH R, 1988, EMBO J, V7, P4355; NOMOTO S, 1990, EMBO J, V9, P691, DOI 10.1002/j.1460-2075.1990.tb08161.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REED SI, 1980, GENETICS, V95, P561; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STONE DE, 1990, MOL CELL BIOL, V10, P4439, DOI 10.1128/MCB.10.9.4439; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	50	75	78	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					785	795		10.1016/0092-8674(91)90386-D	http://dx.doi.org/10.1016/0092-8674(91)90386-D			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1828190				2022-12-28	WOS:A1991FP51600009
J	STEIGER, MJ; QUINN, NP				STEIGER, MJ; QUINN, NP			HORMONE REPLACEMENT THERAPY INDUCED CHOREA	BRITISH MEDICAL JOURNAL			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS				STEIGER, MJ (corresponding author), UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,LONDON WC1N 3BG,ENGLAND.							BOUCHEZ B, 1985, REV NEUROL-FRANCE, V141, P571; BRUYN GW, 1984, EUR NEUROL, V23, P278, DOI 10.1159/000115743; NAUSIEDA PA, 1979, NEUROLOGY, V29, P1605, DOI 10.1212/WNL.29.12.1605; NAUSIEDA PA, 1980, NEUROLOGY, V30, P331, DOI 10.1212/WNL.30.3.331; Willson P, 1932, ARCH INTERN MED, V49, P471, DOI 10.1001/archinte.1932.00150100128011	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					762	762		10.1136/bmj.302.6779.762	http://dx.doi.org/10.1136/bmj.302.6779.762			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	1850638	Bronze, Green Published			2022-12-28	WOS:A1991FF22900025
J	SAXTON, WM; HICKS, J; GOLDSTEIN, LSB; RAFF, EC				SAXTON, WM; HICKS, J; GOLDSTEIN, LSB; RAFF, EC			KINESIN HEAVY-CHAIN IS ESSENTIAL FOR VIABILITY AND NEUROMUSCULAR FUNCTIONS IN DROSOPHILA, BUT MUTANTS SHOW NO DEFECTS IN MITOSIS	CELL			English	Article							BOVINE BRAIN KINESIN; MICROTUBULE MOTILITY; ELECTRON-MICROSCOPY; IMAGINAL DISKS; IDENTIFICATION; MELANOGASTER; LOCALIZATION; AXOPLASM; PROTEIN	The in vivo function of the microtubule motor protein kinesin was examined in Drosophila using genetics and immunolocalization. Kinesin heavy chain mutations (khc) cause abnormal behavior and lethality. Mutant larvae exhibit loss of mobility and tactile responsiveness in the most posterior segments, followed by general paralysis and death during larval or pupal development. Adults homozygous for a temperature-sensitive allele also exhibit a loss in mobility and sensory responses. The data indicate that kinesin function is essential and suggest that kinesin has an important role in the neuromuscular system, perhaps as a motor for axonal transport. The possibility of more general cellular functions remains open, but observation of embryogenesis and morphogenesis in khc mutants suggests that mitosis and the cell cycle can proceed in spite of impaired kinesin function. Immunolocalization suggests that kinesin may have some general cellular functions but that it is not a major component of mitotic spindles.	HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	Harvard University	SAXTON, WM (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016739] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16739] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMOS LA, 1987, J CELL SCI, V87, P105; ANSTROM JA, 1987, DEVELOPMENT, V101, P255; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BONNER JJ, 1976, CHROMOSOMA, V58, P87, DOI 10.1007/BF00293443; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1982, SCIENCE, V218, P1129, DOI 10.1126/science.6183745; COHN SA, 1989, J BIOL CHEM, V264, P4290; CURTIS D, 1989, GENETICS, V122, P653; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Fischer S G, 1979, Methods Enzymol, V68, P183; FOE VE, 1983, J CELL SCI, V61, P31; FYRBERG E, 1990, J CELL BIOL, V110, P1999, DOI 10.1083/jcb.110.6.1999; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; KARR TL, 1986, J CELL BIOL, V102, P1494, DOI 10.1083/jcb.102.4.1494; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LINDSLEY DL, 1985, DROS INF SERV, V62; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; MADHAVAN MM, 1977, ROUX ARCH DEV BIOL, V183, P269, DOI 10.1007/BF00848459; Maniatis T., 1982, MOL CLONING; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MCINTOSH JR, 1989, J BIOL CHEM, V264, P6001; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; ROBERTSON HM, 1988, GENETICS, V118, P461; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHNAPP BJ, 1985, CELL, V40, P455, DOI 10.1016/0092-8674(85)90160-6; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WARN RM, 1986, J CELL SCI S, V5, P311; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1864, DOI 10.1073/pnas.85.6.1864; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	43	177	180	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1093	1102		10.1016/0092-8674(91)90264-Y	http://dx.doi.org/10.1016/0092-8674(91)90264-Y			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	1825937				2022-12-28	WOS:A1991FD55800007
J	SCHOUB, BD; JOHNSON, S; MCANERNEY, JM; BLACKBURN, N; KEW, MC; MCCUTCHEON, JP; CARLIER, ND				SCHOUB, BD; JOHNSON, S; MCANERNEY, JM; BLACKBURN, N; KEW, MC; MCCUTCHEON, JP; CARLIER, ND			INTEGRATION OF HEPATITIS-B VACCINATION INTO RURAL AFRICAN PRIMARY HEALTH-CARE PROGRAMS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMMUNIZATION PROGRAM; MASS VACCINATION; VIRUS-INFECTION; SURFACE-ANTIGEN; ENDEMIC AREA; INFANTS	Objective-To determine the efficacy of hepatitis B vaccine when added to the routine expanded programme on immunisation under field conditions in rural Africa. Design-Infants were immunised according to two schedules-an early schedule at birth, 3 months, and 6 months and a later schedule to correspond with routine vaccination in the expanded programme on immunisation at 3 months, 4 1/2 months, and 6 months. Setting-Venda, northern Transvaal, South Africa, a self governing region of 7460 square kilometres varying from rural villages to small towns. Subjects-The 1989 birth cohort of Venda. Main outcome measures-Coverage for hepatitis B vaccine at first, second, and third doses; serological assessment of vaccine efficacy by prevalence of antibodies to hepatitis B surface antigen in infants who had completed the three dose course of immunisation; antibodies to hepatitis B core antigen to determine if natural infection occurred. Results-Vaccine coverage for hepatitis B dropped sharply from 99% to 53% to 39% for the first, second, and third doses respectively. In contrast, vaccine coverage was maintained at 97-99% for the three doses of poliomyelitis vaccine. Serological evaluation of vaccine efficacy showed that only 3.5% of recipients of all three doses failed to develop antibodies to hepatitis B surface antigen. Only 6.6% of vaccine recipients were vaccinated according to either the early or later schedules whereas 93.4% received their doses of vaccine at intervals beyond the limits of either of the planned schedules. There was, however, no significant difference in seroconversion to the surface antigen between the ''unscheduled'' or scheduled groups or those who were vaccinated according to the early or late schedules. The pattern of prevalence of antibodies to hepatitis B core antigen, which showed a sharp fall in children aged over 7 months, suggested that the antibodies were acquired passively rather than by active infection. Conclusions-Supplementation of the present expanded programme on immunisation with hepatitis B vaccine in rural Africa is fraught with difficulties. However, the vaccine was effective within a fairly wide spacing of dosage. Adding hepatitis B vaccine to diphtheria, tetanus, and pertussis as a tetravalent vaccine is proposed as a means of effectively integrating it into the expanded programme on immunisation in Third World settings.	UNIV WITWATERSRAND, DEPT VIROL, JOHANNESBURG 2131, SOUTH AFRICA; UNIV WITWATERSRAND, DEPT MED, JOHANNESBURG 2001, SOUTH AFRICA; DEPT HLTH, VENDA, BRAZIL	University of Witwatersrand; University of Witwatersrand	SCHOUB, BD (corresponding author), UNIV WITWATERSRAND, NATL INST VIROL, PRIVATE BAG X4, JOHANNESBURG 2131, SOUTH AFRICA.							BOTHA JF, 1984, LANCET, V1, P1210; CHEN DS, 1987, JAMA-J AM MED ASSOC, V257, P2597; COURSAGET P, 1986, LANCET, V2, P1143; COURSAGET P, 1987, LANCET, V2, P1354; COURSAGET P, 1986, INFECT IMMUN, V51, P784, DOI 10.1128/IAI.51.3.784-787.1986; DUSHEIKO GM, 1989, AM J EPIDEMIOL, V129, P138, DOI 10.1093/oxfordjournals.aje.a115102; GOH KT, 1989, B WORLD HEALTH ORGAN, V67, P65; HALL AJ, 1989, LANCET, V1, P1057; MAYNARD JE, 1989, REV INFECT DIS, V11, pS574; PIAZZA M, 1988, LANCET, V2, P1132; PROZESKY OW, 1983, S AFR MED J, V64, P891; SCHOUB BD, 1988, HLTH ALL YEAR 2000; SMEGO RA, 1987, PEDIATR INFECT DIS J, V6, P11, DOI 10.1097/00006454-198701000-00005; YVONNET B, 1987, J MED VIROL, V22, P315, DOI 10.1002/jmv.1890220404; 1988, WEEKLY EPIDEMIOLOGIC, V63, P9; 1990, WEEKLY EPIDEMIOLOGIC, V65, P5; 1987, STATE WORLDS CHILDRE	17	15	15	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 9	1991	302	6772					313	316		10.1136/bmj.302.6772.313	http://dx.doi.org/10.1136/bmj.302.6772.313			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX569	1825799	Green Published, Bronze			2022-12-28	WOS:A1991EX56900020
J	PELLICCIA, A; MARON, BJ; SPATARO, A; PROSCHAN, MA; SPIRITO, P				PELLICCIA, A; MARON, BJ; SPATARO, A; PROSCHAN, MA; SPIRITO, P			THE UPPER LIMIT OF PHYSIOLOGICAL CARDIAC-HYPERTROPHY IN HIGHLY TRAINED ELITE ATHLETES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR HYPERTROPHY; M-MODE ECHOCARDIOGRAPHY; NON-INVASIVE EVALUATION; DOPPLER ECHOCARDIOGRAPHY; CLINICAL MANIFESTATIONS; CARDIOVASCULAR-DISEASE; DIASTOLIC FUNCTION; DISTANCE RUNNERS; PATHO-PHYSIOLOGY; CARDIOMYOPATHY	Background. In some highly trained athletes, the thickness of the left ventricular wall may increase as a consequence of exercise training and resemble that found in cardiac diseases associated with left ventricular hypertrophy, such as hypertrophic cardiomyopathy. In these athletes, the differential diagnosis between physiologic and pathologic hypertrophy may be difficult. Methods. To address this issue, we measured left ventricular dimensions with echocardiography in 947 elite, highly trained athletes who participated in a wide variety of sports. Results. The thickest left ventricular wall among the athletes measured 16 mm. Wall thicknesses within a range compatible with the diagnosis of hypertrophic cardiomyopathy (greater-than-or-equal-to 13 mm) were identified in only 16 of the 947 athletes (1.7 percent); 15 were rowers or canoeists, and 1 was a cyclist. Therefore, the wall was greater-than-or-equal-to 13 mm thick in 7 percent of 219 rowers, canoeists, and cyclists but in none of 728 participants in 22 other sports. All athletes with walls greater-than-or-equal-to 13 mm thick also had enlarged left ventricular end-diastolic cavities (dimensions, 55 to 63 mm). Conclusions. On the basis of these data, a left-ventricular-wall thickness of greater-than-or-equal-to 13 mm is very uncommon in highly trained athletes, virtually confined to athletes training in rowing sports, and associated with an enlarged left ventricular cavity. In addition, the upper limit to which the thickness of the left ventricular wall may be increased by athletic training appears to be 16 mm. Therefore, athletes with a wall thickness of more than 16 mm and a nondilated left ventricular cavity are likely to have primary forms of pathologic hypertrophy, such as hypertrophic cardiomyopathy.	NHLBI,CARDIOL BRANCH,BETHESDA,MD 20892; NHLBI,BIOSTAT RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	PELLICCIA, A (corresponding author), COMITATO OLIMPICO NAZL ITALIANO,INST SPORTS SCI,DEPT MED,VIA CAMPI SPORTIVI 46,I-00197 ROME,ITALY.			Spataro, Antonio/0000-0002-7727-665X				BEKAERT I, 1981, BRIT HEART J, V45, P213; BLAIR NL, 1980, AUST NZ J MED, V10, P540, DOI 10.1111/j.1445-5994.1980.tb04973.x; DEMARIA AN, 1978, CIRCULATION, V57, P237, DOI 10.1161/01.CIR.57.2.237; DEVEREUX RB, 1987, HYPERTENSION, V9, P19; DOUGLAS PS, 1986, AM J CARDIOL, V58, P805, DOI 10.1016/0002-9149(86)90358-9; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; EHSANI AA, 1978, AM J CARDIOL, V42, P52, DOI 10.1016/0002-9149(78)90984-0; FAGARD R, 1983, CIRCULATION, V67, P896, DOI 10.1161/01.CIR.67.4.896; FAGARD R, 1984, BRIT HEART J, V52, P124; FAGARD R, 1987, J AM COLL CARDIOL, V9, P1250, DOI 10.1016/S0735-1097(87)80463-1; FISHER AG, 1989, AM J CARDIOL, V63, P337, DOI 10.1016/0002-9149(89)90342-1; GILBERT CA, 1977, AM J CARDIOL, V40, P528, DOI 10.1016/0002-9149(77)90067-4; HENRY WL, 1980, CIRCULATION, V62, P1054, DOI 10.1161/01.CIR.62.5.1054; IKAHEIMO MJ, 1979, AM J CARDIOL, V44, P24, DOI 10.1016/0002-9149(79)90246-7; KEREN G, 1985, CIRCULATION, V71, P45, DOI 10.1161/01.CIR.71.1.45; LEWIS JF, 1989, AM J CARDIOL, V64, P1029, DOI 10.1016/0002-9149(89)90802-3; LONGHURST JC, 1981, CIRC RES, V48, P171; LOUIE EK, 1987, ANN INTERN MED, V106, P663, DOI 10.7326/0003-4819-106-5-663; MARON BJ, 1987, J AM COLL CARDIOL, V10, P1214, DOI 10.1016/S0735-1097(87)80121-3; MARON BJ, 1983, AM J CARDIOL, V51, P189, DOI 10.1016/S0002-9149(83)80034-4; MARON BJ, 1986, J AM COLL CARDIOL, V7, P190, DOI 10.1016/S0735-1097(86)80282-0; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1981, AM J CARDIOL, V48, P418, DOI 10.1016/0002-9149(81)90068-0; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1987, J AM COLL CARDIOL, V10, P733, DOI 10.1016/S0735-1097(87)80264-4; MARTIN WH, 1986, J AM COLL CARDIOL, V7, P982, DOI 10.1016/S0735-1097(86)80215-7; MORGANROTH J, 1975, ANN INTERN MED, V82, P521, DOI 10.7326/0003-4819-82-4-521; NETER J, 1984, APPLIED LINEAR STATI, P214; NISHIMURA T, 1980, CIRCULATION, V61, P832, DOI 10.1161/01.CIR.61.4.832; OAKLEY D, 1984, BRIT HEART J, V52, P121; PARKER BM, 1978, CHEST, V73, P376, DOI 10.1378/chest.73.3.376; ROST R, 1982, EUR HEART J, V3, P193, DOI 10.1093/eurheartj/3.suppl_A.193; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SHAPIRO LM, 1985, EUR HEART J, V6, P967, DOI 10.1093/oxfordjournals.eurheartj.a061796; SNOECKX LHEH, 1983, EUR J APPL PHYSIOL O, V52, P20, DOI 10.1007/BF00429020; SPIRITO P, 1988, ANN INTERN MED, V109, P122, DOI 10.7326/0003-4819-109-2-122; SPIRITO P, 1989, NEW ENGL J MED, V320, P749, DOI 10.1056/NEJM198903233201201; SPIRITO P, 1990, J AM COLL CARDIOL, V15, P1521, DOI 10.1016/0735-1097(90)92820-R; Underwood R H, 1977, Ann N Y Acad Sci, V301, P297, DOI 10.1111/j.1749-6632.1977.tb38208.x; WIELING W, 1981, BRIT HEART J, V46, P190; YAMAGUCHI H, 1979, AM J CARDIOL, V44, P401, DOI 10.1016/0002-9149(79)90388-6	42	693	706	1	35	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 31	1991	324	5					295	301		10.1056/NEJM199101313240504	http://dx.doi.org/10.1056/NEJM199101313240504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU922	1824720	Bronze			2022-12-28	WOS:A1991EU92200004
J	EARDLEY, DD; KOSHLAND, ME				EARDLEY, DD; KOSHLAND, ME			GLYCOSYLPHOSPHATIDYLINOSITOL - A CANDIDATE SYSTEM FOR INTERLEUKIN-2 SIGNAL TRANSDUCTION	SCIENCE			English	Article							PROTEIN KINASE-C; STIMULATORY FACTOR-I; MURINE B-CELLS; GLYCOSYL-PHOSPHATIDYLINOSITOL; DIFFERENTIATION FACTORS; IL-2 RECEPTOR; KILLER CELLS; CHAIN GENE; INSULIN; EXPRESSION	The mechanism of interleukin-2 (IL-2) signal transduction was analyzed by use of an inducible B lymphoma. Like normal antigen-activated B lymphocytes, the lymphoma cells respond to IL-2 by proliferating and differentiating into antibody-secreting cells; both responses are blocked by a second interleukin, IL-4. Analyses of the signaling pathway showed that IL-2 stimulated the rapid hydrolysis of an inositol-containing glycolipid to yield two possible second messengers, a myristylated diacylglycerol and an inositol phosphate-glycan. The myristylated diacylglycerol response exhibited the same IL-2 dose dependence as the growth and differentiative responses, and the generation of both hydrolysis products was inhibited by IL-4. These correlations implicate the glycosyl-phosphatidylinositol system in the intracellular relay of the IL-2 signal.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720; UNIV CALIF SANTA BARBARA,DEPT BIOL SCI,SANTA BARBARA,CA 93106	University of California System; University of California Berkeley; University of California System; University of California Santa Barbara					PHS HHS [A107079] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; BLACKMAN MA, 1986, CELL, V47, P609, DOI 10.1016/0092-8674(86)90625-2; BROOKS K, 1983, NATURE, V302, P325; BROOKS KH, 1986, J IMMUNOL, V137, P3205; Cambier J C, 1987, Adv Exp Med Biol, V213, P195; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; FRNANDEZBOTRAN R, 1989, J EXP MED, V169, P329; GAULTON GN, 1988, CELL, V53, P963, DOI 10.1016/S0092-8674(88)90509-0; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; KARRAY S, 1990, J IMMUNOL, V145, P1152; KAWAKAMI Y, 1989, J IMMUNOL, V142, P3452; KELLY KL, 1987, P NATL ACAD SCI USA, V84, P6404, DOI 10.1073/pnas.84.18.6404; KELLY KL, 1987, J BIOL CHEM, V262, P15285; LEGRAVEREND C, 1989, EXP CELL RES, V181, P273, DOI 10.1016/0014-4827(89)90201-2; LOUGHNAN MS, 1989, NATURE, V340, P76, DOI 10.1038/340076a0; MARTINEZ OM, 1990, J IMMUNOL, V144, P2211; MCHUGH Y, 1981, B LYMPHOCYTES IMMUNE, P467; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NAGLER A, 1988, J IMMUNOL, V141, P2349; NAKANISHI K, 1984, J EXP MED, V160, P1736, DOI 10.1084/jem.160.6.1736; NAKANISHI K, 1984, J EXP MED, V160, P1605, DOI 10.1084/jem.160.6.1605; PAUL WE, 1987, FASEB J, V1, P456, DOI 10.1096/fasebj.1.6.3315808; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SALTIEL AR, 1987, ENDOCRINOLOGY, V120, P967, DOI 10.1210/endo-120-3-967; SALTIEL AR, 1986, SCIENCE, V233, P967, DOI 10.1126/science.3016898; SALTIEL AR, 1986, P NATL ACAD SCI USA, V83, P5893; SALTZMAN EM, 1989, J BIOL CHEM, V264, P19979; SATO KL, 1987, J BIOL CHEM, V262, P2131; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SPITS H, 1988, J IMMUNOL, V141, P29; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WIDMER MB, 1987, J EXP MED, V166, P1447, DOI 10.1084/jem.166.5.1447; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	39	131	134	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					78	81		10.1126/science.1824727	http://dx.doi.org/10.1126/science.1824727			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1824727				2022-12-28	WOS:A1991EQ60300031
J	VONMOLLARD, GF; SUDHOF, TC; JAHN, R				VONMOLLARD, GF; SUDHOF, TC; JAHN, R			A SMALL GTP-BINDING PROTEIN DISSOCIATES FROM SYNAPTIC VESICLES DURING EXOCYTOSIS	NATURE			English	Article							SECRETION; MEMBRANE; GLUTAMATE; SUGGESTS; CALCIUM; RELEASE	LOW-molecular-weight GTP-binding proteins are strong candidates for regulators of membrane traffic1-3. In yeast, mutations in the sec4 or ypt1 genes encoding small GTP-binding proteins inhibit constitutive membrane flow at the plasma membrane or Golgi complex, respectively4-6. It has been suggested that membrane fusion-fission events are regulated by cycling of small GTP-binding proteins between a membrane-bound and free state7, but although most of these small proteins are found in both soluble and tightly membrane-bound forms, there is no direct evidence to support such cycling. In rat brain a small GTP-binding protein, rab3A, is exclusively associated with synaptic vesicles, the secretory organelles of nerve terminals8,9. Here we use isolated nerve terminals to study the fate of rab3A during synaptic vesicle exocytosis. We find that rab3A dissociates quantitatively from the vesicle membrane after Ca2+-dependent exocytosis and that this dissociation is partially reversible during recovery after stimulation. These results are direct evidence for an association-dissociation cycle of a small GTP-binding protein during traffic of its host membrane.	MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Max Planck Society; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			von Mollard, Gabriele Fischer/A-3935-2012; von Mollard, Gabriele Fischer/O-9778-2019	von Mollard, Gabriele Fischer/0000-0003-3236-1401; von Mollard, Gabriele Fischer/0000-0003-3236-1401; Jahn, Reinhard/0000-0003-1542-3498				ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; DECAMILLI P, 1990, REV PHYSL, V52, P625; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; MCMAHON HT, IN PRESS J NEUROCHEM; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; NICHOLLS DG, 1978, BIOCHEM J, V170, P511, DOI 10.1042/bj1700511; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9	20	303	308	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					79	81		10.1038/349079a0	http://dx.doi.org/10.1038/349079a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1845915				2022-12-28	WOS:A1991EQ60100057
J	CONFINOCOHEN, R; LISHNER, M; SAVIN, H; LANG, R; RAVID, M				CONFINOCOHEN, R; LISHNER, M; SAVIN, H; LANG, R; RAVID, M			RESPONSE OF CARPAL-TUNNEL SYNDROME TO HORMONE REPLACEMENT THERAPY	BRITISH MEDICAL JOURNAL			English	Article									MEIR HOSP,DEPT MED,IL-44281 KEFAR SAVA,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	LISHNER, M (corresponding author), MEIR HOSP,DEPT MED,IL-44281 KEFAR SAVA,ISRAEL.							AMADIO PC, 1985, J HAND SURG-AM, V10A, P237, DOI 10.1016/S0363-5023(85)80112-X; KULICK MI, 1986, J HAND SURG-AM, V11A, P59, DOI 10.1016/S0363-5023(86)80104-6; MILFORD L, 1987, CAMPBELLS OPERATIVE, P459; STRANSKY M, 1989, SOUTHERN MED J, V82, P841, DOI 10.1097/00007611-198907000-00011	4	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1514	1514		10.1136/bmj.303.6816.1514	http://dx.doi.org/10.1136/bmj.303.6816.1514			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1838291	Green Published, Bronze			2022-12-28	WOS:A1991GV47600023
J	VANDERBRUGGEN, P; TRAVERSARI, C; CHOMEZ, P; LURQUIN, C; DEPLAEN, E; VANDENEYNDE, B; KNUTH, A; BOON, T				VANDERBRUGGEN, P; TRAVERSARI, C; CHOMEZ, P; LURQUIN, C; DEPLAEN, E; VANDENEYNDE, B; KNUTH, A; BOON, T			A GENE ENCODING AN ANTIGEN RECOGNIZED BY CYTOLYTIC LYMPHOCYTES-T ON A HUMAN-MELANOMA	SCIENCE			English	Article							IMMUNOGENIC TUM VARIANTS; MOUSE MASTOCYTOMA P815; MUTATED EXON ENCODES; TRANSPLANTATION ANTIGEN-P91A; CELLS; IDENTIFICATION; MUTAGENESIS; TUMOR-P815; CLONING; PEPTIDE	Many human melanoma tumors express antigens that are recognized in vitro by cytolytic T lymphocytes (CTLs) derived from the tumor-bearing patient. A gene was identified that directed the expression of antigen MZ2-E on a human melanoma cell line. This gene shows no similarity to known sequences and belongs to a family of at least three genes. It is expressed by the original melanoma cells, other melanoma cell lines, and by some tumor cells of other histological types. No expression was observed in a panel of normal tissues. Antigen MZ2-E appears to be presented by HLA-A1; anti-MZ2-E CTLs of the original patient recognized two melanoma cell lines of other HLA-A1 patients that expressed the gene. Thus, precisely targeted immunotherapy directed against antigen MZ2-E could be provided to individuals identified by HLA typing and analysis of the RNA of a small tumor sample.	LUDWIG INST CANC RES, B-1200 BRUSSELS, BELGIUM; CATHOLIC UNIV LOUVAIN, CELLULAR GENET UNIT, B-1200 BRUSSELS, BELGIUM; UNIV MAINZ, MED KLIN & POLIKLIN 1, W-6500 MAINZ, GERMANY	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Johannes Gutenberg University of Mainz	BOON, T (corresponding author), LUDWIG INST CANC RES, B-1200 BRUSSELS, BELGIUM.		Bertrand, Mathieu J/P-6465-2016; knuth, alexander/H-2608-2014	Bertrand, Mathieu J/0000-0001-9000-0626; knuth, alexander/0000-0002-9318-2784				ANICHINI A, 1987, IMMUNOL TODAY, V8, P385, DOI 10.1016/0167-5699(87)90215-5; BOON T, 1980, J EXP MED, V152, P1184, DOI 10.1084/jem.152.5.1184; BRUNNER KT, 1981, J EXP MED, V154, P362, DOI 10.1084/jem.154.2.362; CROWLEY NJ, 1990, CANCER RES, V50, P492; DARROW TL, 1989, J IMMUNOL, V142, P3329; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DEPLAEN E, 1988, P NATL ACAD SCI USA, V85, P2274; FEARON ER, 1988, CANCER RES, V48, P2975; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HERIN M, 1987, INT J CANCER, V39, P390, DOI 10.1002/ijc.2910390320; KLEIN G, 1960, CANCER RES, V20, P1561; LAU YF, 1983, P NATL ACAD SCI-BIOL, V80, P5225, DOI 10.1073/pnas.80.17.5225; LUND T, 1982, P NATL ACAD SCI-BIOL, V79, P520, DOI 10.1073/pnas.79.2.520; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MELIEF CJM, 1992, ADV CANCER RES, V58, P143, DOI 10.1016/S0065-230X(08)60294-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PREHN RT, 1957, J NATL CANCER I, V18, P769; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; SLOVIN SF, 1986, J IMMUNOL, V137, P3042; SZIKORA JP, 1990, EMBO J, V9, P1041, DOI 10.1002/j.1460-2075.1990.tb08208.x; TIWARI JL, 1985, HLA DISEASE ASS, P4; TRAVERSARI C, IN PRESS IMMUNOGENET; UYTTENHOVE C, 1983, J EXP MED, V157, P1040, DOI 10.1084/jem.157.3.1040; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VANDENEYNDE B, 1989, INT J CANCER, V44, P634; VANPEL A, 1983, J EXP MED, V157, P1992, DOI 10.1084/jem.157.6.1992; WOLFEL T, 1987, IMMUNOGENETICS, V26, P178, DOI 10.1007/BF00365909	28	2886	3179	5	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 13	1991	254	5038					1643	1647		10.1126/science.1840703	http://dx.doi.org/10.1126/science.1840703			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1840703				2022-12-28	WOS:A1991GV07300045
J	WEISS, DS; BATUT, J; KLOSE, KE; KEENER, J; KUSTU, S				WEISS, DS; BATUT, J; KLOSE, KE; KEENER, J; KUSTU, S			THE PHOSPHORYLATED FORM OF THE ENHANCER-BINDING PROTEIN NTRC HAS AN ATPASE ACTIVITY THAT IS ESSENTIAL FOR ACTIVATION OF TRANSCRIPTION	CELL			English	Article							RNA POLYMERASE-II; NITROGEN REGULATOR-I; ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; INVITRO TRANSCRIPTION; GENE-TRANSCRIPTION; GLNA TRANSCRIPTION; ENTERIC BACTERIA; PLASMID VECTORS; LATE PROMOTER	The NTRC protein of enteric bacteria is an enhancer-binding protein that activates transcription in response to limitation of combined nitrogen. NTRC activates transcription by catalyzing formation of open complexes by RNA polymerase (sigma-54 holoenzyme form) in an ATP-dependent reaction. To catalyze open complex formation, NTRC must be phosphorylated. We show that phosphorylated NTRC has an ATPase activity, and we present biochemical and genetic evidence that NTRC must hydrolyze ATP to catalyze open complex formation. It is likely that all activators of sigma-54 holo-enzyme have an ATPase activity.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	WEISS, DS (corresponding author), UNIV CALIF BERKELEY,DEPT PLANT PATHOL,BERKELEY,CA 94720, USA.		BATUT, Jacques/B-6506-2008		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038361, R37GM038361] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38361] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; BIEKER JJ, 1986, J BIOL CHEM, V261, P9732; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; BUIKEMA WJ, 1985, NUCLEIC ACIDS RES, V13, P4539, DOI 10.1093/nar/13.12.4539; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; Corbin J D, 1974, Methods Enzymol, V38, P287; DEAKIN H, 1963, BIOCHEM J, V89, P296, DOI 10.1042/bj0890296; DRUMMOND M, 1986, EMBO J, V5, P441, DOI 10.1002/j.1460-2075.1986.tb04230.x; DRUMMOND MH, 1990, MOL MICROBIOL, V4, P29, DOI 10.1111/j.1365-2958.1990.tb02012.x; EBERZ G, 1991, J BACTERIOL, V173, P1845, DOI 10.1128/jb.173.6.1845-1854.1991; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; GRIMM C, 1989, J BACTERIOL, V171, P5031, DOI 10.1128/jb.171.9.5031-5038.1989; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; HIRSCHMAN J, 1985, P NATL ACAD SCI USA, V82, P7525, DOI 10.1073/pnas.82.22.7525; INOUYE S, 1988, GENE, V66, P301; KASSAVETIS GA, 1983, CELL, V33, P887, DOI 10.1016/0092-8674(83)90031-4; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KOFOID EC, 1988, P NATL ACAD SCI USA, V85, P4981, DOI 10.1073/pnas.85.14.4981; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MAUPIN JA, 1990, J BACTERIOL, V172, P4798, DOI 10.1128/jb.172.9.4798-4806.1990; MINCHIN SD, 1988, MOL MICROBIOL, V2, P433, DOI 10.1111/j.1365-2958.1988.tb00049.x; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NARASIMHAN N, 1987, P NATL ACAD SCI USA, V84, P4078, DOI 10.1073/pnas.84.12.4078; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; RAMAKRISHNAN G, 1990, P NATL ACAD SCI USA, V87, P2369, DOI 10.1073/pnas.87.6.2369; REITZER LJ, 1985, P NATL ACAD SCI USA, V82, P1979, DOI 10.1073/pnas.82.7.1979; REITZER LJ, 1989, J BACTERIOL, V171, P5512, DOI 10.1128/jb.171.10.5512-5522.1989; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; RONSON CW, 1987, NUCLEIC ACIDS RES, V15, P7921, DOI 10.1093/nar/15.19.7921; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHLENSOG V, 1990, MOL MICROBIOL, V4, P1319, DOI 10.1111/j.1365-2958.1990.tb00711.x; SHUMAN S, 1980, J BIOL CHEM, V255, P5396; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; TABOR S, 1990, CURRENT PROTOCOLS MO; THONY B, 1989, FEMS MICROBIOL LETT, V63, P341; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WEGLENSKI P, 1989, J BACTERIOL, V171, P4479, DOI 10.1128/JB.171.8.4479-4485.1989; WEI GR, 1981, MOL GEN GENET, V183, P392, DOI 10.1007/BF00270646; WEISS DS, 1991, P NATL ACAD SCI USA, V85, P8923; WONG PK, 1987, J BACTERIOL, V169, P2876, DOI 10.1128/jb.169.6.2876-2880.1987; WOZNIAK DJ, 1991, J BACTERIOL, V173, P1406, DOI 10.1128/jb.173.4.1406-1413.1991	56	296	298	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					155	167		10.1016/0092-8674(91)90579-N	http://dx.doi.org/10.1016/0092-8674(91)90579-N			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1833069				2022-12-28	WOS:A1991GJ32000014
J	WELLS, FB; GAHM, SJ; HEDRICK, SM; BLUESTONE, JA; DENT, A; MATIS, LA				WELLS, FB; GAHM, SJ; HEDRICK, SM; BLUESTONE, JA; DENT, A; MATIS, LA			REQUIREMENT FOR POSITIVE SELECTION OF GAMMA-DELTA-RECEPTOR-BEARING T-CELLS	SCIENCE			English	Article							LYMPHOCYTES-T; CYCLOSPORINE-A; STEM-CELLS; ANTIGEN; THYMUS; MICE; EXPRESSION; CD8; SPECIFICITY; RECOGNITION	The alpha-beta and gamma-delta-T cell receptors for antigen (TCR) delineate distinct T cell populations. TCR-alpha-beta-bearing thymocytes must be positively selected by binding of the TCR to major histocompatibility complex (MHC) molecules on thymic epithelium. To examine the requirement for positive selection of TCR gamma-delta-T cells, mice bearing a class I MHC-specific gamma-delta-transgene (Tg) were crossed to mice with disrupted beta-2 microglobulin (beta-2M) genes. The Tg+beta-2M- (class I MHC-) offspring had Tg+ thymocytes that did not proliferate to antigen or Tg-specific monoclonal antibody and few peripheral Tg+ cells. This is evidence for positive selection within the gamma-delta-T cell subset.	NCI, FREDERICK CANC RES & DEV CTR, MOLEC IMMUNOREGULAT LAB, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21702 USA; NCI, HOWARD HUGHES MED INST, RES SCHOLARS PROGRAM, BETHESDA, MD 20892 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, FREDERICK, MD 21701 USA; UNIV CHICAGO, BEN MAY INST, DEPT PATHOL, COMM IMMUNOL, CHICAGO, IL 60637 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Chicago			Hedrick, Stephen M/E-9171-2010	Hedrick, Stephen/0000-0002-6345-8751	NIAID NIH HHS [AI 26847-03, AI00602] Funding Source: Medline; PHS HHS [N01-C0-74102] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026847] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BONNEVILLE M, 1990, NATURE, V344, P163, DOI 10.1038/344163a0; BORN W, 1990, IMMUNOL TODAY, V11, P40; BRUCE J, 1981, J IMMUNOL, V127, P2496; Bucy R P, 1991, Semin Immunol, V3, P109; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CRON RQ, 1989, J IMMUNOL, V142, P3754; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; ITOHARA S, 1990, P NATL ACAD SCI USA, V87, P7935, DOI 10.1073/pnas.87.20.7935; JANEWAY CA, 1984, J IMMUNOL, V132, P662; JENKINS MK, 1988, SCIENCE, V241, P1655, DOI 10.1126/science.3262237; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KOLLER B, UNPUB; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOSUGI A, 1989, J IMMUNOL, V142, P3026; LEFRANCOIS L, 1990, CELL, V63, P333, DOI 10.1016/0092-8674(90)90166-C; MATIS LA, 1987, NATURE, V330, P262, DOI 10.1038/330262a0; PARDOLL DM, 1988, J IMMUNOL, V140, P4091; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SIM GK, 1990, CELL, V61, P397, DOI 10.1016/0092-8674(90)90522-G; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; WELLS FB, UNPUB; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	32	74	74	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 23	1991	253	5022					903	905		10.1126/science.1831565	http://dx.doi.org/10.1126/science.1831565			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1831565				2022-12-28	WOS:A1991GC15200045
J	GODLEE, F				GODLEE, F			MRCGP - EXAMINING THE EXAM	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	12	12	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					235	238		10.1136/bmj.303.6796.235	http://dx.doi.org/10.1136/bmj.303.6796.235			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1809259	Green Published, Bronze			2022-12-28	WOS:A1991FZ56300030
J	TOMALSKI, MD; MILLER, LK				TOMALSKI, MD; MILLER, LK			INSECT PARALYSIS BY BACULOVIRUS-MEDIATED EXPRESSION OF A MITE NEUROTOXIN GENE	NATURE			English	Article							PYEMOTES-TRITICI; TRANSCRIPTION; VECTORS; TOXINS	FEMALE mites of the species Pyemotes tritici inject an extremely potent venom into their insect prey that causes muscle-contraction and paralysis 1-4. These mites are able to paralyse insects 150,000 times their size 5 and their venom is effective in a broad range of insect species 4. A toxin (TxP-I) associated with the mite venom apparatus causes immediate muscle-contractive paralysis when injected into insects but not mice 6. In this report, we describe the cloning, sequencing and expression of a complementary DNA (Tox-34) encoding TxP-I. Insect cells infected with a recombinant baculovirus (vEV-Tox34) expressing Tox-34 secrete three polypeptides related to TxP-I which cause paralysis on injection. Larvae infected with vEV-Tox34 become paralysed during infection, thus reflecting the potential application of this toxin gene in insect biocontrol methods. The toxin gene expression system will also allow further exploration of the neurophysiological basis of its insect-specific effects.	UNIV GEORGIA,DEPT GENET,ATHENS,GA 30602	University System of Georgia; University of Georgia	TOMALSKI, MD (corresponding author), UNIV GEORGIA,DEPT ENTOMOL,ATHENS,GA 30602, USA.							Battey, 1986, BASIC METHODS MOL BI; BISHOP DHL, 1988, RELEASE GENETICALLY, P143; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CARBONELL LF, 1988, GENE, V73, P409, DOI 10.1016/0378-1119(88)90505-7; KRCZAL H, 1959, ACARINA, V1, P385; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER DW, 1986, GENETIC ENG PRINCIPL, V8, P277; MILLER LK, 1983, SCIENCE, V219, P715, DOI 10.1126/science.219.4585.715; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MOSER JC, 1975, T ROY ENT SOC LONDON, V127, P185; OOI BG, 1989, J MOL BIOL, V210, P721, DOI 10.1016/0022-2836(89)90105-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOMALSKI MD, 1989, TOXICON, V27, P1151, DOI 10.1016/0041-0101(89)90009-3; TOMALSKI MD, 1988, VIROLOGY, V167, P591, DOI 10.1016/S0042-6822(88)90122-5; TOMALSKI MD, 1988, TOXICON, V26, P127, DOI 10.1016/0041-0101(88)90164-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAIVANIJKUL P, 1968, P HAWAII ENTOMOL SOC, V20, P443; WANG XZ, 1991, GENE, V100, P131, DOI 10.1016/0378-1119(91)90358-I; WEISER JAROSLAV, 1964, ANN ENTOMOL SOC AMER, V57, P479	19	227	267	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					82	85		10.1038/352082a0	http://dx.doi.org/10.1038/352082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	1840646				2022-12-28	WOS:A1991FV17800077
J	BLACK, PM				BLACK, PM			MEDICAL PROGRESS - BRAIN-TUMORS .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GROWTH-FACTOR RECEPTOR; POSITRON EMISSION TOMOGRAPHY; HUMAN GLIOBLASTOMA; RADIATION-THERAPY; L-3-<I-123>IODO-ALPHA-METHYL TYROSINE; INTRACRANIAL TUMORS; HUMAN ASTROCYTOMAS; RECURRENT GLIOMAS; MALIGNANT GLIOMA; NATIONAL SURVEY		BRIGHAM & WOMENS HOSP,BRAIN TUMOR GRP,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	BLACK, PM (corresponding author), BRIGHAM & WOMENS HOSP,NEUROSURG SERV,75 FRANCIS ST,BOSTON,MA 02115, USA.							[Anonymous], 1990, MALIGNANT CEREBRAL G; APUZZO MLJ, 1987, NEUROSURGERY, V20, P930, DOI 10.1227/00006123-198706000-00019; APUZZO MLJ, 1982, NEUROSURGERY, V10, P547, DOI 10.1227/00006123-198205000-00001; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; BERGER MS, 1991, CONCEPTS NEUROSURGER, V4, P63; BIERSACK HJ, 1989, J NUCL MED, V30, P110; Bigner SH, 1990, BRAIN PATHOL, V1, P12, DOI 10.1111/j.1750-3639.1990.tb00633.x; BIGNER SH, 1988, CANCER RES, V48, P405; BLACK KL, 1989, J NEUROSURG, V71, P342, DOI 10.3171/jns.1989.71.3.0342; BLACK PM, 1987, NEUROSURGERY, V20, P914, DOI 10.1227/00006123-198706000-00016; BLACK PM, 1988, OPERATIVE NEUROSURGI, V1, P299; BLICK M, 1987, CANCER RES, V47, P2986; BRANTZAWADZKI M, 1987, MAGNETIC RESONANCE I; Brem S, 1976, Clin Neurosurg, V23, P440; BRUCE JN, 1987, J NEUROSURG, V67, P880, DOI 10.3171/jns.1987.67.6.0880; BULLARD DE, 1986, SEMIN ONCOL, V13, P94; BURGER PC, 1986, AM J SURG PATHOL, V10, P611, DOI 10.1097/00000478-198609000-00003; BURGER PC, 1990, SURGICAL PATHOLOGY N; COTTRELL JE, 1986, ANESTHESIA NEUROSURG; CROCKARD HA, 1985, ANN ROY COLL SURG, V67, P321; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; DOHRMANN GJ, 1985, NEUROL CLIN, V3, P425, DOI 10.1016/S0733-8619(18)31047-8; DOLENC VV, 1989, ANATOMY SURGERY CAVE; DOYLE WK, 1987, J COMPUT ASSIST TOMO, V11, P563, DOI 10.1097/00004728-198707000-00001; DUMANSKI JP, 1987, P NATL ACAD SCI USA, V84, P9275, DOI 10.1073/pnas.84.24.9275; ELAZOUZI M, 1989, P NATL ACAD SCI USA, V86, P7186, DOI 10.1073/pnas.86.18.7186; Epstein F, 1983, Clin Neurosurg, V31, P497; FINE HA, 1991, P AN M AM SOC CLIN, V10, P125; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FONTANA A, 1984, J IMMUNOL, V132, P1837; FRIEDMAN WA, 1989, NEUROSURGERY, V25, P180, DOI 10.1227/00006123-198908000-00005; GEROSA MA, 1989, J NATL CANCER I, V81, P63, DOI 10.1093/jnci/81.1.63; GREIG NH, 1990, JNCI-J NATL CANCER I, V82, P1621, DOI 10.1093/jnci/82.20.1621; HATLEVOLL R, 1985, CANCER, V56, P41, DOI 10.1002/1097-0142(19850701)56:1<41::AID-CNCR2820560108>3.0.CO;2-W; HEIFETZ MD, 1984, J NEUROSURG, V60, P814, DOI 10.3171/jns.1984.60.4.0814; HEILBRUN MP, 1983, J NEUROSURG, V59, P217, DOI 10.3171/jns.1983.59.2.0217; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; HOCHBERG FH, 1980, NEUROLOGY, V30, P907, DOI 10.1212/WNL.30.9.907; HOCHBERG FH, 1985, J NEUROSURG, V63, P876, DOI 10.3171/jns.1985.63.6.0876; HOSHINO T, 1986, INT J CANCER, V38, P369, DOI 10.1002/ijc.2910380311; KALOFONOS HP, 1989, J NUCL MED, V30, P1636; KARNOFSKY DA, 1951, ARCH INTERN MED, V87, P477, DOI 10.1001/archinte.1951.03810040002001; KAYE AH, 1988, J NEUROSURG, V69, P1, DOI 10.3171/jns.1988.69.1.0001; KELLY PJ, 1986, J NEUROSURG, V64, P427, DOI 10.3171/jns.1986.64.3.0427; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KJELLBERG RN, 1983, NEW ENGL J MED, V309, P269, DOI 10.1056/NEJM198308043090503; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; Koos W.T., 1985, COLOR ATLAS MICRONEU; LARSON DA, 1990, CANCER-AM CANCER SOC, V65, P792, DOI 10.1002/1097-0142(19900201)65:3+<792::AID-CNCR2820651327>3.0.CO;2-P; LASHFORD L, 1989, J NEUROONCOL, V7, pS17; LEIBEL SA, 1987, J NEUROSURG, V66, P1, DOI 10.3171/jns.1987.66.1.0001; Levin VA, 1989, CANCER PRINCIPLES PR, V2, P1557; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LINDEN RD, 1988, CAN J NEUROL SCI, V15, P73, DOI 10.1017/S0317167100027232; LOEFFLER JS, 1990, J NATL CANCER I, V82, P1918, DOI 10.1093/jnci/82.24.1918; LOEFFLER JS, 1990, J CLIN ONCOL, V8, P576, DOI 10.1200/JCO.1990.8.4.576; LOEFFLER JS, 1990, INT J RADIAT ONCOL, V19, P1455, DOI 10.1016/0360-3016(90)90358-Q; LOEFFLER JS, 1988, INT J RADIAT ONCOL, V15, P177, DOI 10.1016/0360-3016(88)90363-X; LUNSFORD LD, 1986, J NEUROSURG, V64, P872, DOI 10.3171/jns.1986.64.6.0872; LUNSFORD LD, 1990, ARCH NEUROL-CHICAGO, V47, P169, DOI 10.1001/archneur.1990.00530020071018; MAHALEY MS, 1983, J NEUROSURG, V59, P201, DOI 10.3171/jns.1983.59.2.0201; MAHALEY MS, 1989, J NEUROSURG, V71, P639, DOI 10.3171/jns.1989.71.5.0639; MAHALEY MS, 1989, J NEUROSURG, V70, P371, DOI 10.3171/jns.1989.70.3.0371; MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MAROON JC, 1976, J NEUROSURG, V44, P556, DOI 10.3171/jns.1976.44.5.0556; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MAXWELL M, 1988, ADV NEUROONCOLOGY, P159; MERCHANT RE, 1988, CANCER, V62, P665, DOI 10.1002/1097-0142(19880815)62:4<665::AID-CNCR2820620403>3.0.CO;2-O; MOORE MR, 1989, NEUROSURGERY, V25, P572, DOI 10.1227/00006123-198910000-00010; MORANTZ RA, 1987, NEUROSURGERY, V20, P975, DOI 10.1227/00006123-198706000-00028; MULLER PJ, 1987, PHOTOCHEM PHOTOBIOL, V46, P929, DOI 10.1111/j.1751-1097.1987.tb04871.x; NEUWELT EA, 1986, NEUROSURGERY, V19, P573, DOI 10.1227/00006123-198610000-00011; NICHOLSON WJ, 1982, ANN NY ACAD SCI, V381, P172, DOI 10.1111/j.1749-6632.1982.tb50381.x; PACKER RJ, 1988, ANN NEUROL, V24, P503, DOI 10.1002/ana.410240405; PANTAZIS P, 1985, P NATL ACAD SCI USA, V82, P2404, DOI 10.1073/pnas.82.8.2404; PATRONAS NJ, 1985, J NEUROSURG, V62, P816, DOI 10.3171/jns.1985.62.6.0816; PATSOURIS F, 1988, ANTICANCER RES, V8, P537; RHOTON AL, 1981, NEUROSURGERY, V8, P357, DOI 10.1227/00006123-198103000-00007; Russell DS, 1982, PATHOLOGY TUMORS NER; RUTKA JT, 1987, CAN J NEUROL SCI, V14, P25; Salcman M, 1983, J Neurooncol, V1, P225, DOI 10.1007/BF00165607; SALCMAN M, 1986, J NEURO-ONCOL, V3, P363, DOI 10.1007/BF00165587; SCHOENBERG BS, 1991, CONCEPTS NEUROSURGER, V4, P13; SEIZINGER BR, 1987, SCIENCE, V236, P317, DOI 10.1126/science.3105060; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SEKHAR LN, 1987, J NEUROSURG, V67, P488, DOI 10.3171/jns.1987.67.4.0488; SHAPIRO WR, 1989, J NEUROSURG, V71, P1, DOI 10.3171/jns.1989.71.1.0001; Stein B M, 1985, Acta Neurochir Suppl (Wien), V35, P42; TEW JM, 1987, LASER APPLICATIONS N, P351; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; URTASUN R, 1976, NEW ENGL J MED, V294, P1364, DOI 10.1056/NEJM197606172942503; WALKER AE, 1985, NEUROLOGY, V35, P219, DOI 10.1212/WNL.35.2.219; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; WARA WM, 1985, CANCER, V55, P2291, DOI 10.1002/1097-0142(19850501)55:9+<2291::AID-CNCR2820551437>3.0.CO;2-C; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Yasargil M G, 1988, Clin Neurosurg, V34, P42; Yasargil MG, 1984, MICROSURGICAL ANATOM, V1; Zulch KJ., 1986, BRAIN TUMORS THEIR B	101	216	224	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1991	324	21					1471	1476		10.1056/NEJM199105233242105	http://dx.doi.org/10.1056/NEJM199105233242105			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM460	1822669				2022-12-28	WOS:A1991FM46000005
J	GOODWIN, FK				GOODWIN, FK			ARE NEUROSTEROIDS BRAINS VALIUM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2657	2657						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	1850809				2022-12-28	WOS:A1991FL98900007
J	BERGER, RG; KNOX, SJ; LEVY, R; SKLAR, JL; COHEN, P; REICHERT, T				BERGER, RG; KNOX, SJ; LEVY, R; SKLAR, JL; COHEN, P; REICHERT, T			MYCOSIS-FUNGOIDES ARTHROPATHY	ANNALS OF INTERNAL MEDICINE			English	Note							CELL		STANFORD UNIV, MED CTR, SCH MED, STANFORD, CA 94305 USA; BECTON DICKINSON, MT VIEW, CA USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Stanford University; Becton Dickinson; Harvard University; Harvard Medical School	BERGER, RG (corresponding author), UNIV N CAROLINA, SCH MED, DIV RHEUMATOL, CAMPUS BOX 7280, CHAPEL HILL, NC 27599 USA.							CLEARY ML, 1984, P NATL ACAD SCI-BIOL, V81, P593, DOI 10.1073/pnas.81.2.593; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; KEYSTONE EC, 1988, ARTHRITIS RHEUM, V31, P1555, DOI 10.1002/art.1780311213; KNOX SJ, 1991, IN PRESS BLOOD; SCHOCKET AL, 1982, BRIT J DERMATOL, V107, P285, DOI 10.1111/j.1365-2133.1982.tb00358.x; WEISS LM, 1987, AM J PATHOL, V126, P417	7	7	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					571	572		10.7326/0003-4819-114-7-571	http://dx.doi.org/10.7326/0003-4819-114-7-571			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	1825772				2022-12-28	WOS:A1991FD66100009
J	SCHWER, B; GUTHRIE, C				SCHWER, B; GUTHRIE, C			PRP16 IS AN RNA-DEPENDENT ATPASE THAT INTERACTS TRANSIENTLY WITH THE SPLICEOSOME	NATURE			English	Article							NUCLEAR RIBONUCLEOPROTEIN PARTICLE; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; POLYACRYLAMIDE GELS; SPLICING INVITRO; ESCHERICHIA-COLI; T-ANTIGEN; YEAST; PROTEIN	The assembly of the spliceosome is an ATP-dependent process. The splicing factor PRP16 contains variations of several motifs that define the eIF-4A-like ATP-dependent RNA helicase family. The protein has now been purified and shown to exhibit RNA-dependent ATPase activity. PRP16 is required specifically for the second catalytic step of the splicing reaction in vitro. This function requires ATP binding and/or hydrolysis, which appears to be concomitant with release of the protein from the spliceosome. PRP16 may be the prototype for a set of splicing factors which use ATP to drive a cycle of conformational changes.			SCHWER, B (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Schwer, Beate/0000-0002-3824-9819				BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BARNES DA, 1986, MOL CELL BIOL, V6, P2828, DOI 10.1128/MCB.6.8.2828; BJORN SP, 1989, MOL CELL BIOL, V9, P3698, DOI 10.1128/MCB.9.9.3698; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CHANG TH, 1988, MOL CELL BIOL, V8, P2379, DOI 10.1128/MCB.8.6.2379; CHANG TH, 1990, P NATL ACAD SCI USA, V87, P1571, DOI 10.1073/pnas.87.4.1571; CHENG SC, 1986, P NATL ACAD SCI USA, V83, P2387, DOI 10.1073/pnas.83.8.2387; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; CLARK R, 1981, J BIOL CHEM, V256, P1854; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; COUTO JR, 1987, GENE DEV, V1, P445, DOI 10.1101/gad.1.5.445; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; ENGLAND TE, 1978, NATURE, V275, P560, DOI 10.1038/275560a0; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; GUTHRIE C, 1989, AM ZOOL, V29, P557; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAMM J, 1987, EMBO J, V6, P3479, DOI 10.1002/j.1460-2075.1987.tb02672.x; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LIN RJ, 1987, GENE DEV, V1, P7, DOI 10.1101/gad.1.1.7; LIN RJ, 1985, J BIOL CHEM, V260, P4780; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; LUHRMANN R, 1988, STRUCTURE FUNCTION M, P71; LUSTIG AJ, 1986, CELL, V47, P953, DOI 10.1016/0092-8674(86)90810-X; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SAWA H, 1988, NUCLEIC ACIDS RES, V16, P3157; SCHENA M, 1990, METHOD ENZYMOL, V194, P389; SERGEANT A, 1984, J MOL BIOL, V180, P577, DOI 10.1016/0022-2836(84)90028-7; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; THOMPSON RC, 1988, TRENDS BIOCHEM SCI, V13, P91, DOI 10.1016/0968-0004(88)90047-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; VIJAYRAGHAVAN U, 1990, MOL CELL BIOL, V10, P324, DOI 10.1128/MCB.10.1.324; WHITTAKER E, 1990, P NATL ACAD SCI USA, V87, P2216, DOI 10.1073/pnas.87.6.2216; WOOLFORD JL, 1989, YEAST, V5, P435; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	51	289	294	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					494	499		10.1038/349494a0	http://dx.doi.org/10.1038/349494a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1825134				2022-12-28	WOS:A1991EW57100056
J	TURSKI, L; BRESSLER, K; RETTIG, KJ; LOSCHMANN, PA; WACHTEL, H				TURSKI, L; BRESSLER, K; RETTIG, KJ; LOSCHMANN, PA; WACHTEL, H			PROTECTION OF SUBSTANTIA-NIGRA FROM MPP+ NEUROTOXICITY BY N-METHYL-D-ASPARTATE ANTAGONISTS	NATURE			English	Article							EXCITATORY AMINO-ACIDS; MOUSE-BRAIN; PARKINSONS-DISEASE; RAT; GLUTAMATE; NEURONS; MPTP; N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM	INTAKE of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) leads to symptoms of Parkinson's disease and produces degeneration of nigrostriatal dopaminergic neurons in humans, giving rise to the hypothesis that this disorder may be caused by endogenous or environmental toxins 1-3. Excitation mediated by dicarboxylic amino acids such as L-glutamate or L-aspartate, has been claimed to be involved in pathogenesis of neurodegenerative disorders 4. We therefore sought to determine whether antagonists active at the NMDA or quisqualate subtypes of L-glutamate receptors prevent toxicity of either MPP+ (1-m ethyl-4-phenyl-pyridinium ion 5, the active metabolite of MPTP 6) or the selective dopaminergic neurotoxin 6-OHDA in the rat substantia nigra pars compacta. We report here that certain selective NMDA antagonists (AP7, CPP, MK-801) 7, but not the preferential quisqualate antagonists CNQX and NBQX, 8 provided short-term (up to 24 h) protection against MPP+ toxicity when coadministered into the substantia nigra. Systemic administration of CPP or MK-801 also offered temporary protection for up to 4 h against MPP+ toxicity. Repeated systemic administration of either compound prolonged protection against MPP+ challenge. Repeated administration for at least 24 h also led to permanent protection, still evident 7 days after intranigral administration of MPP+.			TURSKI, L (corresponding author), SCHERING AG,RES LABS,W-1000 BERLIN 65,GERMANY.							BORMANN J, 1989, EUR J PHARMACOL, V166, P591, DOI 10.1016/0014-2999(89)90385-3; BRADBURY AJ, 1986, NATURE, V319, P56, DOI 10.1038/319056a0; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CALNE DB, 1986, LANCET, V2, P1067, DOI 10.1016/S0140-6736(86)90469-1; CHAPMAN AG, 1983, NEUROSCI LETT, V37, P75, DOI 10.1016/0304-3940(83)90507-4; CHRISTIEPOPE BC, 1989, EXP NEUROL, V104, P235, DOI 10.1016/0014-4886(89)90035-6; COMPTON RP, 1988, NEUROSCI LETT, V84, P339, DOI 10.1016/0304-3940(88)90532-0; DIMONTE D, 1988, REV NEUROSCI, V2, P67; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fallon J.H., 1985, RAT NERVOUS SYSTEM, P353; FINK ROBERT P., 1967, BRAIN RES, V4, P369, DOI 10.1016/0006-8993(67)90166-7; GIBB WRG, 1988, BRAIN RES, V461, P361, DOI 10.1016/0006-8993(88)90268-5; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; IRWIN I, 1989, NEUROSCI LETT, V101, P83, DOI 10.1016/0304-3940(89)90445-X; JOHANNESSEN JN, 1985, LIFE SCI, V36, P219, DOI 10.1016/0024-3205(85)90062-1; Konig JFR, 1963, RAT BRAIN STEREOTAXI; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; MARKEY SP, 1984, NATURE, V311, P464, DOI 10.1038/311464a0; MAWDSLEY C, 1963, LANCET, V2, P795; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OHYA Y, 1989, NEUROSCI LETT, V105, P221, DOI 10.1016/0304-3940(89)90041-4; OLNEY JW, 1987, EUR J PHARMACOL, V142, P319, DOI 10.1016/0014-2999(87)90123-3; OLNEY JW, 1988, FRONTIERS EXCITATORY, P589; OLVERMAN HJ, 1984, NATURE, V307, P460, DOI 10.1038/307460a0; RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V134, P743, DOI 10.1016/S0006-291X(86)80483-1; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SONSALLA PK, 1989, SCIENCE, V243, P398, DOI 10.1126/science.2563176; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; SUN CJ, 1988, J NEURAL TRANSM, V74, P75, DOI 10.1007/BF01245141; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; VEZZANI A, 1989, J PHARMACOL EXP THER, V249, P278; WEISS JH, 1988, SCIENCE, V241, P973, DOI 10.1126/science.3136549	35	539	563	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					414	418		10.1038/349414a0	http://dx.doi.org/10.1038/349414a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1846943				2022-12-28	WOS:A1991EV51400051
J	MUTTON, DE; ALBERMAN, E; IDE, R; BOBROW, M				MUTTON, DE; ALBERMAN, E; IDE, R; BOBROW, M			RESULTS OF 1ST YEAR (1989) OF A NATIONAL REGISTER OF DOWNS-SYNDROME IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY; AGE	Objective - To examine the feasibility of a national register of Down's syndrome and its effectiveness in evaluating prenatal screening for the syndrome. Design - Information for the register was obtained from all eligible cytogenetic laboratories on relevant cytogenetic diagnoses, including date and place of birth or termination, maternal age, indication for karyotyping, and type of diagnostic test used. Setting - Cytogenetic laboratories in England and Wales. Subjects - All fetuses with trisomy 21 diagnosed prenatally and live births with Down's syndrome diagnosed at birth. Main outcome measures - Number of prenatal and postnatal diagnoses of Down's syndrome. National and maternal age specific prevalence of Down's syndrome. Results - For 1989 there were 1060 registrations-323 prenatal diagnoses and 737 postnatal diagnoses -after exclusion of postnatally diagnosed miscarriages and stillbirths. The estimated national rate of affected births for mothers resident in England and Wales was 1-4/1000 live births, assuming no terminations of affected pregnancies and after correction for natural losses which would have occurred in the absence of termination. The corrected maternal age specific rates were close to those found in previous population based studies. The proportion of affected pregnancies diagnosed prenatally in mothers aged 35 to 39 was 44%, and for those aged 40 or more it was 71%. Abnormal findings on ultrasonography played an unexpectedly important part in initiating cytogenetic investigation (13% of the prenatal diagnoses). Conclusions - The findings establish the feasibility of a national Down's syndrome register and its use in evaluating prenatal screening services. Together with information held by the Office of Population Censuses and Surveys on congenital malformations, data from the register will permit studies of environmental variables affecting the prevalence of the syndrome.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV MED & MOLEC GENET,PAEDIAT RES UNIT,LONDON SE1 9RT,ENGLAND; ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,LONDON EC1M 6BQ,ENGLAND	University of London; King's College London; University of London; Queen Mary University London	MUTTON, DE (corresponding author), LONDON HOSP,COLL MED,DEPT EPIDEMIOL & MED STAT,QMW,LONDON E1 4NS,ENGLAND.							BLACK D, 1984, INVESTIGATION POSSIB; CUCKLE H, 1991, PRENATAL DIAG, V11, P29, DOI 10.1002/pd.1970110106; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; CUCKLE HS, 1990, PRENATAL DIAGNOSIS P, P67; HOOK EB, 1988, AM J HUM GENET, V42, P797; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; CONGENITAL MALFORMAT; ABORTION STATISTI AB; 1989, FM1 OFF POP CENS SUR	9	34	35	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1295	1297		10.1136/bmj.303.6813.1295	http://dx.doi.org/10.1136/bmj.303.6813.1295			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1836152	Bronze, Green Published			2022-12-28	WOS:A1991GT01100019
J	COMINGS, DE; COMINGS, BG; MUHLEMAN, D; DIETZ, G; SHAHBAHRAMI, B; TAST, D; KNELL, E; KOCSIS, P; BAUMGARTEN, R; KOVACS, BW; LEVY, DL; SMITH, M; BORISON, RL; EVANS, DD; KLEIN, DN; MACMURRAY, J; TOSK, JM; SVERD, J; GYSIN, R; FLANAGAN, SD				COMINGS, DE; COMINGS, BG; MUHLEMAN, D; DIETZ, G; SHAHBAHRAMI, B; TAST, D; KNELL, E; KOCSIS, P; BAUMGARTEN, R; KOVACS, BW; LEVY, DL; SMITH, M; BORISON, RL; EVANS, DD; KLEIN, DN; MACMURRAY, J; TOSK, JM; SVERD, J; GYSIN, R; FLANAGAN, SD			THE DOPAMINE-D2 RECEPTOR LOCUS AS A MODIFYING GENE IN NEUROPSYCHIATRIC DISORDERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED FAMILY HISTORY; ATTENTION-DEFICIT DISORDER; TOURETTE SYNDROME; ANTISOCIAL PERSONALITY; CHILDHOOD PERSONALITY; PSYCHIATRIC-DISORDERS; D2-DOPAMINE RECEPTOR; LEARNING-DISORDERS; BLOOD SEROTONIN; DRUG-ABUSE	Objective. - The A1 allele of the Taq I polymorphism of the dopamine D2 receptor (DRD2) gene has been earlier reported to occur in 69% of alcoholics, compared with 20% of controls. Other research has reported no significant difference in the prevalence of the A1 allele in alcoholics vs controls and no evidence that the DRD2 gene was linked to alcoholism. We hypothesized that these seemingly conflicting results might be because increases in the prevalence of the A1 allele may not be specific to alcoholism. Thus, we examined other disorders frequently associated with alcoholism or those believed to involve defects in dopaminergic neurotransmission. Design. - Case comparison study. To minimize the effect of racial differences in gene frequencies, the study was restricted to non-Hispanic whites. Setting. - Ambulatory and hospitalized patients. Results. - Among all known controls (n = 314), 77 (24.5%) carried the A1 allele. Of the 69 controls known not to be alcoholics, 10 (14.5%) carried the A1 allele. The prevalence of the A1 allele was significantly increased in patients with Tourette's syndrome (44.9%, n = 147), attention deficit hyperactivity disorder (46.2%, n = 104), autism (54.5%, n = 33), alcoholism (42.3%, n = 104), and posttraumatic stress disorder (45.7%, n = 35). After correction for multiple comparisons (requiring P < .0009 for significance), all remained significant except posttraumatic stress disorder. The prevalence of the A1 allele was not significantly increased in patients with depression, panic attacks, Parkinson's disease, or obesity. The prevalence of the A1 allele in drug addiction and schizophrenia was only significant when compared with that of controls who were not alcoholics, and no correction was made for multiple comparisons. Conclusion. - These results suggest the A1 allele of the DRD2 gene is associated with a number of behavior disorders in which it may act as a modifying gene rather than as the primary etiological agent.	CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV NEUROSCI,DUARTE,CA 91010; MCLEAN HOSP,DEPT RES,BELMONT,MA 02178; HILLSIDE HOSP,DEPT PSYCHIAT RES,GLEN OAKS,NY; SUNY STONY BROOK,DEPT PSYCHOL,STONY BROOK,NY 11794; JERRY L PETTIS MEM VET ADM MED CTR,DEPT PSYCHIAT,LOMA LINDA,GA; N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT PSYCHIAT,MANHASSET,NY 11030; VET ADM MED CTR,PSYCHIAT SERV,AUGUSTA,GA 30904; MED COLL GEORGIA,DEPT PSYCHIAT,AUGUSTA,GA 30912	City of Hope; Beckman Research Institute of City of Hope; Harvard University; McLean Hospital; Northwell Health; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cornell University; Northwell Health; North Shore University Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Georgia; Augusta University	COMINGS, DE (corresponding author), CITY HOPE NATL MED CTR,DEPT MED GENET,1500 E DUARTE RD,DUARTE,CA 91010, USA.				NIMH NIH HHS [MH45908, MH41960] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045908, P50MH041960, P30MH041960] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		APTER A, 1990, PSYCHIAT RES, V32, P191, DOI 10.1016/0165-1781(90)90086-K; BADAWY AAB, 1989, BIOCHEM J, V264, P597, DOI 10.1042/bj2640597; BALLENGER JC, 1979, ARCH GEN PSYCHIAT, V36, P224; BANKI C, 1981, J NEURAL TRANSM, V50, P98; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BOLOS AM, 1990, JAMA-J AM MED ASSOC, V264, P3156; BOULLIN D, 1982, J AUTISM DEV DISORD, V12, P97, DOI 10.1007/BF01531680; BRANCHEY L, 1984, PSYCHIAT RES, V12, P219, DOI 10.1016/0165-1781(84)90027-1; BRASE DA, 1975, LIFE SCI, V16, P1005, DOI 10.1016/0024-3205(75)90184-8; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; BUYDENSBRANCHEY L, 1989, ARCH GEN PSYCHIAT, V46, P231; CADORET RJ, 1971, BIOL PSYCHIAT, V3, P85; CANTWELL DP, 1972, ARCH GEN PSYCHIAT, V27, P414; CLONINGER CR, 1988, ALCOHOL CLIN EXP RES, V12, P494, DOI 10.1111/j.1530-0277.1988.tb00232.x; COMINGS DE, 1989, AM J HUM GENET, V44, P452; COMINGS DE, 1989, AM J MED GENET, V34, P413, DOI 10.1002/ajmg.1320340318; COMINGS DE, 1990, AM J MED GENET, V36, P418, DOI 10.1002/ajmg.1320360410; COMINGS DE, 1991, AM J MED GENET, V39, P180, DOI 10.1002/ajmg.1320390213; COMINGS DE, 1987, AM J HUM GENET, V41, P701; COMINGS DE, 1990, J CLIN PSYCHIAT, V51, P288; COMINGS DE, 1990, J CLIN PSYCHIAT, V51, P281; COMINGS DE, 1984, J AM ACAD CHILD PSY, V23, P138, DOI 10.1097/00004583-198403000-00004; COMINGS DE, 1987, AM J HUM GENET, V41, P839; COMINGS DE, 1990, J CLIN PSYCHIAT, V51, P275; COMINGS DE, 1990, AM J HUM GENET, P46; COMINGS DE, 1909, TOURETTE SYNDROME HU, P1; COMINGS DE, 1991, 2ND INT C GEN PSYCH; CROWE RR, 1988, BIOL PSYCHIAT, V24, P473, DOI 10.1016/0006-3223(88)90189-8; DAUSSET J, 1990, GENOMICS, V6, P676; DEVOR EJ, 1990, HUM HERED, V40, P105, DOI 10.1159/000153914; FOWLER RC, 1975, ACTA PSYCHIAT SCAND, V51, P153, DOI 10.1111/j.1600-0447.1975.tb00001.x; GELERNTER J, 1990, ARCH GEN PSYCHIAT, V47, P1073; GITTELMAN R, 1985, ARCH GEN PSYCHIAT, V42, P937; GLOWINSKI J, 1984, TRENDS NEUROSCI, V7, P415; GOLDMAN D, 1991, JAMA-J AM MED ASSOC, V265, P2668, DOI 10.1001/jama.1991.03460200047018; GRANDE TP, 1984, PSYCHOL REP, V55, P455, DOI 10.2466/pr0.1984.55.2.455; GRANDY DK, 1989, AM J HUM GENET, V45, P778; HELZER JE, 1988, J STUD ALCOHOL, V49, P219, DOI 10.15288/jsa.1988.49.219; HUDSON JI, 1990, AM J PSYCHIAT, V147, P552; JAFFE JH, 1988, J STUD ALCOHOL, V49, P211, DOI 10.15288/jsa.1988.49.211; KNOP J, 1984, LONGITUDINAL RES ALC, P107; KULKA RA, 1990, NATIONAL VIETNAM VET, P1; LEWIS CE, 1983, J NERV MENT DIS, V171, P105, DOI 10.1097/00005053-198302000-00007; Loney J., 1981, PSYCHOSOCIAL ASPECTS, P381; MARTIN RL, 1985, ARCH GEN PSYCHIAT, V42, P47; MERIKANGAS KR, 1985, ARCH GEN PSYCHIAT, V42, P367; MOISES HW, 1989, 1ST WORLD C PSYCH GE; MYERS RD, 1978, SEROTONIN HLTH DISEA, V2, P343; NOBLE EP, 1991, JAMA-J AM MED ASSOC, V265, P2667, DOI 10.1001/jama.1991.03460200047016; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P548; PARSIAN A, 1991, ARCH GEN PSYCHIAT, V48, P655; PAULS DL, 1980, AM J HUM GENET, V32, P639; RITVO ER, 1970, ARCH GEN PSYCHIAT, V23, P566; ROUNSAVILLE BJ, 1991, ARCH GEN PSYCHIAT, V48, P33; SHAYWITZ BA, 1976, SCIENCE, V191, P305, DOI 10.1126/science.942800; SIGVARDSSON S, 1987, J CHILD PSYCHOL PSYC, V28, P929, DOI 10.1111/j.1469-7610.1987.tb00680.x; STABENAU JR, 1984, AM J PSYCHIAT, V141, P1178; SVERD J, 1989, J MULTIHANDICAPPED P, V2, P311; TAKAHASHI D, 1974, FOLIA PSYCHIATR NEUR, V28, P347; VALZELLI L, 1981, PSYCHOBIOLOGY AGGRES, P1; VANPRAAG HM, 1987, J AFFECT DISORDERS, V13, P1, DOI 10.1016/0165-0327(87)90067-X; VIRKKUNEN M, 1979, ACTA PSYCHIAT SCAND, V59, P493, DOI 10.1111/j.1600-0447.1979.tb00248.x; YOUNG AB, 1984, NEUROL CLIN, V2, P417, DOI 10.1016/S0733-8619(18)31082-X; 1987, DIAGNOSTIC STATISTIC, P1	64	494	505	0	42	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1793	1800		10.1001/jama.266.13.1793	http://dx.doi.org/10.1001/jama.266.13.1793			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG551	1832466				2022-12-28	WOS:A1991GG55100031
J	BENDELAC, A; SCHWARTZ, RH				BENDELAC, A; SCHWARTZ, RH			CD4+ AND CD8+ T-CELLS ACQUIRE SPECIFIC LYMPHOKINE SECRETION POTENTIALS DURING THYMIC MATURATION	NATURE			English	Article							MONOCLONAL-ANTIBODIES; MOUSE THYMOCYTES; STEM-CELLS; EXPRESSION; IL-4; SUBSETS; PRECURSORS; DEFINITION; RECEPTORS; PROFILES	PERIPHERAL CD4+ and CD8+ T lymphocytes carry out different functions during immune reactions, partly as a result of the distinct patterns of lymphokines that they secrete upon stimulation. Using thymic cells from adult and newborn mice as well as from fetal organ cultures, we show here that this functional differentiation occurs inside the thymus and is completed during the single positive stage by the time the T-cell receptor becomes fully coupled to the intracellular activation pathways leading to lymphokine secretion. Surprisingly, CD4+8- thymocytes differ from their immediate progeny, naive peripheral CD4+ cells, in that they secrete a broader range of lymphokines, including interleukins 4, 5 and 10 and gamma-interferon, and more closely resemble immunologically experienced (activated or memory) CD4+ lymphocytes.			BENDELAC, A (corresponding author), NIAID,CELLULAR & MOLEC IMMUNOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							AGUS DB, 1991, J EXP MED, V173, P1039, DOI 10.1084/jem.173.5.1039; BENSASSON SZ, 1990, J IMMUNOL, V145, P1127; BEVAN MJ, 1978, IMMUNOL REV, V42, P3, DOI 10.1111/j.1600-065X.1978.tb00256.x; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; BUDD RC, 1987, J IMMUNOL, V138, P3583; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CEREDIG R, 1988, J IMMUNOL, V141, P355; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; CRISPE IN, 1987, J IMMUNOL, V138, P2013; DAHL H, 1972, ACTA PATH MICRO IM B, VB 80, P863; ERNST DN, 1990, J IMMUNOL, V145, P1295; FINKEL TH, 1987, NATURE, V330, P179, DOI 10.1038/330179a0; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; GROSSMANN J, 1991, J IMMUNOL, V146, P293; HAYAKAWA K, 1988, J EXP MED, V168, P1825, DOI 10.1084/jem.168.5.1825; HULI J, 1989, J IMMUNOL, V142, P800; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEE WT, 1990, J IMMUNOL, V144, P3288; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; MICHIE SA, 1988, J EXP MED, V168, P1929, DOI 10.1084/jem.168.5.1929; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1990, J IMMUNOL, V145, P2938; NUSSENZWEIG MC, 1980, J EXP MED, V151, P1196, DOI 10.1084/jem.151.5.1196; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; ORTEGA G, 1984, J IMMUNOL, V133, P1970; PILARSKI LM, 1989, EUR J IMMUNOL, V19, P589, DOI 10.1002/eji.1830190403; SCHUMACHER JH, 1988, J IMMUNOL, V141, P1575; SWAIN SL, 1990, J IMMUNOL, V144, P1788; SWAIN SL, 1988, J IMMUNOL, V141, P3445	30	176	177	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					68	71		10.1038/353068a0	http://dx.doi.org/10.1038/353068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1831881				2022-12-28	WOS:A1991GD80500059
J	CLEARY, LM				CLEARY, LM			DISCOVERIES	ANNALS OF INTERNAL MEDICINE			English	Article											CLEARY, LM (corresponding author), SUNY HLTH SCI CTR, 750 E ADAMS ST, SYRACUSE, NY 13210 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					321	322		10.7326/0003-4819-115-4-321	http://dx.doi.org/10.7326/0003-4819-115-4-321			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854117				2022-12-28	WOS:A1991GA76400013
J	BHATTI, N; GILSON, RJC; BEECHAM, M; WILLIAMS, P; MATTHEWS, MP; TEDDER, RS; WELLER, IVD				BHATTI, N; GILSON, RJC; BEECHAM, M; WILLIAMS, P; MATTHEWS, MP; TEDDER, RS; WELLER, IVD			FAILURE TO DELIVER HEPATITIS-B VACCINE - CONFESSIONS FROM A GENITOURINARY MEDICINE CLINIC	BRITISH MEDICAL JOURNAL			English	Article							HOMOSEXUAL MEN; VIRAL-HEPATITIS; VIRUS-INFECTION; EFFICACY; DISEASE; TRIAL; POPULATION; PREVALENCE; ANTIBODIES; CARRIERS	Objective-To audit hepatitis B immunisation of homosexual or bisexual men in a genitourinary medicine clinic. Design-Retrospective case note review of all homosexual and bisexual men presenting to a genitourinary clinic as new patients during 12 months in 1988 and follow up review of notes to May 1990. Setting-One department of genitourinary medicine, Middlesex Hospital. Patients-758 homosexual or bisexual men, of whom 207 started a course of hepatitis B vaccine in 1988. Case notes were unavailable for one patient. Main outcome measures-The proportion of patients screened for hepatitis B virus markers, the proportion of susceptible patients immunised, the proportion completing the vaccine course, and the proportion rendered immune. Results-25 men had been previously tested for hepatitis markers; of the 732 not previously tested, 440 (60.1%) were screened for hepatitis B markers. 207 (69%) of the 300 patients without hepatitis B serological markers started the vaccine course, and 141 (68%) completed it, with 75 (84%) of the 89 tested after immunisation being immune. An estimated 24% of susceptible new patients were rendered immune as a result of the immunisation policy. Patients who presented with a further episode of a sexually transmitted disease were more likely to have been screened (25% v 12%, p < 0.0001) and immunised (31% v 18% p = 0.02); those known or found to be positive for HIV antibody were more likely to have been screened (23% v 14%, p = 0.047) but less likely to have been immunised (6% v 17%, p = 0.004). Conclusions-The major failure was that in not screening; failure to immunise patients found to be susceptible and failure of compliance with the vaccine course contributed. Non-response to the vaccine was of minor importance. Improvements in vaccine delivery are required. Implications-Other providers should be encouraged to review their performance.	UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON W1N 8AA,ENGLAND; UNIV COLL & MIDDLESEX SCH MED,DEPT MED MICROBIOL,DIV VIROL,LONDON WC1E 6BT,ENGLAND; MIDDLESEX HOSP,DEPT GENITOURINARY MED,LONDON W1N 8AA,ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London			Gilson, Richard J C/C-5123-2009	Tedder, Richard/0000-0002-9672-5721				ADLER MW, 1983, BRIT MED J, V266, P1621; ANDRE FE, 1987, POSTGRAD MED J, V63, P169; BODSWORTH N, 1989, J INFECT DIS, V160, P577, DOI 10.1093/infdis/160.4.577; CARNE CA, 1987, BRIT MED J, V294, P866, DOI 10.1136/bmj.294.6576.866; CHRISTOPHER PJ, 1984, AUST NZ J MED, V14, P491, DOI 10.1111/j.1445-5994.1984.tb03624.x; COLEMAN JC, 1979, J INFECTION, V1, P61, DOI 10.1016/S0163-4453(79)80055-9; COLLIER AC, 1988, ANN INTERN MED, V109, P101, DOI 10.7326/0003-4819-109-2-101; COUTINHO RA, 1983, BRIT MED J, V286, P1305, DOI 10.1136/bmj.286.6374.1305; ELLIS WR, 1979, LANCET, V1, P903; FEFFRIES DJ, 1973, BMJ, V2, P455; FRANCIS DP, 1982, ANN INTERN MED, V97, P362, DOI 10.7326/0003-4819-97-3-362; FULFORD KWM, 1973, LANCET, V1, P1470; GILSON RJC, 1990, HEPATITIS B SEXUALLY, V919, P45; HENTZER B, 1980, SCAND J INFECT DIS, V12, P245, DOI 10.3109/inf.1980.12.issue-4.02; KANE MA, 1989, AM J MED, V87; KROGSGAARD K, 1987, HEPATOLOGY, V7, P37, DOI 10.1002/hep.1840070109; LOKE RHT, 1989, BRIT MED J, V298, P234, DOI 10.1136/bmj.298.6668.234; LOVEDAY C, 1989, BRIT MED J, V298, P419, DOI 10.1136/bmj.298.6671.419; MCCUSKER J, 1990, PUBLIC HEALTH REP, V105, P59; MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103; POLAKOFF S, 1990, J INFECTION, V20, P163, DOI 10.1016/0163-4453(90)93522-T; SCHREEDER MT, 1982, J INFECT DIS, V146, P7, DOI 10.1093/infdis/146.1.7; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; Taylor PE, 1988, VIRAL HEPATITIS LIVE, P198; TEDDER RS, 1980, J MED VIROL, V6, P323, DOI 10.1002/jmv.1890060407; WELLER IVD, 1986, J HEPATOL, V3, pS9, DOI 10.1016/S0168-8278(86)80095-2; 1985, MMWR, V34, P313; 1988, MMWR, V37, P429; 1987, MMWR, V36, P353; 1989, MMWR, V38, P37; 1988, IMMUNISATION INFECTI, P75	31	40	40	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					97	101		10.1136/bmj.303.6794.97	http://dx.doi.org/10.1136/bmj.303.6794.97			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1830505	Green Published, Bronze			2022-12-28	WOS:A1991FW58600024
J	GOODWIN, FK				GOODWIN, FK			CLOZAPINE RESPONSE THRESHOLD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note																		PERRY PJ, 1991, AM J PSYCHIATRY  FEB	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2657	2657						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FL989	1850809				2022-12-28	WOS:A1991FL98900008
J	HOFFMAN, EC; REYES, H; CHU, FF; SANDER, F; CONLEY, LH; BROOKS, BA; HANKINSON, O				HOFFMAN, EC; REYES, H; CHU, FF; SANDER, F; CONLEY, LH; BROOKS, BA; HANKINSON, O			CLONING OF A FACTOR REQUIRED FOR ACTIVITY OF THE AH (DIOXIN) RECEPTOR	SCIENCE			English	Article							ARYL-HYDROCARBON HYDROXYLASE; DNA-BINDING ACTIVITY; MOUSE HEPATOMA LINE; HEAT-SHOCK PROTEIN; XENOBIOTIC RESPONSIVE ELEMENTS; GLUCOCORTICOID RECEPTOR; WILD-TYPE; MUTAGEN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; GENE-PRODUCT; P-450C GENE	The aryl hydrocarbon (Ah) receptor binds various environmental pollutants, such as polycyclic aromatic hydrocarbons, heterocyclic amines, and polychlorinated aromatic compounds (dioxins, dibenzofurans, and biphenyls), and mediates the carcinogenic effects of these agents. The complementary DNA and part of the gene for an 87-kilodalton human protein that is necessary for Ah receptor function have been cloned. The protein is not the ligand-binding subunit of the receptor but is a factor that is required for the ligand-binding subunit to translocate from the cytosol to the nucleus after binding ligand. The requirement for this factor distinguishes the Ah receptor from the glucocorticoid receptor, to which the Ah receptor has been presumed to be similar. Two portions of the 87-kilodalton protein share sequence similarities with two Drosophila proteins, Per and Sim. Another segment of the protein shows conformity to the consensus sequence for the basic helix-loop-helix motif found in proteins that bind DNA as homodimers or heterodimers.	UNIV CALIF LOS ANGELES,DEPT PATHOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,BIOMED & ENVIRONM SCI LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER; NCI NIH HHS [CA 28868, CA 16048] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BROOKS B, 1989, American Journal of Human Genetics, V45, pA132; COON MJ, 1980, MICROSOMES DRUG OXID, P1149; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; CUTHILL S, 1987, J BIOL CHEM, V262, P3477; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DEGAWA M, 1989, CARCINOGENESIS, V10, P1119, DOI 10.1093/carcin/10.6.1119; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1986, J BIOL CHEM, V261, P3987; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1986, EUR J BIOCHEM, V155, P223, DOI 10.1111/j.1432-1033.1986.tb09480.x; DENISON MS, 1988, J BIOL CHEM, V263, P17221; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GEHRING U, 1977, RES STEROIDS, V7, P43; GELBOIN HV, 1983, NEW ENGL J MED, V309, P105, DOI 10.1056/NEJM198307143090210; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; GUDAS JM, 1986, J CELL PHYSIOL, V128, P441, DOI 10.1002/jcp.1041280313; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HANKINSON O, 1981, SOMAT CELL GENET, V7, P373, DOI 10.1007/BF01542983; HANKINSON O, 1985, J BIOL CHEM, V260, P1790; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HANKINSON O, 1988, MICROSOMES DRUG OXID, P39; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HENRY EC, 1989, BIOCHEMISTRY-US, V28, P6430, DOI 10.1021/bi00441a041; HOFFMAN E, UNPUB; JERINA DM, 1983, DRUG METAB DISPOS, V11, P1; KARENLAMPI SO, 1988, J BIOL CHEM, V263, P10111; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; KOURI RE, 1982, CANCER RES, V42, P5030; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; MANCHESTER DK, 1987, CANCER RES, V47, P4861; MCLACHLAN AD, 1984, NUCLEIC ACIDS RES, V12, P9567, DOI 10.1093/nar/12.24.9567; MCMANUS ME, 1989, CARCINOGENESIS, V10, P357, DOI 10.1093/carcin/10.2.357; MIESFELD R, 1984, NATURE, V312, P779, DOI 10.1038/312779a0; MONTISANO DF, 1985, MOL CELL BIOL, V5, P698, DOI 10.1128/MCB.5.4.698; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OHGAKI H, 1986, ENVIRON HEALTH PERSP, V67, P129, DOI 10.2307/3430327; OKUDA T, 1977, CANCER RES, V37, P3904; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1988, J BIOL CHEM, V263, P9848; PFAHL M, 1980, SOMAT CELL GENET, V6, P63, DOI 10.1007/BF01538696; POLAND A, 1987, MOL PHARMACOL, V32, P471; POLAND A, 1984, BANBURY REPORT, V18, P109; RODRIGUES AD, 1989, EUR J BIOCHEM, V181, P627, DOI 10.1111/j.1432-1033.1989.tb14769.x; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SAEZ L, 1988, MOL CELL BIOL, V8, P5378, DOI 10.1128/MCB.8.12.5378; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SNYDERWINE EG, 1989, J NATL CANCER I, V81, P223, DOI 10.1093/jnci/81.3.223; VANGURP JR, 1983, CANCER RES, V43, P6031; WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITLOCK JP, 1984, J BIOL CHEM, V259, P980; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	58	889	907	2	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1991	252	5008					954	958		10.1126/science.1852076	http://dx.doi.org/10.1126/science.1852076			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	1852076				2022-12-28	WOS:A1991FM04000033
J	BRUNET, JF; SHAPIRO, E; FOSTER, SA; KANDEL, ER; IINO, Y				BRUNET, JF; SHAPIRO, E; FOSTER, SA; KANDEL, ER; IINO, Y			IDENTIFICATION OF A PEPTIDE SPECIFIC FOR APLYSIA SENSORY NEURONS BY PCR-BASED DIFFERENTIAL SCREENING	SCIENCE			English	Article							GILL-WITHDRAWAL REFLEX; MECHANOAFFERENT NEURONS; SYNAPTIC CONNECTIONS; RESPONSE PROPERTIES; INNERVATING TAIL; FACILITATION; DISHABITUATION; SENSITIZATION; AMPLIFICATION; HABITUATION	In order to identify genes specific for the sensory neurons of Aplysia, a miniaturized differential screening method based on the polymerase chain reaction and applicable to small amounts of tissue was used. One messenger RNA was isolated that is expressed in every mechanoreceptor sensory cluster of the Aplysia central nervous system. This messenger RNA encodes a peptide that seems to function as an inhibitory cotransmitter. The peptide selectively inhibits certain postsynaptic cells but not others and thereby allows the sensory neurons to achieve target-specific synaptic actions.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University	BRUNET, JF (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,722 W 168 ST,NEW YORK,NY 10032, USA.			Brunet, Jean-Francois/0000-0002-1985-6103				BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BEUSHAUSEN S, 1988, NEURON, V1, P853, DOI 10.1016/0896-6273(88)90133-X; BYRNE J, 1974, J NEUROPHYSIOL, V37, P1041, DOI 10.1152/jn.1974.37.5.1041; BYRNE JH, 1980, J NEUROPHYSIOL, V43, P896, DOI 10.1152/jn.1980.43.4.896; CASTELLUCCI V, 1970, SCIENCE, V167, P1745, DOI 10.1126/science.167.3926.1745; CASTELLUCCI V, 1976, SCIENCE, V194, P1176, DOI 10.1126/science.11560; CROPPER EC, 1987, P NATL ACAD SCI USA, V84, P5483, DOI 10.1073/pnas.84.15.5483; CROPPER EC, 1990, P NATL ACAD SCI USA, V87, P933, DOI 10.1073/pnas.87.3.933; DUBUC B, 1991, J EXP BIOL, V156, P315; ESKIN A, 1989, P NATL ACAD SCI USA, V86, P2458, DOI 10.1073/pnas.86.7.2458; FIORE L, 1980, NEUROBIOLOGY INVERTE, P20; FREMEAU RT, 1986, SCIENCE, V234, P1265, DOI 10.1126/science.3775385; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; HOKFELT T, 1987, EXPERIENTIA, V43, P768; HOKFELT T, 1980, NATURE, V284, P515, DOI 10.1038/284515a0; HOKFELT T, 1983, SCIENCE, V221, P286; KISTLER HB, 1985, J NEUROSCI, V5, P72; Maniatis T., 1982, MOL CLONING; PINSKER H, 1970, SCIENCE, V167, P1740, DOI 10.1126/science.167.3926.1740; RAYPORT SG, 1983, J NEUROPHYSIOL, V49, P864, DOI 10.1152/jn.1983.49.4.864; ROSEN SC, 1979, J NEUROPHYSIOL, V42, P954, DOI 10.1152/jn.1979.42.4.954; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STOLTZ KP, 1987, SCIENCE, V235, P685; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1522, DOI 10.1152/jn.1983.50.6.1522; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1543, DOI 10.1152/jn.1983.50.6.1543	27	82	86	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					856	859		10.1126/science.1840700	http://dx.doi.org/10.1126/science.1840700			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1840700				2022-12-28	WOS:A1991FL12300051
J	BROWN, ZA; BENEDETTI, J; ASHLEY, R; BURCHETT, S; SELKE, S; BERRY, S; VONTVER, LA; COREY, L				BROWN, ZA; BENEDETTI, J; ASHLEY, R; BURCHETT, S; SELKE, S; BERRY, S; VONTVER, LA; COREY, L			NEONATAL HERPES-SIMPLEX VIRUS-INFECTION IN RELATION TO ASYMPTOMATIC MATERNAL INFECTION AT THE TIME OF LABOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLYCOPROTEIN-G; WESTERN BLOT; DELIVERY; TYPE-2; ANTIBODIES; CULTURES; RISK; HISTORY; MOTHERS; INFANTS	Background and Methods. To define the risk factors associated with neonatal acquisition of herpes simplex virus (HSV) infection, we prospectively obtained HSV cultures from the cervis and external genitalia of 15,923 pregnant women in early labor who were without symptoms or signs of genital HSV infection. Follow-up of the women with positive cultures for HSV and their HSV-exposed infants included serologic tests and serial cultures for HSV. Results. HSV was isolated from 56 of the women (0.35 percent), 18 of whom (35 percent) had serologic evidence of a recently acquired, subclinical first episode of genital HSV infection, and 34 of whom (65 percent) had reactivation of HSV. Neonatal HSV developed in 6 of 18 infants (33 percent) born to the women with a first episode of genital HSV, and in 1 of 34 infants (3 percent) born to the women with reactivation of HSV (P < 0.01); neonatal HSV also occurred in three of the infants born to the 15,867 women with negative cultures. Neonatal HSV-2 occurred in 1 of 4 infants born to mothers seronegative at delivery for both HSV-1 and HSV-2, in 4 of 12 infants exposed to HSV-2 whose mothers had only HSV-1 antibodies at delivery, and in none of the infants born to 31 women who were HSV-2-seropositive. An increased risk of neonatal HSV was associated with exposure to viral shredding from the cervix and the use of fetal-scalp electrodes. Conclusions. Of the asymptomatic women who shed HSV in early labor, about a third have recently acquired genital HSV, and their infants are 10 times more likely to have neonatal HSV than those of women with asymptomatic reactivation of HSV. The presence of maternal antibodies specific to HSV-2 but not HSV-1 appears to reduce the neonatal transmission of HSV-2. Further studies are necessary to determine whether screening and prophylactic treatment are warranted for infants of HSV-2-seronegative mothers who shed HSV-1 or HSV-2 in early labor.	CHILDRENS HOSP MED CTR, SEATTLE, WA USA; UNIV WASHINGTON, DEPT LAB MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98195 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	BROWN, ZA (corresponding author), UNIV WASHINGTON, DEPT OBSTET & GYNECOL, RH-20, SEATTLE, WA 98195 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NIAID NIH HHS [AI-20381] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020381] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARVIN AM, 1986, NEW ENGL J MED, V315, P796, DOI 10.1056/NEJM198609253151303; ASHLEY R, 1985, J MED VIROL, V17, P153, DOI 10.1002/jmv.1890170208; ASHLEY RL, 1989, CLIN LAB MED, V9, P405, DOI 10.1016/S0272-2712(18)30611-5; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; ASHLEY RL, 1987, J VIROL METHODS, V18, P159, DOI 10.1016/0166-0934(87)90121-2; BERNSTEIN DI, 1984, AM J MED, V77, P1055, DOI 10.1016/0002-9343(84)90188-8; BOUCHER FD, 1990, PEDIATR INFECT DIS J, V9, P499, DOI 10.1097/00006454-199007000-00009; BROWN ZA, 1987, PEDIATR INFECT DIS J, V6, P1057; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; FORSGREN M, 1990, SCAND J INFECT DIS, P37; GUTMAN LT, 1986, J INFECT DIS, V154, P415, DOI 10.1093/infdis/154.3.415; HANKINS GDV, 1984, AM J OBSTET GYNECOL, V150, P100, DOI 10.1016/S0002-9378(84)80119-2; KEYSERLING HH, 1983, INFECT DIS, P636; LANGENBERG A, 1988, J CLIN MICROBIOL, V26, P1772, DOI 10.1128/JCM.26.9.1772-1774.1988; MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653; NAHMIAS AJ, 1971, AM J OBSTET GYNECOL, V110, P825, DOI 10.1016/0002-9378(71)90580-1; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; PROBER CG, 1987, NEW ENGL J MED, V316, P240, DOI 10.1056/NEJM198701293160503; PROBER CG, 1988, NEW ENGL J MED, V318, P887, DOI 10.1056/NEJM198804073181404; SIMKOVICH JW, 1988, AM J OBSTET GYNECOL, V158, P588, DOI 10.1016/0002-9378(88)90034-8; STAGNO S, 1985, NEW ENGL J MED, V313, P1327, DOI 10.1056/NEJM198511213132105; SULLENDER WM, 1988, J INFECT DIS, V157, P164, DOI 10.1093/infdis/157.1.164; SULLIVANBOLYAI J, 1983, JAMA-J AM MED ASSOC, V250, P3059, DOI 10.1001/jama.250.22.3059; WHITLEY RJ, 1980, PEDIATRICS, V66, P489; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109; YEAGER AS, 1984, PEDIATRICS, V73, P188; [No title captured]	27	317	324	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1991	324	18					1247	1252		10.1056/NEJM199105023241804	http://dx.doi.org/10.1056/NEJM199105023241804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ823	1849612				2022-12-28	WOS:A1991FJ82300004
J	CALKINS, DR; RUBENSTEIN, LV; CLEARY, PD; DAVIES, AR; JETTE, AM; FINK, A; KOSECOFF, J; YOUNG, RT; BROOK, RH; DELBANCO, TL				CALKINS, DR; RUBENSTEIN, LV; CLEARY, PD; DAVIES, AR; JETTE, AM; FINK, A; KOSECOFF, J; YOUNG, RT; BROOK, RH; DELBANCO, TL			FAILURE OF PHYSICIANS TO RECOGNIZE FUNCTIONAL DISABILITY IN AMBULATORY PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article							SICKNESS IMPACT PROFILE; ELDERLY PATIENTS; PRIMARY CARE; QUESTIONNAIRE; RELIABILITY; INSTRUMENT	Objective: To assess the ability of internists to identify functional disabil Design: Comparison of responses by physicians and a random sample of their patients to a 12-item questionnaire about physical and social function. Setting: A hospital-based internal medicine group practice in Boston, Massachusetts, and selected office-based internal medicine practices in Los Angeles, California. Subjects: Five staff physicians, three general internal medicine fellows, and 34 internal medicine residents in the hospital-based practice and 178 of their patients. Seventy-six physicians in the office-based practices and 230 of their patients. Measurements and Main Results: Physicians underestimated or failed to recognize 66% of disabilities reported by patients. Patient-reported disabilities were underestimated or unrecognized more often in the hospital-based practice than in the office-based practices (75% compared with 60%, P < 0.05). Physicians overstated functional impairment in 21% of paired responses in which patients reported no disability. Conclusions: Physicians often underestimate or fail to recognize functional disabilities that are reported by their patients. They overstate functional impairment to a lesser degree. Because these discrepancies may adversely affect patient care and well-being, medical educators and clinicians should pay more attention to the assessment of patient function.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV CALIF LOS ANGELES, CTR HLTH SCI, LOS ANGELES, CA 90024 USA	Harvard University; Harvard Medical School; University of California System; University of California Los Angeles	CALKINS, DR (corresponding author), BETH ISRAEL HOSP, DEPT MED, DIV GEN MED & PRIMARY CARE, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.		Cleary, Paul/AAF-7048-2019	Jette, Alan/0000-0002-2117-9973				ALMY TP, 1988, ANN INTERN MED, V109, P70, DOI 10.7326/0003-4819-109-1-70; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BROOK RH, 1979, MED CARE, V17, P1; Dawson D., 1987, ADV DATA, V133, P1; JETTE AM, 1978, J CHRON DIS, V31, P573, DOI 10.1016/0021-9681(78)90017-6; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; KAUFERT JM, 1979, MED CARE, V17, P807, DOI 10.1097/00005650-197908000-00003; MARTIN DP, 1976, J MED EDUC, V51, P942; NELSON E, 1983, JAMA-J AM MED ASSOC, V249, P3331, DOI 10.1001/jama.249.24.3331; NELSON E C, 1989, Medical Care (Philadelphia), V27, pS77, DOI 10.1097/00005650-198903001-00007; ROWE JW, 1985, NEW ENGL J MED, V312, P827, DOI 10.1056/NEJM198503283121305; RUBENSTEIN LV, 1989, J AM GERIATR SOC, V37, P562, DOI 10.1111/j.1532-5415.1989.tb05690.x; RUBENSTEIN LV, 1989, ANN INTERN MED, V111, P836, DOI 10.7326/0003-4819-111-10-836; RUBENSTEIN LV, 1988, J MED EDUC, V63, P283; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART MA, 1977, MED CARE, V15, P578, DOI 10.1097/00005650-197707000-00005; WARTMAN SA, 1983, PUBLIC HEALTH REP, V98, P141; [No title captured]; 1979, HLTH PEOPLE SURGEONS	19	224	226	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					451	454		10.7326/0003-4819-114-6-451	http://dx.doi.org/10.7326/0003-4819-114-6-451			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1825267				2022-12-28	WOS:A1991FB64000003
J	DYSON, PJ; KNIGHT, AM; FAIRCHILD, S; SIMPSON, E; TOMONARI, K				DYSON, PJ; KNIGHT, AM; FAIRCHILD, S; SIMPSON, E; TOMONARI, K			GENES ENCODING LIGANDS FOR DELETION OF V-BETA-11 T-CELLS COSEGREGATE WITH MAMMARY-TUMOR VIRUS GENOMES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLONAL DELETION; ENTEROTOXIN-B; TOLERANCE; PRODUCTS; REACTIVITY; ANTIGENS; MARKERS; MLS	THE T-cell receptor (TCR) repertoire is selected in the thymus after rearrangement of genes encoding TCR alpha and beta chains 1. Selection is based on the recognition by newly emergent T cells of self-ligands associated with molecules of the major histocompatibility complex: some combinations result in positive selection, others in negative selection. Negative selection, or clonal deletion, is an important mechanism for eliminating autoreactive T cells. A group of self-ligands involved in clonal deletion was identified because they, like exogenous superantigens 2, were recognized by almost all T cells expressing particular TCR V-beta genes. V-beta-17a T cells are deleted by a tissue-specific ligand 3,4; V-beta-6, V-beta-7, V-beta-8.1 and V-beta-9 T cells are deleted by the minor lymphocyte-stimulating (Mls) determinant Mls-1a (refs 5-8); V-beta-3 T cells by Mls-2a and Mls-3a (refs 9,10); V-beta-11 T cells 11 by ligands encoded by independently segregating genes; and V-beta-5 T cells by ligands encoded by two genes 12. Chromosomes mapping using recombinant inbred strains of mice and classic backcrosses show that Mls-1a in DBA/2 mice is encoded on chromosome 1, that one of the two ligand genes for deletion of V-beta-5 T cells maps to chromosome 12 (ref. 12) and that a ligand gene for V-beta-11 deletion is linked to the CD8 locus on chromosome 6 (ref. 11). Here we present evidence from three sets of backcross mice for concordance between V-beta-11 deletion ligand genes on chromosomes 6, 12 and 14 and endogenous mouse mammary tumour virus integrant (Mtv) genomes. Our results indicate that the V-beta-11 deletion ligands are products of Mtv genomes.			DYSON, PJ (corresponding author), CLIN RES CTR,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.			Simpson, Elizabeth/0000-0002-2118-3139				ABE R, 1989, J EXP MED, V170, P1059, DOI 10.1084/jem.170.4.1059; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; DAVISSON MT, 1989, GENETIC VARIANTS STR, P416; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GEBHARD W, 1983, J MOL BIOL, V170, P567, DOI 10.1016/S0022-2836(83)80161-2; GIBSON DM, 1983, IMMUNOGENETICS, V18, P111, DOI 10.1007/BF00368538; HAPP MP, 1989, P NATL ACAD SCI USA, V86, P6293, DOI 10.1073/pnas.86.16.6293; HEBERKATZ E, 1989, IMMUNOL TODAY, V10, P164, DOI 10.1016/0167-5699(89)90174-6; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KING LB, 1990, J IMMUNOL, V144, P3218; KNIGHT AM, 1990, MOL CELL PROBE, V4, P497, DOI 10.1016/0890-8508(90)90008-N; LAWLOR DA, 1990, ANNU REV IMMUNOL, V8, P23, DOI 10.1146/annurev.iy.08.040190.000323; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; Maniatis T., 1982, MOL CLONING; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MOLLICK JA, 1989, SCIENCE, V244, P817, DOI 10.1126/science.2658055; OKADA CY, 1990, J IMMUNOL, V144, P3473; PETERS G, 1986, J VIROL, V59, P535, DOI 10.1128/JVI.59.3.535-544.1986; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; TOMONARI K, 1990, IMMUNOL REV, V116, P139, DOI 10.1111/j.1600-065X.1990.tb00808.x; TOMONARI K, 1988, IMMUNOGENETICS, V28, P445, DOI 10.1007/BF00355377; TOMONARI K, 1990, IMMUNOGENETICS, V32, P60, DOI 10.1007/BF01787331; TOMONARI K, IN PRESS IMMUNOGENET; VACCHIO MS, 1990, J EXP MED, V172, P807, DOI 10.1084/jem.172.3.807; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; YANG JN, 1987, IMMUNOGENETICS, V25, P222, DOI 10.1007/BF00404691	32	329	329	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					531	532		10.1038/349531a0	http://dx.doi.org/10.1038/349531a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846950				2022-12-28	WOS:A1991EW57100069
J	CALLAHAN, CM; DITTUS, RS; KATZ, BP				CALLAHAN, CM; DITTUS, RS; KATZ, BP			ORAL CORTICOSTEROID-THERAPY FOR PATIENTS WITH STABLE CHRONIC OBSTRUCTIVE PULMONARY-DISEASE - A METAANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review							CHRONIC AIRWAYS OBSTRUCTION; AIR-FLOW OBSTRUCTION; CHRONIC-BRONCHITIS; CONTROLLED TRIAL; STEROID-THERAPY; CLINICAL-TRIAL; LIMITATION; PREDNISOLONE; EMPHYSEMA; ASTHMA	Purpose: To evaluate the effectiveness of oral corticosteroid therapy in patients with stable chronic obstructive pulmonary disease. Data Identification: An English-Language literature search using MEDLINE (1966 to 1989) and a bibliographic review of all retrieved articles identified 33 original studies of oral corticosteroid use in chronic obstructive pulmonary disease published since 1951. Study Selection: We submitted a photocopy of each study's "methods" section to three nonstudy physician-investigators who used nine explicit criteria to independently assess study quality. Ten studies met all criteria and five studies met some of the criteria. Data Extraction: To compare outcomes across all qualifying studies, we defined response to therapy as a 20% or greater increase in the baseline forced expiratory volume in 1 second (FEV1); we defined the treatment effect size for each study as the proportion of patients who responded to corticosteroid therapy minus the proportion of patients who responded to placebo. Potential confounding variables as related to eligibility criteria and treatment protocols were also assessed for each study. Results of Data Synthesis: Among ten studies that met all nine criteria, we found no significant differences in eligibility criteria, treatment protocol, or study design. No association was found between treatment effect size and publication date, study size, mean patient age, or FEV1. These studies had reported effect sizes ranging from 0% to 56%; we calculated a weighted mean effect size of 10% (95% CI, 2% to 18%). When studies meeting only some of the criteria were included in the calculation, the weighted mean effect size was 11% (95% CI, 4% to 18%). Conclusions: Patients with stable chronic obstructive pulmonary disease receiving oral corticosteroid therapy have a 20% or greater improvement in baseline FEV1, approximately 10% more often than similar patients receiving placebo.	RICHARD L ROUDEBUSH VET AFFAIRS MED CTR, INDIANAPOLIS, IN USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	CALLAHAN, CM (corresponding author), INDIANA UNIV, SCH MED,REGENSTRIEF HLTH CTR,DEPT MED,5TH FLOOR, 1001 W 10TH ST, INDIANAPOLIS, IN 46202 USA.				BHP HRSA HHS [D28 PE-55009, T32 PE15001] Funding Source: Medline	BHP HRSA HHS		ALBERT RK, 1980, ANN INTERN MED, V92, P753, DOI 10.7326/0003-4819-92-6-753; BEEREL F, 1963, NEW ENGL J MED, V268, P226, DOI 10.1056/NEJM196301312680502; BEEREL FR, 1971, AM REV RESPIR DIS, V104, P264; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BICKERMAN H A, 1955, J Chronic Dis, V2, P247, DOI 10.1016/0021-9681(55)90132-6; BICKERMAN HA, 1954, J ALLERGY, V25, P312, DOI 10.1016/0021-8707(54)90132-X; BLAIR GP, 1984, CHEST, V86, P524, DOI 10.1378/chest.86.4.524; CLIFTON M, 1962, LANCET, V1, P1311; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; CULLEN JH, 1960, AM REV RESPIR DIS, V82, P508; ELIASSON O, 1986, CHEST, V89, P484, DOI 10.1378/chest.89.4.484; EVANS JA, 1974, THORAX, V29, P401, DOI 10.1136/thx.29.4.401; FANTA CH, 1983, AM J MED, V74, P845, DOI 10.1016/0002-9343(83)91076-8; FELIXDAVIES D, 1955, BRIT MED J, V1, P780; FRANKLIN W, 1958, NEW ENGL J MED, V258, P774, DOI 10.1056/NEJM195804172581602; FREEDMAN BJ, 1963, BMJ-BRIT MED J, P1509, DOI 10.1136/bmj.2.5371.1509; FULEIHAN FJ, 1967, AM REV RESPIR DIS, V96, P678; GALDSTON M, 1951, AM J MED, V10, P166, DOI 10.1016/0002-9343(51)90239-2; GUYATT G, 1988, CAN MED ASSOC J, V139, P497; HARDING SM, 1978, THORAX, V33, P214, DOI 10.1136/thx.33.2.214; HAYNES RB, 1987, CONTROL CLIN TRIALS, V8, P12, DOI 10.1016/0197-2456(87)90021-3; HUDSON L D, 1984, Chest, V85, p76S; KENNEDY MCS, 1954, LANCET, V1, P77; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAM WK, 1983, BRIT J DIS CHEST, V77, P189; Light R.J., 1984, SUMMING SCI REV RES; LIGHT RW, 1977, CHEST, V72, P512, DOI 10.1378/chest.72.4.512; LOREN ML, 1980, ANN ALLERGY, V45, P67; LORRIMAN GERARD, 1959, THORAX, V14, P146, DOI 10.1136/thx.14.2.146; LUKAS DS, 1951, AM REV TUBERC PULM, V64, P279; MENDELLA LA, 1982, ANN INTERN MED, V96, P17, DOI 10.7326/0003-4819-96-1-17; MITCHELL DM, 1984, LANCET, V2, P193; MITCHELL DM, 1984, THORAX, V39, P924, DOI 10.1136/thx.39.12.924; MITCHELL DM, 1986, THORAX, V41, P606, DOI 10.1136/thx.41.8.606; MORGAN WKC, 1964, ANN INTERN MED, V61, P248, DOI 10.7326/0003-4819-61-2-248; MOYES EN, 1957, LANCET, V2, P1187; OPPENHEIMER EA, 1968, LANCET, V2, P552; OREILLY JF, 1982, BRIT J DIS CHEST, V76, P374, DOI 10.1016/0007-0971(82)90073-0; Orwin RG, 1983, J ED STAT, V8, P157, DOI [DOI 10.2307/1164923, 10.3102/10769986008002157]; PECORA LJ, 1964, AM REV RESPIR DIS, V89, P528; PETTY TL, 1970, CHEST, V57, P204, DOI 10.1378/chest.57.2.204; POSTMA DS, 1985, EUR J RESPIR DIS, V67, P56; ROBERTSON AS, 1986, EUR J RESPIR DIS, V69, P565; ROSENTHAL R, 1982, PSYCHOL BULL, V92, P500, DOI 10.1037/0033-2909.92.2.500; RUDD R, 1984, BRIT MED J, V288, P1553, DOI 10.1136/bmj.288.6430.1553; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SAHN SA, 1978, CHEST, V73, P389, DOI 10.1378/chest.73.3.389; SHIM C, 1978, J ALLERGY CLIN IMMUN, V62, P363, DOI 10.1016/0091-6749(78)90137-9; SHUBIN H, 1965, DIS CHEST, V48, P287, DOI 10.1378/chest.48.3.287; STOKES TC, 1982, LANCET, V2, P345; STRAIN DS, 1985, CHEST, V88, P718, DOI 10.1378/chest.88.5.718; THACKER SB, 1988, JAMA-J AM MED ASSOC, V259, P1685, DOI 10.1001/jama.259.11.1685; WEBB J, 1981, THORAX, V36, P18, DOI 10.1136/thx.36.1.18; WEST JR, 1951, AM J MED, V10, P156, DOI 10.1016/0002-9343(51)90238-0; WILLIAMS IP, 1980, BRIT J DIS CHEST, V74, P142, DOI 10.1016/0007-0971(80)90025-X; ZIMENT I, 1987, CHRONIC OBSTRUCTIVE, P75	56	161	161	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1991	114	3					216	223		10.7326/0003-4819-114-3-216	http://dx.doi.org/10.7326/0003-4819-114-3-216			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV339	1824614				2022-12-28	WOS:A1991EV33900010
J	OHKURA, H; YANAGIDA, M				OHKURA, H; YANAGIDA, M			S-POMBE GENE SDS22+ ESSENTIAL FOR A MIDMITOTIC TRANSITION ENCODES A LEUCINE-RICH REPEAT PROTEIN THAT POSITIVELY MODULATES PROTEIN PHOSPHATASE-1	CELL			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEIN; GLYCOPROTEIN-IB; RNA-POLYMERASE; SEQUENCE; MITOSIS; HOMOLOGY; CLONING	The fission yeast dis2+ gene encodes one of the two type 1 protein phosphatases (PP1) in this organism. Its semidominant mutant dis2-11 is defective in mitosis. Here we report the characterization of a high dosage suppressor, sds22+, that complements dis2-11. Sequencing of the cloned sds22+ gene predicts a novel 30 kd protein, which consists almost entirely of leucine-rich 22 amino acid repeats and is enriched in the insoluble nuclear fraction. sds22+ is an essential gene required for the mitotic metaphase/anaphase transition; gene disruption causes cell cycle arrest at mid-mitosis. Unexpectedly, the sds22+ gene becomes dispensable upon high dosage of the PP1 genes. The sds22+ product appears to facilitate PP1-dependent dephosphorylation, but does not substitute PP1. We propose that the sds22+ protein forms a repeating helical rod that is capable of enhancing a PP1-dependent dephosphorylation activity that is essential in midmitosis.			OHKURA, H (corresponding author), KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN.							ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; BERNDT N, 1987, FEBS LETT, V223, P340, DOI 10.1016/0014-5793(87)80316-2; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1985, EUR J BIOCHEM, V151, P439, DOI 10.1111/j.1432-1033.1985.tb09121.x; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; FAN JB, 1989, NUCLEIC ACIDS RES, V17, P2801, DOI 10.1093/nar/17.7.2801; FISHER LW, 1989, J BIOL CHEM, V264, P4571; HAGAN I, 1988, J CELL SCI, V91, P587; HAGAN IM, 1988, J CELL SCI, V89, P343; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HIRANO T, 1989, J CELL BIOL, V108, P243, DOI 10.1083/jcb.108.2.243; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; Maniatis T., 1982, MOL CLONING; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; OHKURA H, 1988, EMBO J, V7, P1465, DOI 10.1002/j.1460-2075.1988.tb02964.x; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; YAMAWAKIKATAOKA Y, 1989, P NATL ACAD SCI USA, V86, P5693, DOI 10.1073/pnas.86.15.5693; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989	41	173	174	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					149	157		10.1016/0092-8674(91)90216-L	http://dx.doi.org/10.1016/0092-8674(91)90216-L			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846086				2022-12-28	WOS:A1991ET17500016
J	MANIATIS, T				MANIATIS, T			MECHANISMS OF ALTERNATIVE PRE-MESSENGER-RNA SPLICING	SCIENCE			English	Editorial Material							BINDING PROTEINS; GENE; SEX; INTRON; LEVEL				MANIATIS, T (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; Bindereif A, 1990, Genet Eng (N Y), V12, P201; BINGHAM P, COMMUNICATION; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; DABEVA MD, 1986, P NATL ACAD SCI USA, V83, P5854, DOI 10.1073/pnas.83.16.5854; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; FU XY, 1987, MOL CELL BIOL, V7, P738, DOI 10.1128/MCB.7.2.738; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KRAINER A, COMMUNICATION; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KRAINER AR, 1988, FRONTIERS MOL BIOL T, P131; LASKI FA, 1989, GENE DEV, V3, P720, DOI 10.1101/gad.3.5.720; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; McKeown M, 1990, Genet Eng (N Y), V12, P139; MISRA S, 1990, CELL, V62, P269, DOI 10.1016/0092-8674(90)90365-L; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; RIO DC, 1986, CELL, V44, P21, DOI 10.1016/0092-8674(86)90481-2; ROBERTSON HM, 1989, GENETICS, V123, P815; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752	35	221	222	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					33	34		10.1126/science.1824726	http://dx.doi.org/10.1126/science.1824726			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1824726				2022-12-28	WOS:A1991EQ60300022
J	DIEDERICHS, K; BOONE, T; KARPLUS, PA				DIEDERICHS, K; BOONE, T; KARPLUS, PA			NOVEL FOLD AND PUTATIVE RECEPTOR-BINDING SITE OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR	SCIENCE			English	Article							MOLECULAR-CLONING; 3-DIMENSIONAL STRUCTURE; GM-CSF; IDENTIFICATION; PURIFICATION; REGIONS; MOUSE	Granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates the development of and the cytotoxic activity of white blood cells. Recombinant human GM-CSF has proven useful in the treatment of blood disorders. The structure of GM-CSF, which was determined at 2.4 angstrom resolution by x-ray crystallography, has a novel fold combining a two-stranded antiparallel-beta-sheet with an open bundle of four a helices. Residues implicated in receptor recognition, which are distant in the primary sequence, are on adjacent alpha-helices in the folded protein. A working model for the receptor binding site is presented.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL LAB,ITHACA,NY 14853; AMGEN INC,THOUSAND OAKS,CA 91320	Cornell University; Amgen	KARPLUS, PA (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL LAB,ITHACA,NY 14853, USA.			Karplus, Paul/0000-0001-8725-6292				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ALTMANN SW, 1991, J BIOL CHEM, V266, P5333; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURGESS AW, 1987, BLOOD, V69, P43; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLARKLEWIS I, 1988, J IMMUNOL, V141, P881; CREIGHTON TE, 1984, PROTEIN STRUCTURES M, P226; DIEDERICHS K, 1991, J MOL BIOL, V221, P55, DOI 10.1016/0022-2836(91)90803-E; GASSON JC, 1984, SCIENCE, V226, P1339, DOI 10.1126/science.6390681; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; JANIN J, 1976, J MOL BIOL, V100, P197, DOI 10.1016/S0022-2836(76)80148-9; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; MOONEN P, 1987, P NATL ACAD SCI USA, V84, P4428, DOI 10.1073/pnas.84.13.4428; MOORE MAS, 1991, ANNU REV IMMUNOL, V9, P159; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SAKAMOTO KM, 1991, J PEDIATR-US, V118, pS17, DOI 10.1016/S0022-3476(05)82185-7; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; SHANAFELT AB, 1989, P NATL ACAD SCI USA, V86, P4872, DOI 10.1073/pnas.86.13.4872; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	32	194	209	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1779	1782		10.1126/science.1837174	http://dx.doi.org/10.1126/science.1837174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1837174	Green Submitted			2022-12-28	WOS:A1991GW31600039
J	HARRINGTON, C; CASSEL, C; ESTES, CL; WOOLHANDLER, S; HIMMELSTEIN, DU				HARRINGTON, C; CASSEL, C; ESTES, CL; WOOLHANDLER, S; HIMMELSTEIN, DU			A NATIONAL LONG-TERM CARE PROGRAM FOR THE UNITED-STATES - A CARING VISION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH; FUTURE	The financing and delivery of long-term care (LTC) need substantial reform. Many cannot afford essential services; age restrictions often arbitrarily limit access for the nonelderly, although more than a third of those needing care are under 65 years old; Medicaid, the principal third-party payer for LTC, is biased toward nursing home care and discourages independent living; informal care provided by relatives and friends, the only assistance used by 70% of those needing LTC, is neither supported nor encouraged; and insurance coverage often excludes critically important services that fall outside narrow definitions of medically necessary care. We describe an LTC program designed as an integral component of the national health program advanced by Physicians for a National Health Program. Everyone would be covered for all medically and socially necessary services under a single public plan, federally mandated and funded but administered locally. An LTC payment board in each state would contract directly with providers through a network of local public agencies responsible for eligibility determination and care coordination. Nursing homes, home care agencies, and other institutional providers would be paid a global budget to cover all operating costs and would not bill on a per-patient basis. Alternatively, integrated provider organizations could receive a capitation fee to cover a broad range of LTC and acute care services. Individual practitioners could continue to be paid on a fee-for-service basis or could receive salaries from institutional providers. Support for innovation, training of LTC personnel, and monitoring of the quality of care would be greatly augmented. For-profit providers would be compensated for past investments and phased out. Our program would add between $18 billion and $23.5 billion annually to current spending on LTC. Polls indicate that a majority of Americans want such a program and are willing to pay earmarked taxes to support it.	HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,NATL HLTH PROGRAM,1493 CAMBRIDGE ST,CAMBRIDGE,MA 02139	Harvard University; Cambridge Health Alliance; Cambridge Hospital								BALL R, 1989, BECAUSE WERE ALL THI; BARKER WH, 1987, ADDING LIFE YEARS OR; BLENDON RJ, 1988, JAMA-J AM MED ASSOC, V259, P3587, DOI 10.1001/jama.259.24.3587; BLUMENTHAL D, 1988, RENEWING PROMISE MED; BODENHEIMER T, 1990, INT J HEALTH SERV, V20, P199, DOI 10.2190/DAKX-ULL1-R1EF-X5NR; CALLAHAN JJ, 1989, J AGING SOC POLICY, V1, P181; Campbell L J, 1987, Clin Geriatr Med, V3, P99; ESTES CL, 1989, GERONTOLOGIST, V29, P587, DOI 10.1093/geront/29.5.587; ESTES CL, 1990, LONG TERM CARE REQUI; ESTES CL, 1985, INT PERSPECTIVES LON, P315; ESTES CL, 1983, FISCAL AUSTERITY AGI; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; FIRMAN JP, 1988, PRIVATE LONG TERM CA; FREIDSON F, 1970, PROFESSIONAL DOMINAN; HARRINGTON C, 1985, LONG TERM CARE ELDER; HARRINGTON C, 1987, SOCIAL HLTH MAINTENA, pCH4; HARRIS L, 1988, MAJORITIES FAVOR PAS; HAWES C, 1986, FOR PROFIT ENTERPRIS, P492; HAZZARD WR, 1991, ANN INTERN MED, V115, P229, DOI 10.7326/0003-4819-115-3-229; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; HIMMELSTEIN DU, 1991, JAMA-J AM MED ASSOC, V266, P399, DOI 10.1001/jama.266.3.399; HOLAHAN J, 1989, MILBANK Q, V67, P137, DOI 10.2307/3350072; Institute of Medicine report, 1986, IMPROVING QUALITY CA; JUSTICE D, 1988, STATE LONG TERM CARE; KANE R, 1980, NEW ENGL J MED, V302, P1327, DOI 10.1056/NEJM198006123022402; Kane RA, 1987, LONG TERM CARE PRINC; KANE RL, 1991, NEW ENGL J MED, V324, P627, DOI 10.1056/NEJM199102283240910; Kane Robert L., 1985, WILL WAY WHAT US CAN; KUSSEROW RP, 1987, OA1018600010 US DEP; LAPLANTE MP, 1988, DATA DISABILITY NATI; LEVIT KR, 1988, HEALTH AFFAIR, V7, P124, DOI 10.1377/hlthaff.7.5.124; Liu K, 1985, Health Care Financ Rev, V7, P51; NEWCOMER RJ, 1989, 03283 US DEP HLTH HU; PRICE RJ, 1990, LONG TERM CARE ELDER; RIVLIN AM, 1988, CARING DISABLED ELDE; ROWE JW, 1987, NEW ENGL J MED, V316, P1425, DOI 10.1056/NEJM198705283162229; STONE R, 1987, GERONTOLOGIST, V27, P616, DOI 10.1093/geront/27.5.616; STONE R, 1986, NCHS ADV DATA, P124; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; ZAWADSKI RT, 1983, HOME HEALTH CARE SER, V4, P3; 1988, INTERSTUDYS LONG TER, P2; 1987, VITAL HLTH STAT 13, V97; 1987, MEDICARE MEDICAID ST; 1987, AM PUBLIC VIEWS LONG; 1990, CALL ACTION FINAL RE; 1989, ISSUES FINANCING DEL; 1986, HOSPITAL STATISTICS; 1989, DEV AGING 1988 REPOR, P1; 1990, HLTH MED SERVICES US; 1986, MEDIGAP INSURANCE LA; 1987, LONG TERM CARE C; 1987, NATIONAL HLTH EXPEND, V8, P1; 1988, INTERSTUDYS LONG TER, P1; 1989, PRIVATE LONG TERM CA; 1987, VITAL HLTH STAT 10, V166; 1988, SOURCE BOOK HLTH INS	56	25	25	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3023	3029		10.1001/jama.266.21.3023	http://dx.doi.org/10.1001/jama.266.21.3023			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GR775	1820477				2022-12-28	WOS:A1991GR77500037
J	GOODWIN, FK				GOODWIN, FK			TELLTALE NEUROTOXIN AND DEMENTIAS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,WASHINGTON,DC, USA.							1991, ANN NEUROL, V29, P202	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1619	1619						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1832194				2022-12-28	WOS:A1991GF41900005
J	ISHIJIMA, A; DOI, T; SAKURADA, K; YANAGIDA, T				ISHIJIMA, A; DOI, T; SAKURADA, K; YANAGIDA, T			SUB-PICONEWTON FORCE FLUCTUATIONS OF ACTOMYOSIN INVITRO	NATURE			English	Article							SINGLE KINESIN MOLECULES; ACTIN-FILAMENTS; MUSCLE-CONTRACTION; SLIDING FILAMENTS; MYOSIN; MOVEMENT; MECHANISM; MOTION; DIRECTION; VELOCITY	A new system has been developed for measuring the forces produced by a small number (< 5-150) of myosin molecules interacting with a single actin filament in vitro. The technique can resolve forces of less than a piconewton and has a time resolution in the submillisecond range. It can thus detect fluctuations of force caused by individual molecular interactions. From analysis of these force fluctuations, the coupling between the enzymatic ATPase activity of actomyosin and the resulting mechanical impulses can be elucidated.	OSAKA UNIV,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN; HONDA RES & DEV CO,WAKO RES CTR,WAKO,SAITAMA,JAPAN	Osaka University; Honda Motor Company			Yanagida, Toshio/D-1919-2009; Ishijima, Akihiko/F-4603-2012	Ishijima, Akihiko/0000-0002-8919-9268				BAGSHAW CR, 1990, J MUSCLE RES CELL M, V11, P533, DOI 10.1007/BF01745220; BAGSHAW CR, 1982, MUSCLE CONTRACTION; BERGER CL, 1989, P NATL ACAD SCI USA, V86, P8753, DOI 10.1073/pnas.86.22.8753; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BOREJDO J, 1977, BIOPHYS J, V20, P315, DOI 10.1016/S0006-3495(77)85552-5; BRENNER B, 1990, TOPICS MOL STRUCT BI, V13, P78; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; CRAWFORD AC, 1985, J PHYSIOL-LONDON, V364, P359, DOI 10.1113/jphysiol.1985.sp015750; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; EISENBERG E, 1980, ANNU REV PHYSIOL, V42, P293, DOI 10.1146/annurev.ph.42.030180.001453; FUJME S, 1985, J CELL BIOL, V101, P2335; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; IRVING M, 1985, NATURE, V316, P292, DOI 10.1038/316292a0; KAMIMURA S, 1989, NATURE, V340, P476, DOI 10.1038/340476a0; KATZ B, 1971, NATURE-NEW BIOL, V232, P124, DOI 10.1038/newbio232124b0; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KWAZUMI T, 1987, AM J PHYSIOL, V252, P253; LANDAU L, 1969, STATISTICAL PHYSICS, pCH4; LEE YW, 1969, STAT THEORY COMMUNIC, pCH8; MEISTER M, 1989, BIOPHYS J, V55, P904; MITSUI T, 1988, J MUSCLE RES CELL M, V9, P248, DOI 10.1007/BF01773895; OHNO T, IN PRESS J PHYOL; Oosawa F, 1986, Adv Biophys, V22, P151, DOI 10.1016/0065-227X(86)90005-5; Perrin F, 1934, J PHYS-PARIS, V5, P497, DOI 10.1051/jphysrad:01934005010049700; SELLERS JR, 1990, SCIENCE, V249, P406, DOI 10.1126/science.2377894; SPUDICH JA, 1990, NATURE, V348, P284, DOI 10.1038/348284a0; STEVENS CF, 1972, BIOPHYS J, V12, P1028, DOI 10.1016/S0006-3495(72)86141-1; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TONOMURA Y, 1986, ENERGY TRANSDUCING A; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I; YAMADA A, 1990, J BIOCHEM-TOKYO, V108, P341, DOI 10.1093/oxfordjournals.jbchem.a123203; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; YANAGIDA T, 1985, NATURE, V316, P369; YANOTOYOSHIMA Y, 1990, P NATL ACAD SCI USA, V87, P7130; YANOTOYOSHIMA Y, 1989, NATURE, V341, P154; YANOTOYOSHIMA Y, 1987, NATURE, V328, P536	49	228	230	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					301	306		10.1038/352301a0	http://dx.doi.org/10.1038/352301a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1830130				2022-12-28	WOS:A1991FY28900059
J	MUDRYJ, M; DEVOTO, SH; HIEBERT, SW; HUNTER, T; PINES, J; NEVINS, JR				MUDRYJ, M; DEVOTO, SH; HIEBERT, SW; HUNTER, T; PINES, J; NEVINS, JR			CELL-CYCLE REGULATION OF THE E2F TRANSCRIPTION FACTOR INVOLVES AN INTERACTION WITH CYCLIN-A	CELL			English	Article							DNA-BINDING ACTIVITY; ADENOVIRUS-INFECTED CELLS; SERUM RESPONSE ELEMENT; C-FOS GENE; TRANS-ACTIVATION; MESSENGER-RNA; E1A PROTEINS; E4 GENE; EXPRESSION; IDENTIFICATION	We have examined E2F binding activity in extracts of synchronized NIH 3T3 cells. During the GO to Gl transition, there is a marked increase in the level of active E2F. Subsequently, there are changes in the nature of E2F-containing complexes. A G1-specific complex increases in abundance, disappears, and is then replaced by another complex as S phase begins. Analysis of extracts of thymidine-blocked cells confirms that the complexes are cell cycle regulated. We also show that the cyclin A protein is a component of the S phase complex. Each complex can be dissociated by the adenovirus E1A 12S product, releasing free E2F. The release of E2F from the cyclin A complex coincides with the stimulation of an E2F-dependent promoter. We suggest that these interactions control the activity of E2F and that disruption of the complexes by E1A contributes to a loss of cellular proliferation control.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Salk Institute	MUDRYJ, M (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,GENET SECT,DURHAM,NC 27710, USA.			Pines, Jonathon/0000-0002-5227-6004; Devoto, Stephen/0000-0001-9513-3962	NCI NIH HHS [CA39780] Funding Source: Medline; NIGMS NIH HHS [GM26765] Funding Source: Medline; NINDS NIH HHS [NS08790] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS008790] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABISS LE, 1989, J VIROL, V63, P2709, DOI 10.1128/JVI.63.6.2709-2717.1989; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P43532; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; FELTCHER C, 1987, CELL, V51, P773; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GILMARTIN GM, 1988, GENE DEV, V2, P578, DOI 10.1101/gad.2.5.578; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NAGARAJAN M, 1989, EXP CELL RES, V181, P289, DOI 10.1016/0014-4827(89)90203-6; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	49	360	371	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1243	1253		10.1016/0092-8674(91)90019-U	http://dx.doi.org/10.1016/0092-8674(91)90019-U			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1829647				2022-12-28	WOS:A1991FU89900016
J	YUE, X; CONNOLLY, T; FUTCHER, B; BEACH, D				YUE, X; CONNOLLY, T; FUTCHER, B; BEACH, D			HUMAN D-TYPE CYCLIN	CELL			English	Article							MATURATION-PROMOTING FACTOR; CDC2+ PROTEIN-KINASE; HISTONE H-1 KINASE; SEA-URCHIN EGGS; FISSION YEAST; CELL-CYCLE; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; M-PHASE; SCHIZOSACCHAROMYCES-POMBE	A cDNA library prepared from a human glioblastoma cell line has been introduced into a budding yeast strain that lacks CLN1 and CLN2 and is conditionally deficient for CLN3 function. We rescued a gene that we call cyclin D1. It is related to A-, B-, and CLN-type cyclins, but appears to define a new subclass within the cyclin gene family. Transcription of the cyclin D1 gene gives rise to two major transcripts through alternative polyadenylation. The cyclin D1 gene transcript and its 34 kd product are both abundant in the glioblastoma cell line of origin.			YUE, X (corresponding author), COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA.				NIGMS NIH HHS [GM 45410, GM 39620] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045410, R01GM039620] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1990, P NATL ACAD SCI USA, V87, P4043, DOI 10.1073/pnas.87.11.4043; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BIRCHMEIER C, 1987, P NATL ACAD SCI USA, V84, P9270, DOI 10.1073/pnas.84.24.9270; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUTCHER B, 1986, MOL CELL BIOL, V6, P2213, DOI 10.1128/MCB.6.6.2213; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL M, 1988, CELL, V54, P739; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGAN I, 1988, J CELL SCI, V91, P587; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MOTOKURA T, 1991, IN PRESS NATURE; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nei M., 1987, MOL EVOLUTIONARY GEN, P287; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TACHIBANA K, 1990, DEV BIOL, V140, P241, DOI 10.1016/0012-1606(90)90074-S; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WHEELER EF, 1986, NATURE, V324, P377, DOI 10.1038/324377a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	64	737	791	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1991	65	4					691	699		10.1016/0092-8674(91)90100-D	http://dx.doi.org/10.1016/0092-8674(91)90100-D			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1827756				2022-12-28	WOS:A1991FM03700018
J	UENO, H; COLBERT, H; ESCOBEDO, JA; WILLIAMS, LT				UENO, H; COLBERT, H; ESCOBEDO, JA; WILLIAMS, LT			INHIBITION OF PDGF BETA-RECEPTOR SIGNAL TRANSDUCTION BY COEXPRESSION OF A TRUNCATED RECEPTOR	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; SWISS 3T3 CELLS; TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; INSULIN-RECEPTORS; HUMAN-FIBROBLASTS; ACTIVATION; BINDING; PROTEIN	A mutated form of the platelet-derived growth factor (PDGF) beta-receptor lacking most of its cytoplasmic domain was tested for its ability to block wild-type PDGF receptor function. PDGF induced the formation of complexes consisting of wild-type and truncated receptors. Such complexes were defective in autophosphorylation. When truncated receptors were expressed in excess compared to wild-type receptors, stimulation by PDGF of receptor autophosphorylation, association of phosphatidylinositol-3 kinase with the receptor, and calcium mobilization were blocked. Thus, a truncated receptor can inactivate wild-type receptor function by forming ligand-dependent receptor complexes (probably heterodimers) that are incapable of mediating the early steps of signal transduction.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	UENO, H (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [P01 HL-43821, R01 HL-32898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898, P01HL043821] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CHU SHW, 1985, J CELL PHYSIOL, V124, P391, DOI 10.1002/jcp.1041240306; COLBERT H, UNPUB; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRANTZ CN, 1985, EXP CELL RES, V158, P287, DOI 10.1016/0014-4827(85)90454-9; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KEATING MT, 1987, J BIOL CHEM, V262, P7932; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; UENO H, UNPUB; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	39	184	201	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					844	848		10.1126/science.1851331	http://dx.doi.org/10.1126/science.1851331			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1851331				2022-12-28	WOS:A1991FL12300047
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CORRECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Correction, Addition																		NIGHTINGALE SL, 1991, JAMA-J AM MED ASSOC, V265, P847, DOI 10.1001/jama.265.7.847	1	32	33	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1802	1802		10.1001/jama.265.14.1802	http://dx.doi.org/10.1001/jama.265.14.1802			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	1848642				2022-12-28	WOS:A1991FE86200004
J	CHAKRABORTY, M; CHATTERJEE, D; KELLOKUMPU, S; RASMUSSEN, H; BARON, R				CHAKRABORTY, M; CHATTERJEE, D; KELLOKUMPU, S; RASMUSSEN, H; BARON, R			CELL-CYCLE DEPENDENT COUPLING OF THE CALCITONIN RECEPTOR TO DIFFERENT G-PROTEINS	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; SALMON-CALCITONIN; KINASE-C; ISOLATED OSTEOCLASTS; ADENYLATE-CYCLASE; BINDING-SITES; HEART-CELLS; RAT-BRAIN; K+-ATPASE; PATHWAYS	Calcitonin is a calcium regulating peptide hormone with binding sites in kidney and bone as well as in the central nervous system. The mechanisms of signal transduction by calcitonin receptors were studied in a pig kidney cell line where the hormone was found to regulate sodium pumps. Calcitonin receptors activated the cyclic adenosine monophosphate (cAMP) or the protein kinase C (PKC) pathways. The two transduction pathways required guanosine triphosphate (GTP)-binding proteins (G proteins) (the choleratoxin sensitive G(s) and the pertussis toxin sensitive G(i), respectively) and led to opposite biological responses. Moreover, selective activation of one or the other pathway was cell cycle-dependent. Therefore, calcitonin may induce different biological responses in target cells depending on their positions in the cell cycle. Such a modulation of ligand-induced responses could be of importance in rapidly growing cell populations such as during embryogenesis, growth, and tumor formation.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT ORTHOPED,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE004724, R37DE004724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019813, R37DK019813] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-04724] Funding Source: Medline; NIDDK NIH HHS [DK-19813] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL N, 1986, AM J PHYSIOL, V251, pC825, DOI 10.1152/ajpcell.1986.251.5.C825; AITON JF, 1981, BRIT J PHARMACOL, V73, P333, DOI 10.1111/j.1476-5381.1981.tb10426.x; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; AZRIA M, 1989, CALCITONINS, P152; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220; BARON R, 1986, CELL, V46, P311, DOI 10.1016/0092-8674(86)90748-8; BERTORELLO A, 1989, AM J PHYSIOL, V256, pF370, DOI 10.1152/ajprenal.1989.256.2.F370; BLACK NB, 1980, AM J PHYSIOL, V238, pR406; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; CAMBARDIERE C, 1990, BIOCHEM BIOPH RES CO, V168, P65; CHAKRABORTY M, UNPUB; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHAMBERS TJ, 1982, J PATHOL, V136, P27, DOI 10.1002/path.1711360104; CHAMBERS TJ, 1983, J CLIN ENDOCR METAB, V57, P819, DOI 10.1210/jcem-57-4-819; CLEMENTI G, 1984, EUR J PHARMACOL, V98, P449, DOI 10.1016/0014-2999(84)90298-X; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DAYER JM, 1981, J CELL BIOL, V91, P195, DOI 10.1083/jcb.91.1.195; DOODS HN, 1987, J PHARMACOL EXP THER, V242, P257; DUNLAY R, 1990, AM J PHYSIOL, V258, pF223, DOI 10.1152/ajprenal.1990.258.2.F223; ENJALBERT A, 1986, J BIOL CHEM, V261, P4071; FINDLAY DM, 1980, CANCER RES, V40, P1311; FISCHER JA, 1981, LIFE SCI, V29, P663, DOI 10.1016/0024-3205(81)90018-7; FORBUSH B, 1979, BIOCHEMISTRY-US, V18, P2308, DOI 10.1021/bi00578a027; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HENKE H, 1985, BRAIN RES, V360, P165, DOI 10.1016/0006-8993(85)91232-6; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUNT NH, 1977, BRIT J CANCER, V35, P777, DOI 10.1038/bjc.1977.119; KRIEGER NS, 1980, PHARMACOL REV, V217, P586; KYTE J, 1976, J CELL BIOL, V68, P287, DOI 10.1083/jcb.68.2.287; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1989, J CELL SCI, V92, P131; MACINTYRE I, 1989, ENDOCRINOLOGY, P892; MARBACH I, 1988, EUR J BIOCHEM, V172, P239, DOI 10.1111/j.1432-1033.1988.tb13879.x; MCCALL D, 1979, AM J PHYSIOL, V236, pC87, DOI 10.1152/ajpcell.1979.236.1.C87; MIYATA Y, 1989, J BIOL CHEM, V264, P15565; MORGAN A, 1990, BIOCHEM J, V269, P521, DOI 10.1042/bj2690521; MUALLEM S, 1989, BIOCHEM J, V263, P769, DOI 10.1042/bj2630769; NAKAMUTA H, 1981, JPN J PHARMACOL, V31, P53, DOI 10.1254/jjp.31.53; NAKAMUTA H, 1987, FOLIA PHARMACOL JPN, V89, P191, DOI 10.1254/fpj.89.191; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; OTTE AP, 1989, CELL, V58, P641, DOI 10.1016/0092-8674(89)90099-8; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PECILE A, 1975, EXPERIENTIA, V31, P332, DOI 10.1007/BF01922569; PRALLET B, 1988, CALCIFIED TISSUE INT, V42, pA14; RIZZO AJ, 1981, ENDOCRINOLOGY, V108, P1672, DOI 10.1210/endo-108-5-1672; SCHOFIELD PR, 1990, TRENDS NEUROSCI, V13, P8, DOI 10.1016/0166-2236(90)90052-C; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TWERY MJ, 1982, PEPTIDES, V3, P749, DOI 10.1016/0196-9781(82)90010-9; TWERY MJ, 1988, EUR J PHARMACOL, V155, P285, DOI 10.1016/0014-2999(88)90515-8; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	57	134	135	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1078	1082		10.1126/science.1847755	http://dx.doi.org/10.1126/science.1847755			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1847755				2022-12-28	WOS:A1991EZ66500053
J	LEE, TH; SOLOMON, MJ; MUMBY, MC; KIRSCHNER, MW				LEE, TH; SOLOMON, MJ; MUMBY, MC; KIRSCHNER, MW			INH, A NEGATIVE REGULATOR OF MPF, IS A FORM OF PROTEIN PHOSPHATASE-2A	CELL			English	Article							MATURATION-PROMOTING FACTOR; XENOPUS-LAEVIS OOCYTES; RABBIT SKELETAL-MUSCLE; CYCLIN MESSENGER-RNA; CELL-CYCLE; OKADAIC ACID; CDC2 PROTEIN; CYTOPLASMIC FACTOR; KINASE; PURIFICATION	MPF, a protein kinase complex consisting of cyclin and p34cdc2 subunits, promotes the G2 to M phase transition in eukaryotic cells. The pathway of activation and inactivation of MPF is not well understood, although there is strong evidence that removal of phosphate from a tyrosine residue on p34cdc2 is part of the activation process. INH was originally identified as an activity that could inhibit the posttranslational activation of a latent form of MPF, called pre-MPF, in immature (G2 phase-arrested) Xenopus oocytes. We have purified INH and demonstrated that it is a form of protein phosphatase 2A. Both INH and the catalytic subunit of protein phosphatase 2A can directly inactivate an isolated p34cdc2-cyclin complex. Both cyclin and p34cdc2 become dephosphorylated; the rate of inactivation closely parallels the removal of phosphate from a specific site on p34cdc2. We propose that INH opposes MPF activation by reversing this critical phosphorylation.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LEE, TH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [HL 31107] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HERMANN J, 1988, EUR J BIOCHEM, V173, P17, DOI 10.1111/j.1432-1033.1988.tb13961.x; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MEIJER L, 1986, EXP CELL RES, V163, P489, DOI 10.1016/0014-4827(86)90079-0; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORIA AO, 1989, CELL, V58, P193; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PONDAVEN P, 1989, CR ACAD SCI III-VIE, V309, P563; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1	41	227	230	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 25	1991	64	2					415	423		10.1016/0092-8674(91)90649-J	http://dx.doi.org/10.1016/0092-8674(91)90649-J			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV336	1846321				2022-12-28	WOS:A1991EV33600017
J	HONDA, Z; NAKAMURA, M; MIKI, I; MINAMI, M; WATANABE, T; SEYAMA, Y; OKADO, H; TOH, H; ITO, K; MIYAMOTO, T; SHIMIZU, T				HONDA, Z; NAKAMURA, M; MIKI, I; MINAMI, M; WATANABE, T; SEYAMA, Y; OKADO, H; TOH, H; ITO, K; MIYAMOTO, T; SHIMIZU, T			CLONING BY FUNCTIONAL EXPRESSION OF PLATELET-ACTIVATING-FACTOR RECEPTOR FROM GUINEA-PIG LUNG	NATURE			English	Article							CDNA; GENE; ANTAGONIST; RHODOPSIN; SEQUENCE; FAMILY; CELLS	PLATELET-activating factor (PAF), a unique phospholipid mediator, possesses potent proinflammatory, smooth-muscle contractile and hypotensive activities, and appears to be crucial in the pathogenesis of bronchial asthma and in the lethality of endotoxin and anaphylactic shock1-3. Despite this, little is known of the molecular properties of the PAF receptor and related signal transduction systems. Although several lines of evidence suggest that activation of the PAF receptor stimulates phospholipase C and subsequent inositol trisphosphate formation through G protein(s)4,5, the PAF receptor and calcium channel are reported to show a close relation2,6. As a first approach to cloning lipid autacoid receptors, we have isolated complementary DNA for the PAF receptors. Our strategy involved gene expression in Xenopus laevis oocytes and electrophysiological detection of PAF-induced responses. Sequence analysis indicates that the receptor belongs to the superfamily of G protein-coupled receptors.	UNIV TOKYO,FAC MED,DEPT PHYSIOL CHEM & NUTR,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROBIOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED & PHYS THERAPY,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; University of Tokyo; University of Tokyo								BARZAGHI G, 1989, J PHARMACOL EXP THER, V248, P559; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; DENT G, 1989, EUR J PHARMACOL, V169, P313, DOI 10.1016/0014-2999(89)90029-0; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HAYASHI H, 1985, J BIOCHEM-TOKYO, V97, P1737, DOI 10.1093/oxfordjournals.jbchem.a135232; HWANG SB, 1986, J BIOL CHEM, V261, P532; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; KROEGEL C, 1989, FEBS LETT, V243, P41, DOI 10.1016/0014-5793(89)81214-1; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; OFLAHERTY JT, 1987, PLATELET ACTIVATING, P283; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; Sambrook J., 1989, MOL CLONING; SCHLONDORFF D, 1986, AM J PHYSIOL, V251, pF1, DOI 10.1152/ajprenal.1986.251.1.F1; SCHWERTSCHLAG US, 1988, J BIOL CHEM, V263, P13791; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SHEN TY, 1987, PLATELET ACTIVATING, P153; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; TERASAWA M, 1989, 3RD INT C PLAT ACT F, P10; TERASHITA ZI, 1987, J PHARMACOL EXP THER, V242, P263; TRAVERS JB, 1989, J IMMUNOL, V143, P3708	26	608	627	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					342	346		10.1038/349342a0	http://dx.doi.org/10.1038/349342a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1846231				2022-12-28	WOS:A1991EU50100057
J	ANIKSZTEJN, L; BENARI, Y				ANIKSZTEJN, L; BENARI, Y			NOVEL FORM OF LONG-TERM POTENTIATION PRODUCED BY A K+ CHANNEL BLOCKER IN THE HIPPOCAMPUS	NATURE			English	Article							SYNAPTIC TRANSMISSION; PYRAMIDAL CELLS; NMDA RECEPTORS; AFTER-HYPERPOLARIZATION; POTASSIUM CONDUCTANCES; LASTING POTENTIATION; NEURONS; CALCIUM; ANTAGONISTS; INVITRO	LONG-term potentiation (LTP) of synaptic transmission in the hippocampus is a widely studied model of memory processes1. In the CA1 region, LTP is triggered by the entry of CA2+ through N-methyl-D-aspartate (NMDA) receptor channels and maintained by the activation of CA2+-sensitive intracellular messengers2,3. We now report that in CA1, a transient block by tetraethylammonium of I(C), I(M) and the delayed rectifier (I(K)) produces a Ca2+-dependent NMDA-independent form of LTP. Our results suggest that this new form of LTP (referred as to LTP(K)) is induced by a transient enhanced release of glutamate which generates a depolarization by way of the non-NMDA receptors and the consequent activation of voltage -dependent Ca2+ channels.			ANIKSZTEJN, L (corresponding author), HOP PORT ROYAL,INSERM,U29,123 BLVD PORT ROYAL,F-75014 PARIS,FRANCE.		Aniksztejn, Laurent/E-2072-2017	Aniksztejn, laurent/0000-0001-9215-1698; Ben-Ari, Yehezkel/0000-0001-6208-8480				ANDERSEN P, 1980, J PHYSIOL-LONDON, V302, P463; BLAKE JF, 1988, NEUROSCI LETT, V89, P182, DOI 10.1016/0304-3940(88)90378-3; BROWN DA, 1983, J PHYSIOL-LONDON, V337, P303, DOI 10.1113/jphysiol.1983.sp014625; CHERUBINI E, 1987, NATURE, V328, P70, DOI 10.1038/328070a0; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; GHO M, 1986, BRAIN RES, V385, P411, DOI 10.1016/0006-8993(86)91093-0; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; HIGASHI H, 1990, NEUROSCIENCE, V34, P35, DOI 10.1016/0306-4522(90)90302-K; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KESSLER M, 1989, BRAIN RES, V489, P377, DOI 10.1016/0006-8993(89)90875-5; KRNJEVIC K, 1989, J NEUROPHYSIOL, V62, P896, DOI 10.1152/jn.1989.62.4.896; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P241; MALENKA RC, 1989, TRENDS NEUROSCI, V12, P444, DOI 10.1016/0166-2236(89)90094-5; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, NATURE, V309, P262; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NEUMAN RS, 1988, NEUROSCI LETT, V92, P64, DOI 10.1016/0304-3940(88)90743-4; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; SEGAL M, 1984, J NEUROPHYSIOL, V51, P1409, DOI 10.1152/jn.1984.51.6.1409; SOTRM JF, 1990, PROG BRAIN RES, V83, P161; STORM JF, 1989, J PHYSIOL-LONDON, V409, P171, DOI 10.1113/jphysiol.1989.sp017491; STORM JF, 1987, J PHYSIOL-LONDON, V385, P733, DOI 10.1113/jphysiol.1987.sp016517; STORM JF, 1988, NATURE, V336, P379, DOI 10.1038/336379a0; STURGESS NC, 1985, LANCET, V2, P474; TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WIGSTROM H, 1985, ACTA PHYSIOL SCAND, V125, P159, DOI 10.1111/j.1748-1716.1985.tb07703.x; WRIGHT J M, 1988, Society for Neuroscience Abstracts, V14, P1046	33	254	259	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					67	69		10.1038/349067a0	http://dx.doi.org/10.1038/349067a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1845914				2022-12-28	WOS:A1991EQ60100052
J	BRENT, DA; PERPER, JA; ALLMAN, CJ; MORITZ, GM; WARTELLA, ME; ZELENAK, JP				BRENT, DA; PERPER, JA; ALLMAN, CJ; MORITZ, GM; WARTELLA, ME; ZELENAK, JP			THE PRESENCE AND ACCESSIBILITY OF FIREARMS IN THE HOMES OF ADOLESCENT SUICIDES - A CASE-CONTROL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUN-CONTROL LAWS; RISK-FACTORS; CHILDREN; RELIABILITY; DISORDERS; DIAGNOSIS	Objective. - The presence of guns in the home, the type of gun, and the method of storage were all hypothesized to be associated with risk for adolescent suicide. Design. - Case-control study. Subjects. - The case group consisted of 47 adolescent suicide victims. The two psychiatric inpatient control groups were 47 suicide attempters and 47 never-suicidal psychiatric controls, frequency-matched to the suicide victims on age, gender, and county of origin. Setting. - The cases were a consecutive community sample, whereas the inpatients were drawn from a university psychiatric hospital. Main Outcome Measure. - Odds of the presence of guns in the home of suicide victims (cases) relative to controls. Results. - Guns were twice as likely to be found in the homes of suicide victims as in the homes of attempters (adjusted odds ratio, 2.1; 95% confidence interval, 1.2 to 3.7) or psychiatric controls (adjusted odds ratio, 2.2; 95% confidence interval, 1.4 to 3.5). Handguns were not associated with suicide to any statistically significantly greater extent than long guns. There was no difference in the methods of storage of firearms among the three groups, so that even guns stored locked, or separate from ammunition, were associated with suicide by firearms. Conclusions. - The availability of guns in the home, independent of firearms type or method of storage, appears to increase the risk for suicide among adolescents. Physicians should make a clear and firm recommendation that firearms be removed from the homes of adolescents judged to be at suicidal risk.	ALLEGHENY CTY CORONERS OFF,PITTSBURGH,PA; ST FRANCIS MED CTR,PITTSBURGH,PA		BRENT, DA (corresponding author), WESTERN PSYCHIAT INST & CLIN,SERV TEENS RISK,3811 OHARA ST,PITTSBURGH,PA 15213, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH000581] Funding Source: NIH RePORTER; NIMH NIH HHS [K08 MH00581-01] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDREASEN NC, 1986, ARCH GEN PSYCHIAT, V43, P421; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Beck A.T., 1974, DEV SUICIDAL INTENT; BOYD JH, 1986, AM J PUBLIC HEALTH, V308, P872; BRENT DA, 1987, J AM ACAD CHILD PSY, V26, P87, DOI 10.1097/00004583-198701000-00017; BRENT DA, 1988, ARCH GEN PSYCHIAT, V45, P581, DOI 10.1001/archpsyc.1988.01800300079011; BRENT DA, 1987, JAMA-J AM MED ASSOC, V257, P3369, DOI 10.1001/jama.257.24.3369; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; Hollingshead A.B., 1975, 4 FACTOR INDEX SOCIA; KELLERMANN AL, 1990, AM J EPIDEMIOL, V131, P1080, DOI 10.1093/oxfordjournals.aje.a115600; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; KUPERMAN S, 1988, ARCH GEN PSYCHIAT, V45, P277; LESTER D, 1982, SUICIDE LIFE-THREAT, V12, P131; LESTER D, 1980, AM J PSYCHIAT, V137, P121; MARKUSH RE, 1984, AM J PUBLIC HEALTH, V74, P123, DOI 10.2105/AJPH.74.2.123; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; OTTO U, 1972, ACTA PSYCHIATR SCA S, V233; PATTERSON PJ, 1987, AM J DIS CHILD, V141, P221, DOI 10.1001/archpedi.1987.04460020111042; RICH CL, 1990, AM J PSYCHIAT, V147, P342; RICH CL, 1986, ARCH GEN PSYCHIAT, V43, P577; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SHAFFER D, 1988, J CLIN PSYCHIAT, V49, P36; SHAFII M, 1988, J AFFECT DISORDERS, V15, P227, DOI 10.1016/0165-0327(88)90020-1; SLOAN JH, 1990, NEW ENGL J MED, V322, P369, DOI 10.1056/NEJM199002083220605; WELNER A, 1979, ARCH GEN PSYCHIAT, V36, P689; 1980, DIAGNOSTIC STATISTIC	26	349	351	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2989	2995		10.1001/jama.266.21.2989	http://dx.doi.org/10.1001/jama.266.21.2989			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GR775	1820470				2022-12-28	WOS:A1991GR77500029
J	SACKS, JJ; HOLMGREEN, P; SMITH, SM; SOSIN, DM				SACKS, JJ; HOLMGREEN, P; SMITH, SM; SOSIN, DM			BICYCLE-ASSOCIATED HEAD-INJURIES AND DEATHS IN THE UNITED-STATES FROM 1984 THROUGH 1988 - HOW MANY ARE PREVENTABLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							HELMET USE; SAFETY HELMETS; CHILDREN; ACCIDENTS; VICTORIA	Objective. - To estimate the potential benefits from more widespread bicycle safety helmet use. Design. - Review of death certificates and emergency department injury data for 1984 through 1988. Categorization of deaths and injuries as related to bicycling and head injury Using relative risks of 3.85 and 6.67 derived from a case-control study and varying helmet usage from 10% to 100%, population attributable risk was calculated to estimate preventable deaths and injuries. Setting. - Entire United States. Main Outcome Measures. - Numbers of US residents coded as dying from bicycle-related head injuries, numbers of persons presenting to emergency departments for bicycle-related head injuries, and numbers of attributable bicycle-related deaths and head injuries. Main Results. - From 1984 through 1988, bicycling accounted for 2985 head injury deaths (62% of all bicycling deaths) and 905 752 head injuries (32% of persons with bicycling injuries treated at an emergency department). Forty-one percent of head injury deaths and 76% of head injuries occurred among children less than 15 years of age. Universal use of helmets by all bicyclists could have prevented as many as 2500 deaths and 757 000 head injuries, ie, one death every day and one head injury every 4 minutes. Conclusions. - Effective community-based education programs and legislated approaches for increasing bicycle safety helmet usage have been developed and await only the resources and commitment to reduce these unnecessary deaths and injuries.	CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	SACKS, JJ (corresponding author), CTR DIS CONTROL,NATL CTR ENVIRONM HLTH INJURY CONTROL,DIV INJURY CONTROL F36,ATLANTA,GA 30333, USA.							Bishop P J, 1984, Can J Appl Sport Sci, V9, P94; BUCCINI RV, 1987, OCT AM PUBL HLTH ASS; BUNTAIN WL, 1985, 29TH P ANN M AM ASS, P307; DIGUISEPPI CG, 1989, JAMA-J AM MED ASSOC, V262, P2256, DOI 10.1001/jama.262.16.2256; DORSCH MM, 1987, ACCIDENT ANAL PREV, V19, P183, DOI 10.1016/0001-4575(87)90002-9; FIFE D, 1983, J TRAUMA, V23, P745, DOI 10.1097/00005373-198308000-00011; FLORA JD, 1979, J SAFETY RES, V11, P20; FRIEDE AM, 1985, PEDIATR CLIN N AM, V32, P141; Hodgson V.R., 1990, IMPACT SKID RETENTIO; LUNDAR T, 1985, CHILD NERV SYST, V1, P24, DOI 10.1007/BF00706726; MCDERMOTT FT, 1985, AUST NZ J SURG, V55, P477, DOI 10.1111/j.1445-2197.1985.tb00926.x; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P38; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; WASSERMAN RC, 1988, AM J PUBLIC HEALTH, V78, P1220, DOI 10.2105/AJPH.78.9.1220; WASSERMAN RC, 1990, AM J SPORT MED, V18, P96, DOI 10.1177/036354659001800116; WEISS BD, 1986, PEDIATRICS, V77, P677; WEISS BD, 1986, AM J PUBLIC HEALTH, V76, P1022, DOI 10.2105/AJPH.76.8.1022; WEISS BD, 1987, AM J DIS CHILD, V141, P135, DOI 10.1001/archpedi.1987.04460020025018; WILLIAMS M, 1991, ACCIDENT ANAL PREV, V23, P119, DOI 10.1016/0001-4575(91)90043-5; WOOD T, 1988, ACCIDENT ANAL PREV, V20, P177, DOI 10.1016/0001-4575(88)90002-4; 1984, VITAL STATISTICS MOR; 1987, MMWR, V36, P269; 1986, INTERCENSAL POPULATI, P38; 1990, CONSUMER REP     MAY, P348; 1977, MANUAL INT CLASSIFIC	29	132	132	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3016	3018		10.1001/jama.266.21.3016	http://dx.doi.org/10.1001/jama.266.21.3016			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GR775	1820476				2022-12-28	WOS:A1991GR77500035
J	ABRUTYN, E; BERLIN, JA				ABRUTYN, E; BERLIN, JA			INTRATHECAL THERAPY IN TETANUS - A METAANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MUHIMBILI-MEDICAL-CENTRE; DAR-ES-SALAAM; NEONATAL TETANUS; SERUM HORSE; IMMUNOGLOBULIN; SEROTHERAPY; EXPERIENCE; TRIAL	Objective. - To assess the efficacy of intrathecal therapy with tetanus antibody (antitetanus equine serum or human tetanus immune globulin) in neonatal and adult tetanus using meta-analytical techniques. Data Sources. - Clinical trials identified by searching MEDLINE and by reviewing bibliographies of published articles. Study Selection. - Studies in English with concurrent controls treated without intrathecal therapy Data Extraction. - Data were extracted by one author and verified by the second; conflicts were resolved by discussion. Data Synthesis. - No major treatment effect was found in neonatal tetanus when all studies were considered. A benefit was suggested for antitetanus equine serum in adult disease, but this finding should be accepted with caution. Subgroup analyses were limited in power. Methodological difficulties in neonatal and adult trials were common and safety has not been established. Conclusions. - Intrathecal therapy for tetanus with either antitetanus equine serum or human tetanus immune globulin is not of proven benefit and should only be given in the context of well-designed, controlled trials.	UNIV PENN,SCH MED,GEN INTERNAL MED SECT,CLIN EPIDEMIOL UNIT,PHILADELPHIA,PA 19104	University of Pennsylvania	ABRUTYN, E (corresponding author), MED COLL PENN,VET AFFAIRS MED CTR,INFECT DIS SECT,UNIV & WOODLAND AVE,PHILADELPHIA,PA 19129, USA.							BEAGUE RE, 1991, J INFECT DIS, V164, P419; BEGG CB, 1989, J NATL CANCER I, V81, P107, DOI 10.1093/jnci/81.2.107; BHANDARI B, 1980, INDIAN J MED RES, V72, P685; CHOPRA K, 1986, Indian Pediatrics, V23, P775; CHOPRA K, 1988, Indian Pediatrics, V25, P530; CHUGH K, 1985, Indian Pediatrics, V22, P153; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; GULTEKIN A, 1988, TURKISH J PEDIATR, V30, P9; GUPTA PS, 1980, LANCET, V2, P439; GUPTA PS, 1980, CLINICIAN, V44, P127; HENDRICKSE RG, 1981, PAEDIATRICS TROPICS; Ildirim I, 1967, Turk J Pediatr, V9, P89; Ildirim I, 1974, Turk J Pediatr, V16, P103; Keswani N K, 1980, J Indian Med Assoc, V75, P67; KHAN AA, 1978, MED J ZAMBIA, V12, P121; Light Richard J, 1984, SUMMING UP; Mar I D, 1978, Bull Soc Med Afr Noire Lang Fr, V23, P393; MBISE RL, 1984, E AFR MED J, V61, P892; MONGI PS, 1987, ANN TROP PAEDIATR, V7, P27, DOI 10.1080/02724936.1987.11748469; NEEQUAYE J, 1983, ARCH DIS CHILD, V58, P276, DOI 10.1136/adc.58.4.276; OGATUTI P, 1980, Papua New Guinea Medical Journal, V23, P179; ONUORA CA, 1982, E AFR MED J, V59, P52; PATEL J C, 1959, Indian J Med Sci, V13, P834; PAUL S S, 1984, Indian Pediatrics, V21, P689; SANDERS RKM, 1977, LANCET, V1, P974; SEDAGHATIAN MR, 1979, ARCH DIS CHILD, V54, P623, DOI 10.1136/adc.54.8.623; SINGH AK, 1980, ARCH DIS CHILD, V55, P527, DOI 10.1136/adc.55.7.527; Singh G, 1989, J Indian Med Assoc, V87, P8; SUTTER RW, 1990, AM J EPIDEMIOL, V131, P132, DOI 10.1093/oxfordjournals.aje.a115466; THOMAS PP, 1982, T ROY SOC TROP MED H, V76, P620, DOI 10.1016/0035-9203(82)90224-3; VAKIL BJ, 1979, T ROY SOC TROP MED H, V73, P579, DOI 10.1016/0035-9203(79)90058-0; YONG FY, 1983, MED J MALAYSIA, V38, P74; 1986, 39TH WORLD HLTH ASS	33	35	39	2	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2262	2267		10.1001/jama.266.16.2262	http://dx.doi.org/10.1001/jama.266.16.2262			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK661	1833565				2022-12-28	WOS:A1991GK66100036
J	KAPELRUD, H; BANGSTAD, HJ; DAHLJORGENSEN, K; BERG, K; HANSSEN, KF				KAPELRUD, H; BANGSTAD, HJ; DAHLJORGENSEN, K; BERG, K; HANSSEN, KF			SERUM LP(A) LIPOPROTEIN CONCENTRATIONS IN INSULIN-DEPENDENT DIABETIC-PATIENTS WITH MICROALBUMINURIA	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; URINARY ALBUMIN EXCRETION; APOLIPOPROTEIN-B; RISK-FACTORS; NEPHROPATHY; TYPE-1; PLASMA; PROTEINURIA; CHOLESTEROL; MELLITUS	Objective - To compare the serum concentrations of lipoproteins and apolipoproteins in insulin dependent diabetic patients with and without microalbuminuria. Design - Cross sectional study. Setting - Paediatric and medical outpatient clinic at a university hospital. Patients - 76 insulin dependent diabetic patients: 41 with microalbuminuria (20 males, 21 females) and 35 controls without microalbuminuria (18 males, 17 females). The two groups were similar with respect to age, duration of disease, and haemoglobin A1c concentrations before the study. Main outcome measures - Serum concentrations of Lp(a) lipoprotein, total cholesterol, high density lipoprotein cholesterol, very low density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, and apolipoproteins A-I, A-II, and B. Results - Median serum Lp(a) lipoprotein concentration was 10.0 mg/100 ml in the microalbuminuric group and 4.9 mg/100 ml in the control group (p = 0.007). 17 (41%) of the microalbuminuric patients and five (14%) of the control patients had Lp(a) lipoprotein values above the upper quartile of a normal population. Median serum triglycerides concentrations in the microalbuminuric and control groups were 1.15 mmol/l and 0.88 mmol/l respectively (p = 0.03). Median very low density lipoprotein cholesterol concentration was 0.52 mmol/l in the microalbuminuric group and 0.40 mmol/l in the control group (p = 0.03). No significant differences in serum concentrations of total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, or apolipoproteins A-I, A-II, and B were found between the groups. Conclusions - Serum concentrations of Lp(a) lipoprotein are twice as high in insulin dependent diabetic patients with microalbuminuria as in those without microalbuminuria. Increased concentrations of Lp(a) lipoprotein might partly explain the increased morbidity and mortality from cardiovascular disease observed among patients with diabetic nephropathy.	AKER UNIV HOSP,N-0514 OSLO 5,NORWAY; UNIV OSLO,INST MED GENET,N-0315 OSLO 3,NORWAY	University of Oslo; University of Oslo								ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; ARAUZ C, 1990, DIABETES S1, V39, pA64; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; BERG K, 1974, CLIN GENET, V6, P230; BERG K, 1990, FROM PHENOTYPE TO GENE IN COMMON DISORDERS, P138; Berg K., 1990, LIPOPROTEIN A, P1; BERG K, 1983, PROGR MED GENETICS, P35; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; BROWN MS, 1987, NATURE, V330, P113, DOI 10.1038/330113a0; COOPER ME, 1988, DIABETIC MED, V5, P361, DOI 10.1111/j.1464-5491.1988.tb01006.x; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; DAHLJORGENSEN K, 1988, ACTA ENDOCRINOL-COP, V117, P19, DOI 10.1530/acta.0.1170019; DAHLJORGENSEN K, 1990, DIABETES S1, V39, pA16; DAVIDHOFF E, 1989, DIABETES S2, V38, pA70; DECKERT T, 1989, DIABETOLOGIA, V32, P219, DOI 10.1007/BF00285287; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FRICK MH, 1978, CHEST, V73, P62, DOI 10.1378/chest.73.1.62; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P265, DOI 10.1161/01.ATV.5.3.265; JENSEN T, 1988, DIABETOLOGIA, V31, P142, DOI 10.1007/BF00276846; JENSEN T, 1987, DIABETOLOGIA, V30, P144, DOI 10.1007/BF00274218; JENSEN T, 1989, LANCET, V1, P461; JONES SL, 1989, BRIT MED J, V298, P487, DOI 10.1136/bmj.298.6672.487; MASAREI JRL, 1984, AM J CLIN NUTR, V40, P468, DOI 10.1093/ajcn/40.3.468; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MORTON N E, 1985, Genetic Epidemiology, V2, P113, DOI 10.1002/gepi.1370020202; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROSCHLAU P, 1974, Z KLIN CHEM KLIN BIO, V12, P403; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SCHRIEWER H, 1984, J CLIN CHEM CLIN BIO, V22, P591; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; SIMON DI, 1990, CIRCULATION, V82, P599; VANNINI P, 1984, DIABETES CARE, V7, P151, DOI 10.2337/diacare.7.2.151; WAHLEFELD AW, 1974, METHOD ENZYMAT AN, P1831	38	123	127	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					675	678		10.1136/bmj.303.6804.675	http://dx.doi.org/10.1136/bmj.303.6804.675			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1833011	Green Published, Bronze			2022-12-28	WOS:A1991GG98000018
J	GITTER, MJ; GOLDSMITH, SR; DUNBAR, DN; SHARKEY, SW				GITTER, MJ; GOLDSMITH, SR; DUNBAR, DN; SHARKEY, SW			COCAINE AND CHEST PAIN - CLINICAL-FEATURES AND OUTCOME OF PATIENTS HOSPITALIZED TO RULE OUT MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article							ABUSE; ISCHEMIA	Objective: To investigate the clinical features, electrocardiographic findings, and hospital course in patients admitted with acute chest pain temporally related to cocaine use. Design: Retrospective data analysis. Setting: A 485-bed county hospital. Patients: One hundred and one consecutive patients with cocaine-related chest pain admitted to the hospital to rule out myocardial infarction. Measurements and Main Results: The quality of the chest pain frequently suggested myocardial ischemia. Dyspnea was common (56%). The onset of chest pain occurred during cocaine use in 21% of patients, within 1 hour of use in 37%, and after 1 hour of use in 42%. Admission electrocardiographic findings were interpreted as normal in 32% of patients; as acute myocardial injury in 8%; as early repolarization variant in 32%; as left ventricular hypertrophy in 16%; and as "other" in 12%. Forty-three percent of patients had ST-segment elevation meeting the electrocardiographic criteria for use of thrombolytic therapy, but such elevation was usually due to the early repolarization variant. The initial total creatine kinase was elevated more than 3.3-mu-kat/L (200 U/L) in 43% of patients, and an elevated total creatine kinase was recorded at some time during the hospital course in 47% of patients. The creatine kinase MB fraction was less than 0.02 in all patients. Myocardial infarction was ruled out in all patients. No patient experienced in-hospital cardiovascular complications. Conclusion: The quality of acute chest pain related to cocaine use is indistinguishable from that experienced in acute myocardial ischemia. Abnormal or normal variant electrocardiographic findings are common in patients with chest pain related to cocaine use, but nevertheless the incidence of acute myocardial infarction is low. The ST-segment and T-wave changes can mimic acute myocardial injury and are most likely normal findings in young black men that can be readily recognized in the emergency department. Most of these patients do not require admission to an intensive	HENNEPIN CTY MED CTR, DIV CARDIOL, 701 PK AVE, MINNEAPOLIS, MN 55415 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities								AMIN M, 1990, AM J CARDIOL, V66, P1434, DOI 10.1016/0002-9149(90)90529-A; BLACKMAN NS, 1964, AM HEART J, V67, P304, DOI 10.1016/0002-8703(64)90004-3; BRODY SL, 1990, AM J MED, V88, P325, DOI 10.1016/0002-9343(90)90484-U; CHELTON LG, 1955, AM J MED SCI, V230, P54, DOI 10.1097/00000441-195507000-00008; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; CREGLER LL, 1985, AM J CARDIOL, V56, P794, DOI 10.1016/0002-9149(85)91140-3; GOLDBERGER AL, 1980, MOD CONC CARDIOV DIS, V49, P13; GOLDBERGER AL, 1984, MYOCARDIAL INFARCTIO, P167; GOLDMAN MJ, 1953, AM HEART J, V46, P817, DOI 10.1016/0002-8703(53)90080-5; HERZLICH BC, 1988, ANN INTERN MED, V109, P335, DOI 10.7326/0003-4819-109-4-335; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; LANGE RA, 1989, NEW ENGL J MED, V321, P1557, DOI 10.1056/NEJM198912073212301; LANGE RA, 1990, CARDIOLOGY, V8, P74; LEE TH, 1986, ANN INTERN MED, V105, P221, DOI 10.7326/0003-4819-105-2-221; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LEE TH, 1987, ANN INTERN MED, V106, P181, DOI 10.7326/0003-4819-106-2-181; LITTMANN D, 1946, AM HEART J, V32, P370, DOI 10.1016/0002-8703(46)90797-1; MATHIAS DW, 1986, AM J MED, V81, P675, DOI 10.1016/0002-9343(86)90556-5; OSHER HL, 1953, AM J MED SCI, V226, P541, DOI 10.1097/00000441-195322650-00011; PASCUALLEONE A, 1990, NEUROLOGY, V40, P404, DOI 10.1212/WNL.40.3_Part_1.404; PASTERNACK PF, 1985, AM J CARDIOL, V55, P847, DOI 10.1016/0002-9149(85)90172-9; ROTH D, 1988, NEW ENGL J MED, V319, P673, DOI 10.1056/NEJM198809153191103; RUBIN RB, 1989, AM J MED, V86, P551, DOI 10.1016/0002-9343(89)90383-5; SMITH HWB, 1987, ANN INTERN MED, V107, P13, DOI 10.7326/0003-4819-107-1-13; THOMAS J, 1960, AM J CARDIOL, V5, P468, DOI 10.1016/0002-9149(60)90102-8; Thompson WP, 1943, AM HEART J, V25, P372, DOI 10.1016/S0002-8703(43)90831-2; TOKARSKI GF, 1990, ANN EMERG MED, V19, P1088, DOI 10.1016/S0196-0644(05)81509-4; WIENER L, 1964, AM HEART J, V67, P684, DOI 10.1016/0002-8703(64)90340-0; ZIMMERMAN FH, 1987, J AM COLL CARDIOL, V9, P964, DOI 10.1016/S0735-1097(87)80256-5	29	96	99	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					277	282		10.7326/0003-4819-115-4-277	http://dx.doi.org/10.7326/0003-4819-115-4-277			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854111				2022-12-28	WOS:A1991GA76400006
J	KOMIYAMA, NH; SHIH, DTB; LOOKER, D; TAME, J; NAGAI, K				KOMIYAMA, NH; SHIH, DTB; LOOKER, D; TAME, J; NAGAI, K			WAS THE LOSS OF THE D-HELIX IN ALPHA-GLOBIN A FUNCTIONALLY NEUTRAL MUTATION	NATURE			English	Article							ESCHERICHIA-COLI; HEMOGLOBIN; EXPRESSION; SEQUENCES; MYOGLOBIN	PROTEINS in the globin family are found in a variety of species from bacteria to man 1-3. From the many globin sequences known, evolutionary trees have been constructed showing that alpha and beta-globins diverged from a common ancestor between 425 and 500 million years ago, after vertebrate species had appeared and roughly when sharks and bony vertebrates diverged 4-6. The alpha and beta-globins assemble to form tetrameric haemoglobin, alpha-2-beta-2, which can switch between quaternary states having high and low oxygen affinity 7. This allows the protein to bind oxygen cooperatively and therefore efficiently transport oxygen from the lungs to respiring tissues. The alpha and beta-globins have closely related tertiary structures, being alpha-helical proteins with similar haem-binding sites. Most globins consist of eight helices, designated A to H from the N terminus, connected by short nonhelical segments, but all known vertebrate alpha-globins lack a D helix. Because the loss of this helix by alpha-globin occurred shortly before tetrameric haemoglobin appeared, it might be a functionally important mutation required for a tetramer assembly or allostery. We have now tested this idea by engineering human haemoglobins containing beta-subunits without a D helix and alpha-subunits with a D helix. Both of these mutations have little effect on the oxygen-binding properties of the molecule. Thus it is possible that deletion of the D helix in the alpha-subunit was caused by a neutral mutation 8.	MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND; OREGON HLTH SCI UNIV,DEPT BIOCHEM,PORTLAND,OR 97201; STOMATOGEN INC,BOULDER,CO 80301	MRC Laboratory Molecular Biology; Oregon Health & Science University				Tame, Jeremy/0000-0002-9341-7280				ARUTYUNYAN EG, 1980, SOV PHYS-CRYSTALLOGR, V25, P43; ASCHAUER H, 1985, BIOL CHEM H-S, V366, P589, DOI 10.1515/bchm3.1985.366.1.589; BRAUNITZER G, 1961, H-S Z PHYSIOL CHEM, V325, P283, DOI 10.1515/bchm2.1961.325.1.283; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V0005; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; DODSON G, 1988, PROTEIN ENG, V2, P233, DOI 10.1093/protein/2.3.233; FERMI G, 1981, ATLAS MOL STRUCTURES, V2; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; HUBER R, 1971, EUR J BIOCHEM, V19, P42, DOI 10.1111/j.1432-1033.1971.tb01285.x; Imai K, 1981, Methods Enzymol, V76, P438; KENDREW JC, 1960, NATURE, V185, P422, DOI 10.1038/185422a0; KIMURA M, 1979, SCI AM, V241, P94; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P579; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; LOVE WA, 1973, J MOL BIOL, V74, P331; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; PADLAN EA, 1974, J BIOL CHEM, V249, P4067; PERUTZ MF, 1983, MOL BIOL EVOL, V1, P1; PERUTZ MF, 1990, MECHANISMS COOPERATI; ROYER WE, 1989, J BIOL CHEM, V264, P21052; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; 1985, HEMOGLOBIN, V9, P229	22	21	21	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					349	351		10.1038/352349a0	http://dx.doi.org/10.1038/352349a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852211				2022-12-28	WOS:A1991FY28900076
J	SHEIKH, KH; DAVIDSON, CJ; NEWMAN, GE; KISSLO, KB; SCHWAB, SJ				SHEIKH, KH; DAVIDSON, CJ; NEWMAN, GE; KISSLO, KB; SCHWAB, SJ			INTRAVASCULAR ULTRASOUND ASSESSMENT OF THE RENAL-ARTERY	ANNALS OF INTERNAL MEDICINE			English	Article						RENAL ARTERY; HYPERTENSION; ANGIOPLASTY; ANGIOGRAPHY; ULTRASONOGRAPHY	RENOVASCULAR HYPERTENSION; ANGIOPLASTY; DISEASE; SIZE	Objective: To determine the feasibility and diagnostic value of catheter-based intravascular ultrasound imaging compared with angiography for visualizing renal artery structure. Design: Renal artery images were obtained in patients with renal artery stenosis having percutaneous balloon angioplasty and in normal subjects by digital angiography and by a 20-MHz, mechanically driven, catheter-based, intravascular ultrasound imaging system. Setting. A referral-based university hospital. Patients: Four randomly selected normal subjects without known renal disease and four consecutive patients with known renal artery stenosis referred for percutaneous balloon angioplasty. Interventions: Digital angiograms and intravascular ultrasound images of nine renal artery segments were obtained. In patients with renal artery stenosis, imaging was done before and after balloon angioplasty. Main Results: Digital angiography and ultrasonography correlated closely in the determination of arterial lumen diameter (r = 0.81) and cross-sectional area (r = 0.83). However, ultrasonography provided structural information not shown by angiography. All normal arteries showed discrete intimal, medial, and adventitial wall layers by ultrasonography. In the five stenotic segments, angiography identified the cause of stenosis to be atherosclerosis in four patients and fibromuscular dysplasia in one patient. Ultrasound imaging, however, identified the disease process as atherosclerosis in three patients and as fibromuscular dysplasia in two patients. After renal angioplasty, ultrasonography identified three arterial dissections, only one of which was shown by angiography. Conclusions: These preliminary data indicate that catheter-based intravascular ultrasound imaging of the renal artery is feasible and correlates well with angiography in assessing renal artery size and also provides potentially important additional structural information that permits a better characterization of arterial pathology.	DUKE UNIV, MED CTR, DURHAM, NC 27710 USA	Duke University					NATIONAL CANCER INSTITUTE [R01CA037586] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DAVIDSON CJ, 1990, J AM COLL CARDIOL, V16, P633, DOI 10.1016/0735-1097(90)90354-R; FOSTER JH, 1975, JAMA-J AM MED ASSOC, V231, P1043, DOI 10.1001/jama.231.10.1043; GUSSENHOVEN EJ, 1989, J AM COLL CARDIOL, V14, P947, DOI 10.1016/0735-1097(89)90471-3; HARRISON EG, 1971, MAYO CLIN PROC, V46, P161; HARRISON JK, 1990, J AM COLL CARDIOL, V15, P906, DOI 10.1016/0735-1097(90)90291-V; MCCORMAC.LJ, 1966, AM HEART J, V72, P188, DOI 10.1016/0002-8703(66)90442-X; NICHOLS AB, 1989, J AM COLL CARDIOL, V13, P1094, DOI 10.1016/0735-1097(89)90267-2; PANDIAN NG, 1990, AM J CARDIOL, V65, P1278, DOI 10.1016/0002-9149(90)90993-B; PICKERING TG, 1984, AM J MED, V77, P61, DOI 10.1016/S0002-9343(84)80059-5; SOS TA, 1986, HYPERTENSION KIDNEY, P251; TEGTMEYER CJ, 1984, RADIOLOGY, V153, P77, DOI 10.1148/radiology.153.1.6236477	11	15	15	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1991	115	1					22	25		10.7326/0003-4819-115-1-22	http://dx.doi.org/10.7326/0003-4819-115-1-22			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT937	1828655				2022-12-28	WOS:A1991FT93700005
J	FORSBURG, SL; NURSE, P				FORSBURG, SL; NURSE, P			IDENTIFICATION OF A G1-TYPE CYCLIN PUC1+ IN THE FISSION YEAST SCHIZOSACCHAROMYCES-POMBE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; MATING-PHEROMONE; DNA-REPLICATION; MESSENGER-RNA; CONTROL GENE; M-PHASE; MITOSIS; PROTEIN; DIVISION	IN rapidly growing cells of the budding yeast Saccharomyces cerevisiae, the cell cycle is regulated chiefly at Start, just before the G1-S boundary 1, whereas in the fission yeast Schizosaccharomyces pombe, the cycle is predominantly regulated at G2-M (ref. 2). Both control points are present in both yeasts, and both require the p34cdc2 protein kinase 3-5. At G2-M, p34cdc2 kinase activity in S. pombe requires a B-type cyclin in a complex with p34cdc2 (refs 6-14); this complex is the same as MPF (maturation promoting factor 15,16). The p34cdc2 activity at the G1-S transition in S. cerevisiae may be regulated by a similar cyclin complex, using one of the product of a new class of cyclin genes (CLN1, CLN2 and WHI1 (DAF1/CLN3)) (refs 17-22). At least one is required for progression through the G1-S phase, and deletion of all three leads to G1 arrest 19. WHI1 was isolated as a dominant allele causing budding yeast cells to divide at a reduced size 21 and was later independently identified as DAF1, a dominant allele of which rendered the cells refractory to the G1-arrest induced by the mating pheromone alpha-factor 22. The dominant alleles are truncations thought to yield proteins of increased stability, and the cells are accelerated through G1 (refs 20, 22). Without WHI1 function, the cells are hypersensitive to alpha-factor 22, enlarged and delayed in G1 (refs 20, 22). Heretofore, this G1-class of cyclins has not been identified in other organisms. We have isolated a G1-type cyclin gene called puc1+ from S. pombe, using a functional assay in S. cerevisiae. Expression of puc1+ in S. pombe indicates that it has a cyclin-like role in the fission yeast distinct from the role of the B-type mitotic cyclin.			FORSBURG, SL (corresponding author), UNIV OXFORD, DEPT BIOCHEM,MICROBIOL UNIT,IMPERIAL CANC RES FUND, CELL CYCLE GRP, S PARKS RD, OXFORD OX1 3QU, ENGLAND.			Forsburg, Susan L/0000-0002-4895-8598				BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURKACZ B, 1986, EMBO J, V5, P369, DOI 10.1002/j.1460-2075.1986.tb04221.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GOEBL M, 1988, CELL, V54, P739; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGAN I, 1988, J CELL SCI, V91, P587; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PRINGLE JR, 1981, MOL BIOL YEAST SACCH; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SAZER S, 1990, J CELL SCI, V97, P509; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	32	87	88	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1991	351	6323					245	248		10.1038/351245a0	http://dx.doi.org/10.1038/351245a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	1828291				2022-12-28	WOS:A1991FL99000061
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - DETECTION AND MANAGEMENT OF CONGENITAL-ABNORMALITIES .2.	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1991	302	6783					1013	1016		10.1136/bmj.302.6783.1013	http://dx.doi.org/10.1136/bmj.302.6783.1013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ508	1828182	Green Published, Bronze			2022-12-28	WOS:A1991FJ50800025
J	SHAPIRO, BM				SHAPIRO, BM			THE CONTROL OF OXIDANT STRESS AT FERTILIZATION	SCIENCE			English	Article							SEA-URCHIN EGGS; PROTEIN CROSS-LINKING; GUANYLATE-CYCLASE; ACROSOME REACTION; INTRACELLULAR-PH; STRONGYLOCENTROTUS-PURPURATUS; EXTRACELLULAR-MATRIX; SPERM; MEMBRANE; ENVELOPE	Metazoan eggs alter their coats after fertilization to protect the early embryo. In sea urchins, this modification consists of a rapid, coordinated set of noncovalent macromolecular assembly steps that are stabilized by protein cross-linking. The sea urchin egg uses an oxidative cross-linking reaction that requires hydrogen peroxide and a secreted peroxidase and thus faces the challenge of oxidant stress at the beginning of its development. Protection from the deleterious effects of this oxidative mechanism is afforded by regulation of the production and utilization of oxidizing species. This regulation requires a specific protein kinase C-activated oxidase and ovothiol, an intracellular antioxidant.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98105 USA	University of Washington; University of Washington Seattle								BACKSTROM S, 1959, EXP CELL RES, V18, P347, DOI 10.1016/0014-4827(59)90013-8; BATTAGLIA DE, 1988, J CELL BIOL, V107, P2447, DOI 10.1083/jcb.107.6.2447; BENTLEY JK, 1986, J BIOL CHEM, V261, P4859; CHANDLER DE, 1986, CELL TISSUE RES, V246, P153; CHANDLER DE, 1980, J CELL BIOL, V84, P618, DOI 10.1083/jcb.84.3.618; CHRISTEN R, 1983, J BIOL CHEM, V258, P5392; CHRISTEN R, 1982, J BIOL CHEM, V257, P4881; CIAPA B, 1986, FEBS LETT, V195, P347, DOI 10.1016/0014-5793(86)80191-0; CLAPPER DL, 1985, J BIOL CHEM, V260, P3947; DARSZON A, 1984, EUR J BIOCHEM, V144, P515, DOI 10.1111/j.1432-1033.1984.tb08496.x; DEITS T, 1984, J BIOL CHEM, V259, P3525; DEITS T, 1985, J BIOL CHEM, V260, P7882; DEITS TL, 1986, J BIOL CHEM, V261, P2159; DUBE F, 1985, CELL, V40, P657, DOI 10.1016/0092-8674(85)90214-4; EPEL D, 1981, CELL, V23, P543, DOI 10.1016/0092-8674(81)90150-1; EPEL D, 1969, EXP CELL RES, V58, P312, DOI 10.1016/0014-4827(69)90510-2; Epel D., 1978, Current Topics in Developmental Biology, V12, P185, DOI 10.1016/S0070-2153(08)60597-9; FAHEY RC, 1976, BIOCHIM BIOPHYS ACTA, V437, P445, DOI 10.1016/0304-4165(76)90013-1; FOERDER CA, 1977, P NATL ACAD SCI USA, V74, P4214, DOI 10.1073/pnas.74.10.4214; FOERDER CA, 1978, P NATL ACAD SCI USA, V75, P3183, DOI 10.1073/pnas.75.7.3183; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; GUERRERO A, 1989, J BIOL CHEM, V264, P19593; HALL HG, 1978, CELL, V15, P343, DOI 10.1016/0092-8674(78)90003-X; Harvey EN, 1910, J EXP ZOOL, V8, P355, DOI 10.1002/jez.1400080402; HEINECKE JW, 1989, P NATL ACAD SCI USA, V86, P1259, DOI 10.1073/pnas.86.4.1259; HEINECKE JW, 1990, J BIOL CHEM, V265, P7717; HOLLER TP, 1988, J AM CHEM SOC, V110, P4837, DOI 10.1021/ja00222a057; HOLLER TP, 1990, BIOCHEMISTRY-US, V29, P1953, DOI 10.1021/bi00459a042; ISONO N, 1968, EXP CELL RES, V50, P616, DOI 10.1016/0014-4827(68)90423-0; Isono N., 1963, Journal of the Faculty of Science Tokyo University Zoology, V10, P67; JAFFE LA, 1976, NATURE, V261, P68, DOI 10.1038/261068a0; JAFFE LA, 1986, ANNU REV PHYSIOL, V48, P191, DOI 10.1146/annurev.ph.48.030186.001203; JAFFE LA, 1985, DEV BIOL, V99, P265; KAMEL LC, 1985, LIPIDS, V20, P350, DOI 10.1007/BF02534201; KAY E, 1982, CELL, V29, P867, DOI 10.1016/0092-8674(82)90448-2; KAY ES, 1987, DEV BIOL, V121, P325, DOI 10.1016/0012-1606(87)90168-0; KAY ES, 1985, BIOL FERTILIZATION, V3, P45; KLEBANOFF SJ, 1979, J EXP MED, V149, P938, DOI 10.1084/jem.149.4.938; KRANE SM, 1960, BIOCHIM BIOPHYS ACTA, V43, P369, DOI 10.1016/0006-3002(60)90461-3; LALLIER R, 1971, EXPERIENTIA, V27, P1323, DOI 10.1007/BF02136716; LALLIER R A, 1970, Experimental Cell Research, V63, P460; LASER H., 1939, PROC ROY SOC [LONDON] SER B, V126, P539, DOI 10.1098/rspb.1939.0007; LEE HC, 1983, DEV BIOL, V95, P31, DOI 10.1016/0012-1606(83)90004-0; LEE HC, 1986, J BIOL CHEM, V261, P6026; PALUMBO A, 1982, TETRAHEDRON LETT, V23, P3207, DOI 10.1016/S0040-4039(00)88597-4; PALUMBO A, 1984, COMP BIOCHEM PHYS B, V78, P81, DOI 10.1016/0305-0491(84)90149-4; PETASNE RG, 1987, NATURE, V325, P516, DOI 10.1038/325516a0; RUNNSTROM J, 1966, ADV MORPHOL, V5, P231; SCHACKMANN RW, 1984, J BIOL CHEM, V259, P3914; SCHATTEN H, 1988, CELL BIOL FERTILIZAT; SCHULZ S, 1989, FASEB J, V3, P2026, DOI 10.1096/fasebj.3.9.2568301; SHAPIRO B M, 1988, Biofactors, V1, P85; SHAPIRO BM, 1987, CELL, V49, P293, DOI 10.1016/0092-8674(87)90276-5; SHAPIRO BM, 1988, CELL BIOL FERTILIZAT, P251; Shearer C, 1922, P R SOC LOND B-CONTA, V93, P213, DOI 10.1098/rspb.1922.0016; Sies H., 1985, OXIDATIVE STRESS; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; SOMERS CE, 1989, DEV BIOL, V131, P226, DOI 10.1016/S0012-1606(89)80054-5; SOMERS CE, IN PRESS J BIOL CHEM; SWEZEY RR, 1986, J CELL BIOL, V103, P1509, DOI 10.1083/jcb.103.4.1509; TAYLOR AE, 1986, PHYSL OXYGEN RADICAL; TOMBES RM, 1987, BIOPHYS J, V52, P75, DOI 10.1016/S0006-3495(87)83190-9; TOMBES RM, 1987, J BIOL CHEM, V262, P16011; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; TRIMMER JS, 1986, ANNU REV CELL BIOL, V2, P1; TURNER E, 1986, J BIOL CHEM, V261, P3056; TURNER E, 1988, SCIENCE, V242, P939, DOI 10.1126/science.3187533; TURNER E, 1987, BIOCHEMISTRY-US, V26, P4028, DOI 10.1021/bi00387a043; TURNER E, 1988, RESPIRATORY BURST IT, P385; TURNER PR, 1984, NATURE, V310, P414, DOI 10.1038/310414a0; VANBAALE.C, 1966, NATURE, V211, P951; VERON M, 1977, CELL, V10, P321, DOI 10.1016/0092-8674(77)90226-4; Warburg O, 1908, H-S Z PHYSIOL CHEM, V57, P1, DOI 10.1515/bchm2.1908.57.1-2.1; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; WEIDMAN PJ, 1987, J BIOL CHEM, V262, P15076; WEIDMAN PJ, 1985, J CELL BIOL, V100, P938, DOI 10.1083/jcb.100.3.938; WEIDMAN PJ, 1987, J CELL BIOL, V105, P561, DOI 10.1083/jcb.105.1.561; WHITAKER MJ, 1982, QUANT REV BIOPHYS, V15, P4; WHITAKER MJ, 1985, FERTILIZATION RESPON, V3, P168; WOTHE DD, 1990, P NATL ACAD SCI USA, V87, P5203, DOI 10.1073/pnas.87.13.5203	80	132	137	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1991	252	5005					533	536		10.1126/science.1850548	http://dx.doi.org/10.1126/science.1850548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850548				2022-12-28	WOS:A1991FJ12700037
J	FERRARI, G; ROSSINI, S; GIAVAZZI, R; MAGGIONI, D; NOBILI, N; SOLDATI, M; UNGERS, G; MAVILIO, F; GILBOA, E; BORDIGNON, C				FERRARI, G; ROSSINI, S; GIAVAZZI, R; MAGGIONI, D; NOBILI, N; SOLDATI, M; UNGERS, G; MAVILIO, F; GILBOA, E; BORDIGNON, C			AN INVIVO MODEL OF SOMATIC-CELL GENE-THERAPY FOR HUMAN SEVERE COMBINED IMMUNODEFICIENCY	SCIENCE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; HUMAN ADENOSINE-DEAMINASE; RETROVIRUS-MEDIATED TRANSFER; STEM-CELLS; B-CELLS; EXPRESSION; MICE; DEFICIENCY; VECTOR; CULTURE	Deficiency of adenosine deaminase (ADA) results in severe combined immunodeficiency (SCID), a candidate genetic disorder for somatic cell gene therapy. Peripheral blood lymphocytes from patients affected by ADA- SCID were transduced with a retroviral vector for human ADA and injected into immunodeficient mice. Long-term survival of vector-transduced human cells was demonstrated in recipient animals. Expression of vector-derived ADA restored immune functions, as indicated by the presence in reconstituted animals of human immunoglobulin and antigen-specific T cells. Retroviral vector gene transfer, therefore, is necessary and sufficient for development of specific immune functions in vivo and has therapeutic potential to correct this lethal immunodeficiency.	IST SCI HS RAFFAELE,HEMATOL SERV,HEMATOL LAB,VIA OLGETTINA 60,I-20132 MILAN,ITALY; IST RIC MARIO NEGRI BERGAMO,BERGAMO,ITALY; MEM SLOAN KETTERING CANC CTR,DEPT MOLEC BIOL,NEW YORK,NY 10021	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Memorial Sloan Kettering Cancer Center			Giavazzi, Raffaella/ABB-9768-2020; Ferrari, Giuliana/AAB-5546-2019; Daniela, Maggioni/AAN-6553-2020; Giavazzi, Raffaella/J-7424-2018	Giavazzi, Raffaella/0000-0001-5249-8208; Ferrari, Giuliana/0000-0003-0790-3133; Daniela, Maggioni/0000-0001-9894-6387; Mavilio, Fulvio/0000-0003-0459-4320				ANDERSON WF, 1984, SCIENCE, V226, P401, DOI 10.1126/science.6093246; ARREDONDOVEGA FX, 1990, J CLIN INVEST, V86, P444, DOI 10.1172/JCI114730; BELMONT JW, 1988, MOL CELL BIOL, V8, P5116, DOI 10.1128/MCB.8.12.5116; BELMONT JW, 1986, NATURE, V322, P385, DOI 10.1038/322385a0; BENDER MA, 1989, MOL CELL BIOL, V9, P1426, DOI 10.1128/MCB.9.4.1426; BODINE DM, 1990, P NATL ACAD SCI USA, V87, P3738, DOI 10.1073/pnas.87.10.3738; BORDIGNON C, 1989, P NATL ACAD SCI USA, V86, P6748, DOI 10.1073/pnas.86.17.6748; BORDIGNON C, UNPUB; COLLINS SJ, 1983, P NATL ACAD SCI USA, V80, P4831; CULLITON BJ, 1989, SCIENCE, V246, P751, DOI 10.1126/science.2814495; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; DISEGNI C, 1981, NUCLEIC ACIDS RES, V9, P6709; EGLITIS MA, 1985, SCIENCE, V230, P1395, DOI 10.1126/science.2999985; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GERSHON D, 1990, NATURE, V346, P402, DOI 10.1038/346402a0; GRUBER HE, 1985, SCIENCE, V230, P1057, DOI 10.1126/science.3864246; HANTZOPOULOS PA, 1989, P NATL ACAD SCI USA, V86, P3519, DOI 10.1073/pnas.86.10.3519; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; HOCK RA, 1986, NATURE, V320, P275, DOI 10.1038/320275a0; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KANTOFF PW, 1987, J EXP MED, V166, P219, DOI 10.1084/jem.166.1.219; KANTOFF PW, 1986, P NATL ACAD SCI USA, V83, P6563, DOI 10.1073/pnas.83.17.6563; KASID A, 1990, P NATL ACAD SCI USA, V87, P473, DOI 10.1073/pnas.87.1.473; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KHAN PM, 1971, ARCH BIOCHEM BIOPHYS, V145, P470, DOI 10.1016/S0003-9861(71)80007-3; KWOK WW, 1986, P NATL ACAD SCI USA, V83, P4552, DOI 10.1073/pnas.83.12.4552; LEVY Y, 1988, J PEDIATR-US, V113, P312, DOI 10.1016/S0022-3476(88)80271-3; MARTINI A, 1985, INT J CLIN PHARM RES, V5, P149; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; O'Reilly R J, 1989, Immunodefic Rev, V1, P273; PARKMAN R, 1986, SCIENCE, V232, P1373, DOI 10.1126/science.3520819; ROSEN A, 1983, J IMMUNOL, V130, P2899; Sambrook J, 1989, MOL CLONING LABORATO; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VANDERWEYDEN MB, 1978, CLIN CHIM ACTA, V82, P179, DOI 10.1016/0009-8981(78)90041-4; WILLIAMS DA, 1986, P NATL ACAD SCI USA, V83, P2566, DOI 10.1073/pnas.83.8.2566; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P439, DOI 10.1073/pnas.87.1.439; WOLFE JH, 1990, P NATL ACAD SCI USA, V87, P2877, DOI 10.1073/pnas.87.8.2877	39	113	125	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1991	251	4999					1363	1366		10.1126/science.1848369	http://dx.doi.org/10.1126/science.1848369			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	1848369				2022-12-28	WOS:A1991FB73300046
J	BOYLE, WJ; SMEAL, T; DEFIZE, LHK; ANGEL, P; WOODGETT, JR; KARIN, M; HUNTER, T				BOYLE, WJ; SMEAL, T; DEFIZE, LHK; ANGEL, P; WOODGETT, JR; KARIN, M; HUNTER, T			ACTIVATION OF PROTEIN-KINASE-C DECREASES PHOSPHORYLATION OF C-JUN AT SITES THAT NEGATIVELY REGULATE ITS DNA-BINDING ACTIVITY	CELL			English	Article							LEUCINE ZIPPER; TRANSCRIPTION FACTOR; ONCOGENE JUN; METALLOTHIONEIN GENE; GROWTH-FACTORS; FOS PROTEINS; 3T3 CELLS; V-JUN; AP-1; PRODUCT	In resting human epithelial and fibroblastic cells, c-Jun is phosphorylated on serine and threonine at five sites, three of which are phosphorylated in vitro by glycogen synthase kinase 3 (GSK-3). These three sites are nested within a single tryptic peptide located just upstream of the basic region of the c-Jun DNA-binding domain (residues 227-252). Activation of protein kinase C results in rapid, site-specific dephosphorylation of c-Jun at one or more of these three sites and is coincident with increased AP-1-binding activity. Phosphorylation of recombinant human c-Jun proteins in vitro by GSK-3 decreases their DNA-binding activity. Mutation of serine 243 to phenylalanine blocks phosphorylation of all three sites in vivo and increases the inherent trans-activation ability of c-Jun at least 10-fold. We propose that c-Jun is present in resting cells in a latent, phosphorylated form that can be activated by site-specific dephosphorylation in response to protein kinase C activation.	SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Ludwig Institute for Cancer Research			Messier, Claude/A-2322-2008; Woodgett, Jim/F-1087-2010	Messier, Claude/0000-0002-4791-1763; Woodgett, Jim/0000-0003-3731-5797	NCI NIH HHS [CA39780, CA14195, CA50528] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780, P01CA050528, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, IN PRESS METH ENZYMO; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1984, CELL, V36, P259; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HEMMINGS BA, 1981, EUR J BIOCHEM, V119, P443, DOI 10.1111/j.1432-1033.1981.tb05628.x; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MULLER R, 1987, ONCOGENE RES, V2, P19; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SATAKE M, 1989, J VIROL, V63, P3669, DOI 10.1128/JVI.63.9.3669-3677.1989; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; WOODGETT JR, 1984, BIOCHIM BIOPHYS ACTA, V788, P339, DOI 10.1016/0167-4838(84)90047-5; YANG-YEN H-F, 1990, New Biologist, V2, P351; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	70	1017	1026	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 8	1991	64	3					573	584		10.1016/0092-8674(91)90241-P	http://dx.doi.org/10.1016/0092-8674(91)90241-P			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1846781				2022-12-28	WOS:A1991EX36100013
J	ZHOU, RP; OSKARSSON, M; PAULES, RS; SCHULZ, N; CLEVELAND, D; VANDEWOUDE, GF				ZHOU, RP; OSKARSSON, M; PAULES, RS; SCHULZ, N; CLEVELAND, D; VANDEWOUDE, GF			ABILITY OF THE C-MOS PRODUCT TO ASSOCIATE WITH AND PHOSPHORYLATE TUBULIN	SCIENCE			English	Article							PROTO-ONCOGENE PRODUCT; CELL-CYCLE; MEIOTIC MATURATION; XENOPUS OOCYTES; GERM-CELLS; EXPRESSION; EGGS; OOGENESIS; CLEAVAGE; PROTEINS	The mos proto-oncogene product, pp39mos, is a protein kinase and has been equated with cytostatic factor (CSF), an activity in unfertilized eggs that is thought to be responsible for the arrest of meiosis at metaphase II. The biochemical properties and potential substrates of pp39mos were examined in unfertilized eggs and in transformed cells in order to study how the protein functions both as CSF and in transformation. The pp39mos protein associated with polymers under conditions that favor tubulin oligomerization and was present in an approximately 500-kilodalton "core" complex under conditions that favor depolymerization. beta-Tubulin was preferentially coprecipitated in pp39mos immunoprecipitates and was the major phosphorylated product in a pp39mos-dependent immune complex kinase assay. Immunofluorescence analysis of NIH 3T3 cells transformed with Xenopus c-mos showed that pp39mos colocalizes with tubulin in the spindle during metaphase and in the midbody and asters during telophase. Disruption of microtubules with nocodazole affected tubulin and pp39mos organization in the same way. It therefore appears that pp39mos is a tubulin-associated protein kinase and may thus participate in the modification of microtubules and contribute to the formation of the spindle. This activity expressed during interphase in somatic cells may be responsible for the transforming activity of pp39mos.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University	ZHOU, RP (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702, USA.		Cleveland, Don/AAN-9783-2021	Paules, Richard S/0000-0001-9106-7486	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BORISY GG, 1975, ANN NY ACAD SCI, V253, P107, DOI 10.1111/j.1749-6632.1975.tb19196.x; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FISCHINGER PJ, 1971, J GEN VIROL, V13, P203, DOI 10.1099/0022-1317-13-2-203; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GRAETTA G, 1989, CELL, V56, P829; HEIDEMANN SR, 1980, DEV BIOL, V80, P489, DOI 10.1016/0012-1606(80)90421-2; KATZ W, 1990, MOL CELL BIOL, V10, P5286, DOI 10.1128/MCB.10.10.5286; KLOETZER WS, 1984, VIROLOGY, V138, P143, DOI 10.1016/0042-6822(84)90154-5; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEYERHOF PG, 1977, DEV BIOL, V61, P214, DOI 10.1016/0012-1606(77)90293-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAULES RS, 1988, ONCOGENE, V3, P59; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHIFF PB, 1979, NATURE, V277, P605; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SHIBUYA EK, 1988, DEV BIOL, V129, P253, DOI 10.1016/0012-1606(88)90179-0; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WEINSTEIN B, 1990, MOL CELL BIOL, V10, P5295, DOI 10.1128/MCB.10.10.5295; WEISENBERG RC, 1972, SCIENCE, V177, P1104, DOI 10.1126/science.177.4054.1104; YEW N, IN PRESS MOL CELL BI	40	138	140	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					671	675		10.1126/science.1825142	http://dx.doi.org/10.1126/science.1825142			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1825142				2022-12-28	WOS:A1991EW39900045
J	CHODAK, GW; VOGELZANG, NJ; CAPLAN, RJ; SOLOWAY, M; SMITH, JA				CHODAK, GW; VOGELZANG, NJ; CAPLAN, RJ; SOLOWAY, M; SMITH, JA			INDEPENDENT PROGNOSTIC FACTORS IN PATIENTS WITH METASTATIC (STAGE-D2) PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMA TESTOSTERONE; SURVIVAL; CARCINOMA; THERAPY	The independent prognostic factors affecting survival were assessed in 240 men undergoing treatment for metastatic prostate cancer as part of a randomized clinical trial comparing the gonadotropin releasing hormone analogue Zoladex (goserelin acetate implant) with castration. In a multivariate analysis, the most highly significant predictors were the presence or absence of bone pain, serum testosterone levels, serum alkaline phosphatase levels, and performance status. Patients with all four factors favorable for survival had a 2-year survival rate of 84% as compared with only 8% for patients with none of the four factors favorable for survival. No other factors were significant. A separate analysis of serum testosterone levels revealed that the higher the pretreatment serum testosterone level, the greater the survival rate. Compared with patients with serum testosterone levels less than 6.9 nmol/L, significant differences in survival were observed for patients with serum testosterone levels of 10.4 to 13.9, 13.9 to 17.3, and over 17.3 nmol/L. These results have important implications for the design and analysis of future clinical trials of hormone therapy and for counseling patients regarding the short-term prognosis of their disease.	UNIV CHICAGO, DEPT SURG, UROL SECT, CHICAGO, IL 60637 USA; ICI AMER INC, WILMINGTON, DE 19899 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT UROL, MEMPHIS, TN 38163 USA; UNIV UTAH, DEPT SURG, DIV UROL, SALT LAKE CITY, UT 84112 USA	University of Chicago; University of Tennessee System; University of Tennessee Health Science Center; Utah System of Higher Education; University of Utah				Caplan, Richard/0000-0002-4117-597X				AHLUWALIA B, 1981, CANCER, V48, P2267, DOI 10.1002/1097-0142(19811115)48:10<2267::AID-CNCR2820481023>3.0.CO;2-R; Cockburn A G, 1983, Semin Urol, V1, P280; DOERING CH, 1975, J CLIN ENDOCR METAB, V40, P492, DOI 10.1210/jcem-40-3-492; EMRICH LJ, 1985, CANCER RES, V45, P5173; HARPER ME, 1984, EUR J CANCER CLIN ON, V20, P477, DOI 10.1016/0277-5379(84)90232-3; Hastings R.P, 1986, SUGI SUPPLEMENTAL LI; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; ISHIKAWA S, 1989, J UROLOGY, V141, P1139, DOI 10.1016/S0022-5347(17)41193-1; KALBFLEISTH JD, 1980, STATISTICAL ANAL FAI; KREIS W, 1990, J CLIN ONCOL, V8, P870, DOI 10.1200/JCO.1990.8.5.870; LEYMARIE P, 1974, J STEROID BIOCHEM, V5, P167, DOI 10.1016/0022-4731(74)90124-1; MEE AD, 1984, BRIT J UROL, V56, P698, DOI 10.1111/j.1464-410X.1984.tb06150.x; ROSE RM, 1972, J ENDOCRINOL, V54, P177, DOI 10.1677/joe.0.0540177; Spirnak J P, 1983, Semin Urol, V1, P269; TRACHTENBERG J, 1982, J UROLOGY, V127, P466, DOI 10.1016/S0022-5347(17)53868-9; WALKER KJ, 1984, J ENDOCRINOL, V103, pR1, DOI 10.1677/joe.0.103R001	16	129	129	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	1991	265	5					618	621		10.1001/jama.265.5.618	http://dx.doi.org/10.1001/jama.265.5.618			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV718	1824790				2022-12-28	WOS:A1991EV71800019
J	RANSOHOFF, DF; LANG, CA; KUO, HS				RANSOHOFF, DF; LANG, CA; KUO, HS			COLONOSCOPIC SURVEILLANCE AFTER POLYPECTOMY - CONSIDERATIONS OF COST-EFFECTIVENESS	ANNALS OF INTERNAL MEDICINE			English	Article							COLORECTAL-CANCER; POLYPS; RISK; SIGMOIDOSCOPY; POPULATION; CARCINOMA; HISTORY	Objective: To assess the cost effectiveness of the current recommendation that persons who have had an adenomatous colon polyp removed have periodic colonscopic surveillance at fixed and regular intervals. Design: Cost-effectiveness analysis using data from the medical literature in a simulation model to estimate the costs of and the risk for perforation associated with periodic colonoscopic surveillance for a 50-year-old man followed for 30 years. Main Results: A program of colonoscopy every 3 years would incur cumulatively a 1.4% risk for colon perforation, a 0.11% risk for perforation-related death, and direct physician costs of $2071 for colonoscopy (discounted at 5%). If a 50-year-old man's cumulative remaining risk for death from cancer is 2.5% after the removal of a single small adenoma and if effectiveness of colonoscopic surveillance every 3 years is 100%, then one death from cancer could be prevented by doing 283 colonoscopies, incurring 0.6 perforations, 0.04 perforation-related deaths, and direct physician costs of $82000. If surveillance were 50% effective and the cumulative remaining risk for death from cancer were 1.25%-a plausible scenario-1131 colonoscopies would be required to prevent one death from cancer, incurring 2.3 perforations, 0.17 perforation-related deaths, and physician costs of $331000. Conclusions: The cost effectiveness of colonoscopic surveillance is very sensitive to estimates of the cumulative remaining risk for death from cancer after polypectomy as well as to surveillance efficacy. For persons whose remaining risk for death from cancer may be low, such as persons with a single small adenoma, recommendations for colonoscopic surveillance at fixed and regular intervals may be excessively costly.	UNIV COLORADO, DENVER, CO 80202 USA	University of Colorado System; University of Colorado Denver	RANSOHOFF, DF (corresponding author), YALE UNIV, SCH MED, 1E 61, POB 3333, NEW HAVEN, CT 06510 USA.							ACHKAR E, 1988, ANN INTERN MED, V109, P880, DOI 10.7326/0003-4819-109-11-880; ATKIN W S, 1990, Gastroenterology, V98, pA650; BARRY MJ, 1987, GASTROENTEROLOGY, V93, P301, DOI 10.1016/0016-5085(87)91019-5; BERG JW, 1988, BASIC CLIN PERSPECTI, P13; BOLAND CR, 1989, GASTROINTESTINAL DIS, P1483; BRAHME F, 1974, DIS COLON RECTUM, V17, P166, DOI 10.1007/BF02588099; DIMAGNO EP, 1989, GASTROINTEST ENDOSC, P11; EDDY DM, 1987, GASTROENTEROLOGY, V92, P682, DOI 10.1016/0016-5085(87)90018-7; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; GROSSMAN S, 1989, GASTROENTEROLOGY, V96, P299, DOI 10.1016/0016-5085(89)91551-5; HENRY LG, 1975, ANN SURG, V182, P511, DOI 10.1097/00000658-197510000-00017; LOFTI AM, 1986, MAYO CLIN P, V61, P337; LUK GD, 1990, CURRENT THERAPY GAST, V3, P387; MORSON BC, 1984, CLIN RADIOL, V35, P425, DOI 10.1016/S0009-9260(84)80033-1; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; RICKERT RR, 1979, CANCER-AM CANCER SOC, V43, P1847, DOI 10.1002/1097-0142(197905)43:5<1847::AID-CNCR2820430538>3.0.CO;2-L; RIDER JA, 1959, JAMA-J AM MED ASSOC, V170, P633, DOI 10.1001/jama.1959.03010060001001; ROSEVELT J, 1984, DIGEST DIS SCI, V29, P161, DOI 10.1007/BF01317059; SEIDMAN H, 1985, CANCER, V35, P35; SELBY JV, 1989, JAMA-J AM MED ASSOC, V261, P595; SPENCER RJ, 1984, MAYO CLIN PROC, V59, P305, DOI 10.1016/S0025-6196(12)61425-6; SPIRO HM, 1988, MT SINAI J MED, V55, P251; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; WAYE J, 1990, GASTROINTEST ENDOSC, V36, P226; WAYE JD, 1982, ENDOSCOPY, V14, P79, DOI 10.1055/s-2007-1021585; 1988, BASIC CLIN PERSPECTI, P35; 1988, GASTROINTEST ENDOSC, V34, pS6; 1975, VITAL STATISTICS US, V1	29	102	104	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1991	114	3					177	182		10.7326/0003-4819-114-3-177	http://dx.doi.org/10.7326/0003-4819-114-3-177			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV339	1824613				2022-12-28	WOS:A1991EV33900001
J	PAPAZIAN, DM; TIMPE, LC; JAN, YN; JAN, LY				PAPAZIAN, DM; TIMPE, LC; JAN, YN; JAN, LY			ALTERATION OF VOLTAGE-DEPENDENCE OF SHAKER POTASSIUM CHANNEL BY MUTATIONS IN THE S4-SEQUENCE	NATURE			English	Article							SODIUM-CHANNEL; XENOPUS OOCYTES; ELECTROPHORUS-ELECTRICUS; COMPLEMENTARY-DNA; DROSOPHILA MUSCLE; GATING CURRENTS; MOLECULAR-MODEL; NA CHANNELS; INACTIVATION; LOCUS	Voltage-dependent potassium, sodium and calcium ion channels may share a common mechanism of activation, in which the conserved S4 sequence acts as the primary voltage sensor. Site-directed mutagenesis of the S4 sequence of the Shaker potassium channel and electrophysiological analysis suggest that voltage-dependent activation involves the S4 sequence but is not solely due to electrostatic interactions.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498	NIGMS NIH HHS [R01 GM043459-15, R01 GM043459-11, R01 GM043459-16, R01 GM043459-10, R01 GM043459, R01 GM043459-13, R01 GM043459-17, R01 GM043459-14, R01 GM043459-12, R01 GM043459-15S1, R01 GM043459-09] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043459] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; Almers W, 1978, Rev Physiol Biochem Pharmacol, V82, P96, DOI 10.1007/BFb0030498; ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BAUMANN A, 1987, EMBO J, V6, P3419, DOI 10.1002/j.1460-2075.1987.tb02665.x; BEZANILLA F, 1982, NATURE, V296, P657, DOI 10.1038/296657a0; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; COTA G, 1989, J GEN PHYSIOL, V94, P213, DOI 10.1085/jgp.94.2.213; GOLDMAN L, 1976, Q REV BIOPHYS, V9, P491, DOI 10.1017/S0033583500002651; GONOI T, 1987, J GEN PHYSIOL, V89, P253, DOI 10.1085/jgp.89.2.253; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; Hille B, 1984, IONIC CHANNELS EXCIT; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KOSOWER EM, 1985, FEBS LETT, V182, P234, DOI 10.1016/0014-5793(85)80306-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PERES A, 1985, PFLUG ARCH EUR J PHY, V403, P41, DOI 10.1007/BF00583279; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243; ZAGOTTA WN, 1988, J NEUROSCI, V8, P4765	41	450	458	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					305	310		10.1038/349305a0	http://dx.doi.org/10.1038/349305a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1846229				2022-12-28	WOS:A1991EU50100043
J	CRIQUI, MH				CRIQUI, MH			CHOLESTEROL, PRIMARY AND SECONDARY PREVENTION, AND ALL-CAUSE MORTALITY	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY HEART-DISEASE; LOWERING CHOLESTEROL; TRIALS; MEN; HYPERCHOLESTEROLEMIA; THERAPY; DIET	Clinical trials of cholesterol lowering in apparently healthy persons (primary prevention) and in persons with known coronary disease (secondary prevention) routinely show a decrease in the incidence of nonfatal and fatal coronary events. Primary prevention trials, however, generally have failed to show a beneficial effect of cholesterol lowering on total mortality, because of both low overall death rates and a disturbingly high number of deaths from noncoronary causes in the treatment groups. Studies of secondary prevention give more clear-cut evidence of benefit. The rate of death from coronary heart disease is extremely high in these studies, overwhelming the rates for other causes of death. Thus, a possible increase in noncoronary deaths is of much less concern in secondary prevention studies. A possible link between cholesterol lowering and noncoronarY causes of death should be explored using dose-response analyses of existing data sets, in both individual studies and aggregate meta-analysis; such analyses should be similar to those that have been done to study the relation between cholesterol lowering and coronary events. These analyses would greatly assist us in developing safe, efficacious ways to prevent coronary heart disease.			CRIQUI, MH (corresponding author), UNIV CALIF SAN DIEGO, DEPT COMMUNITY & FAMILY MED, DIV EPIDEMIOL, M-007, LA JOLLA, CA 92093 USA.				NHLBI NIH HHS [HL 01718-03] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRETT AS, 1989, NEW ENGL J MED, V321, P676, DOI 10.1056/NEJM198909073211009; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; HJERMANN I, 1986, AM J MED, V80, P7, DOI 10.1016/0002-9343(86)90154-3; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MOORE TJ, 1989, ATLANTIC MONTHLY SEP, P37; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; PEARCE ML, 1971, LANCET, V1, P464; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; WYSOWSKI DK, 1990, ARCH INTERN MED, V150, P2169, DOI 10.1001/archinte.150.10.2169; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2259, DOI 10.1001/jama.260.15.2259; 1989, LANCET, V1, P473; 1990, JAMA-J AM MED ASSOC, V253, P1795	22	36	36	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1991	115	12					973	976		10.7326/0003-4819-115-12-973	http://dx.doi.org/10.7326/0003-4819-115-12-973			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU417	1835327				2022-12-28	WOS:A1991GU41700012
J	COUPLAND, RM; KORVER, A				COUPLAND, RM; KORVER, A			INJURIES FROM ANTIPERSONNEL MINES - THE EXPERIENCE OF THE INTERNATIONAL-COMMITTEE OF THE RED-CROSS	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective - To describe and quantify patterns of injury from antipersonnel mines in terms of distribution of injury, drain on surgical resources, and residual disability. Design - Retrospective analysis. Setting - Two hospitals for patients injured in war. Subjects - 757 patients with injuries from antipersonnel mines. Main outcome measures - Distribution and number of injuries; number of blood transfusions; number of operations; disability. Results - Pattern 1 injury results from standing on a buried mine. These patients usually sustain traumatic amputation of the foot or leg; they use most surgical time and blood and invariably require surgical amputation of one or both lower limbs. Pattern 2 injury is a more random collection of penetrating injuries caused by multiple fragments from a mine triggered near the victim. The lower limb is injured but there is less chance of traumatic amputation or subsequent surgical amputation. Injuries to the head, neck, chest, or abdomen are common. Pattern 3 injury results from handling a mine: the victim sustains severe upper limb injuries with associated face injuries. Eye injuries are common in all groups. Conclusions - Patients who survive standing on a buried mine have greatest disability. Non-combatants are at risk from these weapons; in developing countries their social and economic prospects after recovery from amputation are poor.			COUPLAND, RM (corresponding author), RED CROSS, INT COMM, DIV MED, CH-1202 GENEVA, SWITZERLAND.							ADAMS DB, 1988, J TRAUMA, V28, pS159, DOI 10.1097/00005373-198801001-00032; CHENG XM, 1990, J TRAUMA S, V6, P169; COUPLAND RM, 1989, ANN ROY COLL SURG, V71, P404; Jones E L, 1968, Arch Surg, V97, P1; TRAVERSO LW, 1981, MIL MED, V146, P682	5	112	115	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 14	1991	303	6816					1509	1512		10.1136/bmj.303.6816.1509	http://dx.doi.org/10.1136/bmj.303.6816.1509			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1838290	Green Published, Bronze			2022-12-28	WOS:A1991GV47600021
J	SILVERMAN, NS; DARBY, MJ; RONKIN, SL; WAPNER, RJ				SILVERMAN, NS; DARBY, MJ; RONKIN, SL; WAPNER, RJ			HEPATITIS-B PREVALENCE IN AN UNREGISTERED PRENATAL POPULATION - IMPLICATIONS FOR NEONATAL THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MUNICIPAL OBSTETRICAL POPULATION; PASSIVE-ACTIVE IMMUNIZATION; POSITIVE CARRIER MOTHERS; ENDEMIC AREA SENEGAL; SURFACE-ANTIGEN; PERINATAL TRANSMISSION; VERTICAL TRANSMISSION; UNITED-STATES; INFANTS BORN; IMMUNE GLOBULIN	Study Objective. -To evaluate the risk and associated cofactors for hepatitis B infection in inner-city pregnant women not registered for prenatal care. Design. - Fifteen-month survey of 208 patients not registered for prenatal care, compared with 1555 women registered for prenatal care during the same period. Setting. - An urban university hospital prenatal clinic and labor unit. Results. - Unregistered patients had a significantly higher rate of hepatitis B surface antigen positivity than patients who had registered with the clinic (6.7% vs 0.8%; P < .0001). Unregistered patients with positive results of urine drug screening (46%) had a relative risk for seropositivity of 29.2%, compared with registered patients who did not have histories of illicit drug use (95% confidence interval, 25.9% to 32.4%), while registered patients with past histories of drug use had a relative risk of 6.7%, compared with the reference group that did not have histories of drug use (95% confidence interval, 1.8% to 24.0%). Conclusions. - Among inner-city pregnant women not registered for prenatal care, a positive result of urine drug screening is a rapidly available marker for increased risk of hepatitis B surface antigen positivity. Infants born to unregistered women with positive results of urine drug screening before maternal hepatitis B surface antigen results are available may warrant empiric initiation of hepatitis B virus-specific prophylaxis.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT OBSTET & GYNECOL, DIV MATERNAL FETAL MED, PHILADELPHIA, PA 19107 USA	Jefferson University				Wapner, Ronald/0000-0003-0727-1244				AREVALO JA, 1988, JAMA-J AM MED ASSOC, V259, P365, DOI 10.1001/jama.259.3.365; BEASLEY RP, 1977, AM J EPIDEMIOL, V105, P94, DOI 10.1093/oxfordjournals.aje.a112370; BEASLEY RP, 1983, LANCET, V2, P1099; BEASLEY RP, 1981, LANCET, V2, P388; BEASLEY RP, 1981, LANCET, V2, P1129; Beasley RP, 1978, VIRAL HEPATITIS, P333; BISWAS SC, 1989, T ROY SOC TROP MED H, V83, P698, DOI 10.1016/0035-9203(89)90401-X; CHRISTIAN SS, 1989, OBSTET GYNECOL, V74, P259; COURSAGET P, 1987, J MED VIROL, V22, P1, DOI 10.1002/jmv.1890220102; DELAPLANE D, 1983, PEDIATRICS, V72, P176; FARMER K, 1987, NEW ZEAL MED J, V100, P412; FRANKS AL, 1989, NEW ENGL J MED, V321, P1301, DOI 10.1056/NEJM198911093211905; JONAS MM, 1990, AM J GASTROENTEROL, V85, P277; JONAS MM, 1987, ANN INTERN MED, V107, P335, DOI 10.7326/0003-4819-107-2-335; KANE MA, 1988, JAMA-J AM MED ASSOC, V259, P408, DOI 10.1001/jama.259.3.408; KORETZ RL, 1989, OBSTET GYNECOL, V74, P808; KUMAR ML, 1987, ANN INTERN MED, V107, P273, DOI 10.7326/0003-4819-107-2-273; LO KJ, 1985, J INFECT DIS, V152, P817, DOI 10.1093/infdis/152.4.817; MALECKI JM, 1986, AM J OBSTET GYNECOL, V154, P625, DOI 10.1016/0002-9378(86)90615-0; MAUPAS P, 1981, LANCET, V1, P289; MAUPAS P, 1976, LANCET, V1, P1367; MAYNARD JE, 1989, REV INFECT DIS, V11, pS574; MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599; OKADA K, 1976, NEW ENGL J MED, V294, P746, DOI 10.1056/NEJM197604012941402; ROSS JW, 1989, JAMA-J AM MED ASSOC, V261, P1727; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P37; SCHALM SW, 1989, PEDIATRICS, V83, P1041; SCHWEITZER IL, 1975, AM J MED SCI, V270, P287, DOI 10.1097/00000441-197509000-00008; SINATRA FR, 1982, PEDIATRICS, V70, P557; STEVENS CE, 1985, JAMA-J AM MED ASSOC, V253, P1740, DOI 10.1001/jama.253.12.1740; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; STEVENS CE, 1983, NEW ENGL J MED, V308, P1163; SZMUNESS W, 1981, LANCET, V1, P575; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; TADA H, 1982, PEDIATRICS, V70, P613; WILLIAMS BC, 1989, ANN INTERN MED, V111, P444, DOI 10.7326/0003-4819-111-5-444; WONG VCW, 1984, LANCET, V1, P921; XU ZY, 1985, PEDIATRICS, V76, P713; 1990, VITAL STATISTICS REP; 1988, MMWR, V37, P341; 1984, MMWR, V33, P285	41	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1991	266	20					2852	2855		10.1001/jama.266.20.2852	http://dx.doi.org/10.1001/jama.266.20.2852			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ722	1834870				2022-12-28	WOS:A1991GQ72200033
J	CLEAVELAND, CR				CLEAVELAND, CR			CPR	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PHYSICIAN-PATIENT RELATIONS; RESUSCITATION; MORTALITY; BURNOUT, PROFESSIONAL; STRESS, PSYCHOLOGICAL		A doctor, after a discouraging week at work, seeks respite in the new film version of Hamlet. However, real tragedy intervenes. In an adjoining theater, an old man collapses, the victim of an apparent cardiac arrest. The doctor responds to the appeal for medical help and does all he can to save the man. The intensity and cathartic nature of this experience lead to revelations and insights of interest to all doctors.											0	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					570	571		10.7326/0003-4819-115-7-570	http://dx.doi.org/10.7326/0003-4819-115-7-570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1810284				2022-12-28	WOS:A1991GG28300011
J	MILES, SH				MILES, SH			INFORMED DEMAND FOR NON-BENEFICIAL MEDICAL-TREATMENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FUTILITY; LIFE				MILES, SH (corresponding author), HENNEPIN CTY MED CTR, MINNEAPOLIS, MN 55415 USA.							[Anonymous], 1990, CRIT CARE MED, V18, P1435; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; LANTOS J D, 1989, American Journal of Medicine, V87, P81, DOI 10.1016/S0002-9343(89)80487-5; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; TOMLINSON T, 1990, GERONTOLOGIST, V30, P54, DOI 10.1093/geront/30.1.54; ZWEIBEL NR, 1989, GERONTOLOGIST, V29, P615, DOI 10.1093/geront/29.5.615; 1991, JAMA-J AM MED ASSOC, V265, P1868; IN PRESS AM REV RESP; 1987, LIFE SUSTAINING TECH	11	110	110	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					512	515		10.1056/NEJM199108153250713	http://dx.doi.org/10.1056/NEJM199108153250713			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1852186				2022-12-28	WOS:A1991GA76300013
J	SHAPER, AG; PHILLIPS, AN; POCOCK, SJ; WALKER, M; MACFARLANE, PW				SHAPER, AG; PHILLIPS, AN; POCOCK, SJ; WALKER, M; MACFARLANE, PW			RISK-FACTORS FOR STROKE IN MIDDLE-AGED BRITISH MEN	BRITISH MEDICAL JOURNAL			English	Article							DIASTOLIC BLOOD-PRESSURE; CIGARETTE-SMOKING; VENTRICULAR HYPERTROPHY; MORTALITY; ALCOHOL; HYPERTENSION	Objective - To determine the risk factors for stroke in a cohort representative of middle aged British men. Design - Prospective study of a cohort of men followed up for eight years. Setting - General practices in 24 towns in England, Wales, and Scotland (the British regional heart study). Subjects - 7735 men aged 40-59 at screening, selected at random from one general practice in each town. Main outcome measure - Fatal and non-fatal strokes. Results - 110 of the men had at least one stroke; there were four times as many non-fatal as fatal strokes. The relative risk of stroke was 12.1 in men who had high blood pressure (systolic blood pressure greater-than-or-equal-to 160 mm Hg) and were current smokers compared with normotensive, non-smoking men. Diastolic blood pressure yielded no additional information, and former cigarette smokers had the same risk as men who had never smoked. Heavy alcohol intake was associated with a relative risk of stroke of 3.8 in men without previously diagnosed cardiovascular disease. Men with pre-existing ischaemic heart disease had an increased risk of stroke, but only when left ventricular hypertrophy on electrocardiography was also present. Conclusions - Systolic blood pressure, cigarette smoking, and left ventricular hypertrophy on electrocardiography in men with pre-existing ischaemic heart disease were found to be the major risk factors for stroke in middle aged British men. Heavy alcohol intake seemed to increase the risk of stroke in men without previously diagnosed cardiovascular disease. A large proportion of strokes should be preventable by controlling blood pressure and stopping smoking.	ROYAL INFIRM,DEPT MED CARDIOL,GLASGOW G4 0SS,SCOTLAND	Royal Infirmary of Edinburgh	SHAPER, AG (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,LONDON NW3 2PF,ENGLAND.		Phillips, Andrew N/B-4427-2008	Phillips, Andrew N/0000-0003-2384-4807				ABBOTT RD, 1986, NEW ENGL J MED, V315, P717, DOI 10.1056/NEJM198609183151201; BLACKWELDER WC, 1980, AM J MED, V68, P165; BONITA R, 1986, BRIT MED J, V293, P6, DOI 10.1136/bmj.293.6538.6; BRUCE NG, 1988, J HYPERTENS, V6, P374; COOK DG, 1989, INT J EPIDEMIOL, V18, P607, DOI 10.1093/ije/18.3.607; DALE S, 1988, STROKE; DAVEYSMITH G, 1990, J EPIDEMIOL COMMUNIT, V44, P257; DONNAN GA, 1989, LANCET, V2, P643; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; ISO H, 1989, NEW ENGL J MED, V324, P4; KANNEL WB, 1983, AM J MED, V75, P4, DOI 10.1016/0002-9343(83)90111-0; MACFARLANE PW, 1981, BRIT HEART J, V45, P402; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MACMAHON SW, 1986, J HYPERTENS, V4, pS14; MENOTTI A, 1989, J HYPERTENS, V7, P595, DOI 10.1097/00004872-198907000-00011; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; RUTAN GH, 1989, J CLIN EPIDEMIOL, V42, P663, DOI 10.1016/0895-4356(89)90010-3; SAUNDERS JB, 1981, LANCET, V2, P653; SHAPER AG, 1988, LANCET, V2, P1267; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; STAMLER J, 1989, HYPERTENSION S1, V13, P12; STOKES J, 1987, CIRCULATION, V75, P56; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; VANDENBAN GC, 1989, INT J EPIDEMIOL, V18, P95, DOI 10.1093/ije/18.1.95; WALKER M, 1984, JR COLL GEN PRACT, V34, P364; WANNAMETHEE G, 1990, EUR J CLIN NUTR, V44, P133; WANNAMETHEE G, 1988, INT J EPIDEMIOL, V17, P201; 1988, BMJ, V297, P126; 1988, BMJ, V296, P1565	31	169	170	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1111	1115		10.1136/bmj.302.6785.1111	http://dx.doi.org/10.1136/bmj.302.6785.1111			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	1828378	Green Published, Bronze			2022-12-28	WOS:A1991FL43900016
J	KLEIN, R; JING, SQ; NANDURI, V; OROURKE, E; BARBACID, M				KLEIN, R; JING, SQ; NANDURI, V; OROURKE, E; BARBACID, M			THE TRK PROTOONCOGENE ENCODES A RECEPTOR FOR NERVE GROWTH-FACTOR	CELL			English	Article							HUMAN NGF RECEPTOR; GENE-TRANSFER; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; PC12 CELLS; EXPRESSION; PURIFICATION; BINDING; BRAIN; FOS	Two classes of receptors with distinct affinities for nerve growth factor (NGF) have been identified. The low affinity receptor (K(d) almost-equal-to 10(-9) to 10(-8) M) is a cysteine-rich glycoprotein encoded by the previously characterized LNGFR gene. The structural nature of the high affinity receptor (K(d) almost-equal-to 10(-11) to 10(-10) M) has yet to be established. In this study we show that the product of the human trk proto-oncogene (gp 140trk) binds NGF with high affinity. Moreover, NGF could be chemically cross-linked to the endogenous gp140trk present in rat PC12 pheochromocytoma cells as well as to gp140trk ectopically expressed in mouse fibroblasts and in insect Sf9 cells. High affinity binding of NGF to gp140trk can occur in the absence of low affinity LNGFR receptors, at least in nonneural cells. Addition of NGF to PC12 cells elicits rapid phosphorylation of gp140trk on tyrosine residues and stimulates its tyrosine kinase activity. These results indicate that gp140trk is a functional NGF receptor that mediates at least some of the signal transduction processes initiated by this neurotrophic factor.			KLEIN, R (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543, USA.		Klein, Ruediger/C-6147-2008	Klein, Ruediger/0000-0002-3109-0163				BARBACID M, 1991, IN PRESS BIOCH BIOPH; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BONGARZONE I, 1989, ONCOGENE, V4, P1457; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DREYFUS CF, 1989, TRENDS PHARMACOL SCI, V10, P145, DOI 10.1016/0165-6147(89)90166-1; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARLOW E, 1988, ANTIBODIES LABORATOR; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MASSAGUE J, 1981, J BIOL CHEM, V256, P9419; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; PINTAR JE, 1987, ONCOGENES GENES GROW, P103; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; SUTTER A, 1979, J BIOL CHEM, V254, P5972; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALE RD, 1985, METHOD ENZYMOL, V109, P21; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A	45	1302	1360	0	53	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					189	197		10.1016/0092-8674(91)90419-Y	http://dx.doi.org/10.1016/0092-8674(91)90419-Y			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1849459	Bronze			2022-12-28	WOS:A1991FF77300020
J	GILBERTSON, TA; SCOBEY, R; WILSON, M				GILBERTSON, TA; SCOBEY, R; WILSON, M			PERMEATION OF CALCIUM-IONS THROUGH NON-NMDA GLUTAMATE CHANNELS IN RETINAL BIPOLAR CELLS	SCIENCE			English	Article							MOUSE CENTRAL NEURONS; EXCITATORY AMINO-ACIDS; SPINAL-CORD NEURONS; HIPPOCAMPAL-NEURONS; NEUROMUSCULAR-JUNCTION; ACTIVATED CHANNELS; DIVALENT-CATIONS; PHOTORECEPTORS; QUISQUALATE; RECEPTORS	The conduction of calcium ions through glutamate-gated channels is important in the induction of long-term potentiation and may trigger other cellular changes. In retinal bipolar cells, which lack the N-methyl-D-aspartate (NMDA) type of glutamate-gated channel, calcium permeability through non-NMDA channels was examined. Changes in extracellular calcium concentration unexpectedly affected the reversal potential for glutamate-induced currents in a manner consistent with these channels being highly permeable to calcium. External magnesium ions promote desensitization of these non-NMDA channels in a voltage-independent way. Thus, in addition to non-NMDA channels that conduct only sodium and potassium, there is a class that is also permeable to calcium.	UNIV CALIF DAVIS, DEPT ZOOL, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, DEPT NEUROL, DAVIS, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis			Gilbertson, Timothy/G-7147-2011	Gilbertson, Timothy/0000-0003-2569-3096	NATIONAL EYE INSTITUTE [R01EY004112] Funding Source: NIH RePORTER; NEI NIH HHS [EY 04112] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P227; ASCHER P, 1986, J PHYSIOL-LONDON, V377, pP34; ATTWELL D, 1987, J PHYSIOL-LONDON, V387, P125, DOI 10.1113/jphysiol.1987.sp016567; AULT B, 1980, J PHYSIOL-LONDON, V307, P413, DOI 10.1113/jphysiol.1980.sp013443; BATES RG, 1970, ANAL CHEM, V42, P867, DOI 10.1021/ac60290a006; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BRANDON C, 1983, P NATL ACAD SCI-BIOL, V80, P5117, DOI 10.1073/pnas.80.16.5117; COPENHAGEN DR, 1989, NATURE, V341, P536, DOI 10.1038/341536a0; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; GILBERTSON TA, UNPUB; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; ISHIDA AT, 1985, P NATL ACAD SCI USA, V82, P1837, DOI 10.1073/pnas.82.6.1837; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JAN LY, 1976, J PHYSIOL-LONDON, V262, P215, DOI 10.1113/jphysiol.1976.sp011593; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MARC RE, 1981, P NATL ACAD SCI-BIOL, V78, P7185, DOI 10.1073/pnas.78.11.7185; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1989, NATURE, V338, P425, DOI 10.1038/338425a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MILLER AM, 1983, J PHYSIOL-LONDON, V334, P325, DOI 10.1113/jphysiol.1983.sp014497; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ODELL TJ, 1989, J NEUROPHYSIOL, V61, P162, DOI 10.1152/jn.1989.61.1.162; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TRUSSELL LO, 1988, P NATL ACAD SCI USA, V85, P4562, DOI 10.1073/pnas.85.12.4562-a	34	202	202	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1991	251	5001					1613	1615		10.1126/science.1849316	http://dx.doi.org/10.1126/science.1849316			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	1849316				2022-12-28	WOS:A1991FD89000039
J	ENNALS, S				ENNALS, S			MOBILITY ALLOWANCE	BRITISH MEDICAL JOURNAL			English	Article											ENNALS, S (corresponding author), ESSENTIAL RIGHTS,94 CHAWORTH RD,NOTTINGHAM NG2 7AD,ENGLAND.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					284	285		10.1136/bmj.302.6771.284	http://dx.doi.org/10.1136/bmj.302.6771.284			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1825613	Bronze, Green Published			2022-12-28	WOS:A1991EX91900028
J	ROGGE, RD; KARLOVICH, CA; BANERJEE, U				ROGGE, RD; KARLOVICH, CA; BANERJEE, U			GENETIC DISSECTION OF A NEURODEVELOPMENTAL PATHWAY - SON OF SEVENLESS FUNCTIONS DOWNSTREAM OF THE SEVENLESS AND EGF RECEPTOR TYROSINE KINASES	CELL			English	Article							FAINT-LITTLE-BALL; DROSOPHILA-MELANOGASTER; COMPOUND EYE; CELL LINEAGE; RETINA; PROTEIN; HOMOLOG; MUTATIONS; ENCODES; DOMAIN	We have isolated a dominant mutation in a gene called Son of sevenless (Sos) that is an allele-specific suppressor of the sevenless phenotype. This suppressor function is autonomously required in R7 and is sensitive to the dosage of the Sos and bride of sevenless genes. Loss-of-function alleles of Sos are recessive lethals, but in the eye Sos has a role in R cell development. Mutations in Sos also interact with the Ellipse allele of the Drosophila EGF receptor. We propose a model suggesting that the Sos product is downstream of sevenless and the EGF receptor, and that the dominant suppression results from the overexpression or increased activity of the gene product.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	ROGGE, RD (corresponding author), UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA.			Rogge, Ronald/0000-0002-1875-3938	NEI NIH HHS [1 R01 EY08152-01A1] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008152] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BANERJEE U, 1987, CELL, V49, P281, DOI 10.1016/0092-8674(87)90569-1; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1988, CELL, V54, P299; BONNERFRASER M, 1988, NATURE, V335, P161; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; BRENNER S, 1965, NATURE, V206, P994, DOI 10.1038/206994a0; CAMPOSORTEGA JA, 1979, ROUX ARCH DEV BIOL, V186, P27, DOI 10.1007/BF00848106; FRANCESCHINI N, 1971, KYBERNETIK, V9, P159, DOI 10.1007/BF02215177; GRIGLIATTI T, 1986, MUTAGENESIS DROSOPHI, P39; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HARTE A, 1990, IN PRESS GENES DEV; HODGKIN J, 1989, GENETICS, V123, P301; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; WOODRUFF RC, 1979, GENETICS, V92, P133	30	191	192	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					39	48		10.1016/0092-8674(91)90207-F	http://dx.doi.org/10.1016/0092-8674(91)90207-F			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846090				2022-12-28	WOS:A1991ET17500007
J	CRESS, WD; TRIEZENBERG, SJ				CRESS, WD; TRIEZENBERG, SJ			CRITICAL STRUCTURAL ELEMENTS OF THE VP16 TRANSCRIPTIONAL ACTIVATION DOMAIN	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; DNA-BINDING PROTEINS; FUNCTIONAL DISSECTION; MUTATIONAL ANALYSIS; REGULATORY PROTEIN; TRANS-ACTIVATOR; FUSION PROTEINS; MAMMALIAN-CELLS; FACTOR VMW65; ALPHA-GENES	Virion protein 16 (VP16) of herpes simplex virus type 1 contains an acidic transcriptional activation domain. Missense mutations within this domain have provided insights into the structural elements critical for its function. Net negative charge contributed to, but was not sufficient for, transcriptional activation by VP16. A putative amphipathic alpha helix did not appear to be an important structural component of the activation domain. A phenylalanine residue at position 442 was exquisitely sensitive to mutation. Transcriptional activators of several classes contain hydrophobic amino acids arranged in patterns resembling that of VP16. Therefore, the mechanism of transcriptional activation by VP16 and other proteins may involve both ionic and specific hydrophobic interactions with target molecules.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University				Triezenberg, Steven/0000-0003-4184-5221	NIAID NIH HHS [AI 27323] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI027323, R01AI027323] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACE CI, 1988, J GEN VIROL, V69, P2595, DOI 10.1099/0022-1317-69-10-2595; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, UNPUB; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GRAVES BJ, 1985, MOL CELL BIOL, V5, P1948, DOI 10.1128/MCB.5.8.1948; GREAVES R, 1989, J VIROL, V63, P1641, DOI 10.1128/JVI.63.4.1641-1650.1989; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1988, CELL, V54, P1043; INGLES CJ, UNPUB; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KRISTIE TM, 1987, P NATL ACAD SCI USA, V84, P71, DOI 10.1073/pnas.84.1.71; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; POST LE, 1981, CELL, V24, P555, DOI 10.1016/0092-8674(81)90346-9; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; WERSTUCK G, 1989, J VIROL, V63, P5509, DOI 10.1128/JVI.63.12.5509-5513.1989; WERSTUCK G, 1989, GENE, V75, P213, DOI 10.1016/0378-1119(89)90267-9; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	39	402	418	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					87	90		10.1126/science.1846049	http://dx.doi.org/10.1126/science.1846049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1846049				2022-12-28	WOS:A1991EQ60300034
J	TEO, KK; YUSUF, S; COLLINS, R; HELD, PH; PETO, R				TEO, KK; YUSUF, S; COLLINS, R; HELD, PH; PETO, R			EFFECTS OF INTRAVENOUS MAGNESIUM IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - OVERVIEW OF RANDOMIZED TRIALS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SYSTEMATIC OVERVIEWS; ARRHYTHMIAS; SULFATE; HEART; DEATH; NEED	Objective - To investigate the effect of intravenous magnesium on mortality in suspected acute myocardial infarction. Design - Systematic overview of all available randomised trials in which patients were allocated to receive either intravenous magnesium or otherwise similar treatment without magnesium. Setting - Coronary care units of several hospitals. Patients - 1301 patients in seven randomised trials. Main outcome measure - Short term mortality. Results - Considering the seven trials collectively there were 25 (3.8%) deaths among 657 patients allocated to receive magnesium and 53 (8.2%) deaths among 644 patients allocated control, generally during hospital follow up. This represents a 55% reduction in the odds of death (p < 0.001) with 95% confidence intervals ranging from about one third to about two thirds. 70 of 648 patients allocated magnesium compared with 109 of 641 controls had serious ventricular arrhythmias, suggesting that magnesium reduces the incidence, though the definition varied among trials. Other adverse effects were rare in the limited number of patients for whom this data were available. Conclusion - Despite the limited number of patients randomised this overview suggests that intravenous magnesium therapy may reduce mortality in patients with acute myocardial infarction. Further large scale trials to confirm (or refute) these findings are desirable.	NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, CLIN TRIALS BRANCH, BETHESDA, MD 20892 USA; UNIV OXFORD, CLIN TRIALS SERV, OXFORD, ENGLAND	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Oxford	YUSUF, S (corresponding author), NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, CLIN TRIALS BRANCH, BETHESDA, MD 20892 USA.			Yusuf, Salim/0000-0003-4776-5601				ABRAHAM AS, 1987, ARCH INTERN MED, V147, P753, DOI 10.1001/archinte.147.4.753; ALTURA BM, 1971, AM J PHYSIOL, V220, P938, DOI 10.1152/ajplegacy.1971.220.4.938; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P320; [Anonymous], 1986, LANCET, V2, P57; CEREMUZYNSKI L, 1989, AM HEART J, V118, P1333, DOI 10.1016/0002-8703(89)90027-6; CHANG C, 1985, J AM COLL CARDIOL, V5, P280, DOI 10.1016/S0735-1097(85)80048-6; COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; COLLINS R, 1991, BRIT HEART J, V66, P250; DYCKNER T, 1980, ACTA MED SCAND, V207, P59; DYCKNER T, 1979, AM HEART J, V97, P12, DOI 10.1016/0002-8703(79)90108-X; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; ELWOOD PC, 1980, LANCET, V2, P720; FELDSTEDT M, 1988, European Heart Journal, V9, P226; FELDSTEDT M, IN PRESS EUR HEART J; GHANI MF, 1977, AM HEART J, V94, P600; HEPTINSTALL S, 1986, LANCET, V1, P552; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; HLATKY MA, 1988, AM J CARDIOL, V61, P515, DOI 10.1016/0002-9149(88)90756-4; ISERI LT, 1986, MAGNESIUM-B, V8, P223; LEARY WP, 1983, S AFR MED J, V64, P775; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; MISHRA R. K., 1960, REV CANADIENNE BIOL, V19, P122; Morton B C, 1984, Magnesium, V3, P346; MORTON BC, 1984, MAGNESIUM-B, V6, P133; MORTON BC, 1981, MAGNESIUM-B, V3, P192; PERTICONE F, 1986, AM HEART J, V112, P847, DOI 10.1016/0002-8703(86)90486-2; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PRASAD DMV, 1978, EUR J PHARMACOL, V52, P421, DOI 10.1016/0014-2999(78)90303-5; RASMUSSEN HS, 1986, ARCH INTERN MED, V146, P872, DOI 10.1001/archinte.146.5.872; RASMUSSEN HS, 1986, LANCET, V1, P234; RASMUSSEN HS, 1988, CLIN CARDIOL, V11, P377, DOI 10.1002/clc.4960110604; SHECHTER M, 1990, AM J CARDIOL, V66, P271, DOI 10.1016/0002-9149(90)90834-N; SHINE KI, 1979, AM J PHYSIOL, V237, pH413, DOI 10.1152/ajpheart.1979.237.4.H413; SMITH LF, 1986, INT J CARDIOL, V12, P175, DOI 10.1016/0167-5273(86)90239-1; TURLAPATY PDMV, 1980, SCIENCE, V208, P198, DOI 10.1126/science.7361117; TZIVONI D, 1988, CIRCULATION, V77, P392, DOI 10.1161/01.CIR.77.2.392; WOODS KL, 1991, BRIT J CLIN PHARMACO, V32, P3, DOI 10.1111/j.1365-2125.1991.tb05605.x; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1991, LANCET, V338, P667	42	261	270	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 14	1991	303	6816					1499	1503		10.1136/bmj.303.6816.1499	http://dx.doi.org/10.1136/bmj.303.6816.1499			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1838289	Bronze, Green Published			2022-12-28	WOS:A1991GV47600018
J	STROBEL, SA; DOUCETTESTAMM, LA; RIBA, L; HOUSMAN, DE; DERVAN, PB				STROBEL, SA; DOUCETTESTAMM, LA; RIBA, L; HOUSMAN, DE; DERVAN, PB			SITE-SPECIFIC CLEAVAGE OF HUMAN CHROMOSOME-4 MEDIATED BY TRIPLE-HELIX FORMATION	SCIENCE			English	Article							HUNTINGTONS-DISEASE GENE; LARGE DNA-MOLECULES; GEL-ELECTROPHORESIS; YEAST CHROMOSOME; SINGLE SITE; G8 PROBE; FIELD; MARKERS; D4S10; BINDING	Direct physical isolation of specific DNA segments from the human genome is a necessary goal in human genetics. For testing whether triple-helix mediated enzymatic cleavage can liberate a specific segment of a human chromosome, the tip of human chromosome 4, which contains the entire candidate region for the Huntington's disease gene, was chosen as a target. A 16-base pyrimidine oligodeoxyribonucleotide was able to locate a 16-base pair purine target site within more than 10 gigabase pairs of genomic DNA and mediate the exact enzymatic cleavage at that site in more than 80 percent yield. The recognition motif is sufficiently generalizable that most cosmids should contain a sequence targetable by triple-helix formation. This method may facilitate the orchestrated dissection of human chromosomes from normal and affected individuals into megabase sized fragments and facilitate the isolation of candidate gene loci.	CALTECH,ARNOLD & MABEL BECKMAN LABS CHEM SYNTH,PASADENA,CA 91125; MIT,CTR CANC RES,CAMBRIDGE,MA 02139	California Institute of Technology; Massachusetts Institute of Technology (MIT)	DERVAN, PB (corresponding author), CALTECH,ARNOLD & MABEL BECKMAN LABS CHEM SYNTH,PASADENA,CA 91125, USA.				NHGRI NIH HHS [HG00329, HG00098] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000329] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BATES GP, 1991, AM J HUM GENET, V49, P7; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BIRREN BW, 1988, NUCLEIC ACIDS RES, V16, P7563, DOI 10.1093/nar/16.15.7563; BUCAN M, 1990, GENOMICS, V6, P1; CARLE GF, 1986, SCIENCE, V232, P65, DOI 10.1126/science.3952500; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CLARK SM, 1988, SCIENCE, V241, P1203, DOI 10.1126/science.3045968; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DERVAN PB, 1988, NUCLEIC ACIDS MOL BI, V2, P49; DOUCETTESTAMM LA, IN PRESS SOMATIC CEL; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FOLSTEIN SE, 1985, SCIENCE, V229, P776, DOI 10.1126/science.2992086; GILLIAM TC, 1987, CELL, V50, P565, DOI 10.1016/0092-8674(87)90029-8; GILLIAM TC, 1987, SCIENCE, V238, P950, DOI 10.1126/science.2890209; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; GUSELLA JF, 1986, COLD SPRING HARB SYM, V51, P359, DOI 10.1101/SQB.1986.051.01.043; GUSELLA JF, IN PRESS GENOMICS; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HORNE DA, 1990, J AM CHEM SOC, V112, P2435, DOI 10.1021/ja00162a063; KOOB M, 1990, SCIENCE, V250, P271, DOI 10.1126/science.2218529; LANDEGENT JE, 1986, HUM GENET, V73, P354, DOI 10.1007/BF00279100; LIPSETT MN, 1964, J BIOL CHEM, V239, P1256; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; POHL TM, 1988, NUCLEIC ACIDS RES, V16, P9185, DOI 10.1093/nar/16.19.9185; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; PRITCHARD CA, 1989, GENOMICS, V4, P408, DOI 10.1016/0888-7543(89)90348-0; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; RICHARDS B, 1991, GENOMICS, V9, P235, DOI 10.1016/0888-7543(91)90247-C; RICHARDS JE, 1988, P NATL ACAD SCI USA, V85, P6437, DOI 10.1073/pnas.85.17.6437; Saiki R.K., 1989, PCR TECHNOLOGY, P7; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SKRAASTAD MI, 1989, AM J HUM GENET, V44, P560; Smith C.L., 1988, P41; STAPLETON PM, 1988, NUCLEIC ACIDS RES, V16, P2735, DOI 10.1093/nar/16.6.2735; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; THEUNE S, 1991, GENOMICS, V9, P511, DOI 10.1016/0888-7543(91)90418-E; WASMUTH JJ, 1988, NATURE, V332, P734, DOI 10.1038/332734a0; YOUNGMAN S, 1989, GENOMICS, V5, P802, DOI 10.1016/0888-7543(89)90122-5	48	195	212	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1639	1642		10.1126/science.1836279	http://dx.doi.org/10.1126/science.1836279			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1836279				2022-12-28	WOS:A1991GV07300044
J	STEIN, HF				STEIN, HF			PUPILS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2941	2942						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820456				2022-12-28	WOS:A1991GR77500001
J	RALSTON, R				RALSTON, R			COMPLEMENTATION OF TRANSFORMING DOMAINS IN E1A/MYC CHIMERAS	NATURE			English	Article							ADENOVIRUS E1A PROTEINS; C-MYC; LARGE-T; ONCOGENES; PRODUCTS; REGIONS; GENE; CELLS; E7	THE myc oncogene is functionally similar to adenovirus E1a in its ability to collaborate with activated ras oncogenes to transform primary fibroblasts 1,2. The transforming functions of E1a and myc have been mapped to two distinct regions in each protein 3,4. I investigated the functional similarities between E1a and myc by constructing E1a/myc chimaeras to discover whether the individual transforming domains of E1a could complement individual myc-transforming domains. Transformation assays in rat embryo fibroblasts demonstrated that the N-terminal transforming domain of E1a (CR1; ref. 5) could complement the C-terminal transforming domain of myc in cis, and that the reciprocal chimaera (N-terminal myc/C-terminal E1a) was also active. Chimaeras constructed using domains from transformation-defective mutants of either E1a or myc were inactive, indicating that both E1a and myc domains contribute to function. These experiments suggest that transformation by myc and E1a may involve interactions with common substrates.			RALSTON, R (corresponding author), CHIRON CORP, 4560 HORTON ST, EMERYVILLE, CA 94608 USA.		Ralston, Robert O/A-6924-2009					ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; JONES NC, 1983, MOL CELL BIOL, V3, P2131, DOI 10.1128/MCB.3.12.2131; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SYMONDS G, 1989, ONCOGENE, V4, P285; VOUSDEN KH, 1989, ONCOGENE, V4, P153; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988	24	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1991	353	6347					866	868		10.1038/353866a0	http://dx.doi.org/10.1038/353866a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1834947				2022-12-28	WOS:A1991GM73200067
J	PORAT, R; CLARK, BD; WOLFF, SM; DINARELLO, CA				PORAT, R; CLARK, BD; WOLFF, SM; DINARELLO, CA			ENHANCEMENT OF GROWTH OF VIRULENT-STRAINS OF ESCHERICHIA-COLI BY INTERLEUKIN-1	SCIENCE			English	Article							RECEPTOR ANTAGONIST; EXPRESSION; UROMODULIN; INHIBITOR; CLONING; PROTEIN; SHOCK; SERUM; BINDS; IL-1	Interleukin-1 (IL-1) is a polypeptide cytokine that mediates many physiological responses to infection and inflammation and is a growth factor for certain mammalian cells. Virulent and avirulent clinical isolates of Escherichia coli were grown in culture media in the presence of human IL-1. IL-1-beta, but not tumor necrosis factor or IL-4, enhanced the growth of virulent, but not avirulent, E. coli. This enhancement was blocked by the IL-1 receptor antagonist (IL-lra). Radiolabeled IL-1 bound to virulent but not avirulent E. coli in a specific and saturable fashion; IL-lra inhibited this binding. Thus, human IL-1 may recognize a functional IL-1-like receptor structure on virulent E. coli and may be a virulence factor for bacterial pathogenicity.	TUFTS UNIV,NEW ENGLAND MED CTR HOSP,DEPT MED,DIV GEOG MED & INFECT DIS,BOSTON,MA 02111	Tufts Medical Center; Tufts University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI015614, R01AI015614, R37AI015614] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AREND WP, 1985, J IMMUNOL, V134, P3868; BJORNSON BH, 1988, INFECT IMMUN, V56, P1602, DOI 10.1128/IAI.56.6.1602-1607.1988; BRODY DT, 1989, J IMMUNOL, V143, P1183; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; DINARELLO CA, 1991, BLOOD, V77, P1627; DOWER SK, COMMUNICATION; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; MANCILLA J, 1989, CYTOKINE, V1, P95; MCCABE WR, 1978, J INFECT DIS, V138, P33, DOI 10.1093/infdis/138.1.33; MUCHMORE AV, 1987, J IMMUNOL, V138, P2541; MUCHMORE AV, 1986, J BIOL CHEM, V261, P3404; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; PENNICA D, 1987, SCIENCE, V236, P83, DOI 10.1126/science.3453112; PORAT R, 1987, INFECT IMMUN, V55, P320, DOI 10.1128/IAI.55.2.320-328.1987; PORAT R, UNPUB; ROANTREE RJ, 1960, J CLIN INVEST, V39, P72, DOI 10.1172/JCI104029; Savage N, 1989, Cytokine, V1, P23, DOI 10.1016/1043-4666(89)91045-4; SECKINGER P, 1987, J IMMUNOL, V139, P1546; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; Sipe J D, 1988, Adv Exp Med Biol, V243, P193; STROM TB, 1988, INFECT IMMUN, V56, P1593; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816	24	159	163	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					430	432		10.1126/science.1833820	http://dx.doi.org/10.1126/science.1833820			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1833820				2022-12-28	WOS:A1991GK72900049
J	CLARKE, ND; BEAMER, LJ; GOLDBERG, HR; BERKOWER, C; PABO, CO				CLARKE, ND; BEAMER, LJ; GOLDBERG, HR; BERKOWER, C; PABO, CO			THE DNA-BINDING ARM OF LAMBDA-REPRESSOR - CRITICAL CONTACTS FROM A FLEXIBLE REGION	SCIENCE			English	Article							OPERATOR; DOMAIN; OR1; CRO	Segments of protein that do not adopt a well-ordered conformation in the absence of DNA can still contribute to site-specific recognition of DNA. The first six residues (NH2-Ser1-Thr2-Lys3-Lys4-Lys5-Pro6-) of phage-lambda repressor are flexible but are important for site-specific binding. Low-temperature x-ray crystallography and codon-directed saturation mutagenesis were used to study the role of this segment. All of the functional sequences have the form [X]1-[X]2-[Lys or Arg]3-[Lys]4-[Lys or Arg]5-[X]6. A high-resolution (1.8 angstrom) crystal structure shows that Lys3 and Lys4 each make multiple hydrogen bonds with guanines and that Lys5 interacts with the phosphate backbone. The symmetry of the complex breaks down near the center of the site, and these results suggest a revision in the traditional alignment of the six lambda-operator sites.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Clarke, Neil/D-9613-2014		NIGMS NIH HHS [GM31471] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031471] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAMER L, UNPUB; BEAMER LJ, 1991, THESIS J HOPKINS U B; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; ELIASON JL, 1985, P NATL ACAD SCI USA, V82, P2339, DOI 10.1073/pnas.82.8.2339; HOCHSCHILD A, 1986, CELL, V47, P807, DOI 10.1016/0092-8674(86)90523-4; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; PABO CO, 1982, NATURE, V298, P441, DOI 10.1038/298441a0; Ptashne M., 1986, A GENETIC SWITCH; SARAI A, 1989, P NATL ACAD SCI USA, V86, P6513, DOI 10.1073/pnas.86.17.6513; SAUER RT, 1979, NATURE, V279, P396, DOI 10.1038/279396a0; WEISS MA, 1984, P NATL ACAD SCI-BIOL, V81, P6019, DOI 10.1073/pnas.81.19.6019	13	100	101	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					267	270		10.1126/science.1833818	http://dx.doi.org/10.1126/science.1833818			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1833818				2022-12-28	WOS:A1991GJ64200033
J	GELERNTER, J; OMALLEY, S; RISCH, N; KRANZLER, HR; KRYSTAL, J; MERIKANGAS, K; KENNEDY, JL; KIDD, KK				GELERNTER, J; OMALLEY, S; RISCH, N; KRANZLER, HR; KRYSTAL, J; MERIKANGAS, K; KENNEDY, JL; KIDD, KK			NO ASSOCIATION BETWEEN AN ALLELE AT THE D2-DOPAMINE RECEPTOR GENE (DRD2) AND ALCOHOLISM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEHYDROGENASE; DEFICIENCY; JAPANESE; DISEASE; LIVER	Objective. - We attempted to replicate a positive allelic association between the A1 allele of DRD2 (the D2 dopamine receptor locus) and alcoholism that has been reported. Design. - We compared allele frequencies at the previously described Taq I restriction fragment length polymorphism system of DRD2 in alcoholics and random population controls. Subjects. - The alcoholic subjects were 44 unrelated white individuals, diagnosed by direct structured interview to have alcohol dependence (by the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition, criteria). The subjects in our random population control group (N = 68) were also white. Results. - For the control group, allele frequencies at DRD2 were 0.20 (A1) and 0.80 (A2). For the alcoholic group overall, allele frequencies were 0.23 (A1) and 0.77 (A2). There were no significant differences in allele frequencies at the DRD2 locus between alcoholics and controls. The allele frequencies in both groups agreed closely with those observed in most previously described control populations. Subtyping the alcoholic group according to presence or absence of family history of alcoholism, presence or absence of antisocial personality disorder, age of onset, presence or absence of physical withdrawal symptoms, or recent alcohol consumption (as a measure of severity) did not in any case reveal significant differences in allele frequencies. Conclusion. - We were not able to replicate the results previously reported. We conclude that our data do not support an allelic association between the A1 allele at DRD2 and alcoholism.	YALE UNIV,SCH MED,DEPT PSYCHIAT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510; UNIV CONNECTICUT,SCH MED,FARMINGTON,CT 06032; YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06510	Yale University; Yale University; University of Connecticut; Yale University	GELERNTER, J (corresponding author), DEPT VET AFFAIRS MED CTR,950 CAMPBELL AVE,W HAVEN,CT 06516, USA.		kranzler, henry/AAS-1113-2020	kranzler, henry/0000-0002-1018-0450; Gelernter, Joel/0000-0002-4067-1859	NIAAA NIH HHS [5RO1AA08033, P50AA03510] Funding Source: Medline; NIMH NIH HHS [MH30929] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH030929, P50MH030929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008033, P50AA003510] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BOLOS AM, 1990, JAMA-J AM MED ASSOC, V264, P3156; Bowcock A M, 1987, Gene Geogr, V1, P47; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; BREG WR, 1980, TRISOMY 21 DOWN SYND, P205; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604; COMINGS DE, 1990, AM J HUM GENET S, V47, P52; CONNEALLY PM, 1991, ARCH GEN PSYCHIAT, V48, P664; FINEMAN RM, 1976, NATURE, V260, P320, DOI 10.1038/260320a0; GELERNTER J, 1990, ARCH GEN PSYCHIAT, V47, P1073; GELERNTER J, 1990, AM J HUM GENET S, V447, P179; GOEDDE HW, 1979, HUM GENET, V51, P331; GOEDERS NE, 1983, SCIENCE, V221, P773, DOI 10.1126/science.6879176; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GRANDY DK, 1989, AM J HUM GENET, V45, P778; HARADA S, 1982, LANCET, V2, P827, DOI 10.1016/s0140-6736(82)92722-2; HARADA S, 1981, LANCET, V2, P982; HAUGE XY, 1991, GENOMICS, V10, P527, DOI 10.1016/0888-7543(91)90431-D; LI TK, 1977, P NATL ACAD SCI USA, V74, P4378, DOI 10.1073/pnas.74.10.4378; MERIKANGAS KR, 1990, PSYCHIAT CLIN N AM, V13, P613; MERIKANGAS KR, 1990, PSYCHOL MED, V20, P11, DOI 10.1017/S0033291700013192; Modell J G, 1990, J Neuropsychiatry Clin Neurosci, V2, P123; MOISES HW, 1991, ARCH GEN PSYCHIAT, V48, P643; NOBLE EP, 1991, JAMA-J AM MED ASSOC, V265, P2667, DOI 10.1001/jama.1991.03460200047016; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P648; PARSIAN A, 1991, ARCH GEN PSYCHIAT, V48, P655; RISCH N, 1987, AM J HUM GENET, V40, P1; Robins LN, 1985, EPIDEMIOLOGIC FIELD, P143; Sambrook J, 1989, MOL CLONING LABORATO; SHIBUYA A, 1988, AM J HUM GENET, V43, P744; SMITH SS, 1991, JAMA-J AM MED ASSOC, V265, P2667, DOI 10.1001/jama.1991.03460200047017; Sobell M. B., 1980, EVALUATING ALCOHOL D, P129, DOI DOI 10.1016/B978-0-08-022997-3.50013-2; Spitzer R., 1985, STRUCTURED CLIN INTE; Spitzer R.L., 1975, SCHEDULE AFFECTIVE D; THOMASSON HR, 1991, AM J HUM GENET, V48, P677; WEISSMAN MM, 1986, ARCH GEN PSYCHIAT, V43, P1104; WISE RA, 1988, J ABNORM PSYCHOL, V97, P118, DOI 10.1037/0021-843X.97.2.118; WISE RA, 1982, PHARMACOL BIOCHEM BE, V17, P239, DOI 10.1016/0091-3057(82)90076-4; WU JS, 1990, AM J HUM GENET, V46, P624; YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258; 1980, DIAGNOSTIC STATISTIC; 1987, DIAGNOSTIC STATISTIC	42	223	228	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1801	1807		10.1001/jama.266.13.1801	http://dx.doi.org/10.1001/jama.266.13.1801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG551	1832467				2022-12-28	WOS:A1991GG55100032
J	GOODWIN, FK				GOODWIN, FK			STRESS OF CARING FOR THE DEMENTED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,WASHINGTON,DC, USA.							KIECOLTGLASER JK, 1991, PSYCHOSOM MED, V53, P345, DOI 10.1097/00006842-199107000-00001; DIAGNOSTIC STATISTIC	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1619	1619						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF419	1832194				2022-12-28	WOS:A1991GF41900006
J	WOOD, PD; STEFANICK, ML; WILLIAMS, PT; HASKELL, WL				WOOD, PD; STEFANICK, ML; WILLIAMS, PT; HASKELL, WL			THE EFFECTS ON PLASMA-LIPOPROTEINS OF A PRUDENT WEIGHT-REDUCING DIET, WITH OR WITHOUT EXERCISE, IN OVERWEIGHT MEN AND WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; ADIPOSE-TISSUE; CHOLESTEROL; PARTICIPANTS; OBESITY; FOLLOW; RISK; PRECIPITATION; QUANTITATION	Background. The National Cholesterol Education Program (NCEP) recommends a low-saturated-fat, low-cholesterol diet, with weight loss if indicated, to correct elevated plasma cholesterol levels. Weight loss accomplished by simple caloric restriction or increased exercise typically increases the level of high-density lipoprotein (HDL) cholesterol. Little is known about the effects on plasma lipoproteins of a hypocaloric NCEP diet with or without exercise in overweight people. Methods. We tested the hypothesis that exercise (walking or jogging) will increase HDL cholesterol levels in moderately overweight, sedentary people who adopt a hypocaloric NCEP diet. We randomly assigned 132 men and 132 women 25 to 49 years old to one of three groups: control, hypocaloric NCEP diet, or hypocaloric NCEP diet with exercise. One hundred nineteen of the men and 112 of the women returned for testing after one year. Results. After one year, the subjects in both intervention groups had reached or closely approached NCEP Step 1 dietary goals and reduced their mean body fat significantly (range of reduction in mean fat weight, 4.0 to 7.8 kg). Weight loss on the NCEP diet alone did not significantly change HDL cholesterol levels in either the men or the women as compared with the subjects in the control group. Plasma levels of HDL cholesterol increased significantly more in the men who exercised and dieted (mean [+/- SE] change, +13 +/- 3 percent) than in the men who only dieted (+2 +/- 3 percent, P < 0.01) or the men who acted as controls (-4 +/- 2 percent, P < 0.001). HDL cholesterol levels remained about the same in the women who exercised and dieted (+1 +/- 2 percent); they were higher than in the women who only dieted (-10 +/- 3 percent, P < 0.01), but not higher than in the controls (-3 +/- 3 percent). Conclusions. Regular exercise in overweight men and women enhances the improvement in plasma lipoprotein levels that results from the adoption of a low-saturated-fat, low-cholesterol diet.			WOOD, PD (corresponding author), STANFORD UNIV,SCH MED,STANFORD CTR RES DIS PREVENT,730 WELCH RD,PALO ALTO,CA 94304, USA.		González, Adela M Gómez/D-2863-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024462, K04HL002183] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24462, HL-02183] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BUSH TL, 1988, CLIN CHEM, V34, pB60; FORTMANN SP, 1988, AM J CARDIOL, V62, P89, DOI 10.1016/0002-9149(88)91370-7; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; HAGBERG JM, 1990, EXERCISE, FITNESS, AND HEALTH, P455; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KRAUSS RM, 1982, MED CLIN N AM, V66, P403, DOI 10.1016/S0025-7125(16)31427-4; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; MACIEJKO JJ, 1987, CLIN CHEM, V33, P2065; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; NAITO HK, 1985, ANN NY ACAD SCI, V454, P230, DOI 10.1111/j.1749-6632.1985.tb11862.x; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; SAMPSON EJ, 1975, CLIN CHEM, V21, P1983; SAVIN WM, 1980, CIRCULATION, V62, P55, DOI 10.1161/01.CIR.62.1.55; Siri W., 1961, TECHNIQUES MEASURING, P223; THOMPSON JK, 1982, PSYCHOL BULL, V91, P55, DOI 10.1037/0033-2909.91.1.55; WARNICK GR, 1982, CLIN CHEM, V28, P1574; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801; 1982, DHEW NIH75628 PUBL; 1990, MMWR, V39, P541; 1986, NUTRIENT DATA BASE V; 1987, DHHS NIH882926 PUBL; [No title captured]; 1989, DHHS NIH892925 PUBL; 1984, JAMA-J AM MED ASSOC, V251, P351	29	459	472	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					461	466		10.1056/NEJM199108153250703	http://dx.doi.org/10.1056/NEJM199108153250703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1852180				2022-12-28	WOS:A1991GA76300003
J	BINGHAM, S				BINGHAM, S			DIETARY ASPECTS OF A HEALTH STRATEGY FOR ENGLAND	BRITISH MEDICAL JOURNAL			English	Article											BINGHAM, S (corresponding author), MRC,DUNN CLIN NUTR CTR,CAMBRIDGE CB2 1QL,ENGLAND.							BINGHAM S, 1990, DIET CANCER BRIEFING; BRETT A, 1986, HUM NUTR-APPL NUTR, V40A, P217; BUSS DH, 1988, P NUTR SOC, V47, P295, DOI 10.1079/PNS19880047; Doll R, 1981, J NATL CANCER I, V66, P1192; Gregory F., 1990, DIETARY NUTR SURVEY; KNIGHT I, 1984, HEIGHTS WEIGHTS ADUL; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; LEAN MEJ, 1988, INT J OBESITY, V12, P15; SHAPER AG, 1988, CORONARY HEART DISEA; Willett W, 1990, NUTRITIONAL EPIDEMIO; 1991, DIETARY REFERENCE VA; 1988, DHHS8850210 DEP HLTH; 1990, WHO TECH REP SER, V797; 1991, HLTH NATION; 1988, MONOGRAPH EVALUATION, V44	15	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					353	355		10.1136/bmj.303.6798.353	http://dx.doi.org/10.1136/bmj.303.6798.353			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1823133	Green Published, Bronze			2022-12-28	WOS:A1991GA60600027
J	MARTUZA, RL; MALICK, A; MARKERT, JM; RUFFNER, KL; COEN, DM				MARTUZA, RL; MALICK, A; MARKERT, JM; RUFFNER, KL; COEN, DM			EXPERIMENTAL-THERAPY OF HUMAN GLIOMA BY MEANS OF A GENETICALLY ENGINEERED VIRUS MUTANT	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; ACYCLOVIR-RESISTANT HERPES; ACQUIRED IMMUNODEFICIENCY SYNDROME; RADIATION-THERAPY; MALIGNANT GLIOMA; INFECTIONS; RADIOTHERAPY; FOSCARNET; GLIOBLASTOMA; THYMIDINE	Malignant gliomas are the most common malignant brain tumors and are almost always fatal. A thymidine kinase-negative mutant of herpes simplex virus-1 (dlsptk) that is attenuated for neurovirulence was tested as a possible treatment for gliomas. In cell culture, dlsptk killed two long-term human glioma lines and three short-term human glioma cell populations. In nude mice with implanted subcutaneous and subrenal U87 human gliomas, intraneoplastic inoculation of dlsptk caused growth inhibition. In nude mice with intracranial U87 gliomas, intraneoplastic inoculation of dlsptk prolonged survival. Genetically engineered viruses such as dlsptk merit further evaluation as novel antineoplastic agents.	HARVARD UNIV,MASSACHUSETTS GEN HOSP E,SCH MED,DEPT SURG NEUROSURG,BOSTON,MA 02129; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; UNIV MICHIGAN,MED CTR,DIV NEUROSURG,ANN ARBOR,MI 48109	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan	MARTUZA, RL (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP E,SCH MED,MOLEC NEUROGENET LAB,BOSTON,MA 02129, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NCRR NIH HHS [SO7RRO5381] Funding Source: Medline; NIAID NIH HHS [R01-AI26126] Funding Source: Medline; NINDS NIH HHS [NS24279] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Austin F C, 1979, Adv Cancer Res, V30, P301, DOI 10.1016/S0065-230X(08)60900-8; BURDICK KH, 1964, CANCER, V17, P708, DOI 10.1002/1097-0142(196406)17:6<708::AID-CNCR2820170604>3.0.CO;2-3; CASSEL WA, 1983, CANCER, V52, P856, DOI 10.1002/1097-0142(19830901)52:5<856::AID-CNCR2820520519>3.0.CO;2-4; CHATIS PA, 1989, NEW ENGL J MED, V320, P297, DOI 10.1056/NEJM198902023200507; COEN DM, 1985, J VIROL, V53, P477, DOI 10.1128/JVI.53.2.477-488.1985; COEN DM, 1989, P NATL ACAD SCI USA, V86, P4736, DOI 10.1073/pnas.86.12.4736; COREY L, 1986, NEW ENGL J MED, V314, P749, DOI 10.1056/NEJM198603203141205; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; ERLICH KS, 1989, ANN INTERN MED, V110, P710, DOI 10.7326/0003-4819-110-9-710; FIELD HJ, 1978, J HYG-CAMBRIDGE, V81, P267, DOI 10.1017/S0022172400025109; FIELD HJ, 1980, ANTIMICROB AGENTS CH, V17, P209, DOI 10.1128/AAC.17.2.209; HIRSCH MS, 1983, NEW ENGL J MED, V309, P963; HIRSCH MS, 1983, NEW ENGL J MED, V309, P1034; HOCHBERG FH, 1980, NEUROLOGY, V30, P907, DOI 10.1212/WNL.30.9.907; JAMIESON AT, 1974, J GEN VIROL, V24, P465, DOI 10.1099/0022-1317-24-3-465; KIM TS, IN PRESS J NEUROSURG; Kobayashi H, 1979, Adv Cancer Res, V30, P279; LEE JK, 1990, NEUROSURGERY, V26, P598, DOI 10.1227/00006123-199004000-00007; LEVIN AL, 1989, CANC PRINCIPLES PRAC, V2, P1557; Luna LG, 1968, MANUAL HISTOLOGIC ST, V3; MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826; MEDHKOUR A, 1989, J NEUROSURG, V71, P545, DOI 10.3171/jns.1989.71.4.0545; MOORE A. E., 1960, PROGR EXPTL TUMOR RES, V1, P411; ONOYAMA Y, 1976, AM J ROENTGENOL, V126, P481, DOI 10.2214/ajr.126.3.481; PEARSON HE, 1956, P SOC EXP BIOL MED, V92, P551; SACKS SL, 1989, ANN INTERN MED, V111, P893, DOI 10.7326/0003-4819-111-11-893; SALAZAR OM, 1979, INT J RADIAT ONCOL, V5, P1733, DOI 10.1016/0360-3016(79)90554-6; SAUTER C, 1978, CURRENT CHEMOTHERAPY, P1112; SCHOENBERG BS, 1983, ONCOLOGY NERVOUS SYS, P1; SHAPIRO WR, 1989, J NEUROSURG, V71, P1, DOI 10.3171/jns.1989.71.1.0001; SIGEL MM, 1955, J IMMUNOL, V75, P386; SOUTHAM CHESTER M., 1960, TRANS NEW YORK ACAD SCI, V22, P657; TENSER RB, 1979, SCIENCE, V205, P915, DOI 10.1126/science.224454; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; YOULE MM, 1988, LANCET, V2, P341	36	741	815	3	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					854	856		10.1126/science.1851332	http://dx.doi.org/10.1126/science.1851332			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1851332				2022-12-28	WOS:A1991FL12300050
J	BASSFORD, P; BECKWITH, J; ITO, K; KUMAMOTO, C; MIZUSHIMA, S; OLIVER, D; RANDALL, L; SILHAVY, T; TAI, PC; WICKNER, B				BASSFORD, P; BECKWITH, J; ITO, K; KUMAMOTO, C; MIZUSHIMA, S; OLIVER, D; RANDALL, L; SILHAVY, T; TAI, PC; WICKNER, B			THE PRIMARY PATHWAY OF PROTEIN EXPORT IN ESCHERICHIA-COLI	CELL			English	Note							SIGNAL-RECOGNITION PARTICLE; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; TRANSLOCATION; MUTATIONS; SEQUENCE; VESICLES; DOMAINS; OMPA; RNA		HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; KYOTO UNIV, INST VIRUS RES, KYOTO 606, JAPAN; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA; UNIV TOKYO, INST APPL MICROBIOL, TOKYO 113, JAPAN; SUNY STONY BROOK, DEPT MICROBIOL, STONY BROOK, NY 11794 USA; WASHINGTON STATE UNIV, BIOCHEM BIOPHYS PROGRAM, PULLMAN, WA 99164 USA; PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA; BOSTON BIOMED RES INST, DEPT METAB REGULAT, BOSTON, MA 02114 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	Harvard University; Harvard Medical School; Kyoto University; Tufts University; University of Tokyo; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Washington State University; Princeton University; Boston Biomedical Research Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	BASSFORD, P (corresponding author), UNIV N CAROLINA, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27514 USA.			Silhavy, Thomas/0000-0001-7672-5153				BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BROWN S, 1989, J MOL BIOL, V209, P79, DOI 10.1016/0022-2836(89)90171-X; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; RAPOPORT TA, 1991, NATURE, V349, P107, DOI 10.1038/349107a0; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; TANI K, 1989, J BIOL CHEM, V264, P18582; WICKNER W, 1991, IN PRESS ANN REV BIO	26	49	52	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1991	65	3					367	368		10.1016/0092-8674(91)90453-6	http://dx.doi.org/10.1016/0092-8674(91)90453-6			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1850320				2022-12-28	WOS:A1991FK18200003
J	DOBLIN, R; KLEIMAN, MAR				DOBLIN, R; KLEIMAN, MAR			MEDICAL USE OF MARIJUANA	ANNALS OF INTERNAL MEDICINE			English	Letter											DOBLIN, R (corresponding author), HARVARD UNIV, JOHN F KENNEDY SCH GOVT, CAMBRIDGE, MA 02138 USA.							CHANG AE, 1979, ANN INTERN MED, V91, P819, DOI 10.7326/0003-4819-91-6-819; SLATER L, 1990, SPINAL NETWORK   WIN, P44; 1988 UN PHARM Q REP; 1989, FED REG         1229, V54, P53767; 1989 UN PHARM ANN RE; 1981, JAMA-J AM MED ASSOC, V246, P1823	6	11	11	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					809	810		10.7326/0003-4819-114-9-809_3	http://dx.doi.org/10.7326/0003-4819-114-9-809_3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	1842667				2022-12-28	WOS:A1991FJ11700022
J	ADAMS, SR; HAROOTUNIAN, AT; BUECHLER, YJ; TAYLOR, SS; TSIEN, RY				ADAMS, SR; HAROOTUNIAN, AT; BUECHLER, YJ; TAYLOR, SS; TSIEN, RY			FLUORESCENCE RATIO IMAGING OF CYCLIC-AMP IN SINGLE CELLS	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; RESONANCE ENERGY-TRANSFER; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; TRANSFER MICROSCOPY; SKELETAL-MUSCLE; EXPRESSION; COMPARTMENTS; RECEPTOR; PROBES	FLUORESCENCE imaging is perhaps the most powerful technique currently available for continuously observing the dynamic intracellular biochemistry of single living cells 1. However, fluorescent indicator dyes have been available only for simple inorganic ions such as Ca2+, H+, Na+, K+, Mg2+ and Cl-. We now report a fluorescent indicator for the adenosine 3',5'-cyclic monophosphate (cAMP) signalling pathway. The sensor consists of cAMP-dependent protein kinase 2 in which the catalytic (C) and regulatory (R) subunits are each labelled with a different fluorescent dye such as fluorescein or rhodamine capable of fluorescence resonance energy transfer in the holoenzyme complex R2C2. When cAMP molecules bind to the R subunits, the C subunits dissociate, thereby eliminating energy transfer. The change in shape of the fluorescence emission spectrum allows cAMP concentrations and the activation of the kinase to be nondestructively visualized in single living cells microinjected with the labelled holoenzyme.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST M-047, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT CHEM M-054, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego								BEAVO JA, 1974, P NATL ACAD SCI USA, V71, P3580, DOI 10.1073/pnas.71.9.3580; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BRIGHT GR, 1989, METHOD CELL BIOL, V30, P157; BUCHLER W, 1990, EUR J BIOCHEM, V188, P253, DOI 10.1111/j.1432-1033.1990.tb15397.x; CARDULLO RA, 1988, P NATL ACAD SCI USA, V85, P8790, DOI 10.1073/pnas.85.23.8790; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; HAUGLAND RP, 1989, HDB FLUORESCENT PROB, P32; HAYES JS, 1982, J CYCLIC NUCL PROT, V8, P1; HERMAN B, 1989, METHOD CELL BIOL, V30, P219; HUGHES RJ, 1982, MOL PHARMACOL, V22, P258; JOHNSON DA, 1984, J BIOL CHEM, V259, P5717; JOVIN TM, 1989, ANNU REV BIOPHYS BIO, V18, P271, DOI 10.1146/annurev.bb.18.060189.001415; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MURRAY KJ, 1989, MOL CELL BIOCHEM, V89, P175; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; SARASWAT LD, 1986, J BIOL CHEM, V261, P1091; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SHABB JB, 1990, J BIOL CHEM, V265, P16031; SLICE LW, 1989, J BIOL CHEM, V264, P20940; TAYLOR SS, 1978, J BIOL CHEM, V253, P2284; TAYLOR SS, 1990, REV BIOCH, V59, P971; TERASAKI WL, 1977, J BIOL CHEM, V252, P1041; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; USTER PS, 1986, J CELL BIOL, V103, P1221, DOI 10.1083/jcb.103.4.1221; WILLIAMS DA, 1990, CELL CALCIUM, V11, P55, DOI 10.1016/0143-4160(90)90058-3; WU FYH, 1974, BIOCHEMISTRY-US, V13, P2567, DOI 10.1021/bi00709a015; YAMASHITA T, 1986, J BIOL CHEM, V261, P6878	30	549	580	1	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 21	1991	349	6311					694	697		10.1038/349694a0	http://dx.doi.org/10.1038/349694a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1847505				2022-12-28	WOS:A1991EY62700047
J	BRUGGEMEIER, U; KALFF, M; FRANKE, S; SCHEIDEREIT, C; BEATO, M				BRUGGEMEIER, U; KALFF, M; FRANKE, S; SCHEIDEREIT, C; BEATO, M			UBIQUITOUS TRANSCRIPTION FACTOR OTF-1 MEDIATES INDUCTION OF THE MMTV PROMOTER THROUGH SYNERGISTIC INTERACTION WITH HORMONE RECEPTORS	CELL			English	Article							MAMMARY-TUMOR VIRUS; RNA POLYMERASE-II; HEAVY-CHAIN PROMOTER; HISTONE H2B GENE; GLUCOCORTICOID RECEPTOR; BINDING-PROTEIN; ADENOVIRUS ORIGIN; STEROID-HORMONES; DNA-REPLICATION; OCTAMER MOTIF	Steroid hormones induce transcription from the mouse mammary tumor virus (MMTV) promoter by complex mechanisms requiring binding of the hormone receptors to the hormone responsive element (HRE) of the long terminal repeat region. Here we show that the MMTV promoter contains two degenerated octamer motifs immediately upstream of the TATA box that together bind OTF-1 (Oct-1, NFIII) with an affinity similar to the octamer consensus. In transfection experiments, mutation of these octamer motifs interferes with the hormonal response of the MMTV promoter. In vitro, these mutations do not influence basal transcription but completely abolish the stimulatory effect of purified progesterone receptor. Progesterone receptor and glucocorticoid receptor bound to the HRE facilitate binding of OTF-1 to the two octamer motifs. Thus, OTF-1 is a natural mediator of hormonal induction of the MMTV promoter and acts through cooperation with the hormone receptors for binding to DNA.	MAX PLANCK INST MOLEC GENET, W-1000 BERLIN, GERMANY	Max Planck Society	BRUGGEMEIER, U (corresponding author), INST MOLEK BIOL & TUMORFORSCH, EMIL MANNKOPFF STR 2, W-3550 MARBURG, GERMANY.		Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222				BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GODING CR, 1989, VIROLOGY, V173, P363; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; MICHALIDES R, 1982, J VIROL, V43, P819, DOI 10.1128/JVI.43.3.819-829.1982; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCHAUER M, 1989, P NATL ACAD SCI USA, V86, P1123, DOI 10.1073/pnas.86.4.1123; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	49	207	209	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 8	1991	64	3					565	572		10.1016/0092-8674(91)90240-Y	http://dx.doi.org/10.1016/0092-8674(91)90240-Y			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1846780				2022-12-28	WOS:A1991EX36100012
J	HALLER, RG; LEWIS, SF				HALLER, RG; LEWIS, SF			GLUCOSE-INDUCED EXERTIONAL FATIGUE IN MUSCLE PHOSPHOFRUCTOKINASE DEFICIENCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NUCLEAR MAGNETIC-RESONANCE; MCARDLES DISEASE; CARDIAC-OUTPUT; EXERCISE; METABOLISM; SPECTROSCOPY	Background. The exercise capacity of patients with muscle phosphofructokinase deficiency is low and fluctuates from day to day. The basis of this variable exercise tolerance is unknown, but out patients with this disorder report that fatigue of active muscles is more rapid after a high-carbohydrate meal. Methods and Results. To determine the effect of carbohydrate on exercise performance, we asked four patients with muscle phosphofructokinase deficiency to perform cycle exercise under conditions of differing availability of substrate - i.e., after an overnight fast, and during an infusion of glucose or triglyceride (with 10 U of heparin per kilogram of body weight) after an overnight fast. As compared with fasting and the infusion of triglyceride with heparin, the glucose infusion lowered plasma levels of free fatty acids and ketones, reduced maximal work capacity by 60 to 70 percent, and lowered maximal oxygen consumption by 30 to 40 percent. Glucose also increased the relative intensity of submaximal exercise, as indicated by a higher heart rate at a given workload during exercise. The maximal cardiac output (i.e., oxygen delivery) was not affected by varying substrate availability, but the maximal systemic arteriovenous oxygen difference was significantly lower during glucose infusion (mean +/- SE, 5.5 +/- 0.3 ml per deciliter) than after fasting (7.6 +/- 0.4 ml per deciliter, P < 0.05) or during the infusion of triglyceride with heparin (8.9 +/- 1.3 ml per deciliter, P < 0.05). Conclusions. In muscle phosphofructokinase deficiency, the oxidative capacity of muscle and the capacity for aerobic exercise vary according to the availability of blood-borne fuels. We believe that glucose infusion lowers exercise tolerance by inhibiting lipolysis and thus depriving muscle of oxidative substrate (plasma free fatty acids and ketones); this impairs the capacity of working muscle to extract oxygen and lowers maximal oxygen consumption.	DEPT VET AFFAIRS MED CTR, DEPT PHYSIOL, DALLAS, TX USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75230 USA; DEPT VET AFFAIRS MED CTR, DEPT NEUROL, DALLAS, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCRR NIH HHS [M01-RR-00633] Funding Source: Medline; NHLBI NIH HHS [HL-01581, HL-06296] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000633] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296, K04HL001581] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGAMANOLIS DP, 1980, MUSCLE NERVE, V3, P456, DOI 10.1002/mus.880030602; ARGOV Z, 1987, ANN NEUROL, V22, P46, DOI 10.1002/ana.410220112; DIMAURO S, 1986, MYOLOGY, P1585; DUBOC D, 1987, NEUROLOGY, V37, P663, DOI 10.1212/WNL.37.4.663; EDWARDS RHT, 1982, LANCET, V1, P725; GOLLNICK PD, 1985, FED PROC, V44, P353; HALLER RG, 1986, NEUROLOGY, V36, P716, DOI 10.1212/WNL.36.5.716; HALLER RG, 1989, J CLIN INVEST, V84, P155, DOI 10.1172/JCI114135; HALLER RG, 1985, ANN NEUROL, V17, P196, DOI 10.1002/ana.410170216; LAUWERYS RR, 1969, ANAL BIOCHEM, V32, P331, DOI 10.1016/0003-2697(69)90093-1; LAYZER RB, 1967, ARCH NEUROL-CHICAGO, V17, P512, DOI 10.1001/archneur.1967.00470290066009; LEWIS SF, 1985, J APPL PHYSIOL, V59, P1991, DOI 10.1152/jappl.1985.59.6.1991; LEWIS SF, 1986, J APPL PHYSIOL, V61, P391, DOI 10.1152/jappl.1986.61.2.391; LEWIS SF, 1984, J APPL PHYSIOL, V57, P1749, DOI 10.1152/jappl.1984.57.6.1749; LEWIS SF, 1989, EXERCISE SPORT SCI R, V17, P67; MINEO I, 1984, MUSCLE NERVE, V7, P552, DOI 10.1002/mus.880070706; PEARSON CM, 1961, AM J MED, V30, P502, DOI 10.1016/0002-9343(61)90075-4; PERNOW BB, 1967, ACTA MED SCAND, VS, P294; PORTE D, 1966, NEW ENGL J MED, V275, P406, DOI 10.1056/NEJM196608252750802; ROWLAND LP, 1986, MYOLOGY, P1603; Sahlin K., 1986, BIOCH EXERCISE, VVI, P323; SCHMID R, 1959, J CLIN INVEST, V38, P2044, DOI 10.1172/JCI103983; TARUI S, 1984, NEUROMUSCULAR DISEAS, P71; TRIEBWASSER JH, 1977, AVIAT SPACE ENVIR MD, V48, P203; VORA S, 1983, J CLIN INVEST, V72, P1995, DOI 10.1172/JCI111164; WILLIAMSON DH, 1962, BIOCHEM J, V82, P90, DOI 10.1042/bj0820090	26	63	63	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 7	1991	324	6					364	369		10.1056/NEJM199102073240603	http://dx.doi.org/10.1056/NEJM199102073240603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW296	1824792	Bronze			2022-12-28	WOS:A1991EW29600003
J	LINGNER, J; KELLERMANN, J; KELLER, W				LINGNER, J; KELLERMANN, J; KELLER, W			CLONING AND EXPRESSION OF THE ESSENTIAL GENE FOR POLY(A) POLYMERASE FROM SACCHAROMYCES-CEREVISIAE	NATURE			English	Article							BINDING-PROTEIN; YEAST; IDENTIFICATION; SEQUENCE; INVITRO; MOTIFS	POLY(A) polymerase is essential for the maturation of messenger RNA, adding tracts of adenosine residues to the 3' end of precursor RNA generated by endonucleolytic cleavage. This mechanism of MRNA 3' processing seems to be similar in yeast and in higher eucaryotes 1, although there are differences in the recognition signals in the pre-mRNA 2. Here we describe the cloning of the gene for yeast poly(A) polymerase. The enzyme is encoded by a single and essential gene located near the centromere on the left arm of chromosome 11. Poly(A) polymerase purified from recombinant Escherichia coli has the same physical and biochemical properties as the yeast enzyme. The yeast poly(A) polymerase shares features of sequence with its mammalian homologue 3,4.	MAX PLANCK INST BIOCHEM, GENZENTRUM, W-8033 MARTINSRIED, GERMANY	Max Planck Society	LINGNER, J (corresponding author), UNIV BASEL, BIOZENTRUM, DEPT CELL BIOL, CH-4056 BASEL, SWITZERLAND.			Lingner, Joachim/0000-0002-2853-5803				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BUTLER JS, 1988, SCIENCE, V242, P1270, DOI 10.1126/science.2848317; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Joyce CM, 1991, CURR OPIN STRUC BIOL, V1, P123, DOI 10.1016/0959-440X(91)90020-T; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; LAZCANO A, 1988, J MOL EVOL, V27, P365, DOI 10.1007/BF02101199; LINGNER J, 1991, J BIOL CHEM, V266, P8741; LUNDBLAD V, 1990, CELL, V60, P529; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, IN PRESS EMBO J; YEH E, 1986, MOL CELL BIOL, V6, P158, DOI 10.1128/MCB.6.1.158; YEH E, 1991, NATURE, V349, P713, DOI 10.1038/349713a0	30	113	115	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 12	1991	354	6353					496	498		10.1038/354496a0	http://dx.doi.org/10.1038/354496a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1840648				2022-12-28	WOS:A1991GV07800066
J	JECKER, NS				JECKER, NS			AGE-BASED RATIONING AND WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; MEDICAL-CARE; OLDER WOMEN; CRITERION	The expense of caring for growing numbers of older individuals can create strong incentives to ration health care based on age. While not directed explicitly at women, this form of rationing would affect women disproportionately because more women than men occupy the ranks of older Americans. A proper understanding of age-based rationing requires attention to gender issues. Once gender issues are taken into account, age-based rationing appears to perpetuate broader gender inequities in the society. This position is supported by three arguments. First, although age-based rationing leads to inequalities between age groups, the inequalities it produces between the sexes are more ethically troubling. Second, these departures from equality cannot be justified even when they benefit society at large by enabling investments in other health care priorities. Finally, since older women represent a disadvantaged and vulnerable group, age-based rationing is difficult to justify even if our obligation to protect the vulnerable is minimal.	STANFORD UNIV,INST RES WOMEN & GENDER,PALO ALTO,CA 94304; STANFORD UNIV,CTR BIOMED ETH,PALO ALTO,CA 94304	Stanford University; Stanford University	JECKER, NS (corresponding author), UNIV WASHINGTON,SCH MED,DEPT MED HIST & ETH,MAIL STOP SB-20,SEATTLE,WA 98195, USA.		Jecker, Nancy/AAJ-6303-2020	Jecker, Nancy/0000-0002-5642-748X				[Anonymous], 1968, REPUBLIC; BINSTOCK RH, 1983, GERONTOLOGIST, V23, P136, DOI 10.1093/geront/23.2.136; Callahan D., 1987, MED GOALS AGEING SOC; Callahan D., 1990, WHAT KIND LIFE; CRYSTAL S, 1986, GERONTOLOGIST, V26, P56, DOI 10.1093/geront/26.1.56; Daniels N, 1988, AM I MY PARENTS KEEP; GUTMAN A, 1983, SECURING ACCESS HLTH, V2, P51; HAUG MR, 1986, J HEALTH SOC BEHAV, V27, P332, DOI 10.2307/2136948; JECKER N, 1991, AGING ETHICS PHILOS; Jecker Nancy S, 1988, Public Aff Q, V2, P51; JECKER NS, 1989, J AM GERIATR SOC, V37, P1067, DOI 10.1111/j.1532-5415.1989.tb06923.x; JECKER NS, IN PRESS J MED PHILO; JECKER NS, 1991, GOOD OLD AGE; KAHN ED, 1984, WOMEN HEALTH, V9, P87, DOI 10.1300/J013v09n04_09; KILNER J, 1990, WHO LIVES WHO DIES; LAMM RD, 1987, SHOULD MED CARE BE R, pR11; LEVINSKY NG, 1990, NEW ENGL J MED, V322, P1813, DOI 10.1056/NEJM199006213222512; LEWIS M, 1985, WOMEN HEALTH, V10, P1; LEWIS M, 1980, OLDER WOMAN, P211; MENZEL PT, 1983, MED COSTS MORAL CHOI; MILLS C, 1988, REPORT I PHILOS PUBL, V8, P1; MINKLER M, 1985, GERONTOLOGIST, V25, P351, DOI 10.1093/geront/25.4.351; Moody H. R., 1991, TOO OLD HLTH CARE CO, P180; MULLER C, 1991, HLTH CARE GENDER; MURRAY TH, 1991, TOO OLD HLTH CARE CO, P164; POST SG, 1991, TOO OLD HLTH CARE, P120; PRESTON SH, 1984, SCI AM, V251, P44, DOI 10.1038/scientificamerican1284-44; SCHNEIDER EL, 1989, JAMA-J AM MED ASSOC, V261, P907; Shklar J.N., 1990, FACES INJUSTICE; SIEGLER M, 1984, HASTINGS CENT REP, V14, P24, DOI 10.2307/3561093; SILVERMAN P, 1987, WIDOWS, V2, P171; Sontag S., 1975, NO LONGER YOUNG OLDE, P31; Thomasma DC., 1991, TOO OLD HLTH CARE CO, P138; VERBRUGGE LM, 1985, PHYSICAL MENTAL HLTH, P41; WETLE T, 1985, LEGAL ETHICAL HLTH C, P258; Young Iris Marion, 1990, JUSTICE POLITICS DIF, DOI DOI 10.1515/9781400839902; 1991, PAYING PREJUDICE REP	37	41	42	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3012	3015		10.1001/jama.266.21.3012	http://dx.doi.org/10.1001/jama.266.21.3012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GR775	1820475				2022-12-28	WOS:A1991GR77500034
J	LEW, DJ; DULIC, V; REED, SI				LEW, DJ; DULIC, V; REED, SI			ISOLATION OF 3 NOVEL HUMAN CYCLINS BY RESCUE OF G1 CYCLIN (CLN) FUNCTION IN YEAST	CELL			English	Article							MATURATION-PROMOTING FACTOR; P34CDC2 PROTEIN-KINASE; EMBRYONIC-CELL CYCLE; HISTONE H-1 KINASE; CONTROL GENE CDC2+; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; M-PHASE; MESSENGER-RNA; DIVISION CYCLE	We have isolated a number of cDNAs derived from human mRNAs that are able to substitute for G1 cyclin genes in S. cerevisiae. Several of these encode human cyclins A, B1, and B2. Three novel genes have been identified, which we call cyclins C, D, and E. The novel proteins are sufficiently distantly related to the other members of the cyclin family and to each other as to constitute three new classes of cyclins. Cyclin C and E mRNAs accumulate periodically through the cell cycle, peaking at different times in G1.			LEW, DJ (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, MB7, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Dulic, Vjekoslav/0000-0003-1201-3901	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038328, R01GM038328, P01GM046006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38328, GM46006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BUCKINGTHROM E, 1973, EXP CELL RES, V76, P99, DOI 10.1016/0014-4827(73)90424-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KOZAK M, 1980, CELL, V22, P7, DOI 10.1016/0092-8674(80)90148-8; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NINOMIYATSUJI J, 1991, IN PRESS P NATL ACAD; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1982, MOL CELL BIOL, V2, P412, DOI 10.1128/MCB.2.4.412; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; Sherman F., 1986, METHODS YEAST GENETI; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WITTENBERG C, 1989, MOL CELL BIOL, V9, P4064, DOI 10.1128/MCB.9.9.4064; YEN A, 1978, EXP CELL RES, V116, P103, DOI 10.1016/0014-4827(78)90068-X; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zetterberg A, 1990, CURR OPIN CELL BIOL, V2, P296, DOI 10.1016/0955-0674(90)90022-7; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	75	820	879	1	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1197	1206		10.1016/0092-8674(91)90042-W	http://dx.doi.org/10.1016/0092-8674(91)90042-W			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1833066				2022-12-28	WOS:A1991GG55200014
J	BOZZETTE, SA; LARSEN, RA; CHIU, J; LEAL, MAE; TILLES, JG; RICHMAN, DD; LEEDOM, JM; MCCUTCHAN, JA				BOZZETTE, SA; LARSEN, RA; CHIU, J; LEAL, MAE; TILLES, JG; RICHMAN, DD; LEEDOM, JM; MCCUTCHAN, JA			FLUCONAZOLE TREATMENT OF PERSISTENT CRYPTOCOCCUS-NEOFORMANS PROSTATIC INFECTION IN AIDS	ANNALS OF INTERNAL MEDICINE			English	Note							ACQUIRED IMMUNODEFICIENCY SYNDROME; MENINGITIS		UNIV CALIF IRVINE, IRVINE, CA 92717 USA	University of California System; University of California Irvine	BOZZETTE, SA (corresponding author), UNIV CALIF SAN DIEGO, MED CTR, DIV INFECT DIS, H-208, 225 DICKINSON, SAN DIEGO, CA 92103 USA.							BOZZETTE SA, 1991, NEW ENGL J MED, V324, P580, DOI 10.1056/NEJM199102283240902; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; DIAMOND RD, 1974, ANN INTERN MED, V80, P176, DOI 10.7326/0003-4819-80-2-176; KOVACS JA, 1985, ANN INTERN MED, V103, P533, DOI 10.7326/0003-4819-103-4-533; LARSEN RA, 1990, ANN INTERN MED, V113, P183, DOI 10.7326/0003-4819-113-3-183; LARSEN RA, 1989, ANN INTERN MED, V111, P125, DOI 10.7326/0003-4819-111-2-125; SAAG MS, 1988, ANTIMICROB AGENTS CH, V32, P1, DOI 10.1128/AAC.32.1.1; STERN JJ, 1988, AM J MED, V85, P477, DOI 10.1016/S0002-9343(88)80081-0; ZUGER A, 1988, ANN INTERN MED, V109, P592, DOI 10.7326/0003-4819-109-7-592; ZUGER A, 1986, ANN INTERN MED, V104, P234, DOI 10.7326/0003-4819-104-2-234	10	23	23	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					285	286		10.7326/0003-4819-115-4-285	http://dx.doi.org/10.7326/0003-4819-115-4-285			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854112				2022-12-28	WOS:A1991GA76400008
J	GRAHAM, DY; LEW, GM; EVANS, DG; EVANS, DJ; KLEIN, PD				GRAHAM, DY; LEW, GM; EVANS, DG; EVANS, DJ; KLEIN, PD			EFFECT OF TRIPLE THERAPY (ANTIBIOTICS PLUS BISMUTH) ON DUODENAL-ULCER HEALING - A RANDOMIZED CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							CAMPYLOBACTER-PYLORI; SUBCITRATE; RELAPSE; ERADICATION; OMEPRAZOLE	Objective: To determine whether antimicrobial therapy for Helicobacter pylori infection accelerates the healing of duodenal ulcers. Design: Single-blind, randomized, controlled trial. Setting: Veterans Affairs hospital. Participants: One hundred and five patients with endoscopically verified duodenal ulcers. Intervention: Patients received either ranitidine, 300 mg/d, or ranitidine, 300 mg/d, plus "triple therapy" (2 g/d of tetracycline, 750 mg/d of metronidazole, and 5 or 8 bismuth subsalicylate tablets per day). Triple therapy was administered for only the first 2 weeks of ulcer treatment. Measurements: Videoendoscopic assessment of ulcer status was done until ulcer healing was complete. Evaluations were done after 2, 4, 8,12, and 16 weeks of therapy. Main Results: Ulcer healing was more rapid in patients receiving ranitidine plus triple therapy than in patients receiving ranitidine alone (P < 0.01). The cumulative percentages of patients with healed ulcers in the group receiving ranitidine plus triple therapy and in the group receiving ranitidine alone were as follows: 37% and 18% after week 2; 74% and 53% after week 4; 84% and 68% after week 8; 96% and 80% after week 12; and 98% and 84% after week 16. Conclusion: Combined therapy with anti-H. pylori agents and ranitidine was superior to ranitidine alone for duodenal ulcer healing. Our results indicate that H. pylori plays a role in duodenal ulcer disease.	BAYLOR COLL MED, HOUSTON, TX 77030 USA; USDA ARS, CHILDRENS NUTR CTR, HOUSTON, TX USA	Baylor College of Medicine; United States Department of Agriculture (USDA)	GRAHAM, DY (corresponding author), VET AFFAIRS MED CTR, 111D, 2002 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.		Graham, David/AAL-2165-2021		NIDDK NIH HHS [DK 39919] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039919] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCHAMBAULT AP, 1988, GASTROENTEROLOGY, V94, P1130, DOI 10.1016/0016-5085(88)90003-0; COGHLAN JG, 1987, LANCET, V2, P1109; EVANS DJ, 1989, GASTROENTEROLOGY, V96, P1004, DOI 10.1016/0016-5085(89)91616-8; GEORGE LL, 1990, MED J AUSTRALIA, V153, P145, DOI 10.5694/j.1326-5377.1990.tb136833.x; GRAHAM D Y, 1989, Gastroenterology, V96, pA181; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1653, DOI 10.1016/0016-5085(91)90665-8; GRAHAM DY, 1987, LANCET, V1, P1174; GRAHAM DY, 1989, GASTROENTEROLOGY, V96, P615, DOI 10.1016/S0016-5085(89)80057-5; GRAHAM DY, 1990, DIGEST DIS SCI, V35, P66, DOI 10.1007/BF01537225; GRAHAM DY, 1991, IN PRESS GASTROENTER; HALL DWR, 1989, SCAND J GASTROENTERO, V24, P3, DOI 10.3109/00365528909091043; KLEIN PD, 1989, CAMPYLOBACTER PYLORI, P94; KOO J, 1982, GASTROENTEROLOGY, V82, P864; LAMBERT JR, 1987, GASTROENTEROLOGY, V92, P1489; LAVY UI, 1976, ARCH INT PHARMACOD T, V224, P291; MAGNUS HA, 1952, MODERN TRENDS GASTRO, P323; MARSHALL BJ, 1988, LANCET, V2, P1437; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SALMON PR, 1987, DIGESTION, V37, P42, DOI 10.1159/000199557; SMITH AC, 1988, GASTROENTEROLOGY, V94, pA431; SOLL AH, 1989, GASTROINTESTINAL DIS, P814	22	247	252	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					266	269		10.7326/0003-4819-115-4-266	http://dx.doi.org/10.7326/0003-4819-115-4-266			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854110				2022-12-28	WOS:A1991GA76400004
J	GOODNOW, CC; BRINK, R; ADAMS, E				GOODNOW, CC; BRINK, R; ADAMS, E			BREAKDOWN OF SELF-TOLERANCE IN ANERGIC LYMPHOCYTES-B	NATURE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; T-CELL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; TRANSGENIC MICE; CLONAL ANERGY; RECEPTOR; INACTIVATION; EXPRESSION; INDUCTION; DELETION	PRODUCTION of autoantibodies, which characterizes most autoimmune diseases, is normally avoided by active elimination 1-7 or functional inactivation (anergy) 8-15 of B and T lymphocytes bearing receptors for self antigens. The mechanisms leading to the escape of self-reactive clones from these normal tolerance mechanisms in autoimmune diseases nevertheless remain obscure. Here, we demonstrate that clonal anergy in B lymphocytes is a reversible process, and that silenced self-reactive B cells can be reactivated under particular conditions to give rise to vigorous antibody responses. Reactivation of anergic lymphocytes may explain many examples of transient autoimmune reactions in normal individuals, and may under pathological conditions be important in the development of chronic autoimmune disease.	STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	GOODNOW, CC (corresponding author), UNIV SYDNEY, CENTENARY INST CANC MED & CELL BIOL, SYDNEY, NSW 2006, AUSTRALIA.		Brink, Robert/B-7910-2010; Goodnow, Christopher C/V-8108-2018	Brink, Robert/0000-0002-9586-3655; Goodnow, Christopher C/0000-0001-5296-6155				ADAMS E, 1990, P NATL ACAD SCI USA, V87, P5687, DOI 10.1073/pnas.87.15.5687; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BONNEVILLE M, 1990, NATURE, V344, P163, DOI 10.1038/344163a0; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; GLEICHMANN E, 1982, EUR J IMMUNOL, V12, P152, DOI 10.1002/eji.1830120210; GLEICHMANN E, 1976, EUR J IMMUNOL, V6, P899, DOI 10.1002/eji.1830061212; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HANG L, 1983, J EXP MED, V157, P874, DOI 10.1084/jem.157.3.874; IZUI S, 1977, J EXP MED, V145, P1115, DOI 10.1084/jem.145.5.1115; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; NAPARSTEK Y, 1986, J EXP MED, V164, P614, DOI 10.1084/jem.164.2.614; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; PRIMI D, 1977, J EXP MED, V145, P21, DOI 10.1084/jem.145.1.21; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; Weigle W O, 1980, Adv Immunol, V30, P159	24	223	223	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 8	1991	352	6335					532	536		10.1038/352532a0	http://dx.doi.org/10.1038/352532a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1830923				2022-12-28	WOS:A1991GA22600064
J	HIGUCHI, H; GOLDMAN, YE				HIGUCHI, H; GOLDMAN, YE			SLIDING DISTANCE BETWEEN ACTIN AND MYOSIN-FILAMENTS PER ATP MOLECULE HYDROLYZED IN SKINNED MUSCLE-FIBERS	NATURE			English	Article							FROG-MUSCLE; STEP SIZE; FIBERS; RABBIT; ADENOSINE-5'-TRIPHOSPHATE; GENERATION; MOVEMENT; FORCE; ASSAY; RIGOR	MUSCLE contraction is generally thought to be driven by tilting 1,2 of the 19-nm-long myosin head 3, part of the thick filament, while attached to actin, part of the thin filament. This motion would produce about 12 nm of filament sliding 4,5. Recent estimates of the sliding distance per ATP molecule hydrolysed by actomyosin in vitro vary widely from 8 nm (ref. 6) to greater-than-or-equal-to 200 nm (ref. 7). The latter value is incompatible with a power stroke incorporating a single tilting motion of the head. We have measured the isotonic sliding distance per ATP molecule hydrolysed during the interaction between myosin and actin in skinned muscle fibres. We directly estimated the proportion of simultaneously attached actomyosin complexes and their ATP use. We report here that at low loads the interaction distance is at least 40 nm. This distance corresponds to the length of the power stroke plus the filament sliding while actomyosin crossbridges bear negative drag forces 5,8. If the power stroke is 12 nm, then our results indicate the drag distance to be at least 28 nm. Our results could also be explained by multiple power strokes per ATP molecule hydrolysed.	UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104; UNIV PENN,PENN MUSCLE INST,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania								Cecchi G, 1976, Boll Soc Ital Biol Sper, V52, P733; ELLIOTT A, 1978, J MOL BIOL, V123, P505, DOI 10.1016/0022-2836(78)90204-8; FERENCZI MA, 1984, J PHYSIOL-LONDON, V352, P575, DOI 10.1113/jphysiol.1984.sp015311; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P605, DOI 10.1113/jphysiol.1984.sp015395; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P577, DOI 10.1113/jphysiol.1984.sp015394; GOLDMAN YE, 1987, BIOPHYS J, V52, P57, DOI 10.1016/S0006-3495(87)83188-0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY AF, 1973, COLD SPRING HARB SYM, V37, P669, DOI 10.1101/SQB.1973.037.01.081; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; TAWADA K, 1984, BIOPHYS J, V45, P593, DOI 10.1016/S0006-3495(84)84197-1; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0	20	92	92	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					352	354		10.1038/352352a0	http://dx.doi.org/10.1038/352352a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852212				2022-12-28	WOS:A1991FY28900077
J	UYEDA, TQP; WARRICK, HM; KRON, SJ; SPUDICH, JA				UYEDA, TQP; WARRICK, HM; KRON, SJ; SPUDICH, JA			QUANTIZED VELOCITIES AT LOW MYOSIN DENSITIES IN AN INVITRO MOTILITY ASSAY	NATURE			English	Article							SINGLE KINESIN MOLECULES; STEP SIZE; ACTIN; MOVEMENT; MUSCLE	An in vitro motility assay has been developed in which single actin filaments move on one or a few heavy meromyosin (HMM) molecules. This movement is slower than when many HMM molecules are involved, in contrast to analogous experiments with microtubules and kinesin. Frequency analysis shows that sliding speeds distribute around integral multiples of a unitary velocity. This discreteness may be due to differences in the numbers of HMM molecules interacting with each actin filament, where the unitary velocity reflects the activity of one HMM molecule. The value of the unitary velocity predicts a step size of 5-20 nm per ATP, which is consistent with the conventional swinging crossbridge model for myosin function.	STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,FAIRCHILD CTR,STANFORD,CA 94305	Stanford University	UYEDA, TQP (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,FAIRCHILD CTR,STANFORD,CA 94305, USA.			Kron, Stephen/0000-0003-1518-2436				BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BRENNER B, 1982, P NATL ACAD SCI-BIOL, V79, P7288, DOI 10.1073/pnas.79.23.7288; DANTZIG JA, 1988, P NATL ACAD SCI USA, V85, P6716, DOI 10.1073/pnas.85.18.6716; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KRON SJ, 1991, J CELL SCI S, V14, P129; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; SCHUTT CE, 1989, J MOL BIOL, V209, P735, DOI 10.1016/0022-2836(89)90603-7; SHIMMEN T, 1988, BOT MAG TOKYO, V101, P533, DOI 10.1007/BF02488095; Taylor E W, 1989, Prog Clin Biol Res, V315, P9; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0	19	164	164	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					307	311		10.1038/352307a0	http://dx.doi.org/10.1038/352307a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852205				2022-12-28	WOS:A1991FY28900060
J	BOWIE, JU; LUTHY, R; EISENBERG, D				BOWIE, JU; LUTHY, R; EISENBERG, D			A METHOD TO IDENTIFY PROTEIN SEQUENCES THAT FOLD INTO A KNOWN 3-DIMENSIONAL STRUCTURE	SCIENCE			English	Article							GENE ACTIVATOR PROTEIN; AMINO-ACID-SEQUENCES; CAMP-BINDING DOMAINS; GEOMETRICAL CONSTRAINTS; PREDICTED STRUCTURES; PHAGE-T4 LYSOZYME; PROFILE ANALYSIS; ALPHA-HELICES; CONTACT AREAS; PACKING	The inverse protein folding problem, the problem of finding which amino acid sequences fold into a known three-dimensional (3D) structure, can be effectively attacked by finding sequences that are most compatible with the environments of the residues in the 3D structure. The environments are described by: (i) the area of the residue buried in the protein and inaccessible to solvent; (ii) the fraction of side-chain area that is covered by polar atoms (O and N); and (iii) the local secondary structure. Examples of this 3D profile method are presented for four families of proteins: the globins, cyclic AMP (adenosine 3',5'-monophosphate) receptor-like proteins, the periplasmic binding proteins, and the actins. This method is able to detect the structural similarity of the actins and 70- kilodalton heat shock proteins, even though these protein families share no detectable sequence similarity.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	BOWIE, JU (corresponding author), UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024, USA.							ALBER T, 1988, SCIENCE, V239, P631, DOI 10.1126/science.3277275; ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; CHOTHIA C, 1987, COLD SPRING HARB SYM, V52, P399, DOI 10.1101/SQB.1987.052.01.046; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Dayhoff MO, 1968, ATLAS PROTEIN SEQUEN; DAYHOFF MO, 1979, ATLAS PROTEIN SEQ S3, V5, P353; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Doolittle R. F., 1990, METHODS ENZYMOLOGY, V183; Doolittle R. F., 1986, URFS ORFS PRIMER ANA; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; DREXLER KE, 1981, P NATL ACAD SCI USA, V78, P5275, DOI 10.1073/pnas.78.9.5275; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; EISENBERG D, 1989, CHEM SCRIPTA, V29A, P217; FANO RM, 1961, TRANSMISSION INFORMA; FITCH WM, 1966, J MOL BIOL, V16; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GEORGE DG, 1986, NUCLEIC ACIDS RES, V14, P11, DOI 10.1093/nar/14.1.11; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; GO M, 1987, COLD SPRING HARB SYM, V52, P915, DOI 10.1101/SQB.1987.052.01.100; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KATZ BA, 1986, J BIOL CHEM, V261, P5480; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LESK AM, 1982, J MOL BIOL, V160, P325, DOI 10.1016/0022-2836(82)90179-6; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LEVITT M, 1975, NATURE, V253, P694, DOI 10.1038/253694a0; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LUTHY R, 1991, PROTEINS, V10, P229, DOI 10.1002/prot.340100307; MCLACHLAN AD, 1972, J MOL BIOL, V62, P409; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEMETHY G, 1977, Quarterly Reviews of Biophysics, V10, P239; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; SAMS CF, 1984, NATURE, V310, P429, DOI 10.1038/310429a0; SANDBERG WS, 1989, SCIENCE, V245, P54, DOI 10.1126/science.2787053; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SPIRO S, 1990, FEMS MICROBIOL LETT, V75, P399, DOI 10.1016/0378-1097(90)90690-R; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; TAYLOR WR, 1989, J MOL BIOL, V208, P1, DOI 10.1016/0022-2836(89)90084-3; TAYLOR WR, 1988, J MOL BIOL, V188, P2333; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WEAVER LH, 1989, BIOCHEMISTRY-US, V28, P3793, DOI 10.1021/bi00435a025; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WEBER IT, 1982, P NATL ACAD SCI-BIOL, V79, P7679, DOI 10.1073/pnas.79.24.7679; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001	60	2247	2533	7	151	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					164	170		10.1126/science.1853201	http://dx.doi.org/10.1126/science.1853201			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1853201				2022-12-28	WOS:A1991FW16000027
J	CUNDY, T; EVANS, M; ROBERTS, H; WATTIE, D; AMES, R; REID, IR				CUNDY, T; EVANS, M; ROBERTS, H; WATTIE, D; AMES, R; REID, IR			BONE-DENSITY IN WOMEN RECEIVING DEPOT MEDROXYPROGESTERONE ACETATE FOR CONTRACEPTION	BRITISH MEDICAL JOURNAL			English	Article							POST-MENOPAUSAL WOMEN; MINERAL-CONTENT; RELATIVE CONTRIBUTIONS; POSTMENOPAUSAL WOMEN; HORMONE-REPLACEMENT; ESTROGENS; AGE; NORETHISTERONE; PROVERA; MPA	Objective-To determine if the use of the injectable contraceptive depot medroxyprogesterone (DMPA), which reduces ovarian oestrogen production, is associated with changes in bone density. Design-Population study. DMPA users were compared with two control groups selected from larger population studies and individually matched for several putative determinants of bone density (age, race, body mass index, and years of oestrogen deficiency). Controls and DMPA users were matched without prior knowledge of their bone density measurements. Setting- Teaching hospital and community family planning clinics. Subjects-30 current users of DMPA with a minimum five years' previous use, 30 premenopausal controls, and 30 postmenopausal controls. Main outcome measure-Lumbar spine and femoral neck bone mineral density assessed by dual energy x ray absorptiometry. Results-Compared with premenopausal controls matched for age, race, and body mass index, DMPA users had significantly reduced bone density in the lumbar spine (mean difference 7.5% (95% confidence interval 1.9% to 13.1%), p = 0.002) and in the femoral neck (6.6%, (0.8% to 12.3%), p = 0.007). Compared with postmenopausal controls matched for body mass index and duration of oestrogen deficiency, DMPA users had greater bone density in the lumbar spine (8.9% (4.3% to 13.5%), p = 0.001), but in the femoral neck the difference in bone density was less (4.0% (-0.4% to 8.5%), p = 0.04). Conclusions-Women using DMPA have bone density values intermediate between those of normal premenopausal and postmenopausal controls; thus, the degree of oestrogen deficiency induced by DMPA may have an adverse effect on bone density.	FAMILY PLANNING ASSOC NEW ZEALAND,AUCKLAND 1,NEW ZEALAND		CUNDY, T (corresponding author), AUCKLAND HOSP,DEPT MED,AUCKLAND 1,NEW ZEALAND.			Cundy, Timothy/0000-0003-4890-9400; Roberts, Helen/0000-0002-8107-5746				ABDALLA HI, 1985, OBSTET GYNECOL, V66, P789; ADAMI S, 1989, BONE MINER, V7, P79, DOI 10.1016/0169-6009(89)90064-0; CANN CE, 1980, JAMA-J AM MED ASSOC, V244, P2056; CANN CE, 1984, JAMA-J AM MED ASSOC, V251, P626, DOI 10.1001/jama.251.5.626; CRILLY RG, 1980, CLIN SCI, V58, P341, DOI 10.1042/cs0580341; DRINKWATER BL, 1984, NEW ENGL J MED, V311, P277, DOI 10.1056/NEJM198408023110501; GALLAGHER JC, 1991, AM J MED, V90, P171; HODGKINSON A, 1982, J CLIN PATHOL, V35, P807, DOI 10.1136/jcp.35.8.807; HORSMAN A, 1983, NEW ENGL J MED, V309, P1405, DOI 10.1056/NEJM198312083092301; JARMAN H, 1990, AUST NZ J OBSTET GYN, V30, P74, DOI 10.1111/j.1479-828X.1990.tb03202.x; JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602; JEPPSSON S, 1973, CONTRACEPTION, V8, P165, DOI 10.1016/0010-7824(73)90122-4; JEPPSSON S, 1982, ACTA ENDOCRINOL-COP, V99, P339, DOI 10.1530/acta.0.0990339; KLIBANSKI A, 1986, NEW ENGL J MED, V315, P542, DOI 10.1056/NEJM198608283150903; KOPPELMAN MCS, 1984, J CLIN ENDOCR METAB, V59, P1050, DOI 10.1210/jcem-59-6-1050; LOBO RA, 1984, OBSTET GYNECOL, V63, P1; MANDEL FP, 1982, J REPROD MED, V27, P511; MATTA WH, 1988, CLIN ENDOCRINOL, V29, P45, DOI 10.1111/j.1365-2265.1988.tb00248.x; MAZESS R, 1989, CALCIFIED TISSUE INT, V44, P228, DOI 10.1007/BF02556569; MELTON LJ, 1988, J CLIN EPIDEMIOL, V41, P985; NORDIN BEC, 1990, J CLIN ENDOCR METAB, V70, P83, DOI 10.1210/jcem-70-1-83; ORTIZ A, 1977, J CLIN ENDOCR METAB, V44, P32, DOI 10.1210/jcem-44-1-32; POWERS MS, 1985, AM J OBSTET GYNECOL, V152, P1099, DOI 10.1016/0002-9378(85)90569-1; PRIOR JC, 1990, NEW ENGL J MED, V323, P1221, DOI 10.1056/NEJM199011013231801; PRIOR JC, 1990, ENDOCR REV, V11, P386, DOI 10.1210/edrv-11-2-386; REDMAN JR, 1988, AM J MED, V85, P65, DOI 10.1016/0002-9343(88)90504-9; REID IR, 1986, BRIT MED J, V292, P1547, DOI 10.1136/bmj.292.6535.1547; RICHELSON LS, 1984, NEW ENGL J MED, V311, P1273, DOI 10.1056/NEJM198411153112002; RIGOTTI NA, 1984, NEW ENGL J MED, V311, P1601, DOI 10.1056/NEJM198412203112503; RIIS BJ, 1990, J CLIN ENDOCR METAB, V70, P920, DOI 10.1210/jcem-70-4-920; SELBY PL, 1985, CLIN SCI, V69, P265, DOI 10.1042/cs0690265; YOUNG MM, 1967, LANCET, V2, P118	32	212	213	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1991	303	6793					13	16		10.1136/bmj.303.6793.13	http://dx.doi.org/10.1136/bmj.303.6793.13			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW128	1830502	Bronze, Green Published			2022-12-28	WOS:A1991FW12800018
J	NAGAFUCHI, S; KASHIWAGI, S; OKADA, K; ANZAI, K; NAKAMURA, M; NISHIMURA, Y; SASAZUKI, T; NIHO, Y				NAGAFUCHI, S; KASHIWAGI, S; OKADA, K; ANZAI, K; NAKAMURA, M; NISHIMURA, Y; SASAZUKI, T; NIHO, Y			REVERSAL OF NONRESPONDERS AND POSTEXPOSURE PROPHYLAXIS BY INTRADERMAL HEPATITIS-B VACCINATION IN JAPANESE MEDICAL PERSONNEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DTH SKIN REACTION; IMMUNE GLOBULIN; FINAL REPORT; VIRUS-INFECTION; SURFACE-ANTIGEN; HEPTAVAX-B; IMMUNOGENICITY; EFFICACY; HBSAG; IMMUNOPROPHYLAXIS	Thirty-one Japanese nonresponders to subcutaneous hepatitis B vaccination and 15 medical personnel who were accidentally exposed to specimens positive for hepatitis B e antigen and were given hepatitis B immunoglobulin were intradermally immunized with 5-mu-g of plasma-derived hepatitis B vaccine every 2 weeks until delayed type hypeersensitivity skin reaction to hepatitis B surface antigen became positive. Thirty (97%) of the 31 nonresponders developed delayed type hypersensitivity skin reactions to hepatitis B surface antigen after 2.3 +/- 1.2 (mean +/- SD) revaccinations. Twenty-nine (94%) of the 31 nonresponders had anti-hepatitis B surface antigen antibody levels greater than 10 IU/L. The immunoglobulin subclass of the antibody to hepatitis B surface antigen was mainly IgG1. After 1 year, 23 (74%) of the 31 nonresponders continued to have anti-hepatitis B surface antigen antibody levels greater than 10 IU/L. Persons accidentally exposed to specimens positive for hepatitis B e antigen developed delayed type hypersensitivity skin reactions to hepatitis B surface antigen following 3.1 +/- 1.1 revaccinations. None developed clinical hepatitis. There was no production of anti-hepatitis B core antigen antibody 1 year after exposure, indicating that protection was 100%. Intradermal hepatitis B vaccination is useful in reversing nonresponsiveness to hepatitis B surface antigen and for prophylaxis after exposure.	KYUSHU UNIV,MED INST BIOREGULAT,DEPT GENET,FUKUOKA 812,JAPAN; KYUSHU UNIV,FAC MED,DEPT PEDIAT,FUKUOKA 812,JAPAN; KYUSHU UNIV,FAC MED,DEPT GEN MED,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University; Kyushu University	NAGAFUCHI, S (corresponding author), KYUSHU UNIV,FAC MED,DEPT INTERNAL MED 1,FUKUOKA 812,JAPAN.							ALPER CA, 1989, NEW ENGL J MED, V321, P708, DOI 10.1056/NEJM198909143211103; CASALI P, 1986, SCIENCE, V234, P476, DOI 10.1126/science.3020687; CHUTIVONGSE S, 1990, LANCET, V335, P896, DOI 10.1016/0140-6736(90)90488-Q; CLARKE JA, 1989, JAMA-J AM MED ASSOC, V262, P2567, DOI 10.1001/jama.262.18.2567; CRAVEN DE, 1986, ANN INTERN MED, V105, P356, DOI 10.7326/0003-4819-105-3-356; DIENSTAG JL, 1989, HEPATOLOGY, V10, P385, DOI 10.1002/hep.1840100323; GRADY GF, 1978, J INFECT DIS, V138, P625, DOI 10.1093/infdis/138.5.625; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; HAYASHI J, 1989, J INFECTION, V19, P119, DOI 10.1016/S0163-4453(89)91839-2; HEIJTINK RA, 1989, J MED VIROL, V27, P151, DOI 10.1002/jmv.1890270216; HOOFNAGLE JH, 1979, ANN INTERN MED, V91, P813, DOI 10.7326/0003-4819-91-6-813; IRVING WL, 1987, LANCET, V2, P561; KAPLAN PM, 1973, J VIROL, V12, P995, DOI 10.1128/JVI.12.5.995-1005.1973; KARASAWA T, 1983, J INFECT DIS, V147, P327, DOI 10.1093/infdis/147.2.327; KASHIWAGI S, 1984, MICROBIOL IMMUNOL, V28, P1355, DOI 10.1111/j.1348-0421.1984.tb00793.x; MASUKO K, 1985, GASTROENTEROLOGY, V88, P151, DOI 10.1016/S0016-5085(85)80147-5; MATHIESEN T, 1989, J NEUROL, V236, P238, DOI 10.1007/BF00314506; MILLER KD, 1983, LANCET, V2, P1454, DOI 10.1016/S0140-6736(83)90800-0; MITSUI T, 1989, HEPATOLOGY, V10, P324, DOI 10.1002/hep.1840100312; NAGAFUCHI S, 1987, LANCET, V2, P1522; NAGAFUCHI S, 1984, MICROBIOL IMMUNOL, V28, P257, DOI 10.1111/j.1348-0421.1984.tb00678.x; NAGAFUCHI S, 1989, MICROBIOL IMMUNOL, V33, P539, DOI 10.1111/j.1348-0421.1989.tb02004.x; NAGAFUCHI S, 1985, CLIN EXP IMMUNOL, V61, P569; NAKAMURA M, 1988, J IMMUNOL, V141, P4165; Paul W.E., 1989, FUNDAMENTAL IMMUNOLO, P95; REDFIELD RR, 1985, JAMA-J AM MED ASSOC, V254, P3203, DOI 10.1001/jama.254.22.3203; SEEFF LB, 1978, ANN INTERN MED, V88, P285, DOI 10.7326/0003-4819-88-3-285; SZMUNESS W, 1981, HEPATOLOGY, V1, P377, DOI 10.1002/hep.1840010502; TERASAKI PI, 1964, NATURE, V204, P998, DOI 10.1038/204998b0; VANDVIK B, 1977, SCAND J IMMUNOL, V6, P651, DOI 10.1111/j.1365-3083.1977.tb02145.x; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; WATANABE H, 1988, HUM IMMUNOL, V22, P9, DOI 10.1016/0198-8859(88)90047-X; WEISSMAN JY, 1988, JAMA-J AM MED ASSOC, V260, P1734, DOI 10.1001/jama.260.12.1734; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; ZOULEK G, 1984, J MED VIROL, V14, P27, DOI 10.1002/jmv.1890140105; ZUCKERMAN AJ, 1988, CURR OPIN INFECT DIS, V1, P829, DOI 10.1097/00001432-198811000-00002; 1985, MMWR, V34, P313	37	39	41	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2679	2683		10.1001/jama.265.20.2679	http://dx.doi.org/10.1001/jama.265.20.2679			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	1827167				2022-12-28	WOS:A1991FL98900031
J	KHUSMITH, S; CHAROENVIT, Y; KUMAR, S; SEDEGAH, M; BEAUDOIN, RL; HOFFMAN, SL				KHUSMITH, S; CHAROENVIT, Y; KUMAR, S; SEDEGAH, M; BEAUDOIN, RL; HOFFMAN, SL			PROTECTION AGAINST MALARIA BY VACCINATION WITH SPOROZOITE SURFACE PROTEIN-2 PLUS CS PROTEIN	SCIENCE			English	Article							CIRCUMSPOROZOITE PROTEIN; MONOCLONAL-ANTIBODIES; PLASMODIUM-YOELII; MAMMALIAN-CELLS; MURINE MALARIA; EXPRESSION; EFFICIENT; VACCINES; ANTIGENS; SYSTEM	The circumsporozoite (CS) protein has been the target for development of malaria sporozoite vaccines for a decade. However, immunization with subunit vaccines based on the CS protein has never given the complete protection found after immunization with irradiated sporozoites. BALB/c mice immunized with irradiated Plasmodium yoelii sporozoites produced antibodies and cytotoxic T cells against a 140-kilodalton protein, sporozoite surface protein 2 (SSP2). Mice immunized with P815 cells that had been transfected with either SSP2 or CS genes were partially protected, and those immunized with a mixture of SSP2 and CS transfectants were completely protected against malaria. These studies emphasize the importance of vaccine delivery systems in achieving protection and define a multi-antigen sporozoite vaccine.	USN,MED RES INST,MALARIA PROGRAM,BETHESDA,MD 20889; NIH,PARASIT DIS LAB,BETHESDA,MD 20892	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA								AGGARWAL A, 1990, J EXP MED, V172, P1083, DOI 10.1084/jem.172.4.1083; [Anonymous], COMMUNICATION; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHAROENVIT Y, 1987, INFECT IMMUN, V55, P604, DOI 10.1128/IAI.55.3.604-608.1987; CHAROENVIT Y, 1991, J IMMUNOL, V146, P1020; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CLYDE DF, 1973, AM J MED SCI, V266, P160; EGAN JE, 1987, SCIENCE, V236, P453, DOI 10.1126/science.3551073; FLYNN JL, 1990, MOL MICROBIOL, V4, P2111, DOI 10.1111/j.1365-2958.1990.tb00572.x; HAMMERLING GJ, 1979, J EXP MED, V150, P108, DOI 10.1084/jem.150.1.108; HEDSTROM RC, 1990, B WORLD HEALTH ORGAN, V68, P152; HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877; HOFFMAN SL, 1987, SCIENCE, V237, P639, DOI 10.1126/science.3299709; KHUSMITH S, UNPUB; KUMAR S, 1988, NATURE, V334, P258, DOI 10.1038/334258a0; LAL AA, 1987, J BIOL CHEM, V262, P2937; LAL AA, 1987, P NATL ACAD SCI USA, V84, P8647, DOI 10.1073/pnas.84.23.8647; MALIK A, 1991, P NATL ACAD SCI USA, V88, P3300, DOI 10.1073/pnas.88.8.3300; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0; POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504; Rieckmann K H, 1979, Bull World Health Organ, V57 Suppl 1, P261; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; SADOFF JC, 1988, SCIENCE, V240, P336, DOI 10.1126/science.3281260; Sedegah M., 1988, Technological Advances in Vaccine Development  (Proceedings of a Genentech, Ortho, Smith Kline & French-UCLA Symposium, 30 Jan.-6 Feb. 1988, Park City, Utah, USA)., P295; SEDEGAH M, 1990, B WORLD HEALTH ORGAN, V68, P109; SEDEGAH M, UNPUB; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAM JP, 1990, J EXP MED, V171, P299, DOI 10.1084/jem.171.1.299; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZAVALA F, 1987, J EXP MED, V166, P1591, DOI 10.1084/jem.166.5.1591	33	181	189	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					715	718		10.1126/science.1827210	http://dx.doi.org/10.1126/science.1827210			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1827210				2022-12-28	WOS:A1991FK18500052
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - DETECTION AND MANAGEMENT OF CONGENITAL-ABNORMALITIES .1.	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					949	950		10.1136/bmj.302.6782.949	http://dx.doi.org/10.1136/bmj.302.6782.949			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	1827741	Bronze, Green Published			2022-12-28	WOS:A1991FH48700024
J	PFALLER, R; SMYTHE, C; NEWPORT, JW				PFALLER, R; SMYTHE, C; NEWPORT, JW			ASSEMBLY DISASSEMBLY OF THE NUCLEAR-ENVELOPE MEMBRANE - CELL-CYCLE DEPENDENT BINDING OF NUCLEAR-MEMBRANE VESICLES TO CHROMATIN INVITRO	CELL			English	Article							XENOPUS CDC2 PROTEIN; CHROMOSOME CONDENSATION; GOLGI-APPARATUS; FREE SYSTEM; COMPONENT; MITOSIS; LAMINA; LAEVIS; KINASE; MATURATION	Dissociation and association of membranes with chromatin at the beginning and end of mitosis are critical in controlling nuclear dynamics during these stages of the cell cycle. Employing purified membrane and cytosolic fractions from Xenopus eggs, a simple assay was developed for the reversible binding of nuclear membrane vesicles to chromatin. We have shown, using phosphatase and kinase inhibitors, that membrane-chromatin association is regulated by a phosphatase/kinase system. In interphase, the balance in this system favors dephosphorylation, possibly of a membrane receptor, which then mediates chromatin binding. At mitosis the membrane receptor is phosphorylated, causing release of chromatin-bound membrane. Purified MPF kinase does not directly cause membranes to dissociate from chromatin. Rather, binding of membranes to chromatin at mitosis appears to be regulated indirectly by MPF through its action on a phosphatase/kinase system that directly modulates the phosphorylation state of a nuclear membrane component.			PFALLER, R (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,B-022,LA JOLLA,CA 92093, USA.				NIGMS NIH HHS [GM 33523-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033523, R37GM033523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1982, FEBS LETT, V147, P54, DOI 10.1016/0014-5793(82)81010-7; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BENAVENTE R, 1985, CELL, V41, P177, DOI 10.1016/0092-8674(85)90072-8; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; CHALY N, 1984, J CELL BIOL, V99, P661, DOI 10.1083/jcb.99.2.661; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; DOERING V, 1990, EMBO (European Molecular Biology Organization) Journal, V9, P4073; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DUNPHY WG, 1988, J CELL BIOL, V106, P2047, DOI 10.1083/jcb.106.6.2047; FIELDS AP, 1988, J CELL BIOL, V107, P833, DOI 10.1083/jcb.107.3.833; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LEAF DS, 1990, DEV BIOL, V141, P1, DOI 10.1016/0012-1606(90)90097-3; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; MCKEON FD, 1984, CELL, V36, P83, DOI 10.1016/0092-8674(84)90076-X; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURRAY AW, 1989, NATURE, V339, P287; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; PADAN R, 1990, J BIOL CHEM, V265, P7808; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STICK R, 1985, CELL, V41, P191, DOI 10.1016/0092-8674(85)90073-X; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1	46	119	119	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					209	217		10.1016/0092-8674(91)90155-R	http://dx.doi.org/10.1016/0092-8674(91)90155-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1849796				2022-12-28	WOS:A1991FH09200004
J	KUMAGAI, A; DUNPHY, WG				KUMAGAI, A; DUNPHY, WG			THE CDC25 PROTEIN CONTROLS TYROSINE DEPHOSPHORYLATION OF THE CDC2 PROTEIN IN A CELL-FREE SYSTEM	CELL			English	Article							ACTIVATED XENOPUS EGGS; CYCLIN MESSENGER-RNA; SEA-URCHIN EGGS; FISSION YEAST; PROMOTING FACTOR; MITOTIC CONTROL; KINASE; MITOSIS; MPF; DIVISION	As a prerequisite for the activation of MPF, the cdc2 protein kinase must undergo tyrosine dephosphorylation. Genetic studies have demonstrated that the cdc25 protein activates the cdc2 protein kinase once DNA replication has been completed. We have produced the cdc25 protein in bacteria and shown that it activates MPF in Xenopus extracts. In extracts that normally cannot enter mitosis owing to inhibition of DNA synthesis, the addition of active cdc25 protein efficiently elicits the mitotic state by inducing premature dephosphorylation of tyrosine on the cdc2 protein. The cdc25-dependent activation reaction can be reconstituted in a partially purified system lacking ATP. These biochemical experiments demonstrate that the cdc25 protein actively drives tyrosine dephosphorylation of the cdc2 protein and offer the prospect for characterizing the individual factors that regulate the activation of MPF during the progression from S phase to mitosis.			KUMAGAI, A (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.							BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1989, J CELL SCI, V92, P131; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TONKS NK, 1988, J BIOL CHEM, V263, P6731; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4	56	444	456	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					903	914		10.1016/0092-8674(91)90315-P	http://dx.doi.org/10.1016/0092-8674(91)90315-P			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1825803				2022-12-28	WOS:A1991FA94000008
J	SMRCKA, AV; HEPLER, JR; BROWN, KO; STERNWEIS, PC				SMRCKA, AV; HEPLER, JR; BROWN, KO; STERNWEIS, PC			REGULATION OF POLYPHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE-C ACTIVITY BY PURIFIED GQ	SCIENCE			English	Article							PROTEIN ALPHA-SUBUNIT; BETA-GAMMA-SUBUNITS; GUANINE-NUCLEOTIDE; PERTUSSIS TOXIN; BOVINE BRAIN; MEMBRANES; AFFINITY; CALCIUM; CELLS	The hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) by phospholipase C yields the second messengers inositol 1,4,5-trisphosphate (InsP3) and 1,2-diacylglycerol. This activity is regulated by a variety of hormones through G protein pathways. However, the specific G protein or proteins involved has not been identified. The alpha-subunit of a newly discovered pertussis toxin-insensitive G protein (G(q)) has recently been isolated and is now shown to stimulate the activity of polyphosphoinositide-specific phospholipase C (PI-PLC) from bovine brain. Both the maximal activity and the affinity of PI-PLC for calcium ion were affected. These results identify G(q) as a G protein that regulates PI-PLC.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM31954, GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497, R01GM031954] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOYER JL, 1989, J BIOL CHEM, V264, P13917; BRADFORD PG, 1986, BIOCHEM J, V239, P97, DOI 10.1042/bj2390097; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; CROOKE ST, 1989, CELL CALCIUM, V10, P309, DOI 10.1016/0143-4160(89)90057-2; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, UNPUB; HARDEN TK, 1988, BIOCHEM J, V252, P583, DOI 10.1042/bj2520583; HARDENTK, 1989, INOSITOL LIPIDS CELL, P113; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MARTIN TFJ, 1989, INOSITOL LIPIDS CELL, P81; MARTIN TFJ, 1986, J BIOL CHEM, V261, P10041; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; PANG IH, 1990, J BIOL CHEM, V265, P18707; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SHAFFNER W, 1973, ANAL BIOCHEM, V56, P502; SMRCKA AV, UNPUB; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; Taylor Suzanne, COMMUNICATION; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254	34	841	847	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					804	807		10.1126/science.1846707	http://dx.doi.org/10.1126/science.1846707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1846707				2022-12-28	WOS:A1991EX57500048
J	WILLEMS, JL; ABREULIMA, C; ARNAUD, P; VANBEMMEL, JH; BROHET, C; DEGANI, R; DENIS, B; GEHRING, J; GRAHAM, I; VANHERPEN, G; MACHADO, H; MACFARLANE, PW; MICHAELIS, J; MOULOPOULOS, SD; RUBEL, P; ZYWIETZ, C				WILLEMS, JL; ABREULIMA, C; ARNAUD, P; VANBEMMEL, JH; BROHET, C; DEGANI, R; DENIS, B; GEHRING, J; GRAHAM, I; VANHERPEN, G; MACHADO, H; MACFARLANE, PW; MICHAELIS, J; MOULOPOULOS, SD; RUBEL, P; ZYWIETZ, C			THE DIAGNOSTIC PERFORMANCE OF COMPUTER-PROGRAMS FOR THE INTERPRETATION OF ELECTROCARDIOGRAMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ECG	Background. Computer programs for the interpretation of electrocardiograms (ECGs) are now widely used. However, a systematic assessment of various computer programs for the interpretation of ECGs has not been performed. Methods. We undertook a large international study to compare the performance of nine electrocardiographic computer programs with that of eight cardiologists in interpreting ECGs in 1220 clinically validated cases of various cardiac disorders. ECGs from the following groups were included in the sample: control patients (n = 382); patients with left ventricular hypertrophy (n = 183), right ventricular hypertrophy (n = 55), or biventricular hypertrophy (n = 53); patients with anterior myocardial infarction (n = 170), inferior myocardial infarction (n = 273), or combined myocardial infarction (n = 73); and patients with combined infarction and hypertrophy (n = 31). The interpretations of the computer programs and the cardiologists were compared with the clinical diagnoses made independently of the ECGs, and the computer interpretations were compared with those of the cardiologists. Results. The percentage of ECGs correctly classified by the computer programs (median, 91.3 percent) was lower than that for the cardiologists (median, 96.0 percent; P < 0.01). The median sensitivity of the computer programs was also significantly lower than that of the cardiologists in diagnosing left ventricular hypertrophy (56.6 percent vs. 63.9 percent, P < 0.02), right ventricular hypertrophy (31.8 percent vs. 46.6 percent, P < 0.01), anterior myocardial infarction (77.1 percent vs. 84.9 percent, P < 0.001), and inferior myocardial infarction (58.8 percent vs. 71.7 percent, P < 0.0001). The median total accuracy level (the percentage of correct classifications) was 6.6 percent lower for the computer programs (69.7 percent) than for the cardiologists (76.3 percent; P < 0.001). However, the performance of the best programs nearly matched that of the most accurate cardiologists. Conclusions. Our study shows that some but not all computer programs for the interpretation of ECGs perform almost as well as cardiologists in identifying seven major cardiac disorders.	CATHOLIC UNIV LEUVEN, DEPT MED INFORMAT, B-3000 LOUVAIN, BELGIUM; UNIV PORTO, DEPT CARDIOL, OPORTO, PORTUGAL; INSERM, U121, F-69008 LYON, FRANCE; ERASMUS UNIV ROTTERDAM, DEPT MED INFORMAT, 3000 DR ROTTERDAM, NETHERLANDS; UNIV CATHOLIQUE LOUVAIN, DEPT CARDIOL, B-1200 BRUSSELS, BELGIUM; CNR, SYST DYNAM & BIOENGN RES INST, I-35100 PADUA, ITALY; UNIV GRENOBLE 1, CARDIOL CLIN, F-38041 GRENOBLE, FRANCE; KLIN HOHENRIED, KARDIOL ABT, BERNRIED, GERMANY; ADELAIDE HOSP, DEPT CARDIOL, DUBLIN, IRELAND; MEATH HOSP, DUBLIN, IRELAND; LEIDEN UNIV, DEPT CARDIOL, 2300 RA LEIDEN, NETHERLANDS; UNIV HOSP SANTA MARIA LISBON, DEPT CARDIOL, LISBON, PORTUGAL; UNIV GLASGOW, DEPT MED CARDIOL, GLASGOW G12 8QQ, SCOTLAND; UNIV MAINZ, INST MED STAT, W-6500 MAINZ, GERMANY; UNIV ATHENS, DEPT MED, ATHENS, GREECE; NATL INST APPL SCI, LYON, FRANCE; HANNOVER MED SCH, DIV BIOSIGNAL PROC, W-3000 HANNOVER 61, GERMANY	KU Leuven; Universidade do Porto; Institut National de la Sante et de la Recherche Medicale (Inserm); Erasmus University Rotterdam; Universite Catholique Louvain; Consiglio Nazionale delle Ricerche (CNR); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Trinity College Dublin; Trinity College Dublin; Leiden University; Leiden University - Excl LUMC; Universidade de Lisboa; Hospital Santa Maria; University of Glasgow; Johannes Gutenberg University of Mainz; National & Kapodistrian University of Athens; Institut National des Sciences Appliquees de Lyon - INSA Lyon; Hannover Medical School	WILLEMS, JL (corresponding author), UNIV HOSP GASTHUISBERG, 49 HERESTR, B-3000 LOUVAIN, BELGIUM.		Rubel, Paul/ABI-7833-2020	Rubel, Paul/0000-0002-0259-7694				AUSTEN WG, 1975, CIRCULATION S, V51, P1; BAILEY JJ, 1988, J ELECTROCARDIOL, V21, pS188, DOI 10.1016/0022-0736(88)90091-X; BAILEY JJ, 1974, CIRCULATION, V50, P73, DOI 10.1161/01.CIR.50.1.73; BAILEY JJ, 1981, COMPUTERIZED INTERPR, V6, P53; BAILEY JJ, 1980, COMPUTERIZED INTERPR, V5, P179; BERNARD P, 1983, J ELECTROCARDIOL, V16, P97, DOI 10.1016/S0022-0736(83)80165-4; BONNER R, 1979, COMPUTERIZED INTERPR, V4, P126; BOURDILLON PJ, 1978, EUR J CARDIOL, V8, P395; BROHET CR, 1979, AM J CARDIOL, V43, P1167, DOI 10.1016/0002-9149(79)90149-8; BRUCE RA, 1972, AM J CARDIOL, V29, P389, DOI 10.1016/0002-9149(72)90536-X; CACERES CA, 1970, AM HEART J, V79, P439, DOI 10.1016/0002-8703(70)90247-4; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; DRAZEN E, 1988, J ELECTROCARDIOL, V21, pS98, DOI 10.1016/0022-0736(88)90068-4; FEINSTEIN AR, 1977, CLIN BIOSTATISTICS, P214; FERUGLIO GA, 1977, TRENDS COMPUTER PROC, P239; GRAHAM IM, 1986, COMPUTER ECG ANAL ST, P191; HARRIS LK, 1976, 1976 EUR C CARD PAR, P725; KHADR NE, 1979, COMPUT CARDIOL, P93; KORNREICH F, 1976, ADV CARDIOL, V16, P121; LAKS MM, 1982, COMPUTERIZED INTERPR, V6, P267; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MACFARLANE PW, 1981, CIRCULATION, V63, P354, DOI 10.1161/01.CIR.63.2.354; MEYER J, 1974, DEUT MED WOCHENSCHR, V23, P1213; MICHAELIS J, 1990, METHOD INFORM MED, V29, P289; MILLIKEN JA, 1977, J ELECTROCARDIOL, V10, P375, DOI 10.1016/S0022-0736(77)80011-3; MILLIKEN JA, 1982, COMPUTERIZED INTERPR, V7, P341; PIPBERGER HV, 1973, CIRCULATION, V47, P918, DOI 10.1161/01.CIR.47.5.918; PIPBERGER HV, 1986, COMPUTER ECG ANAL ST, P3; PIPBERGER HV, 1976, COMPUT CARDIOL, P85; Rautaharju P M, 1978, Am J Cardiol, V41, P158, DOI 10.1016/0002-9149(78)90150-9; RAUTAHARJU PM, 1979, COMPUT BIOMED RES, V12, P39, DOI 10.1016/0010-4809(79)90004-1; RICHMAN HG, 1976, VECTORCARDIOGRAPHY, V3, P199; SIMONSON E, 1966, AM J CARDIOL, V17, P829, DOI 10.1016/0002-9149(66)90379-1; SMETS P, 1975, BIOMETR PRAX, V15, P3; VANBEMMEL JH, 1990, METHOD INFORM MED, V29, P261, DOI 10.1055/s-0038-1634808; WILLEMS JL, 1988, EUR HEART J, V9, P1348, DOI 10.1093/oxfordjournals.eurheartj.a062453; WILLEMS JL, 1990, METHOD INFORM MED, V29, P263; WILLEMS JL, 1985, J AM COLL CARDIOL, V5, P1261, DOI 10.1016/S0735-1097(85)80335-1; WILLEMS JL, 1989, J ELECTROCARDIOL, V22, P135; WILLEMS JL, 1987, AM J CARDIOL, V59, P119, DOI 10.1016/S0002-9149(87)80083-8; Willems JL, 1986, COMPUTER ECG ANAL ST, P11; WILLEMS JL, 1990, CSE10TH PROGR REP; WILLEMS JL, 1986, COMPUTER ECG ANAL ST, P203; WILLEMS JL, 1976, COMPUT CARDIOL, P89; WILLEMS JL, 1986, COMMON STANDARDS QUA; WOLF HK, 1982, COMPUERIZED INTERPRE, V7, P335; 1975, JAMA-J AM MED ASSOC, V231, P1090	47	402	411	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1991	325	25					1767	1773		10.1056/NEJM199112193252503	http://dx.doi.org/10.1056/NEJM199112193252503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV739	1834940				2022-12-28	WOS:A1991GV73900003
J	ROUBENOFF, R; KLAG, MJ; MEAD, LA; LIANG, KY; SEIDLER, AJ; HOCHBERG, MC				ROUBENOFF, R; KLAG, MJ; MEAD, LA; LIANG, KY; SEIDLER, AJ; HOCHBERG, MC			INCIDENCE AND RISK-FACTORS FOR GOUT IN WHITE MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. - To identify potentially modifiable risk factors for the development of gout. Design. - Longitudinal cohort study (The Johns Hopkins Precursors Study). Participants. - Of 1337 eligible medical students, 1271 (95%) received a standardized medical examination and questionnaire during medical school. The participants were predominantly male (91%), white (97%), and young (median age, 22 years) at cohort entry. Outcome Measure. - The development of gout. Results. - Sixty cases of gout (47 primary and 13 secondary) were identified among 1216 men; none occurred among 121 women (P = .01). The cumulative incidence of all gout was 8.6% among men (95% confidence interval, 5.9% to 11.3%). Body mass index at age 35 years (P = .01), excessive weight gain (> 1.88 kg/m2) between cohort entry and age 35 years (P = .007), and development of hypertension (P = .004) were significant risk factors for all gout in univariate analysis. Multivariate Cox proportional hazards models confirmed the association of body mass index at age 35 years (relative risk [RR] = 1.12; P = .02), excessive weight gain (RR = 2.07; P = .02), and hypertension (RR = 3.26; P = .002) as risk factors for all gout. Hypertension, however, was not a significant risk factor for primary gout. Conclusions. - Obesity, excessive weight gain in young adulthood, and hypertension are risk factors for the development of gout. Prevention of obesity and hypertension may decrease the incidence of and morbidity from gout; studies of weight reduction in the primary and secondary prevention of gout are indicated.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV MOLEC & CLIN RHEUMATOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV INTERNAL MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,WELCH CTR PREVENT EPIDEMIOL & CLIN RES,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Liang, Kung-Yee/F-8299-2011	Roubenoff, Ronenn/0000-0002-3959-3179	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG001760] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00722] Funding Source: Medline; NHLBI NIH HHS [HL42734] Funding Source: Medline; NIA NIH HHS [AG01760] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABBOTT RD, 1988, J CLIN EPIDEMIOL, V41, P237, DOI 10.1016/0895-4356(88)90127-8; Campion E W, 1987, Am J Med, V82, P421, DOI 10.1016/0002-9343(87)90441-4; COX DR, 1972, J R STAT SOC B, V34, P187; GLYNN RJ, 1983, ARTHRITIS RHEUM-US, V26, P87, DOI 10.1002/art.1780260115; HALL AP, 1967, AM J MED, V42, P27, DOI 10.1016/0002-9343(67)90004-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAWRENCE RC, 1989, J RHEUMATOL, V16, P427; LEE ET, 1980, STATISTICAL METHODS, P122; MANUEL MA, 1974, AM J MED, V57, P741, DOI 10.1016/0002-9343(74)90847-X; ROUBENOFF R, 1990, RHEUM DIS CLIN N AM, V16, P539; WALLACE SL, 1977, ARTHRITIS RHEUM, V20, P895, DOI 10.1002/art.1780200320; [No title captured]; [No title captured]	13	183	193	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3004	3007		10.1001/jama.266.21.3004	http://dx.doi.org/10.1001/jama.266.21.3004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820473				2022-12-28	WOS:A1991GR77500032
J	DEYO, RA				DEYO, RA			FADS IN THE TREATMENT OF LOW-BACK-PAIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LUMBAR				DEYO, RA (corresponding author), VET AFFAIRS MED CTR, SEATTLE, WA 98108 USA.							ALLAN DB, 1989, ACTA ORTHOP SCAND, V60, P1, DOI 10.3109/17453678909153916; BUTLER D, 1990, SPINE, V15, P111, DOI 10.1097/00007632-199002000-00012; CARETTE S, 1991, NEW ENGL J MED, V325, P1002, DOI 10.1056/NEJM199110033251405; DEYO RA, 1985, ARTHRITIS RHEUM, V28, P1066, DOI 10.1002/art.1780280916; HELBIG T, 1988, SPINE, V13, P61, DOI 10.1097/00007632-198801000-00015; LILIUS G, 1989, J BONE JOINT SURG BR, V71, P681, DOI 10.1302/0301-620X.71B4.2527856; MORAN R, 1988, SPINE, V13, P1407, DOI 10.1097/00007632-198812000-00013; NELSON DA, 1991, PERSPECT BIOL MED, V34, P229; RAYMOND J, 1984, RADIOLOGY, V151, P333, DOI 10.1148/radiology.151.2.6709900; WHITE AA, 1982, SPINE, V7, P141, DOI 10.1097/00007632-198203000-00009	10	57	59	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					1039	1040		10.1056/NEJM199110033251411	http://dx.doi.org/10.1056/NEJM199110033251411			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1832210				2022-12-28	WOS:A1991GH44700011
J	FARISH, E; ROLTON, HA; BARNES, JF; HART, DM				FARISH, E; ROLTON, HA; BARNES, JF; HART, DM			LIPOPROTEIN (A) CONCENTRATIONS IN POSTMENOPAUSAL WOMEN TAKING NORETHISTERONE	BRITISH MEDICAL JOURNAL			English	Article							LP(A) LIPOPROTEIN		STOBHILL GEN HOSP,DEPT OBSTET & GYNAECOL,GLASGOW G21 3UW,SCOTLAND		FARISH, E (corresponding author), STOBHILL GEN HOSP,DEPT BIOCHEM,GLASGOW G21 3UW,SCOTLAND.							ABDALLA HI, 1985, OBSTET GYNECOL, V66, P789; ALBERS JJ, 1984, BIOCHIM BIOPHYS ACTA, V795, P293, DOI 10.1016/0005-2760(84)90078-X; ALBERS JJ, 1975, METABOLISM, V24, P1047, DOI 10.1016/0026-0495(75)90098-0; FARISH E, 1986, CLIN CHIM ACTA, V159, P147; MBEWU AD, 1990, ATHEROSCLEROSIS, V85, P1, DOI 10.1016/0021-9150(90)90177-K	5	125	125	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					694	694		10.1136/bmj.303.6804.694	http://dx.doi.org/10.1136/bmj.303.6804.694			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1833013	Green Published, Bronze			2022-12-28	WOS:A1991GG98000023
J	TAYLOR, DW				TAYLOR, DW			BENEFICIAL EFFECT OF CAROTID ENDARTERECTOMY IN SYMPTOMATIC PATIENTS WITH HIGH-GRADE CAROTID STENOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STROKE MORTALITY; TRENDS; RISK	Background. Without strong evidence of benefit, the use of carotid endarterectomy for prophylaxis against stroke rose dramatically until the mid-1980s, then declined. Our investigation sought to determine whether carotid endarterectomy reduces the risk of stroke among patients with a recent adverse cerebrovascular event and ipsilateral carotid stenosis. Methods. We conducted a randomized trial at 50 clinical centers throughout the United States and Canada, in patients in two predetermined strata based on the severity of carotid stenosis - 30 to 69 percent and 70 to 99 percent. We report here the results in the 659 patients in the latter stratum, who had had a hemispheric or retinal transient ischemic attack or a nondisabling stroke within the 120 days before entry and had stenosis of 70 to 99 percent in the symptomatic carotid artery. All patients received optimal medical care, including antiplatelet therapy. Those assigned to surgical treatment underwent carotid endarterectomy performed by neurosurgeons or vascular surgeons. All patients were examined by neurologists 1, 3, 6, 9, and 12 months after entry and then every 4 months. End points were assessed by blinded, independent case review. No patient was lost to follow-up. Results. Life-table estimates of the cumulative risk of any ipsilateral stroke at two years were 26 percent in the 331 medical patients and 9 percent in the 328 surgical patients - an absolute risk reduction (+/- SE) of 17 +/- 3.5 percent (P < 0.001). For a major or fatal ipsilateral stroke, the corresponding estimates were 13.1 percent and 2.5 percent - an absolute risk reduction of 10.6 +/- 2.6 percent (P < 0.001). Carotid endarterectomy was still found to be beneficial when all strokes and deaths were included in the analysis (P < 0.001). Conclusions. Carotid endarterectomy is highly beneficial to patients with recent hemispheric and retinal transient ischemic attacks or nondisabling strokes and ipsilateral high-grade stenosis (70 to 99 percent) of the internal carotid artery.			TAYLOR, DW (corresponding author), MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, 1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA.		Spence, J. David/K-6396-2013; Buchan, Alastair M/B-9095-2009	Spence, J. David/0000-0001-7478-1098; Buchan, Alastair M/0000-0002-2918-5200; Harbaugh, Robert/0000-0003-3607-7926; Brown, Martin M/0000-0002-3273-1356	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024456] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS-24456] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 1988, BRIT MED J, V296, P320; ARRAIZ GA, 1989, CHRONIC DIS CAN, V10, P22; BAKER WH, 1987, STROKE, V18, P957, DOI 10.1161/str.18.5.957b; BARNETT HJM, 1990, STROKE, V21, P2; BARNETT HJM, 1991, STROKE, V22, P711, DOI 10.1161/01.STR.22.6.711; BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; DION JE, 1987, STROKE, V18, P997, DOI 10.1161/01.STR.18.6.997; EARNEST F, 1984, AM J ROENTGENOL, V142, P247, DOI 10.2214/ajr.142.2.247; EASTCOTT HHG, 1954, LANCET, V2, P994; FIELDS WS, 1970, J AMER MED ASSOC, V211, P1993, DOI 10.1001/jama.211.12.1993; GARRAWAY WM, 1987, JAMA-J AM MED ASSOC, V258, P214, DOI 10.1001/jama.258.2.214; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; KLAG MJ, 1989, STROKE, V20, P14, DOI 10.1161/01.STR.20.1.14; KOTILA M, 1988, STROKE, V19, P1572, DOI 10.1161/str.19.12.1572b; KURTZKE J, 1974, CEREBRAL VASCULAR DI, P190; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; POKRAS R, 1988, STROKE, V19, P1289, DOI 10.1161/01.STR.19.10.1289; SHAW DA, 1984, J NEUROL SCI, V64, P45, DOI 10.1016/0022-510X(84)90054-6; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; STREIFLER JY, 1991, STROKE, V22, P149; SUNDT TM, 1990, MAYO CLIN PROC, V65, P625, DOI 10.1016/S0025-6196(12)65124-6; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WARLOW C, 1984, STROKE, V15, P1068, DOI 10.1161/01.STR.15.6.1068; WHISNANT JP, 1990, STROKE, V21, P707, DOI 10.1161/01.STR.21.5.707	25	6023	6243	1	100	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					445	453						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1852179				2022-12-28	WOS:A1991GA76300001
J	BARROW, CJ; ZAGORSKI, MG				BARROW, CJ; ZAGORSKI, MG			SOLUTION STRUCTURES OF BETA PEPTIDE AND ITS CONSTITUENT FRAGMENTS - RELATION TO AMYLOID DEPOSITION	SCIENCE			English	Article							PAIRED HELICAL FILAMENTS; X-RAY-DIFFRACTION; ALZHEIMERS-DISEASE; PROTEIN-PRECURSOR; MESSENGER-RNA; SENILE PLAQUES; BRAIN; INHIBITOR; IDENTIFICATION; LOCALIZATION	The secondary structures in solution of the synthetic, naturally occurring, amyloid beta-peptides, residues 1 to 42 [beta(1-42)] and beta(1-39), and related fragments, beta(1-28) and beta(29-42), have been studied by circular dichroism and two-dimensional nuclear magnetic resonance spectroscopy. In patients with Alzheimer's disease, extracellular amyloid plaque core is primarily composed of beta(1-42), whereas cerebrovascular amyloid contains the more soluble beta(1-39). In aqueous trifluoroethanol solution, the beta(1-28), beta(1-39), and beta(1-42) peptides adopt monomeric alpha-helical structures at both low and high pH, whereas at intermediate pH (4 to 7) an oligomeric beta-structure (the probable structure in plaques) predominates. Thus, beta-peptide is not by itself an insoluble protein (as originally thought), and localized or normal age-related alterations of pH may be necessary for the self-assembly and deposition of beta-peptide. The hydrophobic carboxyl-terminal segment, beta(29-42), exists exclusively as an oligomeric beta-sheet in solution, regardless of differences in solvent, pH, or temperature, suggesting that this segment directs the folding of the complete beta(1-42) peptide to produce the beta-pleated sheet found in amyloid plaques.	SUNTORY INST BIOORGAN RES,SHIMAMOTO,OSAKA 618,JAPAN	Suntory Holdings Ltd								BAX A, 1989, ANNU REV BIOCHEM, V58, P223; BEHROUZ N, 1989, LAB INVEST, V61, P576; BEYREUTHER K, 1988, ETIOLOGY DEMENTIA AL, P125; CANDY JM, 1986, LANCET, V1, P354; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; EANES ED, 1968, J HISTOCHEM CYTOCHEM, V16, P673, DOI 10.1177/16.11.673; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GILBOE DD, 1986, PHARM CEREBRAL ISCHE, P119; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1988, CELL, V52, P307, DOI 10.1016/S0092-8674(88)80021-7; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOREVIC PD, 1987, BIOCHEM BIOPH RES CO, V147, P854, DOI 10.1016/0006-291X(87)91008-4; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GRONENBORN AM, 1990, ANAL CHEM, V62, P2, DOI 10.1021/ac00200a003; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; Hollosi M, 1989, Pept Res, V2, P109; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KITAGUCHI N, 1990, BIOCHIM BIOPHYS ACTA, V1038, P105, DOI 10.1016/0167-4838(90)90017-A; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEWIS PN, 1971, P NATL ACAD SCI USA, V68, P2293, DOI 10.1073/pnas.68.9.2293; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; MUNCKATA K, 1987, STROKE, V18, P412; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OSTERHOUT JJ, 1989, BIOCHEMISTRY-US, V28, P7059, DOI 10.1021/bi00443a042; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; PRICE DL, 1986, ANNU REV NEUROSCI, V9, P489; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P75; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SPILLANTINI MG, 1990, P NATL ACAD SCI USA, V87, P3947, DOI 10.1073/pnas.87.10.3947; Stewart JM, 1984, SOLID PHASE PEPTIDE; TAGLIAVINI F, 1988, NEUROSCI LETT, V93, P191, DOI 10.1016/0304-3940(88)90080-8; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WISNIEWSKI HM, 1976, J NEUROL SCI, V27, P173, DOI 10.1016/0022-510X(76)90059-9; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V77, P113; YATES CM, 1990, J NEUROCHEM, V55, P1624, DOI 10.1111/j.1471-4159.1990.tb04948.x; ZHANG H, 1989, P NATL ACAD SCI USA, V86, P8045, DOI 10.1073/pnas.86.20.8045	53	554	575	0	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					179	182		10.1126/science.1853202	http://dx.doi.org/10.1126/science.1853202			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1853202				2022-12-28	WOS:A1991FW16000031
J	GALL, JG				GALL, JG			SPLICEOSOMES AND SNURPOSOMES	SCIENCE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; LOCALIZATION; SNRNPS; TRANSCRIPTION; PROTEINS				GALL, JG (corresponding author), CARNEGIE INST WASHINGTON, DEPT EMBRYOL, 115 W UNIV PKWY, BALTIMORE, MD 21210 USA.		Gall, Joseph/AAF-6789-2020					BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; CALLAN HG, 1986, LAMPBRUSH CHROMOSOME, P1; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; FORBES DJ, 1983, J CELL BIOL, V97, P62, DOI 10.1083/jcb.97.1.62; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GALL JG, 1989, P NATL ACAD SCI USA, V86, P6635, DOI 10.1073/pnas.86.17.6635; GALL JG, 1991, ADV DEV BIOCH, V113, P465; KRAINER AR, 1988, FRONTIERS MOL BIOL T, P131; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; OSHEIM YN, 1985, CELL, V43, P143, DOI 10.1016/0092-8674(85)90019-4; REED R, 1988, CELL, V53, P949, DOI 10.1016/S0092-8674(88)90489-8; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; SASS H, 1984, J MOL BIOL, V180, P911, DOI 10.1016/0022-2836(84)90263-8; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; VAZQUEZNIN GH, 1990, CHROMOSOMA, V99, P44, DOI 10.1007/BF01737288; WU Z, IN PRESS J CELL BIOL; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZELLER R, 1983, CELL, V32, P425, DOI 10.1016/0092-8674(83)90462-2; ZIEVE GW, 1990, CRIT REV BIOCHEM MOL, V25, P1, DOI 10.3109/10409239009090604	27	82	82	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	1991	252	5012					1499	1500		10.1126/science.1828621	http://dx.doi.org/10.1126/science.1828621			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR040	1828621				2022-12-28	WOS:A1991FR04000035
J	MAGUIRE, HF; HOEFFLER, JP; SIDDIQUI, A				MAGUIRE, HF; HOEFFLER, JP; SIDDIQUI, A			HBV X-PROTEIN ALTERS THE DNA-BINDING SPECIFICITY OF CREB AND ATF-2 BY PROTEIN-PROTEIN INTERACTIONS	SCIENCE			English	Article							HEPATITIS-B VIRUS; LONG TERMINAL REPEAT; CYCLIC-AMP; RESPONSE ELEMENT; TRANS-ACTIVATION; VIRAL ENHANCERS; MAMMALIAN-CELLS; GENE; TRANSCRIPTION; TRANSACTIVATOR	The hepatitis B virus (HBV) X gene product trans-activates viral and cellular genes. The X protein (pX) does not bind independently to nucleic acids. The data presented here demonstrate that pX entered into a protein-protein complex with the cellular transcriptional factors CREB and ATF-2 and altered their DNA binding specificities. Although CREB and ATF-2 alone did not bind to the HBV enhancer element, a pX-CREB or pX-ATF-2 complex did bind to the HBV enhancer. Thus, the ability of pX to interact with cellular factors broadened the DNA binding specificity of these regulatory proteins and provides a mechanism for pX to participate in transcriptional regulation. This strategy of altered binding specificity may modify the repertoire of genes that can be regulated by transcriptional factors during viral infection.	UNIV COLORADO,SCH MED,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,CTR CANC,DENVER,CO 80262; UNIV COLORADO,SCH MED,DIV MED ONCOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NCI NIH HHS [CA33135, P30-CA46934-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033135, P30CA046934] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FACTOR O, 1990, ONCOGENE, V5, P867; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GODING CR, 1989, VIROLOGY, V173, P363; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARDY S, 1988, P NATL ACAD SCI USA, V85, P4171, DOI 10.1073/pnas.85.12.4171; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, IN PRESS MOL ENDOCRI; HOEFFLER JP, 1990, TRENDS ENDOCRINOL ME, V1, P151; HOEFFLER JP, UNPUB; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7144; JAMEEL S, 1986, MOL CELL BIOL, V6, P710, DOI 10.1128/MCB.6.2.710; JAMEEL S, 1990, J VIROL, V64, P3963, DOI 10.1128/JVI.64.8.3963-3966.1990; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAGUIRE HG, UNPUB; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; TOGNONI A, 1986, NUCLEIC ACIDS RES, V13, P7357; TRUJILLO MA, 1991, P NATL ACAD SCI USA, V88, P3797, DOI 10.1073/pnas.88.9.3797; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; WU J, 1990, CELL, V63, P673; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YEE JK, 1989, SCIENCE, V246, P658, DOI 10.1126/science.2554495; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	41	404	420	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					842	844		10.1126/science.1827531	http://dx.doi.org/10.1126/science.1827531			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1827531				2022-12-28	WOS:A1991FL12300046
J	GERBERT, B; BLEECKER, T; MIYASAKI, C; MAGUIRE, BT				GERBERT, B; BLEECKER, T; MIYASAKI, C; MAGUIRE, BT			POSSIBLE HEALTH-CARE PROFESSIONAL-TO-PATIENT HIV TRANSMISSION - DENTISTS REACTIONS TO A CENTERS-FOR-DISEASE-CONTROL REPORT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								On July 27, 1990, the Centers for Disease Control reported possible transmission of the human immunodeficiency virus (HIV) from a dentist to a patient as a result of patient care. We surveyed a random national probability sample of 300 dentists with a 26-item survey in August and September 1990 to assess reactions to the report (response rate, 59%). Respondents tended not to believe the report (mean was 3.2, median 3.0, where 1 indicated "do not believe" and 7 indicated "believe"). Our sample also tended to believe that transmission of HIV from dentists to patients was unlikely in the future (mean was 2.0, median 2.0, where 1 indicated "not at all likely" and 7 indicated "very likely"). Fifty-one percent of our sample recommended that dentists infected with HIV should discontinue practice, while 38% recommended continuing practice with changes in procedures. Seventy-four percent believed patients should be told if their dentist was infected with HIV. In summary, dentists doubted the possibility of dentist-to-patient transmission of HIV and did not believe the Centers for Disease Control case report, but they did believe infected dentists should refrain from clinical work or modify their practice.	UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	GERBERT, B (corresponding author), UNIV CALIF SAN FRANCISCO,SCH DENT,DEPT DENT PUBL HLTH & HYG,DIV BEHAV SCI,707 PARNASUS,SAN FRANCISCO,CA 94143, USA.				NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Babbie ER, 1973, SURVEY RES METHODS, P165; BLAND A, 1990, AIDS ALERT, V5, P161; BREO DL, 1990, JAMA-J AM MED ASSOC, V264, P1464, DOI 10.1001/jama.264.11.1464; GERBERT B, 1988, JAMA-J AM MED ASSOC, V260, P3481, DOI 10.1001/jama.260.23.3481; GOLDSMITH MF, 1990, JAMA-J AM MED ASSOC, V264, P1079; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; RELMAN AS, 1987, SEARCH MODERN HIPPOC, P198; Shilts R., 1987, BAND PLAYED POLITICS; 1991, MMWR, V40, P33; 1988, JAMA-J AM MED ASSOC, V259, P1360; 1987, MMWR S2S, V36, pS1; 1986, FACTS AIDS DENTAL TE; 1990, MMWR, V39, P489; 1991, MMWR, V40, P21	14	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1845	1848		10.1001/jama.265.14.1845	http://dx.doi.org/10.1001/jama.265.14.1845			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	1848643				2022-12-28	WOS:A1991FE86200025
J	LEVINE, MN; HIRSH, J; GENT, M; TURPIE, AG; LECLERC, J; POWERS, PJ; JAY, RM; NEEMEH, J				LEVINE, MN; HIRSH, J; GENT, M; TURPIE, AG; LECLERC, J; POWERS, PJ; JAY, RM; NEEMEH, J			PREVENTION OF DEEP-VEIN THROMBOSIS AFTER ELECTIVE HIP-SURGERY - A RANDOMIZED TRIAL COMPARING LOW-MOLECULAR-WEIGHT HEPARIN WITH STANDARD UNFRACTIONATED HEPARIN	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-DOSE HEPARIN; POSTOPERATIVE VENOUS THROMBOSIS; FATAL PULMONARY-EMBOLISM; SUBCUTANEOUS HEPARIN; I-125 FIBRINOGEN; GENERAL-SURGERY; DOUBLE-BLIND; REPLACEMENT; THROMBOEMBOLISM; ARTHROPLASTY	Objective: To determine the relative efficacy and safety of low molecular weight (LMW) heparin (Enoxaparin) compared with standard calcium heparin for the prevention of postoperative deep vein thrombosis in patients undergoing elective hip surgery. Design: A double-blind, randomized, controlled trial. Patients: Six hundred sixty-five consecutive patients undergoing hip replacement at five participating hospitals. Interventions: Patients received either fixed-dose LMW heparin, 30 mg subcutaneously twice daily, or fixed-dose standard calcium heparin, 7500 units subcutaneously twice daily; both regimens were started 12 to 24 hours after surgery and continued for 14 days or until discharge if sooner. Measurements: All patients had postoperative I-125-fibrinogen leg scanning and impedance plethysmography. If results of one or both tests were positive, then venography was done. Otherwise, venography was done between day 10 and day 14, or sooner if the patient was ready for discharge. Results: Evaluable venograms were obtained in 258 of the 333 patients randomly assigned to receive LMW heparin and in 263 of the 332 patients assigned to receive calcium heparin. For patients with evaluable venograms, thrombosis was detected in 50 patients (19.4%) who received LMW heparin compared with 61 patients (23.2%) who received standard heparin (difference, - 3.8%; 95% CI, - 11.1% to 3.6%) (P > 0.2). Proximal deep vein thrombosis was detected in 5.4% of the patients receiving LMW heparin and in 6.5% of the patients receiving standard heparin (difference, - 1.1%; CI, - 5.2% to 3.3%) (P > 0.2). For the entire group of 665 patients, venous thrombosis occurred in 17.1% given LMW heparin and in 19.0% given standard heparin. Hemorrhagic complications occurred in 31 patients (9.3%) given standard heparin and in 17 patients (5.1%) given LMW heparin (difference, 4.2%; CI, 0.3% to 8.2%) (P = 0.035). The relative risk reduction was 45%. The rate of major bleeding in the standard heparin group was 5.7% compared with 3.3% in the LMW heparin group (difference, 2.4%; CI, - 1.0% to 5.4%) (P = 0.13). The relative risk reduction was 42%. Conclusion: Low molecular weight heparin is significantly less hemorrhagic than standard unfractionated heparin; the difference in the rate of deep vein thrombosis, although not statistically significant (P > 0.2), favors the use of LMW heparin.	MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA; HAMILTON CIV HOSP, RES CTR, HAMILTON, ONTARIO, CANADA; MCGILL UNIV, MONTREAL H3A 2T5, QUEBEC, CANADA; UNIV MONTREAL, MONTREAL H3C 3J7, QUEBEC, CANADA	McMaster University; McMaster University; McGill University; Universite de Montreal								AIACH M, 1983, THROMB RES, V31, P611, DOI 10.1016/0049-3848(83)90458-9; ANDERSSON G, 1982, THROMB RES, V27, P631, DOI 10.1016/0049-3848(82)90001-9; ANDERSSON LO, 1976, THROMB RES, V9, P575, DOI 10.1016/0049-3848(76)90105-5; BENTLEY PG, 1980, THROMB RES, V18, P177, DOI 10.1016/0049-3848(80)90182-6; BERGQVIST D, 1983, THROMB RES, V32, P381, DOI 10.1016/0049-3848(83)90091-9; BLAJCHMAN MA, 1989, ANN NY ACAD SCI, V556, P245; BONEU B, 1988, SEMIN THROMB HEMOST, V14, P18, DOI 10.1055/s-2007-1002751; CADE JF, 1983, AUST NZ J SURG, V53, P301, DOI 10.1111/j.1445-2197.1983.tb02451.x; CARTER CJ, 1982, BLOOD, V59, P1239; COLDITZ GA, 1986, LANCET, V2, P143; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; COYNE E, 1985, SEMIN THROMB HEMOST, V11, P10, DOI 10.1055/s-2007-1004351; CRUICKSHANK MK, 1989, THROMB HAEMOSTASIS, V62, P830; DECHAVANNE M, 1974, NOUV PRESSE MED, V3, P1317; DOYLE DJ, 1987, ANN INTERN MED, V107, P441, DOI 10.7326/0003-4819-107-4-441; FERNANDEZ F, 1986, THROMB RES, V43, P491, DOI 10.1016/0049-3848(86)90094-0; FRANCIS CW, 1983, JAMA-J AM MED ASSOC, V249, P374, DOI 10.1001/jama.249.3.374; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; GALLUS AS, 1973, NEW ENGL J MED, V288, P545, DOI 10.1056/NEJM197303152881103; HAMPSON WGJ, 1974, LANCET, V2, P795; HIRSH J, 1987, THROMB DIATH HAEMO, P325; HOEK J, 1989, THROMB HAEMOSTASIS, V62, P520; HULL R, 1982, NEW ENGL J MED, V306, P189, DOI 10.1056/NEJM198201283060401; HUME M, 1973, ARCH SURG-CHICAGO, V107, P803; JOHNSON EA, 1976, THROMB HAEMOSTASIS, V35, P586, DOI 10.1055/s-0038-1648001; LEYVRAZ PF, 1983, NEW ENGL J MED, V309, P954, DOI 10.1056/NEJM198310203091605; MANNUCCI PM, 1976, THROMB HAEMOSTASIS, V36, P157; MORRIS GK, 1974, LANCET, V2, P797; MOSKOVITZ PA, 1978, J BONE JOINT SURG AM, V60, P1065, DOI 10.2106/00004623-197860080-00008; OCKELFORD PA, 1982, THROMB RES, V27, P679, DOI 10.1016/0049-3848(82)90006-8; PAIEMENT GD, 1987, CLIN ORTHOP RELAT R, V223, P188; PEZZUOLI G, 1989, INT SURG, V74, P205; PLANES A, 1988, THROMB HAEMOSTASIS, V60, P407; POWERS PJ, 1989, ARCH INTERN MED, V149, P771, DOI 10.1001/archinte.149.4.771; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; RASKOB GE, 1984, CIRCULATION, V70, P360; SALZMAN EM, 1987, HEMOSTASIS THROMBOSI, P1252; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; TURPIE AGG, 1987, LANCET, V1, P523; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; YOUNGHOO JS, 1988, J BONE JOINT SURG AM, V70, P878; 1975, BRIT J SURG, V62, P348; 1986, LANCET, V1, P1202	43	299	299	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					545	551		10.7326/0003-4819-114-7-545	http://dx.doi.org/10.7326/0003-4819-114-7-545			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	1848054				2022-12-28	WOS:A1991FD66100004
J	CHADWICK, DJ; GILLATT, DA; GINGELL, JC				CHADWICK, DJ; GILLATT, DA; GINGELL, JC			MEDICAL OR SURGICAL ORCHIECTOMY - THE PATIENTS CHOICE	BRITISH MEDICAL JOURNAL			English	Article							PROSTATIC-CARCINOMA; ORCHIECTOMY				CHADWICK, DJ (corresponding author), SOUTHMEAD GEN HOSP,DEPT UROL,BRISTOL BS10 5NB,AVON,ENGLAND.							CASSILETH BR, 1989, UROLOGY, V33, P57, DOI 10.1016/0090-4295(89)90108-8; LUNGLMAYR G, 1987, INT C S SERIES, V125, P47; MCCLINTON S, 1989, BRIT J UROL, V63, P309, DOI 10.1111/j.1464-410X.1989.tb05195.x; PEELING WB, 1989, UROLOGY, V33, P45, DOI 10.1016/0090-4295(89)90106-4; 1990, MIMS             DEC, P248	5	33	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					572	572		10.1136/bmj.302.6776.572	http://dx.doi.org/10.1136/bmj.302.6776.572			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	1827036	Green Published, Bronze			2022-12-28	WOS:A1991FB93600023
J	YEH, E; DRISCOLL, R; COLTRERA, M; OLINS, A; BLOOM, K				YEH, E; DRISCOLL, R; COLTRERA, M; OLINS, A; BLOOM, K			A DYNAMIN-LIKE PROTEIN ENCODED BY THE YEAST SPORULATION GENE SPO15	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; MICROTUBULES	THE tightly centromere-linked gene SPO15 is essential for meiotic cell division in the yeast Saccharomyces cerevisiae. Diploid cells without the intact SPO15 gene product are able to complete premeiotic DNA synthesis and genetic recombination, but are unable to traverse the division cycles. Electron microscopy of blocked cells reveals a duplicated but unseparated spindle-pole body. Thus cells are unable to form a bipolar spindle. Sequence analysis of SPO15 DNA reveals an open reading frame that predicts a protein of 704 amino acids. This protein is identical to VPS1, a gene involved in vacuolar protein sorting in yeast which has significant sequence homology (45% overall, 66% over 300 amino acids) to the microtubule bundling-protein, dynamin. The SPO15 gene product expressed in Escherichia coli can be affinity-purified with microtubules. SPO15 encodes a protein that is likely to be involved in a microtubule-dependent process required for the timely separation of spindle-pole bodies in meiosis	UNIV WASHINGTON,DEPT OTOLARYNGOL,SEATTLE,WA 98195; UNIV TENNESSEE,GRAD SCH BIOMED SCI,DIV BIOL,OAK RIDGE NATL LAB,OAK RIDGE,TN 37831	University of Washington; University of Washington Seattle; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville	YEH, E (corresponding author), UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599, USA.		Bloom, Kerry/AAE-5336-2019	Bloom, Kerry/0000-0002-3457-004X				BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; TABOR S, 1990, CURRENT PROTOCOLS MO; YEH E, 1986, MOL CELL BIOL, V6, P158, DOI 10.1128/MCB.6.1.158	11	78	79	1	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					713	715		10.1038/349713a0	http://dx.doi.org/10.1038/349713a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1825352				2022-12-28	WOS:A1991EY62700053
J	XIE, XM; SMART, TG				XIE, XM; SMART, TG			A PHYSIOLOGICAL-ROLE FOR ENDOGENOUS ZINC IN RAT HIPPOCAMPAL SYNAPTIC NEUROTRANSMISSION	NATURE			English	Article							PYRAMIDAL CELLS; BRAIN; LOCALIZATION; RELEASE; NEURONS; ZN-2+; RESPONSES	THE mammalian central nervous system (CNS) contains an abundance of the transition metal zinc, which is highly localized in the neuronal parenchyma 1-4. Zinc is actively taken up 5,6 and stored in synaptic vesicles in nerve terminals 7-10, and stimulation of nerve fibre tracts that contain large amounts of zinc, such as the hippocampal mossy fibre system 4, can induce its release 11-13, suggesting that it may act as a neuromodulator. The known interaction of zinc with the major excitatory and inhibitory amino-acid neurotransmitter receptors in the CNS supports this notion 14-16. That zinc has a role in CNS synaptic transmission, however, has so far not been shown. Here we report a physiological role for zinc in the young rat hippocampus (postnatal, P3-P14 days). Our results indicate that naturally occurring spontaneous giant depolarizing synaptic potentials (GDPs) in young CA3 pyramidal neurones, mediated by the release of GABA (gamma-aminobutyric acid) 17, are induced by endogenously released zinc. These synaptic potentials are inhibited by specific zinc-chelating agents. GDPs are apparently generated by an inhibitory action of zinc on both pre- and postsynaptic GABA(B) receptors in the hippocampus. Our study implies that zinc modulates synaptic transmission in the immature hippocampus, a finding that may have implications for understanding benign postnatal seizures in young children suffering with acute zinc deficiency 18.	UNIV LONDON, DEPT PHARMACOL, 29-39 BRUNSWICK SQ, LONDON WC1N 1AX, ENGLAND	University of London				Xie, Xinmin Simon/0000-0002-4049-6499	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALGER BE, 1982, J PHYSIOL-LONDON, V328, P105, DOI 10.1113/jphysiol.1982.sp014255; ANDERSEN P, 1980, J PHYSIOL-LONDON, V305, P279, DOI 10.1113/jphysiol.1980.sp013363; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; CHARTON G, 1985, EXP BRAIN RES, V58, P202; CRAWFORD IL, 1975, J ORTHOMOL MED, V4, P39; CRAWFORD IL, 1972, J NEUROCHEM, V19, P1451, DOI 10.1111/j.1471-4159.1972.tb05088.x; DANSCHER G, 1975, BRAIN RES, V85, P522, DOI 10.1016/0006-8993(75)90825-2; DANSCHER G, 1984, NEUROBIOLOGY ZINC, VA, P227; DOLLER HJ, 1984, NEUROBIOLOGY ZINC, VB, P163; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; FRIEDMAN B, 1984, J COMP NEUROL, V223, P88, DOI 10.1002/cne.902230108; GOLDBERG HJ, 1982, ARCH DIS CHILD, V57, P633, DOI 10.1136/adc.57.8.633; HESSE GW, 1979, SCIENCE, V205, P1005, DOI 10.1126/science.224456; HIDER RC, 1990, BIOCHEM PHARMACOL, V39, P1005, DOI 10.1016/0006-2952(90)90278-S; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; HOLM IE, 1988, HISTOCHEMISTRY, V89, P289, DOI 10.1007/BF00493154; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; IBATA Y, 1969, J HISTOCHEM CYTOCHEM, V17, P171, DOI 10.1177/17.3.171; MCLAUGHLIN BJ, 1975, BRAIN RES, V85, P355, DOI 10.1016/0006-8993(75)90813-6; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; SCHWARTZKROIN PA, 1981, DEV BRAIN RES, V2, P469, DOI 10.1016/0165-3806(81)90017-1; SMART TG, 1990, BRIT J PHARMACOL, V99, P643, DOI 10.1111/j.1476-5381.1990.tb12984.x; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; WENSINK J, 1988, J NEUROCHEM, V50, P782, DOI 10.1111/j.1471-4159.1988.tb02982.x; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WOLF G, 1984, NEUROSCI LETT, V51, P277, DOI 10.1016/0304-3940(84)90564-0	30	372	381	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 7	1991	349	6309					521	524		10.1038/349521a0	http://dx.doi.org/10.1038/349521a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846946				2022-12-28	WOS:A1991EW57100065
J	BAUER, HM; TING, Y; GREER, CE; CHAMBERS, JC; TASHIRO, CJ; CHIMERA, J; REINGOLD, A; MANOS, MM				BAUER, HM; TING, Y; GREER, CE; CHAMBERS, JC; TASHIRO, CJ; CHIMERA, J; REINGOLD, A; MANOS, MM			GENITAL HUMAN PAPILLOMAVIRUS INFECTION IN FEMALE UNIVERSITY-STUDENTS AS DETERMINED BY A PCR-BASED METHOD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; CERVICAL NEOPLASIA; AMPLIFICATION; PREVALENCE; SEQUENCES; WOMEN	The presence of genital human papillomavirus (HPV) was determined at cervical and vulvar sites using two methods, the Food and Drug Administration-approved ViraPap test and polymerase chain reaction (PCR) DNA amplification technology, in 467 women presenting to a university health service for a routine annual gynecologic examination. The PCR system afforded the sensitive detection of a broad spectrum of genital HPV types. Using PCR, we found that 46% of the study population was infected with HPV; the ViraPap test showed a prevalence of 11% infected. PCR analyses demonstrated that 69% of the HPV-positive women were infected at both genital sites. Subsequent HPV-type determination showed that 33% of the study population had HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, or other previously isolated types, and 13% had yet unidentified types. Almost all (92%) of the women diagnosed by Papanicolaou smear with condylomatous atypia or dysplasia (n = 12) were HPV positive. The PCR method proved to be an informative and rapid way to detect HPV in large numbers of clinical samples. Our results demonstrate that genital HPV infection is common among sexually active young women.	CETUS CORP, DEPT INFECT DIS, 1400 53RD ST, EMERYVILLE, CA 94608 USA; ROCHE BIOMED LABS, DEPT MOLEC BIOL, RES TRIANGLE PK, NC USA; UNIV CALIF BERKELEY, UNIV HLTH SERV, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, PROGRAM EPIDEMIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley								DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; FERRE F, 1989, CANCER CEL, V7, P215; GREGOIRE L, 1989, J CLIN MICROBIOL, V27, P2660, DOI 10.1128/JCM.27.12.2660-2665.1989; KIVIAT NB, 1989, J INFECT DIS, V159, P293, DOI 10.1093/infdis/159.2.293; KIVIAT NB, 1990, AM J CLIN PATHOL, V94, P561, DOI 10.1093/ajcp/94.5.561; KJAER SK, 1990, AM J EPIDEMIOL, V131, P669, DOI 10.1093/oxfordjournals.aje.a115551; KOUTSKY LA, 1988, EPIDEMIOL REV, V10, P122, DOI 10.1093/oxfordjournals.epirev.a036020; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LORINCZ AT, 1990, AM J OBSTET GYNECOL, V162, P645, DOI 10.1016/0002-9378(90)90974-C; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MANOS M, 1990, LANCET, V335, P734, DOI 10.1016/0140-6736(90)90855-Y; MANOS M, 1990, MAY PAP WORKSH HEID; Manos M. M., 1990, PCR PROTOCOLS GUIDE, P356; MANOS MM, 1989, CANCER CEL, V7, P209; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PAO CC, 1990, J INFECT DIS, V161, P113, DOI 10.1093/infdis/161.1.113; REEVES WC, 1989, J INFECT DIS, V160, P599, DOI 10.1093/infdis/160.4.599; REEVES WC, 1989, NEW ENGL J MED, V320, P1437, DOI 10.1056/NEJM198906013202201; RESNICK RM, 1990, JNCI-J NATL CANCER I, V82, P1477, DOI 10.1093/jnci/82.18.1477; ROMAN A, 1989, CLIN MICROBIOL REV, V2, P166, DOI 10.1128/CMR.2.2.166-190.1989; ROSENFELD WD, 1989, AM J DIS CHILD, V143, P1443, DOI 10.1001/archpedi.1989.02150240065018; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHIFFMAN MH, IN PRESS J CLIN MICR; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; SNIJDERS PJF, 1990, J GEN VIROL, V71, P173, DOI 10.1099/0022-1317-71-1-173; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; TIDY J, 1989, LANCET, V2, P1535; TIDY JA, 1989, LANCET, V1, P1225; VILLA LL, 1989, J NATL CANCER I, V81, P332, DOI 10.1093/jnci/81.5.332; WARD P, 1989, LANCET, V2, P170; YOUNG LS, 1989, BRIT MED J, V298, P14, DOI 10.1136/bmj.298.6665.14	31	867	886	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	1991	265	4					472	477		10.1001/jama.265.4.472	http://dx.doi.org/10.1001/jama.265.4.472			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET377	1845912				2022-12-28	WOS:A1991ET37700025
J	VONKRIES, JP; BUHRMESTER, H; STRATLING, WH				VONKRIES, JP; BUHRMESTER, H; STRATLING, WH			A MATRIX SCAFFOLD ATTACHMENT REGION BINDING-PROTEIN - IDENTIFICATION, PURIFICATION, AND MODE OF BINDING	CELL			English	Article							CHROMOSOMAL LOOP ANCHORAGE; DNA TOPOISOMERASE-II; HEAT-SHOCK GENE; INTERPHASE NUCLEI; CHROMATIN DOMAIN; XENOPUS OOCYTES; TRANSCRIPTION; METAPHASE; INVITRO; SITES	Matrix/scaffold attachment regions (MARs/SARs) partition chromatin into functional loop domains. Here we have identified a chicken protein that selectively binds to MARs from the chicken lysozyme locus and to MARs from Drosophila, mouse, and human genes. This protein, named ARBP (for attachment region binding protein), was purified to homogeneity and shown to bind to MARs in a cooperative fashion. ARBP is an abundant nuclear protein and a component of the internal nuclear network. Deletion mutants indicate that multiple AT-rich sequences, if contained in a minimal approximately 350 bp MAR fragment, can lead to efficient binding of ARBP. Furthermore, dimerization mutants show that, to bind ARBP efficiently, MAR sequences can act synergistically over large distances, apparently with the intervening DNA looping out. The binding characteristics of ARBP to MARs reproduce those of unfractionated matrix preparations, suggesting that ARBP is an important nuclear element for the generation of functional chromatin loops.			VONKRIES, JP (corresponding author), UNIV HAMBURG, KRANKENHAUS EPPENDORF, INST PHYSIOL CHEM, MARTINISTR 52, W-2000 HAMBURG 20, GERMANY.							ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COCKERILL PN, 1986, FEBS LETT, V204, P5, DOI 10.1016/0014-5793(86)81377-1; COOK PR, 1978, EUR J BIOCHEM, V84, P465, DOI 10.1111/j.1432-1033.1978.tb12188.x; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HIROSE S, 1988, P NATL ACAD SCI USA, V85, P718, DOI 10.1073/pnas.85.3.718; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HUNG MC, 1984, NUCLEIC ACIDS RES, V12, P1863, DOI 10.1093/nar/12.4.1863; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; IZAURRALDE E, 1988, J MOL BIOL, V200, P111, DOI 10.1016/0022-2836(88)90337-3; JOHNS EW, 1964, BIOCHEM J, V92, P55, DOI 10.1042/bj0920055; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBKOWSKI JS, 1982, J MOL BIOL, V156, P309, DOI 10.1016/0022-2836(82)90331-X; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LUCHNIK AN, 1985, NUCLEIC ACIDS RES, V13, P1135, DOI 10.1093/nar/13.4.1135; MALKAS LH, 1989, P NATL ACAD SCI USA, V86, P70, DOI 10.1073/pnas.86.1.70; Maniatis T., 1982, MOL CLONING; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PETERS KE, 1982, EUR J BIOCHEM, V129, P221, DOI 10.1111/j.1432-1033.1982.tb07043.x; PETRYNIAK B, 1987, CELL, V48, P289, DOI 10.1016/0092-8674(87)90432-6; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAZIN SV, 1981, CELL, V27, P65, DOI 10.1016/0092-8674(81)90361-5; RENZ M, 1976, BIOCHEMISTRY-US, V15, P3220, DOI 10.1021/bi00660a010; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; RYOJI M, 1984, CELL, V37, P21, DOI 10.1016/0092-8674(84)90297-6; SCALENGHE F, 1978, CHROMOSOMA, V66, P299, DOI 10.1007/BF00328531; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STRATLING WH, 1986, BIOCHEMISTRY-US, V25, P495, DOI 10.1021/bi00350a033; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VILLEPONTEAU B, 1984, CELL, V39, P469, DOI 10.1016/0092-8674(84)90454-9; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VOELLMY R, 1982, P NATL ACAD SCI-BIOL, V79, P1776, DOI 10.1073/pnas.79.6.1776; VONKRIES JP, 1990, NUCLEIC ACIDS RES, V18, P3881; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WLASCHEK M, 1988, CHROMOSOMA, V96, P145, DOI 10.1007/BF00331047	61	204	215	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					123	135		10.1016/0092-8674(91)90214-J	http://dx.doi.org/10.1016/0092-8674(91)90214-J			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846084				2022-12-28	WOS:A1991ET17500014
J	WILLIAMS, TM; MOOLTEN, D; BURLEIN, J; ROMANO, J; BHAERMAN, R; GODILLOT, A; MELLON, M; RAUSCHER, FJ; KANT, JA				WILLIAMS, TM; MOOLTEN, D; BURLEIN, J; ROMANO, J; BHAERMAN, R; GODILLOT, A; MELLON, M; RAUSCHER, FJ; KANT, JA			IDENTIFICATION OF A ZINC FINGER PROTEIN THAT INHIBITS IL-2 GENE-EXPRESSION	SCIENCE			English	Article							HUMAN INTERLEUKIN-2 GENE; DNA-BINDING PROTEINS; MESSENGER-RNA; LYMPHOCYTES-T; CHLORAMPHENICOL ACETYLTRANSFERASE; FIREFLY LUCIFERASE; ANTIGEN RECEPTOR; MAMMALIAN-CELLS; PROMOTER; ACTIVATION	Transient activation of the interleukin-2 (IL-2) gene after antigen recognition by T lymphocytes is crucial for subsequent T cell proliferation and differentiation. Several IL-2 gene regulatory elements and binding factors necessary for activation of the IL-2 gene have been defined. However, little is known about negative regulation of IL-2 expression, which is likely to be important in the rapid shut-off of IL-2 transcription. A nucleotide sequence element (NRE-A) that negatively regulates IL-2 expression has been identified within the IL-2 gene. T cell nuclear extracts contained an NRE-A binding activity. A complementary DNA was isolated that encodes a zinc finger-containing protein that suppressed IL-2 gene expression. The observation of negative regulation of the immunoglobulin heavy chain gene enhancer by an element similar to NRE-A suggests that related proteins may regulate multiple immune response genes.	WISTAR INST,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	The Wistar Institute; University of Pennsylvania	WILLIAMS, TM (corresponding author), UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131, USA.				NCI NIH HHS [CA54428, CA23413] Funding Source: Medline; NIAID NIH HHS [AI23879] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA023413, R29CA054428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023879] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1987, CELL, V729; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, pCH4; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EFRAT S, 1984, P NATL ACAD SCI-BIOL, V81, P2601, DOI 10.1073/pnas.81.9.2601; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FORTINI ME, 1991, MECH DEVELOP, V34, P113, DOI 10.1016/0925-4773(91)90048-B; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; KANT JA, 1989, C INSERM, V179, P53; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHAW J, 1988, J IMMUNOL, V140, P2243; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Williams T. J., UNPUB; WILLIAMS TM, 1989, ANAL BIOCHEM, V176, P28, DOI 10.1016/0003-2697(89)90267-4; WILLIAMS TM, 1988, J IMMUNOL, V141, P662; ZUBIAGA AM, 1991, J IMMUNOL, V146, P3857	43	177	181	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1791	1794		10.1126/science.1840704	http://dx.doi.org/10.1126/science.1840704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1840704				2022-12-28	WOS:A1991GW31600043
J	ROUSSEL, MF; CLEVELAND, JL; SHURTLEFF, SA; SHERR, CJ				ROUSSEL, MF; CLEVELAND, JL; SHURTLEFF, SA; SHERR, CJ			MYC RESCUE OF A MUTANT CSF-1 RECEPTOR IMPAIRED IN MITOGENIC SIGNALING	NATURE			English	Article							RECOMBINANT MURINE RETROVIRUS; FACTOR-I RECEPTOR; NIH 3T3 CELLS; C-MYC; GROWTH-FACTOR; BONE-MARROW; TRANSCRIPTION; KINASE; FOS; MACROPHAGES	THE colony-stimulating factor-1 receptor (CSF-1R) mediates its pleiotropic effects through the coupling of its ligand-activated tyrosine kinase to multiple intracellular effector proteins, whose combined actions determine the magnitude and specificity of the biological response. The interaction of cytoplasmic signalling molecules with CSF-1R is mediated in part by sequence motifs flanking sites of receptor tyrosine phosphorylation 1. Mutation of an autophosphorylation site at tyrosine 809 in the cytoplasmic domain of human CSF-1R does not significantly reduce its ligand-stimulated tyrosine kinase activity, binding to phosphatidylinositol 3-kinase, or induction of the immediate early response genes, c-fos and junB (ref. 2). Unlike cells bearing wild-type receptors, mouse NIH3T3 cells expressing mutant CSF-1R(Phe 809) were unable to grow in serum-free medium containing human recombinant CSF-1 and did not form colonies in semi-solid medium in its presence. CSF-1 induction of c-myc messenger RNA in these cells was impaired, but enforced expression of an exogenous c-myc gene restored their ability to proliferate in response to the growth factor. These studies demonstrate a receptor-mediated bifurcation of intracellular signal transduction pathways during the immediate early response and assign a central role for c-myc in CSF-1-induced mitogenesis.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Howard Hughes Medical Institute; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Sherr, Charles J/N-8074-2018; Roussel, Martine F/F-1469-2016	Sherr, Charles J/0000-0002-5516-6206; Roussel, Martine F/0000-0002-1740-8139				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; DEAN M, 1987, ONCOGENE RES, V1, P279; DEAN M, 1986, J BIOL CHEM, V261, P9161; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073	24	170	171	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					361	363		10.1038/353361a0	http://dx.doi.org/10.1038/353361a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1833648				2022-12-28	WOS:A1991GG65400064
J	BOSHART, M; WEIH, F; NICHOLS, M; SCHUTZ, G				BOSHART, M; WEIH, F; NICHOLS, M; SCHUTZ, G			THE TISSUE-SPECIFIC EXTINGUISHER LOCUS TSE1 ENCODES A REGULATORY SUBUNIT OF CAMP-DEPENDENT PROTEIN-KINASE	CELL			English	Article							SOMATIC-CELL HYBRIDS; LIVER-SPECIFIC GENES; AMINO-ACID SEQUENCE; NUCLEAR FACTOR CREB; CYCLIC-AMP; MESSENGER-RNA; MOLECULAR-CLONING; CDNA STRUCTURE; HUMAN TESTIS; TRANSCRIPTION FACTOR	The tissue-specific extinguisher locus TSE1, a dominant negative regulator of transcription in somatic cell hybrids, acts via a cAMP response element (CRE) to repress activity of a hepatocyte-specific enhancer. Guided by the antagonism between TSE1 and cAMP-mediated signal transduction, we identified the regulatory subunit RI-alpha of protein kinase A (PKA) as the product of the TSE1 locus. The evidence derives from concordant expression of RI-alpha mRNA and TSE1 genetic activity, high resolution mapping of the RI-alpha gene and TSE1 on human chromosome 17, and the ability of a transfected RI-alpha cDNA to generate a phenocopy of TSE1-mediated extinction. The mechanism of TSE1/RI-alpha-mediated extinction involves repression of basal PKA activity, reduced phosphorylation of CREB at Ser-133, and a corresponding reduction of in vivo protein binding at the target CRE.			BOSHART, M (corresponding author), GERMAN CANC RES CTR, INST CELL & TUMOR BIOL, NEUENHEIMER FELD 280, W-6900 HEIDELBERG, GERMANY.		Boshart, Michael/A-2700-2011	Boshart, Michael/0000-0002-5070-2663				BECKER PB, 1988, GENETIC ENG, V10, P1; BERGMAN Y, 1990, EMBO J, V9, P849, DOI 10.1002/j.1460-2075.1990.tb08182.x; BOLTON ET, 1962, P NATL ACAD SCI USA, V48, P1390, DOI 10.1073/pnas.48.8.1390; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CHIN AC, 1987, P NATL ACAD SCI USA, V84, P1614, DOI 10.1073/pnas.84.6.1614; CHIN AC, 1989, MOL CELL BIOL, V9, P3736, DOI 10.1128/MCB.9.9.3736; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; DAVIDSON RL, 1974, ANNU REV GENET, V8, P195, DOI 10.1146/annurev.ge.08.120174.001211; DAVIS FM, 1973, BACTERIOL REV, V37, P197, DOI 10.1128/MMBR.37.2.197-214.1973; DAY RN, 1989, J BIOL CHEM, V264, P431; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOURDEAU H, 1990, ANNU REV CELL BIOL, V6, P69, DOI 10.1146/annurev.cb.06.110190.000441; GOURDEAU H, 1989, MOL CELL BIOL, V9, P1813, DOI 10.1128/MCB.9.5.1813; GREENGARD O, 1970, BIOCHEMICAL ACTIONS, V1, P53; GROVE JR, 1989, J BIOL CHEM, V264, P19506; GROVE JR, 1987, SCIENCE, V238, P530; JUNKER S, 1988, EMBO J, V7, P3093, DOI 10.1002/j.1460-2075.1988.tb03175.x; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KUNO T, 1987, BIOCHEM BIOPH RES CO, V146, P878, DOI 10.1016/0006-291X(87)90612-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH RJ, 1989, GENOMICS, V5, P167, DOI 10.1016/0888-7543(89)90043-8; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEM J, 1988, P NATL ACAD SCI USA, V85, P7302, DOI 10.1073/pnas.85.19.7302; MCCORMICK A, 1988, CELL, V55, P379, DOI 10.1016/0092-8674(88)90061-X; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MCKNIGHT GS, 1988, COLD SPRING HARB SYM, V53, P111, DOI 10.1101/SQB.1988.053.01.017; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; NITSCH D, 1990, MOL CELL BIOL, V10, P3334, DOI 10.1128/MCB.10.7.3334; NOWAK I, 1987, EUR J BIOCHEM, V167, P27, DOI 10.1111/j.1432-1033.1987.tb13300.x; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OYEN O, 1988, ENDOCRINOLOGY, V122, P2658; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; PETERSON TC, 1989, MOL BIOL MED, V6, P109; PETIT C, 1986, P NATL ACAD SCI USA, V83, P2561, DOI 10.1073/pnas.83.8.2561; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RUIZBRAVO N, 1982, P NATL ACAD SCI-BIOL, V79, P365, DOI 10.1073/pnas.79.2.365; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; Sambrook J, 1989, MOL CLONING LABORATO; SANDBERG M, 1988, BIOCHEM BIOPH RES CO, V154, P705, DOI 10.1016/0006-291X(88)90197-0; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SANDBERG M, 1990, BIOCHEM BIOPH RES CO, V167, P323, DOI 10.1016/0006-291X(90)91768-N; SCAMBLER P, 1987, AM J HUM GENET, V41, P925; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; STEINBERG RA, 1981, J BIOL CHEM, V256, P731; SVOBODA J, 1960, NATURE, V186, P980, DOI 10.1038/186980b0; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THAYER MJ, 1989, MOL CELL BIOL, V9, P2837, DOI 10.1128/MCB.9.7.2837; THAYER MJ, 1990, MOL CELL BIOL, V10, P2660, DOI 10.1128/MCB.10.6.2660; TRIPPUTI P, 1988, SCIENCE, V241, P1205, DOI 10.1126/science.2842865; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WEIH F, 1988, NUCLEIC ACIDS RES, V16, P1628, DOI 10.1093/nar/16.4.1628; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437; WITTMAACK FM, 1983, EUR J BIOCHEM, V129, P669; WOODFORD TA, 1989, J BIOL CHEM, V264, P13321; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X; ZALLER DM, 1988, MOL CELL BIOL, V8, P1932, DOI 10.1128/MCB.8.5.1932	70	183	185	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					849	859		10.1016/0092-8674(91)90432-X	http://dx.doi.org/10.1016/0092-8674(91)90432-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1832337	Green Published			2022-12-28	WOS:A1991GE46000005
J	IGARASHI, M; NAGATA, A; JINNO, S; SUTO, K; OKAYAMA, H				IGARASHI, M; NAGATA, A; JINNO, S; SUTO, K; OKAYAMA, H			WEE1+-LIKE GENE IN HUMAN-CELLS	NATURE			English	Article							HIGH-EFFICIENCY TRANSFORMATION; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; HUMAN HOMOLOG; INDUCER; DNA	THE wee1+ gene is a mitotic inhibitor controlling the G2 to M transition of the fission yeast Schizosaccharomyces pombe 1 and encodes a protein kinase with both serine- and tyrosine-phosphorylating activities 2. We have cloned a human gene (WEE1Hu) similar to wee1+ by transcomplementation of a yeast mutant 3,4. WEE1Hu encodes a protein homologous to the S. pombe wee1+ and mik1+ (a functionally redundant sibling of wee1+) 5 kinases and effectively rescues a wee1 mutation. We report here that overexpression of WEE1Hu in fission yeast generates very elongated cells as a result of inhibition of the G2-M transition in the cell cycle. In addition, we detected a 3-kilobase-long WEE1Hu messenger RNA in all the human cell lines we examined. We conclude that a wee1+-like gene exists and is expressed in human cells.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOLEC GENET,3-1 YAMADAOKA,SUITA,OSAKA 565,JAPAN	Osaka University								CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; Gutz H., 1974, HDB GENETICS, V1, P395; HANKS SK, 1988, SCIENCE, V241, P24; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; Rothstein R., 1985, DNA CLONING, VII, P45; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOYAMA R, 1990, FEBS LETT, V268, P217, DOI 10.1016/0014-5793(90)81012-D	16	182	191	1	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					80	83		10.1038/353080a0	http://dx.doi.org/10.1038/353080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1840647				2022-12-28	WOS:A1991GD80500064
J	WU, J; MANLEY, JL				WU, J; MANLEY, JL			BASE-PAIRING BETWEEN U2 AND U6 SNRNAS IS NECESSARY FOR SPLICING OF A MAMMALIAN PRE-MESSENGER-RNA	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; BRANCH SITE SELECTION; GENES EVEN THOUGH; U1 SNRNA; EFFICIENT TRANSCRIPTION; DIFFERENT POLYMERASE; 2'-OME RNA; YEAST; PARTICLES; ELEMENTS	SPLICING of pre-messenger RNA in eukaryotic cells occurs in a multicomponent complex termed the spliceosome, which contains small nuclear ribonucleoprotein particles (snRNPs), protein factors and substrate pre-mRNA 1-3. Assembly of the spliceosome involves the stepwise binding of snRNPs and protein factors to the pre-mRNA through a poorly understood mechanism which probably involves specific RNA-RNA, RNA-protein and protein-protein interactions. Of particular interest are the interactions between snRNPs, which are likely to be important not only for assembly of the spliceosome but also for catalysis. U1 snRNP interacts with the 5' splice site and U2 snRNP with the branch site of the pre-mRNA; both of these interactions involve Watson-Crick base pairing 4-9. But very little is known about how other factors such as the U4/U6 and U5 snRNPs reach the spliceosome and function in splicing. Here we report evidence that U6 snRNA interacts directly with U2 snRNA by a mechanism involving base-pairing, and that this interaction can be necessary for splicing of a mammalian pre-mRNA in vivo.			WU, J (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Manley, James/0000-0002-8341-1459				BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLACK DL, 1986, CELL, V46, P697, DOI 10.1016/0092-8674(86)90345-4; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FRENDEWEY D, 1987, COLD SPRING HARB SYM, V52, P287, DOI 10.1101/SQB.1987.052.01.034; FU XY, 1987, MOL CELL BIOL, V7, P738, DOI 10.1128/MCB.7.2.738; FU XY, 1988, MOL CELL BIOL, V8, P3582, DOI 10.1128/MCB.8.9.3582; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LIAO XL, 1990, GENE DEV, V4, P1766, DOI 10.1101/gad.4.10.1766; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; NOBLE JCS, 1988, GENE DEV, V2, P1460, DOI 10.1101/gad.2.11.1460; NOBLE JCS, 1987, CELL, V50, P227, DOI 10.1016/0092-8674(87)90218-2; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5462; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SHANNON KW, 1991, GENE DEV, V5, P773, DOI 10.1101/gad.5.5.773; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	32	160	161	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					818	821		10.1038/352818a0	http://dx.doi.org/10.1038/352818a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1831878				2022-12-28	WOS:A1991GC96400065
J	ELLISEN, LW; BIRD, J; WEST, DC; SORENG, AL; REYNOLDS, TC; SMITH, SD; SKLAR, J				ELLISEN, LW; BIRD, J; WEST, DC; SORENG, AL; REYNOLDS, TC; SMITH, SD; SKLAR, J			TAN-1, THE HUMAN HOMOLOG OF THE DROSOPHILA NOTCH GENE, IS BROKEN BY CHROMOSOMAL TRANSLOCATIONS IN T-LYMPHOBLASTIC NEOPLASMS	CELL			English	Article							HAMSTER OVARY CELLS; CDNA CLONES; PROTEIN; RECEPTOR; LOCUS; NEUROGENESIS; SIMILARITY; SEQUENCES; LEUKEMIA; GROWTH	Previously we described joining of DNA in the beta-T cell receptor gene to DNA of an uncharacterized locus in a t(7;9)(q34;q34.3) chromosomal translocation from a case of human T lymphoblastic leukemia (T-ALL). We now show that the locus on chromosome 9 contains a gene highly homologous to the Drosophila gene Notch. Transcripts of the human gene, for which we propose the name TAN-1, and its murine counterpart are present in many normal human fetal and adult mouse tissues, but are most abundant in lymphoid tissues. In t(7;9)(q34;q34.3) translocations from three cases of T-ALL, the breakpoints occur within 100 bp of an intron in TAN-1, resulting in truncation of TAN-1 transcripts. These observations suggest that TAN-1 may be important for normal lymphocyte function and that alteration of TAN-1 may play a role in the pathogenesis of some T cell neoplasms.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV DIAGNOST MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			West, Daniel/AAW-3111-2020; Ellisen, Leif W/AAA-6572-2022	West, Daniel/0000-0002-0909-4213; Ellisen, Leif W/0000-0003-0444-7910	NCI NIH HHS [CA38621] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038621] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; ARTAVANISTSAKONAS S, 1983, P NATL ACAD SCI-BIOL, V80, P1977, DOI 10.1073/pnas.80.7.1977; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Battey, 1986, BASIC METHODS MOL BI; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOI S, 1987, BLOOD, V70, P1619; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GILLARD S, 1986, P NATL ACAD SCI USA, V83, P5573, DOI 10.1073/pnas.83.15.5573; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; GOETZL DJ, 1990, ADV IMMUNOL, V48, P161; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Maniatis T., 1982, MOL CLONING; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RAIMONDI SC, 1987, BLOOD, V69, P131; REYNOLDS TC, 1987, CELL, V50, P107, DOI 10.1016/0092-8674(87)90667-2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWENK HU, 1975, BLUT, V31, P229; SMITH SD, 1988, BLOOD, V71, P395; SMITH SD, 1989, BLOOD, V73, P2182; SMITH TF, 1985, NUCLEIC ACIDS RES, V13, P645, DOI 10.1093/nar/13.2.645; SPEHNER D, 1988, J VIROL, V62, P1297, DOI 10.1128/JVI.62.4.1297-1304.1988; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; TYCKO B, 1989, J EXP MED, V169, P3369; TYCKO B, 1991, IN PRESS J EXP MED; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	50	1454	1576	2	43	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					649	661		10.1016/0092-8674(91)90111-B	http://dx.doi.org/10.1016/0092-8674(91)90111-B			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1831692				2022-12-28	WOS:A1991GC74500006
J	WRENN, K; SLOVIS, CM; MURPHY, F; GREENBERG, RS				WRENN, K; SLOVIS, CM; MURPHY, F; GREENBERG, RS			AMINOPHYLLINE THERAPY FOR ACUTE BRONCHOSPASTIC DISEASE IN THE EMERGENCY ROOM	ANNALS OF INTERNAL MEDICINE			English	Article							INTRAVENOUSLY ADMINISTERED AMINOPHYLLINE; OBSTRUCTIVE PULMONARY-DISEASE; SERUM THEOPHYLLINE LEVELS; BETA-ADRENERGIC AGONIST; ACUTE ASTHMA; BRONCHODILATOR THERAPY; ORAL THEOPHYLLINE; FATAL ASTHMA; HISTAMINE; BRONCHOCONSTRICTION	Objective: To assess the role of aminophylline in the treatment of acute exacerbations of bronchospastic disease when used in addition to inhaled beta-agonists and intravenous corticosteroids. Design: Randomized, double-blind, placebo-controlled intervention study. Patients: One hundred thirty-three adult patients with either asthma or chronic obstructive pulmonary disease who presented to the emergency department with asthma or wheezing. Interventions: All patients received therapy with both aerosolized metaproterenol and intravenous methylprednisolone. Patients were randomly assigned to receive either a loading dose of aminophylline followed by a routine infusion (n = 65) or an equal volume of placebo as a loading dose and infusion (n = 68). Measurements and Main Results: At discharge from the emergency department, the median serum theophylline concentration for the aminophylline group was 54-mu-mol/L (9.7 mg/L). The two groups showed no differences (P > 0.2) in measurements of forced expiratory volume at 1 second (FEV1), forced vital capacity (FVC), or peak expiratory flow rate (PEFR) at baseline or at 60 or 120 minutes after aminophylline administration. Neither patient satisfaction nor physician assessment of response to therapy differed between the two groups. There was no difference (P > 0.2) in the frequency of side effects, except for a trend toward a higher frequency of nausea (P = 0.13) in the aminophylline group. There was, however, a threefold decrease in the hospital admission rate for patients treated with aminophylline (6%) compared with placebo recipients (21%) (P = 0.016). Conclusion: Aminophylline, in doses producing levels just below the commonly accepted therapeutic range, appears to decrease hospital admissions in patients with acute exacerbation of asthma or chronic obstructive pulmonary disease. This finding, if confirmed in larger studies, may represent a substantial cost savings.	EMORY UNIV, SCH MED, ATLANTA, GA 30322 USA; EMORY UNIV, SCH PUBL HLTH, ATLANTA, GA 30322 USA	Emory University; Emory University	WRENN, K (corresponding author), UNIV ROCHESTER, MED CTR, DEPT EMERGENCY, BOX 655, 601 ELMWOOD AVE, ROCHESTER, NY 14642 USA.		Wrenn, Keith/AAI-7651-2020					AHRENS RC, 1987, CHEST, V92, pS15; AUBIER M, 1981, NEW ENGL J MED, V305, P249, DOI 10.1056/NEJM198107303050503; BARKER AF, 1989, WESTERN J MED, V150, P303; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; BILLING B, 1987, EUR J RESPIR DIS, V70, P35; BRADY HR, 1989, ARCH INTERN MED, V149, P2367, DOI 10.1001/archinte.149.10.2367; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V77, P570, DOI 10.1016/0091-6749(86)90347-7; COLEMAN JJ, 1986, CHEST, V90, P45, DOI 10.1378/chest.90.1.45; DOWELL AR, 1965, NEW ENGL J MED, V273, P1447, DOI 10.1056/NEJM196512302732702; FANTA CH, 1986, AM J MED, V80, P5, DOI 10.1016/0002-9343(86)90041-0; FLETCHER RH, 1988, CLIN EPIDEMIOLOGY ES, P172; GLANTZ SA, 1987, PRIMER BIOSTATISTICS, P88; GUYATT GH, 1988, ARCH INTERN MED, V148, P1949, DOI 10.1001/archinte.148.9.1949; HILL NS, 1988, ARCH INTERN MED, V148, P2579, DOI 10.1001/archinte.148.12.2579; IRAVANI J, 1975, RESPIRATION, V32, P157, DOI 10.1159/000193645; JENNE JW, 1987, CHEST, V92, pS7, DOI 10.1378/chest.92.1.7S; KLEIN JJ, 1983, AM REV RESPIR DIS, V127, P413, DOI 10.1164/arrd.1983.127.4.413; KOETER GH, 1984, RESPIRATION, V45, P139, DOI 10.1159/000194610; LITTENBERG B, 1988, JAMA-J AM MED ASSOC, V259, P1678, DOI 10.1001/jama.259.11.1678; LITTENBERG B, 1986, NEW ENGL J MED, V314, P150, DOI 10.1056/NEJM198601163140304; LUNELL E, 1984, EUR J RESPIR DIS, V65, P28; MATTHAY RA, 1978, AM J MED, V65, P903, DOI 10.1016/0002-9343(78)90741-6; MCWILLIAMS BC, 1986, AM REV RESPIR DIS, V133, P744; MCWILLIAMS BC, 1984, AM REV RESPIR DIS, V130, P193; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; MURCIANO D, 1989, NEW ENGL J MED, V320, P1521, DOI 10.1056/NEJM198906083202304; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; PASSAMONTE PM, 1984, CHEST, V85, P610, DOI 10.1378/chest.85.5.610; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; POLSON JB, 1978, CLIN EXP PHARMACOL P, V5, P535; REBUCK AS, 1987, CAN MED ASSOC J, V136, P483; ROBERTSON C, 1985, CHEST, V87, pS64; ROSSING TH, 1989, ANN INTERN MED, V110, P502, DOI 10.7326/0003-4819-110-7-502; ROSSING TH, 1980, AM REV RESPIR DIS, V122, P365; SIEGEL D, 1985, AM REV RESPIR DIS, V132, P283; SMITH SR, 1986, BRIT J CLIN PHARMACO, V21, P451, DOI 10.1111/j.1365-2125.1986.tb05221.x; SUMMER WR, 1985, CHEST, V87, pS87; TAGER I, 1975, NEW ENGL J MED, V292, P563, DOI 10.1056/NEJM197503132921105; TURNERWARWICK M, 1957, BRIT MED J, V2, P67, DOI 10.1136/bmj.2.5036.67; VOZEH S, 1982, AM REV RESPIR DIS, V125, P181; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; WEISSERT WG, 1986, J HEALTH POLIT POLIC, V11, P463, DOI 10.1215/03616878-11-3-463; WELSH MJ, 1980, J APPL PHYSIOL, V49, P905, DOI 10.1152/jappl.1980.49.5.905; WILSON JD, 1981, LANCET, V1, P1235; WOLFE JD, 1978, NEW ENGL J MED, V298, P363, DOI 10.1056/NEJM197802162980703	45	101	103	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					241	247		10.7326/0003-4819-115-4-241	http://dx.doi.org/10.7326/0003-4819-115-4-241			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854108				2022-12-28	WOS:A1991GA76400001
J	MASLEN, CL; CORSON, GM; MADDOX, BK; GLANVILLE, RW; SAKAI, LY				MASLEN, CL; CORSON, GM; MADDOX, BK; GLANVILLE, RW; SAKAI, LY			PARTIAL SEQUENCE OF A CANDIDATE GENE FOR THE MARFAN-SYNDROME	NATURE			English	Article							MICROFIBRILS; FIBRILLIN; COMPONENT; PROTEINS; COMPLEX	FIBRILLIN is a large (relative molecular mass 350,000) glycoprotein which can be isolated from fibroblast cell cultures and is a component of the microfibrils that are ubiquitous in the connective tissue space 1. The microfibrils of the suspensory ligament of the lens as well as the elastic fibre microfibrils of the blood vessel wall are composed of fibrillin. The ocular and cardiovascular manifestations of the Marfan syndrome are consistent with a defect in the gene coding for a structural constituent of these connective tissues. Immunohistological experiments have recently implicated fibrillin microfibrils in the pathogenesis of the Marfan syndrome 2. Genetic linkage data 3,4 localizing the Marfan gene to chromosome 15 and the in situ hybridization of fibrillin complementary DNA to 15q21.1 (ref. 5) together support fibrillin as a candidate Marfan gene. As a first step towards investigating the function of fibrillin in the architecture and development of connective tissues and its relationship to the Marfan syndrome, we report the cloning and partial sequencing of fibrillin cDNA.	SHRINERS HOSP CRIPPLED CHILDREN,3101 SW SAM JACKSON PK RD,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University								DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; MAGENIS RE, IN PRESS GENOMICS; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SAKAI LY, IN PRESS J BIOL CHEM; STENFLO J, 1988, J BIOL CHEM, V263, P21; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585	14	290	299	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					334	337		10.1038/352334a0	http://dx.doi.org/10.1038/352334a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852207				2022-12-28	WOS:A1991FY28900070
J	BANDARA, LR; ADAMCZEWSKI, JP; HUNT, T; LATHANGUE, NB				BANDARA, LR; ADAMCZEWSKI, JP; HUNT, T; LATHANGUE, NB			CYCLIN-A AND THE RETINOBLASTOMA GENE-PRODUCT COMPLEX WITH A COMMON TRANSCRIPTION FACTOR	NATURE			English	Article							SV40 LARGE-T; E1A PROTEINS; CELL-CYCLE; BINDING; POLYPEPTIDES; ASSOCIATION; ANTIGEN	THE retinoblastoma gene (Rb) product is a negative regulator of cellular proliferation 1 an effect that could be mediated in part at the transcriptional level through its ability to complex with the sequence-specific transcription factor DRTF1 (ref. 2). This interaction is modulated by adenovirus E1a, which sequesters the Rb protein 3 and several other cellular proteins 3, including cyclin A (refs 4, 5), a molecule that undergoes cyclical accumulation and destruction during each cell cycle 6,7 and which is required for cell cycle progression 8. Cyclin A, which also complexes with DRTF1, facilitates the efficient assembly of the Rb protein into the complex. This suggests a role for cyclin A in regulating transcription and defines a transcription factor through which molecules that regulate the cell cycle in a negative fashion, such as Rb, and in a positive fashion, such as cyclin A, interact. Mutant loss-of-function Rb alleles, which occur in a variety of tumour cells, also fail to complex with E1a and large T antigen 9,10. Here we report on a naturally occurring loss-of-function Rb allele encoding a protein that fails to complex with DRTF1. This might explain how mutation in the Rb gene prevents negative growth control.	NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND; IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND	MRC National Institute for Medical Research			Hunt, Tim/O-8544-2019	Hunt, Tim/0000-0001-5174-6038				BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SHIVJI MKK, 1991, MOL CELL BIOL, V11, P1686, DOI 10.1128/MCB.11.3.1686; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	22	287	298	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					249	251		10.1038/352249a0	http://dx.doi.org/10.1038/352249a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1830372				2022-12-28	WOS:A1991FX18500069
J	STEARNS, T; EVANS, L; KIRSCHNER, M				STEARNS, T; EVANS, L; KIRSCHNER, M			GAMMA-TUBULIN IS A HIGHLY CONSERVED COMPONENT OF THE CENTROSOME	CELL			English	Article							HAMSTER OVARY CELLS; YEAST SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; PERICENTRIOLAR MATERIAL; ASPERGILLUS-NIDULANS; CHROMOSOME MOVEMENT; SPINDLE; GENE; IDENTIFICATION; MICROTUBULES	We have cloned and characterized gamma-tubulin genes from both X. laevis and S. pombe, and partial genes from maize, diatom, and a budding yeast. The proteins encoded by these genes are very similar to each other and to the original Aspergillus protein, indicating that gamma-tubulins are an ubiquitous and highly conserved subfamily of the tubulin family. A null mutation of the S. pombe gene is lethal. Gamma-tubulin is a minor protein, present at less than 1% the level of alpha- and beta-tubulin, and is limited to the centrosome. In particular, gamma-tubulin is associated with the pericentriolar material, the microtubule-nucleating material of the centrosome. Gamma-tubulin remains associated with the centrosome when microtubules are depolymerized, suggesting that it is an integral component that might play a role in microtubule organization.			STEARNS, T (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Stearns, Tim/0000-0002-0671-6582				BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; BORNENS M, 1987, CELL MOTIL CYTOSKEL, V8, P238, DOI 10.1002/cm.970080305; BUENDIA B, 1990, J CELL SCI, V97, P259; CALARCOGILLAM PD, 1983, CELL, V35, P621, DOI 10.1016/0092-8674(83)90094-6; CLAYTON L, 1985, J CELL BIOL, V101, P319, DOI 10.1083/jcb.101.1.319; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARD DL, 1987, J CELL BIOL, V105, P2191, DOI 10.1083/jcb.105.5.2191; GOULD RR, 1977, J CELL BIOL, V73, P601, DOI 10.1083/jcb.73.3.601; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HARLOW E, 1988, ANTIBODIES LABORATOR; HEIDEMANN SR, 1980, NATURE, V286, P517, DOI 10.1038/286517a0; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HYAMS JS, 1978, J CELL BIOL, V78, P401, DOI 10.1083/jcb.78.2.401; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KERYER G, 1984, J CELL BIOL, V98, P2222, DOI 10.1083/jcb.98.6.2222; KING RC, 1974, HDB GENETICS; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LITTLE M, 1988, COMP BIOCHEM PHYS B, V90, P655, DOI 10.1016/0305-0491(88)90320-3; LUDUENA RF, 1977, J BIOL CHEM, V252, P7006; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MOROI Y, 1983, CLIN IMMUNOL IMMUNOP, V29, P381, DOI 10.1016/0090-1229(83)90041-7; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEIGHBORS BW, 1988, J CELL BIOL, V106, P1193, DOI 10.1083/jcb.106.4.1193; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; PETERSON JB, 1976, J CELL SCI, V22, P219; RAO PN, 1989, J CELL SCI, V93, P63; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; RIEDER CL, 1982, BIOL CELL, V44, P117; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; Sambrook J, 1989, MOL CLONING LABORATO; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; SCHULZE E, 1988, NATURE, V334, P356, DOI 10.1038/334356a0; Sherman F., 1974, METHODS YEAST GENETI; STEARNS T, 1990, METHOD ENZYMOL, V185, P280; TODA T, 1984, CELL, V37, P233, DOI 10.1016/0092-8674(84)90319-2; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; VOROBJEV IA, 1982, J CELL BIOL, V98, P938; WEIL CF, 1986, MOL CELL BIOL, V6, P2963, DOI 10.1128/MCB.6.8.2963; WHEATLEY DN, 1974, J GEN VIROL, V24, P395, DOI 10.1099/0022-1317-24-2-395; WHEATLEY DN, 1982, CENTRIOLE CENTRAL EN; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; Wilson E.B., 1906, CELL DEV INHERITANCE; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X	51	525	533	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					825	836		10.1016/0092-8674(91)90390-K	http://dx.doi.org/10.1016/0092-8674(91)90390-K			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1840506				2022-12-28	WOS:A1991FP51600013
J	YAN, H; SCHLESSINGER, J; CHAO, MV				YAN, H; SCHLESSINGER, J; CHAO, MV			CHIMERIC NGF-EGF RECEPTORS DEFINE DOMAINS RESPONSIBLE FOR NEURONAL DIFFERENTIATION	SCIENCE			English	Article							NERVE GROWTH-FACTOR; PC12 CELLS; GENE-TRANSFER; PHEOCHROMOCYTOMA CELLS; MOLECULAR-CLONING; EXPRESSION; STIMULATION; INDUCTION; MUTANTS	To determine the domains of the low-affinity nerve growth factor (NGF) receptor required for appropriate signal transduction, a series of hybrid receptors were constructed that consisted of the extracellular ligand-binding domain of the human epidermal growth factor (EGF) receptor (EGFR) fused to the transmembrane and cytoplasmic domains of the human low-affinity NGF receptor (NGFR). Transfection of these chimeric receptors into rat pheochromocytoma PC12 cells resulted in appropriate cell surface expression. Biological activity mediated by the EGF-NGF chimeric receptor was assayed by the induction of neurite outgrowth in response to EGF in stably transfected cells. Furthermore, the chimeric receptor mediated nuclear signaling, as evidenced by the specific induction of transin messenger RNA, an NGF-responsive gene. Neurite outgrowth was not observed with chimeric receptors that contained the transmembrane domain from the EGFR, suggesting that the membrane-spanning region and cytoplasmic domain of the low-affinity NGFR are necessary for signal transduction.	NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University	YAN, H (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT CELL BIOL & ANAT,DIV HEMATOL ONCOL,NEW YORK,NY 10021, USA.			Chao, Moses/0000-0002-6969-3744				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; Berg M.D., UNPUB; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1977, BRAIN RES, V133, P350, DOI 10.1016/0006-8993(77)90770-3; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P4730; HOSANG M, 1985, J BIOL CHEM, V260, P655; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; POLLOCK D, 1990, NEUROSCIENCE, V10, P2626; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TISCHLER AS, 1975, NATURE, V258, P341, DOI 10.1038/258341a0; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; YAN H, UNPUB	27	111	118	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					561	563		10.1126/science.1850551	http://dx.doi.org/10.1126/science.1850551			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850551				2022-12-28	WOS:A1991FJ12700045
J	SCHONRICH, G; KALINKE, U; MOMBURG, F; MALISSEN, M; SCHMITTVERHULST, AM; MALISSEN, B; HAMMERLING, GJ; ARNOLD, B				SCHONRICH, G; KALINKE, U; MOMBURG, F; MALISSEN, M; SCHMITTVERHULST, AM; MALISSEN, B; HAMMERLING, GJ; ARNOLD, B			DOWN-REGULATION OF T-CELL RECEPTORS ON SELF-REACTIVE T-CELLS AS A NOVEL MECHANISM FOR EXTRATHYMIC TOLERANCE INDUCTION	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PANCREATIC BETA-CELLS; CLASS-II MHC; CENTRAL NERVOUS-SYSTEM; TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; ANTIGENS; EXPRESSION; MOLECULES; GENES	By generating two types of transgenic mice we have investigated how extrathymic events can contribute to self tolerance. The major histocompatibility complex class I gene K(b) was expressed under the control of the glial fibrillary acidic protein promoter in cells of neuroectodermal origin outside the thymus. These mice were tolerant to K(b). When crossed to transgenic mice expressing a K(b)-specific T cell receptor (TCR), clonotype+, CD8+CD4- mature T cells could be detected in normal numbers in the thymus of the double-transgenic mice but were strongly reduced in spleen and lymph nodes in comparison with TCR single-transgenic mice. After isolation of clonotype negative splenic T cells and activation in vitro, reappearance of the clonotype+, CD8+CD4- cells was observed. These results indicate that down-regulation of TCR and CD8 molecules on the antigen-specific T cells is a novel mechanism, by which peripheral tolerance to this antigen can occur.	CTR IMMUNOL MARSEILLE LUMINY,F-13288 MARSEILLE 9,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	SCHONRICH, G (corresponding author), GERMAN CANC RES CTR,INST IMMUNOL & GENET,IM NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY.		Malissen, Bernard/AAK-4659-2020	Malissen, Bernard/0000-0003-1340-9342; Schonrich, Gunther/0000-0002-5346-5704; Malissen, Marie/0000-0003-2331-1445; Schmitt-Verhulst, Anne-Marie/0000-0002-1296-2739; Kalinke, Ulrich/0000-0003-0503-9564				ADAMS TE, 1987, NATURE, V325, P223, DOI 10.1038/325223a0; ALBERT F, 1982, IMMUNOGENETICS, V76, P533; ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; ARNOLD B, 1984, CELL, V38, P79, DOI 10.1016/0092-8674(84)90528-2; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BRADBURY M, 1981, TRENDS NEUROSCI, V4, P100, DOI 10.1016/0166-2236(81)90032-1; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; BURNET FM, 1959, CLONAL SELECTION THE; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; COWING C, 1985, IMMUNOL TODAY, V6, P72, DOI 10.1016/0167-5699(85)90018-0; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; HAFLER DA, 1987, IMMUNOL REV, V100, P307, DOI 10.1111/j.1600-065X.1987.tb00537.x; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HOGAN B, 1986, MANIPULATING MOUSE E; HUA C, 1986, J IMMUNOL, V136, P1937; HUE I, 1990, J IMMUNOL, V144, P4410; JONESYOUNGBLOOD SL, 1990, J IMMUNOL, V144, P1187; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOCH S, 1983, TRANSPLANTATION, V36, P177, DOI 10.1097/00007890-198308000-00013; KOURILSKY P, 1987, P NATL ACAD SCI USA, V84, P3400, DOI 10.1073/pnas.84.10.3400; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; KUHLMANNKRIEG S, 1988, DEV BRAIN RES, V39, P269, DOI 10.1016/0165-3806(88)90031-4; KUMAGAI N, 1987, J IMMUNOL, V139, P1393; KYEWSKI BA, 1984, NATURE, V308, P196, DOI 10.1038/308196a0; LAMPSON LA, 1987, TRENDS NEUROSCI, V10, P211, DOI 10.1016/0166-2236(87)90153-6; LEDBETTER JA, 1980, J EXP MED, V152, P280, DOI 10.1084/jem.152.2.280; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; Maniatis T, 1989, DECONTAMINATION DILU; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MARSHAKROTHSTEIN A, 1979, J IMMUNOL, V122, P2491; Miller J F, 1989, Autoimmunity, V4, P299, DOI 10.3109/08916938909014706; MIYADA CG, 1985, P NATL ACAD SCI USA, V82, P2890, DOI 10.1073/pnas.82.9.2890; MOMBURG F, 1989, J IMMUNOL, V142, P352; MORAHAN G, 1989, P NATL ACAD SCI USA, V86, P3782, DOI 10.1073/pnas.86.10.3782; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; PARNES JR, 1982, CELL, V29, P661, DOI 10.1016/0092-8674(82)90182-9; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROMAN LM, 1990, CELL, V61, P383, DOI 10.1016/0092-8674(90)90521-F; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; SPRENT J, 1989, IMMUNOL TODAY, V10, P17, DOI 10.1016/0167-5699(89)90060-1; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TROTTER J, 1989, DEV BRAIN RES, V46, P115, DOI 10.1016/0165-3806(89)90148-X; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEISS E, 1983, EMBO J, V2, P453, DOI 10.1002/j.1460-2075.1983.tb01444.x	60	520	523	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					293	304		10.1016/0092-8674(91)90163-S	http://dx.doi.org/10.1016/0092-8674(91)90163-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1849799				2022-12-28	WOS:A1991FH09200012
J	ESCOBEDO, JA; NAVANKASATTUSAS, S; KAVANAUGH, WM; MILFAY, D; FRIED, VA; WILLIAMS, LT				ESCOBEDO, JA; NAVANKASATTUSAS, S; KAVANAUGH, WM; MILFAY, D; FRIED, VA; WILLIAMS, LT			CDNA CLONING OF A NOVEL 85KD PROTEIN THAT HAS SH2 DOMAINS AND REGULATES BINDING OF PI3-KINASE TO THE PDGF BETA-RECEPTOR	CELL			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; PHOSPHOLIPASE-C-GAMMA; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; CATALYTIC DOMAINS; TRANSFORMATION; ASSOCIATION; ACTIVATION; ELEMENTS	Using immobilized PDGF receptor as an affinity reagent, we purified an 85 kd protein (p85) from cell lysates and we cloned its cDNA. The protein contains an SH3 domain and two SH2 domains that are homologous to domains found in several receptor-associated enzymes. Recombinant p85 overexpressed in mammalian cells inhibited the binding of endogenous p85 and a 110 kd protein to the receptor and also blocked the association of PI3-kinase activity with the receptor. Experiments with receptor mutants and with short peptides derived from the kinase insert region of the PDGF receptor showed that the recombinant p85 binds to a well-defined phosphotyrosine-containing sequence of the receptor. p85 appears to be the subunit of PI3-kinase that links the enzyme to the ligand-activated receptor.	UNIV CALIF SAN FRANCISCO,SCH MED,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; NEW YORK MED COLL,DEPT ANAT & CELL BIOL,VALHALLA,NY 10595	University of California System; University of California San Francisco; New York Medical College	ESCOBEDO, JA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-32898] Funding Source: Medline; PHS HHS [K11-H102410] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; CARPENTER LC, 1990, J BIOL CHEM, V265, P19704; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P362; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; PAWSON T, 1988, ONCOGENE, V3, P491; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Summers MD, 1987, MANUAL METHODS BACUL; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	38	517	541	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					75	82		10.1016/0092-8674(91)90409-R	http://dx.doi.org/10.1016/0092-8674(91)90409-R			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1849460	Bronze			2022-12-28	WOS:A1991FF77300010
J	SURANA, U; ROBITSCH, H; PRICE, C; SCHUSTER, T; FITCH, I; FUTCHER, AB; NASMYTH, K				SURANA, U; ROBITSCH, H; PRICE, C; SCHUSTER, T; FITCH, I; FUTCHER, AB; NASMYTH, K			THE ROLE OF CDC28 AND CYCLINS DURING MITOSIS IN THE BUDDING YEAST SACCHAROMYCES-CEREVISIAE	CELL			English	Article							CELL-DIVISION CYCLE; P34CDC2 PROTEIN-KINASE; CONTROL GENE CDC2+; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; M-PHASE; MITOTIC CONTROL; MESSENGER-RNA; COMPONENT	cdc28-1N is a conditional allele that has normal G1 (Start) function but confers a mitotic defect. We have isolated seven genes that in high dosage suppress the growth defect of cdc28-1N cells but not of Start-defective cdc28-4 cells. Three of these (CLB1, CLB2, and CLB4) encode proteins strongly homologous to G2-specific B-type cyclins. Another gene, CLB3, was cloned using PCR. CLB1 and CLB2 encode a pair of closely related proteins; CLB3 and CLB4 encode a second pair. Neither CLB1 nor CLB2 is essential; however, disruption of both is lethal and causes a mitotic defect. Furthermore, the double mutant cdc28-1N clb2::LEU2 is nonviable, whereas cdc28-4 clb2::LEU2 is viable, suggesting that the cdc28-1N protein may be defective in its interaction with B-type cyclins. Our results are consistent with CDC28 function being required in both G1 and mitosis. Its mitotic role, we believe, involves interaction with a family of at least four G2-specific cyclins.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory	SURANA, U (corresponding author), RES INST MOLEC PATHOL, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA.		Surana, Uttam/H-1142-2011	Nasmyth, Kim/0000-0001-7030-4403; Surana, Uttam/0000-0002-4785-6514				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CARTER LA, 1978, EXP CELL RES, V112, P15; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GOEBL M, 1988, CELL, V54, P739; GORDON CN, 1977, J CELL SCI, V24, P81; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGAN I, 1988, J CELL SCI, V91, P587; HAGAN IM, 1988, J CELL SCI, V89, P343; HARTIG A, 1981, CURR GENET, V4, P29, DOI 10.1007/BF00376783; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHKA MJ, 1989, J CELL SCI, V92, P131; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; Maniatis T., 1982, MOL CLONING; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; NURSE P, 1985, TRENDS GENET, V1, P51, DOI 10.1016/0168-9525(85)90023-X; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1990, New Biologist, V2, P389; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WEINERT T, 1989, J CELL SCI, P145; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WITTENBERG C, 1989, MOL CELL BIOL, V9, P4064, DOI 10.1128/MCB.9.9.4064	64	428	440	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1991	65	1					145	161		10.1016/0092-8674(91)90416-V	http://dx.doi.org/10.1016/0092-8674(91)90416-V			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1849457	Bronze			2022-12-28	WOS:A1991FF77300017
J	GUAN, KL; BROYLES, SS; DIXON, JE				GUAN, KL; BROYLES, SS; DIXON, JE			A TYR SER PROTEIN PHOSPHATASE ENCODED BY VACCINIA VIRUS	NATURE			English	Article							LEUKOCYTE-COMMON ANTIGEN; TYROSINE-PHOSPHATASES; NUCLEOTIDE-SEQUENCE; RECEPTOR; DEPHOSPHORYLATION; IMMUNOGLOBULIN; TRANSCRIPTION; MEMBER; FAMILY	PROTEIN tyrosine phosphorylation is associated with alterations in receptor activity, cellular proliferation and modulation of the cell cycle 1,2. Inappropriate tyrosine phosphorylation can lead to unrestrained cell growth and oncogenesis. Enzymes important in tyrosine dephosphorylation have also been described 3,4-6. Protein tyrosine phosphatases (PTPases) consist of two families. There is a receptor-like family of PTPases with an extracellular domain, transmembrane-spanning region and typically two repeated phosphatase domains 7-11. Proteins of the non-receptor-like family have a single catalytic phosphatase domain 3,12-15, show a substrate specificity for Tyr phosphate and will not hydrolyse Ser or Thr phosphate. Here we report that the vaccinia virus genome contains an open reading frame which shares amino-acid sequence identity with the PTPases 3,12-16. The purified protein encoded by the vaccinia virus H1 open reading frame expressed in bacteria hydrolyses substrates containing phosphotyrosine and phosphoserine. Mutagenesis of an essential Cys in the vaccinia phosphatase abolishes catalytic activity directed towards both substrates, suggesting that hydrolysis proceeds by a common mechanism. Understanding the function of the H1-encoded protein will help to define the role of the phosphatase in viral replication and pathogenesis.	PURDUE UNIV,WALTHER CANC INST,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Walther Cancer Institute	GUAN, KL (corresponding author), PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907, USA.		Guan, Kun-Liang/ADK-7088-2022					BLISKA JB, IN PRESS P NATN ACAD; BOLIN I, 1988, MOL MICROBIOL, V2, P237, DOI 10.1111/j.1365-2958.1988.tb00025.x; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; BROYLES SS, 1986, P NATL ACAD SCI USA, V83, P3141, DOI 10.1073/pnas.83.10.3141; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHERNOFF J, 1983, J BIOL CHEM, V258, P7852; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; EARL PL, 1990, GENETIC MAPS VACCINA; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, IN PRESS ANAL BIOCH; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LI HC, 1981, FED PROC, V40, P1539; MATHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444; MICHIELS T, 1988, MICROB PATHOGENESIS, V5, P449, DOI 10.1016/0882-4010(88)90006-X; PALLEN CJ, 1985, BIOCHEMISTRY-US, V24, P4727, DOI 10.1021/bi00339a003; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; ROSEL JL, 1986, J VIROL, V60, P436, DOI 10.1128/JVI.60.2.436-449.1986; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1988, J BIOL CHEM, V263, P6731; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	30	388	402	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					359	362		10.1038/350359a0	http://dx.doi.org/10.1038/350359a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	1848923				2022-12-28	WOS:A1991FD83800099
J	HARTVEIT, F; BERTELSEN, B; THUNOLD, S; MAEHLE, BO; SKAARLAND, E; CHRISTENSEN, J				HARTVEIT, F; BERTELSEN, B; THUNOLD, S; MAEHLE, BO; SKAARLAND, E; CHRISTENSEN, J			RISK OF CERVICAL INTRAEPITHELIAL NEOPLASIA IN WOMEN WITH GLOMERULONEPHRITIS	BRITISH MEDICAL JOURNAL			English	Article							HUMAN PAPILLOMAVIRUS INFECTION; VIRUS-INFECTION; HPV INFECTIONS; GENITAL-TRACT; CANCER; IMMUNOSUPPRESSION; RECIPIENTS	Objective-To investigate the occurrence of cervical intraepithelial neoplasia in women with glomerulonephritis and its possible association with immunosuppressive treatment. Design-Retrospective study of cytological or histological specimens from women presenting with glomerulonephritis and a group of case and age matched controls. Setting-University department of pathology, Norway. Patients-81 women presenting with glomerulonephritis from 1981 to 1988, from whom gynaecological cytological or histological specimens were available. A group of 162 case and age matched controls. Main outcome measures-Age when glomerulonephritis of cervical intraepithelial neoplasia was diagnosed, type and characteristics of kidney lesion, stage of cervical intraepithelial neoplasia and presence of human papillomavirus, use of immunosuppressive treatment. Results-Cervical intraepithelial neoplasia was more common in women with glomerulonephritis than in their controls (16/81 (20%) upsilon-7/162 (4%), p < 0.001) and was more advanced in those with glomerulonephritis than in the controls (9/81(11%) of the study group had grade III cervical intraepithelial neoplasia compared with 1/162 (1%) of the controls). The increased occurrence of cervical lesions was independent of the use of immunosuppressive treatment, but the individual lesions tended to be more advanced when it was used (four of the seven cervical lesions in women with glomerulonephritis who had received immunosuppressive treatment were carcinoma in situ). Of the nine cervical lesions tested, seven were virus associated. Conclusion-Women with glomerulonephritis should have regular cervical smears, irrespective of their use of immunosuppressive treatment.	UNIV BERGEN,GADE INST,DEPT PATHOL,BERGEN,NORWAY	University of Bergen								ALLOUB MI, 1989, BMJ-BRIT MED J, V298, P153, DOI 10.1136/bmj.298.6667.153; FLETCHER S, 1983, J CLIN PATHOL, V36, P616, DOI 10.1136/jcp.36.6.616; GISSMANN L, 1984, CANCER SURV, V3, P161; HALPERT R, 1986, OBSTET GYNECOL, V68, P251; HAUSEN HZ, 1977, CURR TOP MICROBIOL I, V78, P1; HILLS E, 1979, ACTA CYTOL, V23, P53; KIRCHNER H, 1986, PROG MED VIROL, V33, P1; LAVERTY CR, 1978, ACTA CYTOL, V22, P195; MACLEAN AB, 1986, CLIN NEPHROL, V26, P45; MACNAB JCM, 1986, NEW ENGL J MED, V315, P1052, DOI 10.1056/NEJM198610233151703; MCCANCE DJ, 1988, CANCER SURV, V7, P499; MCVIE JG, 1979, MED IMMUNOLOGY; MEISELS A, 1985, ACTA CYTOL, V25, P7; PENN I, 1979, TRANSPL P, V11, P1047; PENN I, 1986, SURG GYNECOL OBSTET, V162, P603; PFISTER H, 1984, REV PHYSIOL BIOCH P, V99, P111, DOI 10.1007/BFb0027716; Pfister H, 1987, PAPILLOMAVIRUSES HUM, P1; SCHNEIDER V, 1983, ACTA CYTOL, V27, P220; SILLMAN F, 1984, AM J OBSTET GYNECOL, V150, P300, DOI 10.1016/S0002-9378(84)90369-7; SYRJANEN KJ, 1986, PATHOL ANNU, V21, P53	20	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					375	377		10.1136/bmj.302.6773.375	http://dx.doi.org/10.1136/bmj.302.6773.375			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	1848453	Green Published, Bronze			2022-12-28	WOS:A1991EX85800024
J	DOOLEY, DM; MCGUIRL, MA; BROWN, DE; TUROWSKI, PN; MCINTIRE, WS; KNOWLES, PF				DOOLEY, DM; MCGUIRL, MA; BROWN, DE; TUROWSKI, PN; MCINTIRE, WS; KNOWLES, PF			A CU(I)-SEMIQUINONE STATE IN SUBSTRATE-REDUCED AMINE OXIDASES	NATURE			English	Article							BENZYLAMINE OXIDASE; PIG PLASMA	THE role of copper in copper-containing amine oxidases has long been a source of debate and uncertainty1. Numerous electron paramagnetic resonance (EPR) experiments 2-6, including rapid freeze-quench studies 7, have failed to detect changes in the copper oxidation state in the presence of substrate amines. One suggestion that copper reduction might occur 8, has never been confirmed. Copper amine oxidases contain another cofactor, recently identified as 6-hydroxydopa quinone (topa quinone) 9, which is reduced by substrates. Copper has been implicated in the reoxidation of the substrate-reduce enzyme 10-12, but the failure to detect any copper redox change has led to proposals that Cu(II) acts as a Lewis acid 13, that it has an indirect role in catalysis 14, or that it serves a structural role 6. We present evidence for the generation of a Cu(I)-semiquinone state by substrate reduction of several amine oxidases under anaerobic conditions, and suggest that the Cu(I)-semiquinone may be the catalytic intermediate that reacts directly with oxygen.	VET ADM MED CTR,DEPT MOLEC BIOL,SAN FRANCISCO,CA 94121; UNIV LEEDS,DEPT BIOCHEM & BIOPHYS,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Leeds	DOOLEY, DM (corresponding author), AMHERST COLL,DEPT CHEM,AMHERST,MA 01002, USA.		McGuirl, Michele/N-2311-2014					BELLELLI A, 1985, BIOCHEM J, V232, P923, DOI 10.1042/bj2320923; DOOLEY DM, 1990, J AM CHEM SOC, V112, P2782, DOI 10.1021/ja00163a047; DOOLEY DM, 1984, J MOL CATAL, V23, P243, DOI 10.1016/0304-5102(84)80012-7; DOOLEY DM, 1987, FEBS LETT, V214, P274, DOI 10.1016/0014-5793(87)80069-8; FINAZZIAGRO A, 1984, FEBS LETT, V176, P378, DOI 10.1016/0014-5793(84)81200-4; GRANT J, 1978, BIOCHEM BIOPH RES CO, V83, P1216, DOI 10.1016/0006-291X(78)91524-3; Hamilton G., 1971, PROGRESS BIOORGANIC, V1, P83; HILL JM, 1964, BIOCHEM J, V91, P171, DOI 10.1042/bj0910171; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; MONDOVI B, 1969, FEBS LETT, V2, P182, DOI 10.1016/0014-5793(69)80013-X; MONDOVI B, 1967, J BIOL CHEM, V242, P1160; Mondovi B, 1985, STRUCTURE FUNCTIONS; MONDOVI B, 1971, MAGNETIC RESONANCE B, P233; MORPURGO L, 1989, BIOCHEM J, V260, P19, DOI 10.1042/bj2600019; RINALDI A, 1984, BIOCHEM BIOPH RES CO, V120, P242, DOI 10.1016/0006-291X(84)91440-2; ROTILIO G, 1970, BIOCHIM BIOPHYS ACTA, V198, P618, DOI 10.1016/0005-2744(70)90143-9; SUZUKI S, 1986, BIOCHEMISTRY-US, V25, P338, DOI 10.1021/bi00350a009; VANNGARD T, 1967, MAGNETIC RESONANCE B, P213; YADAV KDS, 1981, EUR J BIOCHEM, V114, P139; YAMADA H, 1969, BIOCHIM BIOPHYS ACTA, V191, P751, DOI 10.1016/0005-2744(69)90378-7; YAMADA H, 1963, NATURE, V198, P1092, DOI 10.1038/1981092a0	21	242	245	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 17	1991	349	6306					262	264		10.1038/349262a0	http://dx.doi.org/10.1038/349262a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1846226				2022-12-28	WOS:A1991ET51900064
J	HEIDMANN, O; HEIDMANN, T				HEIDMANN, O; HEIDMANN, T			RETROTRANSPOSITION OF A MOUSE IAP SEQUENCE TAGGED WITH AN INDICATOR GENE	CELL			English	Article							A-PARTICLE GENES; LONG TERMINAL REPEAT; CELL LINE WEHI-3B; C-MOS ONCOGENE; NUCLEOTIDE-SEQUENCE; INTERLEUKIN-3 GENE; DNA REARRANGEMENT; HOMEOBOX GENE; TY ELEMENTS; TRANSPOSITION	We have marked a cloned mouse IAP sequence with a neomycin-containing indicator gene whose expression is conditioned by passage of the transposon through an RNA intermediate. Transposition of the marked IAP introduced into tumor cells could be detected by simple selection of the cell in G418, at a frequency of 10(-6) per cell per generation. Southern blot analysis and nucleotide sequencing after PCR amplification demonstrated "retrotransposition" of the marked element, with splicing out of an intron contained in the indicator gene, and retroviral-like reverse transcription and integration of the transposed IAPs, with 6 bp duplications of the identified target sites. Transposition was found to be mutagenic for the element, as might be expected if the identified marked and endogenous IAP transcripts were coencapsidated into IAP particles as dimers.	INST GUSTAVE ROUSSY, INSERM, U140, F-94805 VILLEJUIF, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	HEIDMANN, O (corresponding author), INST GUSTAVE ROUSSY, CNRS, UNITE BIOCHIM ENZYMOL & PHYSICOCHIM MACROMOLEC 147, F-94805 VILLEJUIF, FRANCE.							BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; CAMPBELL HD, 1985, EUR J BIOCHEM, V150, P297, DOI 10.1111/j.1432-1033.1985.tb09020.x; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1985, NUCLEIC ACIDS RES, V13, P289, DOI 10.1093/nar/13.1.289; CHRISTY RJ, 1988, MOL CELL BIOL, V8, P1093, DOI 10.1128/MCB.8.3.1093; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CIFONE MA, 1981, P NATL ACAD SCI-BIOL, V78, P6949, DOI 10.1073/pnas.78.11.6949; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; EICHINGER DJ, 1988, CELL, V54, P955, DOI 10.1016/0092-8674(88)90110-9; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; FALZON M, 1988, J VIROL, V62, P4070, DOI 10.1128/JVI.62.11.4070-4077.1988; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; GRIGORYAN MS, 1985, EMBO J, V4, P2209, DOI 10.1002/j.1460-2075.1985.tb03916.x; HAWLEY RG, 1984, MOL CELL BIOL, V4, P2565, DOI 10.1128/MCB.4.12.2565; HEIDMANN T, 1988, P NATL ACAD SCI USA, V85, P2219, DOI 10.1073/pnas.85.7.2219; HOROWITZ M, 1984, EMBO J, V3, P2937, DOI 10.1002/j.1460-2075.1984.tb02235.x; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KUFF EL, 1983, NATURE, V302, P547, DOI 10.1038/302547a0; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1985, MOL CELL BIOL, V5, P474, DOI 10.1128/MCB.5.3.474; LUEDERS K, 1989, PROG NUCLEIC ACID RE, V36, P173; LUEDERS KK, 1977, CELL, V11, P83, DOI 10.1016/0092-8674(77)90319-1; LUEDERS KK, 1986, NUCLEIC ACIDS RES, V14, P1495, DOI 10.1093/nar/14.3.1495; LUEDERS KK, 1977, CELL, V12, P963, DOI 10.1016/0092-8674(77)90161-1; LURIA S, 1986, J VIROL, V57, P998, DOI 10.1128/JVI.57.3.998-1003.1986; Luria SE, 1943, GENETICS, V28, P491; MANN R, 1985, J VIROL, V54, P401, DOI 10.1128/JVI.54.2.401-407.1985; MIETZ JA, 1987, J VIROL, V61, P3020, DOI 10.1128/JVI.61.10.3020-3029.1987; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NICOLAS JF, 1983, TERATOCARCINOMA STEM, P469; ONO M, 1980, CELL, V21, P465, DOI 10.1016/0092-8674(80)90483-3; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PIKO L, 1984, P NATL ACAD SCI-BIOL, V81, P488, DOI 10.1073/pnas.81.2.488; RECHAVI G, 1982, NATURE, V300, P607, DOI 10.1038/300607a0; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENONG GLC, 1984, J VIROL, V49, P171, DOI 10.1128/JVI.49.1.171-177.1984; SHENONG GLC, 1982, J VIROL, V42, P411, DOI 10.1128/JVI.42.2.411-421.1982; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; TOHYAMA K, 1990, EMBO J, V9, P1823, DOI 10.1002/j.1460-2075.1990.tb08307.x; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VARMUS H, 1989, MOBILE DNA, P53; WILSON SH, 1974, BIOCHEMISTRY-US, V13, P1087, DOI 10.1021/bi00703a005; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553; YANG SS, 1974, J VIROL, V13, P712, DOI 10.1128/JVI.13.3.712-720.1974; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; YMER S, 1986, NUCLEIC ACIDS RES, V14, P5901, DOI 10.1093/nar/14.14.5901; YOTSUYANAGI Y, 1984, ULTRASTRUCTURE REPRO, P218; [No title captured]	58	131	135	1	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					159	170						12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846087				2022-12-28	WOS:A1991ET17500017
J	PATTERSON, B; GUTHRIE, C				PATTERSON, B; GUTHRIE, C			A U-RICH TRACT ENHANCES USAGE OF AN ALTERNATIVE 3' SPLICE SITE IN YEAST	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; MESSENGER-RNA INTRONS; SACCHAROMYCES-CEREVISIAE; SEQUENCES; PROTEIN; GENES; RECOGNIZES; MUTATIONS; SELECTION	There has been a long-standing belief that the mechanisms of mammalian and yeast splicing differ fundamentally in their requirement for a pyrimidine-rich motif preceding the 3' splice site. Using an in vivo assay, we have tested the influence of uridine content on competition between alternative 3' splice sites in yeast. We find that a uridine-rich tract preceding a PyAG greatly enhances its ability to compete as a splice acceptor. Moreover, a proximal PyAG is often overlooked if a more distal PyAG occurs in a superior sequence context; this observation cannot be accounted for by simple scanning models. Finally, we show that a distal (> 30 nucleotide) 3' splice site that is not preceded be uridines is a poor substrate for the second step of splicing; this argues that recognition of a uridine-rich motif is required for effective identification and utilization of distant splice sites.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021119, R37GM021119] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21119] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1984, MOL CELL BIOL, V4, P1871, DOI 10.1128/MCB.4.9.1871; CASADABAN M, 1983, RECOMBINANT DNA METH, P293; CELLINI A, 1985, EMBO J, V5, P1023; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; FOUSER LA, 1987, MOL CELL BIOL, V7, P3511; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; JACKSON SP, 1988, MOL CELL BIOL, V8, P1067, DOI 10.1128/MCB.8.3.1067; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LEER RJ, 1982, NUCLEIC ACIDS RES, V10, P5869, DOI 10.1093/nar/10.19.5869; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; PADGETT RA, 1986, ANN REV BIOCH, V55, P199; Parker R, 1987, MOL BIOL RNA NEW PER, P133; PIKIELNY CW, 1983, CELL, V34, P395, DOI 10.1016/0092-8674(83)90373-2; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RODRIGUEZ JR, 1984, CELL, V39, P603, DOI 10.1016/0092-8674(84)90467-7; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; RYMOND BC, 1987, GENE DEV, V1, P238, DOI 10.1101/gad.1.3.238; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3711, DOI 10.1128/MCB.6.11.3711; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; WISE JA, 1983, CELL, V35, P743, DOI 10.1016/0092-8674(83)90107-1	32	106	106	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					181	187		10.1016/0092-8674(91)90219-O	http://dx.doi.org/10.1016/0092-8674(91)90219-O			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846089				2022-12-28	WOS:A1991ET17500019
J	MUNOZDORADO, J; INOUYE, S; INOUYE, M				MUNOZDORADO, J; INOUYE, S; INOUYE, M			A GENE ENCODING A PROTEIN SERINE THREONINE KINASE IS REQUIRED FOR NORMAL DEVELOPMENT OF M-XANTHUS, A GRAM-NEGATIVE BACTERIUM	CELL			English	Article							ATP-BINDING SITE; TISSUE-SPECIFIC EXPRESSION; MYXOCOCCUS-XANTHUS; TYROSINE KINASES; DICTYOSTELIUM-DISCOIDEUM; CELL-INTERACTIONS; DNA; PHOSPHORYLATION; BIOSYNTHESIS; REPLACEMENT	PCR reactions were carried out on the genomic DNA of M. xanthus, a soil bacterium capable of differentiation to form fruiting bodies, using oligonucleotides representing highly conserved regions of eukaryotic protein serine/threonine kinases. A gene (pkn1) thus cloned contains an ORF of 693 amino acid residues whose amino-terminal domain shows significant sequence similarity with the catalytic domain of eukaryotic protein serine/threonine kinases. The pkn1 gene was overexpressed in E. coli, and the gene product has been found to be autophosphorylated at both serine and threonine residues. The expression of pkn1 is developmentally regulated to start immediately before spore formation. When pkn1 is deleted, differentiation starts prematurely, resulting in poor spore production. These results indicate that the protein serine/threonine kinase plays an important role in the onset of proper differentiation.			MUNOZDORADO, J (corresponding author), RUTGERS STATE UNIV,UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ 08854, USA.		Inouye, Sharon/R-7216-2019; Munoz-Dorado, Jose/N-6840-2016	Munoz-Dorado, Jose/0000-0001-7765-5687	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026843] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 26843] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APELIAN D, 1990, GENE DEV, V4, P1396, DOI 10.1101/gad.4.8.1396; AVERY L, 1983, MOL GEN GENET, V191, P99, DOI 10.1007/BF00330896; Burchard R.P., 1984, MYXOBACTERIA, P139, DOI 10.1007/978-1-4613-8280-5_7; CAMPOS JM, 1978, J MOL BIOL, V119, P167, DOI 10.1016/0022-2836(78)90431-X; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COZZONE AJ, 1988, ANNU REV MICROBIOL, V42, P97, DOI 10.1146/annurev.mi.42.100188.000525; CUMSKY M, 1979, P NATL ACAD SCI USA, V76, P5505, DOI 10.1073/pnas.76.11.5505; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DWORKIN M, 1964, SCIENCE, V146, P243, DOI 10.1126/science.146.3641.243; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; HAGEN DC, 1978, DEV BIOL, V64, P383; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIBABU B, 1991, P NATL ACAD SCI USA, V88, P1115, DOI 10.1073/pnas.88.4.1115; HSU MY, 1989, J BIOL CHEM, V264, P6214; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; INOUYE M, 1979, P NATL ACAD SCI USA, V76, P209, DOI 10.1073/pnas.76.1.209; INOUYE M, 1979, DEV BIOL, V68, P579, DOI 10.1016/0012-1606(79)90228-8; INOUYE S, 1983, J BIOL CHEM, V258, P38; INOUYE S, 1983, P NATL ACAD SCI-BIOL, V80, P6829, DOI 10.1073/pnas.80.22.6829; INOUYE S, 1989, CELL, V56, P709, DOI 10.1016/0092-8674(89)90593-X; INOUYE S, 1987, SYNTHESIS APPLICATIO, P181; KAISER D, 1986, ANNU REV GENET, V20, P539; KALDERON D, 1989, J BIOL CHEM, V264, P10738; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KAMPS MP, 1989, MICROBIOL REV, V52, P29; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KOMANO T, 1982, J BACTERIOL, V151, P114, DOI 10.1128/JB.151.1.114-118.1982; KROOS L, 1986, DEV BIOL, V117, P252, DOI 10.1016/0012-1606(86)90368-4; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; Maniatis T., 1982, MOL CLONING; MASUI Y, 1983, EXPT MANIPULATION GE, P15; MCBRIDE MJ, 1989, P NATL ACAD SCI USA, V86, P424, DOI 10.1073/pnas.86.2.424; Miller J.H., 1972, EXPT MOL GENETICS; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; ROSNER JL, 1972, VIROLOGY, V49, P679; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMKETS LJ, 1990, MICROBIOL REV, V54, P473, DOI 10.1128/MMBR.54.4.473-501.1990; SHIMKETS LJ, 1983, P NATL ACAD SCI-BIOL, V80, P1406, DOI 10.1073/pnas.80.5.1406; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	61	202	214	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1991	67	5					995	1006		10.1016/0092-8674(91)90372-6	http://dx.doi.org/10.1016/0092-8674(91)90372-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1835671				2022-12-28	WOS:A1991GT75500018
J	ROSENSTOCK, L; REST, KM; BENSON, JA; CANNELLA, JM; COHEN, J; CULLEN, MR; DAVIDOFF, F; LANDRIGAN, PJ; REYNOLDS, RC; CLEVER, LH; ELLIS, GB; GOLDSTEIN, BD				ROSENSTOCK, L; REST, KM; BENSON, JA; CANNELLA, JM; COHEN, J; CULLEN, MR; DAVIDOFF, F; LANDRIGAN, PJ; REYNOLDS, RC; CLEVER, LH; ELLIS, GB; GOLDSTEIN, BD			OCCUPATIONAL AND ENVIRONMENTAL MEDICINE - MEETING THE GROWING NEED FOR CLINICAL SERVICES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEW-YORK-STATE; DISEASE		NATL ACAD SCI,INST MED,DIV HLTH PROMOT & DIS PREVENT,WASHINGTON,DC 20418; UNIV MASSACHUSETTS,WORCESTER,MA 01605; AMER BOARD INTERNAL MED,PORTLAND,OR; MOBIL OIL CORP,NEW YORK,NY; SUNY STONY BROOK,STONY BROOK,NY 11794; YALE UNIV,SCH MED,NEW HAVEN,CT 06510; AMER COLL PHYSICIANS,PHILADELPHIA,PA; MT SINAI MED CTR,NEW YORK,NY 10029; ROBERT WOOD JOHNSON FDN,PRINCETON,NJ 08540; PACIFIC PRESBYTERIAN MED CTR,SAN FRANCISCO,CA; INST MED,WASHINGTON,DC; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ 08854	National Academies of Sciences, Engineering & Medicine; University of Massachusetts System; University of Massachusetts Worcester; Exxon Mobil Corporation; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Yale University; American College of Physicians; Icahn School of Medicine at Mount Sinai; Robert Wood Johnson Foundation (RWJF); California Pacific Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center				cullen, mark/0000-0001-7996-1864				BLANC PD, 1989, ANN INTERN MED, V111, P238, DOI 10.7326/0003-4819-111-3-238; CASTORINA JS, 1990, ANN INTERN MED, V113, P983, DOI 10.7326/0003-4819-113-12-983; CULLEN MR, 1990, NEW ENGL J MED, V322, P594, DOI 10.1056/NEJM199003013220905; CULLEN MR, 1990, NEW ENGL J MED, V322, P675, DOI 10.1056/NEJM199003083221007; DISCHER DP, 1975, DHEW NIOSH75162 PUBL; FAHS MC, 1989, AM J IND MED, V16, P437, DOI 10.1002/ajim.4700160409; MARKOWITZ SB, 1989, AM J IND MED, V16, P417, DOI 10.1002/ajim.4700160408; MCCALLUM DB, 1989, EPA J            MAY, P22; POLLACK ES, 1987, COUNTING INJURIES IL; ROSENSTOCK L, 1987, ANN INTERN MED, V107, P575, DOI 10.7326/0003-4819-107-4-575; 1990, NEW ENGL J MED, V113, P974; 1986, DEP LABOR B; 1990, M PHYSICIANS NEEDS M; 1991, ADDRESSING PHYSICIAN; 1988, ROLE PRIMARY CARE PH	15	32	32	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1991	325	13					924	927		10.1056/NEJM199109263251305	http://dx.doi.org/10.1056/NEJM199109263251305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF856	1815547				2022-12-28	WOS:A1991GF85600005
J	NOJI, S; NOHNO, T; KOYAMA, E; MUTO, K; OHYAMA, K; AOKI, Y; TAMURA, K; OHSUGI, K; IDE, H; TANIGUCHI, S; SAITO, T				NOJI, S; NOHNO, T; KOYAMA, E; MUTO, K; OHYAMA, K; AOKI, Y; TAMURA, K; OHSUGI, K; IDE, H; TANIGUCHI, S; SAITO, T			RETINOIC ACID INDUCES POLARIZING ACTIVITY BUT IS UNLIKELY TO BE A MORPHOGEN IN THE CHICK LIMB BUD	NATURE			English	Article							RECEPTOR GENES; DIFFERENTIAL EXPRESSION; POSITIONAL INFORMATION; LOCAL APPLICATION; HOMEOBOX GENE; PATTERN; CELLS; IDENTIFICATION; ELEMENT; ALPHA	RETINOIC acid is a putative morphogen in limb formation in the chick and other vertebrates 1-5. In chick limb formation, it is thought that retinoic acid is released from the zone of polarizing activity (ZPA) and the concentration gradient of retinoic acid formed from the posterior to the anterior provides positional cues for digit formation 1-4,6. Implantation of a bead containing retinoic acid at the anterior margin of the limb bud induces a mirror-image symmetrical duplication of the digit pattern similar to that observed when the ZPA is grafted into the anterior margin of the host limb bud 7,8. Also, the level of endogenous retinoic acid (25 nM on average) is higher in the posterior one third of the limb bud 1,6. We found that when the bead containing either retinoic acid or an analogue but not the ZPA, was implanted in the anterior margin of the chick limb bud, expression of the retinoic acid receptor type-beta gene was induced around the bead within 4 h. These results indicate that exogenous retinoic acid is not identical with the ZPA morphogen. As the anterior tissue exposed to retinoic acid has polarizing activity 9, we conclude that the primary function of exogenous retinoic acid is to induce polarizing activity in the limb bud.	OKAYAMA UNIV, SCH DENT,DEPT ORAL & MAXILLOFACIAL SURG 1, OKAYAMA 700, JAPAN; OKAYAMA UNIV, SCH DENT,DEPT ORAL & MAXILLOFACIAL SURG 2, OKAYAMA 700, JAPAN; KAWASAKI MED SCH, DEPT PHARMACOL, KURASHIKI, OKAYAMA 70101, JAPAN; TOHOKU UNIV, INST BIOL, SENDAI, MIYAGI 980, JAPAN	Okayama University; Okayama University; Kawasaki Medical School; Tohoku University	NOJI, S (corresponding author), OKAYAMA UNIV, SCH DENT, DEPT BIOCHEM, 2-5-1 SHIKATA CHO, OKAYAMA 700, JAPAN.		Nohno, Tsutomu/B-6923-2008	Nohno, Tsutomu/0000-0002-0351-5603				BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; EICHELE G, 1987, J CELL BIOL, V105, P1917, DOI 10.1083/jcb.105.4.1917; EICHELE G, 1984, ANAL BIOCHEM, V142, P542, DOI 10.1016/0003-2697(84)90504-9; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; IDE H, 1990, DEV GROWTH DIFFER, V32, P1; NOJI S, 1989, FEBS LETT, V257, P93, DOI 10.1016/0014-5793(89)81794-6; NOJI S, 1990, ACTA HISTOCHEM CYTOC, V23, P353, DOI 10.1267/ahc.23.353; NOJI S, 1989, FEBS LETT, V259, P86, DOI 10.1016/0014-5793(89)81501-7; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; OSUMIYAMASHITA N, 1990, FEBS LETT, V264, P71, DOI 10.1016/0014-5793(90)80767-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P227; Summerbell D, 1983, Prog Clin Biol Res, V110 Pt A, P109; TAMURA K, 1990, CELL DIFFER DEV, V32, P17, DOI 10.1016/0922-3371(90)90095-E; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; WOLPERT L, 1989, DEVELOPMENT, V107, P3; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	29	248	254	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1991	350	6313					83	86		10.1038/350083a0	http://dx.doi.org/10.1038/350083a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1848357				2022-12-28	WOS:A1991FA69300072
J	LI, P; WOOD, K; MAMON, H; HASER, W; ROBERTS, T				LI, P; WOOD, K; MAMON, H; HASER, W; ROBERTS, T			RAF-1 - A KINASE CURRENTLY WITHOUT A CAUSE BUT NOT LACKING IN EFFECTS	CELL			English	Review							PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; REQUIREMENT; EXPRESSION; RECEPTOR; FAMILY		HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	LI, P (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115, USA.		Mamon, Harvey J/B-2335-2009	Mamon, Harvey J/0000-0002-6060-9059				AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARROLL MP, 1991, IN PRESS J BIOL CHEM; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; KANAKURA Y, 1991, IN PRESS BLOOD; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TURNER BC, 1991, IN PRESS P NATL ACAD; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247	24	161	162	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					479	482		10.1016/0092-8674(91)90228-Q	http://dx.doi.org/10.1016/0092-8674(91)90228-Q			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1846778				2022-12-28	WOS:A1991EX36100003
J	LAETZ, T; SILBERMAN, G				LAETZ, T; SILBERMAN, G			REIMBURSEMENT POLICIES CONSTRAIN THE PRACTICE OF ONCOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. -To determine the prevalence of off-label anticancer drug use (ie, using drugs to treat conditions other than those listed on the Food and Drug Administration's approved drug label), the extent of reimbursement denials for these uses, and the effect of denials on the treatment of cancer patients. Design, Setting, and Participants. - A three-part questionnaire was sent to a randomized sample of oncologists taken from the 1990 membership of the American Society of Clinical Oncology in March 1990. A response rate of 56% yielded information from 681 oncologists on the drugs they prescribed to 2018 new cancer patients and on those they frequently use in treating 11 specific types of cancer. Main Outcome Measures. - The labeled uses of the drugs prescribed and frequently used in chemotherapies were checked against the indications treated to determine whether they were prescribed for off-label uses. Three drug compendia were used as cited sources of off-label drug uses. The extent of reimbursement denials over the last 12 months and their effects on treatments were based on respondent opinions. Main Results. - Off-label drug use is prevalent and dominates the chemotherapy regimens of cancers that are more difficult to treat and for which there are no cures or agreements on standardized treatment. Most oncologists reported frustration with shifting reimbursement policies in general and with an increasing rate of denials for some off-label drug uses. Indeed, a surprising number of oncologists claimed that these policies caused them to alter preferred treatments and site of care. Conclusion. - These findings suggest the need for public discussion of off-label drug use issues so that appropriate policies can be developed.	US GEN ACCOUNTING OFF,PROGRAM EVALUAT & METHODOL,441 G ST NW,WASHINGTON,DC 20548									DEVITA VT, 1985, PRINCIPLES PRACTICE, P282; 1991, PEMD9114 US GEN ACC; 1989, FED REG         0130, V54, P4302	3	51	53	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2996	2999		10.1001/jama.266.21.2996	http://dx.doi.org/10.1001/jama.266.21.2996			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820471				2022-12-28	WOS:A1991GR77500030
J	KAHN, JG; WALKER, CK; WASHINGTON, AE; LANDERS, DV; SWEET, RL				KAHN, JG; WALKER, CK; WASHINGTON, AE; LANDERS, DV; SWEET, RL			DIAGNOSING PELVIC INFLAMMATORY DISEASE - A COMPREHENSIVE ANALYSIS AND CONSIDERATIONS FOR DEVELOPING A NEW MODEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CHLAMYDIA-TRACHOMATIS INFECTION; SEXUALLY-TRANSMITTED DISEASES; ACUTE SALPINGITIS; LAPAROSCOPIC TREATMENT; ENZYME-IMMUNOASSAY; IMMUNOFLUORESCENCE; EPIDEMIOLOGY; PATHOGENESIS; ETIOLOGY; EFFICACY	Objective. - To examine the accuracy of existing diagnostic indicators for pelvic inflammatory disease and to develop guidelines for a new diagnostic model. Data Sources. - Studies were identified for the period 1969 through 1990. A Medline search of the English-language literature was conducted using the subject terms pelvic inflammatory disease or salpingitis and diagnosis. In addition, abstracts and bibliographies of articles and books were reviewed. Study Selection. - Studies were selected if pelvic inflammatory disease was diagnosed using laparoscopic findings or narrow clinical rules. Of the 15 reports identified, 12 were included in this analysis. The selected studies were grouped by a quality rating based on subject selection, definition of pelvic inflammatory disease, data analysis, and other measures. Data Extraction. - Diagnostic findings were divided into four categories: historical (symptoms), clinical examination (signs), laboratory, and combinations of the above. Sensitivity and specificity were extracted using raw data. Data were classified by quality rating. Data Synthesis. - Historical findings were usually not statistically significant predictors of pelvic inflammatory disease, and when they were they tended toward low sensitivity and high specificity, while clinical findings were somewhat more sensitive and about as specific. Several laboratory tests showed consistent value in pelvic inflammatory disease diagnosis, with high sensitivity and specificity. Combinations of indicators permitted high sensitivity or high specificity but not both simultaneously. Conclusions. - No single or combination diagnostic indicator was found to reliably predict pelvic inflammatory disease. Combining published evidence with practical clinical considerations, a diagnostic approach is proposed that emphasizes diagnostic sensitivity when clinical presentation is mild and more thorough evaluation when a woman is severely ill. Research is needed to evaluate the accuracy and acceptability of specific diagnostic models and to investigate new diagnostic indicators.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET GYNECOL & REPROD SERV,SAN FRANCISCO,CA 94109; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94109	University of California System; University of California San Francisco; University of California System; University of California San Francisco	KAHN, JG (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,11TH FLOOR,1388 SUTTER ST,SAN FRANCISCO,CA 94109, USA.				NIAID NIH HHS [AI24768] Funding Source: Medline; PHS HHS [282-88-0018] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024768] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARAN RK, 1989, 8TH M INT SOC SEX TR; ADDUCCI JE, 1981, INT SURG, V66, P359; ALDER MW, 1982, BR J VENER DIS, V58, P151; AMORTEGUI AJ, 1985, OBSTET GYNECOL, V65, P523; BONGARD F, 1985, AM J SURG, V150, P90, DOI 10.1016/0002-9610(85)90015-7; BYRNE GI, 1988, INFECT IMMUN, V56, P2023, DOI 10.1128/IAI.56.8.2023-2027.1988; Chaparro M V, 1978, Int J Gynaecol Obstet, V15, P307; CHERNESKY MA, 1986, J INFECT DIS, V154, P141, DOI 10.1093/infdis/154.1.141; DAILEY RH, 1988, EMERGENCY MED CONCEP, P27; ESCHENBACH DA, 1980, OBSTET GYNECOL, V55, pS142, DOI 10.1097/00006250-198003001-00037; ESCHENBACH DA, 1975, NEW ENGL J MED, V293, P166, DOI 10.1056/NEJM197507242930403; GILBODY KJ, 1987, EMERGENCY MED COMPRE, P7; GRIFO JA, 1989, AM J OBSTET GYNECOL, V160, P26, DOI 10.1016/0002-9378(89)90080-X; HADGU A, 1986, AM J OBSTET GYNECOL, V155, P954, DOI 10.1016/0002-9378(86)90324-8; HAGER WD, 1983, OBSTET GYNECOL, V61, P113; HEMILA M, 1987, ARCH GYNECOL OBSTET, V241, P177, DOI 10.1007/BF00931315; HENRYSUCHET J, 1984, J REPROD MED, V29, P579; JACOBSON L, 1969, AM J OBSTET GYNECOL, V105, P1088, DOI 10.1016/0002-9378(69)90132-X; JACOBSON L, 1975, International Journal of Gynecology and Obstetrics, V13, P249; JENICEK M, 1989, J CLIN EPIDEMIOL, V42, P35, DOI 10.1016/0895-4356(89)90023-1; KENNEY A, 1974, BMJ-BRIT MED J, V1, P519, DOI 10.1136/bmj.1.5906.519-b; LEHTINEN M, 1986, AM J OBSTET GYNECOL, V154, P158, DOI 10.1016/0002-9378(86)90419-9; MCCABE CJ, 1989, EMERGENCY MED SCI F, P42; METHOD MW, 1987, J REPROD MED, V32, P759; PAAVONEN J, 1985, AM J OBSTET GYNECOL, V151, P645, DOI 10.1016/0002-9378(85)90156-5; PATTON DL, 1989, OBSTET GYNECOL, V73, P622; REICH H, 1987, J REPROD MED, V32, P747; REVEL M, 1989, EXPERIENTIA, V45, P549, DOI 10.1007/BF01990505; ROTHENBERG RB, 1976, JAMA-J AM MED ASSOC, V235, P49, DOI 10.1001/jama.235.1.49; SELLORS JW, 1988, FERTIL STERIL, V49, P451; SELLORS JW, 1989, 8TH M INT SOC SEX TR; SVENSSON L, 1980, AM J OBSTET GYNECOL, V138, P1017, DOI 10.1016/0002-9378(80)91099-6; SWEET RL, 1979, AM J OBSTET GYNECOL, V134, P68, DOI 10.1016/0002-9378(79)90798-1; SWEET RL, 1980, AM J OBSTET GYNECOL, V138, P985, DOI 10.1016/0002-9378(80)91093-5; TAVELLI BG, 1986, SEX TRANSM DIS, V13, P119, DOI 10.1097/00007435-198607000-00001; WALD ER, 1977, AM J DIS CHILD, V131, P1094, DOI 10.1001/archpedi.1977.02120230040006; WASHINGTON AE, 1984, JAMA-J AM MED ASSOC, V251, P2529, DOI 10.1001/jama.251.19.2529; WASHINGTON AE, 1986, JAMA-J AM MED ASSOC, V255, P1735, DOI 10.1001/jama.255.13.1735; WASHINGTON AE, 1985, J ADOLESCENT HEALTH, V6, P298, DOI 10.1016/S0197-0070(85)80067-X; WASSERHEIT JN, 1986, ANN INTERN MED, V104, P187, DOI 10.7326/0003-4819-104-2-187; WESTROM L, 1983, J REPROD MED, V28, P703; WESTROM L, 1990, SEXUALLY TRANSMITTED, P593; WIESMEIER E, 1987, OBSTET GYNECOL, V69, P347; WILLIAMS DM, 1989, INFECT IMMUN, V57, P1351, DOI 10.1128/IAI.57.5.1351-1355.1989; WILLIAMS DM, 1987, INFECT IMMUN, V55, P223, DOI 10.1128/IAI.55.1.223-226.1987; WOLNERHANSSEN P, 1983, OBSTET GYNECOL, V61, P299; WOLNERHANSSEN P, 1985, OBSTET GYNECOL, V66, P223; 1989, MMWR-MORBID MORTAL W, V38, P1; 1991, MMWR-MORBID MORTAL W, V40, P1	49	85	86	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	1991	266	18					2594	2604		10.1001/jama.266.18.2594	http://dx.doi.org/10.1001/jama.266.18.2594			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN660	1834868				2022-12-28	WOS:A1991GN66000037
J	THRON, CD				THRON, CD			MATHEMATICAL-ANALYSIS OF A MODEL OF THE MITOTIC CLOCK	SCIENCE			English	Article											THRON, CD (corresponding author), DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03756, USA.							HIGGINS J, 1967, IND ENG CHEM, V59, P18, DOI 10.1021/ie50689a006; NOREL R, 1991, SCIENCE, V251, P1076, DOI 10.1126/science.1825521	2	20	20	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					122	123		10.1126/science.1833817	http://dx.doi.org/10.1126/science.1833817			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1833817				2022-12-28	WOS:A1991GH60500044
J	DETSKY, AS				DETSKY, AS			PARENTERAL-NUTRITION - IS IT HELPFUL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							META-ANALYSIS				DETSKY, AS (corresponding author), UNIV TORONTO,TORONTO M5G 2C4,ONTARIO,CANADA.							DETSKY AS, 1987, ANN INTERN MED, V107, P195, DOI 10.7326/0003-4819-107-2-195; DETSKY AS, 1987, JPEN-PARENTER ENTER, V11, P440, DOI 10.1177/0148607187011005440; DETSKY AS, 1987, JPEN-PARENTER ENTER, V11, P8, DOI 10.1177/014860718701100108; MCGEER AJ, 1990, NUTRITION, V6, P233; NAYLOR C D, 1987, Renal Failure, V10, P141, DOI 10.3109/08860228709047649; NAYLOR CD, 1989, GASTROENTEROLOGY, V97, P1033, DOI 10.1016/0016-5085(89)91517-5; 1987, ANN INTERN MED, V107, P252; 1991, NEW ENGL J MED, V325, P525; 1990, INT J TECHNOL ASSESS, V6, P655; 1989, ANN INTERN MED, V110, P734	10	18	18	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					573	575		10.1056/NEJM199108223250808	http://dx.doi.org/10.1056/NEJM199108223250808			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1830369				2022-12-28	WOS:A1991GB44700008
J	HASSNER, A; ADELMAN, DC				HASSNER, A; ADELMAN, DC			BIOLOGIC RESPONSE MODIFIERS IN PRIMARY IMMUNODEFICIENCY DISORDERS	ANNALS OF INTERNAL MEDICINE			English	Review							COMMON VARIABLE IMMUNODEFICIENCY; INTRAVENOUS GAMMA-GLOBULIN; CHRONIC MUCOCUTANEOUS-CANDIDIASIS; ADENOSINE-DEAMINASE DEFICIENCY; B-CELL DIFFERENTIATION; HYPERIMMUNOGLOBULIN-E SYNDROME; SELECTIVE IGA DEFICIENCY; PURINE NUCLEOSIDE PHOSPHORYLASE; DEFECTIVE NEUTROPHIL CHEMOTAXIS; RECURRENT-INFECTION SYNDROME	Objective: To propose a new classification for the primary immunodeficiency disorders and to review potential therapeutic applications of biologic response modifiers in these disorders. Data Source: Relevant articles were identified through a search of MEDLINE using the following indexing terms: primary immunodeficiencies (and subclassifications), and human immunomodulators (and subclassifications). Study Selection: Articles were critically reviewed and included if relevant. Data Synthesis: The primary immunodeficiency disorders are classified according to functional abnormalities, specifically, abnormalities in early cellular maturation, differentiation, regulatory cell function, enzymatic function, and cytokine responses. Such a classification clarifies the potential role of biologic response modifiers in primary immunodeficiency disorders. Intravenous gammaglobulin and histamine-2 (H-2)-receptor blockers modify regulatory cell function; retinoids modify abnormal cellular differentiation, gene transfer and enzyme replacement can be applied in disorders characterized by specific functional gene abnormalities; and interferons modify abnormal cytokine responses. Interleukin-2, thymic hormones, transfer factor, and levamisole appear to affect multiple functional defects. Conclusions: Biologic response modifiers are currently important ancillary tools in the treatment of immunodeficiency disorders, and their therapeutic role will become even more important in the future. Multicenter cooperative trials of new and existing agents are needed to fully define their roles and efficacy in the treatment of these disorders.	UNIV CALIF SAN FRANCISCO, SCH MED,DIV ALLERGY IMMUNOL,533 PARNASSUS AVE, U-246, SAN FRANCISCO, CA 94143 USA; TEL AVIV ELIAS SOURASKY MED CTR, TEL AVIV, ISRAEL; TEL AVIV UNIV, IL-69978 TEL AVIV, ISRAEL	University of California System; University of California San Francisco; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University								ABIKO T, 1986, CHEM PHARM BULL, V34, P2133; ABIKO T, 1986, Biotechnology and Applied Biochemistry, V8, P160; ADELMAN DC, 1991, IN PRESS J ALLERGY C; AIUTI F, 1983, LANCET, V1, P551; AMATRUDA TT, 1988, RETINOIDS CELL DIFFE, P95; AMENT ME, 1973, MEDICINE, V52, P227, DOI 10.1097/00005792-197305000-00004; AMMANN AJ, 1971, MEDICINE, V50, P223, DOI 10.1097/00005792-197105000-00004; AMMANN AJ, 1987, BASIC CLIN IMMUNOL, P317; AMMANN AJ, 1970, CLIN EXP IMMUNOL, V1, P833; ANDERSON R, 1977, J IMMUNOL, V118, P1690; ANDERSON WF, 1984, SCIENCE, V226, P401, DOI 10.1126/science.6093246; ANDERSON WF, 1989, J MED PHILOS, V14, P681, DOI 10.1093/jmp/14.6.681; ANTEL JP, 1981, CLIN EXP IMMUNOL, V43, P351; ARIGA T, 1987, TOHOKU J EXP MED, V152, P53, DOI 10.1620/tjem.152.53; ATWATER JS, 1978, CLIN IMMUNOL IMMUNOP, V9, P379, DOI 10.1016/0090-1229(78)90110-1; AUGUST CS, 1968, LANCET, V2, P1210; BALLOW M, 1989, J ALLERGY CLIN IMMUN, V84, P595, DOI 10.1016/0091-6749(89)90196-6; BALLOW M, 1977, CLIN IMMUNOL IMMUNOP, V8, P504, DOI 10.1016/0090-1229(77)90014-9; BARANDUN S, 1962, VOX SANG, V7, P157, DOI 10.1111/j.1423-0410.1962.tb03240.x; BJORKANDER J, 1987, J CLIN IMMUNOL, V7, P8, DOI 10.1007/BF00915419; BORDIGONI P, 1982, LANCET, V2, P293; BORTIN MM, 1977, JAMA-J AM MED ASSOC, V238, P591, DOI 10.1001/jama.238.7.591; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BRENNER MK, 1984, EUR J IMMUNOL, V14, P1021, DOI 10.1002/eji.1830141111; BROCKMEYER NH, 1988, CLIN IMMUNOL IMMUNOP, V48, P50, DOI 10.1016/0090-1229(88)90156-0; BRUTON OC, 1952, PEDIATRICS, V9, P722; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUCKLEY RH, 1983, MONOCLONAL ANTIBODIE, P83; BUSINCO L, 1981, ARCH DIS CHILD, V56, P60, DOI 10.1136/adc.56.1.60; BUSINCO L, 1986, CLIN IMMUNOL IMMUNOP, V39, P222, DOI 10.1016/0090-1229(86)90086-3; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CIBODDO G, 1987, JAMA-J AM MED ASSOC, V258, P1892, DOI 10.1001/jama.1987.03400140054016; CLAASSEN JL, 1990, J IMMUNOL, V144, P2123; CLEVELAND WW, 1968, LANCET, V2, P1211; COWAN MJ, 1989, CLIN IMMUNOL IMMUNOP, V53, P59, DOI 10.1016/0090-1229(89)90101-3; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; CUNNINGHAMRUNDLES C, 1987, J CLIN IMMUNOL, V7, P294, DOI 10.1007/BF00915550; CUNNINGHAMRUNDLES C, 1984, ANN INTERN MED, V101, P435, DOI 10.7326/0003-4819-101-4-435; DAVIS SD, 1966, LANCET, V1, P1013; DECREE J, 1978, ARCH DIS CHILD, V53, P144, DOI 10.1136/adc.53.2.144; DELFRAISSY JF, 1985, BRIT J HAEMATOL, V60, P315, DOI 10.1111/j.1365-2141.1985.tb07417.x; DELPRETE G, 1989, J CLIN INVEST, V84, P1830, DOI 10.1172/JCI114368; DENNERT G, 1978, EUR J IMMUNOL, V8, P23, DOI 10.1002/eji.1830080106; DENNERT G, 1984, RETINOIDS, V2, P373; DESNICK RJ, 1976, PHYSIOL REV, V56, P57, DOI 10.1152/physrev.1976.56.1.57; DiGeorge A. M., 1968, BIRTH DEFECTS OAS, V4, P116; DIGEORGE AM, 1968, IMMUNOL DEFICIENCY, P116; DOI S, 1989, EUR J PEDIATR, V148, P630, DOI 10.1007/BF00441517; DONABEDIAN H, 1982, J CLIN INVEST, V69, P1155, DOI 10.1172/JCI110551; DONABEDIAN H, 1982, NEW ENGL J MED, V307, P290, DOI 10.1056/NEJM198207293070506; DORFLING P, 1987, LEUKOCYTE DIALYSATES, P141; ERSHLER WB, 1983, CLIN IMMUNOL IMMUNOP, V26, P10, DOI 10.1016/0090-1229(83)90168-X; ETZIONI A, 1982, PEDIATR RES, pA221; FALCHUK KR, 1977, INFECT IMMUN, V17, P361, DOI 10.1128/IAI.17.2.361-365.1977; FARRANT J, 1989, CLIN IMMUNOL IMMUNOP, V51, P196, DOI 10.1016/0090-1229(89)90019-6; FAUCI AS, 1987, ANN INTERN MED, V106, P421, DOI 10.7326/0003-4819-106-3-421; FEHR J, 1982, NEW ENGL J MED, V306, P1254, DOI 10.1056/NEJM198205273062102; FERREIRA A, 1988, CLIN IMMUNOL IMMUNOP, V47, P199, DOI 10.1016/0090-1229(88)90072-4; FIORILLI M, 1986, CLIN IMMUNOL IMMUNOP, V38, P256, DOI 10.1016/0090-1229(86)90143-1; FIREMAN P, 1965, J PEDIATR-US, V67, P907; FLOMENBERG N, 1983, J IMMUNOL, V130, P2644; FUDENBERG HH, 1989, ANNU REV PHARMACOL, V29, P475; GALLI E, 1990, ANN ALLERGY, V64, P147; GALLIN JI, 1974, P NATL ACAD SCI USA, V71, P498, DOI 10.1073/pnas.71.2.498; GEHA RS, 1979, J CLIN INVEST, V64, P385, DOI 10.1172/JCI109473; GEHA RS, 1981, J CLIN INVEST, V68, P783, DOI 10.1172/JCI110315; GEHA RS, 1976, CLIN IMMUNOL IMMUNOP, V6, P102, DOI 10.1016/0090-1229(76)90065-9; GIFFORD RRM, 1987, SURGERY, V102, P242; GRISWOLD DE, 1984, J IMMUNOL, V132, P3054; GROOPMAN JE, 1989, ANN INTERN MED, V110, P335, DOI 10.7326/0003-4819-110-5-335; GUPTA A, 1986, AM J DIS CHILD, V140, P143, DOI 10.1001/archpedi.1986.02140160061033; HADDEN JW, 1988, CANCER DETECT PREV, V12, P537; HADDEN JW, 1987, FUNDAM CLIN PHARM, V1, P283, DOI 10.1111/j.1472-8206.1987.tb00566.x; HADDEN JW, 1989, MED ONCOL TUMOR PHAR, V6, P11; HANDZEL ZT, 1986, ISRAEL J MED SCI, V22, P387; HASHIMOTO F, 1986, CLIN EXP IMMUNOL, V65, P409; HASSNER A, 1983, J IMMUNOL, V130, P1567; HASSNER A, 1984, J IMMUNOL, V132, P2844; HEBERT J, 1981, CELL IMMUNOL, V58, P366, DOI 10.1016/0008-8749(81)90230-6; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; HILL HR, 1976, J LAB CLIN MED, V88, P796; HILL HR, 1975, PHAGOCYTIC CELL HOST, P249; HINZ CF, 1963, NEW ENGL J MED, V269, P1329, DOI 10.1056/NEJM196312192692501; HIRSCHHORN R, 1986, CLIN IMMUNOL IMMUNOP, V40, P157, DOI 10.1016/0090-1229(86)90081-4; HITZIG WH, 1971, J PEDIATR-US, V78, P968, DOI 10.1016/S0022-3476(71)80426-2; HOF H, 1979, ANN INST PASTEUR IMM, VC130, P587; HOGAN NA, 1978, J INFECT DIS, V138, P437, DOI 10.1093/infdis/138.4.437; HOROWITZ S, 1975, CLIN IMMUNOL IMMUNOP, V4, P405, DOI 10.1016/0090-1229(75)90009-4; ICHIKAWA Y, 1982, CLIN IMMUNOL IMMUNOP, V25, P252, DOI 10.1016/0090-1229(82)90188-X; INOUE T, 1984, J CLIN IMMUNOL, V4, P235, DOI 10.1007/BF00914971; Isaacs A., 1957, P R SOC LOND B, V147, P258; JORIZZO JL, 1980, ANN INTERN MED, V92, P192, DOI 10.7326/0003-4819-92-2-192; KANTOFF PW, 1986, P NATL ACAD SCI USA, V83, P6563, DOI 10.1073/pnas.83.17.6563; KAWADA K, 1987, EXP HEMATOL, V15, P133; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; Kirkpatrick C H, 1988, Ann N Y Acad Sci, V544, P471, DOI 10.1111/j.1749-6632.1988.tb40444.x; KIRKPATRICK CH, 1972, J CLIN INVEST, V51, P2948, DOI 10.1172/JCI107119; KIRKPATRICK CH, 1976, CLIN EXP IMMUNOL, V23, P414; Kondo M, 1989, Nihon Naika Gakkai Zasshi, V78, P1609; KREDICH NM, 1989, METABOLIC BASIS INHE, P1045; KUMAR A, 1990, DICP ANN PHARMAC, V24, P289, DOI 10.1177/106002809002400316; LANG I, 1982, CLIN IMMUNOL IMMUNOP, V25, P139, DOI 10.1016/0090-1229(82)90173-8; LAWRENCE HS, 1949, P SOC EXP BIOL MED, V71, P516, DOI 10.3181/00379727-71-17242; LAWTON AR, 1972, J LAB CLIN MED, V80, P26; LEICKLY FE, 1987, AM J MED, V82, P159, DOI 10.1016/0002-9343(87)90398-6; LEUNG DYM, 1988, J ALLERGY CLIN IMMUN, V81, P1082, DOI 10.1016/0091-6749(88)90873-1; LEVEY RH, 1963, J NATL CANCER I, V31, P199; LEVY RL, 1971, LANCET, V2, P898; LEVY Y, 1988, J PEDIATR-US, V113, P312, DOI 10.1016/S0022-3476(88)80271-3; LIN CY, 1983, J CLIN IMMUNOL, V1, P1309; LINDE A, 1988, CLIN IMMUNOL IMMUNOP, V49, P341, DOI 10.1016/0090-1229(88)90124-9; LOMNITZER R, 1976, CLIN EXP IMMUNOL, V24, P42; LOPEZBOTET M, 1982, J IMMUNOL, V128, P679; LOTZE MT, 1986, CANCER, V58, P2764, DOI 10.1002/1097-0142(19861215)58:12<2764::AID-CNCR2820581235>3.0.CO;2-Z; MAWHINNEY H, 1980, CLIN IMMUNOL IMMUNOP, V17, P483, DOI 10.1016/0090-1229(80)90144-0; MAYER L, 1984, J CLIN INVEST, V74, P2115, DOI 10.1172/JCI111636; MAYUMI M, 1989, EUR J PEDIATR, V148, P518, DOI 10.1007/BF00441546; MAZUMDER A, 1985, PEDIATR RES, V19, pA278, DOI 10.1203/00006450-198504000-01036; MCIVOR RS, 1987, MOL CELL BIOL, V7, P838, DOI 10.1128/MCB.7.2.838; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MORGAN G, 1987, CLIN EXP IMMUNOL, V70, P491; MULLER W, 1989, EUR J PEDIATR, V149, P96, DOI 10.1007/BF01995856; MUNOZ A, 1986, ANTIMICROB AGENTS CH, V30, P192, DOI 10.1128/AAC.30.1.192; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; NEY U M, 1987, Dermatologica (Basel), V175, P93; OCHS HD, 1971, J CLIN INVEST, V50, P2559, DOI 10.1172/JCI106756; OHNO T, 1987, CLIN IMMUNOL IMMUNOP, V45, P471, DOI 10.1016/0090-1229(87)90098-5; ORKIN SH, 1986, CLIN IMMUNOL IMMUNOP, V40, P151, DOI 10.1016/0090-1229(86)90080-2; OSOBA D, 1964, J EXP MED, V119, P177, DOI 10.1084/jem.119.1.177; PAGANELLI R, 1988, CLIN EXP IMMUNOL, V72, P124; PAHWA R, 1989, P NATL ACAD SCI USA, V86, P5069, DOI 10.1073/pnas.86.13.5069; PASTORELLI G, 1989, CLIN EXP IMMUNOL, V78, P334; PEARL ER, 1978, J IMMUNOL, V120, P1169; PENE J, 1988, J IMMUNOL, V141, P1218; PEREIRA S, 1982, EUR J IMMUNOL, V12, P540, DOI 10.1002/eji.1830120703; PEREZ CA, 1988, INT J RADIAT ONCOL, V15, P1337, DOI 10.1016/0360-3016(88)90229-5; PERRI RT, 1985, BLOOD, V66, P345; POLLACK S, 1982, NEW ENGL J MED, V307, P253; POLMAR SH, 1975, LANCET, V2, P743; POLMAR SH, 1976, NEW ENGL J MED, V295, P1337, DOI 10.1056/NEJM197612092952402; REBORA A, 1980, BRIT J DERMATOL, V102, P49, DOI 10.1111/j.1365-2133.1980.tb05671.x; REDONDO JM, 1987, IMMUNOL LETT, V14, P111, DOI 10.1016/0165-2478(87)90088-5; REINHERZ EL, 1979, NEW ENGL J MED, V301, P1018, DOI 10.1056/NEJM197911083011902; REINHERZ EL, 1981, NEW ENGL J MED, V304, P811, DOI 10.1056/NEJM198104023041403; REINHERZ EL, 1981, J CLIN INVEST, V68, P699, DOI 10.1172/JCI110305; ROCKLIN RE, 1980, CELL IMMUNOL, V51, P226, DOI 10.1016/0008-8749(80)90255-5; ROMAGNANI S, 1989, CLIN IMMUNOL IMMUNOP, V50, pS13, DOI 10.1016/0090-1229(89)90110-4; ROSEN FS, 1966, NEW ENGL J MED, V275, P709, DOI 10.1056/NEJM196609292751307; ROSEN FS, 1984, NEW ENGL J MED, V311, P235, DOI 10.1056/NEJM198407263110406; ROSENTHAL M, 1976, CLIN EXP IMMUNOL, V25, P493; SAIKI O, 1982, P NATL ACAD SCI-BIOL, V79, P6008, DOI 10.1073/pnas.79.19.6008; SAMPSON D, 1976, CANCER RES, V36, P952; SCHAFFER FM, 1989, P NATL ACAD SCI USA, V86, P8015, DOI 10.1073/pnas.86.20.8015; SCHULKIN.ML, 1972, CELL IMMUNOL, V3, P606, DOI 10.1016/0008-8749(72)90122-0; SCHWABER JF, 1981, CLIN IMMUNOL IMMUNOP, V19, P91, DOI 10.1016/0090-1229(81)90050-7; SEGAL R, 1989, J ALLERGY CLIN IMMUN, V84, P753, DOI 10.1016/0091-6749(89)90305-9; SHERR E, 1988, J EXP MED, V168, P55, DOI 10.1084/jem.168.1.55; SIDELL N, 1984, CELL IMMUNOL, V88, P374, DOI 10.1016/0008-8749(84)90170-9; SIDELL N, 1981, EXP CELL BIOL, V49, P239; SIDELL N, 1982, J NATL CANCER I, V68, P589; SOPPI E, 1982, J IMMUNOPHARMACOL, V4, P437; SOUILLET G, 1989, LANCET, V1, P1384; STEELE RW, 1972, NEW ENGL J MED, V287, P787, DOI 10.1056/NEJM197210192871602; STOHL W, 1986, J IMMUNOL, V136, P4407; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; TAKAGI S, 1989, J CLIN IMMUNOL, V9, P39, DOI 10.1007/BF00917126; THOMPSON RA, 1989, LANCET, V2, P630; TREURNIETDONKER AD, 1987, CANCER, V59, P1590, DOI 10.1002/1097-0142(19870501)59:9<1590::AID-CNCR2820590911>3.0.CO;2-R; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; TRIPODI D, 1973, NEW ENGL J MED, V289, P354, DOI 10.1056/NEJM197308162890707; UOTILA A, 1983, IMMUNOBIOLOGY TRANSF, P227; VALERIO D, 1984, GENE, V31, P147, DOI 10.1016/0378-1119(84)90205-1; VERCELLI D, 1990, J CLIN INVEST, V85, P1666, DOI 10.1172/JCI114618; VIRELIZIER JL, 1979, LANCET, V2, P696; VYAS GN, 1968, LANCET, V2, P312; WALDMANN TA, 1988, IMMUNOLOGICAL DISEAS, P411; WARA DW, 1975, NEW ENGL J MED, V292, P70, DOI 10.1056/NEJM197501092920204; WARA DW, 1978, TRANSPLANT P, V10, P203; WEENING RS, 1977, INFLAMMATION FUTURE, P445; WELTE K, 1985, CANCER INVEST, V3, P35, DOI 10.3109/07357908509040606; WHITE WB, 1985, NEW ENGL J MED, V312, P198, DOI 10.1056/NEJM198501243120402; WHITE WB, 1987, AM J MED, V83, P431, DOI 10.1016/0002-9343(87)90752-2; WILLIAMS DA, 1988, HEMATOL ONCOL CLIN N, V2, P277, DOI 10.1016/S0889-8588(18)30621-X; WILLIAMS DA, 1986, P NATL ACAD SCI USA, V83, P2566, DOI 10.1073/pnas.83.8.2566; WILSON GB, 1976, TRANSFER FACTOR BASI, P409; WRIGHT DG, 1977, J CLIN INVEST, V59, P941, DOI 10.1172/JCI108716; WU LYE, 1973, J CLIN INVEST, V52, P3180, DOI 10.1172/JCI107518; WYBRAN J, 1973, NEW ENGL J MED, V288, P710, DOI 10.1056/NEJM197304052881405; 1983, LANCET, V1, P1309	189	7	7	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					294	307		10.7326/0003-4819-115-4-294	http://dx.doi.org/10.7326/0003-4819-115-4-294			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854114				2022-12-28	WOS:A1991GA76400010
J	PETERS, AL; DAVIDSON, MB				PETERS, AL; DAVIDSON, MB			INSULIN PLUS A SULFONYLUREA AGENT FOR TREATING TYPE-2 DIABETES	ANNALS OF INTERNAL MEDICINE			English	Review						DIABETES-MELLITUS, NONINSULIN-DEPENDENT; INSULIN; SULFONYLUREA COMPOUNDS; GLYBURIDE; INSULIN RESISTANCE	ORAL HYPOGLYCEMIC AGENTS; CULTURED RAT HEPATOCYTES; SECONDARY FAILURE; DEPENDENT DIABETICS; GLUCOSE-METABOLISM; GLYBURIDE THERAPY; EXOGENOUS INSULIN; LIPID-METABOLISM; GLYCEMIC CONTROL; DOUBLE-BLIND	Purpose: To review the recent literature on the efficacy of combined insulin and sulfonylurea therapy in patients with type 2 diabetes. Data Sources: Pertinent articles were obtained through an English-language MEDLINE search from 1979 to 1990 and from the references of these articles. Study Selection: We reviewed the studies in which patients with poorly controlled diabetes received insulin and a sulfonylurea agent and in which insulin treatment alone (usually given in conjunction with a placebo) was compared with insulin plus sulfonylurea therapy. Data Extraction: Pre- and post-treatment insulin doses, blood glucose levels, glycated hemoglobin values, C-peptide levels, and insulin levels were analyzed. Other data were analyzed separately. Results of Data Synthesis: Data from similar trials were compared. Data from concurrent trials were analyzed separately from data derived from cross-over trials. Weighted mean fasting blood glucose levels, glycated hemoglobin levels, insulin dosage, and fasting C-peptide concentrations were determined for insulin plus placebo and insulin plus sulfonylurea agent groups for both types of studies. In concurrent trials, the weighted mean post-treatment glycated hemoglobin level was 11.1% after insulin plus placebo compared with 10.0% after insulin plus a sulfonylurea agent. In cross-over trials, the corresponding values were 10.6% and 9.8%. Conclusions: Combination therapy with insulin and a sulfonylurea agent only slightly improved glycemic control in patients with type 2 diabetes. When a sulfonylurea agent was used, less exogenous insulin was needed, but fasting serum insulin levels were not different between the treatment groups. Such therapy did not produce nearly normal blood glucose concentrations and therefore should not be used in patients with poorly controlled type 2 diabetes receiving insulin.	CEDARS SINAI MED CTR, DIV ENDOCRINOL, ROOM B-131, 8700 BEVERLY BLVD, LOS ANGELES, CA 90048 USA	Cedars Sinai Medical Center				Peters, Anne/0000-0003-0520-0776				ALLEN BT, 1985, ARCH INTERN MED, V145, P1900, DOI 10.1001/archinte.145.10.1900; ANDREWS WJ, 1984, DIABETES, V33, P634, DOI 10.2337/diabetes.33.7.634; [Anonymous], 1989, DIABETES CARE, V12, P573; BIEGER WP, 1984, KLIN WOCHENSCHR, V62, P631, DOI 10.1007/BF01721918; BRAND FN, 1989, DIABETES, V38, P504, DOI 10.2337/diabetes.38.4.504; CASNER PR, 1988, CLIN PHARMACOL THER, V44, P594, DOI 10.1038/clpt.1988.199; CASTILLO M, 1987, ACTA ENDOCRINOL-COP, V116, P364, DOI 10.1530/acta.0.1160364; CHU PC, 1968, ANN INTERN MED, V68, P757, DOI 10.7326/0003-4819-68-4-757; COUTURIER E, 1985, Diabetes Research and Clinical Practice, V1, P343, DOI 10.1016/S0168-8227(86)80047-X; DAVIDSON MB, 1987, METABOLISM, V36, P925, DOI 10.1016/0026-0495(87)90125-9; DAVIDSON MB, 1986, AM J MED SCI, V292, P35, DOI 10.1097/00000441-198607000-00007; FIRTH R, 1987, DIABETES, V36, P1130, DOI 10.2337/diabetes.36.10.1130; FIRTH RG, 1986, NEW ENGL J MED, V314, P1280, DOI 10.1056/NEJM198605153142003; FLEIG WE, 1984, DIABETES, V33, P285, DOI 10.2337/diabetes.33.3.285; FRIEDLANDER EO, 1957, NEW ENGL J MED, V257, P11, DOI 10.1056/NEJM195707042570103; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GREENFIELD MS, 1982, DIABETES, V31, P307, DOI 10.2337/diabetes.31.4.307; GROOP L, 1985, ACTA MED SCAND, V217, P33; GROOP L, 1984, ACTA ENDOCRINOL-COP, V106, P97, DOI 10.1530/acta.0.1060097; GUTNIAK M, 1987, DIABETES CARE, V10, P545, DOI 10.2337/diacare.10.5.545; HANSSEN KF, 1986, DIABETOLOGIA, V29, P677, DOI 10.1007/BF00870275; HOLMAN RR, 1987, DIABETIC MED, V4, P457, DOI 10.1111/j.1464-5491.1987.tb00909.x; HUGHES TA, 1985, AM J MED, V79, P86, DOI 10.1016/S0002-9343(85)80013-9; JARRETT RJ, 1988, DIABETOLOGIA, V31, P71, DOI 10.1007/BF00395550; JENG CY, 1989, DIABETIC MED, V6, P303, DOI 10.1111/j.1464-5491.1989.tb01169.x; JUDZEWITSCH RG, 1982, J CLIN ENDOCR METAB, V55, P321, DOI 10.1210/jcem-55-2-321; KINSELL LW, 1956, SCIENCE, V123, P585, DOI 10.1126/science.123.3197.585; KITABCHI AE, 1987, AM J MED SCI, V294, P10, DOI 10.1097/00000441-198707000-00002; KOLTERMAN OG, 1984, DIABETES, V33, P346, DOI 10.2337/diabetes.33.4.346; KYLLASTINEN M, 1985, ANN CLIN RES, V17, P100; LARDINOIS CK, 1985, ARCH INTERN MED, V145, P1028, DOI 10.1001/archinte.145.6.1028; LEWITT MS, 1989, DIABETES CARE, V12, P379, DOI 10.2337/diacare.12.6.379; LINS PE, 1988, ACTA MED SCAND, V223, P171; LONGNECKER MP, 1986, ARCH INTERN MED, V146, P673, DOI 10.1001/archinte.146.4.673; MALOFF BL, 1981, J CLIN INVEST, V68, P85, DOI 10.1172/JCI110257; MANDARINO LJ, 1984, DIABETES CARE, V7, P89; MAUERHOFF T, 1986, DIABETES METAB, V12, P34; OSEI K, 1984, AM J MED, V77, P1002, DOI 10.1016/0002-9343(84)90179-7; PFEIFER MA, 1982, DIABETES, V31, P154, DOI 10.2337/diabetes.31.2.154; QUATRARO A, 1986, DIABETES METAB, V12, P315; REAVEN G, 1967, DIABETES, V16, P487, DOI 10.2337/diab.16.7.487; REAVEN GM, 1983, AM J MED, V75, P8, DOI 10.1016/0002-9343(83)90248-6; REICH A, 1987, DIABETES RES CLIN EX, V6, P99; RIDDLE MC, 1989, DIABETES CARE, V12, P623, DOI 10.2337/diacare.12.9.623; RINNINGER F, 1984, DIABETOLOGIA, V26, P462; SALHANICK AI, 1983, DIABETES, V32, P206, DOI 10.2337/diabetes.32.3.206; SCHADE DS, 1987, JAMA-J AM MED ASSOC, V257, P2441, DOI 10.1001/jama.257.18.2441; SHAPIRO ET, 1989, J CLIN ENDOCR METAB, V69, P571, DOI 10.1210/jcem-69-3-571; SIMONSON DC, 1987, DIABETES, V36, P136, DOI 10.2337/diabetes.36.2.136; SIMONSON DC, 1984, DIABETES, V33, P838, DOI 10.2337/diabetes.33.9.838; STENMAN S, 1988, DIABETOLOGIA, V31, P206, DOI 10.1007/BF00290586; STOUT RW, 1990, DIABETES CARE, V13, P631, DOI 10.2337/diacare.13.6.631; VOLK BW, 1959, AM J MED SCI, V237, P1, DOI 10.1097/00000441-195901000-00001; WARD G, 1985, DIABETES, V34, P241, DOI 10.2337/diabetes.34.3.241	54	66	66	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1991	115	1					45	53		10.7326/0003-4819-115-1-45	http://dx.doi.org/10.7326/0003-4819-115-1-45			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT937	1828656				2022-12-28	WOS:A1991FT93700009
J	JOHNSON, EF				JOHNSON, EF			A PARTNERSHIP BETWEEN THE DIOXIN RECEPTOR AND A BASIC HELIX-LOOP-HELIX PROTEIN	SCIENCE			English	Editorial Material							HEAT-SHOCK PROTEIN; XENOBIOTIC RESPONSIVE ELEMENTS; DNA-BINDING ACTIVITY; AH RECEPTOR; PEROXISOME PROLIFERATORS; AROMATIC-HYDROCARBONS; P-450C GENE; SUPERFAMILY; ENHANCER; CYTOCHROME-P-450				JOHNSON, EF (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.							BARINAGA M, 1991, SCIENCE, V251, P1176, DOI 10.1126/science.1848724; CONNEY AH, 1982, CANCER RES, V42, P4875; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN B M, 1990, New Biologist, V2, P587; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GILLETTE JR, 1979, DRUG METAB REV, V10, P59, DOI 10.3109/03602537908993901; GREENLEE WF, 1990, PROG CLIN BIOL RES, V331, P177; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JOHNSON EF, 1980, CANCER RES, V40, P4456; JONES PBC, 1986, J BIOL CHEM, V261, P6647; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEMOTO T, 1990, J BIOL CHEM, V265, P2269; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; REDDY JK, 1989, MUTAT RES, V214, P63, DOI 10.1016/0027-5107(89)90198-X; REDDY JK, 1990, BIOCHEM SOC T, V18, P92, DOI 10.1042/bst0180092; ROBERTS L, 1991, SCIENCE, V251, P624, DOI 10.1126/science.1846976; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	28	16	16	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1991	252	5008					924	925		10.1126/science.1852074	http://dx.doi.org/10.1126/science.1852074			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	1852074				2022-12-28	WOS:A1991FM04000025
J	STOORVOGEL, W; STROUS, GJ; GEUZE, HJ; OORSCHOT, V; SCHWARTZ, AL				STOORVOGEL, W; STROUS, GJ; GEUZE, HJ; OORSCHOT, V; SCHWARTZ, AL			LATE ENDOSOMES DERIVE FROM EARLY ENDOSOMES BY MATURATION	CELL			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; MANNOSE 6-PHOSPHATE RECEPTOR; HEPATOMA-CELL LINE; HUMAN ASIALOTRANSFERRIN TYPE-3; ASIALOGLYCOPROTEIN RECEPTOR; IMMUNOELECTRON MICROSCOPY; LYSOSOMAL-ENZYME; RAT HEPATOCYTES; TRANSFERRIN RECEPTORS; FREE SYSTEM	Endocytosed proteins destined for degradation in lysosomes are targeted mainly to early endosomes following uptake. Late endosomes are the major site for entry of newly synthesized lysosomal hydrolases via the cation-independent mannose 6-phosphate receptor into the degradative pathway. No consensus exists as to the mechanism of transport from early to late endosomes. We used asialoorosomucoid and transferrin to label selected parts of the degradative and receptor-recycling pathways, respectively, in the human hepatoma cell line HepG2. Intracellular mixing of sequentially endocytosed I-125- and HRP-labeled ligands was monitored by using 3,3'-diaminobenzidine-mediated density perturbation. The entire endocytic pathway of asialoorosomucoid, except for the lysosomes, remained fully accessible to subsequently endocytosed transferrin conjugated to HRP with unchanged kinetics. These results together with immunoelectron microscopic data support a model in which early endosomes gradually mature into late endosomes.	ST LOUIS CHILDRENS HOSP, DEPT HEMATOL ONCOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, EDWARD MALLINKRODT DEPT PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PEDIAT, ST LOUIS, MO 63110 USA	St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	STOORVOGEL, W (corresponding author), STATE UNIV UTRECHT, SCH MED, DEPT CELL BIOL, HEIDELBERGLAAN 100, 3584 CX UTRECHT, NETHERLANDS.							AJIOKA RS, 1986, P NATL ACAD SCI USA, V83, P6445, DOI 10.1073/pnas.83.17.6445; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BENVENISTE M, 1989, J CELL BIOL, V109, P2105, DOI 10.1083/jcb.109.5.2105; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; BRETSCHER MS, 1984, CELL, V38, P3, DOI 10.1016/0092-8674(84)90519-1; BRIDGES K, 1982, P NATL ACAD SCI-BIOL, V79, P350, DOI 10.1073/pnas.79.2.350; CIECHANOVER A, 1983, CELL, V32, P267, DOI 10.1016/0092-8674(83)90517-2; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1981, J CELL BIOL, V89, P653, DOI 10.1083/jcb.89.3.653; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GEUZE HJ, 1983, EUR J CELL BIOL, V32, P38; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MUELLER SC, 1986, J CELL BIOL, V102, P932, DOI 10.1083/jcb.102.3.932; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; PASTAN IH, 1981, ANNU REV PHYSIOL, V43, P239, DOI 10.1146/annurev.ph.43.030181.001323; PEARSE BMF, 1987, EMBO J, V6, P2507, DOI 10.1002/j.1460-2075.1987.tb02536.x; PFEFFER SR, 1987, J CELL BIOL, V105, P229, DOI 10.1083/jcb.105.1.229; REGOECZI E, 1982, P NATL ACAD SCI-BIOL, V79, P2226, DOI 10.1073/pnas.79.7.2226; REGOECZI E, 1985, EXP CELL RES, V160, P1, DOI 10.1016/0014-4827(85)90230-7; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SALZMAN NH, 1988, J CELL BIOL, V106, P1083, DOI 10.1083/jcb.106.4.1083; SCHWARTZ AL, 1980, J BIOL CHEM, V255, P9033; SCHWARTZ AL, 1983, J BIOL CHEM, V258, P1249; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SIMMONS CF, 1984, MOL PHARMACOL, V26, P509; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SLOT JW, 1991, IN PRESS J CELL BIOL; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; TASSIN MT, 1990, EUR J CELL BIOL, V52, P219; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WALL DA, 1980, CELL, V21, P79, DOI 10.1016/0092-8674(80)90116-6; WARD DM, 1989, J BIOL CHEM, V264, P8164; WATTS C, 1984, EMBO J, V3, P1965, DOI 10.1002/j.1460-2075.1984.tb02077.x; WEIGEL PH, 1984, J BIOL CHEM, V259, P1150; WILLINGHAM MC, 1984, P NATL ACAD SCI-BIOL, V81, P175, DOI 10.1073/pnas.81.1.175; WILLINGHAM MC, 1980, CELL, V21, P67, DOI 10.1016/0092-8674(80)90115-4; WILLINGHAM MC, 1981, P NATL ACAD SCI-BIOL, V78, P6967, DOI 10.1073/pnas.78.11.6967; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375	56	258	261	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1991	65	3					417	427		10.1016/0092-8674(91)90459-C	http://dx.doi.org/10.1016/0092-8674(91)90459-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1850321				2022-12-28	WOS:A1991FK18200008
J	HUGIN, AW; VACCHIO, MS; MORSE, HC				HUGIN, AW; VACCHIO, MS; MORSE, HC			A VIRUS-ENCODED SUPERANTIGEN IN A RETROVIRUS-INDUCED IMMUNODEFICIENCY SYNDROME OF MICE	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MURINE LEUKEMIA VIRUSES; T-CELLS; MONOCLONAL-ANTIBODIES; SYNTHETIC PEPTIDES; CLONAL DELETION; C57BL/6 MICE; I-E; MLS; RECEPTOR	The development of an immunodeficiency syndrome of mice caused by a replication-defective murine leukemia virus (MuLV) is paradoxically associated with a rapid activation and proliferation of CD4+ T cells that are dependent on the presence of B cells. The responses of normal spleen cells to B cell lines that express the defective virus indicated that these lines express a cell surface determinant that shares "superantigenic" properties with some microbial antigens and Mls-like self antigens. This antigen elicited a potent proliferative response that was dependent on the presence of CD4+ T cells and was associated with selective expansion of cells bearing V-beta-5. This response was markedly inhibited by a monoclonal antibody specific for the MuLV gag-encoded p30 antigen.	NIAID,IMMUNOPATHOL LAB,BLDG 7,ROOM 304,BETHESDA,MD 20892; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Morse, Herbert/0000-0002-9331-3705	NIAID NIH HHS [N01-AI-72622] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI072622] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE R, 1987, J EXP MED, V166, P1150, DOI 10.1084/jem.166.4.1150; ABE R, 1988, NATURE, V335, P827, DOI 10.1038/335827a0; ABE R, 1988, IMMUNOL TODAY, V9, P230, DOI 10.1016/0167-5699(88)91221-2; ABRIGNANI S, 1990, P NATL ACAD SCI USA, V87, P6136, DOI 10.1073/pnas.87.16.6136; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BERZOFSKY JA, 1988, NATURE, V334, P706, DOI 10.1038/334706a0; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BILL J, 1990, J MOL CELL IMMUNOL, V4, P269; BULLER RML, 1987, J VIROL, V61, P383, DOI 10.1128/JVI.61.2.383-387.1987; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; CERNY A, 1990, J EXP MED, V171, P315, DOI 10.1084/jem.171.1.315; CERNY A, 1990, EUR J IMMUNOL, V20, P1577, DOI 10.1002/eji.1830200725; CERNY A, UNPUB; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; CHATTOPADHYAY SK, UNPUB; CHESEBRO B, 1983, VIROLOGY, V127, P134, DOI 10.1016/0042-6822(83)90378-1; CHEUNG SC, 1991, J VIROL, V65, P823, DOI 10.1128/JVI.65.2.823-828.1991; CHEUNG SC, 1991, J IMMUNOL, V146, P121; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; COLE BC, 1989, J IMMUNOL, V142, P4131; COLE BC, 1990, J IMMUNOL, V144, P425; COLE BC, 1990, J IMMUNOL, V144, P20; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FISCHER H, 1989, J IMMUNOL, V142, P3151; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914; HAMELINBOURASSA D, 1989, IMMUNOGENETICS, V30, P266, DOI 10.1007/BF02421330; HARTLEY JW, 1989, J VIROL, V63, P1223, DOI 10.1128/JVI.63.3.1223-1231.1989; HUANG M, 1989, SCIENCE, V246, P1614, DOI 10.1126/science.2480643; HUANG M, 1990, J VIROL, V64, P5764, DOI 10.1128/JVI.64.12.5764-5772.1990; HUGIN AW, UNPUB; JANEWAY CA, 1985, J IMMUNOL, V134, P2057; JANEWAY CA, 1988, J IMMUNOGENET, V15, P161; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KLINKEN SP, 1988, J IMMUNOL, V140, P1123; KLINMAN DM, 1989, J IMMUNOL, V142, P1144; KROWKA J, 1990, J IMMUNOL, V144, P2535; LEGRAND E, 1981, LEUKEMIA RES, V5, P223, DOI 10.1016/0145-2126(81)90107-7; LIAO NS, 1990, J IMMUNOL, V144, P844; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MAKINO M, 1990, J IMMUNOL, V144, P4347; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MORSE HC, 1989, J IMMUNOL, V143, P844; MOSIER DE, 1985, J EXP MED, V161, P766, DOI 10.1084/jem.161.4.766; NAIR MPN, 1988, P NATL ACAD SCI USA, V85, P6498, DOI 10.1073/pnas.85.17.6498; NORTON SD, 1990, J IMMUNOL, V144, P2089; OKADA CY, 1989, J EXP MED, V169, P1703, DOI 10.1084/jem.169.5.1703; PECK AB, 1977, NATURE, V266, P840, DOI 10.1038/266840a0; PITHA PM, 1988, J IMMUNOL, V141, P3611; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; REICH EP, 1989, NATURE, V341, P326, DOI 10.1038/341326a0; ROSENBERG AS, 1991, TRANSPLANT P, V23, P167; SCHNEIDER R, 1989, J EXP MED, V169, P2149, DOI 10.1084/jem.169.6.2149; SCHRIER RD, 1989, J IMMUNOL, V142, P1166; SICILIANO RF, 1989, J IMMUNOL, V142, P1506; STAERZ UD, 1985, J IMMUNOL, V134, P3994; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; YETTER RA, 1988, J EXP MED, V168, P623, DOI 10.1084/jem.168.2.623; ZALLER DM, 1990, J EXP MED, V171, P1943, DOI 10.1084/jem.171.6.1943	63	209	220	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					424	427		10.1126/science.1850169	http://dx.doi.org/10.1126/science.1850169			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	1850169				2022-12-28	WOS:A1991FH10300038
J	BUCK, L; AXEL, R				BUCK, L; AXEL, R			A NOVEL MULTIGENE FAMILY MAY ENCODE ODORANT RECEPTORS - A MOLECULAR-BASIS FOR ODOR RECOGNITION	CELL			English	Article							SENSITIVE ADENYLATE-CYCLASE; TROUT OLFACTORY ROSETTES; BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; SPATIAL-DISTRIBUTION; BINDING-SPECIFICITY; LIGAND-BINDING; GENES; CILIA; IDENTIFICATION	The mammalian olfactory system can recognize and discriminate a large number of different odorant molecules. The detection of chemically distinct odorants presumably results from the association of odorous ligands with specific receptors on olfactory sensory neurons. To address the problem of olfactory perception at a molecular level, we have cloned and characterized 18 different members of an extremely large multigene family that encodes seven transmembrane domain proteins whose expression is restricted to the olfactory epithelium. The members of this novel gene family are likely to encode a diverse family of odorant receptors.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	BUCK, L (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.			Axel, Richard/0000-0002-3141-4076	NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA 23767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amoore JE., 1982, FRAGRANCE CHEM SCI S, P27; BALTIMORE D, 1981, CELL, V24, P592, DOI 10.1016/0092-8674(81)90082-9; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BRONSHTEIN AA, 1977, TSITOLOGIYA+, V19, P33; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DOVING KB, 1980, ACTA PHYSIOL SCAND, V108, P123, DOI 10.1111/j.1748-1716.1980.tb06509.x; EGEL R, 1981, NATURE, V290, P191, DOI 10.1038/290191a0; FLANAGAN JG, 1984, CELL, V36, P681, DOI 10.1016/0092-8674(84)90348-9; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HOOD L, 1985, CELL, V40, P225, DOI 10.1016/0092-8674(85)90133-3; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; MACKAYSIM A, 1982, J NEUROPHYSIOL, V48, P584, DOI 10.1152/jn.1982.48.2.584; MAEDA N, 1986, ANNU REV GENET, V20, P81; Maniatis T., 1982, MOL CLONING; MOULTON DG, 1967, PHYSIOL REV, V47, P1, DOI 10.1152/physrev.1967.47.1.1; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; REED RR, 1990, CELL, V60, P1, DOI 10.1016/0092-8674(90)90706-K; RHEIN LD, 1983, J NEUROCHEM, V41, P569, DOI 10.1111/j.1471-4159.1983.tb04777.x; RHEIN LD, 1980, P NATL ACAD SCI-BIOL, V77, P4412, DOI 10.1073/pnas.77.8.4412; RUSHTON W A, 1955, J Physiol, V129, P41; RUSHTON WAH, 1965, J PHYSIOL-LONDON, V176, P24, DOI 10.1113/jphysiol.1965.sp007532; Sambrook J, 1989, MOL CLONING LABORATO; SHEPHERD GM, 1985, TASTE OLFACTION CENT, P307; SICARD G, 1985, BRAIN RES, V326, P203, DOI 10.1016/0006-8993(85)90029-0; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; THOMMESEN G, 1978, ACTA PHYSIOL SCAND, V102, P205, DOI 10.1111/j.1748-1716.1978.tb06064.x; THOMMESEN G, 1977, ACTA PHYSIOL SCAND, V99, P270, DOI 10.1111/j.1748-1716.1977.tb10380.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANDERPLOEG L, 1991, GENE REARRANGEMENT, P51; WALD G, 1955, J GEN PHYSIOL, V38, P623, DOI 10.1085/jgp.38.5.623	44	3439	3645	25	503	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					175	187		10.1016/0092-8674(91)90418-X	http://dx.doi.org/10.1016/0092-8674(91)90418-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1840504	Bronze			2022-12-28	WOS:A1991FF77300019
J	BEITMAN, BD; KUSHNER, MG; BASHA, I; LAMBERTI, J; MUKERJI, V; BARTELS, K				BEITMAN, BD; KUSHNER, MG; BASHA, I; LAMBERTI, J; MUKERJI, V; BARTELS, K			FOLLOW-UP STATUS OF PATIENTS WITH ANGIOGRAPHICALLY NORMAL CORONARY-ARTERIES AND PANIC DISORDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHEST PAIN; PSYCHIATRIC-ILLNESS; MAJOR DEPRESSION; CLINICAL COURSE; ARTERIOGRAMS; ANGINA	Cardiology patients with normal coronary angiography demonstrate continuing and substantial social, health, and work disability. We hypothesized that the diagnosis of panic disorder would mark those for whom continuing disability is most likely. We interviewed 72 such patients at the time of their normal angiogram, and then again an average of 38 months later. Those with panic disorder (n = 36) demonstrated significantly more disability at follow-up than did the other study patients. We conclude that those patients with normal angiograms who have panic disorder are more disabled than those who do not have panic disorder. Panic disorder in psychiatric samples have been shown to be highly treatable. Therefore, early identification and treatment of panic disorder in this group is likely to minimize the suffering associated with this condition.										BALLENGER JC, 1986, J CLIN PSYCHIAT, V47, P27; Barlow DH., 2002, ANXIETY ITS DISORDER, VSecond; BASS C, 1983, BRIT MED J, V287, P1505, DOI 10.1136/bmj.287.6404.1505; BEITMAN BD, 1989, AM J CARDIOL, V63, P1399, DOI 10.1016/0002-9149(89)91056-4; BEITMAN BD, 1987, J AFFECT DISORDERS, V13, P51, DOI 10.1016/0165-0327(87)90073-5; BEITMAN BD, 1990, INTERN MED SPEC, V11, P91; BEMILLER CR, 1973, CIRCULATION, V47, P36, DOI 10.1161/01.CIR.47.1.36; BREIER A, 1984, ARCH GEN PSYCHIAT, V41, P1129; CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; CANNON RO, 1990, PRIM CARDIOL, V16, P15; CLOUSE RE, 1983, NEW ENGL J MED, V309, P1337, DOI 10.1056/NEJM198312013092201; COLGAN SM, 1988, POSTGRAD MED J, V64, P743, DOI 10.1136/pgmj.64.756.743; COLOMBOT.J, 1969, PUBLIC HEALTH REP, V84, P773, DOI 10.2307/4593676; DAY LJ, 1976, LANCET, V2, P334; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; EDLUND MJ, 1987, HOSP COMMUNITY PSYCH, V38, P1277; EDLUND MJ, 1987, HOSP COMMUNITY PSYCH, V38, P1288; FAXON DP, 1982, AM J MED, V73, P500, DOI 10.1016/0002-9343(82)90328-X; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; ISNER JM, 1981, AM HEART J, V102, P645, DOI 10.1016/0002-8703(81)90088-0; KATON W, 1988, AM J MED, V84, P1, DOI 10.1016/0002-9343(88)90001-0; KEMP HG, 1973, AM J MED, V54, P735, DOI 10.1016/0002-9343(73)90060-0; KOZAK LJ, 1985, VITAL HLTH STAT, V13; KUSHNER MG, 1990, AM J PSYCHIAT, V147, P685; LAVEY EB, 1979, J CHRON DIS, V32, P191, DOI 10.1016/0021-9681(79)90064-X; MARCHANDISE B, 1978, AM J CARDIOL, V41, P216, DOI 10.1016/0002-9149(78)90159-5; MARKOWITZ JS, 1989, ARCH GEN PSYCHIAT, V46, P984; MARKS IM, 1979, BEHAV RES THER, V17, P263, DOI 10.1016/0005-7967(79)90041-X; OKENE IS, 1980, NEW ENGL J MED, V303, P1249; PAPANICOLAOU MN, 1986, AM J CARDIOL, V58, P1181, DOI 10.1016/0002-9149(86)90378-4; PASTERNAK RC, 1980, AM J MED, V68, P813, DOI 10.1016/0002-9343(80)90199-0; PROUDFIT WL, 1980, CIRCULATION, V62, P712, DOI 10.1161/01.CIR.62.4.712; RICHTER JE, 1989, ANN INTERN MED, V110, P66, DOI 10.7326/0003-4819-110-1-66; ROYBYRNE PP, 1989, INT J PSYCHIAT MED, V19, P315; RUBIN LN, 1984, ARCH GEN PSYCHIAT, V41, P949; SPITZER RL, 1983, STRUCTURED CLIN INTE; WAXLER EB, 1971, AM J CARDIOL, V28, P25, DOI 10.1016/0002-9149(71)90030-0; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111; WOOLEY CF, 1976, CIRCULATION, V53, P749, DOI 10.1161/01.CIR.53.5.749; ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P271; 1987, DIAGNOSTIC STATISTIC	41	72	73	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1545	1549		10.1001/jama.265.12.1545	http://dx.doi.org/10.1001/jama.265.12.1545			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FC604	1825675				2022-12-28	WOS:A1991FC60400029
J	DAVIES, CH; STARKEY, SJ; POZZA, MF; COLLINGRIDGE, GL				DAVIES, CH; STARKEY, SJ; POZZA, MF; COLLINGRIDGE, GL			GABA-B AUTORECEPTORS REGULATE THE INDUCTION OF LTP	NATURE			English	Article							D-ASPARTATE RECEPTORS; COLLATERAL-COMMISSURAL PATHWAY; SYNAPTIC TRANSMISSION; RAT HIPPOCAMPUS; DEPENDENT DEPRESSION; POTENTIATION; INHIBITION; INVITRO; NEURONS; CULTURE	UNDERSTANDING the mechanisms involved in long-term potentiation (LTP) should provide insights into the cellular and molecular basis of learning and memory in vertebrates 1. It has been established that in the CA1 region of the hippocampus the induction of LTP requires the transient activation of the N-methyl-D-aspartate (NMDA) receptor system 21. During low-frequency transmission, significant activation of this system is prevented by gamma-aminobutyric acid (GABA) mediated synaptic inhibition 3,4 which hyperpolarizes neurons into a region where NMDA receptor-operated channels are substantially blocked by Mg2+ (refs. 5, 6). But during high-frequency transmission, mechanisms are evoked that provide sufficient depolarization of the postsynaptic membrane to reduce this block 7 and thereby permit the induction of LTP. We now report that this critical depolarization is enabled because during high-frequency transmission GABA depresses its own release by an action on GABA(B) autoreceptors, which permits sufficient NMDA receptor activation for the induction of LTP. These findings demonstrate a role for GABA(B) receptors in synaptic plasticity.	UNIV BIRMINGHAM, SCH MED, DEPT INTERNAL MED, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; UNIV BRISTOL, SCH MED SCI, DEPT PHARMACOL, BRISTOL BS8 1TD, AVON, ENGLAND	University of Birmingham; University of Bristol			Collingridge, Graham L/C-4605-2015; collingridge, graham/AAI-8362-2020	Collingridge, Graham L/0000-0002-9572-5359; 				ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BENARI Y, 1979, CAN J PHYSIOL PHARM, V57, P1462, DOI 10.1139/y79-218; BLISS TVP, 1988, NEUROLOGY NEUROBIOLO, V35, P3; COAN EJ, 1985, NEUROSCI LETT, V53, P21, DOI 10.1016/0304-3940(85)90091-6; COLLINGRIDGE GL, 1988, J PHYSIOL-LONDON, V399, P283; COLLINGRIDGE GL, 1988, J PHYSIOL-LONDON, V399, P301; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; DINGLEDINE R, 1986, J PHYSIOL-LONDON, V380, P175, DOI 10.1113/jphysiol.1986.sp016279; DUTAR P, 1988, NEURON, V1, P585, DOI 10.1016/0896-6273(88)90108-0; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; HARRISON NL, 1990, J PHYSIOL-LONDON, V422, P433, DOI 10.1113/jphysiol.1990.sp017993; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; LANTHORN TH, 1981, BRAIN RES, V225, P171, DOI 10.1016/0006-8993(81)90326-7; LARSON J, 1988, BRAIN RES, V441, P111, DOI 10.1016/0006-8993(88)91388-1; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MCCARREN M, 1985, J NEUROPHYSIOL, V53, P557, DOI 10.1152/jn.1985.53.2.557; MOTT DD, 1990, NEUROSCI LETT, V113, P222, DOI 10.1016/0304-3940(90)90307-U; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; OLPE HR, 1990, N-S ARCH PHARMACOL, V342, P194, DOI 10.1007/BF00166964; OLPE HR, 1990, EUR J PHARMACOL, V187, P27, DOI 10.1016/0014-2999(90)90337-6; RANDALL AD, 1990, J PHYSIOL-LONDON, V426, pP51; WIGSTROM H, 1983, NATURE, V301, P603, DOI 10.1038/301603a0	25	491	495	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 14	1991	349	6310					609	611		10.1038/349609a0	http://dx.doi.org/10.1038/349609a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	1847993				2022-12-28	WOS:A1991EX57000059
J	ERDMANN, R; WIEBEL, FF; FLESSAU, A; RYTKA, J; BEYER, A; FROHLICH, KU; KUNAU, WH				ERDMANN, R; WIEBEL, FF; FLESSAU, A; RYTKA, J; BEYER, A; FROHLICH, KU; KUNAU, WH			PAS1, A YEAST GENE REQUIRED FOR PEROXISOME BIOGENESIS, ENCODES A MEMBER OF A NOVEL FAMILY OF PUTATIVE ATPASES	CELL			English	Article							SACCHAROMYCES-CEREVISIAE GENE; PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; SENSITIVE METHOD; BETA-OXIDATION; LACZ FUSIONS; SEQUENCE; TRANSFORMATION; MEMBRANE	PAS genes are required for peroxisome biogenesis in the yeast S. cerevisiae. Here we describe the cloning, sequencing, and characterization of the PAS1 gene. Its gene product, Pas1p, has been identified as a rather hydrophilic 117 kd polypeptide. The predicted Pas1p sequence contains two putative ATP-binding sites and reveals a structural relationship to three other groups of proteins associated with different biological processes such as vesicle-mediated protein transport (NSF and Sec18p), control of cell cycle (Cdc48p, VCP, and p97-ATPase), and modulation of gene expression of the human immunodeficiency virus (TBP-1). The proteins share a highly conserved domain of about 185 amino acids including a consensus sequence for ATP binding. We suggest that these proteins are members of a novel family of putative ATPases and may be descendants of one common ancestor.			ERDMANN, R (corresponding author), RUHR UNIV BOCHUM,INST PHYSIOL CHEM,ZELLBIOCHEM ABT,W-4630 BOCHUM 1,GERMANY.							Ausubel FM, 1988, MOL REPROD DEV; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BORST P, 1989, BIOCHIM BIOPHYS ACTA, V1008, P1, DOI 10.1016/0167-4781(89)90163-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUSCHI CV, 1987, YEAST, V3, P131, DOI 10.1002/yea.320030209; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DELAGARZA MM, 1985, EUR J BIOCHEM, V148, P285, DOI 10.1111/j.1432-1033.1985.tb08837.x; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DOOLITTLE RF, 1986, COLD SPRING HARB SYM, V51, P447, DOI 10.1101/SQB.1986.051.01.054; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KOERNER TJ, 1990, IN PRESS METH ENZYMO; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LAZAROW PB, 1978, J BIOL CHEM, V253, P1522; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LIN HC, 1985, ANAL BIOCHEM, V147, P114, DOI 10.1016/0003-2697(85)90016-8; Maniatis T., 1982, MOL CLONING; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; RUBY SW, 1983, METHOD ENZYMOL, V101, P253; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SCHUTGENS RBH, 1986, EUR J PEDIATR, V144, P430, DOI 10.1007/BF00441734; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; Sherman F., 1986, METHODS YEAST GENETI; SHORTLE D, 1982, SCIENCE, V217, P371, DOI 10.1126/science.7046050; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WIEMER EAC, 1989, EUR J CELL BIOL, V50, P407; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	49	300	307	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					499	510		10.1016/0092-8674(91)90234-P	http://dx.doi.org/10.1016/0092-8674(91)90234-P			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1825027				2022-12-28	WOS:A1991EX36100006
J	MASON, JO				MASON, JO			PROTECTING PHYSICIANS FROM VACCINE LIABILITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MASON, JO (corresponding author), US PHS,WASHINGTON,DC 20201, USA.							1991, JAMA-J AM MED ASSOC, V266, P2958; 1991, JAMA-J AM MED ASSOC, V266, P2959	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2951	2951						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GR775	1820459				2022-12-28	WOS:A1991GR77500005
J	SPITAL, A				SPITAL, A			THE SHORTAGE OF ORGANS FOR TRANSPLANTATION - WHERE DO WE GO FROM HERE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PRESUMED CONSENT LAW; PUBLIC-ATTITUDES; KIDNEY DONATION; DONORS; PROCUREMENT				SPITAL, A (corresponding author), UNIV MARYLAND,COLLEGE PK,MD 20742, USA.							ANAISE D, 1990, TRANSPLANTATION, V49, P290, DOI 10.1097/00007890-199002000-00013; BART KJ, 1981, TRANSPLANTATION, V31, P379, DOI 10.1097/00007890-198105010-00015; BENOIT G, 1990, TRANSPLANT P, V22, P320; CAPLAN AL, 1989, CLIN TRANSPLANT, V3, P170; CAPLAN AL, 1983, HASTINGS CENT REP, V13, P23, DOI 10.2307/3560741; CAPLAN AL, 1984, NEW ENGL J MED, V311, P981, DOI 10.1056/NEJM198410113111510; COHEN B, 1985, SCAND J UROL NEPHROL, V92, P77; CORLETT S, 1985, TRANSPLANT P, V17, P103; CWIEK MA, 1984, PUBLIC LAW FORUM, V4, P81; DECHESSER AD, 1986, HEART LUNG, V15, P547; DUKEMINI.J, 1968, NEW ENGL J MED, V279, P413, DOI 10.1056/NEJM196808222790807; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; KATZ BJ, 1984, BEVERLY HILLS BA SUM, P152; KENNEDY I, 1979, J MED ETHICS, V5, P13, DOI 10.1136/jme.5.1.13; LOEWY EH, 1989, TXB MED ETHICS, P109; MACKERSIE RC, 1991, ANN SURG, V213, P143, DOI 10.1097/00000658-199102000-00009; MANNINEN DL, 1985, JAMA-J AM MED ASSOC, V253, P3111, DOI 10.1001/jama.253.21.3111; MARGREITER R, 1987, TRANSPLANT P, V19, P79; Matas A J, 1984, Theor Med, V5, P155, DOI 10.1007/BF00489488; MILLER M, 1987, CIRCULATION, V75, P20, DOI 10.1161/01.CIR.75.1.20; OVERCAST TD, 1984, JAMA-J AM MED ASSOC, V251, P1559, DOI 10.1001/jama.251.12.1559; RANDALL T, 1991, JAMA-J AM MED ASSOC, V265, P1223, DOI 10.1001/jama.265.10.1223; RAPAPORT FT, 1991, TRANSPLANT P, V23, P899; ROELS L, 1990, TRANSPLANT P, V22, P2078; SADLER AM, 1968, J AMER MED ASSOC, V206, P2501, DOI 10.1001/jama.1968.03150110049007; SADLER AM, 1969, NEW ENGL J MED, V280, P862, DOI 10.1056/NEJM196904172801605; SELLS RA, 1979, J MED ETHICS, V5, P165, DOI 10.1136/jme.5.4.165; SINGER PA, 1990, ARCH INTERN MED, V150, P523, DOI 10.1001/archinte.150.3.523; SINGER PA, 1989, NEW ENGL J MED, V321, P620, DOI 10.1056/NEJM198908313210919; SPITAL A, 1988, TRANSPL P, V20, P1051; STUART FP, 1981, TRANSPLANTATION, V31, P238, DOI 10.1097/00007890-198104000-00002; WILLIAMS RH, 1969, ARCH INTERN MED, V124, P215, DOI 10.1001/archinte.124.2.215; 1991, UNOS UPDATE, V7, P14; 1989, END STAGE DISEASE PR	34	92	92	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1243	1246		10.1056/NEJM199110243251710	http://dx.doi.org/10.1056/NEJM199110243251710			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1845039				2022-12-28	WOS:A1991GL28200010
J	STEWART, LA				STEWART, LA			CHEMOTHERAPY IN ADVANCED OVARIAN-CANCER - AN OVERVIEW OF RANDOMIZED CLINICAL-TRIALS	BRITISH MEDICAL JOURNAL			English	Article							ADRIAMYCIN PLUS CYCLOPHOSPHAMIDE; LONG-TERM SURVIVAL; STAGE-III; COMBINATION CHEMOTHERAPY; SINGLE AGENT; CIS-PLATINUM; CARCINOMA; CISPLATIN; MELPHALAN; IV	Objectives - To consider the role of platinum and the relative merits of single agent and combination chemotherapy in the treatment of advanced ovarian cancer. Design - Formal quantitative overview using updated individual patient data from all available randomised trials (published and unpublished). Subjects - 8139 patients (6408 deaths) included in 45 different trials. Results - No firm conclusions could be reached. Nevertheless, the results suggest that in terms of survival immediate platinum based treatment was better than non-platinum regimens (overall relative risk 0.93; 95% confidence interval 0.83 to 1.05); platinum in combination was better than single agent platinum when used in the same dose (overall relative risk 0.85; 0.72 to 1.00); and cisplatin and carboplatin were equally effective (overall relative risk 1.05; 0.94 to 1.18). Conclusions - In the past, randomised clinical trials of chemotherapy in advanced ovarian cancer have been much too small to detect the degree of benefit which this overview suggests is realistic for currently available chemotherapeutic regimens. Hence a new trial comparing cisplatin, doxorubicin, and cyclophosphamide (CAP) with carboplatin has been launched and plans to accrue 2000 patients.			STEWART, LA (corresponding author), MRC,CANC TRIALS OFF,1 BROOKLANDS AVE,CAMBRIDGE CB2 2BB,ENGLAND.		; CONTE, PIERFRANCO/F-7418-2014	Stewart, Lesley/0000-0003-0287-4724; Bruckner, Dr. Howard/0000-0002-7459-7255; CONTE, PIERFRANCO/0000-0002-5210-5344; Bolis, Giorgio/0000-0001-8216-0080				AABO K, 1985, EUR J CANCER CLIN ON, V21, P475, DOI 10.1016/0277-5379(85)90040-9; ADAMS M, 1989, ACTA ONCOL, V28, P57, DOI 10.3109/02841868909111182; ADAMS M, 1982, CLIN RADIOL, V33, P161, DOI 10.1016/S0009-9260(82)80049-4; ALBERTS D, 1989, P AN M AM SOC CLIN, V8, P588; ANDERSON H, 1988, EUR J CANCER CLIN ON, V24, P1471, DOI 10.1016/0277-5379(88)90338-0; BARLOW JJ, 1985, AM J OBSTET GYNECOL, V152, P310, DOI 10.1016/S0002-9378(85)80218-0; BELL DR, 1982, AUST NZ J MED, V12, P245, DOI 10.1111/j.1445-5994.1982.tb02469.x; BERTELSEN K, 1978, GYNECOL ONCOL, V62, P1375; BOLIS G, 1980, CANCER CHEMOTH PHARM, V4, P129; BRODOVSKY HS, 1984, CANCER-AM CANCER SOC, V53, P844, DOI 10.1002/1097-0142(19840215)53:4<844::AID-CNCR2820530405>3.0.CO;2-N; BRUCKNER HW, 1979, CANCER TREAT REP, V63, P297; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; CARMOPEREIRA J, 1983, CANCER CHEMOTH PHARM, V10, P100, DOI 10.1007/BF00446218; CARMOPEREIRA J, 1981, CANCER, V48, P1947, DOI 10.1002/1097-0142(19811101)48:9<1947::AID-CNCR2820480906>3.0.CO;2-M; CHYLAK V, 1986, LIJEC VJESEN, V109, P230; COHEN CJ, 1983, AM J OBSTET GYNECOL, V145, P955, DOI 10.1016/0002-9378(83)90849-9; CONTE PF, IN PRESS J CLIN ONCO; CROWTHER D, 1986, UNPUB RANDOMISED TRI; de Oliveira C F, 1990, Eur J Gynaecol Oncol, V11, P323; DECKER DG, 1982, OBSTET GYNECOL, V60, P481; DELGADO G, 1985, AM J CLIN ONCOL-CANC, V8, P33, DOI 10.1097/00000421-198502000-00042; DEPALO GM, 1977, CANCER TREAT REP, V61, P355; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; EDMONSON JH, 1989, J NATL CANCER I, V81, P1500, DOI 10.1093/jnci/81.19.1500; EDMONSON JH, 1979, CANCER TREAT REP, V61, P355; GILBY E, UNPUB OVARIAN CANCER; GRONROOS M, 1984, EUR J OBSTET GYN R B, V17, P33, DOI 10.1016/0028-2243(84)90078-9; HARVEY HA, 1982, CLIN RES, V30, P418; HUBBARD SM, 1978, CANCER TREAT REP, V62, P1375; HUININK WWT, 1988, CANCER TREAT REV, V15, P9, DOI 10.1016/0305-7372(88)90030-8; KATO T, 1988, JPN J CANC CHEMOTHER, V15, P2297; KEYE S, UNPUB RANDOMISED STU; LEONARD RCF, 1989, CANCER CHEMOTH PHARM, V23, P105; MANGIONI C, 1989, J NATL CANCER I, V81, P1464, DOI 10.1093/jnci/81.19.1464; MARSONI S, 1990, ANN ONCOL, V1, P343, DOI 10.1093/oxfordjournals.annonc.a057772; MASDING J, 1990, BRIT J OBSTET GYNAEC, V97, P342, DOI 10.1111/j.1471-0528.1990.tb01813.x; MEERPOIHL HG, 1990, UNPUB 15TH INT CANC; MILLER A, 1980, CAN MED ASSOC J, V123, P363; OMURA G, 1986, CANCER, V57, P1725, DOI 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J; OMURA GA, 1989, J CLIN ONCOL, V7, P457, DOI 10.1200/JCO.1989.7.4.457; OMURA GA, 1983, CANCER, V51, P783, DOI 10.1002/1097-0142(19830301)51:5<783::AID-CNCR2820510506>3.0.CO;2-Z; PARK RC, 1980, CANCER-AM CANCER SOC, V45, P2529, DOI 10.1002/1097-0142(19800515)45:10<2529::AID-CNCR2820451011>3.0.CO;2-4; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PATER J, 1990, P AM SOC CLIN ONCOL, V9, P121; SENN HJ, 1980, SCHWEIZ MED WSCHR, V110, P1202; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; STURGEON JFG, 1982, P AN M AM SOC CLIN, V1, P108; TOMIROTTI M, 1988, TUMORI, V74, P573, DOI 10.1177/030089168807400514; TROPE C, 1987, OBSTET GYNECOL, V70, P582; TURBOOW MM, 1980, UNPUB CHEMOTHERAPY A; TURBOW MM, 1980, P AM ASSOC CANC RES, V21, P196; VOGL SE, 1982, P AN M AM SOC CLIN, V1, P119; WHARTON JT, 1984, AM J OBSTET GYNECOL, V148, P997, DOI 10.1016/0002-9378(84)90543-X; WILBUR DW, 1987, J SURG ONCOL, V34, P165, DOI 10.1002/jso.2930340306; WILLIAMS CJ, 1985, J CLIN ONCOL, V3, P1455, DOI 10.1200/JCO.1985.3.11.1455; WILLIAMS CJ, 1979, CANCER TREAT REP, V63, P1745; WILLIAMS CJ, 1982, CANCER TREAT REP, V63, P311; WILTSHAW E, 1976, CANCER TREAT REP, V60, P55; WILTSHAW E, 1986, J CLIN ONCOL, V4, P722, DOI 10.1200/JCO.1986.4.5.722; WILTSHAW E, 1985, P AN M AM SOC CLIN, V4, P121; YOUNG RC, 1978, NEW ENGL J MED, V299, P1261, DOI 10.1056/NEJM197812072992301; 1986, UK CANCER TRIALS REG; UNPUB INADEQUACY TRI; IN PRESS J CLIN ONCO; 1990, BRIT J CANCER, V61, P495; 1987, LANCET, V2, P353; 1981, BRIT J OBSTET GYNAEC, V88, P1174; 1986, GYNECOL ONCOL, V23, P1	68	279	279	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 12	1991	303	6807					884	893						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK221	1834291				2022-12-28	WOS:A1991GK22100021
J	KITAMURA, T; SATO, N; ARAI, K; MIYAJIMA, A				KITAMURA, T; SATO, N; ARAI, K; MIYAJIMA, A			EXPRESSION CLONING OF THE HUMAN IL-3 RECEPTOR CDNA REVEALS A SHARED BETA-SUBUNIT FOR THE HUMAN IL-3 AND GM-CSF RECEPTORS	CELL			English	Article							COLONY-STIMULATING FACTOR; MURINE INTERLEUKIN-4 RECEPTOR; MOLECULAR-CLONING; LEUKEMIA-CELLS; LIGAND-BINDING; GENE FAMILY; PROTEINS; MEMBER; GROWTH; LINE	A cDNA for a human interleukin-3 (hIL-3) binding protein has been isolated by a novel expression cloning strategy: a cDNA library was coexpressed with the cDNA for the beta-subunit of human granulocyte/macrophage colony-stimulating factor (GM-CSF) receptor (hGMR-beta) in COS7 cells and screened by binding of I-125-labeled IL-3. The cloned cDNA (DUK-1) encodes a mature protein of 70 kd, which belongs to the cytokine receptor family and which alone binds hIL-3 with extremely low affinity (K(d) = 120 +/- 60 nM). A high affinity IL-3-binding site (K(d) = 140 +/- 30 pM) was reconstituted by coexpressing the DUK-1 protein and hGMR-beta, indicating that hIL-3R and hGMR share the beta-subunit. Therefore, we designated DUK-1 as the alpha-subunit of the hIL-3R. As in human hematopoietic cells, hIL-3 and hGM-CSF compete for binding in fibroblasts expressing the cDNAs for hIL-3R-alpha, GMR-alpha, and the common beta-subunit, indicating that different alpha-subunits compete for a common beta-subunit.	UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo	KITAMURA, T (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,901 CALIF AVE,PALO ALTO,CA 94304, USA.		Sato, Noriko/Y-7693-2019; Kitamura, Toshio/AAA-2071-2021					BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BUDEL LM, 1990, BLOOD, V75, P1439; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIBA S, 1990, CELL REGUL, V1, P327, DOI 10.1091/mbc.1.4.327; CHIBA S, 1990, LEUKEMIA, V4, P29; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; ELIOTT MJ, 1989, BLOOD, V74, P2349; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1989, EMBO J, V8, P3367; GESNER TG, 1988, J CELL PHYSIOL, V136, P493, DOI 10.1002/jcp.1041360314; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1990, BLOOD, V76, P706; KITAMURA T, 1991, INT IMMUNOL, V3, P571, DOI 10.1093/intimm/3.6.571; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUWAKI T, 1989, BIOCHEM BIOPH RES CO, V161, P16, DOI 10.1016/0006-291X(89)91553-2; LOPEZ AF, 1990, J CELL PHYSIOL, V145, P69, DOI 10.1002/jcp.1041450111; Maniatis T., 1982, MOL CLONING; METCALF D, 1986, BLOOD, V67, P257; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; ONETTOPOTHIER N, 1990, BLOOD, V75, P59; PARK LS, 1989, BLOOD, V74, P56; PARK LS, 1989, J BIOL CHEM, V264, P5420; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHRADER JW, 1986, ANNU REV IMMUNOL, V4, P205, DOI 10.1146/annurev.iy.04.040186.001225; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKAKI S, 1991, IN PRESS EMBO J; TAKETAZU F, 1991, J CELL PHYSIOL, V146, P251, DOI 10.1002/jcp.1041460209; UCKUN FM, 1989, BLOOD, V73, P533; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	46	637	662	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1165	1174		10.1016/0092-8674(91)90039-2	http://dx.doi.org/10.1016/0092-8674(91)90039-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1833064				2022-12-28	WOS:A1991GG55200011
J	DATTA, B; WEINER, AM				DATTA, B; WEINER, AM			GENETIC-EVIDENCE FOR BASE-PAIRING BETWEEN U2 AND U6 SNRNA IN MAMMALIAN MESSENGER-RNA SPLICING	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; 2'-OME RNA; YEAST; U1; OLIGONUCLEOTIDES; PARTICLES; SELECTION; INVITRO; U4	REMOVAL of introns from eukaryotic nuclear messenger RNA precursors is catalysed by a large ribonucleoprotein complex called the spliceosome, which consists of four small nuclear ribonucleoprotein particles (U1, U2, U5, and U4/U6 snRNPs) and auxiliary protein factors 1,2. We have begun a genetic analysis of mammalian U2 snRNA by making second-site mutations in a suppressor U2 snRNA 3. Here we find that several mutations in the 5' end of U2 (nucleotides 3-8) are deleterious and that one of these can be rescued by compensatory base changes in the 3' end of U6 (nucleotides 92-95). The results demonstrate genetically that the base-pairing interaction between U2 (nucleotides 3-11) and U6 snRNA (nucleotides 87-95), originally proposed on the basis of psoralen photocrosslinking experiments 4, can influence the efficiency of mRNA splicing in mammals. The U2/U6 interaction in yeast, however, is fairly tolerant to mutation 5 (D. J. Field and J. D. Friesen, personal communication), emphasizing the potential for facultative RNA interactions within the spliceosome.			DATTA, B (corresponding author), YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510, USA.							BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FRENDEWEY D, 1987, COLD SPRING HARB SYM, V52, P287, DOI 10.1101/SQB.1987.052.01.034; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAMM J, 1989, CELL, V59, P159, DOI 10.1016/0092-8674(89)90878-7; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LUCIA JS, IN PRESS BIOCHEMISTR; LUHRMANN R, 1988, STRUCTURE FUNCTION M, P71; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; PAN ZQ, 1989, GENE DEV, V3, P1887, DOI 10.1101/gad.3.12a.1887; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SHUSTER EO, 1990, NATURE, V345, P270, DOI 10.1038/345270a0; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; SUSSMAN JL, 1978, J MOL BIOL, V123, P607, DOI 10.1016/0022-2836(78)90209-7; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; YUO CY, 1989, GENE DEV, V3, P697, DOI 10.1101/gad.3.5.697; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	29	158	160	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					821	824		10.1038/352821a0	http://dx.doi.org/10.1038/352821a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1831879				2022-12-28	WOS:A1991GC96400066
J	CROMBIE, IK; DAVIES, HTO				CROMBIE, IK; DAVIES, HTO			COMPUTERS IN AUDIT - SERVANTS OR SIRENS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICAL AUDIT; SURGICAL AUDIT; MICROCOMPUTER; STRATEGIES; EXPERIENCE; TRIAL				CROMBIE, IK (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT EPIDEMIOL & PUBL HLTH, DUNDEE DD1 9SY, SCOTLAND.							[Anonymous], 1989, CM555; COLVER AF, 1990, BRIT MED J, V300, P1246, DOI 10.1136/bmj.300.6734.1246; DUNN DC, 1988, BRIT MED J, V296, P687, DOI 10.1136/bmj.296.6623.687; ELLIS BW, 1989, BRIT MED J, V298, P1635, DOI 10.1136/bmj.298.6688.1635; ELLIS BW, 1987, J ROY SOC MED, V80, P157, DOI 10.1177/014107688708000311; ELLIS BW, 1991, BMJ-BRIT MED J, V303, P704; FISHER RB, 1990, BRIT MED J, V300, P1560, DOI 10.1136/bmj.300.6739.1560; FOWKES FGR, 1982, MED EDUC, V16, P228; FOWKES FGR, 1986, LANCET, V1, P367; FRATER A, 1991, BRIT J HOSP MED, V45, P47; GRUER R, 1986, LANCET, V1, P23; HOPKINS A, 1991, J EPIDEMIOL COMMUN H, V45, P1, DOI 10.1136/jech.45.1.1; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; MCILWAINE GM, 1979, BMJ-BRIT MED J, V2, P1103, DOI 10.1136/bmj.2.6198.1103; MULBALL D, 1990, BRIT J HLTH CARE COM, V7, P20; NELSON AR, 1976, NEW ENGL J MED, V295, P617, DOI 10.1056/NEJM197609092951111; SHAW C, 1990, MED AUDIT HOSPITAL H; SMITH T, 1990, BRIT MED J, V300, P65, DOI 10.1136/bmj.300.6717.65; TYNDAL R, 1990, COMPUTERS MED AUDIT; WEBB SJ, 1991, BRIT MED J, V302, P390, DOI 10.1136/bmj.302.6773.390; 1990, MED AUDIT GUIDANCE H	21	13	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 17	1991	303	6799					403	404		10.1136/bmj.303.6799.403	http://dx.doi.org/10.1136/bmj.303.6799.403			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB599	1809263	Green Published, Bronze			2022-12-28	WOS:A1991GB59900020
J	KOH, HK				KOH, HK			MEDICAL PROGRESS - CUTANEOUS MELANOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							METASTATIC MALIGNANT-MELANOMA; LYMPH-NODE DISSECTION; TUMOR-INFILTRATING LYMPHOCYTES; STAGE-I MELANOMA; DYSPLASTIC MELANOCYTIC NEVUS; BONE-MARROW TRANSPLANTATION; HIGH-DOSE INTERLEUKIN-2; STUDY-GROUP TRIAL; PROGNOSTIC FACTORS; ADVANCED CANCER		BOSTON UNIV, SCH MED, DEPT MED, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, EPIDEMIOL & BIOSTAT SECT, BOSTON, MA 02118 USA; BOSTON UNIV, SCH PUBL HLTH, BOSTON, MA 02215 USA; UNIV HOSP BOSTON, SKIN ONCOL PROGRAM, BOSTON, MA 02118 USA	Boston University; Boston University; Boston University	KOH, HK (corresponding author), BOSTON UNIV, MED CTR, SCH MED, DEPT DERMATOL, 88 E NEWTON ST, BOSTON, MA 02118 USA.				NATIONAL CANCER INSTITUTE [K07CA001380] Funding Source: NIH RePORTER; NCI NIH HHS [5K07-CA01380-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackerman A B, 1980, Am J Dermatopathol, V2, P309, DOI 10.1097/00000372-198000240-00004; ACKERMAN AB, 1990, CUTANEOUS MELANOMA B, P127; ALBERT VA, 1990, J AM ACAD DERMATOL, V23, P308, DOI 10.1016/0190-9622(90)70214-3; ALBINO AP, 1989, ONCOGENE, V4, P1363; ALPER JC, 1985, ARCH DERMATOL, V121, P734, DOI 10.1001/archderm.121.6.734; ARMSTRONG BK, 1988, J DERMATOL SURG ONC, V14, P835, DOI 10.1111/j.1524-4725.1988.tb03588.x; BALABAN G, 1984, CANCER GENET CYTOGEN, V11, P429, DOI 10.1016/0165-4608(84)90024-4; BALCH CM, 1988, J CLIN ONCOL, V6, P163, DOI 10.1200/JCO.1988.6.1.163; BALCH CM, 1990, J SURG ONCOL, V44, P135, DOI 10.1002/jso.2930440302; BALCH CM, 1981, ANN SURG, V193, P377, DOI 10.1097/00000658-198103000-00023; BALCH CM, 1980, CANCER-AM CANCER SOC, V45, P3012, DOI 10.1002/1097-0142(19800615)45:12<3012::AID-CNCR2820451223>3.0.CO;2-O; BALCH CM, 1983, J CLIN ONCOL, V1, P126, DOI 10.1200/JCO.1983.1.2.126; BALCH CM, 1982, ANN SURG, V196, P677, DOI 10.1097/00000658-198212001-00011; BALCH CM, 1985, CUTANEOUS MELANOMA C; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BERD D, 1990, J CLIN ONCOL, V8, P1858, DOI 10.1200/JCO.1990.8.11.1858; BONETT A, 1989, MED J AUSTRALIA, V151, P502, DOI 10.5694/j.1326-5377.1989.tb128496.x; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BOWMAN KP, 1988, SCIENCE, V239, P48, DOI 10.1126/science.239.4835.48; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BRESLOW A, 1975, ANN SURG, V182, P572, DOI 10.1097/00000658-197511000-00007; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; BRESLOW A, 1977, SURG GYNECOL OBSTET, V145, P691; BYSTRYN JC, 1988, CANCER, V61, P1065, DOI 10.1002/1097-0142(19880315)61:6<1065::AID-CNCR2820610602>3.0.CO;2-L; CADY B, 1988, J CLIN ONCOL, V6, P2, DOI 10.1200/JCO.1988.6.1.2; CASCINELLI N, 1989, TUMORI, V75, P233, DOI 10.1177/030089168907500309; CASCINELLI N, 1975, TUMORI, V61, P481, DOI 10.1177/030089167506100508; CASCINELLI N, 1984, J SURG ONCOL, V25, P240, DOI 10.1002/jso.2930250404; CASSILETH BR, 1986, J AM ACAD DERMATOL, V14, P555, DOI 10.1016/S0190-9622(86)70068-6; CHOI KN, 1985, CANCER, V56, P1, DOI 10.1002/1097-0142(19850701)56:1<1::AID-CNCR2820560102>3.0.CO;2-X; CLARK WH, 1978, ARCH DERMATOL, V114, P732, DOI 10.1001/archderm.114.5.732; CLARK WH, 1969, CANCER RES, V29, P705; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; CLEMENTE C, 1991, HUM PATHOL, V22, P313, DOI 10.1016/0046-8177(91)90078-4; COCHRAN AJ, 1982, INT J CANCER, V30, P295, DOI 10.1002/ijc.2910300307; COHEN MH, 1977, ANN SURG, V186, P635; CREAGAN ET, 1989, MAYO CLIN PROC, V64, P852, DOI 10.1016/S0025-6196(12)61759-5; CREAGAN ET, 1984, AM J CLIN ONCOL-CANC, V7, P543, DOI 10.1097/00000421-198410000-00030; CREAGAN ET, 1986, CANCER, V58, P2576, DOI 10.1002/1097-0142(19861215)58:12<2576::AID-CNCR2820581203>3.0.CO;2-6; CROGHAN MK, 1988, J BIOL RESP MODIF, V7, P409; CUMBERLIN R, 1985, J CLIN ONCOL, V3, P1022, DOI 10.1200/JCO.1985.3.7.1022; DAVIS DL, 1990, LANCET, V336, P474, DOI 10.1016/0140-6736(90)92020-I; Davis N, 1978, Ann Plast Surg, V1, P628, DOI 10.1097/00000637-197811000-00017; DAY CL, 1981, CANCER-AM CANCER SOC, V47, P955, DOI 10.1002/1097-0142(19810301)47:5<955::AID-CNCR2820470523>3.0.CO;2-1; DAY CL, 1982, CA-CANCER J CLIN, V32, P113, DOI 10.3322/canjclin.32.2.113; DAY CL, 1981, ANN SURG, V193, P436, DOI 10.1097/00000658-198104000-00007; DILLMAN RO, 1990, J NATL CANCER I, V82, P1345, DOI 10.1093/jnci/82.16.1345; DOHERTY VR, 1988, BRIT MED J, V297, P388, DOI 10.1136/bmj.297.6645.388; DUGGLEBY WF, 1981, AM J EPIDEMIOL, V114, P63, DOI 10.1093/oxfordjournals.aje.a113175; EILBER FR, 1976, NEW ENGL J MED, V294, P237, DOI 10.1056/NEJM197601292940501; ELDER DE, 1983, PLAST RECONSTR SURG, V71, P66, DOI 10.1097/00006534-198301000-00015; ELDER DE, 1987, PIGMENT CELL, V8, P51; Elder DE, 1981, PATHOLOGY MALIGNANT, P185; ELLIS DL, 1987, NEW ENGL J MED, V317, P1582, DOI 10.1056/NEJM198712173172506; ELWOOD JM, 1984, BRIT MED J, V288, P99, DOI 10.1136/bmj.288.6411.99; EVANS RD, 1988, J DERMATOL SURG ONC, V14, P393, DOI 10.1111/j.1524-4725.1988.tb03373.x; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; FITZPATRICK TB, 1959, J INVEST DERMATOL, V32, P197, DOI 10.1038/jid.1959.37; FRANKLIN HR, 1988, J CLIN ONCOL, V6, P701, DOI 10.1200/JCO.1988.6.4.701; FRIEDMAN RJ, 1985, CA-CANCER J CLIN, V35, P130, DOI 10.3322/canjclin.35.3.130; GELLIN GA, 1969, ARCH DERMATOL, V99, P43, DOI 10.1001/archderm.99.1.43; GHUSSEN F, 1984, ANN SURG, V200, P764; GHUSSEN F, 1988, CANCER-AM CANCER SOC, V61, P654, DOI 10.1002/1097-0142(19880215)61:4<654::AID-CNCR2820610406>3.0.CO;2-V; GILCHREST BA, 1986, J INVEST DERMATOL, V87, P102, DOI 10.1111/1523-1747.ep12523599; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GOLDSMIT.HS, 1970, CANCER, V26, P606, DOI 10.1002/1097-0142(197009)26:3<606::AID-CNCR2820260317>3.0.CO;2-M; GOODMAN GE, 1985, J CLIN ONCOL, V3, P340, DOI 10.1200/JCO.1985.3.3.340; GOWN AM, 1986, AM J PATHOL, V123, P195; GREEN A, 1989, EPIDEMIOL REV, V11, P204, DOI 10.1093/oxfordjournals.epirev.a036037; GREENE MH, 1985, ANN INTERN MED, V102, P458, DOI 10.7326/0003-4819-102-4-458; GREENE MH, 1985, NEW ENGL J MED, V312, P91, DOI 10.1056/NEJM198501103120205; GROSSMAN DJ, 1989, J AM ACAD DERMATOL, V21, P1012, DOI 10.1016/S0190-9622(89)70291-7; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HARRIST TJ, 1984, CANCER, V53, P2183, DOI 10.1002/1097-0142(19840515)53:10<2183::AID-CNCR2820531029>3.0.CO;2-9; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; HERLYN M, 1987, LAB INVEST, V56, P461; HERLYN M, 1988, ANNU REV IMMUNOL, V6, P283; HILL GJ, 1984, CANCER, V53, P1299, DOI 10.1002/1097-0142(19840315)53:6<1299::AID-CNCR2820530613>3.0.CO;2-4; HO VC, 1990, J AM ACAD DERMATOL, V22, P159, DOI 10.1016/0190-9622(90)70019-E; HOLMAN CDJ, 1986, J NATL CANCER I, V76, P403; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; ISCOE N, 1987, PLAST RECONSTR SURG, V80, P233, DOI 10.1097/00006534-198708000-00012; JACQUILLAT C, 1990, CANCER, V66, P1873, DOI 10.1002/1097-0142(19901101)66:9<1873::AID-CNCR2820660904>3.0.CO;2-5; Jensen O M, 1980, World Health Stat Q, V33, P2; KHEIR SM, 1988, ANN SURG, V207, P45; KIRKWOOD JM, 1985, ANN INTERN MED, V103, P32, DOI 10.7326/0003-4819-103-1-32; KOH HK, 1986, HOSP PRACT, V21, P47; KOH HK, 1985, MED PEDIATR ONCOL, V13, P244, DOI 10.1002/mpo.2950130503; KOH HK, 1990, CANCER, V65, P375, DOI 10.1002/1097-0142(19900115)65:2<375::AID-CNCR2820650233>3.0.CO;2-Z; KOH HK, 1984, J CLIN ONCOL, V2, P994, DOI 10.1200/JCO.1984.2.9.994; KOH HK, 1989, J AM ACAD DERMATOL, V20, P159, DOI 10.1016/S0190-9622(89)70017-7; KOH HK, 1986, J CLIN ONCOL, V4, P1238, DOI 10.1200/JCO.1986.4.8.1238; KOH HK, 1990, PHOTOCHEM PHOTOBIOL, V51, P765, DOI 10.1111/php.1990.51.6.765; KOH HK, IN PRESS DERMATOL CL; KOPF A, 1991, CANCER SKIN; KOPF AW, 1987, CANCER, V59, P1236, DOI 10.1002/1097-0142(19870315)59:6<1236::AID-CNCR2820590634>3.0.CO;2-I; KOPF AW, 1986, JAMA-J AM MED ASSOC, V256, P1915; KRADIN RL, 1989, LANCET, V1, P577; KRAEMER KH, 1983, LANCET, V2, P1076; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; Krementz E T, 1979, World J Surg, V3, P289; KREMENTZ ET, 1982, ANN SURG, V195, P632, DOI 10.1097/00000658-198205000-00013; LEE JAH, 1980, BRIT J CANCER, V41, P757, DOI 10.1038/bjc.1980.138; LEGHA, 1987, J CLIN ONCOL, V5, P1858, DOI 10.1200/JCO.1987.5.11.1858; LEGHA SS, 1987, J CLIN ONCOL, V5, P1240, DOI 10.1200/JCO.1987.5.8.1240; LEMISH WM, 1983, CANCER-AM CANCER SOC, V52, P580, DOI 10.1002/1097-0142(19830801)52:3<580::AID-CNCR2820520334>3.0.CO;2-H; LEVINE N, 1980, LANCET, V2, P224; LEW RA, 1983, J DERMATOL SURG ONC, V9, P981, DOI 10.1111/j.1524-4725.1983.tb01051.x; LEY RD, 1989, PHOTOCHEM PHOTOBIOL, V50, P1, DOI 10.1111/j.1751-1097.1989.tb04123.x; LONGSTRETH JD, 1987, ASSESSING RISKS TRAC, V4; LORENTZEN M, 1977, SCAND J PLAST RECONS, V11, P163, DOI 10.3109/02844317709025513; LYNCH HT, 1978, J MED GENET, V15, P352, DOI 10.1136/jmg.15.5.352; MACKIE RM, 1989, LANCET, V2, P487; MARKS R, 1988, MED J AUSTRALIA, V149, P514, DOI 10.5694/j.1326-5377.1988.tb120756.x; MCCARTHY WH, 1985, SURG GYNECOL OBSTET, V161, P575; MCCLAY EF, 1989, CANCER, V63, P1292, DOI 10.1002/1097-0142(19890401)63:7<1292::AID-CNCR2820630711>3.0.CO;2-I; MERYMAN R, 1980, HOPE LOSS SURVIVED, P10; MIHM MC, 1971, NEW ENGL J MED, V284, P1078, DOI 10.1056/NEJM197105132841907; MILLER AB, 1990, INT J CANCER, V46, P761, DOI 10.1002/ijc.2910460502; MISHIMA Y, 1989, LANCET, V2, P388; MITCHELL, 1988, J CLIN ONCOL, V6, P1067, DOI 10.1200/JCO.1988.6.6.1067; MITCHELL MS, 1988, J CLIN ONCOL, V6, P409, DOI 10.1200/JCO.1988.6.3.409; MITCHELL MS, 1990, J CLIN ONCOL, V8, P856, DOI 10.1200/JCO.1990.8.5.856; MOLINA MJ, 1974, NATURE, V249, P810, DOI 10.1038/249810a0; MURPHY JR, 1986, P NATL ACAD SCI USA, V83, P8258, DOI 10.1073/pnas.83.21.8258; NATHANSON L, 1976, NATL CANCER I MONOGR, P67; NICHOLLS EM, 1973, CANCER, V32, P191, DOI 10.1002/1097-0142(197307)32:1<191::AID-CNCR2820320129>3.0.CO;2-W; OVERETT TK, 1985, CANCER, V56, P1222, DOI 10.1002/1097-0142(19850901)56:5<1222::AID-CNCR2820560544>3.0.CO;2-A; OVERGAARD J, 1986, INT J RADIAT ONCOL, V12, P867, DOI 10.1016/0360-3016(86)90378-0; PACK GT, 1952, AMA ARCH SURG, V65, P862, DOI 10.1001/archsurg.1952.01260020856010; PARKINSON DR, 1990, J CLIN ONCOL, V8, P1650, DOI 10.1200/JCO.1990.8.10.1650; PIEPKORN M, 1989, J AM ACAD DERMATOL, V20, P407, DOI 10.1016/S0190-9622(89)70050-5; PRESANT CA, 1982, CANCER, V49, P2192; QUIRT IC, 1991, J CLIN ONCOL, V9, P729, DOI 10.1200/JCO.1991.9.5.729; RHODES AR, 1982, J PEDIATR-US, V100, P219, DOI 10.1016/S0022-3476(82)80638-0; RHODES AR, 1987, JAMA-J AM MED ASSOC, V258, P3146, DOI 10.1001/jama.258.21.3146; RHODES AR, 1985, ARCH DERMATOL, V121, P1266, DOI 10.1001/archderm.121.10.1266; RHODES AR, 1986, MED CLIN N AM, V70, P3, DOI 10.1016/S0025-7125(16)30966-X; RIGEL DS, 1989, CANCER, V63, P386, DOI 10.1002/1097-0142(19890115)63:2<386::AID-CNCR2820630231>3.0.CO;2-6; RIGEL DS, 1987, J AM ACAD DERMATOL, V17, P1050, DOI 10.1016/S0190-9622(87)80487-5; RIGEL DS, 1986, J AM ACAD DERMATOL, V14, P857, DOI 10.1016/S0190-9622(86)70100-X; ROGERS GS, 1986, ARCH DERMATOL, V122, P999, DOI 10.1001/archderm.122.9.999; ROGERS GS, 1983, ARCH DERMATOL, V119, P644, DOI 10.1001/archderm.119.8.644; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1989, J CLIN ONCOL, V7, P1863, DOI 10.1200/JCO.1989.7.12.1863; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROSENBERG SA, 1989, ANN SURG, V210, P474, DOI 10.1097/00000658-198910000-00008; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; ROSES DF, 1981, SURGERY, V89, P654; ROSES DF, 1985, ANN SURG, V201, P103, DOI 10.1097/00000658-198501000-00015; SAGEBIEL RW, 1989, J AM ACAD DERMATOL, V20, P496, DOI 10.1016/S0190-9622(89)80086-6; SCHMOECKEL C, 1983, EUR J CANCER CLIN ON, V19, P227, DOI 10.1016/0277-5379(83)90421-2; SHEA TC, 1988, ARCH DERMATOL, V124, P878, DOI 10.1001/archderm.124.6.878; SIM FH, 1986, MAYO CLIN PROC, V61, P697, DOI 10.1016/S0025-6196(12)62768-2; SLUE W, 1988, ARCH DERMATOL, V124, P1239, DOI 10.1001/archderm.124.8.1239; SOBER AJ, 1987, PHOTODERMATOLOGY, V4, P23; SOBER AJ, 1979, JAMA-J AM MED ASSOC, V242, P2795, DOI 10.1001/jama.242.25.2795; SORENSEN FB, 1989, CANCER, V63, P1784; SPITLER LE, 1991, J CLIN ONCOL, V9, P736, DOI 10.1200/JCO.1991.9.5.736; SPITLER LE, 1987, CANCER RES, V47, P1717; Stehlin J S Jr, 1979, World J Surg, V3, P305; SWERDLOW AJ, 1988, BMJ-BRIT MED J, V297, P647, DOI 10.1136/bmj.297.6649.647; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; THOMSON W, 1989, J AM ACAD DERMATOL, V21, P1280, DOI 10.1016/S0190-9622(89)70344-3; THORN M, 1989, EUR J CANCER CLIN ON, V25, P483, DOI 10.1016/0277-5379(89)90261-7; TOPALIAN SL, 1988, J CLIN ONCOL, V6, P839, DOI 10.1200/JCO.1988.6.5.839; TRENT JM, 1990, NEW ENGL J MED, V322, P1508, DOI 10.1056/NEJM199005243222107; URIST MM, 1985, CANCER-AM CANCER SOC, V55, P1398, DOI 10.1002/1097-0142(19850315)55:6<1398::AID-CNCR2820550639>3.0.CO;2-A; VADHANRAJ S, 1988, J CLIN ONCOL, V6, P1636, DOI 10.1200/JCO.1988.6.10.1636; VANDERESCH EP, 1991, INT J CANCER, V47, P483, DOI 10.1002/ijc.2910470402; VASEN HFA, 1989, EUR J CANCER CLIN ON, V25, P337, DOI 10.1016/0277-5379(89)90027-8; VERONESI U, 1982, CANCER-AM CANCER SOC, V49, P2420, DOI 10.1002/1097-0142(19820601)49:11<2420::AID-CNCR2820491133>3.0.CO;2-2; VERONESI U, 1977, NEW ENGL J MED, V297, P627, DOI 10.1056/NEJM197709222971202; VERONESI U, 1991, ARCH SURG-CHICAGO, V126, P438; VERONESI U, 1988, NEW ENGL J MED, V318, P1159, DOI 10.1056/NEJM198805053181804; VERONESI U, 1982, NEW ENGL J MED, V307, P913, DOI 10.1056/NEJM198210073071503; VERONESI U, 1980, INT J CANCER, V26, P733; VOLLMER RT, 1989, PATHOL ANNU, V24, P383; WALLACK MK, 1989, AM SURGEON, V55, P243; WALTER SD, 1990, AM J EPIDEMIOL, V131, P232, DOI 10.1093/oxfordjournals.aje.a115493; WEARY PE, 1971, J AMER MED ASSOC, V217, P1862, DOI 10.1001/jama.217.13.1862; WEINSTOCK MA, 1987, BRIT J DERMATOL, V116, P303, DOI 10.1111/j.1365-2133.1987.tb05843.x; WEST WH, 1987, NEW ENGL J MED, V316, P898, DOI 10.1056/NEJM198704093161502; WICK MM, 1982, CANCER TREAT REP, V66, P1657; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; WOLFF SN, 1989, J CLIN ONCOL, V7, P245, DOI 10.1200/JCO.1989.7.2.245; ZIEGLER JC, 1986, INT J RADIAT ONCOL, V12, P1839, DOI 10.1016/0360-3016(86)90327-5; 1987, CANCER INCIDENCE 5 C, V5; 1989, GUIDE CLIN PREVENTIV, P71; 1990, NIH902789 NCI; 1966, CANCER INCIDENCE 5 C, V1; 1988, MANUAL STAGING CANCE, P139; 1980, ACS REPORT CANCER RE, V30, P194	193	400	403	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 18	1991	325	3					171	182		10.1056/NEJM199107183250306	http://dx.doi.org/10.1056/NEJM199107183250306			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW752	1805813				2022-12-28	WOS:A1991FW75200006
J	SAMBHARA, SR; MILLER, RG				SAMBHARA, SR; MILLER, RG			PROGRAMMED CELL-DEATH OF T-CELLS SIGNALED BY THE T-CELL RECEPTOR AND THE ALPHA-3 DOMAIN OF CLASS-I MHC	SCIENCE			English	Article							CYTO-TOXIC RESPONSES; LYMPHOCYTES-T; BONE-MARROW; CYTOTOXIC LYMPHOCYTES; MONOCLONAL-ANTIBODIES; SELF ANTIGENS; EXPRESSION; VETO; CD8; RECOGNITION	As well as being activated or rendered unresponsive, mature T lymphocytes can be deleted, depending on the signals received by the cell. Deletion by programmed cell death (apoptosis) is triggered if a T cell that has received a signal through its T cell receptor complex also receives a signal through the alpha-3 domain of its class I major histocompatibility complex (MHC) molecule. Such a signal can be delivered by a CD8 molecule, which recognizes the alpha-3 domain, or by an antibody to this domain. Precursors of both cytotoxic T lymphocytes (CTL's) and T helper cells are sensitive to this signal but become resistant at some point before completing differentiation into functioning CTL's or T helper cells. Because CTL's carry CD8, they can induce cell death in T cells that recognize them. This pathway may be important in both removal of autoreactive T cells and immunoregulation.	UNIV TORONTO,DEPT IMMUNOL,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA	University of Toronto			Sambhara, Suryaprakash/AAC-4428-2021					ALLEN H, 1984, NATURE, V309, P279, DOI 10.1038/309279a0; ALTEVOGT P, 1980, EUR J IMMUNOL, V10, P908, DOI 10.1002/eji.1830101204; AZUMA E, 1988, J IMMUNOL, V141, P2601; BEVAN MJ, 1975, J IMMUNOL, V114, P559; BLUESTONE JA, 1987, NATURE, V326, P82, DOI 10.1038/326082a0; CASSELL DJ, 1990, J IMMUNOL, V144, P4075; CHARRON D, 1980, J EXP MED, V152, P1275; CLAESSON MH, 1984, J EXP MED, V160, P1702, DOI 10.1084/jem.160.6.1702; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; EVANS GA, 1982, NATURE, V300, P755, DOI 10.1038/300755a0; FINK PJ, 1984, J IMMUNOL, V133, P1775; FINK PJ, 1988, ANNU REV IMMUNOL, V6, P115; FINK PJ, 1984, J IMMUNOL, V133, P1769; GRAF L, 1985, MOL IMMUNOL, V22, P1371, DOI 10.1016/0161-5890(85)90059-8; HAMBOR JE, 1990, J IMMUNOL, V145, P1646; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HEUER J, 1985, J IMMUNOL, V134, P4031; KANAGAWA O, 1989, J EXP MED, V170, P901, DOI 10.1084/jem.170.3.901; KAPLAN DR, 1989, P NATL ACAD SCI USA, V86, P8512, DOI 10.1073/pnas.86.21.8512; KIZIROGLU F, 1991, J IMMUNOL, V146, P1104; KO HS, 1979, J EXP MED, V150, P246, DOI 10.1084/jem.150.2.246; KOCH N, 1983, IMMUNOGENETICS, V17, P497, DOI 10.1007/BF00696873; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P119; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; MILLER RG, 1986, IMMUNOL TODAY, V7, P112, DOI 10.1016/0167-5699(86)90151-9; MILLER RG, 1979, J IMMUNOL, V122, P1502; MILLER RG, 1980, NATURE, V287, P544, DOI 10.1038/287544a0; MILLER RG, 1974, CELL IMMUNOL, V14, P284, DOI 10.1016/0008-8749(74)90212-3; MILLER RG, 1980, STRATEGIES IMMUNE RE, P507; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MURAOKA S, 1980, J EXP MED, V152, P54, DOI 10.1084/jem.152.1.54; NAKAMURA H, 1990, TRANSPLANTATION, V49, P931, DOI 10.1097/00007890-199005000-00020; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; RAMMENSEE HG, 1989, INT REV IMMUNOL, V4, P177; RESKEKUNZ AB, 1986, J IMMUNOL, V136, P2033; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAMBHARA SR, UNPUB; Sambrook J, 1989, MOL CLONING LAB MANU, pE3; SHAPIRO HM, 1988, PRACTICAL FLOW CYTOM, P168; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TAKAHASHI T, 1990, J EXP MED, V172, P901, DOI 10.1084/jem.172.3.901; WALLACE VA, 1991, EUR J IMMUNOL, V20, P2471	46	200	211	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1991	252	5011					1424	1427						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP868	1828618				2022-12-28	WOS:A1991FP86800034
J	CADY, RK; WENDT, JK; KIRCHNER, JR; SARGENT, JD; ROTHROCK, JF; SKAGGS, H				CADY, RK; WENDT, JK; KIRCHNER, JR; SARGENT, JD; ROTHROCK, JF; SKAGGS, H			TREATMENT OF ACUTE MIGRAINE WITH SUBCUTANEOUS SUMATRIPTAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							5-HT1-LIKE RECEPTOR AGONIST; NAPROXEN SODIUM; ERGOTAMINE TARTRATE; BASILAR ARTERY; GR43175; HEADACHE; ATTACK; DIHYDROERGOTAMINE; PHARMACOLOGY; CONTRACTION	Sumatriptan succinate, a 5-HT1D receptor agonist, constricts human cranial arteries. Two parallel-group trials for treatment of acute migraines were conducted in the United States. Adult patients were randomized and given either 6 mg of sumatriptan succinate subcutaneously (n = 734) or placebo (n = 370). At 1 hour, sumatriptan was significantly more effective than placebo in reducing moderate or severe headache pain to mild or no pain (70% vs 22%), in completely relieving headaches (49% vs 9%), and in improving clinical disability (76% vs 34%). Sumatriptan also reduced nausea and photophobia significantly better than placebo. Patients with residual migraines received another injection; those who had originally received sumatriptan received either a second active injection (n = 187) or placebo (n = 178), while those who had received placebo received a second placebo injection (n = 335). Statistical evidence for benefit of second sumatriptan injection is absent. Adverse events associated with sumatriptan were tingling, dizziness, warm-hot sensations, and injection-site reactions. Sumatriptan is effective and well tolerated in patients with acute migraine.	MIGRAINE TREATMENT CLIN,OMAHA,NE; MENNINGER FDN,HEADACHE & INTERNAL MED RES CTR,TOPEKA,KS 66601; UNIV ARIZONA,HLTH SCI CTR,DEPT NEUROL,TUCSON,AZ 85721; UNIV CALIF SAN DIEGO,MED CTR,DEPT NEUROL,LA JOLLA,CA 92093; CTR CLIN RES,NEUROL SECT,AUSTIN,TX	University of Arizona; University of Arizona Health Sciences; University of California System; University of California San Diego	CADY, RK (corresponding author), SHEALY INST COMPREHENS HLTH CARE,1328 E EVERGREEN ST,SPRINGFIELD,MO 65803, USA.							ANCALMO N, 1974, ARCH SURG-CHICAGO, V109, P832; ANDERSSON PG, 1975, HEADACHE, V15, P118, DOI 10.1111/j.1526-4610.1975.hed1502118.x; ANTHONY M, 1967, ARCH NEUROL-CHICAGO, V16, P544, DOI 10.1001/archneur.1967.00470230096013; BUZZI MG, 1990, BRIT J PHARMACOL, V99, P202, DOI 10.1111/j.1476-5381.1990.tb14679.x; BYER J, 1989, CEPHALALGIA S10, V9, P349; CALLAHAM M, 1986, HEADACHE, V26, P168, DOI 10.1111/j.1526-4610.1986.hed2604168.x; CONNOR HE, 1989, BRIT J PHARMACOL, V96, P379, DOI 10.1111/j.1476-5381.1989.tb11828.x; DESILVA KL, 1973, PRACTITIONER, V211, P316; DOENICKE A, 1988, LANCET, V1, P1309; ESPIR MLE, 1988, BRIT J IND MED, V45, P336; Goldstein M, 1982, Adv Neurol, V33, P377; GRAHAM JR, 1938, P ASS RES NERV MENT, V18, P638; HAKKARAINEN H, 1979, LANCET, V2, P326; HUMPHREY PPA, 1989, CEPHALALGIA, V9, P23; JOHNSON ES, 1985, CEPHALALGIA, V5, P5, DOI 10.1046/j.1468-2982.1985.0501005.x; KIMBALL RW, 1960, NEUROLOGY, V10, P107, DOI 10.1212/WNL.10.2.107; Lance J W, 1967, Headache, V7, P93, DOI 10.1111/j.1526-4610.1967.hed0703134.x; LANCE JW, 1990, HEADACHE, V1, P17; LASKA EM, 1982, J CLIN PHARMACOL, V22, P531, DOI 10.1002/j.1552-4604.1982.tb02646.x; NESTVOLD K, 1985, CEPHALALGIA, V5, P115, DOI 10.1046/j.1468-2982.1985.0502115.x; ORTON DA, 1982, POSTGRAD MED J, V58, P6, DOI 10.1136/pgmj.58.675.6; OSTERHOUSE JT, 1990, 1990 ANN M AM ASS ST; PARSONS AA, 1989, CEPHALALGIA, V9, P47; PEATFIELD RC, 1986, HDB CLIN NEUROLOGY, V4, P173; PEROUTKA SJ, 1990, HEADACHE, V30, P5, DOI 10.1111/j.1526-4610.1990.hed30s1005.x; PERRIN VL, 1989, CEPHALALGIA, V9, P63; PERRIN VL, 1985, CLIN PHARMACOKINET, V10, P334, DOI 10.2165/00003088-198510040-00004; PRADALIER A, 1985, CEPHALALGIA, V5, P107, DOI 10.1046/j.1468-2982.1985.0502107.x; RASKIN NH, 1986, NEUROLOGY, V36, P995, DOI 10.1212/WNL.36.7.995; SARGENT JD, 1988, HEADACHE, V28, P263, DOI 10.1111/j.1526-4610.1988.hed2804263.x; SNELL NJC, 1978, POSTGRAD MED J, V54, P37, DOI 10.1136/pgmj.54.627.37; SUNSHINE A, 1987, CLIN PHARMACOL THER, V42, P374, DOI 10.1038/clpt.1987.166; TFELTHANSEN P, 1984, CEPHALALGIA, V4, P107, DOI 10.1046/j.1468-2982.1984.0402107.x; TFELTHANSEN P, 1989, CEPHALALGIA, V9, P73; TOKOLA RA, 1988, CEPHALALGIA, V8, P139, DOI 10.1046/j.1468-2982.1988.0803113.x; VOLANS GN, 1975, BRIT J CLIN PHARMACO, V2, P57, DOI 10.1111/j.1365-2125.1975.tb00472.x; WAINSCOTT G, 1974, BMJ-BRIT MED J, V2, P724, DOI 10.1136/bmj.2.5921.724-b; YASUE H, 1981, ANGIOLOGY, V32, P414, DOI 10.1177/000331978103200607; 1989, STATISTICAL ABSTRACT, P118; 1988, CEPHALALGIA S7, V8, P19	40	306	308	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2831	2835		10.1001/jama.265.21.2831	http://dx.doi.org/10.1001/jama.265.21.2831			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	1851894				2022-12-28	WOS:A1991FN85500032
J	PARMAR, H; PHILLIPS, RH; EDWARDS, LE; CHARLTON, C; LIGHTMAN, SL				PARMAR, H; PHILLIPS, RH; EDWARDS, LE; CHARLTON, C; LIGHTMAN, SL			MEDICAL OR SURGICAL ORCHIECTOMY	BRITISH MEDICAL JOURNAL			English	Letter							LONG-ACTING D-TRP-6-LHRH		WESTMINSTER MED SCH & HOSP,DEPT UROL,LONDON SW1 2AP,ENGLAND; WESTMINSTER MED SCH & HOSP,DEPT MED,LONDON SW1 2AP,ENGLAND	Imperial College London; Imperial College London	PARMAR, H (corresponding author), WESTMINSTER MED SCH & HOSP,DEPT CLIN ONCOL,LONDON SW1 2AP,ENGLAND.			Lightman, Stafford/0000-0002-8546-9646				CHADWICK DJ, 1991, BRIT MED J, V302, P572, DOI 10.1136/bmj.302.6776.572; PARMAR H, 1987, BRIT J UROL, V59, P248, DOI 10.1111/j.1464-410X.1987.tb04616.x; PARMAR H, 1985, LANCET, V2, P1201; PARMAR H, 1988, BRIT MED J, V296, P1001, DOI 10.1136/bmj.296.6627.1001-c	4	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1272	1272		10.1136/bmj.302.6787.1272-a	http://dx.doi.org/10.1136/bmj.302.6787.1272-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	1828382	Green Published			2022-12-28	WOS:A1991FP27200038
J	MEYERS, WC				MEYERS, WC			A PROSPECTIVE ANALYSIS OF 1518 LAPAROSCOPIC CHOLECYSTECTOMIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLICATIONS; SURGERY	Background and Methods. The Southern Surgeons Club conducted a prospective study of 1518 patients who underwent laparoscopic cholecystectomy for treatment of gallbladder disease in order to evaluate the safety of this procedure. Results. Seven hundred fifty-eight operations (49.9 percent) were performed at academic hospitals, and 760 (50.1 percent) at private hospitals. In 72 patients (4.7 percent) the operation was converted to conventional open cholecystectomy; the most common reason for the change was the inability to identify the anatomy of the gallbladder as a result of inflammation in the region of this organ. A total of 82 complications occurred in 78 (5.1 percent) of the patients; this is comparable with the rates of 6 to 21 percent that have been reported for conventional cholecystectomy. Overall, the most common complication was superficial infection of the site of insertion of the umbilical trocar. A total of seven injuries to the common bile duct or the hepatic duct occurred during the operation, for a rate of 0.5 percent. Four of the seven injuries were simple lacerations, which were repaired after conversion to conventional cholecystectomy. The incidence of bile-duct injury in the first 13 patients operated on by each surgical group was 2.2 percent, as compared with 0.1 percent for subsequent patients. No complications were attributed directly to either cautery or laser-surgical technique, and similar numbers of complications occurred in academic and private hospitals. The mean hospital stay for the entire group was 1.2 days (range, 6 hours to 30 days). Conclusions. The results of laparoscopic cholecystectomy compare favorably with those of conventional cholecystectomy with respect to mortality, complications, and length of hospital stay. A slightly higher incidence of biliary injury with the laparoscopic procedure is probably offset by the low incidence of other complications.			MEYERS, WC (corresponding author), DUKE UNIV,MED CTR,DIV GASTROINTESTINAL SURG,BOX 3041,DURHAM,NC 27710, USA.			Pappas, Theodore/0000-0001-9110-4849				BODVALL B, 1964, ACTA CHIR SCAND    S, V329, P1; COHEN MM, 1989, AM J PUBLIC HEALTH, V79, P751, DOI 10.2105/AJPH.79.6.751; COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P94, DOI 10.1016/S0016-5107(91)70637-8; DOWDY GS, 1964, ARCH SURG-CHICAGO, V88, P314, DOI 10.1001/archsurg.1964.01310200152032; DUBOIS F, 1990, ANN SURG, V211, P60, DOI 10.1097/00000658-199001000-00010; GLENN F, 1968, SURG GYNECOL OBSTETR, V126, P15; GLENN F, 1967, SURG GYNECOL OBSTETR, V124, P974; KAKOS GS, 1972, ARCH SURG-CHICAGO, V104, P484; MEYERS WC, 1990, TXB LIVER BILIARY SU, P373; RAUTE M, 1988, LANGENBECK ARCH CHIR, V373, P345, DOI 10.1007/BF01272553; REDDICK E J, 1989, Surgical Endoscopy, V3, P131, DOI 10.1007/BF00591357; ROOS LL, 1986, MED CARE, V24, P1044, DOI 10.1097/00005650-198611000-00008; SCHER KS, 1987, AM SURGEON, V53, P16; VIIKARI SJ, 1960, ACTA CHIR SCAND, V119, P83	14	814	856	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1073	1078						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	1826143				2022-12-28	WOS:A1991FG91200001
J	MOTOKURA, T; BLOOM, T; KIM, HG; JUPPNER, H; RUDERMAN, JV; KRONENBERG, HM; ARNOLD, A				MOTOKURA, T; BLOOM, T; KIM, HG; JUPPNER, H; RUDERMAN, JV; KRONENBERG, HM; ARNOLD, A			A NOVEL CYCLIN ENCODED BY A BCL1-LINKED CANDIDATE ONCOGENE	NATURE			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; MESSENGER-RNA; GENE; AMPLIFICATION; DIVISION; KINETICS; MEIOSIS; BCL-1	WE have previously identified a candidate oncogene (PRAD1 or D11S287E) on chromosome 11q13 which is clonally rearranged with the parathyroid hormone locus in a subset of benign parathyroid tumours 1,2. We now report that a cloned human placental PRAD1 complementary DNA encodes a protein of 295 amino acids with sequence similarities to the cyclins. Cyclins can form a complex with and activate p34 cdc2 protein kinase, thereby regulating progress through the cell cycle (reviewed in refs 3-5). PRAD1 messenger RNA levels vary dramatically across the cell cycle in HeLa cells. Addition of the PRAD1 protein to interphase clam embryo lysates containing inactive p34cdc2 kinase and lacking endogenous cyclins allows it to be isolated using beads bearing p13suc1, a yeast protein that binds cdc2 and related kinases with high affinity and coprecipitates kinase-associated proteins. Addition of PRAD1 also induces phosphorylation of histone H1, a preferred substrate of cdc2. These data suggest that PRAD1 encodes a novel cyclin whose overexpression may play an important part in the development of various tumours with abnormalities in 11q13.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,ENDOCRINE UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School			Motokura, Toru/X-3682-2019	Bloom, Theodora/0000-0002-0222-4177				ALI IU, 1989, ONCOGENE, V4, P89; ARNOLD A, 1988, NEW ENGL J MED, V318, P658, DOI 10.1056/NEJM198803173181102; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Battey, 1986, BASIC METHODS MOL BI; BERENSON JR, 1989, ONCOGENE, V4, P1111; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FRIEDMAN E, 1990, J CLIN ENDOCR METAB, V71, P293, DOI 10.1210/jcem-71-2-293; GARDELLA TJ, 1990, J BIOL CHEM, V265, P15854; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; LAMMIE GA, 1991, ONCOGENE, V6, P439; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROSENBERG CL, 1991, ONCOGENE, V6, P449; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; THEILLET C, 1990, ONCOGENE, V5, P147; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431	33	1285	1350	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					512	515		10.1038/350512a0	http://dx.doi.org/10.1038/350512a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	1826542				2022-12-28	WOS:A1991FG14300055
J	ANTONARAKIS, SE				ANTONARAKIS, SE			PARENTAL ORIGIN OF THE EXTRA CHROMOSOME IN TRISOMY-21 AS INDICATED BY ANALYSIS OF DNA POLYMORPHISMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONDISJUNCTION; SEQUENCES; RECOMBINATION; PROBES	Background. Over the past 20 years, the parental origin of the extra chromosome in children with trisomy 21 has been investigated with cytogenetic methods of identifying morphologic variations in chromosome 21. These studies have concluded that the origin of the extra chromosome 21 was maternal in approximately 80 percent of cases and paternal in about 20 percent. Methods. We studied 200 families, each with a single child with trisomy 21, using DNA polymorphisms as markers to determine the parental origin of the nondisjunction causing the extra chromosome 21. These polymorphisms spanned a region of about 120 centimorgans on the long arm of chromosome 21, from the D21S13 locus (the most centromeric) to the COL6A1 gene (the most telomeric). Results. The parental origin of nondisjunction could be determined for all but 7 of the 200 children. It was maternal in 184 children (proportion [+/- SE], 95.3 +/- 1.5 percent) and paternal in 9 (4.7 +/- 1.5 percent). In a subgroup of 31 families, we compared the results of DNA analysis with those of traditional cytogenetic analysis. According to the cytogenetic analyses, nondisjunction originated in the mother in 26 cases (84 percent) and in the father in 5 (16 percent). DNA analysis demonstrated the origin as maternal in 29 (94 percent) and paternal in 2 (6 percent). With the cytogenetic analyses, there were three false determinations of paternal origin. Conclusions. In trisomy 21 the extra chromosome 21 is maternal in origin in about 95 percent of the cases, and paternal in only about 5 percent - considerably less than has been reported with cytogenetic methods. DNA polymorphic analysis is now the method of choice for establishing the parental origin of nondisjunction.			ANTONARAKIS, SE (corresponding author), JOHNS HOPKINS UNIV HOSP,CTR MED GENET,DEPT PEDIAT,CMSC 1003,BALTIMORE,MD 21205, USA.		Petersen, Michael Bjørn B/D-1483-2017; Antonarakis, Stylianos/N-8866-2014	Petersen, Michael Bjørn B/0000-0003-0316-8207; Antonarakis, Stylianos/0000-0001-8907-5823	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024605, K04HD000774, R01HD019591] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD19591, P01HD24605, HD00774] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANTONARAKIS SE, 1985, P NATL ACAD SCI USA, V82, P3360, DOI 10.1073/pnas.82.10.3360; CAROTHERS AD, 1987, AM J HUM GENET, V40, P147; CHAKRAVARTI A, 1989, AM J HUM GENET, V44, P639; DAVIES KE, 1984, HUM GENET, V66, P54, DOI 10.1007/BF00275186; ECONOMOU EP, 1990, P NATL ACAD SCI USA, V87, P2951, DOI 10.1073/pnas.87.8.2951; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; HASSOLD TJ, 1984, ANNU REV GENET, V18, P69, DOI 10.1146/annurev.genet.18.1.69; Jacobs P A, 1977, Prog Med Genet, V2, P251; JUBERG RC, 1970, NEW ENGL J MED, V282, P292, DOI 10.1056/NEJM197002052820602; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LEWIS JG, 1990, GENOMICS, V8, P400, DOI 10.1016/0888-7543(90)90300-J; MIKKELSEN M, 1980, ANN HUM GENET, V44, P17, DOI 10.1111/j.1469-1809.1980.tb00942.x; PETERSEN MB, 1990, GENOMICS, V7, P136, DOI 10.1016/0888-7543(90)90531-X; PETERSEN MB, 1991, AM J HUM GENET, V48, P65; PETERSEN MB, IN PRESS GENOMICS; RUDD NL, 1988, HUM GENET, V78, P175, DOI 10.1007/BF00278191; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART GD, 1988, AM J HUM GENET, V42, P227; STEWART GD, 1985, NUCLEIC ACIDS RES, V13, P4125, DOI 10.1093/nar/13.11.4125; WARREN AC, 1987, SCIENCE, V237, P652, DOI 10.1126/science.2955519; 1972, CYTOGENET CELL GENET, V11, P313	22	202	209	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					872	876		10.1056/NEJM199103283241302	http://dx.doi.org/10.1056/NEJM199103283241302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD111	1825697	Bronze			2022-12-28	WOS:A1991FD11100002
J	LARKMAN, A; STRATFORD, K; JACK, J				LARKMAN, A; STRATFORD, K; JACK, J			QUANTAL ANALYSIS OF EXCITATORY SYNAPTIC ACTION AND DEPRESSION IN HIPPOCAMPAL SLICES	NATURE			English	Article							LONG-TERM POTENTIATION; TRANSMISSION; RELEASE; GLUTAMATE; SYNAPSES; NEURONS; CALCIUM	QUANTAL analysis can provide a quantitative description of important aspects of chemical synaptic transmission and its modification 1-3. The technique has recently been applied to excitatory synapses within the hippocampus 4-10, especially the form of synaptic plasticity known as long-term potentiation 11-13. However, these attempts have met with only limited success, in that the individual quantal amplitudes making up the synaptic response generally could not be resolved. Here we have paid attention to the possible instability of the quantal fluctuation pattern over time. We were able to resolve individual quantal component amplitudes for a high proportion of the experiments, and so demonstrate the quantal nature of excitatory transmission in the CA1 region of the hippocampus. Mean quantal amplitudes for individual excitatory postsynaptic potentials were 84-197-mu-V, with a mean of 131 +/- 29-mu-V. For periods during which the fluctuation pattern was stable, the variance associated with individual quantal amplitudes was low. We have also used quantal analysis to show that synaptic depression following prolonged stimulation at these synapses is primarily a presynaptic phenomenon.			LARKMAN, A (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BENNETT MR, 1989, J PHYSIOL-LONDON, V418, P219, DOI 10.1113/jphysiol.1989.sp017836; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P574, DOI 10.1113/jphysiol.1954.sp005130; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FRIEDLANDER MJ, 1990, J NEUROSCI, V10, P814; HESS G, 1987, NEUROSCI LETT, V77, P187, DOI 10.1016/0304-3940(87)90584-2; JACK JJB, 1981, J PHYSIOL-LONDON, V321, P65, DOI 10.1113/jphysiol.1981.sp013972; JACK JJB, IN PRESS COLD SPRING; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KORN H, 1984, J NEUROSCI, V4, P125; KULLMANN DM, 1989, J NEUROSCI METH, V30, P231, DOI 10.1016/0165-0270(89)90134-9; MAGLEBY KL, 1987, SYNAPTIC FUNCTION, P21; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MARTIN AR, 1977, HDB PHYSL          1, V1, P329; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; RAHAMIMOFF R, 1973, J PHYSIOL-LONDON, V228, P241, DOI 10.1113/jphysiol.1973.sp010084; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; RIVEROS N, 1986, BRAIN RES, V386, P405, DOI 10.1016/0006-8993(86)90181-2; SARANTIS M, 1990, BRAIN RES, V516, P322, DOI 10.1016/0006-8993(90)90935-5; SAYER RJ, 1989, J NEUROSCI, V9, P840; SAYER RJ, 1990, J NEUROSCI, V10, P826; SCHWARTZKROIN PA, 1987, CEREB CORTEX, V6, P295; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; THIES RE, 1965, J NEUROPHYSIOL, V28, P427, DOI 10.1152/jn.1965.28.3.427; TITTERINGTON DM, 1985, STATISTICAL ANAL FIN, P52; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; VILLANUEVA S, 1990, NEUROSCIENCE, V37, P23, DOI 10.1016/0306-4522(90)90188-A; WALMSLEY B, 1988, J NEUROPHYSIOL, V60, P889, DOI 10.1152/jn.1988.60.3.889; WALMSLEY B, 1987, J NEUROSCI, V7, P1037; YAMAMOTO C, 1982, EXP BRAIN RES, V46, P170	34	165	166	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					344	347		10.1038/350344a0	http://dx.doi.org/10.1038/350344a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	1848922				2022-12-28	WOS:A1991FD83800094
J	KELLEY, MA; CARSON, JL; PALEVSKY, HI; SCHWARTZ, JS				KELLEY, MA; CARSON, JL; PALEVSKY, HI; SCHWARTZ, JS			DIAGNOSING PULMONARY-EMBOLISM - NEW FACTS AND STRATEGIES	ANNALS OF INTERNAL MEDICINE			English	Article							DEEP VENOUS THROMBOSIS; PERFUSION LUNG-SCAN; VENTILATION-PERFUSION; LOW-PROBABILITY; COMPLICATIONS; ANGIOGRAPHY; SCINTIGRAPHY; OUTPATIENTS; THERAPY	Purpose: To provide a clinical approach to the diagnosis of pulmonary embolism. Data Identification: An English-language literature search using MEDLINE (1982 to 1990) and bibliographic reviews of textbooks and review articles. Study Selection: In addition to several reviews, studies that evaluated the diagnostic technology of pulmonary embolism were selected. Preference was given to studies with a prospective design, particularly those done within the past decade. Data Extraction: Studies were assessed independently by three unblinded observers. Data were chosen to describe the efficacy of diagnostic technology on the basis of disease prevalence, sensitivity and specificity, and predictive value. Results of Data Analysis: A normal lung scan or pulmonary angiogram rules out the diagnosis of clinically important pulmonary embolism with at least 95% certainty. Lung scan interpretations indicating high or low probability have approximately a 15% error in diagnosing or ruling out pulmonary embolism. The accuracy of either scan result improves when the clinical suspicion of pulmonary embolism matches the lung scan result. Serial impedance plethysmography of the lower extremities may exclude thromboembolism with 95% certainty in patients without high-probability lung scan results or cardiopulmonary disease. Conclusions: The combination of clinical suspicion and the results of the lung scan and impedance plethysmography appear to offer acceptable diagnostic accuracy in evaluating many patients suspected of having pulmonary embolism. The usefulness of this approach for patients with cardiopulmonary disease is still unknown.	UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA; UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, NEW BRUNSWICK, NJ 08903 USA	University of Pennsylvania; Rutgers State University New Brunswick; Rutgers State University Medical Center								ADELSTEIN SJ, 1978, NEW ENGL J MED, V299, P305, DOI 10.1056/NEJM197808102990611; ALAVI A, 1990, RADIOLOGY, V175, P79, DOI 10.1148/radiology.175.1.2315506; ALDERSON PO, 1980, SEMIN NUCL MED, V10, P218, DOI 10.1016/S0001-2998(80)80003-1; ALDERSON PO, 1984, RADIOLOGY, V153, P515, DOI 10.1148/radiology.153.2.6385113; ALDERSON PO, 1976, RADIOLOGY, V120, P633, DOI 10.1148/120.3.633; BECKER DM, 1989, ARCH INTERN MED, V149, P1731, DOI 10.1001/archinte.149.8.1731; BELL WR, 1976, AM HEART J, V92, P700, DOI 10.1016/S0002-8703(76)80005-1; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; BIELLO DR, 1979, AM J ROENTGENOL, V133, P1033, DOI 10.2214/ajr.133.6.1033; BOGREN HG, 1978, ACTA RADIOL DIAGN, V19, P933, DOI 10.1177/028418517801900608; CHEELY R, 1981, AM J MED, V70, P17, DOI 10.1016/0002-9343(81)90406-X; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; DALEN JE, 1975, PROG CARDIOVASC DIS, V17, P259, DOI 10.1016/S0033-0620(75)80017-X; FLETCHER RH, 1988, CLIN EPIDEMIOLOGY ES, P42; HAVIG O, 1977, ACTA CHIR SCAND    S, V478, P42; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, CHEST, V95, P498, DOI 10.1378/chest.95.3.498; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1990, CHEST, V97, P23, DOI 10.1378/chest.97.1.23; HULL RD, 1989, ARCH INTERN MED, V149, P2549, DOI 10.1001/archinte.149.11.2549; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; HULL RD, 1988, ARCH INTERN MED, V148, P838, DOI 10.1001/archinte.148.4.838; KAHN D, 1989, ARCH INTERN MED, V149, P377, DOI 10.1001/archinte.149.2.377; KIPPER MS, 1982, CHEST, V82, P411, DOI 10.1378/chest.82.4.411; LANDEFELD CS, 1989, J CLIN EPIDEMIOL, V42, P711, DOI 10.1016/0895-4356(89)90066-8; LEE ME, 1985, RADIOLOGY, V156, P497, DOI 10.1148/radiology.156.2.4011914; LEVINE MN, 1989, CHEST, V95, pS26, DOI 10.1378/chest.95.2.26S; LOTKE PA, 1984, J BONE JOINT SURG AM, V66A, P202, DOI 10.2106/00004623-198466020-00006; MCLACHLIN J, 1951, SURG GYNECOL OBSTET, V93, P1; MCNEIL BJ, 1974, JAMA-J AM MED ASSOC, V227, P753, DOI 10.1001/jama.227.7.753; MCNEIL BJ, 1976, J NUCL MED, V17, P613; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; MOSER KM, 1990, AM REV RESPIR DIS, V141, P235, DOI 10.1164/ajrccm/141.1.235; NEUMANN RD, 1980, SEMIN NUCL MED, V10, P198, DOI 10.1016/S0001-2998(80)80002-X; NOVELLINE RA, 1978, RADIOLOGY, V126, P561, DOI 10.1148/126.3.561; PETTY GW, 1988, ANN NEUROL, V23, P570, DOI 10.1002/ana.410230607; ROBIN ED, 1977, ANN INTERN MED, V87, P775, DOI 10.7326/0003-4819-87-6-775; SELBY JB, 1990, CLIN NUCL MED, V15, P143, DOI 10.1097/00003072-199003000-00001; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; SOSTMAN HD, 1986, INVEST RADIOL, V21, P443; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WHITE RH, 1989, ANN INTERN MED, V111, P297, DOI 10.7326/0003-4819-111-4-297	42	150	150	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1991	114	4					300	306		10.7326/0003-4819-114-4-300	http://dx.doi.org/10.7326/0003-4819-114-4-300			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX521	1824813				2022-12-28	WOS:A1991EX52100010
J	FRASER, JD; IRVING, BA; CRABTREE, GR; WEISS, A				FRASER, JD; IRVING, BA; CRABTREE, GR; WEISS, A			REGULATION OF INTERLEUKIN-2 GENE ENHANCER ACTIVITY BY THE T-CELL ACCESSORY MOLECULE CD28	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; ANTIGEN RECEPTOR COMPLEX; ACTIVATION PATHWAY; CHROMOSOMAL GENE; LYMPHOCYTES-T; EXPRESSION; INDUCTION; PROMOTER; EVENTS; REGION	The mechanism by which cell surface molecules regulate T cell production of lymphokines is poorly understood. Production of interleukin-2 (IL-2) can be regulated by signal transduction pathways distinct from those induced by the T cell antigen receptor. Stimulation of CD28, a molecule expressed on most human T cells, induced the formation of a protein complex that bound to a site on the IL-2 gene distinct from previously described binding sites and increased IL-2 enhancer activity fivefold. The CD28-responsive complex bound to the IL-2 gene between - 164 and - 154 base pairs from the transcription start site. The sequence of this element is similar to regions conserved in the 5' flanking regions of several other lymphokine genes.	STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT IMMUNOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	FRASER, JD (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39553] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON JP, 1987, ANNU REV IMMUNOL, V5, P503, DOI 10.1146/annurev.iy.05.040187.002443; CAMPBELL HD, 1985, EUR J BIOCHEM, V150, P297, DOI 10.1111/j.1432-1033.1985.tb09020.x; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FRASER JD, UNPUB; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; HARA T, 1985, J EXP MED, V161, P1513, DOI 10.1084/jem.161.6.1513; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; NAGATA S, 1986, EMBO J, V5, P575, DOI 10.1002/j.1460-2075.1986.tb04249.x; QUILL H, 1987, J IMMUNOL, V138, P3704; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; TSUCHIYA M, 1987, EUR J BIOCHEM, V165, P7, DOI 10.1111/j.1432-1033.1987.tb11187.x; WEISS A, 1986, J IMMUNOL, V137, P819; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; YANG YC, 1987, LYMPHOKINES, V15, P375	34	652	700	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 18	1991	251	4991					313	316		10.1126/science.1846244	http://dx.doi.org/10.1126/science.1846244			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET678	1846244				2022-12-28	WOS:A1991ET67800034
J	MIKI, T; FLEMING, TP; BOTTARO, DP; RUBIN, JS; RON, D; AARONSON, SA				MIKI, T; FLEMING, TP; BOTTARO, DP; RUBIN, JS; RON, D; AARONSON, SA			EXPRESSION CDNA CLONING OF THE KGF RECEPTOR BY CREATION OF A TRANSFORMING AUTOCRINE LOOP	SCIENCE			English	Article							GROWTH-FACTOR; CELLS; DIFFERENTIATION; PURIFICATION; LIBRARIES; INSERTS; SYSTEM	An expression cloning strategy was devised to isolate the keratinocyte growth factor (KGF) receptor complementary DNA. NIH/3T3 fibroblasts, which secrete this epithelial cell-specific mitogen, were transfected with a keratinocyte expression complementary DNA library. Among several transformed foci identified, one demonstrated the acquisition of specific high-affinity KGF binding sites. The pattern of binding competition by related fibroblast growth factors (FGFs) indicated that this receptor had high affinity for acidic FGF as well as KGF. The rescued 4.2-kilobase complementary DNA was shown to encode a predicted membrane-spanning tyrosine kinase related to but distinct from the basic FGF receptor. This expression cloning approach may be generally applicable to the isolation of genes that constitute limiting steps in mitogenic signaling pathways.			MIKI, T (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOTTARO DP, UNPUB; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GUROFF G, 1987, ONCOGENES GENES GROW, P191; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KAHN P, 1986, ONCOGENES GROWTH CON; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; Miki T., UNPUB; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P8722; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUBIN J, UNPUB; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1988, ONCOGENE, V3, P9; RUTA M, 1989, P NATL ACAD SCI USA, V86, P5449; SAFRAN A, 1990, ONCOGENE, V5, P635; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8	35	448	475	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					72	75		10.1126/science.1846048	http://dx.doi.org/10.1126/science.1846048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1846048				2022-12-28	WOS:A1991EQ60300029
J	FEAVER, WJ; GILEADI, O; LI, Y; KORNBERG, RD				FEAVER, WJ; GILEADI, O; LI, Y; KORNBERG, RD			CTD KINASE ASSOCIATED WITH YEAST RNA POLYMERASE-II INITIATION FACTOR-B	CELL			English	Article							TRANSCRIPTION FACTOR; SUBUNIT COMPOSITION; PURIFICATION; PHOSPHORYLATION; PROMOTER; REQUIREMENT; ELONGATION; INVITRO; SYSTEM; REPEAT	A kinase activity specific for the C-terminal repeat domain (CTD) of RNA polymerase II is associated with nearly homogeneous yeast general initiation factor b by three criteria: cofractionation on the basis of size and charge and coinactivation by mild heat treatment. The kinase phosphorylates the CTD at multiple sites in a processive manner. Factor b may possess a DNA-dependent ATPase activity as well. Both kinase and DNA-dependent ATPase activities exhibit the same nucleotide requirements as previously demonstrated for the initiation of transcription. These results support the idea that phosphorylation of the CTD lies on the pathway of transcription initiation and identify a catalytic activity of a general factor essential for the initiation process.			FEAVER, WJ (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305, USA.		Gileadi, Opher/F-1105-2013	Gileadi, Opher/0000-0001-6886-898X	NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1991, IN PRESS J BIOL CHEM; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1990, J BIOL CHEM, V265, P5629; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; KIM WY, 1989, J BIOL CHEM, V264, P3169; KIM WY, 1988, J BIOL CHEM, V263, P18880; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SOPTA M, 1985, J BIOL CHEM, V260, P353; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZHANG J, 1991, J BIOL CHEM, V266, P2290	34	189	193	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1223	1230		10.1016/0092-8674(91)90298-D	http://dx.doi.org/10.1016/0092-8674(91)90298-D			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1836979				2022-12-28	WOS:A1991GX16400020
J	GROSSMAN, W				GROSSMAN, W			SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - DIASTOLIC DYSFUNCTION IN CONGESTIVE-HEART-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LEFT-VENTRICULAR RELAXATION; PACING-INDUCED ISCHEMIA; SARCOPLASMIC-RETICULUM CA-2+-ATPASE; EXERCISE-INDUCED ISCHEMIA; PRESSURE-VOLUME RELATIONS; CORONARY-ARTERY DISEASE; CARDIAC GENE-EXPRESSION; FAILING HUMAN-HEART; MYOCARDIAL-INFARCTION; DILATED CARDIOMYOPATHY		BETH ISRAEL HOSP, CHARLES A DANA RES INST, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	GROSSMAN, W (corresponding author), BETH ISRAEL HOSP, DEPT MED, DIV CARDIOVASC, HARVARD THORNDIKE LAB, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044431, P01HL038189] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38189, HL 44431] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPLEGATE RJ, 1990, CIRCULATION, V81, P1380, DOI 10.1161/01.CIR.81.4.1380; APSTEIN CS, 1987, J MOL CELL CARDIOL, V19, P119, DOI 10.1016/S0022-2828(87)80551-5; AROESTY JM, 1985, CIRCULATION, V71, P889, DOI 10.1161/01.CIR.71.5.889; BARRY WH, 1990, CIRCULATION, V82, P652, DOI 10.1161/01.CIR.82.2.652; BARRY WH, 1974, CIRCULATION, V49, P255, DOI 10.1161/01.CIR.49.2.255; BRISTOW MR, 1990, CIRCULATION, V82, P12; BRONZWAER JGF, 1991, CIRCULATION, V84, P211, DOI 10.1161/01.CIR.84.1.211; CARROLL JD, 1983, CIRCULATION, V67, P521, DOI 10.1161/01.CIR.67.3.521; CARROLL JD, 1985, CIRCULATION, V72, P119, DOI 10.1161/01.CIR.72.1.119; CHARLAT ML, 1989, J AM COLL CARDIOL, V13, P185, DOI 10.1016/0735-1097(89)90569-X; CORIN WJ, 1991, CIRCULATION, V83, P797, DOI 10.1161/01.CIR.83.3.797; CUOCOLO A, 1990, CIRCULATION, V81, P978, DOI 10.1161/01.CIR.81.3.978; DOUGLAS PS, 1991, J AM COLL CARDIOL, V17, P530, DOI 10.1016/S0735-1097(10)80127-5; FACTOR SM, 1991, J AM COLL CARDIOL, V17, P1343, DOI 10.1016/S0735-1097(10)80145-7; FELDMAN AM, 1991, CIRCULATION, V83, P1866, DOI 10.1161/01.CIR.83.6.1866; FELDMAN AM, 1988, J CLIN INVEST, V82, P189, DOI 10.1172/JCI113569; FELDMAN MD, 1987, CIRCULATION, V75, P331, DOI 10.1161/01.CIR.75.2.331; FIFER MA, 1986, CIRCULATION, V74, P675, DOI 10.1161/01.CIR.74.4.675; FRAGASSO G, 1991, J AM COLL CARDIOL, V17, P1251, DOI 10.1016/S0735-1097(10)80131-7; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; GROSSMAN W, 1979, CARDIOVASC RES, V13, P514, DOI 10.1093/cvr/13.9.514; GROSSMAN W, 1974, CIRCULATION, V49, P129, DOI 10.1161/01.CIR.49.1.129; GWATHMEY JK, 1990, J CLIN INVEST, V85, P1599, DOI 10.1172/JCI114611; GWATHMEY JK, 1991, J CLIN INVEST, V87, P1023, DOI 10.1172/JCI115061; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; HARIGAYA S, 1969, CIRC RES, V25, P781, DOI 10.1161/01.RES.25.6.781; HITTINGER L, 1989, CIRC RES, V65, P971, DOI 10.1161/01.RES.65.4.971; HUMPHREY LS, 1988, CIRCULATION, V77, P886, DOI 10.1161/01.CIR.77.4.886; IKENOUCHI H, 1991, J CLIN INVEST, V88, P55, DOI 10.1172/JCI115304; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KASS DA, 1990, CIRCULATION, V81, P447, DOI 10.1161/01.CIR.81.2.447; KATZ AM, 1990, NEW ENGL J MED, V322, P100; KIHARA Y, 1989, CIRC RES, V65, P1029, DOI 10.1161/01.RES.65.4.1029; KITZMAN DW, 1991, J AM COLL CARDIOL, V17, P1065, DOI 10.1016/0735-1097(91)90832-T; KORETSUNE Y, 1991, CIRC RES, V68, P255, DOI 10.1161/01.RES.68.1.255; LAKATTA EG, 1987, ANNU REV PHYSIOL, V49, P519; LAMAS GA, 1991, AM HEART J, V121, P1194, DOI 10.1016/0002-8703(91)90682-8; LECARPENTIER Y, 1987, CIRC RES, V61, P107, DOI 10.1161/01.RES.61.1.107; LIMAS CJ, 1987, CARDIOVASC RES, V21, P601, DOI 10.1093/cvr/21.8.601; LORELL BH, 1987, J AM COLL CARDIOL, V9, P1189, DOI 10.1016/S0735-1097(87)80326-1; LORELL BH, 1988, CIRC RES, V63, P457, DOI 10.1161/01.RES.63.2.457; LORELL BH, 1982, CIRCULATION, V65, P499, DOI 10.1161/01.CIR.65.3.499; MACIEL LMZ, 1990, CIRC RES, V67, P230, DOI 10.1161/01.RES.67.1.230; MANN T, 1977, CIRCULATION, V55, P761, DOI 10.1161/01.CIR.55.5.761; MCKAY RG, 1986, CIRCULATION, V74, P693, DOI 10.1161/01.CIR.74.4.693; MCLAURIN LP, 1973, AM J CARDIOL, V32, P751, DOI 10.1016/S0002-9149(73)80002-5; MERCADIER JJ, 1990, J CLIN INVEST, V85, P305, DOI 10.1172/JCI114429; MIYAZAKI S, 1990, CIRCULATION, V81, P1058, DOI 10.1161/01.CIR.81.3.1058; MOMOMURA S, 1984, CIRC RES, V55, P203, DOI 10.1161/01.RES.55.2.203; MOMOMURA S, 1985, CIRC RES, V57, P822, DOI 10.1161/01.RES.57.6.822; MONRAD ES, 1984, CIRCULATION, V70, P1030, DOI 10.1161/01.CIR.70.6.1030; MOVSESIAN MA, 1989, CIRC RES, V65, P1141, DOI 10.1161/01.RES.65.4.1141; OLIVETTI G, 1991, CIRC RES, V68, P856, DOI 10.1161/01.RES.68.3.856; PAULUS WJ, 1985, AM J PHYSIOL, V248, pH719, DOI 10.1152/ajpheart.1985.248.5.H719; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; PISCIONE F, 1987, J AM COLL CARDIOL, V10, P1294, DOI 10.1016/S0735-1097(87)80134-1; POULEUR H, 1984, CIRCULATION, V69, P696, DOI 10.1161/01.CIR.69.4.696; SASAYAMA S, 1985, J AM COLL CARDIOL, V5, P599, DOI 10.1016/S0735-1097(85)80382-X; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; SERIZAWA T, 1980, CIRC RES, V46, P430, DOI 10.1161/01.RES.46.3.430; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SOUFER R, 1985, AM J CARDIOL, V55, P1032, DOI 10.1016/0002-9149(85)90741-6; STARKSEN NF, 1986, P NATL ACAD SCI USA, V83, P8348, DOI 10.1073/pnas.83.21.8348; THIEDEMANN KU, 1983, BASIC RES CARDIOL, V78, P140, DOI 10.1007/BF01906668; VATNER DE, 1985, J CLIN INVEST, V76, P2259, DOI 10.1172/JCI112235; WARREN SE, 1988, J AM COLL CARDIOL, V11, P12, DOI 10.1016/0735-1097(88)90159-3; WATANABE J, 1990, CIRC RES, V67, P923, DOI 10.1161/01.RES.67.4.923; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849	68	291	303	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1991	325	22					1557	1564						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR380	1834939				2022-12-28	WOS:A1991GR38000006
J	CHENG, SWC; LYNCH, EC; LEASON, KR; COURT, DL; SHAPIRO, BA; FRIEDMAN, DI				CHENG, SWC; LYNCH, EC; LEASON, KR; COURT, DL; SHAPIRO, BA; FRIEDMAN, DI			FUNCTIONAL IMPORTANCE OF SEQUENCE IN THE STEM-LOOP OF A TRANSCRIPTION TERMINATOR	SCIENCE			English	Article							ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; OPERON ATTENUATOR; GENE-EXPRESSION; RNA-POLYMERASE; NINR REGION; EFFICIENCY; PROMOTERS; PROTEIN; SITES	Intrinsic transcription terminators of prokaryotes are distinguished by a common RNA motif: a stem-loop structure high in guanine and cytosine content, followed by multiple uridine residues. Models explaining intrinsic terminators postulate that the stem-loop sequence is necessary only to form structure. In the tR2 terminator of coliphage lambda, single-nucleotide changes reducing potential RNA stem stability eliminated tR2 activity, and a compensatory change that restored the stem structure restored terminator activity. However, multiple changes in the stem sequence that should have either maintained or increased stability reduced terminator activity. These results suggest that the ability of the stem-loop structure to signal transcription termination depends on sequence specificity and secondary structure.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,CHROMOSOME BIOL,FREDERICK,MD 21701; NCI,FREDERICK CANC RES & DEV CTR,MATH BIOL LAB,IMAGING PROC SECT,FREDERICK,MD 21701	University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Friedman, David/G-3198-2015	Friedman, David/0000-0002-2741-4671	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIAID NIH HHS [AI1459-10] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADHYA S, 1979, NATURE, V279, P492, DOI 10.1038/279492a0; CARAFA YD, 1991, J MOL BIOL, V21, P835; Cheng S.-F., UNPUB; COSTANTINO N, 1990, J BACTERIOL, V172, P4610, DOI 10.1128/jb.172.8.4610-4615.1990; COURT D, 1969, VIROLOGY, V39, P348, DOI 10.1016/0042-6822(69)90060-9; Daniels D., 1983, LAMBDA, P469; Fiandt M., 1971, BACTERIOPHAGE LAMBDA, P329; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; FRIEDMAN DI, 1981, P NATL ACAD SCI-BIOL, V78, P1115, DOI 10.1073/pnas.78.2.1115; FRIEDMAN DI, 1988, BACTERIOPHAGES, V2, P263; GOLIGER JA, 1989, J MOL BIOL, V205, P331, DOI 10.1016/0022-2836(89)90344-6; GREENBLATT J, 1981, NATURE, V292, P215, DOI 10.1038/292215a0; JOHNSTON HM, 1981, J MOL BIOL, V145, P725; KRINKE L, 1990, NUCLEIC ACIDS RES, V18, P4809, DOI 10.1093/nar/18.16.4809; KROGER M, 1982, GENE, V20, P25, DOI 10.1016/0378-1119(82)90084-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDICK R, 1987, CELLULAR MOL BIOL, P1276; LEASON KR, 1988, J BACTERIOL, V170, P5051, DOI 10.1128/jb.170.11.5051-5058.1988; LYNN SP, 1988, J BIOL CHEM, V263, P472; LYNN SP, 1985, J MOL BIOL, V183, P529, DOI 10.1016/0022-2836(85)90169-X; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; McKenney K, 1981, Gene Amplif Anal, V2, P383; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; RAY DS, 1981, INITIATION DNA REPLI, P169; REYNOLDS R, IN PRESS J MOL BIOL; REYNOLDS R, IN PRESS J MOL BIOLJ; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICHARDSON JP, 1991, CELL, V64, P1047, DOI 10.1016/0092-8674(91)90257-Y; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SALSTROM JS, 1978, J MOL BIOL, V124, P195, DOI 10.1016/0022-2836(78)90156-0; SCHMIDT MC, 1987, J MOL BIOL, V195, P809, DOI 10.1016/0022-2836(87)90486-4; SPENCER CA, 1990, ONCOGENE, V5, P777; TELESNITSKY APW, 1989, J MOL BIOL, V205, P315, DOI 10.1016/0022-2836(89)90343-4; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; YAGER TD, 1987, CELLULAR MOL BIOL, P1241; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	41	61	61	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1991	254	5035					1205	1207		10.1126/science.1835546	http://dx.doi.org/10.1126/science.1835546			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ834	1835546				2022-12-28	WOS:A1991GQ83400048
J	FLYNN, GC; POHL, J; FLOCCO, MT; ROTHMAN, JE				FLYNN, GC; POHL, J; FLOCCO, MT; ROTHMAN, JE			PEPTIDE-BINDING SPECIFICITY OF THE MOLECULAR CHAPERONE BIP	NATURE			English	Article							NEWLY SYNTHESIZED PROTEINS; HEAT-SHOCK; CELLS; HYDROPHOBICITY; TRANSLOCATION; DEGRADATION; CATALYSTS; CORE; ATP	Members of the heat-shock protein family (hsp70s) can distinguish folded from unfolded proteins. This property is crucial to the role of hsp70s as molecular chaperones and is attributable to the amino-acid specificity of the peptide-binding site. The specificity for peptide ligands is investigated using a set of peptides of random sequence but defined chain length. The peptide-binding site selects for aliphatic residues and accommodates them in an environment energetically equivalent to the interior of a folded protein.	EMORY UNIV, SCH MED, MICROCHEM FACIL, ATLANTA, GA 30322 USA; PRINCETON UNIV, DEPT MOLEC BIOL, MICROCHEM CORE FACIL, PRINCETON, NJ 08544 USA	Emory University; Princeton University	FLYNN, GC (corresponding author), SLOAN KETTERING MEM CANC CTR, ROCKEFELLER RES LAB, PROGRAM CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA.							BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P618; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FLAJNIK MF, 1991, P NATL ACAD SCI USA, V88, P537, DOI 10.1073/pnas.88.2.537; FLAJNIK MF, IN PRESS IMMUNOGENET; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KAPPER MH, 1977, BIOCHEM BIOPH RES CO, V78, P1018; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; POHL J, 1990, FEBS LETT, V272, P200, DOI 10.1016/0014-5793(90)80484-Z; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; TACK BF, 1980, J BIOL CHEM, V255, P8842; TANFORD C, 1962, J AM CHEM SOC, V84, P4240, DOI 10.1021/ja00881a009	35	680	705	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	1991	353	6346					726	730		10.1038/353726a0	http://dx.doi.org/10.1038/353726a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1834945				2022-12-28	WOS:A1991GL69600057
J	CARETTE, S; MARCOUX, S; TRUCHON, R; GRONDIN, C; GAGNON, J; ALLARD, Y; LATULIPPE, M				CARETTE, S; MARCOUX, S; TRUCHON, R; GRONDIN, C; GAGNON, J; ALLARD, Y; LATULIPPE, M			A CONTROLLED TRIAL OF CORTICOSTEROID INJECTIONS INTO FACET JOINTS FOR CHRONIC LOW-BACK-PAIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Chronic low back pain is a common problem with many treatments, few of which have been rigorously evaluated. This randomized, placebo-controlled trial was designed to evaluate the efficacy of injections of corticosteroid into facet joints to treat chronic low back pain. Methods. Patients with chronic low back pain who reported immediate relief of their pain after injections of local anesthetic into the facet joints between the fourth and fifth lumbar vertebrae and the fifth lumbar and first sacral vertebrae were randomly assigned to receive under fluoroscopic guidance injections of either methylprednisolone acetate (20 mg; n = 49) or isotonic saline (n = 48) in the same facet joints. Ninety-five patients were followed for six months and their condition assessed with scales of pain severity, back mobility, and limitation of function. Results. After one month, none of the outcome measures evaluating pain, functional status, and back flexion differed clinically or statistically between the two study groups. Forty-two percent of the patients who received methylprednisolone and 33 percent of those who received placebo reported marked or very marked improvement (95 percent confidence interval for the difference, -11 to 28 percentage points; P = 0.53). The results were similar after three months. At the six-month evaluation, the patients treated with methylprednisolone reported more improvement, less pain on the visual-analogue scale, and less physical disability. The differences were reduced, however, when concurrent interventions were taken into account. Moreover, only 11 patients (22 percent) in the methylprednisolone group and 5 (10 percent) in the placebo group had sustained improvement from the first month to the sixth month (95 percent confidence interval for the difference, -2 to 26; P = 0.19). Conclusions. We conclude that injecting methylprednisolone acetate into the facet joints is of little value in the treatment of patients with chronic low back pain.	UNIV LAVAL,DEPT MED,QUEBEC CITY G1K 7P4,QUEBEC,CANADA; UNIV LAVAL,DEPT SOCIAL & PREVENT MED,QUEBEC CITY G1K 7P4,QUEBEC,CANADA; UNIV LAVAL,DEPT ANESTHESIOL,QUEBEC CITY G1K 7P4,QUEBEC,CANADA; UNIV LAVAL,DEPT RADIOL,QUEBEC CITY G1K 7P4,QUEBEC,CANADA	Laval University; Laval University; Laval University; Laval University								[Anonymous], 1987, SPINE, V12, pS1; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; CARRERA GF, 1980, RADIOLOGY, V137, P665, DOI 10.1148/radiology.137.3.6449717; DESTOUET JM, 1982, RADIOLOGY, V145, P321, DOI 10.1148/radiology.145.2.6215674; DEYO RA, 1990, NEW ENGL J MED, V322, P1627, DOI 10.1056/NEJM199006073222303; DEYO RA, 1983, SPINE, V8, P635, DOI 10.1097/00007632-198309000-00009; Goldthwait JE, 1911, BOSTON MED SURG J, V164, P365, DOI 10.1056/NEJM191103161641101; HIRSCH CARL, 1963, ACTA ORTHOPAED SCAND, V33, P1, DOI 10.3109/17453676308999829; HOLLANDER JL, 1954, ANN RHEUM DIS, V13, P297, DOI 10.1136/ard.13.4.297; JACKSON RP, 1988, SPINE, V13, P966, DOI 10.1097/00007632-198809000-00002; LAU LSW, 1985, MED J AUSTRALIA, V143, P563, DOI 10.5694/j.1326-5377.1985.tb119951.x; LILIUS G, 1989, J BONE JOINT SURG BR, V71, P681, DOI 10.1302/0301-620X.71B4.2527856; LIPPITT AB, 1984, SPINE, V9, P746, DOI 10.1097/00007632-198410000-00016; LYNCH MC, 1986, J BONE JOINT SURG BR, V68, P138, DOI 10.1302/0301-620X.68B1.2934398; MCCALL IW, 1979, SPINE, V4, P441, DOI 10.1097/00007632-197909000-00009; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Mooney V, 1976, Clin Orthop Relat Res, P149; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; VADEBONCOEUR R, 1986, UNION MED CAN, V115, P458	19	290	301	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					1002	1007		10.1056/NEJM199110033251405	http://dx.doi.org/10.1056/NEJM199110033251405			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1832209				2022-12-28	WOS:A1991GH44700005
J	CHELLAPPAN, SP; HIEBERT, S; MUDRYJ, M; HOROWITZ, JM; NEVINS, JR				CHELLAPPAN, SP; HIEBERT, S; MUDRYJ, M; HOROWITZ, JM; NEVINS, JR			THE E2F TRANSCRIPTION FACTOR IS A CELLULAR TARGET FOR THE RB PROTEIN	CELL			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; ADENOVIRUS E1A PROTEINS; DNA-BINDING ACTIVITY; TRANS-ACTIVATION; ENCODED PROTEIN; PRODUCT; EXPRESSION; CYCLE; PHOSPHORYLATION; ASSOCIATION	Although it is generally believed that the product of the retinoblastoma susceptibility gene (RB1) is an important regulator of cell proliferation, the biochemical mechanism for its action is unclear. We now show that the RB protein is found in a complex with the E2F transcription factor and that only the underphosphorylated form of RB is in the E2F complex. Moreover, the adenovirus E1A protein can dissociate the E2F-RB complex, dependent on E1A sequence also critical for E1A to bind to RB. These sequences are also critical for E1A to immortalize primary cell cultures and to transform in conjunction with other oncogenes. Taken together, these results suggest that the interaction of RB with E2F is an important event in the control of cellular proliferation and that the dissociation of the complex is part of the mechanism by which E1A inactivates RB function.	DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,GENET SECT,DURHAM,NC 27710	Duke University; Duke University	CHELLAPPAN, SP (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.		Hiebert, Scott W/C-9979-2010		NATIONAL CANCER INSTITUTE [R01CA053248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026765] Funding Source: NIH RePORTER; NCI NIH HHS [CA53248] Funding Source: Medline; NIGMS NIH HHS [GM26765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EGAN C, 1989, ONCOGENE, V4, P383; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; MUDRYJ M, 1991, IN PRESS CELL; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; RAYCHAUDHURI P, 1991, IN PRESS GENES DEV; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; VARLEY JM, 1989, ONCOGENE, V4, P725; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YOKOTA J, 1988, ONCOGENE, V3, P471; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	52	1304	1328	2	53	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1053	1061		10.1016/0092-8674(91)90557-F	http://dx.doi.org/10.1016/0092-8674(91)90557-F			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1828392				2022-12-28	WOS:A1991FR04700016
J	CAPSON, TL; BENKOVIC, SJ; NOSSAL, NG				CAPSON, TL; BENKOVIC, SJ; NOSSAL, NG			PROTEIN DNA CROSS-LINKING DEMONSTRATES STEPWISE ATP-DEPENDENT ASSEMBLY OF T4-DNA POLYMERASE AND ITS ACCESSORY PROTEINS ON THE PRIMER-TEMPLATE	CELL			English	Article								T4 DNA polymerase, the 44/62 and 45 polymerase accessory proteins, and 32 single-stranded DNA-binding protein catalyze ATP-dependent DNA synthesis. Using DNA primers with cross-linkable residues at specific positions, we obtained structural data that reveal how these proteins assemble on the primer-template. With the nonhydrolyzable ATP analog ATP-gamma-S, assembly of the 44/62 and 45 proteins on the primer requires 32 protein but not polymerase. ATP hydrolysis changes the position and intensity of cross-linking to each of the accessory proteins and allows cross-linking of polymerase. Our data indicate that the initial binding of the three accessory proteins and ATP to a 32 protein-covered primer-template is followed by ATP hydrolysis, binding of polymerase, and movement of the accessory proteins to yield a complex capable of processive DNA synthesis.	PENN STATE UNIV, DEPT CHEM, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	CAPSON, TL (corresponding author), NIDDKD, NUCL ACID BIOCHEM SECT, BIOCHEM PHARMACOL LAB, BLDG 8, ROOM 2A-15, BETHESDA, MD 20892 USA.				NIGMS NIH HHS [GM 12011, GM 13306] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012011] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ALBERTS BM, 1980, ICN UCLA S MOL CELL, V19, P449; BARTHOLOMEW B, 1990, J BIOL CHEM, V265, P3731; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; Bayley H, 1977, Methods Enzymol, V46, P69; BAYLEY H, 1983, LABORATORY TECHNIQUE, V12; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; DISSINGER S, 1990, J BIOL CHEM, V265, P7662; EVANS RK, 1987, BIOCHEMISTRY-US, V26, P269, DOI 10.1021/bi00375a037; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GIBSON KJ, 1987, NUCLEIC ACIDS RES, V15, P6455, DOI 10.1093/nar/15.16.6455; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HOCKENSMITH JW, 1986, J BIOL CHEM, V261, P3512; JARVIS TC, 1990, UCLA SYM BI, V127, P261; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; MACE DC, 1984, J MOL BIOL, V177, P279, DOI 10.1016/0022-2836(84)90457-1; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MUNN M, 1986, THESIS U CALIFORNIA; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; PIPERNO JR, 1978, J BIOL CHEM, V253, P5180; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; RUSH J, 1989, PREP BIOCHEM, V19, P329, DOI 10.1080/10826068908544921; RUSH J, 1989, J BIOL CHEM, V264, P10943; SELICK HE, 1987, DNA REPLICATION RECO, V47, P183; STOCCHI V, 1985, ANAL BIOCHEM, V146, P118, DOI 10.1016/0003-2697(85)90405-1; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WOLD MS, 1989, J BIOL CHEM, V264, P2801	42	91	91	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1991	65	2					249	258		10.1016/0092-8674(91)90159-V	http://dx.doi.org/10.1016/0092-8674(91)90159-V			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1849797				2022-12-28	WOS:A1991FH09200008
J	BERNANDER, R; DASGUPTA, S; NORDSTROM, K				BERNANDER, R; DASGUPTA, S; NORDSTROM, K			THE ESCHERICHIA-COLI CELL-CYCLE AND THE PLASMID R1 REPLICATION CYCLE IN THE ABSENCE OF THE DNAA PROTEIN	CELL			English	Article							ESCHERICHIA-COLI; CHROMOSOME-REPLICATION; MINICHROMOSOME REPLICATION; INITIATION; GENE; ORIGIN; EXPRESSION; MUTANTS; OVERPRODUCTION; SUPPRESSION	In E. coli strain EC::71CW chromosome replication is under the control of the R1 miniplasmid pOU71. A dnaA850::Tn10 derivative of EC::71CW was viable, which confirmed that R1 can replicate in the absence of the DnaA protein. The frequency of initiation of replication was, however, lowered and cell division was severely disturbed due to underreplication of the chromosome. Both replication and cell division could be restored to normal by increasing the production of RepA, the rate-limiting protein for initiation of replication from the integrated R1 origin. Therefore, the RepA protein seems to compensate for the absence of DnaA in the initiation of replication and assembly of replisomes. The role of the DnaA protein in the initiation of DNA replication, and as an overall regulator of the chromosome replication and cell division cycles of E. coli, is discussed in view of these results.			BERNANDER, R (corresponding author), UNIV UPPSALA,CTR BIOMED,DEPT MICROBIOL,BOX 581,S-75123 UPPSALA,SWEDEN.							ABELES AL, 1990, J BACTERIOL, V172, P4386, DOI 10.1128/jb.172.8.4386-4391.1990; ANDERSON P, 1981, P NATL ACAD SCI-BIOL, V78, P3113, DOI 10.1073/pnas.78.5.3113; ATLUNG T, 1987, MOL GEN GENET, V206, P51, DOI 10.1007/BF00326535; BERNANDER R, 1989, J BACTERIOL, V171, P674, DOI 10.1128/jb.171.2.674-683.1989; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BREMER H, 1985, J BACTERIOL, V164, P922, DOI 10.1128/JB.164.2.922-924.1985; CHANDLER M, 1977, J BACTERIOL, V131, P421, DOI 10.1128/JB.131.2.421-430.1977; CHIARAMELLO AE, 1989, J BACTERIOL, V171, P4272, DOI 10.1128/JB.171.8.4272-4280.1989; CHURCHWARD G, 1983, MOL GEN GENET, V192, P506, DOI 10.1007/BF00392197; DONACHIE WD, 1989, J BACTERIOL, V171, P4633, DOI 10.1128/jb.171.9.4633-4639.1989; DONACHIE WD, 1984, MICROBIAL DEV, P27; GEORGOPOULOS C, 1989, TRENDS GENET, V5, P319, DOI 10.1016/0168-9525(89)90118-2; GUSTAFSSON P, 1978, PLASMID, V1, P187, DOI 10.1016/0147-619X(78)90038-0; HANSEN EB, 1986, P NATL ACAD SCI USA, V83, P4423, DOI 10.1073/pnas.83.12.4423; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; KOGOMA T, 1983, EMBO J, V2, P463, DOI 10.1002/j.1460-2075.1983.tb01445.x; KOPPES L, 1986, CELL, V44, P117, DOI 10.1016/0092-8674(86)90490-3; LARSEN JEL, 1984, GENE, V28, P45, DOI 10.1016/0378-1119(84)90086-6; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; MAHAFFY JM, 1989, J THEOR BIOL, V140, P453, DOI 10.1016/S0022-5193(89)80109-2; Maniatis T., 1982, MOL CLONING; MASAI H, 1987, P NATL ACAD SCI USA, V84, P4781, DOI 10.1073/pnas.84.14.4781; MASAI H, 1983, P NATL ACAD SCI USA, V80, P6841; MESSER W, 1988, BIOCHIM BIOPHYS ACTA, V951, P351, DOI 10.1016/0167-4781(88)90106-6; Miller J.H., 1972, EXPT MOL GENETICS; MORIYA S, 1990, EMBO J, V9, P2905, DOI 10.1002/j.1460-2075.1990.tb07481.x; NAGATA T, 1988, MOL GEN GENET, V213, P163, DOI 10.1007/BF00333414; NORDSTROM K, 1980, PLASMID, V4, P215, DOI 10.1016/0147-619X(80)90011-6; NORDSTROM K, 1991, IN PRESS MOL MICROBI; ORTEGA S, 1986, NUCLEIC ACIDS RES, V14, P4865, DOI 10.1093/nar/14.12.4865; PIERUCCI O, 1987, J BACTERIOL, V169, P1871, DOI 10.1128/jb.169.5.1871-1877.1987; SAKAKIBARA Y, 1982, MOL GEN GENET, V186, P87, DOI 10.1007/BF00422917; SKARSTAD K, 1989, MOL GEN GENET, V218, P50, DOI 10.1007/BF00330564; SKARSTAD K, 1988, J BACTERIOL, V170, P852, DOI 10.1128/jb.170.2.852-858.1988; TANG XB, 1989, J BACTERIOL, V171, P5290, DOI 10.1128/jb.171.10.5290-5295.1989; XU YC, 1988, MOL GEN GENET, V211, P138, DOI 10.1007/BF00338404	40	38	38	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1145	1153		10.1016/0092-8674(91)90269-5	http://dx.doi.org/10.1016/0092-8674(91)90269-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	1848482				2022-12-28	WOS:A1991FD55800012
J	GILLESGONZALEZ, MA; DITTA, GS; HELINSKI, DR				GILLESGONZALEZ, MA; DITTA, GS; HELINSKI, DR			A HEMOPROTEIN WITH KINASE-ACTIVITY ENCODED BY THE OXYGEN SENSOR OF RHIZOBIUM-MELILOTI	NATURE			English	Article							ESCHERICHIA-COLI; PHOSPHORYLATION; EXPRESSION; GENES; NIFA	THE expression of the nitrogen-fixation genes of Rhizobium meliloti is controlled by oxygen 1,2. These genes are induced when the free oxygen concentration is reduced to microaerobic levels. Two regulator proteins, FixL and FixJ, initiate the oxygen-response cascade, and the genes that encode them have been cloned 2,3. The fixL product seems to be a transmembrane sensor that modulates the activity of the fixJ product, a cytoplasmic regulator 3. FixL and FixJ are homologous to a family of bacterial two-component regulators 4, for which the mode of signal transduction is phosphorylation (reviewed in refs 5-9). We report here the purification of both FixJ and a soluble truncated FixL (FixL*), overproduced from a single plasmid construct. FixL* catalyses its own phosphorylation and the transfer of the gamma-phosphate of ATP to FixJ. The resulting FixJ-phosphate linkage is sensitive to base, as are the aspartyl phosphates of homologous systems. Visible spectra of purified FixL* show that it is an oxygen-binding haemoprotein. We propose that FixL senses oxygen through its haem moiety and transduces this signal by controlling the phosphorylation of FixJ.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	GILLESGONZALEZ, MA (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,0634,LA JOLLA,CA 92093, USA.							ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; DAVID M, 1988, CELL, V54, P671, DOI 10.1016/S0092-8674(88)80012-6; DITTA G, 1987, J BACTERIOL, V169, P3217, DOI 10.1128/jb.169.7.3217-3223.1987; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; Gibson T.J., 1984, THESIS CAMBRIDGE U U; GROSS R, 1989, MOL MICROBIOL, V3, P1661, DOI 10.1111/j.1365-2958.1989.tb00152.x; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; JIN SG, 1990, J BACTERIOL, V172, P525, DOI 10.1128/jb.172.2.525-530.1990; MELCHERS LS, 1989, EMBO J, V8, P1919, DOI 10.1002/j.1460-2075.1989.tb03595.x; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; STOCK AM, 1988, COLD SPRING HARB SYM, V53, P49, DOI 10.1101/SQB.1988.053.01.009; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; VIRTS EL, 1988, P NATL ACAD SCI USA, V85, P3062, DOI 10.1073/pnas.85.9.3062; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	16	435	440	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					170	172		10.1038/350170a0	http://dx.doi.org/10.1038/350170a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	1848683				2022-12-28	WOS:A1991FB64500065
J	SCHIEBEL, E; DRIESSEN, AJM; HARTL, FU; WICKNER, W				SCHIEBEL, E; DRIESSEN, AJM; HARTL, FU; WICKNER, W			DELTA-MU-H+ AND ATP FUNCTION AT DIFFERENT STEPS OF THE CATALYTIC CYCLE OF PREPROTEIN TRANSLOCASE	CELL			English	Article							MALTOSE-BINDING-PROTEIN; ESCHERICHIA-COLI SECB; PURIFIED PRECURSOR PROTEIN; BACTERIAL LEADER PEPTIDASE; ENDOPLASMIC-RETICULUM; TRIGGER FACTOR; COAT PROTEIN; PRO-OMPA; MEMBRANE TRANSLOCATION; CYTOPLASMIC MEMBRANE	Preprotein translocation in E. coli requires ATP, the membrane electrochemical potential DELTA-mu-H+, and translocase, an enzyme with an ATPase domain (SecA) and the membrane-embedded SecY/E. Studies of translocase and proOmpA reveal a five-step catalytic cycle: First, proOmpA binds to the SecA domain. Second, SecA binds ATP. Third, ATP-binding energy permits translocation of approximately 20 residues of proOmpA. Fourth, ATP hydrolysis releases proOmpA. ProOmpA may then rebind to SecA and reenter this cycle, allowing progress through a series of transmembrane intermediates. In the absence of DELTA-mu-H+ or association with SecA, proOmpA passes backward through the membrane, but moves forward when either ATP and SecA or a membrane electrochemical potential is supplied. However, in the presence of DELTA-mu-H+ (fifth step), proOmpA rapidly completes translocation. DELTA-mu-H+ - driven translocation is blocked by SecA plus nonhydrolyzable ATP analogs, indicating that DELTA-mu-H+ drives translocation when ATP and proOmpA are not bound to SecA.	UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	SCHIEBEL, E (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.		Hartl, F. Ulrich/Y-8206-2019; Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; CHEN LL, 1986, J BACTERIOL, V168, P828, DOI 10.1128/jb.168.2.828-832.1986; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DRIESSEN AJM, 1991, IN PRESS P NATL ACAD; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GELLER BL, 1989, J BIOL CHEM, V264, P16465; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; ITO K, 1980, J BIOL CHEM, V255, P2123; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUHN A, 1987, EMBO J, V6, P501, DOI 10.1002/j.1460-2075.1987.tb04781.x; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LECKER SH, 1990, EMBO J, V9, P2309, DOI 10.1002/j.1460-2075.1990.tb07402.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; OHNOIWASHITA Y, 1983, J BIOL CHEM, V258, P1895; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VESTWEBER D, 1988, J CELL BIOL, V107, P2045, DOI 10.1083/jcb.107.6.2045; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WILSON C, 1988, J CELL BIOL, V107, P69, DOI 10.1083/jcb.107.1.69; WOLFE PB, 1984, CELL, V36, P1067, DOI 10.1016/0092-8674(84)90056-4; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; ZIMMERMANN R, 1983, J BIOL CHEM, V258, P3920	58	402	408	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1991	64	5					927	939		10.1016/0092-8674(91)90317-R	http://dx.doi.org/10.1016/0092-8674(91)90317-R			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1825804				2022-12-28	WOS:A1991FA94000010
J	FRANKEL, WN; RUDY, C; COFFIN, JM; HUBER, BT				FRANKEL, WN; RUDY, C; COFFIN, JM; HUBER, BT			LINKAGE OF MLS GENES TO ENDOGENOUS MAMMARY-TUMOR VIRUSES OF INBRED MICE	NATURE			English	Article							INDUCED IMMUNODEFICIENCY SYNDROME; CHROMOSOMAL DISTRIBUTION; MOUSE CHROMOSOME-1; RETROVIRUS; LOCI; GR; DETERMINANTS; SEGREGATION; EXPRESSION; INDUCTION	T CELLS that recognize self antigen are clonally deleted in the thymus-a maturation process that occurs in the context of histocompatibility molecules and the T-cell receptor. The minor lymphocyte stimulation antigens (Mls) effect these deletions through interactions with the V-beta portion of the T-cell receptor, thus mimicking bacterial 'superantigens'. Intrigued by the fact that each known Mls gene maps to the same chromosomal region as an endogenous mouse mammary tumour virus (Mtv), we reevaluated the linkage relationships between the two gene families. Here we report perfect concordance in inbred and recombinant inbred mice between the presence of four Mtv proviruses with the expression of Mls gene products. These data suggest a general model in which mammary tumour virus gene products themselves are the ligands that shape a considerable portion of the immunological repertoire of common laboratory mice.	TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MOLEC BIOL,BOSTON,MA 02111	Tufts University; Tufts University								ABE R, 1987, J EXP MED, V165, P1113, DOI 10.1084/jem.165.4.1113; ABE R, IN PRESS IMMUNOGENET; ABROMSONLEEMAN SR, 1988, J IMMUNOL, V140, P1726; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BALL JK, 1985, VIROLOGY, V140, P159, DOI 10.1016/0042-6822(85)90455-6; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; CHO M, IN PRESS MAMM GENOME; DUDLEY J, 1984, J VIROL, V49, P92, DOI 10.1128/JVI.49.1.92-101.1984; EICHER EM, 1990, GENETICS, V125, P431; FESTENSTEIN H, 1977, IMMUNOGENETICS, V5, P357, DOI 10.1007/BF01570493; FRANKEL WN, 1990, GENETICS, V124, P221; GRAY DA, 1986, VIROLOGY, V148, P237, DOI 10.1016/0042-6822(86)90421-6; JANEWAY CA, 1990, CELL, V63, P659, DOI 10.1016/0092-8674(90)90130-7; KAPPLER JW, 1989, COLD SPRING HARB SYM, V54, P401; KING LB, 1990, J IMMUNOL, V144, P3218; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; LEE BK, 1990, J VIROL, V64, P4568, DOI 10.1128/JVI.64.9.4568-4572.1990; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MACINNES JI, 1984, VIROLOGY, V132, P12, DOI 10.1016/0042-6822(84)90087-4; MAJORS JE, 1981, NATURE, V289, P253, DOI 10.1038/289253a0; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; Maniatis T., 1982, MOL CLONING; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MICHALIDES R, 1985, VIROLOGY, V142, P278, DOI 10.1016/0042-6822(85)90336-8; MICHALIDES R, 1982, J VIROL, V43, P819, DOI 10.1128/JVI.43.3.819-829.1982; MORSE HC, 1989, J IMMUNOL, V143, P844; MORSE HC, 1981, MOUSE BIOMEDICAL RES; PAULEY RJ, 1984, VIRUS RES, V1, P381, DOI 10.1016/0168-1702(84)90025-X; PETERS G, 1986, J VIROL, V59, P535, DOI 10.1128/JVI.59.3.535-544.1986; PROCHAZKA M, 1990, MOUSE GENOME, V87, P111; PULLEN AM, 1989, J IMMUNOL, V142, P3033; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RYAN JJ, 1990, J IMMUNOL, V144, P2506; SELDIN MF, 1988, J IMMUNOGENET, V15, P59; Seldin MF, 1988, GENOMICS, V2, P48, DOI 10.1016/0888-7543(88)90108-5; SILVER J, 1985, J HERED, V76, P436, DOI 10.1093/oxfordjournals.jhered.a110140; STOYE J, 1985, RNA TUMOR VIRUSES, P357; TRAINA VL, 1981, J VIROL, V40, P735, DOI 10.1128/JVI.40.3.735-744.1981; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	41	367	368	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					526	528		10.1038/349526a0	http://dx.doi.org/10.1038/349526a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846948				2022-12-28	WOS:A1991EW57100067
J	POTTER, E; BEHAN, DP; FISCHER, WH; LINTON, EA; LOWRY, PJ; VALE, WW				POTTER, E; BEHAN, DP; FISCHER, WH; LINTON, EA; LOWRY, PJ; VALE, WW			CLONING AND CHARACTERIZATION OF THE CDNAS FOR HUMAN AND RAT CORTICOTROPIN RELEASING FACTOR-BINDING PROTEINS	NATURE			English	Article							AMINO-ACID SEQUENCE; HUMAN-PLASMA; MATERNAL PLASMA; HUMAN-PLACENTA; PREGNANCY; HORMONE; ACTH; ADRENALECTOMY; SECRETION; OXYTOCIN	CORTICOTROPIN-releasing factor (CRF)1, is a potent stimulator of synthesis and secretion of preopiomelanocortin-derived peptides. Although CRF concentrations in the human peripheral circulation are normally low 2-4, they increase throughout pregnancy 4-8 and fall rapidly after parturition. Maternal plasma CRF probably originates from the placenta, which responds to the bioactive peptide 5, 9, 10 and produces the peptide 9 and its messenger RNA 11. Even though CRF concentrations in late gestational maternal plasma are similar to those in rat hypothalamic portal blood 12,13 and to those that can stimulate release of adrenocorticotropic hormone (ACTH) in vitro, maternal plasma ACTH concentrations increase only slightly with advancing gestation and remain within the normal range 14. Several groups have now reported the existence of a CRF-binding protein in human plasma which inactivates CRF 15-20 and which has been proposed to prevent inappropriate pituitary-adrenal stimulation in pregnancy. The binding protein was recently purified from human plasma 19. We have now isolated and partially sequenced the binding protein, allowing us to clone and characterize its complementary DNA from human liver and rat brain. Expression of the cDNAs for human and rat binding protein in COS7 cells showed that these proteins bind CRF with the same affinity as the native human protein 15. Both rat and human recombinant binding proteins inhibit CRF binding to a CRF antibody and inhibit CRF-induced ACTH release by pituitary cells in vitro.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92037; UNIV READING,SCH ANIM & MICROBIAL SCI,DEPT BIOCHEM & PHYSIOL,READING RG6 2AJ,BERKS,ENGLAND	University of California System; University of California San Diego; University of Reading	POTTER, E (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN PEPTIDE BIOL,LA JOLLA,CA 92138, USA.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; Ausubel FM, 1988, MOL REPROD DEV; BEHAN DP, 1989, J ENDOCRINOL, V122, P23, DOI 10.1677/joe.0.1220023; CAMPBELL EA, 1987, J CLIN ENDOCR METAB, V64, P1054, DOI 10.1210/jcem-64-5-1054; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNAH D, 1987, J ENDOCRINOL, V113, P123, DOI 10.1677/joe.0.1130123; DESOUZA EB, 1990, CORTICOTROPIN RELEAS; ELLIS MJ, 1988, J ENDOCRINOL, V117, P299, DOI 10.1677/joe.0.1170299; FINK G, 1988, J PHYSIOL-LONDON, V401, P329, DOI 10.1113/jphysiol.1988.sp017165; FISCHER WH, IN PRESS METH NEUROS; GOLAND RS, 1986, J CLIN ENDOCR METAB, V63, P1199, DOI 10.1210/jcem-63-5-1199; GRINO M, 1987, BIOCHEM BIOPH RES CO, V148, P1208, DOI 10.1016/S0006-291X(87)80261-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAATIKAINEN T, 1987, NEUROPEPTIDES, V10, P343, DOI 10.1016/S0143-4179(87)90101-6; LINTON EA, 1987, J CLIN ENDOCR METAB, V64, P1047, DOI 10.1210/jcem-64-5-1047; LINTON EA, 1988, CLIN ENDOCRINOL, V28, P315, DOI 10.1111/j.1365-2265.1988.tb01218.x; LINTON EA, 1989, J CLIN ENDOCR METAB, V70, P174; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; ORTH DN, 1987, BIOCHEM BIOPH RES CO, V143, P411, DOI 10.1016/0006-291X(87)91369-6; PETRAGLIA F, 1987, NATURE, V328, P717, DOI 10.1038/328717a0; PLOTSKY PM, 1987, ENDOCRINOLOGY, V120, P1361, DOI 10.1210/endo-120-4-1361; REES LH, 1975, NATURE, V254, P620, DOI 10.1038/254620b0; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI A, 1984, J CLIN ENDOCR METAB, V59, P812; SHIBASAKI T, 1982, J CLIN ENDOCR METAB, V55, P384, DOI 10.1210/jcem-55-2-384; SUDA T, 1988, J CLIN ENDOCR METAB, V67, P1278, DOI 10.1210/jcem-67-6-1278; SUDA T, 1985, J CLIN INVEST, V76, P2026, DOI 10.1172/JCI112204; SUDA T, 1989, BIOCHEM BIOPH RES CO, V165, P703, DOI 10.1016/S0006-291X(89)80023-3; Vale W, 1986, Methods Enzymol, V124, P389; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699	33	320	328	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					423	426		10.1038/349423a0	http://dx.doi.org/10.1038/349423a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1846945				2022-12-28	WOS:A1991EV51400054
J	OEHEN, S; HENGARTNER, H; ZINKERNAGEL, RM				OEHEN, S; HENGARTNER, H; ZINKERNAGEL, RM			VACCINATION FOR DISEASE	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; TOXIC T-CELLS; RESPIRATORY SYNCYTIAL VIRUS; RECOMBINANT VACCINIA VIRUS; MURINE MODEL; HOST DISEASE; HEPATITIS-B; MICE; IMMUNIZATION; INFECTIONS	Recombinant virus vaccines that express a limited number of epitopes are currently being developed to prevent disease by changing the relative balance between viral spread and the immune response. Some circumstances, however, were found in infections with a noncytopathic virus in which vaccination caused disease; sensitive parameters included the genetic background of the host, the time or dose of infection, and the constituents of the vaccine. Thus, immunopathologic damage by T cells may be an unwanted consequence of vaccination with the new types of peptide or recombinant vaccines that are being investigated for the human immunodeficiency viruses and other pathogens.	UNIV ZURICH, INST PATHOL, EXPTL PATHOL LAB, CH-8091 ZURICH, SWITZERLAND	University of Zurich								AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; BAENZIGER J, 1986, EUR J IMMUNOL, V16, P387, DOI 10.1002/eji.1830160413; BIANCHI L, 1981, SPRINGER SEMIN IMMUN, V3, P421, DOI 10.1007/BF01951491; BOLOGNESI DP, 1989, NATURE, V340, P431, DOI 10.1038/340431a0; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; Cerottini J C, 1974, Adv Immunol, V18, P67, DOI 10.1016/S0065-2776(08)60308-9; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; COLE GA, 1972, NATURE, V238, P335, DOI 10.1038/238335a0; DOHERTY PC, 1974, TRANSPLANT REV-DENMA, V19, P89; DOHERTY PC, 1988, CLIN IMMUNOL IMMUNOP, V47, P19, DOI 10.1016/0090-1229(88)90141-9; EZZELL C, 1987, NATURE, V328, P747, DOI 10.1038/328747a0; FULGINITI VA, 1967, J AMER MED ASSOC, V202, P1075, DOI 10.1001/jama.202.12.1075; GOLLINS SW, 1986, NATURE, V321, P244, DOI 10.1038/321244a0; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HANY M, 1989, EUR J IMMUNOL, V19, P417, DOI 10.1002/eji.1830190302; HOMSY J, 1989, SCIENCE, V244, P1357, DOI 10.1126/science.2786647; HOTCHIN J, 1962, COLD SPRING HARB SYM, V27, P479, DOI 10.1101/SQB.1962.027.001.046; HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0; LEHMANNGRUBE F, 1977, J GEN VIROL, V37, P85, DOI 10.1099/0022-1317-37-1-85; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P1; LEIST TP, 1987, J IMMUNOL, V138, P2278; LEIST TP, 1988, J EXP MED, V167, P1749, DOI 10.1084/jem.167.5.1749; Mackett M., 1985, DNA CLONING PRACTICA, P191; MCCHESNEY MB, 1989, ADV IMMUNOL, V45, P335, DOI 10.1016/S0065-2776(08)60696-3; MICHEL F, 1988, EUR J IMMUNOL, V18, P1917, DOI 10.1002/eji.1830181208; MIMS CA, 1968, J IMMUNOL, V101, P717; MIMS CA, 1982, PATHOGENESIS INFECTI, P1; MOLLER G, 1983, IMMUNOL REV, V70, P5; MONDELLI M, 1984, SEMIN LIVER DIS, V4, P47, DOI 10.1055/s-2008-1040645; MUSTAFA AS, 1986, NATURE, V319, P63, DOI 10.1038/319063a0; NOTKINS AL, 1975, VIRAL IMMUNOLOGY IMM, P1; OLDSTONE MB, 1973, J EXP MED, V137, P1201, DOI 10.1084/jem.137.5.1201; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; ORENTAS RJ, 1990, SCIENCE, V248, P1234, DOI 10.1126/science.2190315; PANICALI D, 1983, P NATL ACAD SCI-BIOL, V80, P5364, DOI 10.1073/pnas.80.17.5364; PFAU CJ, 1982, J EXP MED, V156, P79, DOI 10.1084/jem.156.1.79; PFAU CJ, 1983, J GEN VIROL, V64, P1827, DOI 10.1099/0022-1317-64-8-1827; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; ROBINSON WE, 1990, P NATL ACAD SCI USA, V87, P3185, DOI 10.1073/pnas.87.8.3185; ROSENBERG ZF, 1989, ADV IMMUNOL, V47, P377; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; SMITH GL, 1983, NATURE, V302, P490, DOI 10.1038/302490a0; STOTT EJ, 1985, ARCH VIROL, V84, P1, DOI 10.1007/BF01310552; VIA CS, 1987, J IMMUNOL, V139, P1840; VIA CS, 1988, IMMUNOL TODAY, V9, P207, DOI 10.1016/0167-5699(88)91215-7; ZAGURY D, 1987, NATURE, V326, P249, DOI 10.1038/326249a0; ZINKERNAGEL RM, 1986, J EXP MED, V164, P1075, DOI 10.1084/jem.164.4.1075; ZINKERNAGEL RM, 1985, NATURE, V316, P814, DOI 10.1038/316814a0	49	102	104	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 11	1991	251	4990					195	198		10.1126/science.1824801	http://dx.doi.org/10.1126/science.1824801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1824801				2022-12-28	WOS:A1991ET17300040
J	STERN, RS; BOUDREAUX, C; ARNDT, KA				STERN, RS; BOUDREAUX, C; ARNDT, KA			DIAGNOSTIC-ACCURACY AND APPROPRIATENESS OF CARE FOR SEBORRHEIC KERATOSES - A PILOT-STUDY OF AN APPROACH TO QUALITY ASSURANCE FOR CUTANEOUS SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In 1985 there were more than 40 million visits for ambulatory surgical procedures in the United States. Although benign cutaneous lesions are among the most frequent conditions to receive surgical treatment in ambulatory settings, their treatment is seldom subject to peer review. In this pilot study we assessed diagnostic accuracy and appropriateness of care using information available from the surgical pathology laboratory. We assessed these two measures of physician performance of 527 seborrheic keratoses removed by 133 clinicians affiliated with four different institutions. Overall, a correct preoperative diagnosis was provided in only 49% of cases. Dermatologists had the highest diagnostic accuracy (61% vs 35% for all other physicians). An appropriate procedure for the actual pathological diagnosis was performed in only 50% of cases. Lesions with a correct preoperative diagnosis were more than eight times more likely to receive appropriate care. Our data suggest that many clinicians fail to note a correct diagnosis of common cutaneous lesions before surgical removal, and many patients are treated with procedures that are more invasive than necessary for the final pathological diagnosis. Because the approach used in this pilot study relies on data already available, it has promise as a low-cost method of monitoring the quality of care of ambulatory surgery.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, CHARLES DANA RES INST, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	STERN, RS (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT DERMATOL, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							ARNDT KA, 1989, MANUAL DERMATOLOGIC, P106; CARO WA, 1985, DERMATOLOGY, P1533; CASHMORE RW, 1985, GERIATRICS, V40, P69; CLARK RA, 1983, J AM ACAD DERMATOL, V9, P787, DOI 10.1016/S0190-9622(83)70193-3; EPSTEIN E, 1969, J AMER MED ASSOC, V208, P1369; LEADER S, 1989, HEALTH AFFAIR, V8, P158, DOI 10.1377/hlthaff.8.1.158; LEDERMAN JS, 1985, J AM ACAD DERMATOL, V13, P983, DOI 10.1016/S0190-9622(85)70249-6; MOHS FE, 1970, J AMER MED ASSOC, V212, P1956; NORMAN GR, 1989, ARCH DERMATOL, V125, P1063, DOI 10.1001/archderm.125.8.1063; PALMER RH, 1988, INQUIRY-J HEALTH CAR, V25, P119; SRZEWIECKI KT, 1980, SCAND J PLAST RECONS, V14, P141; THOMPSON MS, 1984, AM J PUBLIC HEALTH, V74, P1244, DOI 10.2105/AJPH.74.11.1244; 1990, B AM ACAD DERMATOL S, V8, P12	13	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					74	77		10.1001/jama.265.1.74	http://dx.doi.org/10.1001/jama.265.1.74			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP555	1824572				2022-12-28	WOS:A1991EP55500031
J	FIORE, MC				FIORE, MC			THE NEW VITAL SIGN - ASSESSING AND DOCUMENTING SMOKING STATUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CIGARETTE-SMOKING; NICOTINE GUM; INTERVENTION; CESSATION; PHYSICIAN; TRIAL		UNIV WISCONSIN,SCH MED,DEPT MED,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	FIORE, MC (corresponding author), UNIV WISCONSIN,SCH MED,TOBACCO RES & INTERVENT PROGRAM,7275 MED SCI CTR,1300 UNIV AVE,MADISON,WI 53706, USA.							ANDA RF, 1987, JAMA-J AM MED ASSOC, V257, P1916; COHEN SJ, 1987, AM J PUBLIC HEALTH, V77, P313, DOI 10.2105/AJPH.77.3.313; CUMMINGS SR, 1988, JAMA-J AM MED ASSOC, V260, P1565, DOI 10.1001/jama.260.11.1565; DAUGHTON DM, 1991, ARCH INTERN MED, V151, P749, DOI 10.1001/archinte.151.4.749; FIORE MC, 1990, DIS MON, V35, P181; FISHER M, 1989, REPORT US PREVENTIVE, P289; FRANK E, 1991, JAMA-J AM MED ASSOC, V266, P3139, DOI 10.1001/jama.266.22.3139; HURT RD, 1990, MAYO CLIN PROC, V65, P1529, DOI 10.1016/S0025-6196(12)62186-7; MANLEY M, 1991, JAMA-J AM MED ASSOC, V266, P3172, DOI 10.1001/jama.266.22.3172; MUSHER DM, 1987, NEW ENGL J MED, V316, P115, DOI 10.1056/NEJM198701083160221; OCKENE JK, 1987, AM J PUBLIC HEALTH, V77, P782, DOI 10.2105/AJPH.77.7.782; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P61, DOI 10.1001/jama.261.1.61; SAMUELS B, 1991, JAMA-J AM MED ASSOC, V266, P2110, DOI 10.1001/jama.266.15.2110; Seguin E, 1867, MED REC, V1, P516; Seguin E, 1866, CHICAGO M J, V23, P193; SOLBERG LI, 1990, J FAM PRACTICE, V30, P647; TLYNN T, 1989, NIH893064 DEP HLTH H; WILSON DM, 1988, JAMA-J AM MED ASSOC, V260, P1570, DOI 10.1001/jama.260.11.1570; 1988, CDC888406 DEP HLTH H; 1991, PHS9150212 DEP HLTH; 1991, MMWR, V40, P62	21	80	83	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1991	266	22					3183	3184		10.1001/jama.266.22.3183	http://dx.doi.org/10.1001/jama.266.22.3183			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT654	1823545				2022-12-28	WOS:A1991GT65400031
J	FACCHINI, F; CHEN, YDI; HOLLENBECK, CB; REAVEN, GM				FACCHINI, F; CHEN, YDI; HOLLENBECK, CB; REAVEN, GM			RELATIONSHIP BETWEEN RESISTANCE TO INSULIN-MEDIATED GLUCOSE-UPTAKE, URINARY URIC-ACID CLEARANCE, AND PLASMA URIC-ACID CONCENTRATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; RISK FACTOR	Objective. - To define the relationship, if any, between insulin-mediated glucose disposal and serum uric acid. Design. - Cross-sectional study of healthy volunteers. Setting. - General Clinical Research Center, Stanford (Calif) University Medical Center. Participants. - Thirty-six presumably healthy individuals, nondiabetic, without a history of gout. Measurements. - Obesity (overall and regional), plasma glucose and insulin responses to a 75-g oral glucose load, fasting uric acid concentrations, plasma triglyceride and high-density lipoprotein-cholesterol concentrations, systolic and diastolic blood pressure, insulin-mediated glucose disposal, and urinary uric acid clearance. Results. - Magnitude of insulin resistance and serum uric acid concentration were significantly related (r = .69; P < .001), and the relationship persisted when differences in age, sex, overall obesity, and abdominal obesity were taken into account (r = .57; P < .001). Insulin resistance was also inversely related to urinary uric acid clearance (r= -.49; P < .002), and, in addition, urinary uric acid clearance was inversely related to serum uric acid concentration (r = -.61; P < .001). Conclusions. - Urinary uric acid clearance appears to decrease in proportion to increases in insulin resistance in normal volunteers, leading to an increase in serum uric acid concentration. Thus, it appears that modulation of serum uric concentration by insulin resistance is exerted at the level of the kidney.	VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN,3801 MIRANDA AVE,PALO ALTO,CA 94304; STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University					NCRR NIH HHS [RR-00070] Funding Source: Medline; NHLBI NIH HHS [HL-08506] Funding Source: Medline; NIDDK NIH HHS [DK-07217] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007217] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRAND FN, 1985, AM J EPIDEMIOL, V121, P11, DOI 10.1093/oxfordjournals.aje.a113972; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; GERTLER MM, 1951, ANN INTERN MED, V34, P1421, DOI 10.7326/0003-4819-34-6-1421; GOLAY A, 1990, J CLIN ENDOCR METAB, V71, P1299, DOI 10.1210/jcem-71-5-1299; GREENFIELD MS, 1981, DIABETES, V30, P387, DOI 10.2337/diabetes.30.5.387; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; HOLLENBECK CB, 1984, DIABETES, V33, P460, DOI 10.2337/diabetes.33.5.460; HOLMES EW, 1972, KIDNEY INT, V2, P115, DOI 10.1038/ki.1972.81; KADISH AH, 1968, CLIN CHEM, V14, P116; KAGAN A, 1975, INT J EPIDEMIOL, V4, P271, DOI 10.1093/ije/4.4.271; KAPLAN AL, 1989, CLIN CHEM, P1016; KLEIN R, 1973, ARCH INTERN MED, V132, P401, DOI 10.1001/archinte.132.3.401; MODAN M, 1987, DIABETOLOGIA, V30, P713, DOI 10.1007/BF00296994; MYERS AR, 1968, AM J MED, V45, P520, DOI 10.1016/0002-9343(68)90168-X; PERSKY VW, 1979, CIRCULATION, V59, P969, DOI 10.1161/01.CIR.59.5.969; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Takkunen H, 1977, Adv Exp Med Biol, V76B, P238; TRIVEDI RC, 1978, CLIN CHEM, V24, P1908; WYNGAARDEN JB, 1976, GOUT HYPEURICEMIA; Wyngaarden JB, 1983, METABOLIC BASIS INHE, P1043; 1976, J CHRON DIS, V29, P557	21	621	656	0	36	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3008	3011		10.1001/jama.266.21.3008	http://dx.doi.org/10.1001/jama.266.21.3008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820474				2022-12-28	WOS:A1991GR77500033
J	THOMAS, KR; MUSCI, TS; NEUMANN, PE; CAPECCHI, MR				THOMAS, KR; MUSCI, TS; NEUMANN, PE; CAPECCHI, MR			SWAYING IS A MUTANT ALLELE OF THE PROTOONCOGENE WNT-1	CELL			English	Article							MOUSE MAMMARY ONCOGENE; SEGMENT POLARITY GENE; EMBRYONIC-DEVELOPMENT; NUCLEOTIDE-SEQUENCE; RAT CEREBELLUM; INT-1 PROTOONCOGENE; MOLECULAR-CLONING; WINGLESS GENE; TUMOR VIRUS; EXPRESSION	Mice homozygous for the recessive mutation swaying (sw) am characterized by ataxia and hypertonia, attributed to the malformation of anterior regions of the cerebellum. We show that sw is a deletion of a single base pair from the proto-oncogene Wnt-1. The deletion is Predicted to cause premature termination of translation, eliminating the carboxy-terminal half of the Wnt-1 Protein. Histological examination shows that sw is phenotypically identical to a previously described wnt-1 mutation introduced into mice by gene targeting. Although both mutations in Wnt-1 disrupt primarily the development of the anterior cerebellum, they also exhibit a variability in expressivity such that rostrally adjacent structures in the midbrain and caudally adjacent structures in the posterior cerebellum can also be affected.	CHILDRENS HOSP MED CTR, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	THOMAS, KR (corresponding author), UNIV UTAH, MED CTR, COLL MED, HOWARD HUGHES MED INST, ECCLES INST HUMAN GENET, SALT LAKE CITY, UT 84112 USA.			Neumann, Paul/0000-0002-8480-4799				ALTMAN J, 1985, J COMP NEUROL, V231, P1, DOI 10.1002/cne.902310103; ALTMAN J, 1985, J COMP NEUROL, V231, P42, DOI 10.1002/cne.902310105; ALTMAN J, 1985, J COMP NEUROL, V231, P27, DOI 10.1002/cne.902310104; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BURGESS AW, 1988, BIOESSAYS, V8, P40, DOI 10.1002/bies.950080111; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HERRUP K, 1982, NEUROSCIENCE, V7, P2185, DOI 10.1016/0306-4522(82)90129-4; HESS EJ, 1991, NEURON, V6, P123, DOI 10.1016/0896-6273(91)90127-L; HOGAN B, 1986, MANIPULATING MOUSE E; Jacobson M., 2013, DEV NEUROBIOL; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; Lane P. W., 1967, MOUSE NEWS LETT, V36, P40; Lane PW, 1990, MOUSE GENOME, V86, P237; LANE PW, 1970, MOUSE NEWS LETT, V42, P30; Lyon M., 1989, GENETIC VARIANTS STR; MARTINEZ S, 1989, EUR J NEUROSCI, V1, P549, DOI 10.1111/j.1460-9568.1989.tb00362.x; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; MERUELO D, 1987, IMMUNOGENETICS, V25, P361, DOI 10.1007/BF00396102; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; Mullen R. J., 1984, Chimeras in developmental biology., P353; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; ROSS ME, 1990, P NATL ACAD SCI USA, V87, P4189, DOI 10.1073/pnas.87.11.4189; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SIDMAN R L, 1968, PHYSIOLOGICAL AND BIOCHEMICAL ASPECTS OF NERVOUS INTEGRATION, P163; Sidman RL., 1965, CATALOG NEUROLOGICAL, DOI [10.4159/harvard.9780674424326, DOI 10.4159/HARVARD.9780674424326]; SIDMAN RL, 1983, GENETICS NEUROLOGICA, P19; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; VANTVEER LJ, 1984, MOL CELL BIOL, V4, P2532, DOI 10.1128/MCB.4.11.2532; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	53	217	221	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					969	976		10.1016/0092-8674(91)90369-A	http://dx.doi.org/10.1016/0092-8674(91)90369-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1835670				2022-12-28	WOS:A1991GT75500015
J	RAHEMTULLA, A; FUNGLEUNG, WP; SCHILHAM, MW; KUNDIG, TM; SAMBHARA, SR; NARENDRAN, A; ARABIAN, A; WAKEHAM, A; PAIGE, CJ; ZINKERNAGEL, RM; MILLER, RG; MAK, TW				RAHEMTULLA, A; FUNGLEUNG, WP; SCHILHAM, MW; KUNDIG, TM; SAMBHARA, SR; NARENDRAN, A; ARABIAN, A; WAKEHAM, A; PAIGE, CJ; ZINKERNAGEL, RM; MILLER, RG; MAK, TW			NORMAL DEVELOPMENT AND FUNCTION OF CD8+ CELLS BUT MARKEDLY DECREASED HELPER-CELL ACTIVITY IN MICE LACKING CD4	NATURE			English	Article							EMBRYONIC STEM-CELLS; TOXIC T-CELL; HOMOLOGOUS RECOMBINATION; ANTIGEN EXPRESSION; PRECURSOR CELLS; VIRUS-INFECTION; SUBSETS; THYMOCYTES; RESPONSES; INVIVO	T CELLs express T-cell antigen receptors (TCR) for the recognition of antigen in conjunction with the products of the major histocompatibility complex 1,2. They also express two key surface coreceptors, CD4 and CD8, which are involved in the interaction with their ligands 3,4. As CD4 is expressed on the early haemopoietic progenitor 5 as well as the early thymic precursor cells 6, a role for CD4 in haemopoiesis and T-cell development is implicated. Thymocytes undergo a series of differentiation 7 and selection steps 8,9 to become mature CD4+8- or CD4-8+ (single positive) T cells 10,11. Studies of the role of CD4+ T cells in vivo have been based on adoptive transfer of selected or depleted lymphocytes, or in vivo treatment of thymectomized mice with monoclonal antibodies causing depletion of CD4+ T cells 12-14. In order to study the role of the CD4 molecule in the development and function of lymphocytes, we have disrupted the CD4 gene in embryonic stem cells 15,16 by homologous recombination 17,18. Germ-like transmission 19,20 of the mutation produces mutant mouse strains that do not express CD4 on the cell surface. In these mice, the development of CD8+ T cells and myeloid components is unaltered, indicating that expression of CD4 on progenitor cells and CD4+ CD8+ (double positive) thymocytes is not obligatory. Here we report that these mice have markedly decreased helper cell activity for antibody responses, although cytotoxic T-cell activity against viruses is in the normal range. This differential requirement for CD4+ helper T cells is important to our understanding of immune disorders, including AIDS, in which CD4+ cells are reduced or absent.	UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS & IMMUNOL, 500 SHERBOURNE ST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV ZURICH, INST PATHOL, CH-8091 ZURICH, SWITZERLAND	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Zurich			Schilham, Marco W./AAL-7223-2021; Sambhara, Suryaprakash/AAC-4428-2021	Schilham, Marco W./0000-0003-4391-6003; Fung-Leung, Wai-Ping/0000-0001-7013-8855				AHMED R, 1988, J VIROL, V62, P2102, DOI 10.1128/JVI.62.6.2102-2106.1988; ASHMAN RB, 1979, J EXP MED, V150, P1277, DOI 10.1084/jem.150.5.1277; BENNINK JR, 1978, NATURE, V276, P829, DOI 10.1038/276829a0; BULLER RML, 1987, NATURE, V328, P77, DOI 10.1038/328077a0; CANTOR H, 1975, J EXP MED, V141, P1376, DOI 10.1084/jem.141.6.1376; COBBOLD S, 1986, TRANSPLANTATION, V41, P634, DOI 10.1097/00007890-198605000-00016; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FREDRICKSON GG, 1989, J EXP MED, V169, P1473, DOI 10.1084/jem.169.4.1473; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GILLIS S, 1978, J IMMUNOL, V120, P2027; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HUDSON L, 1989, PRACTICAL IMMUNOLOGY; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAST WM, 1986, J EXP MED, V164, P723, DOI 10.1084/jem.164.3.723; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEIST TP, 1989, SCAND J IMMUNOL, V30, P679, DOI 10.1111/j.1365-3083.1989.tb02476.x; LEIST TP, 1987, J IMMUNOL, V138, P2278; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MATHIESON BJ, 1984, IMMUNOL REV, V82, P141, DOI 10.1111/j.1600-065X.1984.tb01121.x; NASH AA, 1987, J GEN VIROL, V68, P825, DOI 10.1099/0022-1317-68-3-825; PARNES JR, 1989, ADV IMMUNOL, V44, P265; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P897, DOI 10.1084/jem.147.3.897	34	643	658	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	1991	353	6340					180	184		10.1038/353180a0	http://dx.doi.org/10.1038/353180a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1832488				2022-12-28	WOS:A1991GE73100058
J	VANDEPERRE, P; SIMONON, A; MSELLATI, P; HITIMANA, DG; VAIRA, D; BAZUBAGIRA, A; VANGOETHEM, C; STEVENS, AM; KARITA, E; SONDAGTHULL, D; DABIS, F; LEPAGE, P				VANDEPERRE, P; SIMONON, A; MSELLATI, P; HITIMANA, DG; VAIRA, D; BAZUBAGIRA, A; VANGOETHEM, C; STEVENS, AM; KARITA, E; SONDAGTHULL, D; DABIS, F; LEPAGE, P			POSTNATAL TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 FROM MOTHER TO INFANT - A PROSPECTIVE COHORT STUDY IN KIGALI, RWANDA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-MILK; HIV-INFECTION; AIDS; SHEEP; CELL	Background. Although transmission of human immunodeficiency virus type 1 (HIV-1) from mother to infant has been well documented during pregnancy and delivery, little is known about the possible transmission of HIV-1 during the postnatal period. Methods. We conducted a prospective cohort study in Kigali, Rwanda, of 212 mother-infant pairs who were seronegative for HIV-1 at delivery. All the infants were breast-fed. The subjects were followed at three-month intervals, with Western blot assays for antibodies to HIV-1 and testing of mononuclear cells by a double polymerase chain reaction (PCR) using three sets of primers. To evaluate potential risk factors, each mother who seroconverted was matched with three seronegative control women. Results. After a mean follow-up of 16.6 months, 16 of the 212 mothers became seropositive for HIV-1. Of their 16 infants, 9 became seropositive. One infant was excluded from the analysis because of a positive test by PCR on the blood sample obtained at birth. Postnatal seroconversion to HIV-1 occurred in four of the five infants born to the mothers who seroconverted during the first 3 months post partum, and in four infants of the 10 mothers who seroconverted between month 4 and month 21. In all cases, the infant seroconverted during the same three-month period as the mother. The main risk factor for maternal seroconversion was being single. Conclusions. HIV-1 infection can be transmitted from mothers to infants during the postnatal period. Colostrum and breast milk may be efficient routes for the transmission of HIV-1 from recently infected mothers to their infants.	CTR HOSP,DEPT PEDIAT,KIGALI,RWANDA; UNIV BORDEAUX 2,INSERM,U330,F-33076 BORDEAUX,FRANCE; STATE UNIV LIEGE,CTR TRANSFUS,B-4000 LIEGE,BELGIUM	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; University of Liege	VANDEPERRE, P (corresponding author), NATL AIDS CONTROL PROGRAM,AIDS REFERENCE LAB,BP 780,KIGALI,RWANDA.		DABIS, FRANCOIS/S-9298-2019; Van de Perre, Philippe/B-9692-2008	DABIS, FRANCOIS/0000-0002-1614-8857; Van de Perre, Philippe/0000-0002-3912-0427				ALLEN S, 1990, 6TH INT C AIDS SAN F, V3, P104; BUCENS M, 1988, 4TH P INT C AIDS STO, V1; COMMEAU A, 1990, GENETIC SCREENING NE, P159; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P271; GOLDMAN AS, 1982, J PEDIATR-US, V100, P563, DOI 10.1016/S0022-3476(82)80753-1; GOUDSMIT J, 1986, LANCET, V2, P177; HINO S, 1989, Acta Paediatrica Japonica, V31, P428; HIRA SK, 1990, J PEDIATR-US, V117, P421, DOI 10.1016/S0022-3476(05)81084-4; LAWTON JWM, 1977, LANCET, V1, P253; LEPAGE P, 1991, AIDS, V5, P295, DOI 10.1097/00002030-199103000-00008; LEPAGE P, 1981, LANCET, V2, P409; LEVY JA, 1988, JAMA-J AM MED ASSOC, V259, P3037, DOI 10.1001/jama.259.20.3037; NARAYAN O, 1985, REV INFECT DIS, V7, P89; NATHANSON N, 1985, REV INFECT DIS, V7, P75; OXTOBY MJ, 1988, PEDIATR INFECT DIS J, V7, P825, DOI 10.1097/00006454-198807120-00001; OXTOBY MJ, 1990, PEDIATR INFECT DIS J, V9, P609; POKROVSKY VV, 1990, 6TH INT C AIDS SAN F, V1, P145; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; THIRY L, 1985, LANCET, V2, P891; TUDORWILLIAMS G, 1991, AIDS, V5, P103, DOI 10.1097/00002030-199101000-00017; VOGT MW, 1986, LANCET, V1, P525; WELSH JK, 1979, J PEDIATR-US, V94, P1, DOI 10.1016/S0022-3476(79)80340-6; WILLIAMS P, 1990, AIDS, V4, P393, DOI 10.1097/00002030-199005000-00003; 1986, MMWR, V35, P76; 1985, OCT WORKSH AIDS CENT; 1989, MMWR, V38, P1	26	288	292	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1991	325	9					593	598		10.1056/NEJM199108293250901	http://dx.doi.org/10.1056/NEJM199108293250901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC328	1812850	Bronze			2022-12-28	WOS:A1991GC32800001
J	SCHORLE, H; HOLTSCHKE, T; HUNIG, T; SCHIMPL, A; HORAK, I				SCHORLE, H; HOLTSCHKE, T; HUNIG, T; SCHIMPL, A; HORAK, I			DEVELOPMENT AND FUNCTION OF T-CELLS IN MICE RENDERED INTERLEUKIN-2 DEFICIENT BY GENE TARGETING	NATURE			English	Article							EMBRYONIC STEM-CELLS; SEVERE COMBINED IMMUNODEFICIENCY; GERM-LINE TRANSMISSION; MOUSE INTERLEUKIN-2; HPRT GENE; RECEPTOR; ANTIBODY; DIFFERENTIATION; CULTURE	INTERLEUKIN-2 (IL-2) is a lymphocytotropic hormone which is thought to have a key role in the immune response of mammalian cells. It is produced by a subpopulation of activated T-lymphocytes and acts in vitro as the principal auto- and paracrine T-cell growth factor (for reviews see refs 1-3). IL-2 is, however, not the sole T-cell growth factor 4,5, nor does it act exclusively on T cells, also promoting growth of NK cells 6 and differentiation of B cells 7. A role for IL-2 in T-cell development has been postulated but remains controversial 8-12. Here we test the requirement for IL using IL-2-deficient mice generated by targeted recombination. We find that mice homozygous for the IL-2 gene mutation are normal with regard to thymocyte and peripheral T-cell subset composition, but that a dysregulation of the immune system is manifested by reduced polyclonal in vitro T-cell responses and by dramatic changes in the isotype levels of serum immunoglobulins.	UNIV WURZBURG, INST VIROL & IMMUNOBIOL, VERSBACHERSTR 7, W-8700 WURZBURG, GERMANY	University of Wurzburg			Schorle, Hubert/M-5001-2016; Schorle, Hubert/S-1713-2019	Schorle, Hubert/0000-0001-8272-0076; 				CHAZEN GD, 1989, P NATL ACAD SCI USA, V86, P5923, DOI 10.1073/pnas.86.15.5923; CHENBETTECKEN U, 1985, P NATL ACAD SCI USA, V82, P7384, DOI 10.1073/pnas.82.21.7384; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FUSE A, 1984, NUCLEIC ACIDS RES, V12, P9323, DOI 10.1093/nar/12.24.9323; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JENKINSON EJ, 1987, NATURE, V329, P160, DOI 10.1038/329160a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; MACDONALD HR, 1988, IMMUNOL REV, V104, P157, DOI 10.1111/j.1600-065X.1988.tb00762.x; MOLINARO GA, 1975, EUR J IMMUNOL, V5, P771, DOI 10.1002/eji.1830051108; MOSMANN TR, 1989, PROG IMMUNOL, V7, P611; PAHWA R, 1989, P NATL ACAD SCI USA, V86, P5069, DOI 10.1073/pnas.86.13.5069; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PLUM J, 1988, EUR J IMMUNOL, V18, P795, DOI 10.1002/eji.1830180521; Shortman K, 1990, Semin Immunol, V2, P3; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TAKACS L, 1984, EUR J IMMUNOL, V14, P1152, DOI 10.1002/eji.1830141217; TENTORI L, 1988, J EXP MED, V168, P1741, DOI 10.1084/jem.168.5.1741; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; TRINCHIERI G, 1984, J EXP MED, V160, P1147, DOI 10.1084/jem.160.4.1147; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZURAWSKI SM, 1988, EMBO J, V7, P1061, DOI 10.1002/j.1460-2075.1988.tb02914.x	29	780	788	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					621	624		10.1038/352621a0	http://dx.doi.org/10.1038/352621a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1830926				2022-12-28	WOS:A1991GB21100056
J	DAAR, I; NEBREDA, AR; YEW, N; SASS, P; PAULES, R; SANTOS, E; WIGLER, M; VANDEWOUDE, GF				DAAR, I; NEBREDA, AR; YEW, N; SASS, P; PAULES, R; SANTOS, E; WIGLER, M; VANDEWOUDE, GF			THE RAS ONCOPROTEIN AND M-PHASE ACTIVITY	SCIENCE			English	Article							MOS PROTO-ONCOGENE; MATURATION-PROMOTING FACTOR; MURINE SARCOMA-VIRUS; XENOPUS OOCYTES; CELL-CYCLE; MEIOTIC MATURATION; GENE-PRODUCT; ARREST; P21; EGGS	The endogenous mos proto-oncogene product (Mos) is required for meiotic maturation In Xenopus oocytes, the ras oncogene product (Ras) can induce meiotic maturation and high levels of M-phase-promoting factor (MPF) independent of endogenous Mos, indicating that a parallel pathway to metaphase exists. In addition, Ras, like Mos and cytostatic factor, can arrest Xenopus embryonic cell cleavage in mitosis and maintain high levels of MPF. Thus, in the Xenopus oocyte and embryo systems Ras functions in the M phase of the cell cycle. The embryonic cleavage arrest assay is a rapid and sensitive test for Ras function.	NCI,FREDERIK CANC RES & DEV CTR,BASIC RES PROGRAM,ABL,FREDERICK,MD 21701; NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892; LEDERLE LAB,PEARL RIVER,NY 10965; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Cold Spring Harbor Laboratory			Nebreda, Angel Rodriguez/R-9594-2019	Paules, Richard S/0000-0001-9106-7486; Daar, Ira/0000-0003-2657-526X; Wigler, Michael/0000-0003-4396-1971	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENDE CC, 1988, FEBS LETT, V234, P426, DOI 10.1016/0014-5793(88)80130-3; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHAKALAPARAMPIL I, 1988, CELL, V52, P801; DAAR IO, UNPUB; DESPHANDE AK, 1987, MOL CELL BIOL, V7, P1285; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURKIN JP, 1987, MOL CELL BIOL, V7, P444, DOI 10.1128/MCB.7.1.444; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FISCHINGER PJ, 1971, J GEN VIROL, V13, P203, DOI 10.1099/0022-1317-13-2-203; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HAYAG N, 1990, ONCOGENE, V5, P1481; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; KIM R, 1990, MOL CELL BIOL, V10, P5945, DOI 10.1128/MCB.10.11.5945; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; MEYERHOF PG, 1977, DEV BIOL, V61, P214, DOI 10.1016/0012-1606(77)90293-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NEBREDA AR, UNPUB; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARK M, 1989, METABOLIC BASIS INHE, V1, P251; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANTOS E, 1988, J BIOL CHEM, V263, P9853; SHIBUYA E, 1989, DEVELOPMENT CAMBRIDG, V106, P779; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x	42	73	73	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					74	76		10.1126/science.1829549	http://dx.doi.org/10.1126/science.1829549			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1829549				2022-12-28	WOS:A1991FV17700037
J	HARPER, JF; SUSSMAN, MR; SCHALLER, GE; PUTNAMEVANS, C; CHARBONNEAU, H; HARMON, AC				HARPER, JF; SUSSMAN, MR; SCHALLER, GE; PUTNAMEVANS, C; CHARBONNEAU, H; HARMON, AC			A CALCIUM-DEPENDENT PROTEIN-KINASE WITH A REGULATORY DOMAIN SIMILAR TO CALMODULIN	SCIENCE			English	Article							PLANT; SEQUENCE; FAMILY	Calcium can function as a second messenger through stimulation of calcium-dependent protein kinases. A protein kinase that requires calcium but not calmodulin or phospholipids for activity has been purified from soybean. The kinase itself binds calcium with high affinity. A complementary DNA clone for this kinase has been identified; it encodes a protein with a predicted molecular mass of 57,175 daltons. This protein contains a catalytic domain similar to that of calmodulin-dependent kinases and a calmodulin-like region with four calcium binding domains (EF hands). The predicted structure of this kinase explains its direct regulation via calcium binding and establishes it as a prototype for a new family of calcium-regulated protein kinases.	UNIV WISCONSIN,DEPT HORT,MADISON,WI 53706; UNIV FLORIDA,DEPT BOT,GAINESVILLE,FL 32611; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Wisconsin System; University of Wisconsin Madison; State University System of Florida; University of Florida; University System of Georgia; University of Georgia; University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM15731] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JM, 1980, BIOCHEMISTRY-US, V19, P3113, DOI 10.1021/bi00554a043; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; CHARBONNEAU H, 1985, BIOCHEMISTRY-US, V24, P6762, DOI 10.1021/bi00345a006; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDIE G, 1988, NATURE, V335, P592, DOI 10.1038/335592a0; HARMON AC, 1987, PLANT PHYSIOL, V83, P830, DOI 10.1104/pp.83.4.830; HARPER J, UNPUB CDNA SEQUENCE; HARPER JF, 1990, J BIOL CHEM, V265, P13601; HEPLER PK, 1985, ANNU REV PLANT PHYS, V36, P397, DOI 10.1146/annurev.pp.36.060185.002145; LUKAS TJ, 1984, PLANT PHYSIOL, V75, P788, DOI 10.1104/pp.75.3.788; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PUTNAMEVANS C, 1989, CELL MOTIL CYTOSKEL, V12, P12, DOI 10.1002/cm.970120103; PUTNAMEVANS CL, 1990, BIOCHEMISTRY-US, V29, P2488, DOI 10.1021/bi00462a008; RANJEVA R, 1983, P NATL ACAD SCI-BIOL, V80, P5222, DOI 10.1073/pnas.80.17.5222; ROBERTS DM, 1986, CRIT REV PLANT SCI, V4, P311, DOI 10.1080/07352688609382230; SCHALLER G, UNPUB; STULL JT, 1986, ENZYMES, V17, P113; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094	22	355	381	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1991	252	5008					951	954		10.1126/science.1852075	http://dx.doi.org/10.1126/science.1852075			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	1852075				2022-12-28	WOS:A1991FM04000032
J	WARRELL, RP; FRANKEL, SR; MILLER, WH; SCHEINBERG, DA; ITRI, LM; HITTELMAN, WN; VYAS, R; ANDREEFF, M; TAFURI, A; JAKUBOWSKI, A; GABRILOVE, J; GORDON, MS; DMITROVSKY, E				WARRELL, RP; FRANKEL, SR; MILLER, WH; SCHEINBERG, DA; ITRI, LM; HITTELMAN, WN; VYAS, R; ANDREEFF, M; TAFURI, A; JAKUBOWSKI, A; GABRILOVE, J; GORDON, MS; DMITROVSKY, E			DIFFERENTIATION THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA WITH TRETINOIN (ALL-TRANS-RETINOIC ACID)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREMATURE CHROMOSOME CONDENSATION; ACUTE MYELOID-LEUKEMIA; RECEPTOR-ALPHA GENE; T(15-17) TRANSLOCATION; CELL-DIFFERENTIATION; CYTOGENETIC ANALYSIS; 15-17 TRANSLOCATION; REMISSION INDUCTION; INVITRO; PATIENT	Background and Methods. Patients with acute promyelocytic leukemia have a characteristic (15;17) translocation, with a breakpoint on chromosome 17 in the region of the retinoic acid receptor-alpha (RAR-alpha). Since this receptor has been shown to be involved with growth and differentiation of myeloid cells in vitro, and since recent clinical studies have reported that tretinoin (all-trans-retinoic acid) induces complete remission in patients with acute promyelocytic leukemia, we studied the effects of tretinoin on cellular maturation and molecular abnormalities in patients undergoing the induction of remission with this agent. Results. Eleven patients with acute promyelocytic leukemia were treated with tretinoin administered orally at a dose of 45 mg per square meter of body-surface area per day. Nine of the 11 patients entered complete remission. In two patients, complete remission was preceded by striking leukocytosis that then resolved despite continued drug treatment. Serial studies of cellular morphologic features, cell-surface immunophenotypic analysis, and fluorescence in situ hybridization with a chromosome 17 probe revealed that clinical response was associated with maturation of the leukemic clone. All patients who responded to treatment who were tested by Northern blot analysis had expression of aberrant RAR-alpha. As patients entered complete remission,the expression of the abnormal RAR-alpha message decreased markedly; however, it was still detectable in several patients after complete morphologic and cytogenetic remission had been achieved. Conclusions. Tretinoin is a safe and highly effective agent for inducing complete remission in patients with acute promyelocytic leukemia. Clinical response to this agent is associated with leukemic-cell differentiation and is linked to the expression of an aberrant RAR-alpha nuclear receptor. Molecular detection of the aberrant receptor may serve as a useful marker for residual leukemia in patients with this disease.	MEM SLOAN KETTERING CANC CTR, HEMATOPOIET CANC IMMUNOCHEM LAB, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, LEUKOCYTE BIOL LAB, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, MOLEC MED LAB, NEW YORK, NY 10021 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MED ONCOL, HOUSTON, TX 77030 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center	WARRELL, RP (corresponding author), MEM SLOAN KETTERING CANC CTR, DEPT MED, LEUKEMIA & DEV CHEMOTHERAPY SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA.		Tafuri, Agostino/AAC-2186-2019	Tafuri, Agostino/0000-0001-7911-9263	NCI NIH HHS [CA-09207-14] Funding Source: Medline; FDA HHS [FD-R-000674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREEFF M, 1980, BLOOD, V55, P282; ANDREEFF M, 1985, TUMOR ANEUPLOIDY, P81; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHESON BD, 1990, J CLIN ONCOL, V8, P813, DOI 10.1200/JCO.1990.8.5.813; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; CHOMIENNE C, 1989, LANCET, V2, P746, DOI 10.1016/S0140-6736(89)90812-X; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DAENEN S, 1986, BLOOD, V67, P559; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DMITROVSKY E, 1990, ONCOGENE, V5, P543; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; FLYNN PJ, 1983, BLOOD, V62, P1211; FONTANA JA, 1986, CANCER-AM CANCER SOC, V57, P209, DOI 10.1002/1097-0142(19860115)57:2<209::AID-CNCR2820570204>3.0.CO;2-K; GROOPMAN J, 1979, AM J HEMATOL, V7, P395, DOI 10.1002/ajh.2830070412; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HITTELMAN WN, 1988, CANCER GENET CYTOGEN, V30, P301, DOI 10.1016/0165-4608(88)90199-9; HITTELMAN WN, 1988, BLOOD, V72, P1950; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KANTARJIAN HM, 1985, J CLIN ONCOL, V3, P793, DOI 10.1200/JCO.1985.3.6.793; KESSLER JF, 1983, LANCET, V1, P1345; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LEMONS RS, 1990, GENE CHROMOSOME CANC, V2, P79, DOI 10.1002/gcc.2870020202; LICHTMAN MA, 1982, BLOOD, V60, P279; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILLER WH, 1990, J NATL CANCER I, V82, P1932, DOI 10.1093/jnci/82.24.1932; MILLER WH, IN PRESS CLIN RES; MOHAMED AN, 1986, CANCER GENET CYTOGEN, V20, P209, DOI 10.1016/0165-4608(86)90076-2; MUINDI J, IN PRESS P AM SOC CL; NILSSON B, 1984, BRIT J HAEMATOL, V57, P365, DOI 10.1111/j.1365-2141.1984.tb02910.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PRATT, 1990, MOL CELLULAR BIOL, V0010; SCHEINBERG DA, 1989, LEUKEMIA, V3, P440; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONE RM, 1988, BLOOD, V71, P690; TERSTAPPEN LWMM, 1990, LEUKEMIA, V4, P657; TKACHUK DC, 1990, SCIENCE, V250, P559, DOI 10.1126/science.2237408; TOBLER A, 1986, J CLIN INVEST, V78, P303, DOI 10.1172/JCI112565; WALLACE PJ, 1989, AM J HEMATOL, V31, P266, DOI 10.1002/ajh.2830310410; WIJERMANS PW, 1989, BLOOD, V73, P800	48	1229	1271	2	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1385	1393		10.1056/NEJM199105163242002	http://dx.doi.org/10.1056/NEJM199105163242002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	1850498				2022-12-28	WOS:A1991FL12500002
J	GOW, JW; BEHAN, WMH; CLEMENTS, GB; WOODALL, C; RIDING, M; BEHAN, PO				GOW, JW; BEHAN, WMH; CLEMENTS, GB; WOODALL, C; RIDING, M; BEHAN, PO			ENTEROVIRAL RNA SEQUENCES DETECTED BY POLYMERASE CHAIN-REACTION IN MUSCLE OF PATIENTS WITH POSTVIRAL FATIGUE SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							VIRUSES	Objective-To determine the presence of enteroviral sequences in muscle of patients with the postviral fatigue syndrome. Design-Detection of sequences with the polymerase chain reaction in a well defined group of patients with the syndrome and controls over the same period. Setting-Institute of Neurological Sciences, Glasgow. Subjects-60 consecutive patients admitted to the institute with the postviral fatigue syndrome who had undergone extensive investigation to exclude other conditions. 41 controls from the same catchment area without evidence of fatigue, all undergoing routine surgery. Main outcome measures-Routine investigations, serological screen for antibodies to a range of viruses, and presence of enteroviral RNA sequences in muscle biopsy specimens. Results-15 (25%) patients and 10 (24.4%) controls had important serological findings. 12 patients had neutralising antibody titres of greater-than-or-equal-to 256 to coxsackieviruses B1-5 (six positive for enteroviral RNA sequences, six negative); three were positive for Epstein-Barr virus specific IgM (two positive, one negative). Six controls had similar neutralising antibody titres to coxsackieviruses (all negative); one was positive for Epstein-Barr virus specific IgM (negative); and three had titres of complement fixing antibody greater-than-or-equal-to 256 to cytomegalovirus (all negative). Overall, significantly more patients than controls had enteroviral RNA sequences in muscle (32/60, 53% v 6/41, 15%; odds ratio 6.7, 95% confidence interval 2.4 to 18.2). This was not correlated with duration of disease, patient and age, or to raised titres of antibodies to coxsackieviruses B1-5. Conclusions-Persistent enteroviral infection of muscle may occur in some patients with postviral fatigue syndrome and may have an aetiological role.	UNIV GLASGOW,DEPT NEUROL,GLASGOW G12 8QQ,SCOTLAND; UNIV GLASGOW,DEPT PATHOL,GLASGOW G12 8QQ,SCOTLAND; RUCHILL HOSP,REG VIRUS LAB,GLASGOW G20 9NB,SCOTLAND; RUCHILL HOSP,SCOTTISH SERUM BANK,GLASGOW G20 9NB,SCOTLAND	University of Glasgow; University of Glasgow								ACHESON ED, 1959, AM J MED, V26, P569, DOI 10.1016/0002-9343(59)90280-3; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; ARNOLD DL, 1984, LANCET, V1, P1367; BEHAN PO, 1985, J INFECTION, V10, P211, DOI 10.1016/S0163-4453(85)92488-0; BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157; CALDER BD, 1987, J ROY COLL GEN PRACT, V37, P11; CHAPMAN NM, 1990, J CLIN MICROBIOL, V28, P843, DOI 10.1128/JCM.28.5.843-850.1990; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM L, 1990, J GEN VIROL, V71, P1399, DOI 10.1099/0022-1317-71-6-1399; DUBOWITZ V, 1985, MUSCLE BIOPSY PRACTI, P3; EISENSTEIN BI, 1990, NEW ENGL J MED, V322, P178; FEGAN KG, 1983, J ROY COLL GEN PRACT, V33, P335; HENDERSON DA, 1959, NEW ENGL J MED, V260, P757, DOI 10.1056/NEJM195904092601506; HERMANS A, 1988, LEUKEMIA, V2, P628; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; HYYPIA T, 1989, J GEN VIROL, V70, P3261, DOI 10.1099/0022-1317-70-12-3261; JAMAL GA, 1989, EUR NEUROL, V29, P272; MILLER NA, 1991, BMJ-BRIT MED J, V302, P140, DOI 10.1136/bmj.302.6769.140; OLDSTONE MBA, 1989, J INFECT DIS, V159, P384, DOI 10.1093/infdis/159.3.384; WILFERT CM, 1977, NEW ENGL J MED, V296, P1485, DOI 10.1056/NEJM197706302962601; YOUSEF GE, 1988, LANCET, V1, P146	21	157	158	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					692	696		10.1136/bmj.302.6778.692	http://dx.doi.org/10.1136/bmj.302.6778.692			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	1850635	Bronze, Green Published			2022-12-28	WOS:A1991FE33300022
J	HAIG, D; GRAHAM, C				HAIG, D; GRAHAM, C			GENOMIC IMPRINTING AND THE STRANGE CASE OF THE INSULIN-LIKE GROWTH FACTOR-II RECEPTOR	CELL			English	Review							BINDING		UNIV OXFORD,DEPT ZOOL,OXFORD OX1 3RA,ENGLAND	University of Oxford	HAIG, D (corresponding author), UNIV OXFORD,DEPT PLANT SCI,OXFORD OX1 3RA,ENGLAND.							BAKER AEM, 1981, BEHAV ECOL SOCIOBIOL, V8, P83, DOI 10.1007/BF00300819; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; CLAIRMONT KB, 1989, J BIOL CHEM, V264, P16390; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; HAIG D, 1989, AM NAT, V134, P147, DOI 10.1086/284971; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KIESS W, 1987, J BIOL CHEM, V262, P12745; KIESS W, 1988, J BIOL CHEM, V263, P9339; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; MATHIEU M, 1990, MOL ENDOCRINOL, V4, P1327, DOI 10.1210/mend-4-9-1327; MCLAREN A, 1965, J REPROD FERTIL, V9, P79, DOI 10.1530/jrf.0.0090079; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; SMITH CC, 1974, AM NAT, V108, P499, DOI 10.1086/282929; WITTENBERGER JF, 1980, ANNU REV ECOL SYST, V11, P197, DOI 10.1146/annurev.es.11.110180.001213	17	371	373	0	51	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1045	1046						2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	1848481				2022-12-28	WOS:A1991FD55800001
J	ESCALANTE, B; ERLIJ, D; FALCK, JR; MCGIFF, JC				ESCALANTE, B; ERLIJ, D; FALCK, JR; MCGIFF, JC			EFFECT OF CYTOCHROME-P450 ARACHIDONATE METABOLITES ON ION-TRANSPORT IN RABBIT KIDNEY LOOP OF HENLE	SCIENCE			English	Article							THICK ASCENDING LIMB; ACID METABOLISM; ATPASE; SODIUM; CELLS; SUSPENSION; PUMP	In the medullary segment of the thick ascending limb of the loop of Henle (mTALH), arachidonic acid (AA) is metabolized by a cytochrome P450-dependent monooxygenase to products that affect ion transport. The linkage between changes in ion transport and AA metabolism in isolated cells of the mTALH was examined. AA produced a concentration-dependent inhibition of Rb-86 uptake - an effect that was prevented by selective blockade of cytochrome P450 monooxygenases. Inhibition by cytochrome P450 blockade of the effect of AA on Rb-86 uptake could be circumvented by addition of the principal products of AA metabolism in the mTALH.	SUNY DOWNSTATE MED CTR,DEPT PHYSIOL,BROOKLYN,NY 11203; UNIV TEXAS,HLTH SCI CTR,DEPT MOLEC GENET,DALLAS,TX 75235	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Texas System; University of Texas Dallas	ESCALANTE, B (corresponding author), NEW YORK MED COLL,DEPT PHARMACOL,VALHALLA,NY 10595, USA.			Falck, John/0000-0002-9219-7845	NHLBI NIH HHS [HL34300, R01 HL25394] Funding Source: Medline; NIDDK NIH HHS [R01 DK33612] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025394, P01HL034300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033612] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN ML, 1988, AM J PHYSIOL, V255, pF704, DOI 10.1152/ajprenal.1988.255.4.F704; CANTIELLO HF, 1988, AM J PHYSIOL, V255, pF574, DOI 10.1152/ajprenal.1988.255.4.F574; CHAMBERLIN ME, 1984, AM J PHYSIOL, V247, pF955, DOI 10.1152/ajprenal.1984.247.6.F955; DOWNING DT, 1970, BIOCHEM BIOPH RES CO, V40, P218, DOI 10.1016/0006-291X(70)91069-7; EVELOFF J, 1981, PFLUG ARCH EUR J PHY, V389, P263, DOI 10.1007/BF00584788; FERRERI NR, 1984, J PHARMACOL EXP THER, V231, P441; HIRT DL, 1989, J CLIN INVEST, V84, P1805, DOI 10.1172/JCI114365; KATZ AI, 1982, AM J PHYSIOL, V242, pF207, DOI 10.1152/ajprenal.1982.242.3.F207; KINNE R, 1985, RENAL BIOCH CELLS ME, P99; MAINES MD, 1977, J BIOL CHEM, V252, P5900; Overbeck HW, 1976, CIRC RES, V38, P48, DOI 10.1161/01.RES.38.6.48; ROMERO MF, 1990, ADV PROSTAGLANDIN TH, P205; SCHWARTZMAN M, 1985, NATURE, V314, P620, DOI 10.1038/314620a0; SCHWARTZMAN ML, 1986, BIOCHEM J, V238, P283, DOI 10.1042/bj2380283; SERI I, 1988, AM J PHYSIOL, V255, pF666, DOI 10.1152/ajprenal.1988.255.4.F666; TAKAHASHI K, 1990, AM J PHYSIOL, V258, pF781, DOI 10.1152/ajprenal.1990.258.4.F781	16	223	225	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					799	802		10.1126/science.1846705	http://dx.doi.org/10.1126/science.1846705			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1846705				2022-12-28	WOS:A1991EX57500046
J	LEE, CC; PEARLMAN, JA; CHAMBERLAIN, JS; CASKEY, CT				LEE, CC; PEARLMAN, JA; CHAMBERLAIN, JS; CASKEY, CT			EXPRESSION OF RECOMBINANT DYSTROPHIN AND ITS LOCALIZATION TO THE CELL-MEMBRANE	NATURE			English	Article							PROTEIN PRODUCT; MUSCLE; GENE; MYOFIBERS; EFFICIENT; MICE	DUCHENNE'S muscular dystrophy (DMD) is an X-linked progressive myopathy caused by a defect in the DMD gene locus 1,2. The gene corresponding to the DMD locus produces a 14-kilobase (kb) messenger RNA that codes for a large cytoskeletal membrane protein, dystrophin 3,4. DMD and Becker's muscular dystrophy are the consequences of dystrophin mutations 4,5. The exact biological function of dystrophin remains unknown but it has been demonstrated that it is localized to the cytoplasmic face of the cell membrane and has direct interaction with several other membrane proteins 6,7. We report here the synthesis of a 14-kb full-length complementary DNA for the mouse muscle dystrophin mRNA and the expression of this cDNA in COS cells. The recombinant dystrophin is indistinguishable from mouse muscle dystrophin by western blot analysis with anti-dystrophin antibodies and was shown by an immunofluorescent technique to be localized in the cell membrane. Our successful construction of a functional full-length cDNA opens opportunities for the study of structure and function of dystrophin and provides an opportunity to initiate gene therapy studies.	BAYLOR UNIV,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR UNIV,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor University; Baylor University; Howard Hughes Medical Institute				Chamberlain, Jeffrey/0000-0001-5299-0059				CHAMBERLAIN JS, 1990, CURRENT NEUROLOGY, V10, pCH2; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; EMERGY AEH, 1987, OXFORD MONOGRAPHS ME, V15; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1987, SCIENCE, V238, P347, DOI 10.1126/science.3659917; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; MONACO AP, 1989, TRENDS BIOCHEM SCI, V14, P412, DOI 10.1016/0968-0004(89)90290-9; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; MONGINI T, 1988, NEUROLOGY, V38, P476, DOI 10.1212/WNL.38.3.476; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	20	78	80	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					334	336		10.1038/349334a0	http://dx.doi.org/10.1038/349334a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1824797				2022-12-28	WOS:A1991EU50100054
J	ODIN, JA; EDBERG, JC; PAINTER, CJ; KIMBERLY, RP; UNKELESS, JC				ODIN, JA; EDBERG, JC; PAINTER, CJ; KIMBERLY, RP; UNKELESS, JC			REGULATION OF PHAGOCYTOSIS AND [CA2+]I FLUX BY DISTINCT REGIONS OF AN FC RECEPTOR	SCIENCE			English	Article							MEDIATED PHAGOCYTOSIS; HUMAN NEUTROPHIL; ACTIVATION; EXPRESSION; HETEROGENEITY; FLUORESCENCE; GENERATION; PROTEIN; IGG	The binding of multivalent immunoglobulin G complexes to Fc receptors (Fc-gamma-Rs) on macrophages activates multiple immune functions. A murine macrophage cell fine, but not a fibroblast cell line, that was transfected with human Fc-gamma-RIIA mediated phagocytosis and an intracellular Ca2+ concentration ([Ca2+]i) flux upon cross-linking of human Fc-gamma-RIIA. Transfected macrophages that expressed a truncated receptor lacking 17 carboxy-terminal amino acids phagocytosed small antibody complexes. However, only wild-type transfectants phagocytosed labeled erythrocytes and fluxed [Ca2+]i. Thus, the cytoplasmic domain of human Fc-gamma-RIIA contains distinct functional regions.	MT SINAI MED CTR,DEPT BIOCHEM,NEW YORK,NY 10029; CORNELL UNIV,MED CTR,DEPT MED,NEW YORK,NY 10021	Icahn School of Medicine at Mount Sinai; Cornell University	UNKELESS, JC (corresponding author), MT SINAI MED CTR,DEPT BIOCHEM,NEW YORK,NY 10029, USA.			Kimberly, Robert/0000-0002-5330-3086	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024671, R01AI024322, R37AI024322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033062] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 24671, AI 24322] Funding Source: Medline; NIAMS NIH HHS [AR 33062] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSSON T, 1988, FEBS LETT, V239, P371, DOI 10.1016/0014-5793(88)80954-2; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; EDBERG JC, UNPUB; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GRESHAM HD, 1990, J BIOL CHEM, V265, P7819; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOLTZMAN E, 1989, LYSOSOMES, pCH2; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; MACINTYRE EA, 1988, J IMMUNOL, V141, P4333; MARTIN MM, 1975, J LUMIN, V10, P381, DOI 10.1016/0022-2313(75)90003-4; MIDOUX P, 1987, CYTOMETRY, V8, P327, DOI 10.1002/cyto.990080314; MILLER J, 1985, J IMMUNOL, V134, P4212; MUNN DH, 1991, CANCER RES, V51, P1117; ODIN JA, 1990, RECEPTORS INFLAMMATO, V1, P1; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; Sambrook J, 1989, MOL CLONING LABORATO; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P216; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	24	159	160	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1785	1788		10.1126/science.1837175	http://dx.doi.org/10.1126/science.1837175			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1837175				2022-12-28	WOS:A1991GW31600041
J	LEE, WS; KAO, CC; BRYANT, GO; LIU, X; BERK, AJ				LEE, WS; KAO, CC; BRYANT, GO; LIU, X; BERK, AJ			ADENOVIRUS E1A ACTIVATION DOMAIN BINDS THE BASIC REPEAT IN THE TATA BOX TRANSCRIPTION FACTOR	CELL			English	Article							FUNCTIONAL DOMAINS; CELLULAR TARGETS; ESCHERICHIA-COLI; EARLY REGION-1A; INFECTED CELLS; DNA-SYNTHESIS; PROTEIN; GENE; TRANSACTIVATION; CLONING	The adenovirus large E1A protein is a potent activator of transcription. We use several different experimental approaches to demonstrate that the large E1A protein binds specifically and stably to the TATA box-binding factor (TFIID), the general polymerase II transcription factor that initiates assembly of transcription complexes. Sedimentation velocity centrifugation revealed that TFIID and E1A form a heterodimer in vitro. We demonstrate that the activation domain of E1A (conserved region 3) binds to TFIID. E1A interacts with a 51 residue region from the conserved C-terminal domain of TFIID that includes a repeat of basic residues between the homologous direct repeats of TFIID. Analysis of TFIID binding by various E1A mutants indicates that TFIID binding is necessary, although not sufficient, for E1A transactivation.			LEE, WS (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA.		BERK, ARNOLD/AAF-7052-2020		NATIONAL CANCER INSTITUTE [R37CA025235, R01CA025235] Funding Source: NIH RePORTER; NCI NIH HHS [CA25235] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DASMAHAPATRA B, 1987, NUCLEIC ACIDS RES, V15, P3933, DOI 10.1093/nar/15.9.3933; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HOEIJMAKERS JHJ, 1990, NATURE, V343, P417, DOI 10.1038/343417b0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LEONG K, 1988, MOL CELL BIOL, V8, P1765, DOI 10.1128/MCB.8.4.1765; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIEBERMAN PM, 1990, J VIROL, V64, P2560, DOI 10.1128/JVI.64.6.2560-2568.1990; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; NAGAI K, 1990, NATURE, V343, P418, DOI 10.1038/343418a0; PEI R, 1989, J VIROL, V63, P3499, DOI 10.1128/JVI.63.8.3499-3506.1989; PENNINGTON TH, 1974, J GEN VIROL, V25, P433, DOI 10.1099/0022-1317-25-3-433; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUCKA R, 1990, FEBS LETT, V261, P223, DOI 10.1016/0014-5793(90)80558-Z; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	54	376	378	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					365	376		10.1016/0092-8674(91)90188-5	http://dx.doi.org/10.1016/0092-8674(91)90188-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1833071				2022-12-28	WOS:A1991GL47000016
J	LEE, B; GODFREY, M; VITALE, E; HORI, H; MATTEI, MG; SARFARAZI, M; TSIPOURAS, P; RAMIREZ, F; HOLLISTER, DW				LEE, B; GODFREY, M; VITALE, E; HORI, H; MATTEI, MG; SARFARAZI, M; TSIPOURAS, P; RAMIREZ, F; HOLLISTER, DW			LINKAGE OF MARFAN-SYNDROME AND A PHENOTYPICALLY RELATED DISORDER TO 2 DIFFERENT FIBRILLIN GENES	NATURE			English	Article							ABNORMALITIES; MICROFIBRILS; DEFECT	MARFAN Syndrome (MFS), one of the most common genetic disorders of connective tissue, is characterized by skeletal, cardiovascular and ocular abnormalities 1. The incidence of the disease is about 1 in 20,000, with life expectancy severely reduced because of cardiovascular complications. As the underlying defect is unknown, MFS diagnosis is based solely on clinical criteria. Certain phenotypic features of MFS are also shared by other conditions, which may be genetically distinct entities although part of a clinical continuum. Immunohistochemical studies have implicated fibrillin, a major component of elastin-associated microfibrils 2, in MFS aetiology 3,4. Genetic linkage analysis with random probes has independently localized the MFS locus to chromosome 15 (refs 5-7). Here we report that these two experimental approaches converge with the cloning and mapping of the fibrillin gene to chromosome 15q15-21, and with the establishment of linkage to MFS. We also isolated a second fibrillin gene and mapped it to chromosome 5q23-31. We linked this novel gene to a condition, congenital contractural arachnodactyly, that shares some of the features of MFS 1. Thus, the cosegregation of two related genes with two related syndromes implies that fibrillin mutations are likely to be responsible for different MFS phenotypes.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,1 GUSTAVE LEVY PL,NEW YORK,NY 10029; UNIV NEBRASKA,MED CTR,DEPT PEDIAT,MEYER REHABIL INST,MUNROE CTR HUMAN GENET,OMAHA,NE 68131; HOP ENFANTS LA TIMONE,INSERM,U242,F-13385 MARSEILLE,FRANCE; UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,MOLEC GENET LAB,FARMINGTON,CT 06030; TOKYO MED & DENT UNIV,MED RES INST,DEPT TISSUE PHYSIOL,TOKYO 101,JAPAN; UNIV NEBRASKA,MED CTR,DEPT PATHOL,OMAHA,NE 68131	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Nebraska System; University of Nebraska Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Connecticut; Tokyo Medical & Dental University (TMDU); University of Nebraska System; University of Nebraska Medical Center			vitale, emilia/A-5282-2011	Vitale, Emilia/0000-0003-4651-3875				BEALS RK, 1971, J BONE JOINT SURG AM, VA 53, P987, DOI 10.2106/00004623-197153050-00013; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; GODFREY M, 1990, AM J HUM GENET, V46, P652; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; INOUE S, 1986, AM J ANAT, V176, P121, DOI 10.1002/aja.1001760203; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEE B, 1991, J BIOL CHEM, V266, P5256; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; MADDOX BK, 1989, J BIOL CHEM, V264, P21382; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; OTT J, 1974, AM J HUM GENET, V26, P588; PYERITZ RE, 1990, PRINCIPLES PRACTICE, P1047; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TSIPOURAS P, P NATL ACAD SCI USA, V88, P4486; WALKER BA, 1969, ANN INTERN MED, V71, P349, DOI 10.7326/0003-4819-71-2-349	19	578	600	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					330	334		10.1038/352330a0	http://dx.doi.org/10.1038/352330a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852206				2022-12-28	WOS:A1991FY28900069
J	FITZGIBBONS, R				FITZGIBBONS, R			LAPAROSCOPIC CHOLECYSTECTOMY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FITZGIBBONS, R (corresponding author), CREIGHTON UNIV,SCH MED,OMAHA,NE 68178, USA.								0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					269	269		10.1001/jama.266.2.269	http://dx.doi.org/10.1001/jama.266.2.269			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	1829119				2022-12-28	WOS:A1991FU89600041
J	ALBERTI, A; CHEMELLO, L; CAVALLETTO, D; TAGGER, A; DALCANTON, A; BIZZARO, N; TAGARIELLO, G; RUOL, A				ALBERTI, A; CHEMELLO, L; CAVALLETTO, D; TAGGER, A; DALCANTON, A; BIZZARO, N; TAGARIELLO, G; RUOL, A			ANTIBODY TO HEPATITIS-C VIRUS AND LIVER-DISEASE IN VOLUNTEER BLOOD-DONORS	ANNALS OF INTERNAL MEDICINE			English	Article							RECOMBINANT IMMUNOBLOT ASSAY; NON-B-HEPATITIS; NON-A; TRANSFUSION	Objective: To evaluate the specificity of antibodies to hepatitis C virus (anti-HCV) and their relation to liver disease in blood donors. Design: Case series of consecutive blood donors found positive for anti-HCV by enzyme-linked immunosorbent assay (ELISA). Patients were evaluated for antibody specificity using a recombinant immunoblotting assay (RIBA) and were evaluated for biochemical evidence of liver disease. Patients showing increased alanine aminotransferase (ALT) levels had a liver biopsy. Setting: University hospital. Participants: Fifty consecutive blood donors found to be anti-HCV positive on both an initial and repeat ELISA. Inclusion criteria were as follows: an absence of hepatitis B surface antigens and non-organ-specific autoantibodies; a daily alcohol intake of < 50 g; no history of recent hepatotoxic drug use; and normal serum levels of alpha, antitrypsin, ceruloplasmin, and copper. Main Results: Anti-HCV positivity was confirmed by RIBA in only 13 of 50 donors (26%) who had positive ELISA results. These 13 donors had an elevated ALT level and histologic evidence of chronic hepatitis, which was active in 8 patients (62%) and had already produced cirrhosis in 2 patients (15%). In contrast, the 17 donors with an intermediate RIBA pattern had only mild and often nonspecific histologic liver abnormalities. The 20 patients with a negative RIBA result had normal ALT levels. Conclusion: In blood donors, the anti-HCV RIBA is not only more specific than the anti-HCV ELISA, but is also useful in identifying patients who have an underlying chronic liver disease.	IST VIROL, MILAN, ITALY; OSPED CASTELFRANCO VENETO, CTR TRASFUS, I-31033 CASTELFRANCO VENETO, ITALY; OSPED S DONA PIAVE, S DONA PIAVE, ITALY	ULSS 2 Marca TV; Ospedale Castelfranco Veneto	ALBERTI, A (corresponding author), CLIN MED 2, VIA GIUSTINIANI 2, I-35100 PADUA, ITALY.		chemello, liliana/AAU-9414-2020; dal canton, antonio/G-4388-2013	ALBERTI, ALFREDO/0000-0001-9926-2382				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BALDI M, 1990, HEPATOLOGY, V12, P960; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; EBELING F, 1990, LANCET, V335, P982, DOI 10.1016/0140-6736(90)91055-F; ESTEBAN JI, 1989, LANCET, V2, P294; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; SKIDMORE S, 1990, LANCET, V335, P1346, DOI 10.1016/0140-6736(90)91230-8; VANDERPOEL CL, 1990, LANCET, V336, P187, DOI 10.1016/0140-6736(90)91718-P; 1990, LANCET, V335, P1431	10	85	85	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1010	1012		10.7326/0003-4819-114-12-1010	http://dx.doi.org/10.7326/0003-4819-114-12-1010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	1851402				2022-12-28	WOS:A1991FQ55500003
J	RESNICOW, K; BERENSON, G; SHEA, S; SRINIVASAN, S; STRONG, W; WYNDER, EL				RESNICOW, K; BERENSON, G; SHEA, S; SRINIVASAN, S; STRONG, W; WYNDER, EL			THE CASE AGAINST THE CASE AGAINST CHILDHOOD CHOLESTEROL SCREENING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY HEART-DISEASE; PLASMA-CHOLESTEROL; UNITED-STATES; CHILDREN; PREVENTION; HYPERCHOLESTEROLEMIA; DISTRIBUTIONS; INTERVENTION; PERSPECTIVE; PREVALENCE		LOUISIANA STATE UNIV,MED CTR,CARDIOL SECT,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,DEPT MED,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM,NEW ORLEANS,LA 70112; COLUMBIA PRESBYTERIAN MED CTR,DEPT MED,NEW YORK,NY 10032; COLUMBIA PRESBYTERIAN MED CTR,CHILDRENS CARDIOVASC HLTH CTR,NEW YORK,NY 10032; MED COLL GEORGIA,PEDIAT CARDIOL SECT,AUGUSTA,GA 30912	Louisiana State University System; Louisiana State University System; Louisiana State University System; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; University System of Georgia; Augusta University	RESNICOW, K (corresponding author), AMER HLTH FDN,DIV HLTH PROMOT RES,320 E 43RD ST,NEW YORK,NY 10017, USA.							CHRISTENSEN B, 1980, PEDIATR RES, V14, P194, DOI 10.1203/00006450-198003000-00004; Cook T.C., 1979, QUASIEXPERIMENTATION; DAVID MM, 1990, PREV MED, V19, P181; FRERICHS RR, 1976, CIRCULATION, V54, P302, DOI 10.1161/01.CIR.54.2.302; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; KOLBE LJ, 1986, HLTH ED          OCT, P19; LAUER RM, 1975, J PEDIATR-US, V86, P697, DOI 10.1016/S0022-3476(75)80353-2; LAUER RM, 1990, JAMA-J AM MED ASSOC, V264, P3034, DOI 10.1001/jama.264.23.3034; LIFSHITZ F, 1989, AM J DIS CHILD, V143, P537, DOI 10.1001/archpedi.1989.02150170035015; MCGUIRE WJ, 1981, PUBLIC COMMUNICATION, P41; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEWMAN TB, 1990, JAMA-J AM MED ASSOC, V264, P3039, DOI 10.1001/jama.264.23.3039; OLSON RE, 1986, JAMA-J AM MED ASSOC, V255, P2204, DOI 10.1001/jama.255.16.2204; PUGLIESE MT, 1987, PEDIATRICS, V80, P175; RESNICOW K, 1989, J SCHOOL HEALTH, V59, P74, DOI 10.1111/j.1746-1561.1989.tb05397.x; RESNICOW K, 1991, ANN NY ACAD SCI, V623, P285, DOI 10.1111/j.1749-6632.1991.tb43738.x; RESNICOW K, 1989, PEDIATRICS, V84, P969; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3527, DOI 10.1001/jama.258.24.3527; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; STRONG WB, 1988, PEDIATR REV, V910, P303; STRONG WB, 1990, PEDIATR REV, V12, P36; TYROLER HA, 1987, CIRCULATION, V76, P515, DOI 10.1161/01.CIR.76.3.515; VANSTIPHOUT WAHJ, 1985, PREV MED, V14, P169, DOI 10.1016/0091-7435(85)90032-5; WYNDER EL, 1989, PREV MED, V18, P323, DOI 10.1016/0091-7435(89)90048-0; 1991, HIGHLIGHTS REPORT EX; 1980, 801527 US DEP HLTH H; 1988, ARCH INTERN MED, V148, P36; 1990, PHS DHHS9150212 US D	29	28	28	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					3003	3005		10.1001/jama.265.22.3003	http://dx.doi.org/10.1001/jama.265.22.3003			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	1805810				2022-12-28	WOS:A1991FP63500041
J	KAPLAN, DR; HEMPSTEAD, BL; MARTINZANCA, D; CHAO, MV; PARADA, LF				KAPLAN, DR; HEMPSTEAD, BL; MARTINZANCA, D; CHAO, MV; PARADA, LF			THE TRK PROTOONCOGENE PRODUCT - A SIGNAL TRANSDUCING RECEPTOR FOR NERVE GROWTH-FACTOR	SCIENCE			English	Article							SYMPATHETIC-GANGLIA MEMBRANES; SIMIAN SARCOMA-VIRUS; TYROSINE PHOSPHORYLATION; PHEOCHROMOCYTOMA CELLS; GENE-TRANSFER; CHICK-EMBRYO; PC12 CELLS; EXPRESSION; AFFINITY; SYSTEM	The trk proto-oncogene encodes a 140-kilodalton, membrane-spanning protein tyrosine kinase (p140prototrk) that is expressed only in neural tissues. Nerve growth factor (NGF) stimulates phosphorylation of p140prototrk in neural cell lines and in embryonic dorsal root ganglia. Affinity cross-linking and equilibrium binding experiments with I-125-labeled NGF indicate that p140prototrk binds NGF specifically in cultured cells with a dissociation constant of 10(-9) molar. The identification of p140prototrk as an NGF receptor indicates that this protein participates in the primary signal transduction mechanism of NGF.	NCI,FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ADV BIOSCI LAB,FREDERICK,MD 21701; CORNELL UNIV,MED CTR,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV HEMATOL ONCOL,NEW YORK,NY 10021	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Cornell University; Cornell University			Parada, luis F/B-9400-2014	Chao, Moses/0000-0002-6969-3744	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANERJEE U, 1987, CELL, V49, P281, DOI 10.1016/0092-8674(87)90569-1; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BASLER K, 1988, TRENDS GENET, V3, P74; Black I.B., 1990, Current Topics in Developmental Biology, V24, P161; BOTHWELL MA, 1980, CELL, V21, P857, DOI 10.1016/0092-8674(80)90449-3; BUXSER S, 1985, J BIOL CHEM, V260, P1917; CHAO MV, 1986, SCIENCE, V232, P418; CHAO MV, 1990, HDB EXPT PHARM, P135; CNATLEY LC, 1991, CELL, V64, P281; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; COUGHLIN MD, 1977, P NATL ACAD SCI USA, V74, P3438, DOI 10.1073/pnas.74.8.3438; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GREEN SH, 1986, J BIOL CHEM, V261, P5316; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HAMBURGER V, 1949, J EXP ZOOL, V111, P457, DOI 10.1002/jez.1401110308; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HEMPSTEAD BL, UNPUB; HEMPSTEAD RL, UNPUB; HENDRY IA, 1976, J NEUROCYTOL, V5, P351, DOI 10.1007/BF01175120; HOSANG M, 1985, J BIOL CHEM, V260, P655; HOSANG M, 1985, J CELL BIOCHEM, V29, P265, DOI 10.1002/jcb.240290310; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON EM, 1987, BIOCHEM PHARMACOL, V36, P4189, DOI 10.1016/0006-2952(87)90658-7; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; KAPLAN D, 1991, NATURE, V350, P160; KAPLAN DE, UNPUB; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KESHET E, IN PRESS EMBO J; KLEIN R, 1990, DEVELOPMENT, V109, P845; KOUCHALAKOS RN, 1986, J BIOL CHEM, V261, P6054; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; MAHER PA, 1989, J NEUROSCI RES, V24, P29, DOI 10.1002/jnr.490240106; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MARTINZANCA D, 1990, AVIAN MODEL IN DEVELOPMENT BIOLOGY : FROM ORGANISM TO GENES, P291; MARTINZANCA D, 1991, NATURE, V350, P678; MASSAGUE J, 1981, J BIOL CHEM, V256, P9419; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; OPPENHEIM RW, 1981, STUDIES DEV NEUROBIO; PARADA L, UNPUB; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; SUTTER A, 1979, J BIOL CHEM, V254, P5972; VETTER ML, IN PRESS P NATL ACAD; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	56	1262	1301	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					554	558		10.1126/science.1850549	http://dx.doi.org/10.1126/science.1850549			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850549				2022-12-28	WOS:A1991FJ12700043
J	STRUTHERS, RS; VALE, WW; ARIAS, C; SAWCHENKO, PE; MONTMINY, MR				STRUTHERS, RS; VALE, WW; ARIAS, C; SAWCHENKO, PE; MONTMINY, MR			SOMATOTROPH HYPOPLASIA AND DWARFISM IN TRANSGENIC MICE EXPRESSING A NON-PHOSPHORYLATABLE CREB MUTANT	NATURE			English	Article							HORMONE-RELEASING FACTOR; NUCLEAR FACTOR CREB; SOMATOSTATIN GENE; PITUITARY; TRANSCRIPTION; HYPERPLASIA; BINDING; PROTEIN; CELLS	MOST of the transcriptional effects of cyclic AMP are mediated by the cAMP response element binding protein (CREB) 1, 2. After activation of cAMP-dependent protein kinase A, the catalytic subunits of this enzyme apparently mediate the phosphorylation and activation of CREB 3, 4. As cAMP serves as a mitogenic signal for anterior pituitary somatotrophic cells 5, we investigated whether CREB similarly regulates proliferation of these cells. We prepared transgenic mice expressing a transcriptionally inactive mutant of CREB (CREBM1), which cannot be phosphorylated, in cells of the anterior pituitary. If CREB activity is required for proliferation, the overexpressed mutant protein would effectively compete with wild-type CREB activity and thereby block the response to cAMP. As predicted, the CREBM1 transgenic mice exhibited a dwarf phenotype with atrophied pituitary glands markedly deficient in somatotroph but not other cell types. We conclude that transcriptional activation of CREB is necessary for the normal development of a highly restricted cell type, and that environmental cues, possibly provided by the hypothalamic growth hormone-releasing factor, are necessary for population of the pituitary by somatotrophic cells.	UNIV CALIF SAN DIEGO,GRAD PROGRAM BIOMED SCI,LA JOLLA,CA 92093; SALK INST BIOL STUDIES,NEURONAL STRUCT & FUNCT LAB,LA JOLLA,CA 92037	University of California System; University of California San Diego; Salk Institute	STRUTHERS, RS (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BILLESTRUP N, 1987, MOL ENDOCRINOL, V1, P300, DOI 10.1210/mend-1-4-300; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BORELLI E, 1989, NATURE, V339, P593; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; GERFEN CR, 1984, BRAIN RES, V290, P219, DOI 10.1016/0006-8993(84)90940-5; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIRA SA, 1988, P NATL ACAD SCI USA, V85, P4755, DOI 10.1073/pnas.85.13.4755; MAYO KE, 1988, MOL ENDOCRINOL, V2, P606, DOI 10.1210/mend-2-7-606; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; THORNER MO, 1982, J CLIN INVEST, V70, P965, DOI 10.1172/JCI110708; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; 1986, MANIPULATING MOUSE E	21	266	268	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					622	624		10.1038/350622a0	http://dx.doi.org/10.1038/350622a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	1826763				2022-12-28	WOS:A1991FH11200063
J	KECHIJIAN, P				KECHIJIAN, P			DERMATOPHYTE INFECTION OF TOENAILS - THE AJAX CURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KECHIJIAN, P (corresponding author), NYU MED CTR,NEW YORK,NY 10016, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					2004	2004						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	1826137				2022-12-28	WOS:A1991FF76800030
J	PLOTKIN, SA; STARR, SE; FRIEDMAN, HM; BRAYMAN, K; HARRIS, S; JACKSON, S; TUSTIN, NB; GROSSMAN, R; DAFOE, D; BARKER, C				PLOTKIN, SA; STARR, SE; FRIEDMAN, HM; BRAYMAN, K; HARRIS, S; JACKSON, S; TUSTIN, NB; GROSSMAN, R; DAFOE, D; BARKER, C			EFFECT OF TOWNE LIVE VIRUS-VACCINE ON CYTOMEGALOVIRUS DISEASE AFTER RENAL-TRANSPLANT - A CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							ALLOGRAFT RECIPIENTS; RISK FACTOR; MARROW TRANSPLANTATION; IMMUNE GLOBULIN; LYMPHOCYTES-T; INFECTION; STRAIN; IMMUNIZATION; CYCLOSPORINE; PREVENTION	Objective: To test the efficacy of vaccination with the Towne live attenuated cytomegalovirus vaccine. Design: A double-blind, randomized, placebo-controlled trial in candidates for renal transplantation. The cytomegalovirus serologic status of both recipients and donors was determined, and the recipients were followed for periods of 6 months to 7 years after transplant. Setting: A university transplant center. Patients: The analyses were made on 237 patients who were given either vaccine or placebo, received renal transplants, and were followed for at least 6 months. Intervention: Subcutaneous inoculation with Towne live attenuated virus or with placebo. Main Outcome Measures: The presence of cytomegalovirus infection was defined by virus isolation and antibody tests. If infection occurred, a prearranged scoring system for cytomegalovirus disease was used to objectify disease severity. Results: The vaccine was well tolerated, and there were no discernible long-term adverse effects. Recipients who were originally seropositive did not clearly benefit from vaccination. Protective efficacy was analyzed in the group at highest risk for cytomegalovirus disease: recipients who were seronegative at the time of vaccination and who received a kidney from a seropositive donor. Compared with placebo recipients, vaccinated patients in this group had significantly less severe cytomegalovirus disease, with a significant reduction in disease scores (P = 0.03) and 85% decrease in the most severe disease (95% CI, 35% to 96%), although infection rates were similar. Graft survival at 36 months was improved in vaccinated recipients of cadaver kidneys (8 of 16) compared with unvaccinated recipients (4 of 16) (P = 0.04). Conclusions: Previous vaccination of seronegative renal transplant recipients with live cytomegalovirus results in reduction of disease severity mimicking the action of naturally derived immunity.	HOSP UNIV PENN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	PLOTKIN, SA (corresponding author), UNIV PENN, CHILDRENS HOSP PHILADELPHIA, DIV INFECT DIS, 34TH ST & CIV CTR BLVD, PHILADELPHIA, PA 19104 USA.				PHS HHS [R01-A125822-03] Funding Source: Medline; FDA HHS [FD-R-000267-03, FDA-OP-90-1] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); FDA HHS		Balfour H H Jr, 1984, Birth Defects Orig Artic Ser, V20, P289; BALFOUR HH, 1989, NEW ENGL J MED, V320, P1381, DOI 10.1056/NEJM198905253202105; BECK S, 1988, NATURE, V331, P269, DOI 10.1038/331269a0; BECKWITH DG, 1985, J CLIN MICROBIOL, V21, P328, DOI 10.1128/JCM.21.3.328-331.1985; BORYSIEWICZ LK, 1988, J EXP MED, V168, P919, DOI 10.1084/jem.168.3.919; BORYSIEWICZ LK, 1983, EUR J IMMUNOL, V13, P804, DOI 10.1002/eji.1830131005; BRAYMAN KL, 1988, ARCH SURG-CHICAGO, V123, P1502; CAPPEL R, 1978, ARCH VIROL, V56, P149, DOI 10.1007/BF01317289; CARNEY WP, 1983, J INFECT DIS, V147, P958, DOI 10.1093/infdis/147.5.958; DUMMER JS, 1986, TRANSPLANTATION, V41, P725, DOI 10.1097/00007890-198606000-00012; FENG CS, 1986, TRANSFUSION, V26, P203, DOI 10.1046/j.1537-2995.1986.26286152916.x; FLEISHER GR, 1982, AM J DIS CHILD, V136, P294, DOI 10.1001/archpedi.1982.03970400012003; FRYD DS, 1980, TRANSPLANTATION, V30, P436, DOI 10.1097/00007890-198012000-00010; GEHRZ RC, 1980, ARCH INTERN MED, V140, P936, DOI 10.1001/archinte.140.7.936; GLAZER JP, 1979, ANN INTERN MED, V91, P676, DOI 10.7326/0003-4819-91-5-676; GLENN J, 1981, REV INFECT DIS, V3, P1151; GORENSEK MJ, 1988, J INFECT DIS, V158, P884, DOI 10.1093/infdis/158.4.884; GRUNDY JE, 1988, J MED VIROL, V25, P483, DOI 10.1002/jmv.1890250412; GRUNDY JE, 1987, J GEN VIROL, V68, P793, DOI 10.1099/0022-1317-68-3-793; HO M, 1983, TRANSPLANT P, V15, P2768; JOHNSON PC, 1988, TRANSPLANTATION, V45, P116, DOI 10.1097/00007890-198801000-00026; KURTZ JB, 1984, Q J MED, V53, P341; LUDWIN D, 1987, TRANSPLANT P, V19, P3433; METSELAAR HJ, 1988, SCAND J INFECT DIS, V20, P135, DOI 10.3109/00365548809032429; MEYERS JD, 1986, J INFECT DIS, V153, P478, DOI 10.1093/infdis/153.3.478; NAJARIAN JS, 1985, ANN SURG, V201, P142, DOI 10.1097/00000658-198502000-00003; PASS RF, 1980, J INFECT DIS, V142, P9, DOI 10.1093/infdis/142.1.9; PLOTKIN SA, 1976, J INFECT DIS, V134, P470, DOI 10.1093/infdis/134.5.470; PLOTKIN SA, 1984, LANCET, V1, P528; PLOTKIN SA, 1975, INFECT IMMUN, V12, P521, DOI 10.1128/IAI.12.3.521-527.1975; PLOTKIN SA, 1985, J INFECT DIS, V152, P395, DOI 10.1093/infdis/152.2.395; POLLAK R, 1987, ANN SURG, V205, P302, DOI 10.1097/00000658-198703000-00014; QUINNAN GV, 1984, ANN INTERN MED, V101, P478, DOI 10.7326/0003-4819-101-4-478; RAKELA J, 1987, TRANSPL P, V19, P2399; REDDEHASE MJ, 1987, J VIROL, V61, P3102, DOI 10.1128/JVI.61.10.3102-3108.1987; REEDMAN BM, 1975, INT J CANCER, V15, P566, DOI 10.1002/ijc.2910150406; RICHARDSON WP, 1981, NEW ENGL J MED, V305, P57, DOI 10.1056/NEJM198107093050201; ROOK AH, 1984, TRANSPLANT P, V16, P1466; RUBIN RH, 1985, TRANSPLANTATION, V40, P243, DOI 10.1097/00007890-198509000-00004; SALIBA F, 1987, TRANSPLANT P, V19, P4081; SINGH N, 1988, J INFECT DIS, V158, P124, DOI 10.1093/infdis/158.1.124; SNYDMAN DR, 1987, NEW ENGL J MED, V317, P1049, DOI 10.1056/NEJM198710223171703; STAGNO S, 1986, JAMA-J AM MED ASSOC, V256, P1904, DOI 10.1001/jama.256.14.1904; STARR SE, 1981, J INFECT DIS, V143, P585, DOI 10.1093/infdis/143.4.585; STARR SE, 1981, CLIN EXP IMMUNOL, V46, P484; WALTZER WC, 1987, TRANSPL P, V19, P4077; WINSTON DJ, 1985, ANN INTERN MED, V102, P16, DOI 10.7326/0003-4819-102-1-16; WREGHITT TG, 1987, TRANSPLANT P, V19, P2495; 1985, NEW VACCINE DEV ESTA, V1	49	176	181	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					525	531		10.7326/0003-4819-114-7-525	http://dx.doi.org/10.7326/0003-4819-114-7-525			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	1848053				2022-12-28	WOS:A1991FD66100001
J	CUNNINGHAM, CC; STOSSEL, TP; KWIATKOWSKI, DJ				CUNNINGHAM, CC; STOSSEL, TP; KWIATKOWSKI, DJ			ENHANCED MOTILITY IN NIH-3T3 FIBROBLASTS THAT OVEREXPRESS GELSOLIN	SCIENCE			English	Article							MYOSIN HEAVY-CHAIN; ACTIN-FILAMENTS; CA-2+ CONTROL; DICTYOSTELIUM; BINDING; GENE; INACTIVATION; EXPRESSION; PROTEIN; CELLS	Increasing the content of the actin-binding protein gelsolin in cultured mouse fibroblasts by up to 125 percent by gene transfection proportionally enhanced the rate at which the cells migrated through porous filters toward a gradient of serum and closed a wound made on a confluent monolayer of cells in a tissue culture dish. These results provide direct evidence that gelsolin, which promotes both actin assembly and disassembly in vitro, is an important element in fibroblast locomotion and demonstrate that the manipulation of intracellular machinery can increase cell motility.			CUNNINGHAM, CC (corresponding author), MASSACHUSETTS GEN HOSP,HEMATOL ONCOL UNIT,BLDG 149,13TH ST,BOSTON,MA 02129, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL019429, R01HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028465] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07680, HL19429] Funding Source: Medline; NIAID NIH HHS [AI28465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; CHAPONNIER C, 1990, J CELL BIOL, V110, P1983; COOPER JA, 1987, J CELL BIOL, V104, P491, DOI 10.1083/jcb.104.3.491; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FRANCK Z, 1990, J CELL BIOL, V111, P2478; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; HUCKRIEDE A, 1990, CELL MOTIL CYTOSKEL, V16, P229, DOI 10.1002/cm.970160403; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KUPFER A, 1982, P NATL ACAD SCI-BIOL, V79, P2603, DOI 10.1073/pnas.79.8.2603; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; MEHL RE, 1988, J CELL BIOL, V106, P373; NOEGEL AA, 1988, DEV GENET, V9, P531, DOI 10.1002/dvg.1020090429; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; YIN HL, 1980, J BIOL CHEM, V255, P9494; YIN HL, 1981, J BIOL CHEM, V256, P9693	27	276	284	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1233	1236		10.1126/science.1848726	http://dx.doi.org/10.1126/science.1848726			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1848726				2022-12-28	WOS:A1991FA69100042
J	GOLDSCHMIDTCLERMONT, PJ; KIM, JW; MACHESKY, LM; RHEE, SG; POLLARD, TD				GOLDSCHMIDTCLERMONT, PJ; KIM, JW; MACHESKY, LM; RHEE, SG; POLLARD, TD			REGULATION OF PHOSPHOLIPASE-C-GAMMA-1 BY PROFILIN AND TYROSINE PHOSPHORYLATION	SCIENCE			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; BOVINE BRAIN; RECEPTOR	Epidermal growth factor and platelet-derived growth factor can stimulate the production of the second messenger inositol trisphosphate in responsive cells, but the biochemical pathway for these signaling events has been uncertain because the reactions have not been reconstituted with purified molecules in vitro. A reconstitution is described that requires not only the growth factor, its receptor with tyrosine kinase activity, and the soluble phospholipase C-gamma-1, but also the small soluble actin-binding protein profilin. Profilin binds to the substrate phosphatidylinositol 4,5-bisphosphate and inhibits its hydrolysis by unphosphorylated phospholipase C-gamma-1. Phosphorylation of phospholipase C-gamma-1 by the epidermal growth factor receptor tyrosine kinase overcomes the inhibitory effect of profilin and results in an effective activation of phospholipase C-gamma-1.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	GOLDSCHMIDTCLERMONT, PJ (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205, USA.		Machesky, Laura/Z-4554-2019	Machesky, Laura/0000-0002-7592-9856	NIGMS NIH HHS [GM-26338] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARTER HR, 1990, BIOCHIM BIOPHYS ACTA, V1054, P119, DOI 10.1016/0167-4889(90)90213-W; GOLDSCHMIDTCLER.PJ, IN PRESS J CELL BIOL; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; KIM JW, 1990, J BIOL CHEM, V265, P3940; LASSING I, 1988, J CELL BIOCHEM, V37, P255, DOI 10.1002/jcb.240370302; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RHEE S, UNPUB; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, J BIOL CHEM, V262, P12511; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	29	512	515	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1231	1233		10.1126/science.1848725	http://dx.doi.org/10.1126/science.1848725			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1848725				2022-12-28	WOS:A1991FA69100041
J	SAWAGUCHI, T; GOLDMANRAKIC, PS				SAWAGUCHI, T; GOLDMANRAKIC, PS			D1 DOPAMINE-RECEPTORS IN PREFRONTAL CORTEX - INVOLVEMENT IN WORKING MEMORY	SCIENCE			English	Article							CEREBRAL-CORTEX; TYROSINE-HYDROXYLASE; HUMAN-BRAIN; AUTORADIOGRAPHIC DISTRIBUTION; H-3 RACLOPRIDE; RHESUS-MONKEY; D-2 RECEPTORS; SCH 23390; INNERVATION; BINDING	The prefrontal cortex is involved in the cognitive process of working memory. Local injections of SCH23390 and SCH39166, selective antagonists of the D1 dopamine receptor, into the prefrontal cortex of rhesus monkeys induced errors and increased latency in performance on an oculomotor task that required memory-guided saccades. The deficit was dose-dependent and sensitive to the duration of the delay period. These D1 antagonists had no effect on performance in a control task requiring visually guided saccades, indicating that sensory and motor functions were unaltered. Thus, D1 dopamine receptors play a selective role in the mnemonic, predictive functions of the primate prefrontal cortex.			SAWAGUCHI, T (corresponding author), YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510, USA.				NIMH NIH HHS [MH44866, MH38546] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH044866, R01MH038546, R37MH038546] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERGER B, 1989, Society for Neuroscience Abstracts, V15, P428; BERGER B, 1988, J COMP NEUROL, V273, P99, DOI 10.1002/cne.902730109; BISCHOFF S, 1986, EUR J PHARMACOL, V129, P367, DOI 10.1016/0014-2999(86)90449-8; BROWN RM, 1979, BRAIN RES, V168, P133, DOI 10.1016/0006-8993(79)90132-X; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; CAMPS M, 1989, NEUROSCIENCE, V28, P275, DOI 10.1016/0306-4522(89)90179-6; CHIPKIN RE, 1988, J PHARMACOL EXP THER, V247, P1093; CORTES R, 1989, NEUROSCIENCE, V28, P263, DOI 10.1016/0306-4522(89)90178-4; FARDE L, 1988, PSYCHOPHARMACOLOGY, V94, P471, DOI 10.1007/BF00212840; FARDE L, 1987, PSYCHOPHARMACOLOGY, V92, P278, DOI 10.1007/BF00210831; FUNAHASHI S, 1986, Society for Neuroscience Abstracts, V12, P554; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; GASPAR P, 1989, J COMP NEUROL, V279, P249, DOI 10.1002/cne.902790208; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1990, J NEUROSCI, V10, P2125; HALL H, 1988, J NEURAL TRANSM, V73, P7, DOI 10.1007/BF01244618; KEBABIAN JW, 1986, TRENDS PHARMACOL SCI, V7, P96, DOI 10.1016/0165-6147(86)90272-5; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KOHLER C, 1985, BIOCHEM PHARMACOL, V34, P2251, DOI 10.1016/0006-2952(85)90778-6; LEVITT P, 1984, J COMP NEUROL, V225, P1; LEWIS DA, 1988, BRAIN RES, V449, P225, DOI 10.1016/0006-8993(88)91040-2; LEWIS DA, 1987, J NEUROSCI, V7, P279; LIDOW MS, 1989, P NATL ACAD SCI USA, V86, P6412, DOI 10.1073/pnas.86.16.6412; MEMO M, 1986, J NEURAL TRANSM-SUPP, V22, P19; MYERS RD, 1966, PHYSIOL BEHAV, V1, P171, DOI 10.1016/0031-9384(66)90064-3; RICHFIELD EK, 1989, J COMP NEUROL, V286, P409, DOI 10.1002/cne.902860402; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1385, DOI 10.1152/jn.1990.63.6.1385; SAWAGUCHI T, 1988, NEUROSCI RES, V5, P465, DOI 10.1016/0168-0102(88)90030-2	28	1066	1081	5	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					947	950		10.1126/science.1825731	http://dx.doi.org/10.1126/science.1825731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	1825731				2022-12-28	WOS:A1991EY62900048
J	PETERS, PJ; NEEFJES, JJ; OORSCHOT, V; PLOEGH, HL; GEUZE, HJ				PETERS, PJ; NEEFJES, JJ; OORSCHOT, V; PLOEGH, HL; GEUZE, HJ			SEGREGATION OF MHC CLASS-II MOLECULES FROM MHC CLASS-I MOLECULES IN THE GOLGI-COMPLEX FOR TRANSPORT TO LYSOSOMAL COMPARTMENTS	NATURE			English	Article							MANNOSE 6-PHOSPHATE; RECEPTORS; ANTIGEN; CHAINS; CELLS; PATHWAYS; ASIALOGLYCOPROTEIN; BIOSYNTHESIS; HEPATOCYTES; ENDOCYTOSIS	Traffic of MHC molecules dictates the source of peptides that are presented to T cells. The intracellular distribution of MHC class I and class II molecules reflects the dichotomy in presentation of antigen from endogenous and exogenous origin, respectively. In human B lymphoblastoid cells, class I molecules are present in compartments constituting the biosynthetic pathway, whereas class II molecules enter structures related to lysosomes during their biosynthesis.	NETHERLANDS CANC INST, DEPT CELLULAR BIOCHEM, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute	PETERS, PJ (corresponding author), STATE UNIV UTRECHT, SCH MED, CELL BIOL LAB, HEIDELBERGLAAN 100, 3584 CX UTRECHT, NETHERLANDS.		Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211				ACTON SL, 1990, J CELL BIOL, V111, P1419, DOI 10.1083/jcb.111.4.1419; ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; ANDERSON RGW, 1984, P NATL ACAD SCI-BIOL, V81, P4838, DOI 10.1073/pnas.81.15.4838; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRODSKY FM, 1984, IMMUNOL TODAY, V5, P350, DOI 10.1016/0167-5699(84)90078-1; CHAIN BM, 1988, IMMUNOL REV, V106, P33, DOI 10.1111/j.1600-065X.1988.tb00772.x; CRESSWELL P, 1987, CRIT REV IMMUNOL, V7, P31; DARNELL J, 1990, MOL CELL BIOL, P596; DAVIS JE, 1990, J IMMUNOL, V144, P990; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1984, EMBO J, V3, P2677, DOI 10.1002/j.1460-2075.1984.tb02193.x; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HAMMERLING GJ, 1990, IMMUNOL TODAY, V11, P337; HOPKINS CR, 1986, TRENDS BIOCHEM SCI, V11, P473, DOI 10.1016/0968-0004(86)90250-1; JARAQUEMADA D, 1990, J EXP MED, V172, P947, DOI 10.1084/jem.172.3.947; KLAUSNER R D, 1989, New Biologist, V1, P3; KOCH N, 1989, TRENDS BIOCHEM SCI, V14, P383, DOI 10.1016/0968-0004(89)90013-3; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LONG EO, 1989, IMMUNOL TODAY, V10, P232, DOI 10.1016/0167-5699(89)90259-4; MACHY P, 1990, J IMMUNOL, V145, P1350; METZELAAR MJ, IN PRESS J BIOL CHEM; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NGUYEN QV, 1989, HUM IMMUNOL, V24, P153, DOI 10.1016/0198-8859(89)90056-6; NOWELL J, 1985, J EXP MED, V162, P1371, DOI 10.1084/jem.162.4.1371; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; OTTEN G, 1989, CURR OPIN IMMUNOL, V2, P204, DOI 10.1016/0952-7915(89)90189-1; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROTH J, 1984, J BIOL CHEM, V93, P350; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHWARTZ AL, 1990, ANNU REV IMMUNOL, V8, P195, DOI 10.1146/annurev.immunol.8.1.195; SLOT JW, 1989, AM J ANAT, V185, P271, DOI 10.1002/aja.1001850220; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SLOT JW, IN PRESS J CELL BIOL; STAM NJ, 1986, J IMMUNOL, V137, P2299; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; TASSIN MT, 1990, EUR J CELL BIOL, V52, P219; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	51	628	633	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 21	1991	349	6311					669	676		10.1038/349669a0	http://dx.doi.org/10.1038/349669a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1847504				2022-12-28	WOS:A1991EY62700038
J	WELLS, DL; HOPFENSPERGER, DJ; ARDEN, NH; HARMON, MW; DAVIS, JP; TIPPLE, MA; SCHONBERGER, LB				WELLS, DL; HOPFENSPERGER, DJ; ARDEN, NH; HARMON, MW; DAVIS, JP; TIPPLE, MA; SCHONBERGER, LB			SWINE INFLUENZA-VIRUS INFECTIONS - TRANSMISSION FROM ILL PIGS TO HUMANS AT A WISCONSIN AGRICULTURAL FAIR AND SUBSEQUENT PROBABLE PERSON-TO-PERSON TRANSMISSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In September 1988, a previously healthy 32-year-old pregnant woman was hospitalized for pneumonia and died 8 days later. The only detected was an influenza virus antigenically related to the swine influenza virus (SIV). Four days before illness onset, the patient visited a county fair swine exhibition where there was widespread influenzalike illness among the swine. To detect other persons who were possibly infected by contact with the ill swine, we measured serum SIV hemagglutination-inhibition antibody titer in 25 swine exhibitors who were 9 to 19 years old. Nineteen (76%) had SIV hemagglutination-inhibition titers of 20 or greater. Antibody was undetectable in serum samples from 25 swine exhibitors from a neighboring county. Additional studies suggest that one to three health care personnel who had contact with the patient developed influenzalike illnesses with laboratory evidence of SIV infection. An outbreak of apparent SIV infection in swine resulted in multiple human infections, and, although no recognized community outbreak resulted, there was evidence of virus transmission from the patient to health care personnel.	WISCONSIN DEPT HLTH & SOCIAL SERV,BUR COMMUNITY HLTH & PREVENT,MADISON,WI; WISCONSIN DEPT HLTH & SOCIAL SERV,SE REG OFF,MILWAUKEE,WI		WELLS, DL (corresponding author), CTR DIS CONTROL,DIV VIRAL & RICKETTSIAL DIS,MS-A32,1600 CLIFTON RD,ATLANTA,GA 30333, USA.							Andrewes CH, 1935, BRIT J EXP PATHOL, V16, P566; BEARE AS, 1976, LANCET, V2, P4; DASCO CC, 1984, J CLIN MICROBIOL, V20, P833; DAVENPORT FM, 1953, J EXP MED, V98, P641, DOI 10.1084/jem.98.6.641; DOWDLE WR, 1977, J INFECT DIS, V136, pS386, DOI 10.1093/infdis/136.Supplement_3.S386; Francis T, 1960, P AM PHILOS SOC, V104, P572, DOI DOI 10.1371/JOURNAL.PPAT.1005806; GAYDOS JC, 1977, J INFECT DIS, V136, pS356, DOI 10.1093/infdis/136.Supplement_3.S356; HATWICK MAW, 1976, B PAN AM HLTH ORG, V10, P283; HINSHAW VS, 1978, VIROLOGY, V84, P51, DOI 10.1016/0042-6822(78)90217-9; MCKINNEY WP, 1990, ARCH INTERN MED, V150, P213, DOI 10.1001/archinte.150.1.213; NAKAMURA RM, 1972, B WORLD HEALTH ORGAN, V47, P481; NOBLE GR, 1977, J INFECT DIS, V136, pS686, DOI 10.1093/infdis/136.Supplement_3.S686; OBRIEN RJ, 1977, J INFECT DIS, V136, pS390, DOI 10.1093/infdis/136.Supplement_3.S390; PATRIARCA PA, 1984, AM J EPIDEMIOL, V119, P152, DOI 10.1093/oxfordjournals.aje.a113733; ROTA PA, 1989, J CLIN MICROBIOL, V27, P1413, DOI 10.1128/JCM.27.6.1413-1416.1989; SCHNURRENBERGER PR, 1970, AM REV RESPIR DIS, V102, P356; SHOPE RE, 1958, PUBLIC HEALTH REP, V73, P165, DOI 10.2307/4590072; SMITH JW, 1976, NEW ENGL J MED, V295, P732; SMITH TF, 1976, NEW ENGL J MED, V294, P708, DOI 10.1056/NEJM197603252941308; THOMPSON RL, 1976, NEW ENGL J MED, V295, P714, DOI 10.1056/NEJM197609232951307; TOP FH, 1977, J INFECT DIS, V136, pS376, DOI 10.1093/infdis/136.Supplement_3.S376; 1976, MMWR, V25, P402; 1988, 1988 COUNTY DISTRICT; 1976, MMWR, V25, P376; 1976, MMWR, V25, P392	25	89	109	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	1991	265	4					478	481		10.1001/jama.265.4.478	http://dx.doi.org/10.1001/jama.265.4.478			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET377	1845913				2022-12-28	WOS:A1991ET37700026
J	BASHIR, ZI; ALFORD, S; DAVIES, SN; RANDALL, AD; COLLINGRIDGE, GL				BASHIR, ZI; ALFORD, S; DAVIES, SN; RANDALL, AD; COLLINGRIDGE, GL			LONG-TERM POTENTIATION OF NMDA RECEPTOR-MEDIATED SYNAPTIC TRANSMISSION IN THE HIPPOCAMPUS	NATURE			English	Article							COLLATERAL-COMMISSURAL PATHWAY; D-ASPARTATE RECEPTORS; MOUSE CENTRAL NEURONS; SPINAL-CORD NEURONS; RAT HIPPOCAMPUS; ACTIVATION; ANTAGONISTS; EXPRESSION; INDUCTION; RESPONSES	Neurotransmission at most excitatory synapses in the brain operates through two types of glutamate receptor termed alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) and N-methyl-D-aspartate (NMDA) receptors; these mediate the fast and slow components of excitatory postsynaptic potentials respectively 1-3. Activation of NMDA receptors can also lead to a long-lasting modification in synaptic efficiency at glutamatergic synapses; this is exemplified in the CAl region of the hippocampus, where NMDA receptors mediate the induction of long-term potentiation (LTP) 4. It is believed that in this region LTP is maintained by a specific increase in the AMPA receptor-mediated synaptic response can undergo robust, synapse-specific LTP. This findings has implications for neuropathologies such as epilepsy and neurodegeneration, in which excessive NMDA receptor activation has been implicated 7. It adds fundamentally to theories of synaptic plasticity because NMDA receptor activation may, in addition to causing increased synaptic efficiency, directly alter the plasticity of synapses.	UNIV BRISTOL, SCH MED SCI, DEPT PHARMACOL, BRISTOL BS8 1TD, AVON, ENGLAND; UNIV BIRMINGHAM, SCH MED, DEPT PHARMACOL, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; UNIV BRISTOL, SCH MED SCI, DEPT BIOCHEM, BRISTOL BS8 1TD, AVON, ENGLAND	University of Bristol; University of Birmingham; University of Bristol			collingridge, graham/AAI-8362-2020; Collingridge, Graham L/C-4605-2015	Collingridge, Graham L/0000-0002-9572-5359; Randall, Andrew/0000-0001-8852-3671; Bashir, Zafar/0000-0003-3650-2136; Alford, Simon/0000-0002-0454-4246	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARTOLA A, 1990, EUR J NEUROSCI, V2, P254, DOI 10.1111/j.1460-9568.1990.tb00417.x; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BINDMAN LJ, 1988, J PHYSIOL-LONDON, V406, pP176; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS T V P, 1988, P3; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLLINGRIDGE GL, 1988, J PHYSIOL-LONDON, V399, P283; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DALE N, 1985, J PHYSIOL-LONDON, V363, P35, DOI 10.1113/jphysiol.1985.sp015694; DANGELO E, 1990, NATURE, V346, P467, DOI 10.1038/346467a0; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DINGLEDINE R, 1986, J PHYSIOL-LONDON, V380, P175, DOI 10.1113/jphysiol.1986.sp016279; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; LEONARD J P, 1989, Society for Neuroscience Abstracts, V15, P535; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; RANDALL AD, 1990, NEUROSCI LETT, V114, P191, DOI 10.1016/0304-3940(90)90070-P; SCHARFMAN HE, 1989, SCIENCE, V246, P257, DOI 10.1126/science.2508225; SLATER NT, 1985, NEUROSCI LETT, V60, P25, DOI 10.1016/0304-3940(85)90376-3; STASHEFF SF, 1989, SCIENCE, V245, P648, DOI 10.1126/science.2569762; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121	31	318	325	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 10	1991	349	6305					156	158		10.1038/349156a0	http://dx.doi.org/10.1038/349156a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1846031				2022-12-28	WOS:A1991ER41800058
J	MAHLEY, RW; WEISGRABER, KH; INNERARITY, TL; RALL, SC				MAHLEY, RW; WEISGRABER, KH; INNERARITY, TL; RALL, SC			GENETIC-DEFECTS IN LIPOPROTEIN METABOLISM - ELEVATION OF ATHEROGENIC LIPOPROTEINS CAUSED BY IMPAIRED CATABOLISM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN APOLIPOPROTEIN-E; LOW-DENSITY LIPOPROTEINS; RECEPTOR-BINDING DOMAIN; AMINO-ACID SEQUENCE; III HYPERLIPOPROTEINEMIA; CHOLESTEROL HOMEOSTASIS; MOLECULAR-BIOLOGY; VARIANT; ATHEROSCLEROSIS; B-100	Certain proteins (called apolipoproteins B and E) on the surface of lipoprotein particles are responsible for mediating the binding of cholesterol-rich particles to specific lipoprotein receptors on the surface of cells and represent a major pathway controlling blood cholesterol levels. Three important disorders of lipoprotein metabolism, which provide insights into the molecular mechanisms responsible for the elevation of specific atherogenic lipoproteins, are the following: (1) Type III hyperlipoproteinemia results from specific mutations in apolipoprotein E that prevent the normal binding of chylomicron remnants and very-low-density lipoprotein remnants to lipoprotein receptors. Patients with this disorder who have elevated levels of these remnant lipoproteins develop atherosclerosis. (2) Familial defective apolipoprotein B-100 results from a single amino acid substitution in apolipoprotein B that prevents low-density lipoprotein from binding normally to the low-density lipoprotein receptor and elevates plasma cholesterol levels. (3) Familial hypercholesterolemia, which results in elevated levels of plasma low-density lipoprotein and premature atherosclerosis, is caused by a variety of mutations in the low-density lipoprotein receptor that interfere with the normal binding of lipoproteins to this receptor. These observations not only provide insights into the mechanisms responsible for normal lipoprotein metabolism, but also highlight the potential role of specific lipoproteins in atherogenesis.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	MAHLEY, RW (corresponding author), GLADSTONE FDN LABS CARDIOVASC DIS,CARDIOVASC RES INST,POB 40608,SAN FRANCISCO,CA 94140, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRESLOW JL, 1989, J CLIN INVEST, V84, P373, DOI 10.1172/JCI114176; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1984, SCI AM, V251, P58, DOI 10.1038/scientificamerican1184-58; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CHEN SH, 1986, J BIOL CHEM, V261, P2918; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; EHNHOLM C, 1984, P NATL ACAD SCI-BIOL, V81, P5566, DOI 10.1073/pnas.81.17.5566; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; HAVEKES L, 1986, HUM GENET, V73, P157, DOI 10.1007/BF00291607; HAVEL RJ, 1983, J CLIN INVEST, V72, P379, DOI 10.1172/JCI110978; HAVEL RJ, 1989, METABOLIC BASIS INHE, P1129; Havel RJ, 1980, METABOLIC CONTROL DI, P393; INNERARITY TL, 1990, J LIPID RES, V31, P1337; INNERARITY TL, 1987, P NATL ACAD SCI USA, V84, P6919, DOI 10.1073/pnas.84.19.6919; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1984, J BIOL CHEM, V259, P7261; INNERARITY TL, 1986, LIPOPROTEIN DEFICIEN, P273; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KOO C, 1986, J BIOL CHEM, V261, P1194; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; LAW SW, 1986, P NATL ACAD SCI USA, V83, P8142, DOI 10.1073/pnas.83.21.8142; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MAHLEY RW, 1986, COLD SPRING HARB SYM, V51, P821, DOI 10.1101/SQB.1986.051.01.095; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MAHLEY RW, 1985, CIRCULATION, V72, P943, DOI 10.1161/01.CIR.72.5.943; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1985, ANN NY ACAD SCI, V454, P209, DOI 10.1111/j.1749-6632.1985.tb11860.x; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MAHLEY RW, 1989, ARTERIOSCLER, V9, P14; MAHLEY RW, 1990, CURRENT OPINION LIPI, V1, P87; MANN WA, 1989, BIOCHIM BIOPHYS ACTA, V1005, P239, DOI 10.1016/0005-2760(89)90043-X; MILNE R, 1989, J BIOL CHEM, V264, P19754; PEASE RJ, 1990, J BIOL CHEM, V265, P553; PITAS RE, 1990, J BIOL CHEM, V265, P12722; PITAS RE, 1983, ARTERIOSCLEROSIS, V3, P2, DOI 10.1161/01.ATV.3.1.2; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; RALL SC, 1982, P NATL ACAD SCI-BIOL, V79, P4696, DOI 10.1073/pnas.79.15.4696; RALL SC, 1983, J CLIN INVEST, V72, P1288, DOI 10.1172/JCI111085; SCHUSTER H, 1990, ARTERIOSCLEROSIS, V10, P577, DOI 10.1161/01.ATV.10.4.577; SORIA LF, 1989, P NATL ACAD SCI USA, V86, P587, DOI 10.1073/pnas.86.2.587; STEINBERG D, 1983, ARTERIOSCLEROSIS, V3, P283, DOI 10.1161/01.ATV.3.4.283; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TYBJAERGHANSEN A, 1990, ATHEROSCLEROSIS, V80, P235, DOI 10.1016/0021-9150(90)90031-D; WARDELL MR, 1987, J CLIN INVEST, V80, P483, DOI 10.1172/JCI113096; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; WEISGRABER KH, 1988, P NATL ACAD SCI USA, V85, P9758, DOI 10.1073/pnas.85.24.9758; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; 1985, JAMA-J AM MED ASSOC, V253, P2080; 1988, ARCH INTERN MED, V48, P361	49	67	67	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					78	83		10.1001/jama.265.1.78	http://dx.doi.org/10.1001/jama.265.1.78			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP555	1845776				2022-12-28	WOS:A1991EP55500032
J	PARK, RHR; PARK, MP				PARK, RHR; PARK, MP			GOYA LIVING SKELETON	BRITISH MEDICAL JOURNAL			English	Article									GLASGOW ROYAL INFIRM,GLASGOW G4 0SF,SCOTLAND; HAGGS CASTLE MUSEUM,GLASGOW,SCOTLAND	University of Glasgow								Altick Richard, 1975, SHOWS LONDON; GASSIER P, 1973, DRAWINGS GOYA COMPLE, P616; GEORGE MD, 1952, CATALOGUE PERSONAL P, V10, P257; HONE W, 1826, EVERYDAY BOOK, V1, P1017; KLIPPEL M, 1912, B SOC ANTHROPOL PAR, V65, P101; Nunez de Arenas M., 1950, B HISPANIQUE, V52, P229; RAVITCH MM, 1986, TXB SURGERY BIOL BAS, P2080; Sprengel O.G, 1891, ARCH KLIN CHIR, V42, P545; TIBBLES JAR, 1986, BRIT MED J, V293, P683, DOI 10.1136/bmj.293.6548.683; 1825, LANCET, V8, P178	10	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1594	1596		10.1136/bmj.303.6817.1594	http://dx.doi.org/10.1136/bmj.303.6817.1594			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	GX956	1820772	Green Published, Bronze			2022-12-28	WOS:A1991GX95600015
J	GRAY, JT; CELANDER, DW; PRICE, CM; CECH, TR				GRAY, JT; CELANDER, DW; PRICE, CM; CECH, TR			CLONING AND EXPRESSION OF GENES FOR THE OXYTRICHA TELOMERE-BINDING PROTEIN - SPECIFIC SUBUNIT INTERACTIONS IN THE TELOMERIC COMPLEX	CELL			English	Article							TERMINAL TRANSFERASE-ACTIVITY; TETRAHYMENA TRANSFER-RNASGLN; SIZED DNA-MOLECULES; MACRONUCLEAR DNA; NUCLEOPROTEIN COMPLEXES; ANTICODON MUTATIONS; CILIATE EVOLUTION; GLUTAMINE CODONS; DRAMATIC EVENTS; 3' TERMINUS	Telomeres of Oxytricha nova macronuclear chromosomes consist of a repeated T4G4 sequence, single-stranded at the 3' terminus, bound by a heterodimeric protein. The cloning of genes for the two polypeptides and their separate expression in E. coli have enabled evaluation of their individual contributions to DNA binding. The 56 kd alpha-subunit binds single-stranded DNA by itself, one polypeptide per T4G4 block; multiple subunits can coat a (T4G4)n multimer. The derived amino acid sequence of alpha does not reveal any known DNA-binding motif, so it appears to represent a novel type of DNA-binding protein. The previously cloned 41 kd beta-subunit does not by itself protect DNA from methylation, but is required along with alpha to recreate the pattern of methylation protection indicative of telomeres in vivo. The unusual ability of the protein to engage in two different interactions with the same telomeric DNA sequence might provide the versatility necessary for diverse telomere functions.			GRAY, JT (corresponding author), UNIV COLORADO, HOWARD HUGHES MED INST, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA.		Gray, John T/D-2916-2016	Gray, John T/0000-0002-1888-4612; PRICE, Carolyn/0000-0002-7865-2303				AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COREN JS, 1991, MOL CELL BIOL, V11, P2282, DOI 10.1128/MCB.11.4.2282; DANCIS BM, 1979, J THEOR BIOL, V78, P211, DOI 10.1016/0022-5193(79)90265-0; DILLON JR, 1985, RECOMBINANT DNA METH; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOTTSCHLING DE, 1984, CELL, V38, P501, DOI 10.1016/0092-8674(84)90505-1; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GRESLIN AF, 1989, P NATL ACAD SCI USA, V86, P6264, DOI 10.1073/pnas.86.16.6264; HANYU N, 1986, EMBO J, V5, P1307, DOI 10.1002/j.1460-2075.1986.tb04360.x; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HERRICK G, 1987, GENE DEV, V1, P1047, DOI 10.1101/gad.1.10.1047; HICKE BJ, 1990, P NATL ACAD SCI USA, V87, P1481, DOI 10.1073/pnas.87.4.1481; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAWRENCE CB, 1988, COMPUT APPL BIOSCI, V4, P25; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LIU ZP, 1991, GENE DEV, V5, P49, DOI 10.1101/gad.5.1.49; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; McClintock B, 1942, P NATL ACAD SCI USA, V28, P458, DOI 10.1073/pnas.28.11.458; McClintock B, 1941, GENETICS, V26, P234; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Muller H.J., 1938, COLLECTING NET, V13, P181; NIELSEN H, 1986, EMBO J, V5, P2711, DOI 10.1002/j.1460-2075.1986.tb04555.x; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; Prescott D.M., 1983, Modern Cell Biology, V2, P329; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; QUIRES CH, 1988, J BIOL CHEM, V263, P16297; RAGHURAMAN MK, 1989, CELL, V59, P719, DOI 10.1016/0092-8674(89)90018-4; RAGHURAMAN MK, 1989, NUCLEIC ACIDS RES, V17, P4235, DOI 10.1093/nar/17.11.4235; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SWANTON MT, 1980, CHROMOSOMA, V77, P217, DOI 10.1007/BF00329546; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WU M, 1986, P NATL ACAD SCI USA, V83, P8674, DOI 10.1073/pnas.83.22.8674; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	47	142	161	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1991	67	4					807	814		10.1016/0092-8674(91)90075-A	http://dx.doi.org/10.1016/0092-8674(91)90075-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1840510				2022-12-28	WOS:A1991GQ40700017
J	OHTA, Y; STOSSEL, TP; HARTWIG, JH				OHTA, Y; STOSSEL, TP; HARTWIG, JH			LIGAND-SENSITIVE BINDING OF ACTIN-BINDING PROTEIN TO IMMUNOGLOBULIN-G FC RECEPTOR-I (FC-GAMMA-RI)	CELL			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; PERIPHERAL-BLOOD MONOCYTES; IMMUNE INTERFERON; MONOCLONAL-ANTIBODIES; TRANSIENT ACTIVATION; HUMAN-PLATELETS; CYTO-TOXICITY; CROSS-LINKING; NADPH OXIDASE; CELL-LINE	The high affinity receptor that binds the Fc domain of immunoglobulin G (IgG) subclasses 1 and 3 (Fc-gamma-RI) mediates important immune defense functions by inducing cell surface changes on human leukocytes. In this article, we document direct high affinity binding of Fc-gamma-RI to the actin filament cross-linking protein, actin-binding protein (ABP). In the absence of IgG, all Fc-gamma-RI molecules in undifferentiated cells of myeloid line U937 bound to ABP over a 9-fold range of Fc-gamma-RI expression induced by human IFN-gamma. Binding of IgG to U937 cells constitutively expressing Fc-gamma-RI or to COS cells genetically transfected to express Fc-gamma-RI rapidly decreased the avidity of Fc-gamma-RI for ABP. This finding suggests the existence of a pathway communicating a signal between a functional IgG receptor and intracellular components involved in the effector responses to Fc-gamma-RI-ligand interaction.	HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	OHTA, Y (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV EXPTL MED,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028465] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-19429, HL-45154] Funding Source: Medline; NIAID NIH HHS [AI-28465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKERLEY WL, 1991, BLOOD, V77, P607; AKIYAMA Y, 1984, CANCER RES, V44, P5127; ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; ANDERSON CL, 1986, J BIOL CHEM, V261, P2856; ANDERSON CL, 1982, J EXP MED, V156, P1794, DOI 10.1084/jem.156.6.1794; ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; DEBETS JMH, 1990, J IMMUNOL, V144, P1304; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FOX JEB, 1985, J BIOL CHEM, V260, P1970; GOMEZ F, 1989, BLOOD, V74, P1058; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GRAZIANO RF, 1987, J IMMUNOL, V138, P945; GUYRE PM, 1989, J IMMUNOL, V143, P1650; GUYRE PM, 1990, J CLIN INVEST, V86, P1892, DOI 10.1172/JCI114921; GUYRE PM, 1983, J CLIN INVEST, V72, P393, DOI 10.1172/JCI110980; HARTWIG JH, 1986, J CELL BIOL, V103, P1007, DOI 10.1083/jcb.103.3.1007; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; JONES DH, 1985, J CELL BIOL, V100, P558, DOI 10.1083/jcb.100.2.558; KINET JP, 1989, CELL, V57, P351, DOI 10.1016/0092-8674(89)90910-0; KURLANDER RJ, 1982, J CLIN INVEST, V69, P1, DOI 10.1172/JCI110419; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBECK MD, 1985, J IMMUNOL, V135, P1299; ODIN JA, 1990, CELLULAR MOL MECHANI; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; PERUSSIA B, 1983, J EXP MED, V158, P1092, DOI 10.1084/jem.158.4.1092; PFEFFERKORN LC, 1989, J BIOL CHEM, V264, P14112; PFEFFERKORN LC, 1989, J IMMUNOL, V143, P2640; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STOSSEL TP, 1976, J CELL BIOL, V68, P602, DOI 10.1083/jcb.68.3.602; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; WEITZ JI, 1987, J EXP MED, V166, P1836, DOI 10.1084/jem.166.6.1836; WRIGHT SD, 1984, NATURE, V309, P359, DOI 10.1038/309359a0	38	92	93	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					275	282		10.1016/0092-8674(91)90179-3	http://dx.doi.org/10.1016/0092-8674(91)90179-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1833070				2022-12-28	WOS:A1991GL47000007
J	ROMERO, DP; BLACKBURN, EH				ROMERO, DP; BLACKBURN, EH			A CONSERVED SECONDARY STRUCTURE FOR TELOMERASE RNA	CELL			English	Article							TERMINAL TRANSFERASE-ACTIVITY; POLYMERASE-III PROMOTER; RIBONUCLEASE-P RNA; RIBOSOMAL-RNA; U6 SNRNA; RIBONUCLEOPROTEIN ENZYME; TETRAHYMENA; DNA; GENE; TRANSCRIPTION	The RNA moiety of the ribonucleoprotein enzyme telomerase contains the template for telomeric DNA synthesis. We present a secondary structure model for telomerase RNA, derived by a phylogenetic comparative analysis of telomerase RNAs from seven tetrahymenine ciliates. The telomerase RNA genes from Tetrahymena malaccensis, T. pyriformis, T. hyperangularis, T. pigmentosa, T. hegewishii, and Glaucoma chattoni were cloned, sequenced, and compared with the previously cloned RNA gene from T. thermophila and with each other. To define secondary structures of these RNAs, homologous complementary sequences were identified by the occurrence of covariation among putative base pairs. Although their primary sequences have diverged rapidly overall, a strikingly conserved secondary structure was identified for all these telomerase RNAs. Short regions of nucleotide conservation include a block of 22 totally conserved nucleotides that contains the telomeric templating region.			ROMERO, DP (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026259, R37GM026259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 26259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; ANDREAZZOLI M, 1991, EMBO J, V10, P767, DOI 10.1002/j.1460-2075.1991.tb08008.x; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHALLONER PB, 1986, NUCLEIC ACIDS RES, V14, P6299, DOI 10.1093/nar/14.15.6299; CHASTAIN M, 1991, PROG NUCL ACIDS RES, V41, P131; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; DAGGETT PM, 1989, AM TYPE CULTURE CO S; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DRAPER DE, 1990, RIBOSOME, P160; FOX GE, 1975, NATURE, V256, P505, DOI 10.1038/256505a0; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GREENWOOD SJ, 1991, J PROTOZOOL, V38, P1, DOI 10.1111/j.1550-7408.1991.tb04783.x; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUERRIERTAKADA C, 1984, BIOCHEMISTRY-US, V23, P6327, DOI 10.1021/bi00321a006; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; KATZEN AL, 1981, CELL, V24, P313, DOI 10.1016/0092-8674(81)90321-4; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LONGFELLOW CE, 1990, BIOCHEMISTRY-US, V29, P278, DOI 10.1021/bi00453a038; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; NOLLER HF, 1990, RIBOSOME, P73; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0; PREPARATA RM, 1989, J MOL EVOL, V28, P427, DOI 10.1007/BF02603078; ROIHA H, 1989, GENE, V82, P137, DOI 10.1016/0378-1119(89)90038-3; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SAMPSON JR, 1990, BIOCHEMISTRY-US, V29, P2523, DOI 10.1021/bi00462a014; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SILICIANO PG, 1987, CELL, V50, P585, DOI 10.1016/0092-8674(87)90031-6; SOGIN ML, 1986, EMBO J, V5, P3625, DOI 10.1002/j.1460-2075.1986.tb04691.x; STROHMAN RC, 1977, CELL, V10, P265, DOI 10.1016/0092-8674(77)90220-3; TANI T, 1991, NUCLEIC ACIDS RES, V19, P2495, DOI 10.1093/nar/19.9.2495; Tinoco I. Jr., 1990, Nucleic Acids and Molecular Biology, V4, P205; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAIBEL F, 1990, NUCLEIC ACIDS RES, V18, P3451, DOI 10.1093/nar/18.12.3451; WHITE SA, 1989, BIOCHEMISTRY-US, V28, P1892, DOI 10.1021/bi00430a069; YU GL, 1990, MOL CELL BIOL, V10, P2070, DOI 10.1128/MCB.10.5.2070; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	65	216	240	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					343	353		10.1016/0092-8674(91)90186-3	http://dx.doi.org/10.1016/0092-8674(91)90186-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1840508				2022-12-28	WOS:A1991GL47000014
J	ROMAN, C; COHN, L; CALAME, K				ROMAN, C; COHN, L; CALAME, K			A DOMINANT NEGATIVE FORM OF TRANSCRIPTION ACTIVATOR MTFE3 CREATED BY DIFFERENTIAL SPLICING	SCIENCE			English	Article							LOOP-HELIX PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING; DNA-BINDING; THYROID-HORMONE; MESSENGER-RNA; DOMAIN; CELLS; EXTRAMACROCHAETAE; DIMERIZATION; DROSOPHILA	Transcription factor E3 (mTFE3) is a murine transcription activator that binds to the intronic enhancer of the immunoglobulin heavy chain gene. A naturally occurring splice product of mTFE3 messenger RNA (mRNA) lacked 105 nucleotides that encode an activation domain; both absolute and relative amounts of long and truncated mRNAs varied in different tissues. Cells were cotransfected with complementary DNAs that encoded the two mRNA forms in amounts that corresponded to the amounts of each mRNA found in different cells. Small changes in substoichiometric amounts of the truncated form of mRNA effected trans-dominant negative modulation of mTFE3 activity. These findings identify a function for differential splicing in the regulation of transcription factor activity.	UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	University of California System; University of California Los Angeles; Columbia University; Columbia University; Columbia University; Columbia University					NCI NIH HHS [R01CA38571] Funding Source: Medline; NIGMS NIH HHS [R01GM28361] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038571] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HUBBERT NL, 1988, P NATL ACAD SCI USA, V85, P5864, DOI 10.1073/pnas.85.16.5864; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KILEDJIAN M, 1990, NUCLEIC ACIDS RES, V18, P957, DOI 10.1093/nar/18.4.957; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MERCOLA M, 1985, SCIENCE, V227, P266, DOI 10.1126/science.3917575; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; PETERSON CL, 1989, MOL CELL BIOL, V9, P776, DOI 10.1128/MCB.9.2.776; RAMAKRISHNAN L, 1988, MOL CELL BIOL, V8, P5216, DOI 10.1128/MCB.8.12.5216; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; Roman C., UNPUB; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077	33	115	117	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					94	97		10.1126/science.1840705	http://dx.doi.org/10.1126/science.1840705			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1840705				2022-12-28	WOS:A1991GH60500035
J	VIGILANT, L; STONEKING, M; HARPENDING, H; HAWKES, K; WILSON, AC				VIGILANT, L; STONEKING, M; HARPENDING, H; HAWKES, K; WILSON, AC			AFRICAN POPULATIONS AND THE EVOLUTION OF HUMAN MITOCHONDRIAL-DNA	SCIENCE			English	Article							PAPUA-NEW-GUINEA; HUMAN ORIGINS; SEQUENCES; PRIMATES; TIME	The proposal that all mitochondrial DNA (mtDNA) types in contemporary humans stem from a common ancestor present in an African population some 200,000 years ago has attracted much attention. To study this proposal further, two hypervariable segments of mtDNA were sequenced from 189 people of diverse geographic origin, including 121 native Africans. Geographic specificity was observed in that identical mtDNA types are shared within but not between populations. A tree relating these mtDNA sequences to one another and to a chimpanzee sequence has many deep branches leading exclusively to African mtDNAs. An African origin for human mtDNA is supported by two statistical tests. With the use of the chimpanzee and human sequences to calibrate the rate of mtDNA evolution, the age of the common human mtDNA ancestor is placed between 166,000 and 249,000 years. These results thus support and extend the African origin hypothesis of human mtDNA evolution.	UNIV CALIF BERKELEY,DEPT BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720; UNIV UTAH,DEPT ANTHROPOL,SALT LAKE CITY,UT 84112	University of California System; University of California Berkeley; Utah System of Higher Education; University of Utah	VIGILANT, L (corresponding author), PENN STATE UNIV,DEPT ANTHROPOL,UNIVERSITY PK,PA 16802, USA.		Klein, Richard G/B-5910-2009					AQUADRO CF, 1983, GENETICS, V103, P287; Bowcock A M, 1987, Gene Geogr, V1, P47; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; BRAUER G, 1989, HUMAN REVOLUTION, P123; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CANN RL, 1987, NATURE, V329, P111, DOI 10.1038/329111c0; CANN RL, 1984, GENETICS, V106, P479; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CAVALLISFORZA LL, 1988, P NATL ACAD SCI USA, V85, P6002, DOI 10.1073/pnas.85.16.6002; DARLU P, 1987, HUM EVOL, V2, P407; DIRIENZO A, 1991, P NATL ACAD SCI USA, V88, P1597, DOI 10.1073/pnas.88.5.1597; EXCOFFIER L, 1989, AM J HUM GENET, V44, P73; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FORAN DR, 1988, NUCLEIC ACIDS RES, V16, P5841, DOI 10.1093/nar/16.13.5841; GAUT BS, 1991, P NATL ACAD SCI USA, V88, P2060, DOI 10.1073/pnas.88.6.2060; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; HASEGAWA M, 1991, J MOL EVOL, V32, P37, DOI 10.1007/BF02099927; HASEGAWA M, 1990, J MOL EVOL, V31, P113, DOI 10.1007/BF02109480; HASEGAWA M, IN PRESS NEW APSECTS; HORAI S, 1990, AM J HUM GENET, V46, P828; Howells W.W., 1980, YEARB PHYS ANTHROPOL, V23, P1, DOI DOI 10.1002/AJPA.1330230503; Kimura M., 1983, NEUTRAL THEORY MOL E; KOCHER TD, 1991, EVOLUTION OF LIFE, P391; KRUGER J, 1989, HUM GENET, V82, P308; LONG JC, 1990, AM J PHYS ANTHROPOL, V81, P113, DOI 10.1002/ajpa.1330810112; NEI M, 1982, EVOL BIOL, V14, P1; NEI M, 1991, EVOLUTION OF LIFE, P415; PRAGER EM, 1988, J MOL EVOL, V27, P326, DOI 10.1007/BF02101195; SAITOU N, 1987, NATURE, V327, P288, DOI 10.1038/327288a0; SMITH FH, 1989, YEARB PHYS ANTHROPOL, V32, P35; Sokal R. R, 1981, BIOMETRY; SPUHLER JN, 1988, YEARB PHYS ANTHROPOL, V31, P15; STONEKING M, 1990, GENETICS, V124, P717; STONEKING M, 1986, COLD SPRING HARB SYM, V51, P433, DOI 10.1101/SQB.1986.051.01.052; STONEKING M, 1989, HUMAN REVOLUTION, P17; STRINGER CB, 1989, HUMAN REVOLUTION, P232; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; Swofford David L., 1990, P411; SWOFFORD DL, 1990, PAUP VERSION 3 0; VIGILANT L, 1989, P NATL ACAD SCI USA, V86, P9350, DOI 10.1073/pnas.86.23.9350; VIGILANT L, 1990, THESIS U CALIFORNIA; WAINSCOAT JS, 1986, NATURE, V319, P491, DOI 10.1038/319491a0; Wilson A. C., 1987, HUM GENET, P158; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5; WILSON AC, IN PRESS SYS ZOOL; Wolpoff M. H, 1980, PALEOANTHROPOLOGY; WOLPOFF MH, 1989, HUMAN REVOLUTION, P62; ZUCKERKANDL EMILE, 1965, P97	49	990	1024	2	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1991	253	5027					1503	1507		10.1126/science.1840702	http://dx.doi.org/10.1126/science.1840702			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG651	1840702				2022-12-28	WOS:A1991GG65100032
J	BERRY, MJ; BANU, L; CHEN, Y; MANDEL, SJ; KIEFFER, JD; HARNEY, JW; LARSEN, PR				BERRY, MJ; BANU, L; CHEN, Y; MANDEL, SJ; KIEFFER, JD; HARNEY, JW; LARSEN, PR			RECOGNITION OF UGA AS A SELENOCYSTEINE CODON IN TYPE-I DEIODINASE REQUIRES SEQUENCES IN THE 3' UNTRANSLATED REGION	NATURE			English	Article							NUCLEOTIDE-SEQUENCE; CDNA; EXPRESSION	SELENOCYSTEINE is incorporated cotranslationally at UGA codons, normally read as stop codons, in several bacterial proteins 1,2 and in the mammalian proteins glutathione peroxidase (GPX) 3-5, selenoprotein P 6 and Type I iodothyronine 5' deiodinase (5'DI) 7. Previous analyses in bacteria have suggested that a stem-loop structure involving the UGA codon and adjacent sequences is necessary and sufficient for selenocysteine incorporation into formate dehydrogenase and glycine reductase 2,8,9. We used the recently cloned 5'DI to investigate selenoprotein synthesis in eukaryotes. We show that successful incorporation of selenocysteine into this enzyme requires a specific 3' untranslated (3'ut) segment of about 200 nucleotides, which is found in both rat and human 5'DI messenger RNAs. These sequences are not required for expression of a cysteine-mutant deiodinase. Although there is little primary sequence similarity between the 3'ut regions of these mRNAs and those encoding GPX, the 3'ut sequences of rat GPX can substitute for the 5'DI sequences in directing selenocysteine insertion. Computer analyses predict similar stem-loop structures in the 3'ut regions of the 5'DI and GPX mRNAs. Limited mutations in these structures reduce or eliminate their capacity to permit 5'DI translation. These results identify a 'selenocysteine-insertion sequence' motif in the 3'ut region of these mRNAs that is essential for successful translation of 5'DI, presumably GPX, and possibly other eukaryotic selenocysteine-containing proteins.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV THYROID,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	BERRY, MJ (corresponding author), BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,75 FRANCIS ST,BOSTON,MA 02115, USA.							ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GARCIA GE, 1991, J BACTERIOL, V173, P2093, DOI 10.1128/jb.173.6.2093-2098.1991; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HILL KE, 1991, J BIOL CHEM, V266, P10050; HO YS, 1988, NUCLEIC ACIDS RES, V16, P5207, DOI 10.1093/nar/16.11.5207; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; TAKAHASHI K, 1990, J BIOCHEM-TOKYO, V108, P145, DOI 10.1093/oxfordjournals.jbchem.a123172; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	15	526	544	2	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1991	353	6341					273	276		10.1038/353273a0	http://dx.doi.org/10.1038/353273a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1832744				2022-12-28	WOS:A1991GF67400065
J	WIECK, A; KUMAR, R; HIRST, AD; MARKS, MN; CAMPBELL, IC; CHECKLEY, SA				WIECK, A; KUMAR, R; HIRST, AD; MARKS, MN; CAMPBELL, IC; CHECKLEY, SA			INCREASED SENSITIVITY OF DOPAMINE-RECEPTORS AND RECURRENCE OF AFFECTIVE PSYCHOSIS AFTER CHILDBIRTH	BRITISH MEDICAL JOURNAL			English	Article							HORMONE; APOMORPHINE; ESTRADIOL; DISORDERS; ESTROGEN; NEURONS	Objective - To test the hypothesis that affective psychosis after childbirth is associated with an altered sensitivity to dopaminergic stimulation. Design - Prospective study of pregnant women at high risk of developing an affective psychosis after childbirth. Clinical assessments in pregnancy and after delivery were made by using a semistructured interview (schedule for affective disorders and schizophrenia) and psychiatric illnesses were categorised according to operational criteria (research diagnostic criteria). Setting - Obstetric and psychiatric departments in and around Greater London. Subjects - 29 pregnant women with a history of bipolar or schizoaffective psychosis and 47 control pregnant women. Of these, 16 from each group participated in a growth hormone challenge test and the results for 15 women in each group were analysed. Interventions - On the fourth day postpartum women participating in the hormone challenge test were given a subcutaneous injection of a small dose (0.005 mg/kg) of the dopamine agonist apomorphine. Main outcome measures - Growth hormone secretion in response to apomorphine as an index of the functional state of hypothalamic dopamine receptors. Results - Eight of the 15 women at risk of psychosis subsequently had a recurrence of illness (five bipolar, one schizomanic, and two major depressive illnesses); these women had significantly greater growth hormone responses to apomorphine than the seven at risk women who remained well and the 15 controls, and there were no significant differences between groups in average baseline growth hormone concentrations. The mean (SD) concentrations for women with recurrence, women at risk who remained well, and control women respectively were: average baseline concentrations 1.06 (1.14), 1.44 (1.39), and 0.90 (1.34) mU/l; peak increase in concentrations 13.68 (12.95), 3.46 (4.68), and 3.40 (3.83) mU/l (between group difference p < 0.05); average increase in concentrations 6.74 (7.01), 1.78 (3.39), and 1.40 (2.05) mU/l (p < 0.05). Conclusions - The onset of affective psychosis after childbirth was associated with increased sensitivity of dopamine receptors in the hypothalamus and possibly elsewhere in the brain. Such changes may be triggered by the sharp fall in circulating oestrogen concentrations after delivery.	INST PSYCHIAT,DEPT PSYCHIAT,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,DEPT NEUROSCI,LONDON SE5 8AF,ENGLAND	University of London; King's College London; University of London; King's College London								BACKSTROM T, 1976, J STEROID BIOCHEM, V7, P469, DOI 10.1016/0022-4731(76)90114-X; BLUM M, 1987, J BIOL CHEM, V262, P817; CHECKLEY SA, 1980, PSYCHOL MED, V10, P35, DOI 10.1017/S0033291700039593; CHECKLEY SA, 1986, BIOL DEPRESSION, P100; COOKSON JC, 1985, J AFFECT DISORDERS, V8, P233, DOI 10.1016/0165-0327(85)90021-7; CORN TH, 1984, BRIT J PSYCHIAT, V144, P636, DOI 10.1192/bjp.144.6.636; DEAKIN JWF, 1988, MOTHERHOOD MENTAL IL, P113; DEAN C, 1989, PSYCHOL MED, V19, P637, DOI 10.1017/S0033291700024235; DEMAREST KT, 1984, NEUROENDOCRINOLOGY, V39, P193, DOI 10.1159/000123979; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; ETTIGI P, 1975, J CLIN ENDOCR METAB, V40, P1094, DOI 10.1210/jcem-40-6-1094; GELATO MC, 1984, J CLIN ENDOCR METAB, V59, P197, DOI 10.1210/jcem-59-2-197; HAMILTON JA, 1982, MOTHERHOOD MENTAL IL, P1; KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; KUMAR R, 1983, BRIT J PSYCHIAT, V142, P618, DOI 10.1192/bjp.142.6.618; LAL S, 1981, J NEURAL TRANSM, V50, P39, DOI 10.1007/BF01254912; MATUSSEK N, 1988, CURRENT TOPICS NEURO, V8, P141; MELTZER HY, 1980, SCHIZOPHRENIA BULL, V6, P456, DOI 10.1093/schbul/6.3.456; ROSS RJM, 1987, CLIN ENDOCRINOL, V27, P155, DOI 10.1111/j.1365-2265.1987.tb01140.x; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; VANHARTESVELDT C, 1986, NEUROSCI BIOBEHAV R, V10, P1, DOI 10.1016/0149-7634(86)90029-1; WIECK A, 1989, BAILLIERE CLIN OB GY, V3, P857, DOI 10.1016/S0950-3552(89)80069-0; WIECK A, 1989, BRIT J CLIN PHARMACO, V27, pP700	23	119	121	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					613	616		10.1136/bmj.303.6803.613	http://dx.doi.org/10.1136/bmj.303.6803.613			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF675	1805821	Bronze, Green Published			2022-12-28	WOS:A1991GF67500021
J	ORENTLICHER, D				ORENTLICHER, D			GENDER DISPARITIES IN CLINICAL DECISION-MAKING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY-BYPASS SURGERY; SEX-DIFFERENCES; LUNG-CANCER; MYOCARDIAL-INFARCTION; DETECTION BIAS; MEDICAL-CARE; WOMEN; MEN; MORTALITY; ILLNESS				ORENTLICHER, D (corresponding author), AMER MED ASSOC,COUNCIL ETH & JUDICIAL AFFAIRS,515 N STATE ST,CHICAGO,IL 60610, USA.							ARMITAGE KJ, 1979, JAMA-J AM MED ASSOC, V241, P2186, DOI 10.1001/jama.241.20.2186; BARKERBENFIELD B, 1973, AM FAMILY SOCIOHISTO; BERNSTEIN B, 1981, MED CARE, V19, P600, DOI 10.1097/00005650-198106000-00004; BROVERMA.IK, 1970, J CONSULT CLIN PSYCH, V34, P1, DOI 10.1037/h0028797; CLEARY PD, 1982, J HEALTH SOC BEHAV, V23, P106, DOI 10.2307/2136508; COLAMECO S, 1983, J FAM PRACTICE, V16, P1117; COTTON P, 1990, JAMA-J AM MED ASSOC, V263, P1051, DOI 10.1001/jama.263.8.1051; COTTON P, 1990, JAMA-J AM MED ASSOC, V263, P1049, DOI 10.1001/jama.263.8.1049; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; Eggers P W, 1984, Health Care Financ Rev, V5, P69; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GOVE WR, 1979, AM SOCIOL REV, V44, P126, DOI 10.2307/2094822; Hamilton J, 1983, J Am Med Womens Assoc (1972), V38, P126; HAMILTON JA, 1985, WOMENS HLTH REPORT P, P2; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; HIBBARD JH, 1986, WOMEN HEALTH, V11, P21, DOI 10.1300/J013v11n02_03; KARLIN BG, 1988, ANN INTERN MED, V108, P149; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KJELLSTRAND CM, 1987, NEPHRON, V45, P257, DOI 10.1159/000184160; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MARCUS AC, 1981, J HEALTH SOC BEHAV, V22, P174, DOI 10.2307/2136293; MCFARLANE MJ, 1986, ARCH INTERN MED, V146, P1695, DOI 10.1001/archinte.146.9.1695; MCFARLANE MJ, 1987, JAMA-J AM MED ASSOC, V258, P331, DOI 10.1001/jama.258.3.331; NATANSON CA, 1975, SOC SCI MED, V9, P57; RASKIN A, 1974, J NERV MENT DIS, V159, P120, DOI 10.1097/00005053-197408000-00006; SAVAGE WD, 1983, MED EDUC, V17, P159, DOI 10.1111/j.1365-2923.1983.tb00656.x; SCHOENBERG JB, 1989, AM J EPIDEMIOL, V130, P688, DOI 10.1093/oxfordjournals.aje.a115390; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOBIN JN, 1988, ANN INTERN MED, V108, P149; VERBRUGGE LM, 1982, PUBLIC HEALTH REP, V97, P417; VERBRUGGE LM, 1981, MED CARE, V19, P609, DOI 10.1097/00005650-198106000-00005; WAISBERG J, 1988, WOMEN HEALTH, V14, P3, DOI 10.1300/J013v14n01_02; WELLS CK, 1988, AM J EPIDEMIOL, V128, P1016; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557; WENGER NK, 1985, ANNU REV MED, V36, P285; 1985, WOMENS HLTH REPORT P, P2	37	147	148	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	1991	266	4					559	562						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FX021	1843800				2022-12-28	WOS:A1991FX02100032
J	GUTHRIE, C				GUTHRIE, C			MESSENGER-RNA SPLICING IN YEAST - CLUES TO WHY THE SPLICEOSOME IS A RIBONUCLEOPROTEIN	SCIENCE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; COMPENSATORY BASE CHANGE; SNRNP-SNRNP INTERACTIONS; U1 SNRNA; SACCHAROMYCES-CEREVISIAE; INTRON SEQUENCES; U2 SNRNA; MAMMALIAN INTRONS; BINDING PROTEINS; SITE SELECTION	The removal of introns from eukaryotic messenger RNA precursors shares mechanistic characteristics with the self-splicing of certain introns, prompting speculation that the catalytic reactions of nuclear pre-messenger RNA splicing are fundamentally RNA-based. The participation of five small nuclear RNAs (snRNAs) in splicing is now well documented. Genetic analysis in yeast has revealed the requirement, in addition, for several dozen proteins. Some of these are tightly bound to snRNAs to form small nuclear ribonucleoproteins (snRNPs); such proteins may promote interactions between snRNAs or between an snRNA and the intron. Other, non-snRNP proteins appear to associate transiently with the spliceosome. Some of these factors, which include RNA-dependent adenosine triphosphatases, may promote the accurate recognition of introns.			GUTHRIE, C (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021119, R37GM021119] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21119] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELSON J, IN PRESS HARVEY SOC; ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; ANDERSON GJ, 1989, NATURE, V342, P819, DOI 10.1038/342819a0; ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BERGET SM, 1977, P NATL ACAD SCI USA, V74, P3171, DOI 10.1073/pnas.74.8.3171; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BORDONNE R, 1990, GENE DEV, V4, P1185, DOI 10.1101/gad.4.7.1185; BRINGMANN P, 1984, EMBO J, V3, P1357, DOI 10.1002/j.1460-2075.1984.tb01977.x; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1989, NATURE, V337, P14, DOI 10.1038/337014a0; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHABOT B, 1985, SCIENCE, V230, P1344, DOI 10.1126/science.2933810; CHANG TH, 1988, MOL CELL BIOL, V8, P2379, DOI 10.1128/MCB.8.6.2379; CHANG TH, 1990, P NATL ACAD SCI USA, V87, P1571, DOI 10.1073/pnas.87.4.1571; CHEN JH, 1990, NUCLEIC ACIDS RES, V18, P6447, DOI 10.1093/nar/18.21.6447; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; CHOW LT, 1977, CELL, V12, P1, DOI 10.1016/0092-8674(77)90180-5; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; COUTO JR, 1987, GENE DEV, V1, P445, DOI 10.1101/gad.1.5.445; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; DALRYMPLE MA, 1989, CELL, V58, P811, DOI 10.1016/0092-8674(89)90930-6; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FABRIZIO P, UNPUB; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; GARCIABLANCO MA, 1990, P NATL ACAD SCI USA, V87, P3082, DOI 10.1073/pnas.87.8.3082; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAMM J, 1989, CELL, V59, P159, DOI 10.1016/0092-8674(89)90878-7; HASHIMOTO C, 1984, NUCLEIC ACIDS RES, V12, P3283, DOI 10.1093/nar/12.7.3283; JACQUIER A, 1985, CELL, V43, P423, DOI 10.1016/0092-8674(85)90172-2; JAMIESON DJ, 1991, NATURE, V5, P629; JONES MH, 1990, EMBO J, V9, P2555, DOI 10.1002/j.1460-2075.1990.tb07436.x; KING DS, 1990, NUCLEIC ACIDS RES, V18, P6559, DOI 10.1093/nar/18.22.6559; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LAMOND AI, 1990, TRENDS BIOCHEM SCI, V15, P451, DOI 10.1016/0968-0004(90)90292-J; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LEGRAIN P, 1990, EMBO J, V9, P2775, DOI 10.1002/j.1460-2075.1990.tb07465.x; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; LIAO XL, 1990, GENE DEV, V4, P1766, DOI 10.1101/gad.4.10.1766; LIN RJ, 1987, GENE DEV, V1, P7, DOI 10.1101/gad.1.1.7; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; LUHRMANN R, 1988, STRUCTURE FUNCTION M, P71; LUSTIG AJ, 1986, CELL, V47, P953, DOI 10.1016/0092-8674(86)90810-X; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; McKeown M, 1990, Genet Eng (N Y), V12, P139; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PAN ZQ, 1989, GENE DEV, V3, P1887, DOI 10.1101/gad.3.12a.1887; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; PETERSENBJORN S, 1989, MOL CELL BIOL, V9, P3698; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; PINTO AL, 1989, P NATL ACAD SCI USA, V86, P8742, DOI 10.1073/pnas.86.22.8742; RAY BK, 1990, MOL CELL BIOL, V10, P1134; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; RUBY SW, 1991, TRENDS GENET, V7, P79; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; RYMOND BC, 1987, GENE DEV, V1, P238, DOI 10.1101/gad.1.3.238; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SHANNON KW, 1991, GENE DEV, V5, P773, DOI 10.1101/gad.5.5.773; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SHUSTER EO, 1988, CELL, V55, P41, DOI 10.1016/0092-8674(88)90007-4; SILICIANO PG, 1987, SCIENCE, V237, P1484, DOI 10.1126/science.3306922; SILICIANO PG, 1987, CELL, V50, P585, DOI 10.1016/0092-8674(87)90031-6; SILICIANO PG, 1988, GENE DEV, V2, P125; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TANI T, 1989, NATURE, V337, P87, DOI 10.1038/337087a0; TANI T, COMMUNICATION; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; THOMPSON RC, 1988, TRENDS BIOCHEM SCI, V13, P91, DOI 10.1016/0968-0004(88)90047-3; TOLLERVEY D, 1987, EMBO J, V6, P469, DOI 10.1002/j.1460-2075.1987.tb04777.x; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; VIJAYRAGHAVAN U, 1990, MOL CELL BIOL, V10, P324, DOI 10.1128/MCB.10.1.324; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; VIJAYRAGHAVAN U, 1989, NUCLEIC ACIDS MOL BI, V25, P1; WEISSBACH H, 1980, RIBOSOMES STRUCTURE, P377; WHITTAKER E, 1990, P NATL ACAD SCI USA, V87, P2216, DOI 10.1073/pnas.87.6.2216; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	110	410	417	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					157	163		10.1126/science.1853200	http://dx.doi.org/10.1126/science.1853200			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1853200				2022-12-28	WOS:A1991FW16000026
J	KOES, BW; BOUTER, LM; BECKERMAN, H; VANDERHEIJDEN, GJMG; KNIPSCHILD, PG				KOES, BW; BOUTER, LM; BECKERMAN, H; VANDERHEIJDEN, GJMG; KNIPSCHILD, PG			PHYSIOTHERAPY EXERCISES AND BACK PAIN - A BLINDED REVIEW	BRITISH MEDICAL JOURNAL			English	Review							OUTPATIENT TREATMENT; CONSERVATIVE TREATMENT; CLINICAL-TRIAL; MANIPULATION; MANAGEMENT; INPATIENT; THERAPY	Objective - To determine the quality of randomised controlled trials of exercise therapy for back pain. Design - Computer aided search of published papers and blinded assessment of the methods of studies. Subjects - 23 randomised controlled trials, of which 16 studied exercise therapy given by physiotherapists to individual patients with back pain. Other conservative treatments could be included. Main outcome measures - Score for quality of methods (based on four main categories: study population, interventions, measurement of effect, and data presentation and analysis) and main conclusion of author(s) with regard to exercise therapy. Results - Only four studies scored more than 50 points (maximum 100), indicating that most were of poor quality. Six studies found that exercise was better than reference treatments and 10 reported it to be no better or worse than the reference treatment. Those reporting positive results tended to have higher methods scores (4/6 positive v 4/10 negative scored greater-than-or-equal-to 42). Conclusions - No conclusion can be drawn about whether exercise therapy is better than other conservative treatments for back pain or whether a specific type of exercise is more effective. Further trials are needed in which greater attention is paid to methods of study.			KOES, BW (corresponding author), STATE UNIV LIMBURG,DEPT EPIDEMIOL & HLTH CARE RES,POB 616,6200 MD MAASTRICHT,NETHERLANDS.		Koes, Bart w/K-4614-2016	Koes, Bart w/0000-0002-0450-9969; Bouter, Lex/0000-0002-2659-5482; Beckerman, Heleen/0000-0002-8421-3630				BUSWELL J, 1982, ZEALAND J PHYSIOTHER, V10, P13; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; COXHEAD CE, 1981, LANCET, V1, P1065; DAVIES JE, 1979, RHEUMATOL REHABIL, V18, P243, DOI 10.1093/rheumatology/18.4.243; DEYO RA, 1990, NEW ENGL J MED, V322, P1627, DOI 10.1056/NEJM199006073222303; DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057; EVANS C, 1987, Physiotherapy Canada, V39, P96; FARRELL JP, 1982, MED J AUSTRALIA, V1, P160, DOI 10.5694/j.1326-5377.1982.tb132242.x; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; GILBERT JR, 1985, BRIT MED J, V291, P791, DOI 10.1136/bmj.291.6498.791; GOLDIE I, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P117; HARKAPAA K, 1989, SCAND J REHABIL MED, V21, P81; JACKSON CP, 1983, CLIN ORTHOP RELAT R, V179, P39; JACKSON CP, 1983, CLIN ORTHOP RELAT R, V179, P46; KELSEY JL, 1980, SPINE, V5, P133, DOI 10.1097/00007632-198003000-00007; Kendall PH, 1968, PHYSIOTHERAPY, V54, P154; KLABERMOFFETT JA, 1986, SPINE, V11, P120; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; LANDEN BR, 1987, PHYS THER, V47, P1126; Lidstrom A, 1970, Scand J Rehabil Med, V2, P37; MACDONALD RS, 1990, SPINE, V15, P364, DOI 10.1097/00007632-199005000-00005; MANNICHE C, 1988, LANCET, V2, P1473; MARTIN PR, 1980, INT REHABILITATION M, V8, P34; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; Meinert CL., 1986, CLIN TRIALS DESIGN C; MELLIN G, 1989, SCAND J REHABIL MED, V21, P91; NACHEMSON A, 1979, SCAND J REHABIL MED, V11, P143; NWUGA G, 1985, Physiotherapy Practice, V1, P99; NWUGA VCB, 1982, AM J PHYS MED REHAB, V61, P273; Spitzer WO, 1987, SPINE, V12, P1, DOI DOI 10.1097/00007632-198701000-00001; STANKOVIC R, 1990, SPINE, V15, P120, DOI 10.1097/00007632-199002000-00014; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; TYSEN J, 1983, J PEDIATR, V102, P10; WATERWORTH RF, 1985, NZ MED J, V95, P372; WHITE AWM, 1966, CAN MED ASSOC J, V95, P50; ZYLBERGOLD RS, 1981, ARCH PHYS MED REHAB, V62, P176	37	173	177	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1572	1576		10.1136/bmj.302.6792.1572	http://dx.doi.org/10.1136/bmj.302.6792.1572			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1830233	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1991FU54900025
J	CHEN, MS; OBAR, RA; SCHROEDER, CC; AUSTIN, TW; POODRY, CA; WADSWORTH, SC; VALLEE, RB				CHEN, MS; OBAR, RA; SCHROEDER, CC; AUSTIN, TW; POODRY, CA; WADSWORTH, SC; VALLEE, RB			MULTIPLE FORMS OF DYNAMIN ARE ENCODED BY SHIBIRE, A DROSOPHILA GENE INVOLVED IN ENDOCYTOSIS	NATURE			English	Article							MECHANOCHEMICAL ENZYME; MICROTUBULES; MELANOGASTER; PROTEINS; IDENTIFICATION; TRANSLOCATION; EXPRESSION; SEQUENCE; CLONING; MUTANT	DYNAMIN was discovered in bovine brain tissue as a nucleotide-sensitive microtubule-binding protein of relative molecular mass 100,000 1. It was found to cross-link microtubules into highly ordered bundles, and appeared to have a role in intermicrotubule sliding in vitro. Cloning and sequencing of rat brain dynamin complementary DNA identified an N-terminal region of about 300 amino acids which contained the three consensus elements characteristic of GTP-binding proteins 2. Extensive homology was found between this domain and the mammalian Mx proteins which are involved in interferon-induced viral resistance 3,4, and with the product of the VPS1 locus in Saccharomyces cerevisiae, which has been implicated both in membrane protein sorting 5, and in meiotic spindle pole separation 6. Dynamin-containing microtubule bundles were not observed in an immunofluorescence study of cultured mammalian cells 7, but a role for a GTP-requiring protein in intermicrotubule sliding during mitosis in plants has been reported 8. We report here that Drosophila melanogaster contains multiple tissue-specific and developmentally-regulated forms of dynamin, which are products of the shibire locus previously implicated in endocytic protein sorting 9,10.	WORCESTER FDN EXPTL BIOL INC, CELL BIOL GRP, SHREWSBURY, MA 01545 USA; UNIV CALIF SANTA CRUZ, DEPT BIOL, SANTA CRUZ, CA 95064 USA	Worcester Foundation for Biomedical Research; University of California System; University of California Santa Cruz								ASADA T, 1991, NATURE, V350, P238, DOI 10.1038/350238a0; BLOOM GS, 1983, J CELL BIOL, V96, P1523, DOI 10.1083/jcb.96.6.1523; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cramer L., 1980, DROS INFORM SERV, V55, P200; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; GRIGLIATTI TA, 1973, MOL GEN GENET, V120, P107, DOI 10.1007/BF00267238; HERMAN B, 1984, J CELL BIOL, V98, P565, DOI 10.1083/jcb.98.2.565; ITOH N, 1986, P NATL ACAD SCI USA, V83, P4081, DOI 10.1073/pnas.83.11.4081; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCCHESI JC, 1973, ANNU REV GENET, V7, P225, DOI 10.1146/annurev.ge.07.120173.001301; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; POODRY CA, 1990, DEV BIOL, V138, P464, DOI 10.1016/0012-1606(90)90212-2; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; POODRY CA, 1990, DROSOPHILA INFORMATI, V68, P207; POODRY CA, 1980, DROS INFORM SERV, V55, P210; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; STAEHELI P, 1988, MOL CELL BIOL, V8, P4524, DOI 10.1128/MCB.8.10.4524; VALLEE RB, 1986, METHOD ENZYMOL, V134, P104; YEH E, 1991, NATURE, V349, P713, DOI 10.1038/349713a0	26	476	481	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1991	351	6327					583	586		10.1038/351583a0	http://dx.doi.org/10.1038/351583a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1828536				2022-12-28	WOS:A1991FR03400064
J	STEPHENS, LR; HUGHES, KT; IRVINE, RF				STEPHENS, LR; HUGHES, KT; IRVINE, RF			PATHWAY OF PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE SYNTHESIS IN ACTIVATED NEUTROPHILS	NATURE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; INOSITOL PHOSPHATES; BOVINE BRAIN; 4,5-BISPHOSPHATE; IDENTIFICATION; 4-PHOSPHATE; POLYPHOSPHOINOSITIDE; PHOSPHODIESTERASE; TRANSFORMATION; TRISPHOSPHATE	Neutrophils activated by the formyl peptide f-Met-LeuPhe transiently accumulate a small subset of highly polar inositol lipids. A similar family of lipids also appear in many other cells in response to a range of growth factors and activated oncogenes, and are presumed to be the direct or indirect products of 3-phosphatidylinositol kinase. The structures of these lipids are shown to be phosphatidylinositol 3-phosphate, phosphatidylinositol-(3,4)bisphosphate and phosphatidylinositol-(3,4,5)trisphosphate, and we present evidence that in intact neutrophils a phosphatidyl-inositol-(4,5)bisphosphate-3-kinase seems to be the focal point through which agonists stimulate the formation of 3-phosphorylated inositol lipids.	AMERSHAM INT PLC,CARDIFF CF4 7YT,WALES		STEPHENS, LR (corresponding author), AFRC,INST ANIM PHYSIOL & GENET RES,CAMBRIDGE RES STN,DEPT BIOCHEM,CAMBRIDGE CB2 4AT,ENGLAND.			stephens, len/0000-0002-2771-3487				ALLEN D, 1978, BIOCHIM BIOPHYS ACTA, V508, P277; ASCOLI M, 1990, J BIOL CHEM, V265, P1718; Auger K. R., 1990, METHODS INOSITIDE RE, P159; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BENNETT JP, 1982, BIOCHEM J, V208, P801, DOI 10.1042/bj2080801; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROCKERHOFF H, 1962, J BIOL CHEM, V237, P1764; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CREBA JA, 1983, BIOCHEM J, V212, P733, DOI 10.1042/bj2120733; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; DOWNES P, 1982, CELL CALCIUM, V3, P467, DOI 10.1016/0143-4160(82)90031-8; ENDOMANN G, 1990, J BIOL CHEM, V265, P396; GEE NS, 1988, BIOCHEM J, V253, P777, DOI 10.1042/bj2530777; IMBODEN JB, 1987, J CLIN INVEST, V79, P1538, DOI 10.1172/JCI112986; INHORN RC, 1987, P NATL ACAD SCI USA, V84, P2170, DOI 10.1073/pnas.84.8.2170; IRVINE RF, 1984, BIOCHEM J, V218, P177, DOI 10.1042/bj2180177; IRVINE RF, 1978, BIOCHEM J, V176, P475, DOI 10.1042/bj1760475; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KING CE, 1989, BIOCHEM J, V259, P893, DOI 10.1042/bj2590893; KING CE, 1987, BIOCHEM J, V244, P209, DOI 10.1042/bj2440209; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LETCHER AJ, 1990, METHODS INOSITIDE RE, P31; LIPS DL, 1989, J BIOL CHEM, V264, P19911; LOW MG, 1986, BIOCHEM J, V237, P139, DOI 10.1042/bj2370139; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; PALMER FBSC, 1981, J LIPID RES, V22, P1296; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SIM SS, 1990, J BIOL CHEM, V265, P10367; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; Stephens L. R., 1990, METHODS INOSITIDE RE, P9; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1990, BIOCHEM J, V269, P65, DOI 10.1042/bj2690065; STEPHENS LR, 1989, BIOCHEM J, V262, P727, DOI 10.1042/bj2620727; TAKAZAWA K, 1989, BIOCHEM J, V261, P483, DOI 10.1042/bj2610483; TOMLINSON R, 1961, J BIOL CHEM, V236, P1902; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VADNAL RE, 1989, BIOCHEM BIOPH RES CO, V163, P995, DOI 10.1016/0006-291X(89)92320-6; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	50	438	450	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					33	39		10.1038/351033a0	http://dx.doi.org/10.1038/351033a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	1851250				2022-12-28	WOS:A1991FK19300049
J	WONG, YH; FEDERMAN, A; PACE, AM; ZACHARY, I; EVANS, T; POUYSSEGUR, J; BOURNE, HR				WONG, YH; FEDERMAN, A; PACE, AM; ZACHARY, I; EVANS, T; POUYSSEGUR, J; BOURNE, HR			MUTANT ALPHA-SUBUNITS OF GI2 INHIBIT CYCLIC-AMP ACCUMULATION	NATURE			English	Article							BINDING REGULATORY COMPONENT; ADENYLATE-CYCLASE; G-PROTEINS; MUTATIONS; MEMBRANES; RECEPTOR; SITE; IDENTIFICATION; DISSOCIATION; STIMULATION	ONE or more of three G(i) proteins, G(i1-3), mediates hormonal inhibition of adenylyl cyclase 1-3. Whether this inhibition is mediated by the alpha or by the beta-gamma-subunits of G(i) proteins is unclear 1,2. Mutations inhibiting the intrinsic GTPase activity of another G protein, the stimulatory regulator of adenylyl cyclase (G(s)), constitutively activate it by replacing either of two conserved amino acids in its alpha-subunit (alpha-s) 4-7. These mutations create the gsp oncogene which is found in human pituitary and thyroid tumours 5,8. In a second group of human endocrine tumours, somatic mutations in the alpha-subunit of G(i2) replace a residue cognate to one of those affected by gsp mutations 8. This implies that the mutations convert the alpha-i2 gene into a dominantly acting oncogene, called gip2 (ref. 8), and that the mutant alpha-i2 subunits are constitutively active. We have therefore assessed cyclic AMP accumulation in cultured cells which stably or transiently express exogenous wild-type alpha-i2 complementary DNA or either of two mutant alpha-i2 cDNAs. The results show that putatively oncogenic mutations in alpha-i2 constitutively activate the protein's ability to inhibit cAMP accumulation.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; GENENTECH INC, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV NICE, FAC SCI, CNRS, CTR BIOCHIM, F-06034 NICE, FRANCE	University of California System; University of California San Francisco; Roche Holding; Genentech; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur				Wong, Yung Hou/0000-0002-0123-7697				BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHANG FH, 1987, ENDOCRINOLOGY, V121, P1711, DOI 10.1210/endo-121-5-1711; EVANS T, 1987, J BIOL CHEM, V262, P176; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HILDEBRANDT JD, 1983, NATURE, V302, P706, DOI 10.1038/302706a0; HILDEBRANDT JD, 1982, J BIOL CHEM, V257, P4723; HILDEBRANDT JD, 1984, J BIOL CHEM, V259, P3178; JAKOBS KH, 1983, P NATL ACAD SCI-BIOL, V80, P3899, DOI 10.1073/pnas.80.13.3899; JAKOBS KH, 1983, NATURE, V303, P177, DOI 10.1038/303177a0; KATADA T, 1984, J BIOL CHEM, V259, P3586; KATADA T, 1986, J BIOL CHEM, V261, P5215; KATADA T, 1984, J BIOL CHEM, V259, P3578; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K	30	250	251	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	1991	351	6321					63	65		10.1038/351063a0	http://dx.doi.org/10.1038/351063a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	1851251				2022-12-28	WOS:A1991FK19300060
J	TRAVERS, AF				TRAVERS, AF			EVERYDAY AIDS AND APPLIANCES - RAMPS AND RAILS	BRITISH MEDICAL JOURNAL			English	Article											TRAVERS, AF (corresponding author), UNIV LEEDS,RHEUMATOL & REHABILIT RES UNIT,LEEDS LS2 9NZ,ENGLAND.							HALL RGP, 1990, BRIT MED J, V301, P424, DOI 10.1136/bmj.301.6749.424; JAY P, 1984, COPING DISABILITY; MANDELSTAM M, 1990, GET EQUIPMENT DISABI; Sweeney G. M., 1989, BR J OCCUPAT THERAPY, V52, P473; 1990, CAPITAL RANGE GRAB R; 1990, PURPOSE BUILT TAXIS	6	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					951	954		10.1136/bmj.302.6782.951	http://dx.doi.org/10.1136/bmj.302.6782.951			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	1827742	Bronze, Green Published			2022-12-28	WOS:A1991FH48700025
J	LUBIN, I; FAKTOROWICH, Y; LAPIDOT, T; GAN, Y; ESHHAR, Z; GAZIT, E; LEVITE, M; REISNER, Y				LUBIN, I; FAKTOROWICH, Y; LAPIDOT, T; GAN, Y; ESHHAR, Z; GAZIT, E; LEVITE, M; REISNER, Y			ENGRAFTMENT AND DEVELOPMENT OF HUMAN T-CELLS AND B-CELLS IN MICE AFTER BONE-MARROW TRANSPLANTATION	SCIENCE			English	Article							DEPENDENT DIABETES-MELLITUS; COMBINED IMMUNE-DEFICIENCY; RED-BLOOD-CELLS; SCID-HU MOUSE; SOYBEAN AGGLUTININ; RESISTANCE; SUSCEPTIBILITY; RECIPIENTS; ALLOGRAFTS; GRAFTS	A model for human lymphocyte ontogeny has been developed in a normal mouse. Human bone marrow, depleted of mature T and B lymphocytes, and bone marrow from mice with severe combined immunodeficiency were transplanted into lethally irradiated BALB/c mice. Human B and T cells were first detected 2 to 4 months after transplantation and persisted for at least 6 months. Most human thymocytes (30 to 50 percent of total thymocytes) were CD3+ CD4+ CD8+. Human immunoglobulin was detected in some chimeras, and a human antibody response to dinitrophenol could be generated after primary and secondary immunization.	WEIZMANN INST SCI,DEPT BIOPHYS,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; CHAIM SHEBA MED CTR,DEPT PEDIAT,IL-62621 TEL HASHOMER,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center			Lapidot, Tsvee/A-1812-2010; Reisner, Yair/AAA-4772-2019	Reisner, Yair/0000-0002-3354-6945				KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KEEVER CA, 1989, BLOOD, V73, P1340; KIESSLING R, 1977, EUR J IMMUNOL, V7, P655, DOI 10.1002/eji.1830070915; LAPIDOT T, 1989, BLOOD, V73, P2025; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MURPHY WJ, 1987, J EXP MED, V165, P1212, DOI 10.1084/jem.165.4.1212; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055; OREILLY RJ, 1986, PRIMARY IMMUNODEFICI, P301; REISNER Y, 1983, BLOOD, V61, P341; REISNER Y, 1978, P NATL ACAD SCI USA, V75, P2933, DOI 10.1073/pnas.75.6.2933; REISNER Y, 1981, LANCET, V2, P327; RONNINGEN KS, 1989, HUM IMMUNOL, V26, P215; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SCHWARTZ E, 1987, J IMMUNOL, V138, P460; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; VANBEKKUM DW, 1985, BONE MARROW TRANSPL, P311	18	87	102	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					427	431		10.1126/science.1826797	http://dx.doi.org/10.1126/science.1826797			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	1826797				2022-12-28	WOS:A1991FH10300039
J	KAKLAMANI, E; TRICHOPOULOS, D; TZONOU, A; ZAVITSANOS, X; KOUMANTAKI, Y; HATZAKIS, A; HSIEH, CC; HATZIYANNIS, S				KAKLAMANI, E; TRICHOPOULOS, D; TZONOU, A; ZAVITSANOS, X; KOUMANTAKI, Y; HATZAKIS, A; HSIEH, CC; HATZIYANNIS, S			HEPATITIS-B AND HEPATITIS-C VIRUSES AND THEIR INTERACTION IN THE ORIGIN OF HEPATOCELLULAR-CARCINOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC NON-A; ANTIBODIES; PREVALENCE; SMOKING	Serum taken from patients in a case-control study in Athens, Greece, was used to examine the interactive roles of hepatitis B virus (HBV) and hepatitis C virus (HCV) in the origin of hepatocellular carcinoma (HCC). An enzyme immunoassay for anti-HCV was used to test serum taken from 185 cases with HCC, 35 cases with metastatic liver cancer (MLC), and 432 hospital controls. Weakly positive anti-HCV results were more strongly related to MLC than to HCC, implying that these anti-HCV results are false positive. By contrast, strongly positive anti-HCV results were significantly related to HCC (relative risk [RR], 6.3), whereas no significant association was evident for MLC (RR, 0.6). The association of anti-HCV with HCC was substantially higher among subjects whose radioimmunoassay was positive for hepatitis B surface antigen (RR, 20.0) than among those whose radioimmunoassay was negative for this marker (RR, 4.8). These findings indicate that HCV infection has an interactive role in the origin of HCC.	HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,677 HUNTINGTON AVE,BOSTON,MA 02115; UNIV ATHENS,SCH MED,DEPT HYG & EPIDEMIOL,ATHENS,GREECE; IPPOKRATEION HOSP,ACAD DEPT MED,ATHENS,GREECE	Harvard University; Harvard T.H. Chan School of Public Health; Athens Medical School; National & Kapodistrian University of Athens								ALTER H, 1989, 1ST P INT S HEP C VI, P25; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRUIX J, 1989, LANCET, V2, P1004; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; Davis W, 1980, IARC SCI PUBL, V32, P192; ESTEBAN JI, 1989, LANCET, V2, P294; GILLIAM JH, 1984, ANN INTERN MED, V101, P794, DOI 10.7326/0003-4819-101-6-794; GRAY JJ, 1990, LANCET, V335, P609, DOI 10.1016/0140-6736(90)90398-O; GRAY JJ, 1989, SERODIAG IMMUN INF D, V3, P389, DOI 10.1016/0888-0786(89)90057-7; HIRAYAMA T, 1989, CANCER CHEMOTH PHARM, V23, pS114, DOI 10.1007/BF00647254; KEW MC, 1990, LANCET, V335, P873, DOI 10.1016/0140-6736(90)90474-J; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MORGANCAPNER P, 1988, LANCET, V1, P1397; MUNOZ N, 1987, NEOPLASMS LIVER, P3, DOI DOI 10.1007/978-4-431-68349-0_1; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PURCELL RH, 1989, CANCER DETECT PREV, V14, P203; SIMONETTI RG, 1989, LANCET, V2, P1338; TRICHOPOULOS D, 1987, INT J CANCER, V39, P45, DOI 10.1002/ijc.2910390109; TRICHOPOULOS D, 1978, LANCET, V2, P1217; WREGHITT TG, 1990, LANCET, P789; YU MC, 1990, JNCI-J NATL CANCER I, V82, P1038, DOI 10.1093/jnci/82.12.1038; 1988, IARC SCI PUBL, V44, P207	24	201	201	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1974	1976		10.1001/jama.265.15.1974	http://dx.doi.org/10.1001/jama.265.15.1974			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	1848908				2022-12-28	WOS:A1991FF76800023
J	STROBEL, SA; DERVAN, PB				STROBEL, SA; DERVAN, PB			SINGLE-SITE ENZYMATIC CLEAVAGE OF YEAST GENOMIC DNA MEDIATED BY TRIPLE HELIX FORMATION	NATURE			English	Article							GEL-ELECTROPHORESIS; SACCHAROMYCES-CEREVISIAE; SEQUENCE; ENDONUCLEASE; RECOGNITION; SEPARATION; PROTEINS; MATURASE; BINDING	PHYSICAL mapping of chromosomes would be facilitated by methods of breaking large DNA into manageable fragments, or cutting uniquely at genetic markers of interest. Key issues in the design of sequence-specific DNA cleaving reagents are the specificity of binding, the generalizability of the recognition motif, and the cleavage yield. Oligonucleotide-directed triple helix formation is a generalizable motif for specific binding to sequences longer than 12 base pairs within DNA of high complexity 1-3. Studies with plasmid DNA show that triple helix formation can limit the operational specificity of restriction enzymes to endonuclease recognition sequences that overlap oligonucleotide-binding sites 4,5. Triple helix formation, followed by methylase protection, triple helix-disruption, and restriction endonuclease digestion produces near quantitative cleavage at the single overlapping triple helix-endonuclease site 4,5. As a demonstration that this technique may be applicable to the orchestrated cleavage of large genomic DNA, we report the near quantitative single-site enzymatic cleavage of the Saccharomyces cerevisiae genome mediated by triple helix formation. The 340-kilobase yeast chromosome III was cut uniquely at an overlapping homopurine-EcoRI target site 27 base pairs long to produce two expected cleavage products of 110 and 230 kilobases. No cleavage of any other chromosome was detected. The potential generalizability of this technique, which is capable of near quantitative cleavage at a single site in at lease 14 megabase pairs of DNA, could enable selected regions of chromosomal DNA to be isolated without extensive screening of genomic libraries.	CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125	California Institute of Technology								ANDREADIS A, 1982, CELL, V31, P319, DOI 10.1016/0092-8674(82)90125-8; BARLOW DP, 1987, TRENDS GENET, V3, P167, DOI 10.1016/0168-9525(87)90219-8; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HORNE DA, 1990, J AM CHEM SOC, V112, P2435, DOI 10.1021/ja00162a063; KEESEY JK, 1979, J BIOL CHEM, V254, P7427; KOOB M, 1988, SCIENCE, V241, P1084, DOI 10.1126/science.2842862; KOOB M, 1990, SCIENCE, V250, P271, DOI 10.1126/science.2218529; LIPSETT MN, 1964, J BIOL CHEM, V239, P1256; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MORTIMER RK, 1985, MICROBIOL REV, V49, P181, DOI 10.1128/MMBR.49.3.181-213.1985; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PATEL Y, 1990, NUCLEIC ACIDS RES, V18, P1603, DOI 10.1093/nar/18.6.1603; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; WEIL MD, 1989, P NATL ACAD SCI USA, V86, P51, DOI 10.1073/pnas.86.1.51; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6	27	135	142	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					172	174		10.1038/350172a0	http://dx.doi.org/10.1038/350172a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	1848684				2022-12-28	WOS:A1991FB64500066
J	YAYON, A; KLAGSBRUN, M; ESKO, JD; LEDER, P; ORNITZ, DM				YAYON, A; KLAGSBRUN, M; ESKO, JD; LEDER, P; ORNITZ, DM			CELL-SURFACE, HEPARIN-LIKE MOLECULES ARE REQUIRED FOR BINDING OF BASIC FIBROBLAST GROWTH-FACTOR TO ITS HIGH-AFFINITY RECEPTOR	CELL			English	Article							CAPILLARY ENDOTHELIAL-CELLS; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; PLASMINOGEN-ACTIVATOR PRODUCTION; PROTEIN-TYROSINE KINASE; SULFATE; PROTEOGLYCAN; GLYCOSAMINOGLYCANS; PURIFICATION; STIMULATION; METABOLISM	The role of low affinity, heparin-like binding sites for basic fibroblast growth factor (bFGF) was investigated in CHO cells mutant in their metabolism of glycosaminoglycans. Heparan sulfate-deficient mutants transfected to express a cloned mouse FGF receptor cDNA are not able to bind bFGF. It is demonstrated that free heparin and heparan sulfate can reconstitute a low affinity receptor that is, in turn, required for the high affinity binding of bFGF. These studies suggest that the low affinity receptor is an accessory molecule required for binding of bFGF to the high affinity site. Such an obligatory interaction of low and high affinity FGF receptors suggests a physiological role for heparin-like, low affinity receptors and constitutes a novel mechanism for the regulation of growth factor-receptor interactions.	HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35294; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	YAYON, A (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.			Ornitz, David/0000-0003-1592-7629	NATIONAL CANCER INSTITUTE [P01CA045548, R01CA037329] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063, R01GM033063] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37329, CA 45548] Funding Source: Medline; NIGMS NIH HHS [GM 33063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZIZKHAN RG, 1980, J EXP MED, V152, P931, DOI 10.1084/jem.152.4.931; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; IMAMURA T, 1987, EXP CELL RES, V172, P92, DOI 10.1016/0014-4827(87)90096-6; KANER RJ, 1990, SCIENCE, V248, P1410, DOI 10.1126/science.2162560; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KINOSHITA S, 1979, EXP CELL RES, V123, P229, DOI 10.1016/0014-4827(79)90463-4; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LATERRA J, 1980, P NATL ACAD SCI-BIOL, V77, P6662, DOI 10.1073/pnas.77.11.6662; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MUELLER SN, 1989, J CELL PHYSIOL, V140, P439, DOI 10.1002/jcp.1041400306; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; NADER HB, 1984, J BIOL CHEM, V259, P1431; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PRESTA M, 1989, CANCER RES, V48, P68; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SUDHALTER J, 1989, J BIOL CHEM, V264, P6892; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; YAYON A, 1990, CANCER METAST REV, V9, P191, DOI 10.1007/BF00046360	47	2304	2380	3	130	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					841	848		10.1016/0092-8674(91)90512-W	http://dx.doi.org/10.1016/0092-8674(91)90512-W			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1847668				2022-12-28	WOS:A1991EZ47800018
J	TEH, HS; GARVIN, AM; FORBUSH, KA; CARLOW, DA; DAVIS, CB; LITTMAN, DR; PERLMUTTER, RM				TEH, HS; GARVIN, AM; FORBUSH, KA; CARLOW, DA; DAVIS, CB; LITTMAN, DR; PERLMUTTER, RM			PARTICIPATION OF CD4 CORECEPTOR MOLECULES IN T-CELL REPERTOIRE SELECTION	NATURE			English	Article							ANTIGEN RECEPTOR; TRANSGENIC MICE; RECOGNITION; EXPRESSION; LINES; MOUSE; GENE	DURING thymocyte development, progenitor cells bearing both CD4 and CD8 coreceptor molecules mature into functional T lymphocytes that express these proteins in a mutually exclusive way 1. Although T-cell specificity is determined primarily by the structure of the T-cell antigen receptor (TCR) heterodimer 2, a developmentally regulated process acts to ensure that cells bearing class II-restricted TCRs are CD4+ and those bearing class I-restricted TCRs express, only CD8 (ref.3). To investigate this maturation process, we have engineered transgenic mice in which CD4 is expressed in all thymocyte subsets and in all peripheral T cells. Peripheral CD4+8+ T lymphocytes from these mice react with both class I and class II alloantigens. Moreover, expression of the CD4 transgene disrupts the positive selection of doubly transgenic thymocytes bearing a class I-restricted TCR specific for the male (H-Y) antigen. Hence the CD4 coreceptor participates directly in T-cell repertoire selection.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT IMMUNOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED MED GENET, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV BRITISH COLUMBIA, DEPT MICROBIOL, VANCOUVER V6T 1W5, BC, CANADA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of British Columbia			Teh, Hung-Sia/A-5710-2008					BAILEY DW, 1971, IMMUNOGENETICS H2 SY, P155; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; CHAFFIN K, IN PRESS EMBO J; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; GALLAGHER PF, 1989, P NATL ACAD SCI USA, V86, P10044, DOI 10.1073/pnas.86.24.10044; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEWIS DB, IN PRESS J EXP MED; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; MCKENZIE IFC, 1979, J EXP MED, V150, P1323, DOI 10.1084/jem.150.6.1323; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROBEY E, 1990, CELL, V60, P697, DOI 10.1016/0092-8674(90)90082-P; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; STAERZ UD, 1985, J IMMUNOL, V134, P3994; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; Teh H S, 1990, Dev Immunol, V1, P1, DOI 10.1155/1990/18208; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	27	85	85	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 17	1991	349	6306					241	243		10.1038/349241a0	http://dx.doi.org/10.1038/349241a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1824796				2022-12-28	WOS:A1991ET51900056
J	SMYTH, JF; COLEMAN, RE; NICOLSON, M; GALLMEIER, WM; LEONARD, RCF; CORNBLEET, MA; ALLAN, SG; UPADHYAYA, BK; BRUNTSCH, U				SMYTH, JF; COLEMAN, RE; NICOLSON, M; GALLMEIER, WM; LEONARD, RCF; CORNBLEET, MA; ALLAN, SG; UPADHYAYA, BK; BRUNTSCH, U			DOES DEXAMETHASONE ENHANCE CONTROL OF ACUTE CISPLATIN INDUCED EMESIS BY ONDANSETRON	BRITISH MEDICAL JOURNAL			English	Article							HIGH-DOSE METOCLOPRAMIDE; PLUS DEXAMETHASONE; CIS-PLATINUM; DOUBLE-BLIND; CHEMOTHERAPY; TRIAL; ANTAGONIST; EFFICACY	Objective - To determine the contribution of dexamethasone to the efficacy of the 5-hydroxy-tryptamine antagonist ondansetron in control of cisplatin induced nausea and vomiting. Design - Randomised double blind crossover study. Setting - Two cancer centres in teaching hospitals, one in the United Kingdom and the other in Germany. Subjects - 100 patients (53 men and 47 women) new to cisplatin chemotherapy, 84 of whom completed two consecutive courses of chemotherapy. Interventions - Patients were given intravenous dexamethasone (20 mg) or physiological saline with intravenous ondansetron 8 mg before cisplatin, then ondansetron 1 mg/h for 24 hours. Oral ondansetron 8 mg was taken three times daily on days 2-6. Main outcome measures-Incidence of complete or major control of emesis (0-2 episodes in the 24 hours after chemotherapy). Results - Complete or major control was obtained in 49 out of 71 (69%) of patients after receiving ondansetron plus dexamethasone compared with 40 out of 71 (56%) when they were given ondansetron alone (p = 0.012). This effect was most pronounced in the first 12 hours after chemotherapy. Patients receiving the combination also had significantly less nausea. Of the 53 patients who expressed a preference, 38 (72%) preferred the combination treatment (p = 0.002) to ondansetron alone. The effect of ondansetron on delayed emesis was less pronounced. Conclusions - Dexamethasone makes a significant contribution to the efficacy of ondansetron in the control of acute platinum induced emesis.	KLINIKUM NORD,NURNBERG,GERMANY; GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND	Klinikum Nurnberg Nord; GlaxoSmithKline	SMYTH, JF (corresponding author), WESTERN GEN HOSP,IMPERIAL CANC RES FUND,MED ONCOL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							AAPRO MS, 1981, CANCER CHEMOTH PHARM, V7, P11; ALLAN SG, 1984, EUR J CANCER CLIN ON, V20, P1481, DOI 10.1016/0277-5379(84)90140-8; ALLAN SG, 1984, BRIT MED J, V289, P878, DOI 10.1136/bmj.289.6449.878-a; ALLAN SG, 1986, CANCER CHEMOTH PHARM, V18, P86, DOI 10.1007/BF00253072; BENRUBI GI, 1985, GYNECOL ONCOL, V21, P306, DOI 10.1016/0090-8258(85)90268-9; CUNNINGHAM D, 1989, LANCET, V1, P1323; HAWTHORN J, 1990, BRIT J CANCER, V61, P56, DOI 10.1038/bjc.1990.12; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; KOCH GG, 1972, BIOMETRICS, V28, P577, DOI 10.2307/2556170; KRIS MG, 1989, J CLIN ONCOL, V7, P108, DOI 10.1200/JCO.1989.7.1.108; LAZLO J, 1981, NEW ENGL J MED, V305, P948; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; MARTY M, 1989, EUR J CANCER CLIN ON, V25, pS41; Prescott R. J., 1981, Applied Statistics, V30, P9, DOI 10.2307/2346652; PRIESTMAN TJ, 1989, EUR J CANCER CLIN ON, V25, pS29; ROILA F, 1990, P AM SOC CLIN ONCOL, V9, pA1312; SMITH DB, 1990, BRIT J CANCER, V61, P323, DOI 10.1038/bjc.1990.62; TYERS MB, 1989, EUR J CANCER CLIN ON, V25, pS15	18	120	120	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1423	1426		10.1136/bmj.303.6815.1423	http://dx.doi.org/10.1136/bmj.303.6815.1423			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1837743	Green Published, Bronze			2022-12-28	WOS:A1991GU38500019
J	MONTESANO, R; MATSUMOTO, K; NAKAMURA, T; ORCI, L				MONTESANO, R; MATSUMOTO, K; NAKAMURA, T; ORCI, L			IDENTIFICATION OF A FIBROBLAST-DERIVED EPITHELIAL MORPHOGEN AS HEPATOCYTE GROWTH-FACTOR	CELL			English	Article							SCATTER FACTOR; ANGIOGENESIS INVITRO; MOLECULAR-CLONING; HEPATOPOIETIN-A; MESSENGER-RNA; PURIFICATION; CELLS; EXPRESSION; EMBRYOGENESIS; MONOLAYERS	We have previously shown that Madin-Darby canine kidney (MDCK) epithelial cells grown in collagen gels in the presence of fibroblasts or fibroblast-conditioned medium (CM) form branching tubules, instead of the spherical cysts that develop under control conditions. We now report that the fibroblast-derived molecule responsible for epithelial tubulogenesis is hepatocyte growth factor (HGF). First, addition of exogenous HGF to cultures of MDCK cells induces formation of epithelial tubules. Second, the tubulogenic activity of fibroblast CM is completely abrogated by antibodies to HGF. These results demonstrate that HGF, a polypeptide that was identified as a mitogen for cultured hepatocytes, has the properties of a paracrine mediator of epithelial morphogenesis, and suggest that it may play important roles in the formation of parenchymal organs during embryonic development.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN	Kyushu University	MONTESANO, R (corresponding author), UNIV GENEVA,MED CTR,INST HISTOL & EMBRYOL,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND.							ASAMI O, 1991, J BIOCHEM-TOKYO, V109, P8; Bernfield M., 1984, ROLE EXTRACELLULAR M, P545; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAMBARD M, 1981, J CELL BIOL, V91, P157, DOI 10.1083/jcb.91.1.157; COFFER A, 1991, BIOCHEM J, V278, P35, DOI 10.1042/bj2780035; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GROBSTEIN C, 1956, ADV CANCER RES, V4, P187, DOI 10.1016/S0065-230X(08)60725-3; HALL HG, 1982, P NATL ACAD SCI-BIOL, V79, P4672, DOI 10.1073/pnas.79.15.4672; HIGUCHI O, 1991, BIOCHEM BIOPH RES CO, V176, P599, DOI 10.1016/S0006-291X(05)80226-8; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; KONISHI T, 1991, IN PRESS BIOCH BIOPH; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; MATSUMOTO K, 1991, IN PRESS CRIT REV ON; MCATEER JA, 1987, ANAT REC, V217, P229, DOI 10.1002/ar.1092170303; MERCOLA M, 1988, DEVELOPMENT, V102, P451; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1983, J CELL BIOL, V97, P935, DOI 10.1083/jcb.97.3.935; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MONTESANO R, 1991, P NATL ACAD SCI USA, V66, P697; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; PRAT PM, 1991, IN PRESS INT J CANCE; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Saxen L., 1976, CELL SURFACE ANIMAL, P331; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SLACK JMW, 1989, LANCET, V1, P1312; SPORN MB, 1990, HDB EXPT PHARM, V1; SPORN MB, 1990, HDB EXPT PHARM, V2; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; UENO N, 1990, Progress in Growth Factor Research, V2, P113, DOI 10.1016/0955-2235(90)90027-H; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WOLF HK, 1991, AM J PATHOL, V138, P1035; YANG J, 1979, P NATL ACAD SCI USA, V76, P3401, DOI 10.1073/pnas.76.7.3401; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZARNEGAR R, 1989, CANCER RES, V49, P3314	57	1160	1201	1	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1991	67	5					901	908		10.1016/0092-8674(91)90363-4	http://dx.doi.org/10.1016/0092-8674(91)90363-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1835669				2022-12-28	WOS:A1991GT75500009
J	SHIMELL, MJ; FERGUSON, EL; CHILDS, SR; OCONNOR, MB				SHIMELL, MJ; FERGUSON, EL; CHILDS, SR; OCONNOR, MB			THE DROSOPHILA DORSAL-VENTRAL PATTERNING GENE TOLLOID IS RELATED TO HUMAN BONE MORPHOGENETIC PROTEIN-1	CELL			English	Article							GROWTH-FACTOR-BETA; MOLECULAR-WEIGHT COMPLEX; BLASTODERM FATE MAP; AMINO-ACID SEQUENCE; HUMAN FACTOR-IX; LARVAL CUTICLE; ZYGOTIC LOCI; SEGMENTAL ORGANIZATION; DECAPENTAPLEGIC GENE; NUCLEAR-LOCALIZATION	Mutations in the Drosophila tolloid (tld) gene lead to a partial transformation of dorsal ectoderm into ventral ectoderm. The null phenotype of tld is similar to, but less severe than decapentaplegic (dpp), a TGF-beta family member required for the formation of all dorsal structures. We have cloned the tld locus by P element tagging. At the blastoderm stage, tld RNA is expressed dorsally, similar to that described for dpp. Analysis of a tld cDNA reveals three sequence motifs: an N terminal region of similarity to a metalloprotease, two EGF-like repeats, and five copies of a repeat found in human complement proteins C1r and C1s. tld sequence is 41% identical to human bone morphogenetic protein 1 (BMP-1); the closest members to dpp within the TGF-beta superfamily are BMP-2 and BMP-4, two other bone morphogenetic proteins. These findings suggest that these genes are members of a signal generating pathway that has been conserved between insects and mammals.	UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Irvine; University of California System; University of California Berkeley	SHIMELL, MJ (corresponding author), UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717, USA.		O'Connor, Michael B/C-9977-2014	O'Connor, Michael B/0000-0002-3067-5506; Ferguson, Edwin/0000-0003-4125-4253	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042546, R01GM035437] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07299] Funding Source: Medline; NIGMS NIH HHS [GM35437, GM42546] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; ARLAUD GJ, 1987, IMMUNOL TODAY, V8, P106, DOI 10.1016/0167-5699(87)90860-7; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BLANCHARD MG, 1974, PEDIATR RES, V8, P968, DOI 10.1203/00006450-197412000-00011; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GELBART WM, 1989, DEVELOPMENT, V107, P65; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IP YT, 1991, CELL, V64, P439; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JONES CM, 1991, DEVELOPMENT, V111, P531; JOURNET A, 1986, BIOCHEM J, V240, P783, DOI 10.1042/bj2400783; JURGENS G, 1987, ROUX ARCH DEV BIOL, V196, P141, DOI 10.1007/BF00376308; JURGENS G, 1986, ROUX ARCH DEV BIOL, V195, P359, DOI 10.1007/BF00402870; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KAPLAN FS, 1990, CALCIFIED TISSUE INT, V47, P117, DOI 10.1007/BF02555995; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MACKINNON CM, 1987, EUR J BIOCHEM, V169, P547, DOI 10.1111/j.1432-1033.1987.tb13644.x; Maniatis T., 1982, MOL CLONING; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATTHEWS BW, 1974, J BIOL CHEM, V249, P8030; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; RAY RP, 1991, IN PRESS DEVELOPMENT; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; REUTER R, 1990, DEVELOPMENT, V110, P1031; Roberts D. B., 1986, DROSOPHILA PRACTICAL, P279; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUSHLOW C, 1987, GENE DEV, V1, P1268, DOI 10.1101/gad.1.10.1268; Rushlow C, 1990, Adv Genet, V27, P277; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SERVER AC, 1976, J BIOL CHEM, V251, P165; SIMON J, 1990, EMBO J, V9, P3945, DOI 10.1002/j.1460-2075.1990.tb07615.x; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; SPRADLING AC, 1982, SCIENCE, V218, P348; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STOCKER W, 1988, BIOCHEMISTRY-US, V27, P5026; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR JM, 1974, J BIOL CHEM, V249, P2188; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TITANI K, 1987, BIOCHEMISTRY-US, V26, P222, DOI 10.1021/bi00375a029; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	75	274	289	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 1	1991	67	3					469	481		10.1016/0092-8674(91)90522-Z	http://dx.doi.org/10.1016/0092-8674(91)90522-Z			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GN664	1840509				2022-12-28	WOS:A1991GN66400004
J	BEASLEY, CM; DORNSEIF, BE; BOSOMWORTH, JC; SAYLER, ME; RAMPEY, AH; HEILIGENSTEIN, JH; THOMPSON, VL; MURPHY, DJ; MASICA, DN				BEASLEY, CM; DORNSEIF, BE; BOSOMWORTH, JC; SAYLER, ME; RAMPEY, AH; HEILIGENSTEIN, JH; THOMPSON, VL; MURPHY, DJ; MASICA, DN			FLUOXETINE AND SUICIDE - A METAANALYSIS OF CONTROLLED TRIALS OF TREATMENT FOR DEPRESSION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DISORDER	Objective - A comprehensive meta-analysis of clinical trial data was performed to assess the possible association of fluoxetine and suicidality (suicidal acts and ideation). Design - Retrospective analysis of pooled data from 17 double blind clinical trials in patients with major depressive disorder comparing fluoxetine (n = 1765) with a tricyclic antidepressant (n = 731) or placebo (n = 569), or both. Main outcome measures - Multiple data sources were searched to identify patients with suicidal acts. Suicidal ideation was assessed with item 3 of the Hamilton depression rating scale, which systematically rates suicidality. Emergence of substantial suicidal ideation was defined as a change in the rating of this item from 0 or 1 at baseline to 3 or 4 during double blind treatment; worsening was defined as any increase from baseline; improvement was defined as a decrease from baseline at the last visit during the treatment. Results - Suicidal acts did not differ significantly in comparisons of fluoxetine with placebo (0.2% v 0.2%, p = 0.494, Mantel-Haenszel adjusted incidence difference) and with tricyclic antidepressants (0.7% v 0.4%, p = 0.419). The pooled incidence of suicidal acts was 0.3% for fluoxetine, 0.2% for placebo, and 0.4% for tricyclic antidepressants, and fluoxetine did not differ significantly from either placebo (p = 0.533, Pearson's chi-2) or tricyclic antidepressants (p = 0.789). Suicidal ideation emerged marginally significantly less often with fluoxetine than with placebo (0.9% v 2.6%, p = 0.094) and numerically less often than with tricyclic antidepressants (1.7% v 3.6%, p = 0.102). The pooled incidence of emergence of substantial suicidal ideation was 1.2% for fluoxetine, 2.6% for placebo, and 3.6% for tricyclic antidepressants. The incidence was significantly lower with fluoxetine than with placebo (p = 0.042) and tricyclic antidepressants (p = 0.001). Any degree of worsening of suicidal ideation was similar with fluoxetine and placebo (15.4% v 17.9%, p = 0.196) and with fluoxetine and tricyclic antidepressants (15.6% v 16.3%, p = 0.793). The pooled incidence of worsening of suicidal ideation was 15.3% for fluoxetine, 17.9% for placebo, and 16.3% for tricyclic antidepressants. The incidence did not differ significantly with fluoxetine and placebo (p = 0.141) or tricyclic antidepressants (p = 0.542). Suicidal ideation improved significantly more with fluoxetine than with placebo (72.0% v 54.8%, p < 0.001) and was similar to the improvement with tricyclic antidepressants (72.5% v 69.8%, p = 0.294). The pooled incidence of improvement of suicidal ideation was 72.2% for fluoxetine, 54.8% for placebo, and 69.8% for tricyclic antidepressants. The incidence with fluoxetine was significantly greater than with placebo (p < 0.001) and did not differ from that with tricyclic antidepressants (p = 0.296). Conclusion - Data from these trials do not show that fluoxetine is associated with an increased risk of suicidal acts or emergence of substantial suicidal thoughts among depressed patients.			BEASLEY, CM (corresponding author), ELI LILLY & CO, LILLY RES LAB, DIV CLIN NEUROSCI, LILLY CORP CTR 2128, INDIANAPOLIS, IN 46285 USA.		Beasley, Charles M./AAB-8141-2021	Beasley, Charles M./0000-0001-8743-7691				Black D.W., 1989, ANN CLIN PSYCHIATRY, V1, P165, DOI [10.3109/10401238909149975, DOI 10.3109/10401238909149975]; BLACK DW, 1990, SUICIDE LIFE CYCLE R, P135; BRENT DA, 1988, AM PSYCHIATRIC REV P, V7, P353; Buda M, 1990, SUICIDE LIFE CYCLE R, P17; DAMLUJI NF, 1988, J CLIN PSYCHOPHARM, V8, P347; DASGUPTA K, 1990, AM J PSYCHIAT, V147, P1570, DOI 10.1176/ajp.147.11.1570; FAVA M, 1991, J CLIN PSYCHIAT, V52, P108; FAWCETT J, 1990, AM J PSYCHIAT, V147, P1189; Fleiss JL, 1981, STATISTICAL METHODS, P61; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GUZE SB, 1970, BRIT J PSYCHIAT, V117, P437, DOI 10.1192/bjp.117.539.437; Hamilton M., 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [10.1111/j.2044-8260.1967.tb00530.x, DOI 10.1111/J.2044-8260.1967.TB00530.X]; HIRSCHFELD RMA, 1988, REV PSYCHIATRY, V7, P307; HOOVER CE, 1990, AM J PSYCHIAT, V147, P1570; HOOVER CE, 1991, AM J PSYCHIAT, V148, P542; JOHNSON J, 1990, ARCH GEN PSYCHIAT, V47, P805; KING RA, 1991, J AM ACAD CHILD PSY, V30, P179, DOI 10.1097/00004583-199103000-00003; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; MASAND P, 1991, NEW ENGL J MED, V324, P420; MUIJEN M, 1988, ACTA PSYCHIAT SCAND, V78, P384, DOI 10.1111/j.1600-0447.1988.tb06353.x; MURPHY GE, 1988, PSYCHIATRY UPDATE AM, P403; PAYKEL ES, 1974, BRIT J PSYCHIAT, V124, P460, DOI 10.1192/bjp.124.5.460; ROOSE SP, 1988, DEPRESSION MANIA, P76; ROUILLON F, 1989, Encephale, V15, P527; SACCHETTI E, 1991, INT C S SERIES, V165; SATO T, 1990, ENV HLTH PERSPECT, V37, P95; Spitzer R.L., 1984, RES DIAGNOSTIC CRITE; TALBOTT MW, 1987, J CLIN RES DRUG DEV, V1, P53; TEICHER MH, 1990, AM J PSYCHIAT, V147, P207; WAKELIN JS, 1988, ADV BIOL PSYCHIAT, V17, P70; 1989, STATXACT USER MANUAL; 1980, DIAGNOSTIC STATISTIC; 1985, SAS USERS GUIDE STAT	33	300	305	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	1991	303	6804					685	692		10.1136/bmj.303.6804.685	http://dx.doi.org/10.1136/bmj.303.6804.685			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1833012	Green Published, Bronze			2022-12-28	WOS:A1991GG98000021
J	BLOOM, DE; GLIED, S				BLOOM, DE; GLIED, S			BENEFITS AND COSTS OF HIV TESTING	SCIENCE			English	Article							IMMUNODEFICIENCY VIRUS HIV; UNITED-STATES; AIDS; MEN; PREVENTION; KNOWLEDGE; IMPACT; COHORT; TRIAL	The benefits and costs of human immunodeficiency virus (HIV) testing in employment settings are examined from two points of view: that of private employers whose profitability may be affected by their testing policies and that of public policy-makers who may affect social welfare through their design of regulations related to HIV testing. The results reveal that HIV testing is clearly not cost-beneficial for most firms, although the benefits of HIV testing may outweigh the costs for some large firms that offer generous fringe-benefit packages and that recruit workers from populations in which the prevalence of HIV infection is high. The analysis also indicates that the testing decisions of unregulated employers are not likely to yield socially optimal economic outcomes and that existing state and federal legislation related to HIV testing in employment settings has been motivated primarily by concerns over social equity.	COLUMBIA UNIV,SCH PUBL HLTH,NEW YORK,NY 10027; COLUMBIA UNIV,DEPT ECON,NEW YORK,NY 10027	Columbia University; Columbia University	BLOOM, DE (corresponding author), COLUMBIA UNIV,DEPT ECON,NEW YORK,NY 10027, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025914] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25914-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANTA WF, 1989, COMPLETE HDB COMBATT; BLOOM DE, 1988, SCIENCE, V239, P604, DOI 10.1126/science.3277273; BLOOM DE, 1989, HEALTH POLICY, V11, P187, DOI 10.1016/0168-8510(89)90035-3; BODEN LI, 1986, J OCCUP ENVIRON MED, V28, P751, DOI 10.1097/00043764-198608000-00040; BOWLEG IA, 1989, SUMMARY AIDS LAWS 19; Brown Charles, 1990, EMPLOYERS LARGE SMAL; BURKE DS, 1988, NEW ENGL J MED, V319, P961, DOI 10.1056/NEJM198810133191501; CATES W, 1988, AM J PUBLIC HEALTH, V78, P1533, DOI 10.2105/AJPH.78.12.1533; DECRESCE RP, 1989, DRUG TESTING WORKPLA; EDEN J, 1988, AIDS HLTH INSURANCE; FEHRS LJ, 1988, LANCET, V2, P379; GAIL MH, 1989, STAT MED, V8, P59, DOI 10.1002/sim.4780080108; GLIED S, 1990, THESIS HARVARD U; GOLDEN JA, 1989, LANCET, V1, P654; HAY JW, 1988, J ACQ IMMUN DEF SYND, V1, P466; KOTLIKOFF LJ, 1983, PENSIONS AM EC; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P1499; LEONARD AS, 1987, AIDS LAW GUIDE PUBLI, P109; LONG JE, 1982, REV ECON STAT, V64, P211, DOI 10.2307/1924300; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P462, DOI 10.2105/AJPH.78.4.462; MIIKE L, 1987, COMMUNICATION   1019; Ostrow D G, 1989, AIDS Educ Prev, V1, P1; Parsons D. O., 1986, HDB LABOR EC, V2, P789; RATCLIFFE JM, 1986, J OCCUP  MED, V28, P907; RUTHERFORD W, 1987, DEC PRES COMM HUM IM; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; TEWKSBURY RL, 1984, HDB EMPLOYEE BENEFIT, P678; TURNOCK BJ, 1989, JAMA-J AM MED ASSOC, V261, P23; VALDISERRI RO, 1988, AM J PUBLIC HEALTH, V78, P801, DOI 10.2105/AJPH.78.7.801; VANDENHOEK JAR, 1989, AM J PUBLIC HEALTH, V79, P1355, DOI 10.2105/AJPH.79.10.1355; VANGRIENSVEN GJP, 1989, AM J EPIDEMIOL, V129, P596; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1987, MORB MORTAL WKLY REP, V38, pS6; 1990, SCIENCE, V249, P20; 1988, HLTH US 1987; 1989, PROTECTION AIDS RELA; 1990, HIV AIDS SURVEIL NOV; NIH ND2591401 GRANT; 1988, FORTUNE; 1987, HOUSEHD EC STUD P70; 1988, JAMA-J AM MED ASSOC, V260, P935; 1986, BUR LABOR STAT B, V2262; 1990, STATISTICAL ABSTRACT; 1989, MORB MORTAL WKLY REP, V38, pS4; 1987, HLTH CARE COVERAGE C	45	30	30	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1798	1804		10.1126/science.1829547	http://dx.doi.org/10.1126/science.1829547			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FU061	1829547				2022-12-28	WOS:A1991FU06100028
J	ORGAN, CH; HENDERSON, VJ				ORGAN, CH; HENDERSON, VJ			SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXTRACORPOREAL MEMBRANE-OXYGENATION; PERSISTENT PULMONARY-HYPERTENSION; LUNG TRANSPLANTATION; COLORECTAL CANCERS; CHOLECYSTECTOMY; IDENTIFICATION; LASER				ORGAN, CH (corresponding author), UNIV CALIF DAVIS E BAY,OAKLAND,CA, USA.							BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CAMERON JL, 1991, ANN SURG, V213, P1; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CHIU ES, 1990, SURG FORUM, V41, P636; COOPER JD, 1990, ANN SURG, V212, P249, DOI 10.1097/00000658-199009000-00003; DWORETZ AR, 1989, PEDIATRICS, V84, P1; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FOGLIA RP, 1990, ARCH SURG-CHICAGO, V125, P1286; HARRISON MR, 1990, NEW ENGL J MED, V322, P1582, DOI 10.1056/NEJM199005313222207; HOWE JR, 1990, SURG FORUM, V41, P447; LYNCH HT, 1990, ARCH SURG-CHICAGO, V125, P698; MILLER F, 1990, SURG FORUM, V41, P461; MOURET P, 1990, BRIT J SURG, V77, P1006, DOI 10.1002/bjs.1800770916; OROURKE PP, 1989, PEDIATRICS, V84, P957; ORROM WJ, 1990, DIS COLON RECTUM, V33, P490, DOI 10.1007/BF02052144; PETERS JH, 1991, ANN SURG, V213, P3, DOI 10.1097/00000658-199101000-00002; RAJU S, 1990, ANN SURG, V211, P681, DOI 10.1097/00000658-199006000-00006; REDDICK EJ, 1990, AM J SURG, V160, P485, DOI 10.1016/S0002-9610(05)81009-8; SCHUELER S, 1990, SURG FORUM, V41, P405; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOYLES CR, 1990, AM J SURG, V160, P457, DOI 10.1016/S0002-9610(05)81001-3	21	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3172	3175						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	1828274				2022-12-28	WOS:A1991FQ77000043
J	WARMKE, J; DRYSDALE, R; GANETZKY, B				WARMKE, J; DRYSDALE, R; GANETZKY, B			A DISTINCT POTASSIUM CHANNEL POLYPEPTIDE ENCODED BY THE DROSOPHILA-EAG LOCUS	SCIENCE			English	Article							PROTEIN-KINASE-C; RAT-BRAIN; SUBSTRATE-SPECIFICITY; SHAKER MUTANTS; ION CHANNELS; GENE FAMILY; CLONING; EXPRESSION; SEQUENCE; MOUSE	Many of the signaling properties of neurons and other electrically excitable cells are determined by a diverse family of potassium channels. A number of genes that encode potassium channel polypeptides have been cloned from various organisms on the basis of their sequence similarity to the Drosophila Shaker (Sh) locus. As an alternative strategy, a molecular analysis of other Drosophila genes that were defined by mutations that perturb potassium channel function was undertaken. Sequence analysis of complementary DNA from the ether a go-go (eag) locus revealed that it encodes a structural component of potassium channels that is related to but is distinct from all identified potassium channel polypeptides.	UNIV WISCONSIN, GENET LAB, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison				Drysdale, Rachel/0000-0003-3037-0216	NIGMS NIH HHS [T32GM07131] Funding Source: Medline; NINDS NIH HHS [NS15390] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015390] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRYSDALE R, 1991, GENETICS, V127, P497; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GANETZKY B, 1985, TRENDS NEUROSCI, V8, P322, DOI 10.1016/0166-2236(85)90113-4; Ganetzky B, 1983, J NEUROGENET, V1, P17, DOI 10.3109/01677068309107069; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KAPLAN WD, 1969, GENETICS, V61, P399; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK T, 1990, P NATL ACAD SCI USA, V87, P5227, DOI 10.1073/pnas.87.13.5227; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; SALKOFF L, 1981, NATURE, V293, P228, DOI 10.1038/293228a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; WU CF, 1985, J NEUROSCI, V5, P2626; WU CF, 1983, SCIENCE, V220, P1076, DOI 10.1126/science.6302847; WU CF, 1986, NEUROTOX 88 MOL BASI, P311; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZHONG Y, 1991, SCIENCE, V252, P1562, DOI 10.1126/science.2047864	41	290	300	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	1991	252	5012					1560	1562		10.1126/science.1840699	http://dx.doi.org/10.1126/science.1840699			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR040	1840699				2022-12-28	WOS:A1991FR04000051
J	STRAUSFELD, U; LABBE, JC; FESQUET, D; CAVADORE, JC; PICARD, A; SADHU, K; RUSSELL, P; DOREE, M				STRAUSFELD, U; LABBE, JC; FESQUET, D; CAVADORE, JC; PICARD, A; SADHU, K; RUSSELL, P; DOREE, M			DEPHOSPHORYLATION AND ACTIVATION OF A P34CDC2 CYCLIN-B COMPLEX INVITRO BY HUMAN CDC25 PROTEIN	NATURE			English	Article							M-PHASE; FISSION YEAST; TYROSINE PHOSPHORYLATION; PERIODIC ACTIVATION; POSSIBLE MECHANISM; MITOTIC INDUCER; KINASE; PURIFICATION; STARFISH; MITOSIS	OOCYTES arrested in the G2 phase of the cell cycle contain a p34cdc2/cyclin B complex which is kept in an inactive form by phosphorylation of its p34cdc2 subunit on tyrosine, threonine and perhaps serine residues (see refs 1 and 2 for review). The phosphatase(s) involved in p34cdc2 dephosphorylation is unknown, but the product of the fission yeast cdc25+ gene 3,4, and its homologues in budding yeast 5 and Drosophila 6 are probably positive regulators of the transition from G2 to M phase. We have purified the inactive p34cdc2/cyclin B complex from G2-arrested starfish oocytes. Addition of the purified bacterially expressed product of the human homologue of the fission yeast cdc25+ gene 7 (p54CDC25H) triggers p34cdc2 dephosphorylation and activates H1 histone kinase activity in this preparation. We propose that the cdc25+ gene product directly activates the p34cdc2-cyclin B complex.	LAB ARAGO, F-66650 BANYULS SUR MER, FRANCE; Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; INSERM, F-34033 MONTPELLIER, FRANCE	Scripps Research Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	STRAUSFELD, U (corresponding author), CNRS, BP 5051, F-34033 MONTPELLIER, FRANCE.		Fesquet, didier/M-9750-2019; labbe, jean-claude/B-2277-2009; Fesquet, Didier/A-1490-2009	Fesquet, didier/0000-0001-5657-9689; 				Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; GOULD K, 1991, NATURE, V250, P1573; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LABBE JC, 1988, DEV BIOL, V127, P157, DOI 10.1016/0012-1606(88)90197-2; LABBE JC, IN PRESS METH ENZYM; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; TONKS NK, 1988, J BIOL CHEM, V263, P6722	21	532	550	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1991	351	6323					242	245		10.1038/351242a0	http://dx.doi.org/10.1038/351242a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	1828290				2022-12-28	WOS:A1991FL99000060
J	LOTURCO, JJ; KRIEGSTEIN, AR				LOTURCO, JJ; KRIEGSTEIN, AR			CLUSTERS OF COUPLED NEUROBLASTS IN EMBRYONIC NEOCORTEX	SCIENCE			English	Article							GAP JUNCTIONAL COMMUNICATION; MAMMALIAN CEREBRAL-CORTEX; SINGLE-CHANNEL CURRENTS; FETAL MONKEY NEOCORTEX; VISUAL-CORTEX; RECOMBINANT RETROVIRUS; CORTICAL-NEURONS; MIGRATION; TRANSPLANTATION; GUIDANCE	The neocortex of the brain develops from a simple germinal layer into a complex multilayer structure. To investigate cellular interactions during early neocortical development, whole-cell patch clamp recordings were made from neuroblasts in the ventricular zone of fetal rats. During early corticogenesis, neuroblasts are physiologically coupled by gap junctions into clusters of 15 to 90 cells. The coupled cells form columns within the ventricular zone and, by virtue of their membership in clusters, have low apparent membrane resistances and generate large responses to the inhibitory neurotransmitter gamma-aminobutyric acid. As neuronal migration out of the ventricular zone progresses, the number of cells within the clusters decreases. These clusters allow direct cell to cell interaction at the earliest stages of corticogenesis.			LOTURCO, JJ (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL & NEUROSURG,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021223, P01NS012151, P50NS012151] Funding Source: NIH RePORTER; NINDS NIH HHS [NS12151, NS07280, NS21223] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; BARFIELD J A, 1990, Society for Neuroscience Abstracts, V16, P1272; BERRY M, 1965, J ANAT, V99, P691; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLANTON MG, 1990, P NATL ACAD SCI USA, V87, P8027, DOI 10.1073/pnas.87.20.8027; CONNORS BW, 1984, J NEUROSCI, V4, P1324; DERMIETZEL R, 1989, P NATL ACAD SCI USA, V86, P10148, DOI 10.1073/pnas.86.24.10148; GILULA NB, 1972, NATURE, V235, P262, DOI 10.1038/235262a0; GOODALL H, 1984, J EMBRYOL EXP MORPH, V79, P53; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; GUTHRIE SC, 1989, TRENDS NEUROSCI, V12, P12, DOI 10.1016/0166-2236(89)90150-1; GUTNICK MJ, 1981, SCIENCE, V211, P67, DOI 10.1126/science.7444449; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; JENSEN KF, 1984, P NATL ACAD SCI-BIOL, V81, P964, DOI 10.1073/pnas.81.3.964; JONES EG, 1975, SCIENCE, V190, P572, DOI 10.1126/science.810887; KAZNOWSKI CE, 1990, SOC NEUR ABSTR, V16, P1272; KRIEGSTEIN A R, 1990, Society for Neuroscience Abstracts, V16, P57; LEE S, 1987, CELL, V51, P851, DOI 10.1016/0092-8674(87)90108-5; LOTURCO JJ, IN PRESS J NEUROSCI; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCCONNELL SK, 1985, SCIENCE, V229, P1268, DOI 10.1126/science.4035355; Miller M, 1988, DEV MATURATION CEREB, V7, P133; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; PETERS A, 1975, J ANAT EMBRYOL, V141, P3; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1978, POSTGRAD MED J, V54, P25; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; RAKIC P, 1975, BRAIN MECHANISMS MEN, P3; ROBERTSON JD, 1963, J CELL BIOL, V19, P201, DOI 10.1083/jcb.19.1.201; SIDMAN RL, 1959, EXP NEUROL, V1, P322, DOI 10.1016/0014-4886(59)90024-X; SIMPSON I, 1977, SCIENCE, V195, P294, DOI 10.1126/science.831276; SOMOGYI P, 1989, J NEUROSCI, V9, P2197; TURIN L, 1980, J PHYSIOL-LONDON, V300, P489, DOI 10.1113/jphysiol.1980.sp013174; VEENSTRA RD, 1986, SCIENCE, V233, P972, DOI 10.1126/science.2426781	41	277	279	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					563	566		10.1126/science.1850552	http://dx.doi.org/10.1126/science.1850552			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850552				2022-12-28	WOS:A1991FJ12700046
J	SOUHAMI, RL; SPIRO, SG; CULLEN, M				SOUHAMI, RL; SPIRO, SG; CULLEN, M			CHEMOTHERAPY AND RADIATION-THERAPY AS COMPARED WITH RADIATION-THERAPY IN STAGE-III NON-SMALL-CELL CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									UNIV COLL HOSP LONDON,WC1 LONDON,ENGLAND; QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University College London Hospitals NHS Foundation Trust; University of Birmingham	SOUHAMI, RL (corresponding author), UNIV COLL & MIDDLESEX SCH MED,LONDON W2P 8BT,ENGLAND.							DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403; HUGHES MD, 1988, STAT MED, V7, P1231, DOI 10.1002/sim.4780071204; TANNOCK IF, 1990, NEW ENGL J MED, V323, P989, DOI 10.1056/NEJM199010043231410	3	10	10	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1136	1136						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	1848918				2022-12-28	WOS:A1991FG91200019
J	ENNALS, S				ENNALS, S			UNDERSTANDING BENEFITS - INDUSTRIAL INJURIES BENEFITS	BRITISH MEDICAL JOURNAL			English	Article											ENNALS, S (corresponding author), ESSENTIAL RIGHTS,94 CHAWORTH RD,NOTTINGHAM NG2 7AD,ENGLAND.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					400	401		10.1136/bmj.302.6773.400	http://dx.doi.org/10.1136/bmj.302.6773.400			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	1825930	Green Published, Bronze			2022-12-28	WOS:A1991EX85800032
J	CHRISTIAN, TF; CLEMENTS, IP; BEHRENBECK, T; HUBER, KC; CHESEBRO, JH; GERSH, BJ; GIBBONS, RJ				CHRISTIAN, TF; CLEMENTS, IP; BEHRENBECK, T; HUBER, KC; CHESEBRO, JH; GERSH, BJ; GIBBONS, RJ			LIMITATIONS OF THE ELECTROCARDIOGRAM IN ESTIMATING INFARCTION SIZE AFTER ACUTE REPERFUSION THERAPY FOR MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article							QRS SCORING SYSTEM; INTRA-CORONARY THROMBOLYSIS; WASHINGTON INTRAVENOUS STREPTOKINASE; VENTRICULAR EJECTION FRACTION; TECHNETIUM-99M ISONITRILE; ARTERY DISEASE; ANGIOPLASTY; TRIAL; SURVIVAL; SALVAGE	Objective: To assess the ability of the 12-lead electrocardiogram to estimate infarction size after reperfusion therapy for acute myocardial infarction. Design: The presence or absence of Q waves and the Selvester QRS score obtained before and after hospital discharge were compared with radionuclide estimates of infarction size and ejection fraction at discharge and 6 weeks later, regional wall motion at discharge and 6 weeks later, and myocardial perfusion defect size quantitated with Tc-99m-sestamibi at discharge. Setting: A tertiary referral center. Patients: A consecutive series of 43 patients with acute myocardial infarction who received acute reperfusion therapy and were assessed using 12-lead electrocardiography, radionuclide angiography, and Tc-99m-sestamibi tomographic imaging before discharge. Interventions: All 43 patients received acute reperfusion therapy: 21 patients received intravenous tissue plasminogen activator, and 22 patients underwent primary percutaneous transluminal coronary angioplasty. Main Outcome Measure: The correlation of QRS score and Q waves with three radionuclide estimates of infarction size. Results: A significant correlation was found between myocardial perfusion defect size at discharge and both left ventricular ejection fraction and regional wall motion at discharge and 6 weeks later (r = -0.71 to -0.81; all comparisons, P < 0.001). Little correlation was found between electrocardiographic findings and radionuclide measurements of left ventricular function and perfusion. Presence or absence of Q waves at discharge was not associated with any difference in ejection fraction, regional wall motion, or perfusion defect at discharge. No correlation was found between QRS score and ejection fraction or myocardial perfusion defect size at discharge. The QRS score at discharge correlated only weakly with regional wall motion at discharge and 6 weeks later. This lack of correlation was unchanged when electrocardiograms obtained after hospital discharge were analyzed. Conclusion: Although inexpensive and readily available, the 12-lead electrocardiogram does not appear to provide a reliable estimate of infarction size after reperfusion therapy for acute myocardial infarction.			CHRISTIAN, TF (corresponding author), MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA.							ANDERSON WD, 1988, AM J CARDIOL, V61, P729, DOI 10.1016/0002-9149(88)91056-9; ASKENAZI J, 1978, AM J CARDIOL, V41, P494, DOI 10.1016/0002-9149(78)90005-X; BELLER GA, 1977, CARDIOVASC RES, V11, P489, DOI 10.1093/cvr/11.6.489; BLUMENTHAL MR, 1975, AM J CARDIOL, V36, P225, DOI 10.1016/0002-9149(75)90531-7; CALLAHAN RJ, 1982, J NUCL MED, V23, P315; COWAN M, 1987, J ELECTROCARDIOL, V20, P78; DALEN JE, 1988, AM J CARDIOL, V62, P179, DOI 10.1016/0002-9149(88)90208-1; GANZ W, 1981, AM HEART J, V101, P4, DOI 10.1016/0002-8703(81)90376-8; GIBBONS RJ, 1989, CIRCULATION, V80, P1277, DOI 10.1161/01.CIR.80.5.1277; GIBBONS RJ, 1988, J AM COLL CARDIOL, V11, P28, DOI 10.1016/0735-1097(88)90162-3; GOLDHABER SZ, 1983, CIRCULATION, V67, P778, DOI 10.1161/01.CIR.67.4.778; GOLDSMITH SR, 1983, CIRCULATION, V68, P77; GROTTUM P, 1987, J ELECTROCARDIOL, V20, P81; HACKWORTHY RA, 1986, BRIT HEART J, V56, P222; HINDMAN N, 1986, AM J CARDIOL, V58, P31, DOI 10.1016/0002-9149(86)90236-5; HOGG KJ, 1989, BRIT HEART J, V61, P489; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; MACHAC J, 1989, J AM COLL CARDIOL, V14, P1685, DOI 10.1016/0735-1097(89)90016-8; MADDAHI J, 1981, AM HEART J, V102, P664, DOI 10.1016/0002-8703(81)90091-0; MARKIS JE, 1981, NEW ENGL J MED, V305, P777, DOI 10.1056/NEJM198110013051401; MIKELL FL, 1986, AM J CARDIOL, V57, P923, DOI 10.1016/0002-9149(86)90731-9; MILLER RR, 1974, CIRCULATION, V49, P447, DOI 10.1161/01.CIR.49.3.447; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; NESTICO PF, 1984, AM J CARDIOL, V53, P359, DOI 10.1016/0002-9149(84)90468-5; OCONNOR MK, 1990, EUR J NUCL MED, V17, P69, DOI 10.1007/BF00819407; OKADA RD, 1988, CIRCULATION, V77, P491, DOI 10.1161/01.CIR.77.2.491; ONEILL W, 1986, NEW ENGL J MED, V314, P812, DOI 10.1056/NEJM198603273141303; PALMERI ST, 1982, NEW ENGL J MED, V306, P4, DOI 10.1056/NEJM198201073060102; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; POPE JE, 1988, AM J CARDIOL, V61, P734, DOI 10.1016/0002-9149(88)91057-0; RITCHIE JL, 1988, J AM COLL CARDIOL, V11, P689, DOI 10.1016/0735-1097(88)90197-0; ROCCO TP, 1989, J AM COLL CARDIOL, V14, P1678, DOI 10.1016/0735-1097(89)90015-6; SAVAGE RM, 1977, CIRCULATION, V55, P279, DOI 10.1161/01.CIR.55.2.279; SIMOONS ML, 1982, EUR HEART J, V3, P433, DOI 10.1093/oxfordjournals.eurheartj.a061329; SIMOONS ML, 1986, J AM COLL CARDIOL, V7, P717, DOI 10.1016/S0735-1097(86)80329-1; SINUSAS AJ, 1989, J AM COLL CARDIOL, V14, P1785, DOI 10.1016/0735-1097(89)90034-X; STACK RS, 1988, J AM COLL CARDIOL, V11, P1141, DOI 10.1016/0735-1097(88)90274-4; TILLISCH J, 1986, NEW ENGL J MED, V314, P884, DOI 10.1056/NEJM198604033141405; VERANI MS, 1988, J AM COLL CARDIOL, V12, P1573, DOI 10.1016/S0735-1097(88)80028-7; VLIETSTRA RE, 1981, MAYO CLIN PROC, V56, P287; VONESSEN R, 1985, BRIT HEART J, V54, P6; WACKERS FJT, 1989, J AM COLL CARDIOL, V14, P861, DOI 10.1016/0735-1097(89)90456-7; WAGNER GS, 1982, CIRCULATION, V65, P342, DOI 10.1161/01.CIR.65.2.342; YUSUF S, 1979, BRIT HEART J, V42, P286; 1987, LANCET, V1, P871; 1987, LANCET, V1, P502	47	40	40	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1991	114	4					264	270		10.7326/0003-4819-114-4-264	http://dx.doi.org/10.7326/0003-4819-114-4-264			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX521	1824812				2022-12-28	WOS:A1991EX52100002
J	ROTZLER, S; SCHRAMEK, H; BRENNER, HR				ROTZLER, S; SCHRAMEK, H; BRENNER, HR			METABOLIC STABILIZATION OF END-PLATE ACETYLCHOLINE-RECEPTORS REGULATED BY CA2+ INFLUX ASSOCIATED WITH MUSCLE-ACTIVITY	NATURE			English	Article							MAMMALIAN SKELETAL-MUSCLE; CA-2+ CHANNELS; CALCIUM CURRENTS; MEMBRANE; DEGRADATION; RYANODINE; CELLS; ENANTIOMERS; DENERVATION; FRACTION	DURING formation of the neuromuscular junction, acetylcholine receptors in the endplate membrane become matabolically stabilized under neural control, their half-life increasing from about 1 day to about 10 days (see ref. 1 for review). The metabolic stability of the receptors is regulated by the electrical activity induced in the muscle by innervation 2-4. We report here that metabolic stabilization of endplate receptors but not of extrajunctional receptors can be induced in the absence of muscle activity if muscles are treated with the calcium ionophore A23187. Acetylcholine receptor stabilization was also induced by culturing non-stimulated muscle in elevated K+ with the Ca2+ channel activator (+)-SDZ202-791. Conversely, activity-dependent receptor stabilization is prevented in muscle stimulated in the presence of the Ca2+ channel blockers (+)-PN200-110 or D-600. Treatment of muscles with ryanodine, which induces Ca2+ release from the sarcoplasmic reticulum in the absence of activity, does not cause stabilization of junctional receptors. Evidently, muscle activity induces metabolic acetylcholine receptor stabilization by way of an influx of Ca2+ ions through dihydropyridine-sensitive Ca2+ channels in the endplate membrane, whereas Ca2+ released from the sarcoplasmic reticulum is ineffective in this developmental process.	UNIV BASEL,DEPT PHYSIOL,VESALGASSE 1,CH-4051 BASEL,SWITZERLAND	University of Basel								BEAM KG, 1988, J GEN PHYSIOL, V91, P799, DOI 10.1085/jgp.91.6.799; BEAM KG, 1988, J GEN PHYSIOL, V91, P781, DOI 10.1085/jgp.91.6.781; BEVAN S, 1983, J PHYSIOL-LONDON, V336, P159, DOI 10.1113/jphysiol.1983.sp014574; BRENNER HR, 1989, J PHYSIOL-LONDON, V410, P501, DOI 10.1113/jphysiol.1989.sp017546; COGNARD C, 1986, P NATL ACAD SCI USA, V83, P517, DOI 10.1073/pnas.83.2.517; COGNARD C, 1986, P NATL ACAD SCI USA, V83, P1518, DOI 10.1073/pnas.83.5.1518; FAIRHURST AS, 1970, EUR J BIOCHEM, V13, P504, DOI 10.1111/j.1432-1033.1970.tb00953.x; FAIRHURST AS, 1974, AM J PHYSIOL, V227, P1124, DOI 10.1152/ajplegacy.1974.227.5.1124; FUMAGALLI G, 1990, NEURON, V4, P563, DOI 10.1016/0896-6273(90)90114-U; HARRIS JB, 1971, ACTA PHYSIOL SCAND, V83, P382, DOI 10.1111/j.1748-1716.1971.tb05091.x; HOF RP, 1985, J CARDIOVASC PHARM, V7, P689, DOI 10.1097/00005344-198507000-00012; JENDEN DJ, 1969, PHARMACOL REV, V21, P1; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; KOKUBUN S, 1986, MOL PHARMACOL, V30, P571; LEVITT TA, 1981, NATURE, V291, P239, DOI 10.1038/291239a0; LINDEN DC, 1979, NEUROSCIENCE, V4, P527, DOI 10.1016/0306-4522(79)90129-5; MCCLESKEY EW, 1985, J PHYSIOL-LONDON, V361, P231, DOI 10.1113/jphysiol.1985.sp015643; MILEDI R, 1980, J PHYSIOL-LONDON, V300, P197, DOI 10.1113/jphysiol.1980.sp013158; PAPPONE PA, 1980, J PHYSIOL-LONDON, V306, P377, DOI 10.1113/jphysiol.1980.sp013403; PEZZEMENTI L, 1981, J BIOL CHEM, V256, P2651; ROTZLER S, 1990, J CELL BIOL, V111, P655, DOI 10.1083/jcb.111.2.655; SALPETER MM, 1986, J CELL BIOL, V103, P1399, DOI 10.1083/jcb.103.4.1399; SALPETER MM, 1985, PROG NEUROBIOL, V25, P297, DOI 10.1016/0301-0082(85)90018-8; SCHMID A, 1984, FEBS LETT, V172, P114, DOI 10.1016/0014-5793(84)80885-6; SCHMIDT J, 1973, ANAL BIOCHEM, V52, P349, DOI 10.1016/0003-2697(73)90036-5; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0	26	58	58	5	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					337	339		10.1038/349337a0	http://dx.doi.org/10.1038/349337a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1846230				2022-12-28	WOS:A1991EU50100055
J	TRUJILLO, KA; AKIL, H				TRUJILLO, KA; AKIL, H			INHIBITION OF MORPHINE-TOLERANCE AND DEPENDENCE BY THE NMDA RECEPTOR ANTAGONIST MK-801	SCIENCE			English	Article							ANALGESIC TOLERANCE; LOCUS COERULEUS; MECHANISMS; NEURONS; RATS	The N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor is an important mediator of several forms of neural and behavioral plasticity. The present studies examined whether NMDA receptors might be involved in the development of opiate tolerance and dependence, two examples of behavioral plasticity. The noncompetitive NMDA receptor antagonist MK-801 attenuated the development of tolerance to the analgesic effect of morphine without affecting acute morphine analgesia. In addition, MK-801 attenuated the development of morphine dependence as assessed by nalox-one-precipitated withdrawal. These results suggest that NMDA receptors may be important in the development of opiate tolerance and dependence.			TRUJILLO, KA (corresponding author), UNIV MICHIGAN, MENTAL HLTH RES INST, 205 WASHTENAW PL, ANN ARBOR, MI 48109 USA.		Trujillo, Keith/E-8427-2012	Trujillo, Keith/0000-0002-8059-6347	NIDA NIH HHS [DA05336, DA02265] Funding Source: Medline; NIMH NIH HHS [MH422251] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002265, F32DA005336] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AGHAJANIAN GK, 1978, NATURE, V276, P186, DOI 10.1038/276186a0; ANDRADE R, 1983, EUR J PHARMACOL, V91, P161, DOI 10.1016/0014-2999(83)90461-2; BAKER TB, 1985, PSYCHOL REV, V92, P78, DOI 10.1037/0033-295X.92.1.78; BLASIG J, 1973, PSYCHOPHARMACOLOGIA, V33, P19; BUCHAN A, 1990, J NEUROSCI, V10, P311; Christie M J, 1987, NIDA Res Monogr, V78, P158; CHRISTIE MJ, 1987, MOL PHARMACOL, V32, P633; CLOUET DH, 1975, ANNU REV PHARMACOL, V15, P49, DOI 10.1146/annurev.pa.15.040175.000405; COLLIER HOJ, 1980, NATURE, V283, P625, DOI 10.1038/283625a0; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; CRISWELL HE, 1990, BRAIN RES, V512, P284, DOI 10.1016/0006-8993(90)90638-R; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; DAFTERS R, 1989, BEHAV NEUROSCI, V103, P1082, DOI 10.1037/0735-7044.103.5.1082; FRANCIS DL, 1971, BRIT J PHARMACOL, V41, pP424; Goudie A. J., 1986, BEHAVIORAL BASIS DRU, P225; HARRIS LS, 1964, J PHARMACOL EXP THER, V143, P141; JOHNSON SM, 1989, PHARMACOL REV, V41, P435; KARLER R, 1989, LIFE SCI, V45, P599, DOI 10.1016/0024-3205(89)90045-3; LEWIS JW, 1987, BRAIN RES, V424, P65, DOI 10.1016/0006-8993(87)91193-0; NEHLS DG, 1990, BRAIN RES, V511, P271, DOI 10.1016/0006-8993(90)90172-8; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; RASMUSSEN K, 1989, BRAIN RES, V505, P346, DOI 10.1016/0006-8993(89)91466-2; RAY BA, 1988, NIDA RES MONOGR, V84; SHARP CW, 1984, NIDA RES MONOGR, V54; SIEGEL S, 1976, SCIENCE, V193, P323, DOI 10.1126/science.935870; Siegel S., 1983, RES ADV ALCOHOL DRUG, V7, P207; TIFFANY ST, 1988, BEHAV NEUROSCI, V102, P534, DOI 10.1037/0735-7044.102.4.534; TUNG CS, 1990, ACTA PHYSIOL SCAND, V138, P581, DOI 10.1111/j.1748-1716.1990.tb08888.x; WATKINS JC, 1989, NMDA RECEPTOR; WEI E, 1973, PSYCHOPHARMACOLOGIA, V28, P35, DOI 10.1007/BF00413955; WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611; WIKLER A, 1948, AM J PSYCHIAT, V105, P329, DOI 10.1176/ajp.105.5.329; WIKLER A, 1976, PAVLOVIAN J BIOL SCI, V11, P191	34	1065	1113	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 4	1991	251	4989					85	87		10.1126/science.1824728	http://dx.doi.org/10.1126/science.1824728			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1824728				2022-12-28	WOS:A1991EQ60300033
J	GALAKTIONOV, K; BEACH, D				GALAKTIONOV, K; BEACH, D			SPECIFIC ACTIVATION OF CDC25 TYROSINE PHOSPHATASES BY B-TYPE CYCLINS - EVIDENCE FOR MULTIPLE ROLES OF MITOTIC CYCLINS	CELL			English	Article							MATURATION-PROMOTING FACTOR; P34CDC2 PROTEIN-KINASE; HISTONE H-1 KINASE; SEA-URCHIN EGGS; FISSION YEAST; CELL-CYCLE; MESSENGER-RNA; M-PHASE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE	Two previously unidentified human cdc25 genes have been isolated, cdc25A and cdc25B. Both genes rescue a cdc25ts mutant of fission yeast. Microinjection of anti-cdc25A antibodies into HeLa cells causes their arrest in mitosis. cdc25A and cdc25B display endogenous tyrosine phosphatase activity that is stimulated several-fold, in the absence of cdc2, by stoichiometric addition of either cyclin B1 or B2 but not A or D1. Association between cdc25A and cyclin B1/cdc2 was detected in the HeLa cells. These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the cdc2 protein kinase, but also activate the cdc25 tyrosine phosphatase, of which cdc2 is the physiological substrate. A region of amino acid similarity between cyclins and tyrosine PTPases has been detected. This region is absent in cdc25 phosphatases. The motif may represent an activating domain that has to be provided to cdc25 by intermolecular interaction with cyclin B.			GALAKTIONOV, K (corresponding author), COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA.				NIGMS NIH HHS [GM39620] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039620] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FANTES P, 1979, NATURE, V279, P428, DOI 10.1038/279428a0; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HAYLES J, 1987, MOL CELL BIOL, V7, P504; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; JESSUS C, 1992, IN PRESS CELL, V68; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	85	478	500	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1181	1194		10.1016/0092-8674(91)90294-9	http://dx.doi.org/10.1016/0092-8674(91)90294-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1836978				2022-12-28	WOS:A1991GX16400016
J	KOES, BW; ASSENDELFT, WJJ; VANDERHEIJDEN, GJMG; BOUTER, LM; KNIPSCHILD, PG				KOES, BW; ASSENDELFT, WJJ; VANDERHEIJDEN, GJMG; BOUTER, LM; KNIPSCHILD, PG			SPINAL MANIPULATION AND MOBILIZATION FOR BACK AND NECK PAIN - A BLINDED REVIEW	BRITISH MEDICAL JOURNAL			English	Review							CLINICAL-TRIALS; THERAPY; MOBILIZATION; MANAGEMENT; SCIATICA	Objective - To assess the efficacy of spinal manipulation for patients with back or neck pain. Design - Computer aided search for published papers and blinded assessment of the methods of the studies. Subjects - 35 randomised clinical trials comparing spinal manipulation with other treatments. Main outcome measures - Score for quality of methods (based on four main categories: study population, interventions, measurement of effect, and data presentation and analysis) and main conclusion of author(s) with regard to spinal manipulation. Results - No trial scored 60 or more points (maximum score 100) suggesting that most were of poor quality. Eighteen studies (51%) showed favourable results for manipulation. In addition, five studies (140/o) reported positive results in one or more subgroups. Of the four studies with 50-60 points, one reported that manipulation was better, two reported that manipulation was better in only a subgroup, and one reported that manipulation was no better or worse than reference treatment. Eight trials attempted to compare manipulation with some placebo, with inconsistent results. Conclusions - Although some results are promising, the efficacy of manipulation has not been convincingly shown. Further trials are needed, but much more attention should be paid to the methods of study.			KOES, BW (corresponding author), UNIV LIMBURG,DEPT EPIDEMIOL & BIOSTAT,POB 616,6200 MD MAASTRICHT,NETHERLANDS.		Koes, Bart w/K-4614-2016; assendelft, willem/AAW-1854-2021; Assendelft, W.J.J./H-8008-2014	Koes, Bart w/0000-0002-0450-9969; assendelft, willem/0000-0002-2966-3778; Assendelft, W.J.J./0000-0002-2966-3778; Bouter, Lex/0000-0002-2659-5482				ARKUSZEWSKI Z, 1986, MANUAL MED, V2, P68; BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S, V170, P11; BRODIN H, 1984, INT J REHABIL RES, V7, P190, DOI 10.1097/00004356-198406000-00008; BRODIN H, 1983, MED PHYS, V6, P67; Bronfort G., 1989, AM J CHIROPRACTIC ME, V2, P145; BRUNARSKI DJ, 1984, J MANIP PHYSIOL THER, V7, P243; BUERGER AA, 1980, MANUAL MED, V2, P17; COXHEAD CE, 1981, LANCET, V1, P1065; DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DIFABIO RP, 1986, PHYS THER, V66, P51, DOI 10.1093/ptj/66.1.51; DORAN DML, 1975, BRIT MED J, V2, P161, DOI 10.1136/bmj.2.5964.161; EVANS DP, 1978, RHEUMATOL REHABIL, V17, P46, DOI 10.1093/rheumatology/17.1.46; FARRELL JP, 1982, MED J AUSTRALIA, V1, P160, DOI 10.5694/j.1326-5377.1982.tb132242.x; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; GATTERMAN MI, 1990, CHIROPRACTIC MANAGEM, P37; GIBSON T, 1985, LANCET, V1, P1258; GLOVER JR, 1974, BRIT J IND MED, V31, P59; GODFREY CM, 1984, SPINE, V9, P301, DOI 10.1097/00007632-198404000-00015; GREENLAND S, 1980, J OCCUP ENVIRON MED, V22, P670, DOI 10.1097/00043764-198010000-00014; HADLER NM, 1987, SPINE, V12, P703, DOI 10.1097/00007632-198709000-00012; Helliwell PS, 1987, PHYSICIAN        APR, P187; HOEHLER FK, 1981, JAMA-J AM MED ASSOC, V245, P1835, DOI 10.1001/jama.245.18.1835; HOWE DH, 1983, J ROY COLL GEN PRACT, V33, P574; JAYSON MIV, 1981, SPINE, V6, P409, DOI 10.1097/00007632-198107000-00012; KELSEY JL, 1980, SPINE, V5, P133, DOI 10.1097/00007632-198003000-00007; KINALSKI R, 1989, MANUAL MED, V4, P44; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; MACDONALD RS, 1990, SPINE, V15, P364, DOI 10.1097/00007632-199005000-00005; MATHEWS JA, 1987, BRIT J RHEUMATOL, V26, P416; MATHEWS W, 1988, Physiotherapy Practice, V4, P201; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; MEALY K, 1986, BRIT MED J, V292, P656, DOI 10.1136/bmj.292.6521.656; Meinert CL., 1986, CLIN TRIALS DESIGN C; NORDEMAR R, 1980, PAIN, V10, P93; Nwuga VCB, 1982, AM J PHYS MED, V1, P160; ONGLEY MJ, 1987, LANCET, V2, P143; OTTENBACHER K, 1985, SPINE, V10, P833, DOI 10.1097/00007632-198511000-00010; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; Postacchini F, 1988, NEURO-ORTHOPEDICS, V6, P28; Rasmussen G. G., 1979, MANUAL MED, V17, P8; RUPERT RL, 1985, ICA INT REV CHIR WIN, P58; Siehl D, 1971, J Am Osteopath Assoc, V70, P433; SIMSWILLIAMS H, 1978, BMJ-BRIT MED J, V2, P1338, DOI 10.1136/bmj.2.6148.1338; SIMSWILLIAMS H, 1979, BMJ-BRIT MED J, V2, P1318, DOI 10.1136/bmj.2.6201.1318; SLOOP PR, 1982, SPINE, V7, P532, DOI 10.1097/00007632-198211000-00003; Spitzer W. O., 1987, SPINE, V12, P1; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; TOBIS JS, 1983, B NY ACAD MED, V7, P660; Waagen GN, 1986, MANUAL MED, V2, P63; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; WATERWORTH RF, 1985, NEW ZEAL MED J, V98, P372; ZYLBERGOLD RS, 1981, ARCH PHYS MED REHAB, V62, P176	55	196	194	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1298	1303		10.1136/bmj.303.6813.1298	http://dx.doi.org/10.1136/bmj.303.6813.1298			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1836153	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1991GT01100020
J	SHARIEF, MK; HENTGES, R				SHARIEF, MK; HENTGES, R			ASSOCIATION BETWEEN TUMOR-NECROSIS-FACTOR-ALPHA AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE-SCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-BRAIN-BARRIER; STATUS SCALE EDSS; CEREBROSPINAL-FLUID; LESIONS; CYCLOPHOSPHAMIDE; PLASMAPHERESIS; ASTROCYTES; EXCHANGE; SERUM; GAMMA	Background. Cachectin, or tumor necrosis factor-alpha (TNF-alpha), is a principal mediator of the inflammatory response and may be important in the pathogenesis and progression of multiple sclerosis, an inflammatory disease of the central nervous system. Methods. In a 24-month prospective study, we used a sensitive enzyme-linked immunosorbent assay to determine levels of TNF-alpha in cerebrospinal fluid and serum in 32 patients with chronic progressive multiple sclerosis and in 20 with stable multiple sclerosis and 85 with other neurologic diseases. An attempt was made to relate TNF-alpha levels with the degree of disability of the patients with multiple sclerosis and with their neurologic deterioration during the 24 months of observation. Results. High levels of TNF-alpha were found in the cerebrospinal fluid of 53 percent of the patients with chronic progressive multiple sclerosis and in none of those with stable multiple sclerosis (P < 0.001). TNF-alpha was detected in the cerebrospinal fluid of 7 percent of the controls (P < 0.01) with other neurologic disease. In patients with chronic progressive multiple sclerosis, mean TNF-alpha levels were significantly higher in the cerebrospinal fluid than in corresponding serum samples (52.41 vs. 11.88 U per milliliter; range, 2 to 178 vs. 2 to 39; P < 0.001). In these patients, cerebrospinal fluid levels of TNF-alpha correlated with the degree of disability (r = 0.834, P < 0.001) and the rate of neurologic deterioration (r = 0.741, P < 0.001) before the start of the study. Cerebrospinal fluid levels also correlated with the increase in neurologic disability after 24 months of observation (r = 0.873, P < 0.001). Conclusions. These data provide evidence of intrathecal synthesis of TNF-alpha in multiple sclerosis and suggest that the level of TNF-alpha in cerebrospinal fluid correlates with the severity and progression of the disease. Our results suggest that TNF-alpha may reflect histologic disease activity in multiple sclerosis and could be used to monitor outcomes or responses to therapy.	FREE UNIV BRUSSELS, DEPT NEUROPSYCHIAT, B-1050 BRUSSELS, BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel	SHARIEF, MK (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, INST NEUROL, DEPT CLIN NEUROCHEM, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							ADAMS CWM, 1989, J NEUROL SCI, V92, P291, DOI 10.1016/0022-510X(89)90144-5; BECK J, 1988, ACTA NEUROL SCAND, V78, P318, DOI 10.1111/j.1600-0404.1988.tb03663.x; BJORVATN B, 1984, BRIT MED J, V288, P439, DOI 10.1136/bmj.288.6415.439; BROSNAN CF, 1988, J NEUROIMMUNOL, V18, P87, DOI 10.1016/0165-5728(88)90137-3; CAMPBELL MJ, 1988, BRIT MED J, V296, P1454, DOI 10.1136/bmj.296.6634.1454; CHUNG IY, 1990, J IMMUNOL, V144, P2999; EBERS GC, 1986, DIS NERV SYST, P1268; FRANCIOTTA DM, 1989, ANN NEUROL, V26, P787, DOI 10.1002/ana.410260618; GALLO P, 1991, J NEUROL SCI, V101, P227, DOI 10.1016/0022-510X(91)90050-H; GAY D, 1991, BRAIN, V114, P557, DOI 10.1093/brain/114.1.557; GOODKIN DE, 1987, ARCH NEUROL-CHICAGO, V44, P823, DOI 10.1001/archneur.1987.00520200027013; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; HAUSER SL, 1986, ANN NEUROL, V19, P578, DOI 10.1002/ana.410190610; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; JAMES PB, 1989, LANCET, V1, P46; JERSILD C, 1973, LANCET, V2, P1221; KERMODE AG, 1990, BRAIN, V113, P1477, DOI 10.1093/brain/113.5.1477; KHATRI BO, 1985, NEUROLOGY, V35, P312, DOI 10.1212/WNL.35.3.312; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LUXTON RW, 1989, CLIN CHEM, V35, P1731; MAIMONE D, 1991, J NEUROIMMUNOL, V32, P67, DOI 10.1016/0165-5728(91)90073-G; MCCULLAGH P, 1983, GENERALIZED LINEAR M, P99; MCLAUGHLIN PJ, 1990, IMMUNOL CELL BIOL, V68, P51, DOI 10.1038/icb.1990.7; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MINTZ M, 1989, AM J DIS CHILD, V143, P771, DOI 10.1001/archpedi.1989.02150190021012; MUSTAFA M M, 1989, Pediatric Infectious Disease Journal, V8, P907, DOI 10.1097/00006454-198912000-00037; MUSTAFA MM, 1989, J PEDIATR-US, V115, P208, DOI 10.1016/S0022-3476(89)80067-8; NOSEWORTHY JH, 1990, NEUROLOGY, V40, P971, DOI 10.1212/WNL.40.6.971; NOSEWORTHY JH, 1991, LANCET, V337, P441; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; POSER S, 1982, ACTA NEUROL SCAND, V66, P355; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; ROBERTSON B, 1988, J IMMUNOL, V140, P4300; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SLUNGAARD A, 1990, J EXP MED, V171, P2025, DOI 10.1084/jem.171.6.2025; TOURTELLOTTE WW, 1978, NEUROLOGY, V28, P76, DOI 10.1212/WNL.28.9_Part_2.76; TOURTELLOTTE WW, 1988, J NEUROIMMUNOL, V20, P217, DOI 10.1016/0165-5728(88)90163-4; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; TROTTER JL, 1989, ANN NEUROL, V25, P172, DOI 10.1002/ana.410250211; WAKSMAN BH, 1984, P SOC EXP BIOL MED, V175, P282; WALKER RWH, 1983, J NEUROIMMUNOL, V4, P141, DOI 10.1016/0165-5728(83)90018-8; WOLINSKY JS, 1990, ANN NEUROL, V27, P591	43	710	731	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					467	472		10.1056/NEJM199108153250704	http://dx.doi.org/10.1056/NEJM199108153250704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1852181	Bronze			2022-12-28	WOS:A1991GA76300004
J	MCLELLAN, DL				MCLELLAN, DL			REHABILITATION	BRITISH MEDICAL JOURNAL			English	Article											MCLELLAN, DL (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,REHABIL RES UNIT,LEVEL C,W WING,SOUTHAMPTON S09 4XY,ENGLAND.							Alexander J. L., 1979, Evaluation of Efficacy of Medical Action, P287; BEARDSHAW V, 1988, LAST LIST COMMUNITY; CANTRELL E, 1985, PRISONERS HANDICAP; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; Cornes P, 1991, Int Disabil Stud, V13, P5; EDWARDS FC, 1990, HLTH SERVICES ADULTS; GODFREY HPD, 1988, ARCH PHYS MED REHAB, V69, P458; MCLELLAN DL, 1987, J SOC OCCUP MED, V37, P94; ROBINE JM, 1991, BMJ-BRIT MED J, V302, P457, DOI 10.1136/bmj.302.6774.457; THOMAS AP, 1989, CLIN DEV MED, V106; WILSON BA, 1988, NEUROPSYCHOL REHABIL, P69; 1989, SURVEY DISABILITY GR, V1; 1991, CM1523	13	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					355	357		10.1136/bmj.303.6798.355	http://dx.doi.org/10.1136/bmj.303.6798.355			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1833005	Green Published, Bronze			2022-12-28	WOS:A1991GA60600028
J	LIAO, NS; BIX, M; ZIJLSTRA, M; JAENISCH, R; RAULET, D				LIAO, NS; BIX, M; ZIJLSTRA, M; JAENISCH, R; RAULET, D			MHC CLASS-I DEFICIENCY - SUSCEPTIBILITY TO NATURAL-KILLER (NK) CELLS AND IMPAIRED NK ACTIVITY	SCIENCE			English	Article							BONE-MARROW ALLOGRAFTS; T-CELLS; INTERFERON INDUCERS; ANTIGEN EXPRESSION; LYMPHOMA VARIANTS; MICE; REJECTION; GENE; LYSIS; TRANSFECTION	The role of major histocompatibility complex (MHC) class I expression in natural killer (NK) cell target recognition is controversial. Normal T cell blasts from MHC class I-deficient mutant mice were found to serve as target cells for NK cells in vitro, which suggests that MHC class I molecules are directly involved in NK cell recognition. Spleen cells from the mutant mice were deficient in their ability to lyse MHC class I-deficient target cells or NK-susceptible tumor targets, and mutant mice could not reject allogeneic bone marrow. Thus, class I molecules may participate in the positive selection or tolerance induction of NK cells.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	University of California System; University of California Berkeley; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Liao, Nan-Shih/ABE-7580-2020	Liao, Nan-Shih/0000-0003-3707-4145; Bix, Mark/0000-0003-4617-0497; Raulet, David/0000-0002-1257-8649	NCI NIH HHS [R35 CA44339] Funding Source: Medline; NIAID NIH HHS [R01 AI30171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; CICCONE E, 1990, J EXP MED, V172, P47, DOI 10.1084/jem.172.1.47; CUDKOWICZ G, 1964, NATURE, V204, P450, DOI 10.1038/204450a0; CUDKOWICZ G, 1971, J EXP MED, V134, P1513, DOI 10.1084/jem.134.6.1513; DEGLIANTONI G, 1985, J EXP MED, V162, P1512, DOI 10.1084/jem.162.5.1512; DENNERT G, 1988, J IMMUNOL, V140, P2472; DJEU JY, 1979, J IMMUNOL, V122, P175; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; GIDLUND M, 1978, NATURE, V273, P759, DOI 10.1038/273759a0; HARELBELLAN A, 1986, P NATL ACAD SCI USA, V83, P5688, DOI 10.1073/pnas.83.15.5688; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOO GC, 1984, HYBRIDOMA, V3, P301, DOI 10.1089/hyb.1984.3.301; KRIMPENFORT P, 1987, EMBO J, V6, P1673, DOI 10.1002/j.1460-2075.1987.tb02416.x; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEVITSKY HI, 1991, J IMMUNOL, V146, P1113; LJUNGGREN HG, 1990, J IMMUNOL, V145, P380; MASON LH, 1990, J IMMUNOL, V145, P751; MURPHY WJ, 1987, J EXP MED, V166, P1499, DOI 10.1084/jem.166.5.1499; NISHIMURA MI, 1988, J IMMUNOL, V141, P4403; OHLEN C, 1989, J IMMUNOL, V142, P3336; OHLEN C, 1989, SCIENCE, V246, P666, DOI 10.1126/science.2814488; RAULET DH, 1982, J EXP MED, V155, P1766, DOI 10.1084/jem.155.6.1766; RAULET DH, 1980, J IMMUNOL, V125, P1136; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SENTMAN CL, 1989, J IMMUNOL, V142, P1847; SHIMIZU Y, 1989, EUR J IMMUNOL, V19, P447, DOI 10.1002/eji.1830190306; STORKUS WJ, 1989, J IMMUNOL, V143, P3853; STURMHOFEL K, 1990, EUR J IMMUNOL, V20, P171, DOI 10.1002/eji.1830200125; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZIJLSTRA M, UNPUB	32	423	430	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					199	202		10.1126/science.1853205	http://dx.doi.org/10.1126/science.1853205			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1853205				2022-12-28	WOS:A1991FW16000038
J	LIVDAHL, TP; WILLEY, MS				LIVDAHL, TP; WILLEY, MS			PROSPECTS FOR AN INVASION - COMPETITION BETWEEN AEDES-ALBOPICTUS AND NATIVE AEDES-TRISERIATUS	SCIENCE			English	Article							TREE-HOLE MOSQUITOS; NORTH-AMERICA; UNITED-STATES; CULICIDAE; DIPTERA	Competition between larval populations of the native North American treehole mosquito Aedes triseriatus and Aedes albopictus, recently introduced from Asia to North America, was assessed by comparing per capita growth rate estimates for experimental cohorts of larvae developing under a variety of initial density combinations in fluid obtained from tires or from treeholes. Estimates of carrying capacities and competition coefficients indicate that competition between the two species will result in stable coexistence in treehole communities but local extinction of A. triseriatus in tire habitats.			LIVDAHL, TP (corresponding author), CLARK UNIV,DEPT BIOL,WORCESTER,MA 01610, USA.				NIAID NIH HHS [R15AI27940] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI027940] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLACK WC, 1989, J MED ENTOMOL, V26, P260, DOI 10.1093/jmedent/26.4.260; BRADSHAW WE, 1988, OECOLOGIA, V74, P507, DOI 10.1007/BF00380047; BRADSHAW WE, 1983, OECOLOGIA, V57, P239, DOI 10.1007/BF00379586; COPELAND RS, 1990, ANN ENTOMOL SOC AM, V83, P1063, DOI 10.1093/aesa/83.6.1063; HARD JJ, 1989, OIKOS, V54, P137, DOI 10.2307/3565259; HAWLEY WA, 1987, SCIENCE, V236, P1114, DOI 10.1126/science.3576225; HO C, 1989, J MED ENTOMOL, V26, P615; LIVDAHL TP, 1984, J ANIM ECOL, V53, P573, DOI 10.2307/4535; OMEARA G, 1990, 1990 ANN M ENT WOC A; PETERSEN JJ, 1969, MOSQ NEWS, V29, P134; SCHREIBER ET, 1988, J AM MOSQUITO CONTR, V4, P9; SHROYER DA, 1986, J AM MOSQUITO CONTR, V2, P424; SOKAL RR, 1981, BIOMETRY, P795; SPRENGER D, 1986, J AM MOSQUITO CONTR, V2, P217; WALKER ED, 1988, ENVIRON ENTOMOL, V17, P199, DOI 10.1093/ee/17.2.199; 1989, AM MOSQ CONTROL ASS, V15, P15; 1990, AM MOSQ CONTROL ASS, V16, P13; 1990, AM MOSQ CONTROL ASS, V16, P5	18	156	158	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					189	191		10.1126/science.1853204	http://dx.doi.org/10.1126/science.1853204			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1853204				2022-12-28	WOS:A1991FW16000034
J	DOERING, TL; RAPER, J; BUXBAUM, LU; ADAMS, SP; GORDON, JI; HART, GW; ENGLUND, PT				DOERING, TL; RAPER, J; BUXBAUM, LU; ADAMS, SP; GORDON, JI; HART, GW; ENGLUND, PT			AN ANALOG OF MYRISTIC ACID WITH SELECTIVE TOXICITY FOR AFRICAN TRYPANOSOMES	SCIENCE			English	Article							VARIANT SURFACE GLYCOPROTEIN; PHOSPHATIDYLINOSITOL MEMBRANE ANCHORS; GLYCOSYL-PHOSPHATIDYLINOSITOL; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; BRUCEI; BIOSYNTHESIS; PROTEIN; IDENTIFICATION; PURIFICATION	Trypanosoma brucei, the protozoan parasite responsible for African sleeping sickness, evades the host immune response through the process of antigenic variation. The variant antigen, known as the variant surface glycoprotein (VSG), is anchored to the cell surface by a glycosyl phosphatidylinositol (GPI) structure that contains myristate (n-tetradecanoate) as its only fatty acid component. The utilization of heteroatom-containing analogs of myristate was studied both in a cell-free system and in vivo. Results indicated that the specificity of fatty acid incorporation depends on chain length rather than on hydrophobicity. One analog, 10-(propoxy)decanoic acid, was highly toxic to trypanosomes in culture although it is nontoxic to mammalian cells.	MONSANTO CO,ST LOUIS,MO 64167; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Monsanto; Washington University (WUSTL)	DOERING, TL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21210, USA.			Hart, Gerald/0000-0001-7812-4351; Raper, Jayne/0000-0002-8723-9748	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, R01AI021334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27179, AI21334] Funding Source: Medline; NIGMS NIH HHS [5T32GM07309] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITMAN C, 1990, TROP DIS RES NEWS, V31, P3; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BRYANT ML, 1991, P NATL ACAD SCI USA, V88, P2055, DOI 10.1073/pnas.88.6.2055; BRYANT ML, 1989, P NATL ACAD SCI USA, V86, P8655, DOI 10.1073/pnas.86.22.8655; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; DIXON H, 1967, T ROY SOC TROP MED H, V61, P12; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; DOERING TL, UNPUB; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HAJDUK SL, 1989, TROPICAL GEOGRAPHIC, P268; HAMM B, 1990, MOL BIOCHEM PARASIT, V40, P13, DOI 10.1016/0166-6851(90)90075-W; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P8511, DOI 10.1073/pnas.87.21.8511; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MELLORS A, 1989, PARASITOL TODAY, V5, P239, DOI 10.1016/0169-4758(89)90255-X; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; RABEN DM, UNPUB; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001	32	75	77	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1851	1854		10.1126/science.1829548	http://dx.doi.org/10.1126/science.1829548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	1829548				2022-12-28	WOS:A1991FU06100041
J	XIAO, JH; DAVIDSON, I; MATTHES, H; GARNIER, JM; CHAMBON, P				XIAO, JH; DAVIDSON, I; MATTHES, H; GARNIER, JM; CHAMBON, P			CLONING, EXPRESSION, AND TRANSCRIPTIONAL PROPERTIES OF THE HUMAN ENHANCER FACTOR TEF-1	CELL			English	Article							UBIQUITOUS NUCLEAR PROTEINS; SIMIAN VIRUS-40 ENHANCER; FIBROBLAST GROWTH-FACTOR; HUMAN ESTROGEN-RECEPTOR; CELL TYPE-SPECIFICITY; DNA-BINDING DOMAIN; NON-AUG CODONS; SV40 ENHANCER; MESSENGER-RNA; MAMMALIAN-CELLS	We describe the cDNA encoding the SV40 transcriptional enhancer factor 1 (TEF-1) and show that its translation initiates exclusively at an AUU codon in vivo. Cloned TEF-1, which is unrelated to other known transcription factors, specifically binds the SV40 GT-IIC and Sph enhansons. Cloned TEF-1 does not activate these enhansons in lymphoid MPC11 cells where they are known to be inactive, but represses the endogenous HeLa TEF-1 activity in vivo and in vitro. Repression is also observed with chimeras where the DNA-binding domain of the GAL4 activator replaces that of TEF-1, showing that repression results from interference/squelching. Such chimeras stimulate transcription in HeLa, but not in MPC11, cells in vivo and in HeLa cell extracts in vitro. However, high concentrations result in self-interference/squelching. These results strongly suggest that the trans-activation function of TEF-1 is mediated by a highly limiting, possible cell-specific, titratable transcriptional intermediary factor(s).	FAC MED STRASBOURG,INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Davidson, Irwin/0000-0001-5533-1171				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHAMBON P, 1984, RECENT PROG HORM RES, V40, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clemens MJ, 1989, CURR OPIN CELL BIOL, V1, P1160, DOI 10.1016/S0955-0674(89)80067-5; COSMAN D, 1987, IMMUNOL TODAY, V8, P16, DOI 10.1016/0167-5699(87)90826-7; CULP JS, 1988, P NATL ACAD SCI USA, V85, P6450, DOI 10.1073/pnas.85.17.6450; CURRAN J, 1988, EMBO J, V7, P245, DOI 10.1002/j.1460-2075.1988.tb02806.x; DAVIDSON I, 1986, NATURE, V323, P544, DOI 10.1038/323544a0; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; FRANKEL AD, 1988, P NATL ACAD SCI USA, V85, P6297, DOI 10.1073/pnas.85.17.6297; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUPTA KC, 1988, J BIOL CHEM, V263, P8553; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HATZOPOULOS AK, 1988, TRANSCRIPTION SPLICI, P43; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERMAN RC, 1989, TRENDS BIOCHEM SCI, V14, P219, DOI 10.1016/0968-0004(89)90030-3; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIUCHI T, 1990, J BIOL CHEM, V265, P6521; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JOHNSTON M, 1987, P NATL ACAD SCI USA, V84, P2401, DOI 10.1073/pnas.84.8.2401; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; KIM KS, 1989, NATURE, V342, P200, DOI 10.1038/342200a0; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOZAK M, 1986, ADV VIRUS RES, V31, P229, DOI 10.1016/S0065-3527(08)60265-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KOZAK M, 1979, J BIOL CHEM, V254, P4731; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGHANGUE NB, 1988, TRANSCRIPTION SPLICI, P1; LAMAIRE P, 1990, MOL CELL BIOL, V10, P3456; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LANDOLFI NF, 1987, P NATL ACAD SCI USA, V84, P3851, DOI 10.1073/pnas.84.11.3851; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MACCHI M, 1989, EMBO J, V8, P4215, DOI 10.1002/j.1460-2075.1989.tb08607.x; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; Mattaj IW, 1990, CURR OPIN CELL BIOL, V2, P528, DOI 10.1016/0955-0674(90)90138-5; MEHDI H, 1990, GENE, V91, P173, DOI 10.1016/0378-1119(90)90085-6; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; NOMIYAMA H, 1987, P NATL ACAD SCI USA, V84, P7881, DOI 10.1073/pnas.84.22.7881; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; PAYRE V, 1988, FEBS LETT, V234, P245; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PUSZTAI R, 1989, J VIROL, V63, P3516, DOI 10.1128/JVI.63.8.3516-3518.1989; ROSALES R, 1987, EMBO J, V6, P3015, DOI 10.1002/j.1460-2075.1987.tb02607.x; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHIRM S, 1987, GENE DEV, V1, P65, DOI 10.1101/gad.1.1.65; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; TAIRA M, 1990, J BIOL CHEM, V265, P16491; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TOOZE J, 1982, MOL BIOL TUMOR VIR 2, P799; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREIZENBERG SJ, 1988, GENE DEV, V2, P718; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WASYLYK B, 1988, CRC CR REV BIOCH MOL, V23, P77, DOI 10.3109/10409238809088317; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WILDEMAN AG, 1986, MOL CELL BIOL, V6, P2098, DOI 10.1128/MCB.6.6.2098; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x; ZHENG XM, 1990, NATURE, V344, P556, DOI 10.1038/344556a0; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	120	360	367	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					551	568		10.1016/0092-8674(91)90088-G	http://dx.doi.org/10.1016/0092-8674(91)90088-G			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1851669				2022-12-28	WOS:A1991FM03700006
J	YAMAMURA, Y; OGAWA, H; CHIHARA, T; KONDO, K; ONOGAWA, T; NAKAMURA, S; MORI, T; TOMINAGA, M; YABUUCHI, Y				YAMAMURA, Y; OGAWA, H; CHIHARA, T; KONDO, K; ONOGAWA, T; NAKAMURA, S; MORI, T; TOMINAGA, M; YABUUCHI, Y			OPC-21268, AN ORALLY EFFECTIVE, NONPEPTIDE VASOPRESSIN-VI RECEPTOR ANTAGONIST	SCIENCE			English	Article							ARGININE-VASOPRESSIN; ADENYLATE-CYCLASE; RAT; MEMBRANES; RESPONSES; HORMONE	An orally effective, nonpeptide, vasopressin V1 receptor antagonist, OPC-21268, has been identified. This compound selectively antagonized binding to the V1 subtype of the vasopressin receptor in a competitive manner. In vivo, the compound acted as a specific antagonist of arginine vasopressin (AVP)-induced vasoconstriction. After oral administration in conscious rats, the compound also antagonized pressor responses to AVP. OPC-21268 can be used to study the physiological role of AVP and may be therapeutically useful in the treatment of hypertension and congestive heart failure.			YAMAMURA, Y (corresponding author), OTSUKA PHARMACEUT CO LTD,TOKUSHIMA INST NEW DRUG RES 2,46310 KAGASUNO KAWAUCHI CHO,TOKUSHIMA 77101,JAPAN.							ANDERSON WA, 1963, BIOCHIM BIOPHYS ACTA, V67, P674; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOCKAERT J, 1973, J BIOL CHEM, V248, P5922; GILLESPIE JS, 1967, BRIT J PHARM CHEMOTH, V30, P78, DOI 10.1111/j.1476-5381.1967.tb02114.x; KNAPE JTA, 1988, ARCH INT PHARMACOD T, V291, P142; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNING M, 1981, J MED CHEM, V24, P701, DOI 10.1021/jm00138a012; MANNING M, 1977, J MED CHEM, V20, P1228, DOI 10.1021/jm00219a026; MANNING M, 1989, J LAB CLIN MED, V114, P617; NAKAHARA T, 1978, J BIOL CHEM, V253, P3211; NAKAMURA T, 1983, J BIOL CHEM, V258, P9283; SAWYER WH, 1981, SCIENCE, V212, P49, DOI 10.1126/science.7209515; TOLBERT MEM, 1980, J BIOL CHEM, V255, P1938; YAMAMURA Y, UNPUB	15	303	317	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					572	574		10.1126/science.1850553	http://dx.doi.org/10.1126/science.1850553			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850553				2022-12-28	WOS:A1991FJ12700049
J	HUANG, J; SCHNEIDER, RJ				HUANG, J; SCHNEIDER, RJ			ADENOVIRUS INHIBITION OF CELLULAR PROTEIN-SYNTHESIS INVOLVES INACTIVATION OF CAP-BINDING PROTEIN	CELL			English	Article							DOUBLE-STRANDED-RNA; RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; 5' NONTRANSLATED REGION; MESSENGER-RNA; INITIATION-FACTOR; VAI-RNA; TRIPARTITE LEADER; TRANSLATIONAL CONTROL; INFECTED CELLS; GENE-EXPRESSION	Adenovirus (Ad) infection results in a marked inhibition of cellular protein synthesis that initiates during the late phase of the viral infectious cycle. We show that the mechanism used for suppression of cellular protein synthesis during cell cycle progression is exploited by Ad to repress host and enhance late viral mRNA translation. Discrimination between cellular and late Ad mRNAs and inhibition of host protein synthesis are shown to involve viral-mediated underphosphorylation of cap-binding protein (CBP) and subsequent inactivation of CBP complex, a large enzymatic complex required for cap-dependent mRNA translation. Late Ad mRNAs, like those of poliovirus, possess the unique ability to translate independent of a normal cap recognition process and do not require the activity of CBP complex. Inhibition of cellular translation by these two viruses is quite similar, except that whereas CBP complex is proteolytically degraded by poliovirus, it is functionally inactivated by Ad.	NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	New York University	HUANG, J (corresponding author), NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016, USA.				NATIONAL CANCER INSTITUTE [R01CA042357] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONSOCAPLEN FV, 1988, J VIROL, V62, P1606, DOI 10.1128/JVI.62.5.1606-1616.1988; ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; BABICH A, 1983, MOL CELL BIOL, V3, P1212, DOI 10.1128/MCB.3.7.1212; BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BELTZ GA, 1979, J MOL BIOL, V131, P353, DOI 10.1016/0022-2836(79)90081-0; BERKNER KL, 1985, NUCLEIC ACIDS RES, V13, P841, DOI 10.1093/nar/13.3.841; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; CHERNEY CS, 1979, J VIROL, V5, P533; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DERY I, 1987, TRANSLATIONAL REGULA; DOLPH PJ, 1988, J VIROL, V62, P2059, DOI 10.1128/JVI.62.6.2059-2066.1988; DOLPH PJ, 1990, J VIROL, V64, P2669, DOI 10.1128/JVI.64.6.2669-2677.1990; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; FLINT SJ, 1984, COMPR VIROL, V19, P297; GINSBERG HS, 1984, J GEN VIROL, V36, P59; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HAYES BW, 1990, J VIROL, V64, P2732, DOI 10.1128/JVI.64.6.2732-2742.1990; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; HUANG JT, 1990, P NATL ACAD SCI USA, V87, P7115, DOI 10.1073/pnas.87.18.7115; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1985, P NATL ACAD SCI USA, V82, P689, DOI 10.1073/pnas.82.3.689; KITAJEWSKI J, 1986, MOL CELL BIOL, V6, P4493, DOI 10.1128/MCB.6.12.4493; KITAJEWSKI J, 1986, CELL, V45, P195, DOI 10.1016/0092-8674(86)90383-1; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LOGAN J, 1984, P NATL ACAD SCI-BIOL, V81, P3655, DOI 10.1073/pnas.81.12.3655; MANSOUR SL, 1986, MOL CELL BIOL, V6, P2684, DOI 10.1128/MCB.6.7.2684; MARAN A, 1988, VIROLOGY, V164, P106, DOI 10.1016/0042-6822(88)90625-3; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; MOORE M, 1987, MOL CELL BIOL, V7, P4505, DOI 10.1128/MCB.7.12.4505; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OMALLEY RP, 1989, VIROLOGY, V168, P112, DOI 10.1016/0042-6822(89)90409-1; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PETTERSSON U, 1978, CELL, V12, P741; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; REICHEL PA, 1985, NATURE, V313, P196, DOI 10.1038/313196a0; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RYCHLIK W, 1986, J BIOL CHEM, V261, P71; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SCHNEIDER RJ, 1984, CELL, V37, P291, DOI 10.1016/0092-8674(84)90325-8; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SCHNEIDER RJ, 1985, P NATL ACAD SCI USA, V82, P4321, DOI 10.1073/pnas.82.13.4321; SEN GC, 1983, J GEN VIROL, V64, P2213, DOI 10.1099/0022-1317-64-10-2213; SIEKIERKA J, 1985, P NATL ACAD SCI USA, V82, P1959, DOI 10.1073/pnas.82.7.1959; SONENBERG N, 1987, ADV VIRUS RES, V33, P175, DOI 10.1016/S0065-3527(08)60318-8; TARNOWKA MA, 1979, J CELL PHYSIOL, V99, P359, DOI 10.1002/jcp.1040990311; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZHANG Y, 1989, J BIOL CHEM, V264, P10679; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	64	153	161	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					271	280		10.1016/0092-8674(91)90161-Q	http://dx.doi.org/10.1016/0092-8674(91)90161-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1849798	hybrid			2022-12-28	WOS:A1991FH09200010
J	DAAR, ES; MOUDGIL, T; MEYER, RD; HO, DD				DAAR, ES; MOUDGIL, T; MEYER, RD; HO, DD			TRANSIENT HIGH-LEVELS OF VIREMIA IN PATIENTS WITH PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY HIV INFECTION; HTLV-III; CEREBROSPINAL-FLUID; SEROCONVERSION; INFLUENZA; CAPACITY; PLASMA; AIDS	Background. The rapidly evolving clinical picture of primary infection with the human immunodeficiency virus type 1 (HIV-1) suggests that a better understanding of the kinetics of viral replication in vivo during the short period before seroconversion may provide insight into the pathogenesis of the acquired immunodeficiency syndrome (AIDS). Methods and Results. Titers of infectious HIV-1 were determined by end-point-dilution culture in sequential samples of plasma and peripheral-blood mononuclear cells from four patients with primary infection, with peak titers of 1000 to 10,000 tissue-culture-infective doses per milliliter of plasma and 100 to 10,000 infective doses per 10(6) peripheral-blood mononuclear cells. The high viral burden in mononuclear cells was confirmed by quantitative studies using a polymerase-chain-reaction method. In as little as 10 days, the high HIV-1 load in both plasma and cells decreased spontaneously and precipitously, at least 100-fold, in all four patients. Conclusions. Although p24 core antigenemia and viral isolation have previously been described during primary HIV-1 infection, this report documents the large viral burden during the acute phase of infection. The rapid and spontaneous decline in the viral load suggests an effective immune response in the host that, if understood, may be used to combat AIDS.	NYU HOSP,SCH MED,AARON DIAMOND AIDS RES CTR,455 1ST AVE,NEW YORK,NY 10016; UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DEPT MED,DIV INFECT DIS,LOS ANGELES,CA 90048	New York University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025541, P30AI027742, R01AI028747] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 28747, AI 25541, AI 27742] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT J, 1987, J MED VIROL, V23, P67, DOI 10.1002/jmv.1890230108; ASJO B, 1986, LANCET, V2, P660; BALTIMORE D, 1989, NEW ENGL J MED, V321, P1673, DOI 10.1056/NEJM198912143212409; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CARNE CA, 1985, LANCET, V2, P1206; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; COOPER DA, 1985, LANCET, V1, P537; ENNIS FA, 1981, LANCET, V2, P887; GAINES H, 1987, LANCET, V1, P1317; GOUDSMIT J, 1986, LANCET, V2, P177; HO DD, 1985, ANN INTERN MED, V103, P880, DOI 10.7326/0003-4819-103-6-880; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1985, NEW ENGL J MED, V313, P1493, DOI 10.1056/NEJM198512123132401; LINDSKOV R, 1986, LANCET, V1, P447; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; STRAMER SL, 1989, JAMA-J AM MED ASSOC, V262, P64, DOI 10.1001/jama.262.1.64; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	19	773	798	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1991	324	14					961	964		10.1056/NEJM199104043241405	http://dx.doi.org/10.1056/NEJM199104043241405			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE376	1823118	Bronze			2022-12-28	WOS:A1991FE37600005
J	CHIANG, HL; SCHEKMAN, R				CHIANG, HL; SCHEKMAN, R			REGULATED IMPORT AND DEGRADATION OF A CYTOSOLIC PROTEIN IN THE YEAST VACUOLE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; CATABOLITE INACTIVATION; STRUCTURAL GENE; FRUCTOSE-1,6-BISPHOSPHATASE; TRANSLOCATION; PHOSPHORYLATION; PROTEOLYSIS; ENCODES; GLUCOSE	The key regulatory enzyme in gluconeogenesis, fructose 1,6-bisphosphatase (FBPase) is subject to glucose-stimulated proteolytic degradation in Saccharomyces cerevisiae. This process involves the regulated transfer of FBPase directly from the cytosol into the vacuole or a vacuole-related organelle. Glucose may regulate the production of an FBPase receptor or import factor that is transported to the vacuole through the secretory pathway.			CHIANG, HL (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DIV BIOCHEM & MOLEC BIOL, 401 BARKER HALL, BERKELEY, CA 94720 USA.							AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BURLINI N, 1988, BIOCHIM BIOPHYS ACTA, V972, P353, DOI 10.1016/0167-4889(88)90212-1; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; FUNAGUMA T, 1985, BIOCHEM BIOPH RES CO, V130, P467, DOI 10.1016/0006-291X(85)90440-1; FUNAYAMA S, 1980, EUR J BIOCHEM, V109, P61, DOI 10.1111/j.1432-1033.1980.tb04767.x; Guerra R. de la, 1988, FEBS Letters, V242, P149, DOI 10.1016/0014-5793(88)81004-4; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOLZER H, 1980, ANNU REV BIOCHEM, V49, P63, DOI 10.1146/annurev.bi.49.070180.000431; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LAMPONI S, 1987, FEBS LETT, V216, P265, DOI 10.1016/0014-5793(87)80703-2; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; RITTENHOUSE J, 1987, J BIOL CHEM, V262, P10114; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROGERS DT, 1988, J BIOL CHEM, V263, P6051; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; ROTHMAN JH, 1986, P NATL ACAD SCI USA, V83, P3248, DOI 10.1073/pnas.83.10.3248; SCHAFER W, 1987, BIOCHIM BIOPHYS ACTA, V925, P150, DOI 10.1016/0304-4165(87)90104-8; SEDIVY JM, 1985, J MOL BIOL, V186, P307, DOI 10.1016/0022-2836(85)90107-X; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YOSHIHISA T, 1990, J BIOL CHEM, V265; ZUBENKO GS, 1981, GENETICS, V97, P45	32	140	140	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	1991	350	6316					313	318		10.1038/350313a0	http://dx.doi.org/10.1038/350313a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	1848921				2022-12-28	WOS:A1991FD83800082
J	BERRY, MJ; BANU, L; LARSEN, PR				BERRY, MJ; BANU, L; LARSEN, PR			TYPE-I IODOTHYRONINE DEIODINASE IS A SELENOCYSTEINE-CONTAINING ENZYME	NATURE			English	Article							SELENIUM GLUTATHIONE-PEROXIDASE; PROTEIN DISULFIDE ISOMERASE; RAT-LIVER; NUCLEOTIDE-SEQUENCE; ACTIVE-SITE; EXPRESSION; THYROXINE; TRIIODOTHYRONINE; INHIBITION; DEFICIENCY	ALTHOUGH thyroxine (3,5,3',5'-tetraiodonthyroine, T4) is the principal secretory product of the vertebrate thyroid, its essential metabolic and developmental effects are all mediated by 3,5,3'-triiodothyronine (T3), which is produced from the prohormone by 5'-deiodination. The type-I iodothyronine deiodinase, a thiol-requiring propylthiouracil-sensitive oxidoreductase, is found mainly in liver and kidney and provides most of the circulating T3(1) but so far this enzyme has not been purified. Using expression cloning in the Xenopus oocyte, we have isolated a 2.1-kilobase complementary DNA of this deiodinase from a rat liver cDNA library. The kinetic properties of the protein expressed in transient assay systems, the tissue distribution of the messenger RNA, and its changes with thyroid status, all confirm its identity. We find that the mRNA for this enzyme contains a UGA codon for selenocysteine which is necessary for maximal enzyme activity. This explains why conversion to T4 to T3 is impaired in experimental selenium deficiency 2-6 and identifies an essential role for this trace element in thyroid hormone action.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV THYROID,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	BERRY, MJ (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,HOWARD HUGHES MED INST LAB,75 FRANCIS ST,BOSTON,MA 02115, USA.							ARTHUR JR, 1988, RES VET SCI, V45, P122, DOI 10.1016/S0034-5288(18)30906-8; ARTHUR JR, 1990, J INORG BIOCHEM, V39, P101, DOI 10.1016/0162-0134(90)80018-S; ARTHUR JR, 1990, CLIN CHEM ENZYMOL CO, V3, P209; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BECKETT GJ, 1987, BIOCHEM J, V248, P443, DOI 10.1042/bj2480443; BECKETT GJ, 1989, BIOCHEM J, V259, P887, DOI 10.1042/bj2590887; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; BEHNE D, 1990, BIOCHIM BIOPHYS ACTA, V1033, P219, DOI 10.1016/0304-4165(90)90124-F; BERRY MJ, 1990, MOL ENDOCRINOL, V4, P743, DOI 10.1210/mend-4-5-743; BOADO RJ, 1988, BIOCHEM BIOPH RES CO, V155, P1297, DOI 10.1016/S0006-291X(88)81282-8; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHAUDIERE J, 1984, J INORG BIOCHEM, V20, P313, DOI 10.1016/0162-0134(84)85030-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FORSTROM JW, 1978, BIOCHEMISTRY-US, V17, P2639, DOI 10.1021/bi00606a028; FRUMESS RD, 1975, METABOLISM, V24, P547, DOI 10.1016/0026-0495(75)90079-7; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; ISHIDA K, 1987, NUCLEIC ACIDS RES, V15, P10051, DOI 10.1093/nar/15.23.10051; KOHRLE J, 1990, J BIOL CHEM, V265, P6146; LARSEN PR, 1981, ENDOCR REV, V2, P87, DOI 10.1210/edrv-2-1-87; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; Leonard JL, 1986, THYROID HORMONE META, P189; MENON NK, 1987, J BACTERIOL, V169, P5401, DOI 10.1128/jb.169.12.5401-5407.1987; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; OPPENHEI.JH, 1972, J CLIN INVEST, V51, P2493, DOI 10.1172/JCI107063; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENMAKERS CHH, 1989, BIOCHEM BIOPH RES CO, V162, P857, DOI 10.1016/0006-291X(89)92389-9; STGERMAIN DL, 1989, J BIOL CHEM, V264, P3054; TAPPEL AL, 1984, CURR TOP CELL REGUL, V24, P87; VISSER TJ, 1983, MOL CELL ENDOCRINOL, V33, P321, DOI 10.1016/0303-7207(83)90177-6; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	31	810	846	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					438	440		10.1038/349438a0	http://dx.doi.org/10.1038/349438a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1825132				2022-12-28	WOS:A1991EV51400059
J	SHULKIN, DJ; ESCARCE, JJ; ENARSON, C; EISENBERG, JM				SHULKIN, DJ; ESCARCE, JJ; ENARSON, C; EISENBERG, JM			IMPACT OF THE MEDICARE FEE SCHEDULE ON AN ACADEMIC DEPARTMENT OF MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN	Objective. - To examine the effect of the Medicare Fee Schedule (MFS) on Medicare revenues in the department of medicine at an urban academic medical center after the MFS is fully implemented. Methods. - Department revenues from Medicare were compared with projected revenues using the MFS proposed by the Health Care Financing Administration on June 5, 1991. National Medicare claims data were used to determine differences in service mix between community and academic internists and the impact of the geographic component of the MFS on department revenues. Results. - Department revenues from Medicare in 1996 are projected to be 25.5% lower under the MFS than if the current system had continued. Subspecialty sections that perform large numbers of procedures and special tests had the largest decrease in revenues (eg, gastroenterology, -29.8%); however, this did not differ greatly from decreases in sections that mainly provide visits and consultations (eg, general internal medicine, -24.7%). Conclusion. - The proposed MFS is projected to lead to substantial reductions in department revenues from Medicare. While relative values for services and geographic location will play a role in how individual departments fare under the MFS, the value of the conversion factor used in the final MFS will be the factor of greatest importance.	UNIV PENN,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania								FLEXNER A, 1910, MED ED US CANADA REP, P136; GINSBURG PB, 1990, HEALTH AFFAIR, V9, P178, DOI 10.1377/hlthaff.9.1.178; INGLEHART JK, 1990, NEW ENGL J MED, V322, P1247; LEE PR, 1989, JAMA-J AM MED ASSOC, V261, P2382, DOI 10.1001/jama.261.16.2382; LEE PR, 1991, JAMA-J AM MED ASSOC, V266, P1562, DOI 10.1001/jama.266.11.1562; LEVY JM, 1990, JAMA-J AM MED ASSOC, V264, P717; MACLEOD GK, 1986, JAMA-J AM MED ASSOC, V256, P58, DOI 10.1001/jama.256.1.58; SHULKIN DJ, 1991, CLIN RES, V39, pA609; 1990, 03272 BUR DAT MAN ST; 1989, ANN REPORT C; 1991, FED REG         0605, V56, P25792; 1989, PHYSICIANS CURRENT P; 1991, ANN REPORT C; 1991, IMPACT MEDICARE PAYM; 1991, 916 PHYS PAYM REV CO	15	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3000	3003		10.1001/jama.266.21.3000	http://dx.doi.org/10.1001/jama.266.21.3000			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820472				2022-12-28	WOS:A1991GR77500031
J	SOKOL, S; CHRISTIAN, JL; MOON, RT; MELTON, DA				SOKOL, S; CHRISTIAN, JL; MOON, RT; MELTON, DA			INJECTED WNT RNA INDUCES A COMPLETE BODY AXIS IN XENOPUS EMBRYOS	CELL			English	Article							MESODERM INDUCTION; GROWTH-FACTORS; AMPHIBIAN DEVELOPMENT; INT-1 PROTOONCOGENE; LAEVIS EMBRYOS; ACTIVIN-A; PATTERN; TRANSCRIPTION; EMBRYOGENESIS; EXPRESSION	Studies in Xenopus have shown that growth factors of the TGF-beta and Wnt oncogene families can mimic aspects of dorsal axis formation. Here we directly compare the inductive properties of two Wnt proteins by injecting synthetic mRNA into developing embryos. The results show that Wnt-1 and Xwnt-8 can induce a new and complete dorsal axis and can rescue the development of axis-deficient, UV-irradiated embryos. In contrast, activin mRNA injection induces only a partial dorsal axis that lacks anterior structures. These studies demonstrate that the mechanism of Wnt-induced axis duplication results from the creation of an independent Spemann organizer. The relationship between the properties of the endogenous dorsal inducer and the effects of Wnts and activins is discussed.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	SOKOL, S (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.		Young, Richard A/F-6495-2012; Moon, Randall/M-5605-2019; Moon, Randall T/B-1743-2014	Young, Richard A/0000-0001-8855-8647; Moon, Randall/0000-0002-9352-1408; Moon, Randall T/0000-0002-9352-1408; Sokol, Sergei/0000-0002-3963-9202				ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; COOKE J, 1989, DEVELOPMENT, V107, P229; COOKE J, 1987, DEVELOPMENT, V101, P893; DALE L, 1987, DEVELOPMENT, V99, P527; ELINSON RP, 1989, DEV GROWTH DIFFER, V31, P423; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; JONES EA, 1987, DEVELOPMENT, V101, P557; KAGEURA H, 1990, DEV BIOL, V142, P432, DOI 10.1016/0012-1606(90)90365-P; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MCMAHON AP, 1989, DEVELOPMENT, V107, P161; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MOHUN TJ, 1984, NATURE, V311, P715; MOODY SA, 1987, DEV BIOL, V119, P560, DOI 10.1016/0012-1606(87)90059-5; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NAKAMURA O, 1970, P JPN ACAD, V46, P546, DOI 10.2183/pjab1945.46.546; NAKAMURA O, 1978, ORG MILESTONE HALF C, P179; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V163, P298, DOI 10.1007/BF00577017; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NIEUWKOOP PD, 1969, ROUX ARCH DEVEL BIOL, V62, P341; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OGI K-I, 1967, Science Reports of the Tohoku University Fourth Series (Biology), V33, P239; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PATERNO GD, 1989, DEVELOPMENT, V106, P79; Roberts AB, 1990, GROWTH FACTORS, V3, P277, DOI 10.3109/08977199009003670; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; Ruiz i Altaba A, 1989, Nature, V341, P33; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1989, DEVELOPMENT, V105, P665; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; Spemann H., 1938, EMBRYONIC DEV INDUCT; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VIZE PD, 1991, XENOPUS LAEVIS PRACT; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	54	461	470	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					741	752		10.1016/0092-8674(91)90069-B	http://dx.doi.org/10.1016/0092-8674(91)90069-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1834344				2022-12-28	WOS:A1991GQ40700011
J	MORIYOSHI, K; MASU, M; ISHII, T; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S				MORIYOSHI, K; MASU, M; ISHII, T; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S			MOLECULAR-CLONING AND CHARACTERIZATION OF THE RAT NMDA RECEPTOR	NATURE			English	Article							AMINO-ACID RECEPTORS; GLUTAMATE RECEPTOR; XENOPUS OOCYTES; FUNCTIONAL EXPRESSION; PROTEIN-KINASE; ACETYLCHOLINE-RECEPTOR; BRAIN; SEQUENCE; CHANNEL; KAINATE	A complementary DNA encoding the rat NMDA receptor has been cloned and characterized. The single protein encoded by the cDNA forms a receptor-channel complex that has electrophysiological and pharmacological properties characteristic of the NMDA receptor. This protein has a significant sequence similarity to the AMPA/kainate receptors and contains four putative transmembrane segments following a large extracellular domain. The NMDA receptor messenger RNA is expressed in neuronal cells throughout the brain regions, particularly in the hippocampus, cerebral cortex and cerebellum.	KYOTO UNIV,DEPT MORPHOL BRAIN SCI,KYOTO 606,JAPAN	Kyoto University	MORIYOSHI, K (corresponding author), KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN.		Shigemoto, Ryuichi/E-3628-2013	Shigemoto, Ryuichi/0000-0001-8761-9444				BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CHANGEUX JP, 1987, TRENDS PHARMACOL SCI, V8, P459, DOI 10.1016/0165-6147(87)90039-3; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HONORE T, 1989, EUR J PHARM-MOLEC PH, V172, P239, DOI 10.1016/0922-4106(89)90054-0; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; IKIN AF, 1990, BIOCHEMISTRY-US, V29, P2290, DOI 10.1021/bi00461a012; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEONARD JP, 1990, NEURON, V4, P53, DOI 10.1016/0896-6273(90)90443-J; LODGE D, 1990, TRENDS PHARMACOL SCI, V11, P81, DOI 10.1016/0165-6147(90)90323-Z; LY AM, 1991, BIOCHEMISTRY-US, V30, P4307, DOI 10.1021/bi00231a029; MADISON DV, 1991, REV NEUROSCI, V14, P379; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NOHNO T, 1986, MOL GEN GENET, V205, P260, DOI 10.1007/BF00430437; SAITO M, 1989, BRAIN RES, V481, P16, DOI 10.1016/0006-8993(89)90480-0; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SONDERS MS, 1990, J BIOL CHEM, V265, P6776; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VERDOORN TA, 1988, MOL PHARMACOL, V34, P298; VERDOORN TA, 1987, SCIENCE, V238, P1114, DOI 10.1126/science.2825347; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; YOUNG AB, 1990, TRENDS PHARMACOL SCI, V11, P126, DOI 10.1016/0165-6147(90)90199-I	44	1724	1764	1	41	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					31	37		10.1038/354031a0	http://dx.doi.org/10.1038/354031a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1834949				2022-12-28	WOS:A1991GN82900048
J	PAOLINI, R; JOUVIN, MH; KINET, JP				PAOLINI, R; JOUVIN, MH; KINET, JP			PHOSPHORYLATION AND DEPHOSPHORYLATION OF THE HIGH-AFFINITY RECEPTOR FOR IMMUNOGLOBULIN-E IMMEDIATELY AFTER RECEPTOR ENGAGEMENT AND DISENGAGEMENT	NATURE			English	Article							CELL ANTIGEN RECEPTOR; NATURAL-KILLER-CELLS; FC-GAMMA RECEPTOR; IGE RECEPTOR; ZETA-CHAIN; MOLECULAR-CLONING; CD16; EXPRESSION; SUBUNIT; RIII	TRIGGERING of mast cells and basophils by immunoglobulin E (IgE) and antigen induces various biochemical signals, including tyrosine kinase activation 1,2, which lead to cell degranulation and the release of mediators of the allergic reaction. The high-affinity receptor for IgE (Fc-epsilon-RI) responsible for initiating these events is a complex structure composed of an IgE-binding alpha-chain, a beta-chain and a homodimer of gamma-chains 3. It has been assumed that beta and gamma, which have extensive cytoplasmic domains, play an important but undefined role in coupling Fc-epsilon-RI to signal transduction mechanisms. Here we show that Fc-epsilon-RI engagement induces immediate in vivo phosphorylation on beta (tyrosine and serine) and gamma (tyrosine and threonine) by at least two different non-receptor kinases. We take advantage of unique features of this receptor system to demonstrate that the phosphorylation signal is restricted to activated receptors and is immediately reversible upon receptor disengagement by undefined phosphatases. Rapid phosphorylation and dephosphorylation may be a general mechanism to couple and uncouple activated receptors to other effector molecules. This could be particularly relevant to other multimeric receptors containing Fc-epsilon-RI gamma-chains or the related-zeta and eta-chains such as the T-cell antigen receptor (TCR) 4-6 and the low-affinity receptor for immunoglobulin G (Fc-gamma-RIII, CD16) (refs 7-11).			PAOLINI, R (corresponding author), NIAID,MOLEC ALLERGY & IMMUNOL SECT,TWINBROOK II BLDG,12441 PARKLAWN DR,ROCKVILLE,MD 20852, USA.			PAOLINI, Rossella/0000-0001-7605-1531				ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CUNHAMELO JR, 1987, J BIOL CHEM, V262, P11455; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LANE PJL, 1991, J IMMUNOL, V146, P715; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LIU FT, 1980, J IMMUNOL, V124, P2728; MILLARD PJ, 1988, P NATL ACAD SCI USA, V85, P1854, DOI 10.1073/pnas.85.6.1854; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; PEREZMONTFORT R, 1983, BIOCHEMISTRY-US, V22, P5733, DOI 10.1021/bi00294a009; QUARTO R, 1986, MOL IMMUNOL, V23, P1215, DOI 10.1016/0161-5890(86)90154-9; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; STEPHAN V, 1991, FASEB J, V5; VIVIER E, 1991, J IMMUNOL, V146, P206; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377	28	284	287	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1991	353	6347					855	858		10.1038/353855a0	http://dx.doi.org/10.1038/353855a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1834946				2022-12-28	WOS:A1991GM73200063
J	BURG, G; DUMMER, R; WILHELM, M; NESTLE, F; OTT, MM; FELLER, A; HEFNER, H; LANZ, U; SCHWINN, A; WIEDE, J				BURG, G; DUMMER, R; WILHELM, M; NESTLE, F; OTT, MM; FELLER, A; HEFNER, H; LANZ, U; SCHWINN, A; WIEDE, J			A SUBCUTANEOUS DELTA-POSITIVE T-CELL LYMPHOMA THAT PRODUCES INTERFERON-GAMMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CYTOPHAGIC HISTIOCYTIC PANNICULITIS; MONOCLONAL-ANTIBODY; HUMAN-SKIN; LYMPHOCYTES; EXPRESSION; PAPULOSIS; ANTIGENS; DISEASE; BENIGN		UNIV WURZBURG,INST HIST,W-8700 WURZBURG,GERMANY; UNIV WURZBURG,DEPT DERMATOL,W-8700 WURZBURG,GERMANY; UNIV WURZBURG,INTERNAL MED POLYCLIN,W-8700 WURZBURG,GERMANY; UNIV WURZBURG,DEPT PATHOL,W-8700 WURZBURG,GERMANY	University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg			Feller, Alfred/E-3853-2010; Wilhelm, Martin/J-3964-2014					AISENBERG AC, 1981, BLOOD, V58, P818; BARRON DR, 1985, CANCER, V55, P2538, DOI 10.1002/1097-0142(19850601)55:11<2538::AID-CNCR2820551104>3.0.CO;2-U; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOS JD, 1990, J INVEST DERMATOL, V94, P37, DOI 10.1111/1523-1747.ep12873333; BURG G, 1983, CUTANEOUS LYMPHOMAS, P95; CROTTY CP, 1981, J AM ACAD DERMATOL, V4, P181, DOI 10.1016/S0190-9622(81)70022-7; DUMMER R, 1989, Journal of Cutaneous Pathology, V16, P301; DUMMER R, IN PRESS DERMATOLOGI; DUPUY P, 1990, J INVEST DERMATOL, V94, P764, DOI 10.1111/1523-1747.ep12874626; FALINI B, 1989, BLOOD, V74, P2501; GROH V, 1989, J EXP MED, V169, P1277, DOI 10.1084/jem.169.4.1277; HORN TD, 1989, J CUTAN PATHOL, V16, P300; KADIN M, 1985, AM J PATHOL, V119, P315; KAPLAN EH, 1990, J NATL CANCER I, V82, P208, DOI 10.1093/jnci/82.3.208; KAUDEWITZ P, 1985, DERMATOL CLIN, V3, P749, DOI 10.1016/S0733-8635(18)30870-2; KURZROCK R, 1985, CANCER RES, V45, P2866; MACAULAY WL, 1968, ARCH DERMATOL, V97, P23, DOI 10.1001/archderm.97.1.23; MICHIE SA, 1989, J INVEST DERMATOL, V93, P116, DOI 10.1111/1523-1747.ep12277376; NESTLE F, 1990, Archives of Dermatological Research, V281, P557; PICKER LJ, 1988, AM J PATHOL, V132, P401; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; WEISS LM, 1986, NEW ENGL J MED, V315, P475, DOI 10.1056/NEJM198608213150802; Winkelmann RK, 1980, GIORN ITAL DERMAT V, V115, P175; YOSHIKAI Y, 1984, NATURE, V312, P521, DOI 10.1038/312521a0	24	139	141	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1991	325	15					1078	1081		10.1056/NEJM199110103251506	http://dx.doi.org/10.1056/NEJM199110103251506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ108	1832485				2022-12-28	WOS:A1991GJ10800006
J	NASMYTH, K; DIRICK, L				NASMYTH, K; DIRICK, L			THE ROLE OF SWI4 AND SWI6 IN THE ACTIVITY OF G1 CYCLINS IN YEAST	CELL			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; HO GENE; FISSION YEAST; ESCHERICHIA-COLI; MATING-PHEROMONE; DNA; DIVISION; IDENTIFICATION; TRANSCRIPTION	Entry into the mitotic cycle (START) requires a protein kinase encoded by the CDC28 gene and one of three redundant G1-specific cyclins encoded by CLN1, -2, and -3. SWI4 and SWI6 are transcription factors required for the START-dependent activation of the HO endonuclease gene. They also fulfill an overlapping but essential role for cell division since cells deleted for both genes are inviable. We show that the essential role of SWI4 and SWI6 is to ensure the activity of G1-specific cyclin genes. SWI4 and SWI6 appear necessary for the transcription of CLN1 and CLN2, but not for that of CLN3. CLN3 function is, however, also dependent on SWI4 and SWI6.			NASMYTH, K (corresponding author), INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1989, NATURE, V342, P803; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CARTER BLA, 1980, GENETICS, V96, P561; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HABER JE, 1977, GENETICS, V87, P33; HADWIGER JA, 1990, NUCLEIC ACIDS RES, V18, P4025, DOI 10.1093/nar/18.13.4025; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MORTIMER RK, 1969, YEASTS, V1, P385; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SOCKANATHAN S, 1991, THESIS U CAMBRIDGE C; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	46	291	296	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					995	1013		10.1016/0092-8674(91)90444-4	http://dx.doi.org/10.1016/0092-8674(91)90444-4			19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1832338				2022-12-28	WOS:A1991GE46000017
J	SCANU, AM; LAWN, RM; BERG, K				SCANU, AM; LAWN, RM; BERG, K			LIPOPROTEIN(A) AND ATHEROSCLEROSIS	ANNALS OF INTERNAL MEDICINE			English	Discussion							CORONARY HEART-DISEASE; LP(A) LIPOPROTEIN; DENSITY-LIPOPROTEIN; HUMAN-PLASMA; SERUM-LIPOPROTEINS; HUMAN-PLASMINOGEN; APOLIPOPROTEIN-B; MESSENGER-RNA; LP ANTIGEN; GENE	Lipoprotein(a) [Lp(a)], a lipoprotein variant, was relegated for almost 25 years to the study of a few specialists. During the past 3 to 4 years, however, there has been a tremendous upsurge of interest in Lp(a), primarily because of multidisciplinary efforts in structural and molecular biology. Findings emerging from these efforts include the following: Lp(a) represents a cholesteryl-ester, low-density-lipoprotein (LDL)-like particle with apolipoprotein (apo) B-100 linked to apo(a); apo(a) is a glycoprotein coded by a single gene locus on the long arm of chromosome 6, which has several alleles, accounting for its remarkable size polymorphism (300 to 800 kD); apo(a) size polymorphism relates to plasma levels and density distribution of Lp(a); apo(a) is strikingly similar to plasminogen; and in vitro, Lp(a), in appropriate levels, competes for some physiologic functions of plasminogen in the coagulation and fibrinolytic cascade and may thus be thrombogenic. The LDL-like properties of Lp(a) may also confer atherogenic potential, but the mechanisms underlying this atherogenicity remain to be defined. In epidemiologic studies, high plasma Lp(a) levels have been associated with an increased incidence of atherosclerotic cardiovascular disease, especially in patients less than 60 years of age. Moreover, Lp(a) has been found as an intact particle in the arterial intima, particularly in association with atherosclerotic plaque. This finding suggests that Lp(a) can traverse the endothelium, possibly by a non-receptor-mediated process, and, at the intimal level, acquire thrombogenic and atherogenic potentials. Current information justifies the need to determine plasma Lp(a) levels in patients with a history of atherosclerotic cardiovascular disease. Unfortunately, the available techniques need to be standardized. Apolipoprotein(a) exists in isoforms of different sizes, and the importance of determining apo(a) phenotypes in clinical practice remains to be established.	UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT BIOCHEM, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOLEC BIOL, CHICAGO, IL 60637 USA; STANFORD UNIV, MED CTR, SCH MED, DIV CARDIOVASC MED, STANFORD, CA 94305 USA; UNIV OSLO, INST MED GENET, OSLO 3, NORWAY; GENENTECH INC, S SAN FRANCISCO, CA USA; ULLEVAL HOSP, OSLO CITY HOSP, DEPT MED GENET, OSLO 1, NORWAY	University of Chicago; University of Chicago; University of Chicago; Stanford University; University of Oslo; Roche Holding; Genentech; University of Oslo					PHS HHS [18577] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBERS JJ, 1977, J LIPID RES, V18, P331; ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; BERG K, 1990, CLIN GENET, V37, P473; BERG K, 1983, PROG MED GENET, V5, P35; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; BERG K, 1990, FROM PHENOTYPE TO GENE IN COMMON DISORDERS, P77; BERG K, 1976, LANCET, V1, P499; BERG K, 1974, CLIN GENET, V6, P230; BERG K, 1968, Series Haematologica, V1, P111; BERG K, 1989, LANCET, V2, P812; BERG K, 1990, FROM PHENOTYPE TO GENE IN COMMON DISORDERS, P138; Berg K., 1990, LIPOPROTEIN A, P1; BERG K, 1979, BIOCH ATHEROSCLEROSI, P419; BERG K, 1971, HUM GENET, P352; BERG K, 1987, ATHEROSCLEROSIS BIOL, P323; BROWN MS, 1987, NATURE, V330, P113, DOI 10.1038/330113a0; CARLSON LA, 1989, J INTERN MED, V226, P271, DOI 10.1111/j.1365-2796.1989.tb01393.x; CASTELLINO FJ, 1987, J MOL EVOL, V26, P358, DOI 10.1007/BF02101155; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; DAHLEN G, 1978, CLIN GENET, V14, P115; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; Dahlen GH, 1990, LIPOPROTEIN A, P151; DRAYNA DT, 1988, GENOMICS, V3, P230, DOI 10.1016/0888-7543(88)90084-5; DURRINGTON PN, 1988, LANCET, V1, P1070; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; FLESS GM, 1982, ARTERIOSCLEROSIS, V2, P475, DOI 10.1161/01.ATV.2.6.475; FLESS GM, 1984, J BIOL CHEM, V259, P1470; FLESS GM, 1990, J LIPID RES, V31, P909; GAUBATZ JW, 1983, J BIOL CHEM, V258, P4582; GAVISH D, 1989, J CLIN INVEST, V84, P2021, DOI 10.1172/JCI114395; GENEST J, 1989, CIRCULATION S2, V80, P80; GURAKAR A, 1985, ATHEROSCLEROSIS, V57, P293, DOI 10.1016/0021-9150(85)90041-3; HABERLAND ME, 1989, ARTERIOSCLEROSIS, V9, pA700; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HIXSON JE, 1989, J BIOL CHEM, V264, P6013; HOFMANN SL, 1990, J CLIN INVEST, V85, P1542, DOI 10.1172/JCI114602; KERVINEN K, 1991, LIFE SCI, V48, P2183, DOI 10.1016/0024-3205(91)90152-2; KOLTRINGER P, 1985, ATHEROSCLEROSIS, V58, P187, DOI 10.1016/0021-9150(85)90065-6; KONDO I, 1990, CLIN GENET, V37, P132; KOSCHINSKY ML, 1990, BIOCHEMISTRY-US, V29, P640, DOI 10.1021/bi00455a007; LAPLAUD PM, 1988, J LIPID RES, V29, P1157; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MAARTMANNMOE K, 1981, CLIN GENET, V20, P352; MAEDA N, 1983, P NATL ACAD SCI-BIOL, V80, P5012, DOI 10.1073/pnas.80.16.5012; MARTH E, 1982, ANN NUTR METAB, V26, P56, DOI 10.1159/000176544; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MORRISETT JD, 1987, PLASMA LIPOPROTEINS, P129; MORTON N E, 1985, Genetic Epidemiology, V2, P113, DOI 10.1002/gepi.1370020202; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RATH M, 1990, P NATL ACAD SCI USA, V87, P9388, DOI 10.1073/pnas.87.23.9388; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; RITTNER C, 1971, VOX SANG, V20, P526, DOI 10.1111/j.1423-0410.1971.tb00464.x; SCANU AM, 1990, J LAB CLIN MED, V116, P142; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1988, ARCH PATHOL LAB MED, V112, P1045; SCANU AM, 1991, MOSBY YB, P249; SCHULTZ JS, 1974, ANN HUM GENET, V38, P39, DOI 10.1111/j.1469-1809.1974.tb01991.x; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; SING CF, 1974, ANN HUM GENET, V38, P47, DOI 10.1111/j.1469-1809.1974.tb01992.x; THIERY J, 1988, KLIN WOCHENSCHR, V66, P462, DOI 10.1007/BF01745519; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; TREXLER M, 1982, J BIOL CHEM, V257, P7401; UTERMANN G, 1983, FEBS LETT, V154, P357, DOI 10.1016/0014-5793(83)80182-3; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1989, P NATL ACAD SCI USA, V86, P4171, DOI 10.1073/pnas.86.11.4171; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; WALTON KW, 1972, PROTIDES BIOL FLUIDS, P225; WEITKAMP LR, 1988, HUM GENET, V79, P80, DOI 10.1007/BF00291716; WOLF K, 1989, CIRCULATION S, V80, P2078	72	265	274	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1991	115	3					209	218		10.7326/0003-4819-115-3-209	http://dx.doi.org/10.7326/0003-4819-115-3-209			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY152	1829339				2022-12-28	WOS:A1991FY15200009
J	DAVIES, TF; MARTIN, A; CONCEPCION, ES; GRAVES, P; COHEN, L; BENNUN, A				DAVIES, TF; MARTIN, A; CONCEPCION, ES; GRAVES, P; COHEN, L; BENNUN, A			EVIDENCE OF LIMITED VARIABILITY OF ANTIGEN RECEPTORS ON INTRATHYROIDAL T-CELLS IN AUTOIMMUNE THYROID-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYELIN BASIC-PROTEIN; GRAVES-DISEASE; ANTITHYROID DRUGS; CLONES; LYMPHOCYTES; ENCEPHALOMYELITIS; THYROGLOBULIN; HETEROGENEITY; TRANSCRIPTS; LINES	Background. Patients with autoimmune thyroid diseases, including Graves' disease and Hashimoto's disease, have marked lymphocytic infiltration in their thyroid glands. We examined the gene for the variable regions of the alpha-chain of the human T-cell receptor (the V-alpha gene) in intrathyroidal T cells to determine whether the infiltration is a secondary heterogeneous immune response or a more restricted, and therefore primary and presumably pathogenetic, reaction to thyroid autoantigens. Methods. We used the polymerase chain reaction to detect small numbers of T cells expressing the variable region of the V-alpha gene. Different oligonucleotides were used to amplify complementary DNA for the 18 known families of the V-alpha gene in intrathyroidal T cells from 9 patients with autoimmune thyroid disease. We compared the findings with the results in patients with nonautoimmune thyroid disease as well as those in normal subjects. Results. We found marked restriction in the expression of T-cell-receptor V-alpha genes by T cells from the thyroid tissue of patients with autoimmune thyroid disease. An average of only 5 of the 18 V-alpha genes were expressed in such samples, as compared with 17 V-alpha genes expressed in peripheral-blood T cells from the same patients. No such restriction was found in thyroid tissue from patients with nonautoimmune thyroid disease. The predominantly expressed V-alpha genes differed from patient to patient, however, with no clear association with the type of disease. Conclusions. Intrathyroidal T-cell accumulation in autoimmune thyroid disease is highly restricted and points to the primacy of T cells in causing thyroid disorders. These results present the possibility of using antibodies to the T-cell receptor for the specific inhibition of abnormal T-cell function in autoimmune thyroid disease.	CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029; WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Weizmann Institute of Science					NIDDK NIH HHS [DK28243, DK35764] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035764, R01DK028243] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BENNUN A, 1991, P NATL ACAD SCI USA, V88, P2466, DOI 10.1073/pnas.88.6.2466; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; FISFALEN ME, 1988, J CLIN ENDOCR METAB, V66, P776, DOI 10.1210/jcem-66-4-776; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOODMAN MG, 1982, B LYMPHOCYTES TODAY, P63; JANSSON R, 1983, J CLIN ENDOCR METAB, V56, P1164, DOI 10.1210/jcem-56-6-1164; KIMURA H, 1991, CLIN IMMUNOL IMMUNOP, V58, P195, DOI 10.1016/0090-1229(91)90136-X; LONDEI M, 1985, SCIENCE, V228, P85, DOI 10.1126/science.3871967; MACKENZIE WA, 1987, IMMUNOLOGY, V61, P101; MACKENZIE WA, 1987, J CLIN ENDOCR METAB, V64, P818, DOI 10.1210/jcem-64-4-818; MARGOLICK JB, 1984, AM J MED, V76, P815, DOI 10.1016/0002-9343(84)90992-6; MARON R, 1983, J IMMUNOL, V131, P2316; MARTIN A, 1990, AUTOIMMUNITY, V6, P269, DOI 10.3109/08916939008998419; MOEBIUS U, 1990, EUR J IMMUNOL, V20, P889, DOI 10.1002/eji.1830200426; OKSENBERG JR, 1990, NATURE, V345, P344, DOI 10.1038/345344a0; ROMAN SH, 1984, CLIN CHEM, V30, P246; ROMBALL CG, 1987, J IMMUNOL, V138, P1092; SPINELLA DG, 1987, J IMMUNOL, V138, P3991; VOLPE R, 1986, CLIN ENDOCRINOL, V25, P453, DOI 10.1111/j.1365-2265.1986.tb01712.x; WEISS I, 1981, J CLIN ENDOCR METAB, V53, P1223, DOI 10.1210/jcem-53-6-1223; WUCHERPFENNIG KW, 1990, SCIENCE, V248, P1016, DOI 10.1126/science.1693015	22	212	213	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 25	1991	325	4					238	244		10.1056/NEJM199107253250404	http://dx.doi.org/10.1056/NEJM199107253250404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX627	1829139	Bronze			2022-12-28	WOS:A1991FX62700004
J	LAUER, MS; ANDERSON, KM; KANNEL, WB; LEVY, D				LAUER, MS; ANDERSON, KM; KANNEL, WB; LEVY, D			THE IMPACT OF OBESITY ON LEFT-VENTRICULAR MASS AND GEOMETRY - THE FRAMINGHAM-HEART-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AORTIC REGURGITATION; GLUCOSE-INTOLERANCE; BLOOD-PRESSURE; BODY BUILD; HYPERTROPHY; HYPERTENSION; DISEASE; CARDIOMYOPATHY; REDUCTION; CRITERIA	Objective.- To determine the relationship of varying degrees of obesity with left ventricular mass and geometry. Design.- Survey. Setting.- Population-based epidemiologic study. Participants and Methods.- M-mode echocardiograms, which were adequate for estimation of left ventricular mass, were obtained in 3922 healthy participants of the Framingham Heart Study Measured height and weight were used to calculate body-mass index, a measure of obesity. Results.- Body-mass index was strongly correlated with left ventricular mass. After adjusting for age and blood pressure, body-mass index remained a strong independent predictor of left ventricular mass, left ventricular wall thickness, and left ventricular internal dimension (P < .01 for all). Body-mass index was associated with prevalence of echocardiographic left ventricular hypertrophy, particularly in subjects with a body-mass index exceeding 30 kg/m2. Conclusions.- Obesity is significantly correlated with left ventricular mass, even after controlling for age and blood pressure. The increase in left ventricular mass associated with increasing adiposity reflects increases in both left ventricular wall thickness and left ventricular internal dimension.	BETH ISRAEL HOSP, CHARLES A DANA RES INST, BOSTON, MA 02215 USA; BOSTON UNIV, SCH MED, DIV EPIDEMIOL & PREVENT MED, BOSTON, MA 02118 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT MED, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP,DEPT MED,DIV CARDIOL, THORNDIKE LAB, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Boston University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	LAUER, MS (corresponding author), NHLBI, FRAMINGHAM HEART STUDY, 5 THURBER ST, FRAMINGHAM, MA 02215 USA.		Levy, Daniel/ABB-2752-2021; Lauer, Michael S/L-9656-2013; Levy, Daniel/ABF-6873-2021	Lauer, Michael S/0000-0002-9217-8177; Levy, Daniel/0000-0003-1843-8724	NHLBI NIH HHS [HL07374, N01-HC-38038] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007374] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER J K, 1962, Cardiovasc Res Cent Bull, V1, P39; ALEXANDER JK, 1985, PROG CARDIOVASC DIS, V27, P325, DOI 10.1016/S0033-0620(85)80002-5; BOROW K, 1989, TXB ADULT PEDIATRIC, P108; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DEDIVITIIS O, 1981, CIRCULATION, V64, P477, DOI 10.1161/01.CIR.64.3.477; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; FEIGENBAUM H, 1981, ECHOCARDIOGR-J CARD, P51; GARDIN JM, 1987, HYPERTENSION, V9, P36; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; HAMMOND IW, 1988, J AM COLL CARDIOL, V12, P996, DOI 10.1016/0735-1097(88)90467-6; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1967, ANN INTERN MED, V67, P48, DOI 10.7326/0003-4819-67-1-48; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; KATZ AM, 1990, NEW ENGL J MED, V322, P100; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; MACMAHON SW, 1986, NEW ENGL J MED, V314, P334, DOI 10.1056/NEJM198602063140602; MESSERLI FH, 1981, ARCH INTERN MED, V141, P81, DOI 10.1001/archinte.141.1.81; MESSERLI FH, 1983, ANN INTERN MED, V99, P757, DOI 10.7326/0003-4819-99-6-757; MESSERLI FH, 1982, LANCET, V1, P1165; OSTLUND RE, 1990, NEW ENGL J MED, V322, P229, DOI 10.1056/NEJM199001253220404; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SAVAGE DD, 1990, AM J CARDIOL, V65, P371, DOI 10.1016/0002-9149(90)90304-J; SAVAGE DD, 1987, CIRCULATION, V75, P26; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SORLIE P, 1980, JAMA-J AM MED ASSOC, V243, P1828, DOI 10.1001/jama.243.18.1828; TOBIAN L, 1978, NEW ENGL J MED, V298, P46, DOI 10.1056/NEJM197801052980110; VANDENBOSSCHE JL, 1984, J AM COLL CARDIOL, V4, P1195, DOI 10.1016/S0735-1097(84)80138-2; WILSON JR, 1980, AM J MED, V68, P664, DOI 10.1016/0002-9343(80)90252-1; WILSON PW, 1981, AM J EPIDEMIOL, V114, P697, DOI 10.1093/oxfordjournals.aje.a113240	37	457	478	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					231	236		10.1001/jama.266.2.231	http://dx.doi.org/10.1001/jama.266.2.231			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	1829117				2022-12-28	WOS:A1991FU89600031
J	CHITTENDEN, T; LIVINGSTON, DM; KAELIN, WG				CHITTENDEN, T; LIVINGSTON, DM; KAELIN, WG			THE T/E1A-BINDING DOMAIN OF THE RETINOBLASTOMA PRODUCT CAN INTERACT SELECTIVELY WITH A SEQUENCE-SPECIFIC DNA-BINDING PROTEIN	CELL			English	Article							E2F TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS; LARGE T-ANTIGENS; SUSCEPTIBILITY GENE; REGULATORY PROTEINS; TRANS-ACTIVATION; CELL-CYCLE; RB GENE; SV40; PROMOTER	A DNA-binding site selection and enrichment procedure revealed a sequence-specific DNA-binding activity selectively associated with glutathione S-transferase-retinoblastoma protein chimeras (GST-RB) that had been incubated with a human cell extract. Appropriate mutant forms of GST-RB, incubated in equivalent extracts, did not associate with this specific DNA-binding activity, and a peptide replica of the HPV E7 RB-binding segment selectively inhibited the association of GST-RB with the sequence-specific DNA-binding protein(s). Sequence analysis of oligonucleotides with high affinity for GST-RB complexes, as well as the results of competition binding studies, strongly suggest that RB can associate specifically with the transcription factor E2F or with a protein having closely related DNA-binding properties.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	CHITTENDEN, T (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.							BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES RE, 1990, J BIOL CHEM, V265, P12782; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Maniatis T., 1982, MOL CLONING; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PIENTENPOL JA, 1990, CELL, V61, P777; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x	41	396	414	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1073	1082		10.1016/0092-8674(91)90559-H	http://dx.doi.org/10.1016/0092-8674(91)90559-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1828394				2022-12-28	WOS:A1991FR04700018
J	CONNOLLY, T; RAPIEJKO, PJ; GILMORE, R				CONNOLLY, T; RAPIEJKO, PJ; GILMORE, R			REQUIREMENT OF GTP HYDROLYSIS FOR DISSOCIATION OF THE SIGNAL RECOGNITION PARTICLE FROM ITS RECEPTOR	SCIENCE			English	Article								The signal recognition particle (SRP) directs signal sequence specific targeting of ribosomes to the rough endoplasmic reticulum. Displacement of the SRP from the signal sequence of a nascent polypeptide is a guanosine triphosphate (GTP)-dependent reaction mediated by the membrane-bound SRP receptor. A nonhydrolyzable GTP analog can replace GTP in the signal sequence displacement reaction, but the SRP then fails to dissociate from the membrane. Complexes of the SRP with its receptor containing the nonhydrolyzable analog are incompetent for subsequent rounds of protein translocation. Thus, vectorial targeting of ribosomes to the endoplasmic reticulum is controlled by a GTP hydrolysis cycle that regulates the affinity between the SRP, signal sequences, and the SRP receptor.	UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035687] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35687] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; CONNOLLY T, UNPUB; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; HOFFMAN KE, 1988, J BIOL CHEM, V263, P4381; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MEYER DI, 1980, J CELL BIOL, V87, P498, DOI 10.1083/jcb.87.2.498; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALTER P, 1983, J CELL BIOL, V97, P1693, DOI 10.1083/jcb.97.6.1693; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WILSON C, 1988, J CELL BIOL, V107, P69, DOI 10.1083/jcb.107.1.69	27	172	174	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1991	252	5009					1171	1173		10.1126/science.252.5009.1171	http://dx.doi.org/10.1126/science.252.5009.1171			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	1851576				2022-12-28	WOS:A1991FN05600050
J	HEMPSTEAD, BL; MARTINZANCA, D; KAPLAN, DR; PARADA, LF; CHAO, MV				HEMPSTEAD, BL; MARTINZANCA, D; KAPLAN, DR; PARADA, LF; CHAO, MV			HIGH-AFFINITY NGF BINDING REQUIRES COEXPRESSION OF THE TRK PROTOONCOGENE AND THE LOW-AFFINITY NGF RECEPTOR	NATURE			English	Article							NERVE GROWTH-FACTOR; PC12 PHEOCHROMOCYTOMA CELLS; HUMAN NEURO-BLASTOMA; HUMAN-MELANOMA CELLS; NEUROTROPHIC FACTOR; RAT PHEOCHROMOCYTOMA; MOLECULAR-CLONING; GENE-TRANSFER; EXPRESSION; BRAIN	Nerve growth factor (NGF) interacts with two different low-affinity receptors that can be distinguished by affinity crosslinking. Reconstitution experiments by membrane fusion and transient transfection into heterologous cells indicate that high-affinity NGF binding requires coexpression and binding to both the low-affinity NGF receptor and the tyrosine kinase trk gene product. These studies reveal a new growth factor receptor-mediated mechanism of cellular differentiation involving trk and the low-affinity NGF receptor.	NCI, FREDERICK CANC RES & DEV CTR, MOLEC EMBRYOL GRP, FREDERICK, MD 21701 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	HEMPSTEAD, BL (corresponding author), CORNELL UNIV, MED CTR,COLL MED,DEPT MED,DEPT CELL BIOL & ANAT, DIV HEMATOL ONCOL, 1300 YORK AVE, NEW YORK, NY 10021 USA.		Parada, luis F/B-9400-2014	Chao, Moses/0000-0002-6969-3744				ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Berg M.D., UNPUB; BERND P, 1984, J BIOL CHEM, V259, P5509; BLOCK T, 1983, J NEUROCHEM, V40, P1654, DOI 10.1111/j.1471-4159.1983.tb08139.x; BOTHWELL MA, 1980, CELL, V21, P857, DOI 10.1016/0092-8674(80)90449-3; BURTON J, 1990, P NATL ACAD SCI USA, V87, P7329, DOI 10.1073/pnas.87.18.7329; BUXSER SE, 1983, J CELL BIOCHEM, V22, P219, DOI 10.1002/jcb.240220404; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; ESCANDON E, 1990, DEV BIOL, V142, P293, DOI 10.1016/0012-1606(90)90350-R; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GREEN SH, 1986, J BIOL CHEM, V261, P5316; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1977, BRAIN RES, V133, P350, DOI 10.1016/0006-8993(77)90770-3; GROB PM, 1983, P NATL ACAD SCI-BIOL, V80, P6819, DOI 10.1073/pnas.80.22.6819; GROB PM, 1985, J BIOL CHEM, V260, P8044; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HEMPSTEAD B, 1988, COLD SPRING HARB SYM, V53, P477, DOI 10.1101/SQB.1988.053.01.055; HEMPSTEAD BL, 1989, RECENT PROG HORM RES, V45, P441; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HEUER JG, 1990, DEV BIOL, V137, P287, DOI 10.1016/0012-1606(90)90255-H; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1987, EMBO J, V6, P1197, DOI 10.1002/j.1460-2075.1987.tb02354.x; HOSANG M, 1985, J BIOL CHEM, V260, P655; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON EM, 1987, BIOCHEM PHARMACOL, V36, P4189, DOI 10.1016/0006-2952(87)90658-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, IN PRESS SCIENCE; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MASSAGUE J, 1981, J BIOL CHEM, V256, P9419; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLENDER EJ, 1980, J BIOL CHEM, V255, P9338; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; ROBB RJ, 1986, P NATL ACAD SCI USA, V83, P3992, DOI 10.1073/pnas.83.11.3992; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SHARON M, 1990, P NATL ACAD SCI USA, V87, P4869, DOI 10.1073/pnas.87.12.4869; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SONNENFELD KH, 1985, J NEUROSCI, V5, P1717; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; TANIUCHI M, 1986, J BIOL CHEM, V261, P3342; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P1950, DOI 10.1073/pnas.83.6.1950; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VALE RD, 1982, J CELL BIOL, V94, P710, DOI 10.1083/jcb.94.3.710; Volonte C, 1990, GROWTH FACTORS, V2, P321; WALDEMAN TA, 1990, ANNU REV BIOCHEM, V58, P875; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAN H, IN PRESS SCIENCE; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	79	1129	1154	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	1991	350	6320					678	683		10.1038/350678a0	http://dx.doi.org/10.1038/350678a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	1850821				2022-12-28	WOS:A1991FJ13000050
J	STEINBERG, KK; THACKER, SB; SMITH, SJ; STROUP, DF; ZACK, MM; FLANDERS, WD; BERKELMAN, RL				STEINBERG, KK; THACKER, SB; SMITH, SJ; STROUP, DF; ZACK, MM; FLANDERS, WD; BERKELMAN, RL			A METAANALYSIS OF THE EFFECT OF ESTROGEN REPLACEMENT THERAPY ON THE RISK OF BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							EXOGENOUS ESTROGENS; MENOPAUSAL ESTROGENS; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; CLINICAL-TRIALS; HORMONE USE; WOMEN; EPIDEMIOLOGY; OOPHORECTOMY; COHORT	To quantify the effect of estrogen replacement therapy on breast cancer risk, we combined dose-response slopes of the relative risk of breast cancer against the duration of estrogen use across 16 studies. Using this summary dose-response slope, we calculated the proportional increase in risk of breast cancer for each year of estrogen use. For women who experienced any type of menopause, risk did not appear to increase until after at least 5 years of estrogen use. After 15 years of estrogen use, we found a 30% increase in the risk of breast cancer (relative risk, 1.3; 95% confidence interval [Cl], 1.2 to 1.6). The increase in risk was largely due to results of studies that included premenopausal women or women using estradiol (with or without progestin), studies for which the estimated relative risk was 2.2 (Cl, 1.4 to 3.4) after 15 years. Among women with a family history of breast cancer, those who had ever used estrogen replacement had a significantly higher risk (3.4; Cl, 2.0 to 6.0) than those who had not (1.5; Cl, 1.2 to 1.7).	CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333; CTR DIS CONTROL,CTR CHRON DIS PREVENT & HLTH PROMOT,ATLANTA,GA 30333; CTR DIS CONTROL,CTR INFECT DIS,ATLANTA,GA 30333; EMORY UNIV,SCH PUBL HLTH,ATLANTA,GA 30322	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University	STEINBERG, KK (corresponding author), CTR DIS CONTROL,CTR ENVIRONM HLTH & INJURY CONTROL,MS F-18,1600 CLIFTON RD,ATLANTA,GA 30333, USA.							ANGELL M, 1989, NEW ENGL J MED, V321, P464, DOI 10.1056/NEJM198908173210708; [Anonymous], 1974, N Engl J Med, V290, P15; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; BERGKVIST L, 1988, INT J EPIDEMIOL, V17, P732, DOI 10.1093/ije/17.4.732; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BLAND KI, 1980, CANCER, V45, P3027, DOI 10.1002/1097-0142(19800615)45:12<3027::AID-CNCR2820451225>3.0.CO;2-2; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; BRINTON LA, 1979, J NATL CANCER I, V62, P37; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; BURING JE, 1987, AM J EPIDEMIOL, V125, P939, DOI 10.1093/oxfordjournals.aje.a114632; BUSH TL, 1985, EPIDEMIOL REV, V7, P80, DOI 10.1093/oxfordjournals.epirev.a036287; BUSH TL, 1983, JAMA-J AM MED ASSOC, V249, P903, DOI 10.1001/jama.249.7.903; BYRD BF, 1977, ANN SURG, V185, P574, DOI 10.1097/00000658-197705000-00010; CASAGRANDE J, 1976, J NATL CANCER I, V56, P839, DOI 10.1093/jnci/56.4.839; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; CRAIG TJ, 1974, J NATL CANCER I, V53, P1577; CUTTS JH, 1969, CANCER RES, V24, P1116; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DIXON WJ, 1953, BIOMETRICS, V9, P74, DOI 10.2307/3001634; DUPONT WD, 1989, CANCER-AM CANCER SOC, V63, P948, DOI 10.1002/1097-0142(19890301)63:5<948::AID-CNCR2820630527>3.0.CO;2-U; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; GAMBRELL RD, 1980, J AM GERIATR SOC, V28, P251, DOI 10.1111/j.1532-5415.1980.tb00530.x; GAMBRELL RD, 1983, OBSTET GYNECOL, V62, P435; GENANT HK, 1982, ANN INTERN MED, V97, P699, DOI 10.7326/0003-4819-97-5-699; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P537, DOI 10.1016/0002-9378(79)90289-8; HAMMOND CB, 1986, CLIN OBSTET GYNECOL, V29, P407, DOI 10.1097/00003081-198606000-00022; HARLAP S, 1984, INT J FERTIL, V29, P73; HEMMINKI E, 1988, American Journal of Public Health, V78, P1479, DOI 10.2105/AJPH.78.11.1479; HENDERSO.BE, 1974, J NATL CANCER I, V53, P609, DOI 10.1093/jnci/53.3.609; HENDERSON BE, 1988, AM J OBSTET GYNECOL, V159, P312, DOI 10.1016/S0002-9378(88)80074-7; HENDERSON BE, 1986, AM J OBSTET GYNECOL, V154, P1181, DOI 10.1016/0002-9378(86)90696-4; HENDERSON BE, 1982, CANCER RES, V42, P3232; HENDERSON BE, 1988, FERTIL STERIL, V49, pS9; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; HOOVER R, 1976, NEW ENGL J MED, V295, P401, DOI 10.1056/NEJM197608192950801; HOOVER R, 1981, J NATL CANCER I, V67, P815; HORWITZ RI, 1984, AM J MED, V76, P192, DOI 10.1016/0002-9343(84)90773-3; HULKA BS, 1982, AM J OBSTET GYNECOL, V143, P638, DOI 10.1016/0002-9378(82)90108-9; HULKA BS, 1990, CA-CANCER J CLIN, V40, P289, DOI 10.3322/canjclin.40.5.289; JICK H, 1980, AM J EPIDEMIOL, V112, P586, DOI 10.1093/oxfordjournals.aje.a113031; KAUFMAN DW, 1984, JAMA-J AM MED ASSOC, V252, P63, DOI 10.1001/jama.252.1.63; KELSEY JL, 1988, CANCER RES, V48, P5615; KELSEY JL, 1981, JNCI-J NATL CANCER I, V67, P327; LAVECCHIA C, 1986, INT J CANCER, V38, P853, DOI 10.1002/ijc.2910380612; LINDSAY R, 1980, LANCET, V2, P1151; LONGNECKER MP, 1988, JAMA-J AM MED ASSOC, V260, P652; LUFKIN EG, 1988, MAYO CLIN P, V27, P201; MACK TM, 1975, NEW ENGL J MED, V292, P1366, DOI 10.1056/NEJM197506262922603; MANN JI, 1975, BMJ-BRIT MED J, V2, P241, DOI 10.1136/bmj.2.5965.241; MCDONALD JA, 1986, BREAST CANCER RES TR, V7, P193, DOI 10.1007/BF01806250; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; RAVINHAR BA, 1979, EUR J CANCER, V15, P395; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P344; SARTWELL PE, 1977, JNCI-J NATL CANCER I, V59, P1589, DOI 10.1093/jnci/59.6.1589; SHERMAN B, 1983, CANCER, V51, P1527, DOI 10.1002/1097-0142(19830415)51:8<1527::AID-CNCR2820510828>3.0.CO;2-T; THACKER SB, 1988, JAMA-J AM MED ASSOC, V259, P1685, DOI 10.1001/jama.259.11.1685; THOMAS DB, 1982, JNCI-J NATL CANCER I, V69, P1017; THOMAS DB, 1984, CANCER-AM CANCER SOC, V53, P595, DOI 10.1002/1097-0142(19840201)53:3+<595::AID-CNCR2820531304>3.0.CO;2-Y; UTIAN WH, 1972, S AFR MED J, V46, P732; WALLACH S, 1959, JAMA-J AM MED ASSOC, V171, P1637, DOI 10.1001/jama.1959.03010300011002; WILSON RA, 1962, JAMA-J AM MED ASSOC, V182, P327, DOI 10.1001/jama.1962.03050430001001; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; WREN BG, 1982, MED J AUSTRALIA, V2, P329, DOI 10.5694/j.1326-5377.1982.tb132453.x; WYNDER EL, 1978, CANCER-AM CANCER SOC, V41, P2341, DOI 10.1002/1097-0142(197806)41:6<2341::AID-CNCR2820410637>3.0.CO;2-N; 1987, CHEM ABSTR, V37, P12; 1979, IARC MONOGRAPHS S11, V21; 1983, JAMA-J AM MED ASSOC, V249, P1591; 1989, STATISTICAL ABSTRACT	71	567	576	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1985	1990		10.1001/jama.265.15.1985	http://dx.doi.org/10.1001/jama.265.15.1985			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	1826136				2022-12-28	WOS:A1991FF76800026
J	KOREN, MJ; DEVEREUX, RB; CASALE, PN; SAVAGE, DD; LARAGH, JH				KOREN, MJ; DEVEREUX, RB; CASALE, PN; SAVAGE, DD; LARAGH, JH			RELATION OF LEFT-VENTRICULAR MASS AND GEOMETRY TO MORBIDITY AND MORTALITY IN UNCOMPLICATED ESSENTIAL-HYPERTENSION	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERTENSION; HEART ENLARGEMENT; LEFT VENTRICULAR MASS AND GEOMETRY; CARDIOVASCULAR DISEASES; RISK FACTORS	BLOOD-PRESSURE; ECHOCARDIOGRAPHIC DETERMINATION; ELECTROCARDIOGRAPHIC DETECTION; SYSTEMIC HYPERTENSION; CONSCIOUS DOGS; HYPERTROPHY; CRITERIA; VALIDATION; OCCLUSION; DISEASE	Objective: To assess the prognostic significance of left ventricular mass and geometry in initially healthy persons with essential hypertension. Design: An observational study of a prospectively identified cohort. Setting: University medical center. Patients: Two hundred and eight patients with essential hypertension and pre-existing cardiac disease were evaluated using echocardiography between 1976 and 1981. Two hundred and fifty-three subjects or their family members (90%) were contacted for a follow-up interview an average of 10.2 years after the initial echocardiogram was obtained; the survival status of 27 patients lost to follow-up was ascertained using National Death Index data. Measurements and Main Results: Left ventricular mass exceeded 125 g/m2 in 69 of 253 patients (27%). Cardiovascular events occurred in a higher proportion of patients with than without left ventricular hypertrophy (26% compared with 12%; p = 0.006). Patients with increased ventricular mass were also at higher risk for cardiovascular death (14% compared with 0.5%; P < 0.001) and all-cause mortality (16% compared with 2%; P = 0.001). Electrocardiographic left ventricular hypertrophy did not predict risk. Patients with normal left ventricular geometry had the fewest adverse outcomes (no cardiac deaths; morbid events in 11%), and those with concentric hypertrophy had the most (death in 21%; morbid events in 31%). In a multivariate analysis, only age and left ventricular mass-but not gender, blood pressure, or serum cholesterol level-independently predicted all three outcome measures. Conclusions: Echocardiographically determined left ventricular mass and geometry stratify risk in patients with essential hypertension independently of and more strongly than blood pressure or other potentially reversible risk factors and may help to stratify the need for intensive treatment.	CORNELL UNIV, MED CTR,NEW YORK HOSP,DIV CARDIOL,BOX 222, 525 E 68TH ST, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT MED, NEW YORK, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital					NHLBI NIH HHS [HL 18323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1980, CARDIOLOGY REV REPOR, V1, P509; [Anonymous], 1980, LANCET, V1, P1261; BLAKE J, 1988, AM J CARDIOL, V62, P246, DOI 10.1016/0002-9149(88)90220-2; BLAKE J, 1990, AM J MED, V88, P477, DOI 10.1016/0002-9343(90)90426-E; BRESLIN DJ, 1966, CIRCULATION, V33, P87, DOI 10.1161/01.CIR.33.1.87; CASALE PN, 1985, J AM COLL CARDIOL, V6, P572, DOI 10.1016/S0735-1097(85)80115-7; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; CHIKOS PM, 1977, AM J ROENTGENOL, V128, P367, DOI 10.2214/ajr.128.3.367; COOPER RS, 1990, AM J CARDIOL, V65, P441, DOI 10.1016/0002-9149(90)90807-D; CUTLER JA, 1989, HYPERTENSION S1, V13, P36; DEVEREUX RB, 1984, J AM COLL CARDIOL, V3, P82, DOI 10.1016/S0735-1097(84)80433-7; DEVEREUX RB, 1987, HYPERTENSION, V9, P97; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1984, AM J CARDIOL, V54, P592, DOI 10.1016/0002-9149(84)90255-8; DEVEREUX RB, 1983, CIRCULATION, V67, P907, DOI 10.1161/01.CIR.67.4.907; DEVEREUX RB, 1983, CIRCULATION, V68, P470, DOI 10.1161/01.CIR.68.3.470; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DEVEREUX RB, 1984, J AM COLL CARDIOL, V4, P1222, DOI 10.1016/S0735-1097(84)80141-2; DEVEREUX RB, 1987, HYPERTENSION, V9, P69; DIXON WJ, 1988, BMDP STATISTICAL SOF; FUJITA M, 1988, J AM COLL CARDIOL, V12, P1048, DOI 10.1016/0735-1097(88)90475-5; GANAU A, 1989, Journal of the American College of Cardiology, V13, p245A; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HAMMOND IW, 1988, J AM COLL CARDIOL, V12, P996, DOI 10.1016/0735-1097(88)90467-6; HAMMOND IW, 1986, J AM COLL CARDIOL, V7, P639, DOI 10.1016/S0735-1097(86)80476-4; HOUGHTON JL, 1990, J AM COLL CARDIOL, V15, P43, DOI 10.1016/0735-1097(90)90173-M; KANNEL WB, 1972, NEW ENGL J MED, V287, P782; KOYANAGI S, 1982, CIRCULATION, V65, P1192, DOI 10.1161/01.CIR.65.6.1192; KOYANAGI S, 1982, CIRC RES, V50, P55, DOI 10.1161/01.RES.50.1.55; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1987, AM J CARDIOL, V59, P836, DOI 10.1016/0002-9149(87)91102-7; MacMahon S., 1989, HYPERTENSION S1, V13, P45; MESSERLI FH, 1990, CIRCULATION, V81, P1128, DOI 10.1161/01.CIR.81.3.1128; MESSERLI FH, 1983, ANN INTERN MED, V99, P757, DOI 10.7326/0003-4819-99-6-757; MESSERLI FH, 1984, AM J MED, V77, P18, DOI 10.1016/0002-9343(84)90430-3; POLESE A, 1990, Journal of the American College of Cardiology, V15, p111A; REICHEK N, 1981, CIRCULATION, V63, P1391, DOI 10.1161/01.CIR.63.6.1391; REICHEK N, 1982, AM HEART J, V103, P202, DOI 10.1016/0002-8703(82)90493-8; REN JF, 1985, J AM COLL CARDIOL, V5, P1224, DOI 10.1016/S0735-1097(85)80029-2; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5; SAVAGE DD, 1987, CIRCULATION, V75, P26; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SCHMIEDER RE, 1988, CIRCULATION, V78, P951, DOI 10.1161/01.CIR.78.4.951; SILBERBERG JS, 1989, KIDNEY INT, V36, P286, DOI 10.1038/ki.1989.192; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; SOKOLOW M, 1961, CIRCULATION, V23, P697, DOI 10.1161/01.CIR.23.5.697; 1972, CIRCULATION, V45, P991; 1979, JAMA-J AM MED ASSOC, V242, P2572	51	1994	2078	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					345	352		10.7326/0003-4819-114-5-345	http://dx.doi.org/10.7326/0003-4819-114-5-345			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1825164				2022-12-28	WOS:A1991EZ17400001
J	KAELIN, WG; PALLAS, DC; DECAPRIO, JA; KAYE, FJ; LIVINGSTON, DM				KAELIN, WG; PALLAS, DC; DECAPRIO, JA; KAYE, FJ; LIVINGSTON, DM			IDENTIFICATION OF CELLULAR PROTEINS THAT CAN INTERACT SPECIFICALLY WITH THE T/E1A-BINDING REGION OF THE RETINOBLASTOMA GENE-PRODUCT	CELL			English	Article							SV40 LARGE-T; SUSCEPTIBILITY GENE; DNA-BINDING; ADENOVIRUS E1A; RB GENE; SV40-TRANSFORMED CELLS; ENCODED PROTEIN; OSTEO-SARCOMA; 1A PROTEINS; EXPRESSION	The SV40 T antigen (T)/adenovirus E1A-binding domain of the retinoblastoma gene product (pRB) has been fused to S. japonicum glutathione S-transferase, and the chimera, bound to insoluble glutathione, was used to search for cellular proteins that can interact specifically with pRB. At least seven such proteins were detected in extracts of multiple human tumor cell lines. These proteins failed to bind to a family of pRB fusion proteins that harbor inactivating mutations in the T/E1A-binding domain and to the wild-type fusion protein in the presence of a peptide replica of the pRB-binding domain of T. Therefore, the binding of one or more of these proteins may contribute to the growth-suppressing function of pRB.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; NCI,USN,MED ONCOL BRANCH,BETHESDA,MD 20814; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Uniformed Services University of the Health Sciences - USA	KAELIN, WG (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.		kaye, frederic/E-2437-2011		NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA057327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FIGGE J, 1988, NATURE, V334, P109, DOI 10.1038/334109a0; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; HYTE P, 1989, CELL, V56, P67; JENSEN RH, 1977, J HISTOCHEM CYTOCHEM, V25, P573, DOI 10.1177/25.7.70448; JONES RE, 1990, J BIOL CHEM, V265, P12782; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P357; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; PALLAS D, 1982, CELL, V30, P407, DOI 10.1016/0092-8674(82)90238-0; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RADKE K, 1983, J CELL BIOL, V97, P1601, DOI 10.1083/jcb.97.5.1601; REISSMANN PT, 1989, ONCOGENE, V4, P839; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHEN JY, 1990, CELL GROWTH DIFF, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; VARLEY JM, 1989, ONCOGENE, V4, P725; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807; YOKOTA J, 1988, ONCOGENE, V3, P471	66	545	563	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					521	532		10.1016/0092-8674(91)90236-R	http://dx.doi.org/10.1016/0092-8674(91)90236-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1825028				2022-12-28	WOS:A1991EX36100008
J	MEINWALD, J; THOMPSON, WR; PEARSON, DL; KONIG, WA; RUNGE, T; FRANCKE, W				MEINWALD, J; THOMPSON, WR; PEARSON, DL; KONIG, WA; RUNGE, T; FRANCKE, W			INHALATIONAL ANESTHETICS STEREOCHEMISTRY - OPTICAL RESOLUTION OF HALOTHANE, ENFLURANE, AND ISOFLURANE	SCIENCE			English	Article							GENERAL-ANESTHETICS; GAS-CHROMATOGRAPHY; STEREOISOMERS; BINDING	Halothane (I), enflurane (II), and isoflurane (III), which are among the most important inhalation anesthetics, are currently administered as racemic mixtures. The pure enantiomers have not been described, and no analytical method for resolving the commercially available racemic mixtures has been reported. Complete optical resolution of (+/-)-I and (+/-)-III on per-n-pentylated alpha-cyclodextrin (Lipodex A) and of (+/-)-II and (+/-)-III on octakis(6-O-methyl-2,3-di-O-pentyl)-gamma-cyclodextrin capillary columns has been achieved, making rapid and convenient determination of enantiomeric ratios in samples of all three of these anesthetics possible.	PARK PLAZA HOSP,DEPT ANESTHESIOL,HOUSTON,TX 77004; UNIV HAMBURG,INST ORGAN CHEM,W-2000 HAMBURG 13,GERMANY	University of Hamburg	MEINWALD, J (corresponding author), CORNELL UNIV,DEPT CHEM,ITHACA,NY 14853, USA.				NIGMS NIH HHS [GM37018] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORMAN S, 1990, CHEM ENG NEWS, V68, P9, DOI 10.1021/cen-v068n028.p009; BOUCHE J, 1968, J GAS CHROMATOGR, V6, P501, DOI 10.1093/chromsci/6.10.501; CALVERLEY RK, 1989, CLIN ANESTH, P3; Calverley RK, 1986, SURV ANESTHESIA, V29, P170; DECAMP WH, 1989, CHIRALITY, V1, P2, DOI 10.1002/chir.530010103; DLUZEWSKI AR, 1983, MOL ASPECTS MED, V6, P459, DOI 10.1016/0098-2997(83)90001-8; EVERS AS, 1987, NATURE, V328, P157, DOI 10.1038/328157a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; KENDIG JJ, 1973, ANESTHESIOLOGY, V39, P518, DOI 10.1097/00000542-197311000-00011; Konig W. A., 1990, J HIGH RES CHROMATOG, V13, P702; KONIG WA, 1983, J CHROMATOGR, V280, P135, DOI 10.1016/S0021-9673(00)91548-6; KONIG WA, 1988, ANGEW CHEM INT EDIT, V27, P979, DOI 10.1002/anie.198809791; KONIG WA, 1988, ANGEW CHEM, V100, P989; PEARSON DL, 1990, THESIS CORNELL U ITH; STEVENS WC, 1989, CLIN ANESTH, P293; SUCKLING CW, 1957, BRIT J ANAESTH, V29, P466, DOI 10.1093/bja/29.10.466; TERRELL RC, 1971, J MED CHEM, V14, P517, DOI 10.1021/jm00288a014	17	59	61	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					560	561		10.1126/science.1846702	http://dx.doi.org/10.1126/science.1846702			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1846702				2022-12-28	WOS:A1991EV45900051
J	SUN, XH; BALTIMORE, D				SUN, XH; BALTIMORE, D			AN INHIBITORY DOMAIN OF E12 TRANSCRIPTION FACTOR PREVENTS DNA-BINDING IN E12 HOMODIMERS BUT NOT IN E12 HETERODIMERS	CELL			English	Article							MUSCLE-SPECIFIC ENHANCER; SCUTE GENE-COMPLEX; DROSOPHILA-MELANOGASTER; IMMUNOGLOBULIN ENHANCERS; SEX DETERMINATION; MYC; PROTEIN; EXPRESSION; SEQUENCE; HOMOLOGY	The kappa-E2 sequence binding proteins, E12 and E47, are generated by alternative splicing of the E2A gene, giving closely related basic and helix-loop-helix structures crucial for DNA binding and dimerization. Measurements of dimerization constants and binding strengths to the optimal DNA sequence (the kappa-E2 site or its near relatives) showed that E47 homodimers and MyoD heterodimers with E12 or E47 dimerized and bound avidly, but E12 homodimerized efficiently and bound to DNA poorly; MyoD homodimerized poorly and bound strongly. An inhibitory domain N-terminal to the basic region of E12 prevents E12 homodimers but not E12/MyoD heterodimers from binding to DNA. Thus, E47 binds to DNA both as a heterodimer with MyoD and as a homodimer, while E12 and MyoD bind to DNA efficiently only as heterodimers.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; ROCKEFELLER UNIV,NEW YORK,NY 10021	Massachusetts Institute of Technology (MIT); Rockefeller University	SUN, XH (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039458] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOULET AM, 1986, P NATL ACAD SCI USA, V83, P3599, DOI 10.1073/pnas.83.11.3599; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EHENTHORN P, 1990, SCIENCE, V247, P467; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P677, DOI 10.1093/nar/18.3.677; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KILEDJIAN M, 1988, MOL CELL BIOL, V8, P145, DOI 10.1128/MCB.8.1.145; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOSS LG, 1988, MOL CELL BIOL, V8, P2620, DOI 10.1128/MCB.8.6.2620; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; MURRE C, 1990, IN PRESS MOL CELL BI; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PIEPER FR, 1987, EMBO J, V6, P3611, DOI 10.1002/j.1460-2075.1987.tb02692.x; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WANG Y, 1988, NEURON, V1, P527, DOI 10.1016/0896-6273(88)90183-3; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	52	384	386	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 25	1991	64	2					459	470		10.1016/0092-8674(91)90653-G	http://dx.doi.org/10.1016/0092-8674(91)90653-G			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV336	1846322				2022-12-28	WOS:A1991EV33600021
J	GLOTZER, M; MURRAY, AW; KIRSCHNER, MW				GLOTZER, M; MURRAY, AW; KIRSCHNER, MW			CYCLIN IS DEGRADED BY THE UBIQUITIN PATHWAY	NATURE			English	Article							RECOGNITION PARTICLE SRP; EMBRYONIC-CELL CYCLE; SHORT-LIVED PROTEIN; SEA-URCHIN EGGS; MESSENGER-RNA; PHYTOCHROME DEGRADATION; BIOCHEMICAL-MUTANTS; PROTEOLYTIC SYSTEM; CONJUGATING ENZYME; ACTIVATING ENZYME	Cyclin degradation is the key step governing exit from mitosis and progress into the next cell cycle. When a region in the N terminus of cyclin is fused to a foreign protein, it produces a hybrid protein susceptible to proteolysis at mitosis. During the course of degradation, both cyclin and the hybrid form conjugates with ubiquitin. The kinetic properties of the conjugates indicate that cyclin is degraded by ubiquitin-dependent proteolysis. Thus anaphase may be triggered by the recognition of cyclin by the ubiquitin-conjugating system.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	GLOTZER, M (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; CALLIS J, 1990, J BIOL CHEM, V265, P12486; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1989, TRENDS BIOCHEM SCI, V14, P483, DOI 10.1016/0968-0004(89)90180-1; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FERBER S, 1986, J BIOL CHEM, V261, P3128; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; JABBEN M, 1989, J BIOL CHEM, V264, P4998; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; KULKA RG, 1988, J BIOL CHEM, V263, P15726; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MNSHULL J, 1990, EMBO J, V9, P2865; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; REDMAN KL, 1989, NATURE, V338, P438, DOI 10.1038/338438a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SCHIMKE RT, 1970, ANNU REV BIOCHEM, V39, P929, DOI 10.1146/annurev.bi.39.070170.004433; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431	49	2078	2140	3	122	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					132	138		10.1038/349132a0	http://dx.doi.org/10.1038/349132a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1846030				2022-12-28	WOS:A1991ER41800049
J	GOODWIN, FK				GOODWIN, FK			ANABOLIC-STEROIDS AND DEPENDENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,WASHINGTON,DC, USA.							BROWER KJ, 1991, BRIT J ADDICT, V86, P759	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1619	1619						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF419	1832194				2022-12-28	WOS:A1991GF41900007
J	POWELL, SK; CUNNINGHAM, BA; EDELMAN, GM; RODRIGUEZBOULAN, E				POWELL, SK; CUNNINGHAM, BA; EDELMAN, GM; RODRIGUEZBOULAN, E			TARGETING OF TRANSMEMBRANE AND GPI-ANCHORED FORMS OF N-CAM TO OPPOSITE DOMAINS OF A POLARIZED EPITHELIAL-CELL	NATURE			English	Article							ADHESION MOLECULE UVOMORULIN; MDCK CELLS; PROTEINS; COMPONENT; KIDNEY; CDNAS; LINE	THE calcium-independent neural cell adhesion molecule N-CAM is expressed transiently during development in many tissues, including epithelia 1. The three naturally occurring principal isoforms 2,3 of N-CAM differ in the way in which they associate with the membrane and in their cytoplasmic domains 4. These isoforms are generated by developmentally regulated alternative splicing of a single gene 4-6: the large cytoplasmic domain (ld) form (relative molecular mass 180,000 (M(r) 180K)) is specific for post-mitotic neurons; the 120K small cytoplasmic domain (ssd) and 140K small surface domain (sd) forms also occur on other cell types 7. One function of the different isoforms could be to specify cellular localization; for example, glycosyl phosphatidyl inositol (GPI)-membrane anchoring acts as a targeting signal for expression on the apical surface of polarized epithelial cells 8,9. Neurons and epithelial cells may use similar mechanisms for polarizing their plasma membrane proteins 10,11. We have therefore investigated the targeting of GPI-anchored (ssd N-CAM, 120K) and transmembrane forms of N-CAM (sd N-CAM, 140K; Id N-CAM, 180K) by comparing the expression of each after transfection of the appropriate complementary DNAs into polarized epithelial cells. We find that isoforms with alternative modes of membrane association are targeted to different surfaces of polarized epithelial cells: ssd N-CAM is expressed on the apical surface, whereas sd and ld N-CAM are expressed on the basolateral surface. These results suggest that the different isoforms of N-CAM determine their own diverse cellular destinations. They also support the hypothesis that the GPI anchor acts as an apical targeting signal in epithelia.	ROCKEFELLER UNIV,DEPT DEV & MOLEC BIOL,NEW YORK,NY 10021	Rockefeller University	POWELL, SK (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT CELL BIOL & ANAT,1300 YORK AVE,NEW YORK,NY 10021, USA.							CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; CUNNINGHAM BA, 1990, MORPHOREGULATORY MOL; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P9822, DOI 10.1073/pnas.83.24.9822; KLEIN G, 1988, DEVELOPMENT, V102, P749; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LETOURNEAU PC, 1989, DEVELOPMENT, V105, P505; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; MURRAY BA, 1986, J CELL BIOL, V102, P189, DOI 10.1083/jcb.102.1.189; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; PERSOHN E, 1989, J COMP NEUROL, V288, P92, DOI 10.1002/cne.902880108; PIZZEY JA, 1989, J CELL BIOL, V109, P3465, DOI 10.1083/jcb.109.6.3465; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; THIERY JP, 1982, P NATL ACAD SCI-BIOL, V79, P6737, DOI 10.1073/pnas.79.21.6737	27	105	106	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					76	77		10.1038/353076a0	http://dx.doi.org/10.1038/353076a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1831882				2022-12-28	WOS:A1991GD80500062
J	KISTLER, JP; BUONANNO, FS; GRESS, DR				KISTLER, JP; BUONANNO, FS; GRESS, DR			CAROTID ENDARTERECTOMY - SPECIFIC THERAPY BASED ON PATHOPHYSIOLOGY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NATURAL-HISTORY; STROKE; RISK; BRUITS; DISEASE; SURGERY; ARTERY				KISTLER, JP (corresponding author), MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA.							CALL GK, 1988, STROKE, V19, P584, DOI 10.1161/01.STR.19.5.584; CHAMBERS BR, 1986, NEW ENGL J MED, V315, P860, DOI 10.1056/NEJM198610023151404; EAGLE KA, 1989, NEW ENGL J MED, V321, P1330, DOI 10.1056/NEJM198911093211909; EASTCOTT HHG, 1954, LANCET, V2, P994; EASTON JD, 1977, STROKE, V8, P565, DOI 10.1161/01.STR.8.5.565; Fisher C M, 1975, Clin Neurosurg, V22, P117; FISHER CM, 1962, CAN MED ASSOC J, V86, P1091; FISHER CM, 1951, ARCH NEUROL PSYCHIAT, V65, P346; HEYMAN A, 1980, NEW ENGL J MED, V302, P838, DOI 10.1056/NEJM198004103021504; HOUSER OW, 1974, J NEUROSURG, V41, P321, DOI 10.3171/jns.1974.41.3.0321; MEISSNER I, 1987, Journal of the American Medical Association, V258, P2704, DOI 10.1001/jama.258.19.2704; Ojemann R G, 1975, Clin Neurosurg, V22, P214; PESSIN MS, 1979, ANN NEUROL, V6, P245, DOI 10.1002/ana.410060311; ROEDERER GO, 1984, STROKE, V15, P605, DOI 10.1161/01.STR.15.4.605; ROPPER AH, 1982, NEW ENGL J MED, V307, P1388, DOI 10.1056/NEJM198211253072207; WOLF PA, 1981, JAMA-J AM MED ASSOC, V245, P1442, DOI 10.1001/jama.245.14.1442; 1988, SURGICAL MANAGEMENT, P1; 1991, LANCET, V337, P1235; 1991, NEW ENGL J MED, V325, P445	19	23	23	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					505	507		10.1056/NEJM199108153250709	http://dx.doi.org/10.1056/NEJM199108153250709			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1852183				2022-12-28	WOS:A1991GA76300009
J	KRAHN, M; NAYLOR, CD; BASINSKI, AS; DETSKY, AS				KRAHN, M; NAYLOR, CD; BASINSKI, AS; DETSKY, AS			COMPARISON OF AN AGGRESSIVE (UNITED-STATES) AND A LESS AGGRESSIVE (CANADIAN) POLICY FOR CHOLESTEROL SCREENING AND TREATMENT	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; TREATING HYPERCHOLESTEROLEMIA; UTILITY; LIFE; PREVENTION; MORTALITY; PROGRAMS; THERAPY; IMPACT	Objective: To determine the point at which adverse quality-of-life effects engendered by an aggressive cholesterol-lowering strategy dictate the use of a less aggressive approach. Design: Decision analysis was used to compare the effects of the National Cholesterol Education Program (NCEP) guidelines, an aggressive program, with those of the Canadian Task Force on the Periodic Health Examination (CTF) guidelines, a more conservative program. Quality-adjusted life expectancy was calculated for a theoretical cohort of middle-aged men treated according to each program using Markov cohort analysis. Measurements: Guidelines were applied to the population of the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), under the assumption that cholesterol levels had the distribution of the age- and sex-matched general population. Outcomes were calculated using a three-state (health, coronary heart disease, and death) Markov model. State transition probabilities were calculated using bivariate (age and cholesterol) proportional hazards and logistic regression functions. Main Results: The result was a "toss-up"; the number of expected quality-adjusted life years was similar for both programs at all time intervals, although the conservative program was consistently slightly favored. The result was very sensitive to the disutility of dietary therapy (threshold value, 0.0014 compared with the baseline estimate of 0.02) but was also affected by the time frame of the analysis and the rate at which adverse effects of treatment decline. Conclusions: Even small disutilities associated with treatment may outweigh the benefits of aggressive cholesterol-lowering strategies. Research should be directed toward measuring these disutilities and finding ways to reduce their size. Incorporation of the disutility of treatment into policy formulation may result in less interventionist and less costly policies.	SUNNYBROOK HLTH SCI CTR, TORONTO, ONTARIO, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	KRAHN, M (corresponding author), UNIV TORONTO, TORONTO WESTERN HOSP, WW1-810, 399 BATHURST ST, TORONTO M5T 2S8, ONTARIO, CANADA.			Krahn, Murray/0000-0001-5836-397X				ALDERMAN MH, 1976, J OCCUP ENVIRON MED, V18, P793, DOI 10.1097/00043764-197612000-00004; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRETT AS, 1989, NEW ENGL J MED, V321, P676, DOI 10.1056/NEJM198909073211009; BROWNER WS, 1986, AM J EPIDEMIOL, V123, P143, DOI 10.1093/oxfordjournals.aje.a114208; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; FARCHI G, 1987, AM J EPIDEMIOL, V126, P400, DOI 10.1093/oxfordjournals.aje.a114671; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GARBER AM, 1989, COSTS EFFECTIVENESS; HALL JP, 1988, MED J AUSTRALIA, V148, P271; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; HULLEY SB, 1983, ARCH INTERN MED, V143, P667, DOI 10.1001/archinte.143.4.667; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; LEFEBVRE RC, 1988, ARCH INTERN MED, V148, P1993, DOI 10.1001/archinte.148.9.1993; MOSSEY JM, 1981, CLIN INVEST MED, V4, P201; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; PALUMBO PJ, 1989, JAMA-J AM MED ASSOC, V262, P91, DOI 10.1001/jama.262.1.91; PLISKIN JS, 1980, OPER RES, V28, P206, DOI 10.1287/opre.28.1.206; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RIFKIND BM, 1983, J CHRON DIS, V36, P467; SACKETT DL, 1978, J CHRON DIS, V31, P697, DOI 10.1016/0021-9681(78)90072-3; TAYLOR WC, 1987, ANN INTERN MED, V106, P605, DOI 10.7326/0003-4819-106-4-605; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; WEINBLATT E, 1982, JAMA-J AM MED ASSOC, V247, P1576, DOI 10.1001/jama.247.11.1576; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; ZUMOFF B, 1966, ANN INTERN MED, V64, P595, DOI 10.7326/0003-4819-64-3-595; [No title captured]; 1987, REPORT BRIT CARDIAC; 1988, 1988 CAN CONS C CHOL; VITAL HLTH STATIS 11, V236; 1990, J CLIN EPIDEMIOL, V43, P1028	33	32	32	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					248	255		10.7326/0003-4819-115-4-248	http://dx.doi.org/10.7326/0003-4819-115-4-248			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854109				2022-12-28	WOS:A1991GA76400002
J	PRENDERGAST, GC; LAWE, D; ZIFF, EB				PRENDERGAST, GC; LAWE, D; ZIFF, EB			ASSOCIATION OF MYN, THE MURINE HOMOLOG OF MAX, WITH C-MYC STIMULATES METHYLATION-SENSITIVE DNA-BINDING AND RAS COTRANSFORMATION	CELL			English	Article							MAJOR LATE PROMOTER; CASEIN KINASE-II; LEUCINE ZIPPER; TRANSCRIPTION FACTOR; EARLY REGION-1A; CELLS; PROTEINS; ONCOGENE; FOS; TRANSFORMATION	Myn, a novel murine approximately 18 kd basic/helix-loop-helix/"leucine zipper" (B/HLH/LZ) protein, forms a specific DNA-binding complex with the c-Myc oncoprotein through the HLH/LZ motif in both proteins. c-Myc/Myn recognizes a c-Myc-binding site (GACCACGTGGTC) with higher affinity than either protein by itself. CpG methylation of the recognition site greatly inhibits DNA binding, suggesting that DNA methylation may regulate the c-Myc/Myn complex in vivo. In 3T3 fibroblasts, Myn mRNA levels are induced several-fold by serum with delayed early kinetics, suggesting regulation by immediate-early gene products. Coexpression of Myn in a myc/ras rat embryo fibroblast focus formation assay specifically augmented c-myc transforming activity. We suggest that interaction of Myn with c-Myc stabilizes sequence-specific DNA binding in vivo.	NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	New York University	PRENDERGAST, GC (corresponding author), NYU MED CTR,KAPLAN CANC CTR,HOWARD HUGHES MED INST,MSB 397,NEW YORK,NY 10016, USA.			Ziff, Edward/0000-0001-7389-8649				BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTOR TH, 1988, GENE, V74, P9, DOI 10.1016/0378-1119(88)90238-7; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CROUCH DH, 1990, ONCOGENE, V5, P433; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GIBSON TJ, 1990, DNA MAP SEQ, V1, P3; GORHAM JD, 1990, DEV BRAIN RES, V57, P235, DOI 10.1016/0165-3806(90)90049-5; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JONES PA, 1986, CANCER RES, V46, P461; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KERKHOFF E, 1991, IN PRESS P NATL ACAD; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULTZ WH, 1987, SCIENCE, V240, P1759; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MULLER R, 1987, ONCOGENE RES, V2, P19; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Penn L J, 1990, Semin Cancer Biol, V1, P69; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; PRENDERGAST GC, 1991, IN PRESS EMBO J; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAJCHEL A, 1987, NUCLEIC ACIDS RES, V16, P2347; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088	63	572	580	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					395	407		10.1016/0092-8674(91)90457-A	http://dx.doi.org/10.1016/0092-8674(91)90457-A			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1840505	hybrid			2022-12-28	WOS:A1991FK18200006
J	WISSINGER, B; SCHUSTER, W; BRENNICKE, A				WISSINGER, B; SCHUSTER, W; BRENNICKE, A			TRANS SPLICING IN OENOTHERA MITOCHONDRIA - NAD1-MESSENGER RNAS ARE EDITED IN EXON AND TRANSSPLICING GROUP-II INTRON SEQUENCES	CELL			English	Article							GENE ORGANIZATION; PLANT-MITOCHONDRIA; NUCLEOTIDE-SEQUENCE; WHEAT MITOCHONDRIA; RIBOSOMAL-PROTEIN; CHLOROPLAST DNA; CDNA LIBRARIES; EXPRESSION; GENOME; SUBUNIT	The complete NADH dehydrogenase subunit 1 (nad1) ORF in Oenothera mitochondria is encoded by five exons. These exons are located in three distant locations of the mitochondrial genome. One genomic region encodes exon a, the second encodes exons b and c, and the third specifies exons d and e. Cis-splicing group II introns separate exons b and c and d and e, while trans-splicing reactions are required to link exons a and b and c and d. The two parts of the group II intron sequences involved in these trans-splicing events can be aligned in domain IV. Exon sequences and the maturase-related ORF in intron d/e are edited by numerous C to U alterations in the mRNA. Two RNA editing events in the trans-splicing intron a/b improve conservation of the secondary structure in the stem of domain VI. RNA editing in intron sequences may thus be required for the trans-splicing reaction.			WISSINGER, B (corresponding author), INST GENBIOL FORSCHUNG,IHNESTR 63,W-1000 BERLIN 33,GERMANY.							ADEMA GJ, 1990, NUCLEIC ACIDS RES, V18, P5365, DOI 10.1093/nar/18.18.5365; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BLAND MM, 1986, MOL GEN GENET, V204, P8, DOI 10.1007/BF00330180; BOER PH, 1988, EMBO J, V7, P3501, DOI 10.1002/j.1460-2075.1988.tb03226.x; BONEN L, 1987, NUCLEIC ACIDS RES, V15, P10393, DOI 10.1093/nar/15.24.10393; BRENNICKE A, 1980, PLANT PHYSIOL, V65, P1207, DOI 10.1104/pp.65.6.1207; BURGER G, 1985, ACHIEVEMENTS PERSPEC, V2, P305; CHAPDELAINE Y, 1991, CELL, V65; CHOQUET Y, 1988, CELL, V52, P903, DOI 10.1016/0092-8674(88)90432-1; CLARY DO, 1985, J MOL EVOL, V22, P252, DOI 10.1007/BF02099755; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; CUMMINGS DJ, 1988, CURR GENET, V14, P253, DOI 10.1007/BF00376746; FOX TD, 1981, CELL, V26, P315, DOI 10.1016/0092-8674(81)90200-2; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAYMERLE H, 1986, NUCLEIC ACIDS RES, V14, P8615, DOI 10.1093/nar/14.21.8615; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HIESEL R, 1987, EMBO J, V6, P29, DOI 10.1002/j.1460-2075.1987.tb04714.x; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KRAWETZ SA, 1989, NUCLEIC ACIDS RES, V17, P819, DOI 10.1093/nar/17.2.819; KUCK U, 1987, EMBO J, V6, P2185, DOI 10.1002/j.1460-2075.1987.tb02489.x; LAMATTINA L, 1989, FEBS LETT, V258, P79, DOI 10.1016/0014-5793(89)81620-5; LEAVER CJ, 1982, ANNU REV PLANT PHYS, V33, P373, DOI 10.1146/annurev.pp.33.060182.002105; LEVINGS CS, 1989, CELL, V56, P171, DOI 10.1016/0092-8674(89)90890-8; LONSDALE DM, 1989, BIOCH PLANTS COMPREH, V15, P229; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; NEWTON KJ, 1988, ANNU REV PLANT PHYS, V39, P503, DOI 10.1146/annurev.arplant.39.1.503; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; RUTLEDGE RG, 1988, GENE, V68, P151, DOI 10.1016/0378-1119(88)90607-5; Sambrook J, 1989, MOL CLONING LABORATO; SCHMELZER C, 1986, CELL, V46, P557, DOI 10.1016/0092-8674(86)90881-0; SCHUSTER W, 1987, MOL GEN GENET, V210, P44, DOI 10.1007/BF00337757; SCHUSTER W, 1990, EMBO J, V9, P263, DOI 10.1002/j.1460-2075.1990.tb08104.x; SCHUSTER W, 1988, PLANT SCI, V54, P1, DOI 10.1016/0168-9452(88)90049-0; SCHUSTER W, 1988, THESIS U TUBINGEN GE; SCHUSTER W, 1988, PLANT MOL BIOL PRACT, P79; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; STERN DB, 1986, CURR GENET, V10, P857, DOI 10.1007/BF00418532; STERN DB, 1982, NATURE, V299, P698, DOI 10.1038/299698a0; STERN DB, 1984, P NATL ACAD SCI-BIOL, V81, P1946, DOI 10.1073/pnas.81.7.1946; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; WAHLEITHNER JA, 1990, P NATL ACAD SCI USA, V87, P548, DOI 10.1073/pnas.87.2.548; WARD BL, 1981, CELL, V25, P793, DOI 10.1016/0092-8674(81)90187-2; WISSINGER B, 1990, MOL GEN GENET, V224, P389, DOI 10.1007/BF00262433; WISSINGER B, 1988, MOL GEN GENET, V212, P56, DOI 10.1007/BF00322444; ZAITA N, 1987, FEBS LETT, V210, P153, DOI 10.1016/0014-5793(87)81326-1	50	167	172	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					473	482		10.1016/0092-8674(91)90465-B	http://dx.doi.org/10.1016/0092-8674(91)90465-B			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1850322				2022-12-28	WOS:A1991FK18200014
J	LEE, JS; RO, JY; SAHIN, AA; HONG, WK; BROWN, BW; MOUNTAIN, CF; HITTELMAN, WN				LEE, JS; RO, JY; SAHIN, AA; HONG, WK; BROWN, BW; MOUNTAIN, CF; HITTELMAN, WN			EXPRESSION OF BLOOD-GROUP ANTIGEN-A - A FAVORABLE PROGNOSTIC FACTOR IN NON-SMALL-CELL LUNG-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							URINARY-BLADDER; CARCINOMA; ABH; GLYCOSYLATION; ANTIBODIES; RECEPTOR; TUMORS	Background. New prognostic factors are needed to guide the treatment of patients with non-small-cell lung cancer. We evaluated the prognostic value of altered expression of ABH blood-group antigens, which has been implicated in the multistep process of carcinogenesis and tumor progression. Methods. The presence of blood-group antigens was assessed immunohistochemically in paraffin-embedded tumor samples from 164 patients who underwent curative surgery for non-small-cell lung cancer from 1980 through 1982. Monoclonal antibodies were used to detect the A and B antigens, and Ulex europaeus agglutinin I to detect H antigen. Results. Survival of the 28 patients with blood type A or AB who had primary tumors negative for blood-group antigen A was significantly shorter than that of the 43 patients with antigen A-positive tumors (P < 0.001) and of the 93 patients with blood type B or O (P =0.002). The respective median survival times were 15, 71, and 39 months. Disease progressed significantly earlier in the 28 patients with tumors negative for blood-group antigen A than in the antigen A-positive patients (P < 0.001). Expression of blood-group antigen B or H in tumor cells did not correlate with survival. Cox proportional-hazards regression analysis showed that expression of blood-group antigen A in tumor cells added significantly to the prediction of overall survival provided by other known prognostic factors among the patients with blood type A or AB (P = 0.004). Conclusions. Expression of blood-group antigen A in tumor cells is an important favorable prognostic factor in patients with non-small-cell lung cancer. This variable needs to be considered in the design of future trials of therapy.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT BIOMATH, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT THORAC SURG, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT PATHOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	LEE, JS (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MED ONCOL, BOX 80, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.				NCI NIH HHS [CA-45746, CA-11672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1982, AM J CLIN PATHOL, V77, P123; BLACK MM, 1956, AM J CLIN PATHOL, V26, P250; CAREY TE, 1987, OTOLARYNG HEAD NECK, V96, P221, DOI 10.1177/019459988709600301; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; COX DR, 1972, J R STAT SOC B, V34, P187; DABELSTEEN E, 1975, ACTA PATH MICRO IM A, VA 83, P292; DABELSTEEN E, 1988, APMIS, V96, P813, DOI 10.1111/j.1699-0463.1988.tb00948.x; DABELSTEEN E, 1974, ACTA PATH MICRO IM A, VA 82, P431; DAVIDSOHN I, 1973, ARCH PATHOL, V95, P132; DAVIDSOHN I, 1972, AM J CLIN PATHOL, V57, P715; DAVIDSOHN I, 1969, AM J PATHOL, V57, P307; FINKELSTEIN DM, 1986, J CLIN ONCOL, V4, P702, DOI 10.1200/JCO.1986.4.5.702; FUJIOKA T, 1986, UROL INT, V41, P397, DOI 10.1159/000281242; GIBLETT ER, 1983, HEMATOLOGY, P1491; GOOI HC, 1985, BIOSCIENCE REP, V5, P83; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HIROHASHI S, 1984, J NATL CANCER I, V72, P1299; HONG WK, 1989, P AN M AM SOC CLIN, V8, P167; JUHL BR, 1986, CANCER, V57, P1768, DOI 10.1002/1097-0142(19860501)57:9<1768::AID-CNCR2820570910>3.0.CO;2-E; JUHL BR, 1986, CANCER, V58, P1184; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAY HE, 1961, J NATL CANCER I, V26, P1349; LEE JS, 1989, P AN M AM SOC CLIN, V8, P226; LIMAS C, 1979, CANCER, V44, P2099, DOI 10.1002/1097-0142(197912)44:6<2099::AID-CNCR2820440621>3.0.CO;2-I; MACKENZIE IC, 1977, ACTA PATH MICRO IM A, V85, P49; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; NARUKE, 1989, J THORAC CARDIOV SUR, V97, P350; NARUKE T, 1988, J THORAC CARDIOV SUR, V96, P440; ORNTOFT TF, 1987, CANCER, V60, P2641, DOI 10.1002/1097-0142(19871201)60:11<2641::AID-CNCR2820601112>3.0.CO;2-5; SCHOENTAG R, 1984, CANCER, V53, P503, DOI 10.1002/1097-0142(19840201)53:3<503::AID-CNCR2820530323>3.0.CO;2-J; Snedecor G.W., 1980, STAT METHODS, V7; SUMMERS JL, 1983, CANCER RES, V43, P934; YARDEN Y, 1985, J BIOL CHEM, V260, P315	34	206	216	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1084	1090		10.1056/NEJM199104183241603	http://dx.doi.org/10.1056/NEJM199104183241603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	1848917	Bronze			2022-12-28	WOS:A1991FG91200003
J	KLAUSNER, RD; SAMELSON, LE				KLAUSNER, RD; SAMELSON, LE			T-CELL ANTIGEN RECEPTOR ACTIVATION PATHWAYS - THE TYROSINE KINASE CONNECTION	CELL			English	Review							CD4 RECEPTOR				KLAUSNER, RD (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.							ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; COOKE M P, 1989, New Biologist, V1, P66; DIANZANI U, 1990, EUR J IMMUNOL, V20, P2249, DOI 10.1002/eji.1830201014; FRANK SJ, 1990, SCIENCE, V249, P173; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; KORETZKY GA, 1991, IN PRESS P NATL ACAD; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NEL AE, 1990, J IMMUNOL, V145, P971; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; OSHEA JJ, 1990, IN PRESS P NATL ACAD; PRINGEL JT, 1989, CELL, V58, P1055; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085	30	490	508	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					875	878		10.1016/0092-8674(91)90310-U	http://dx.doi.org/10.1016/0092-8674(91)90310-U			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1848158				2022-12-28	WOS:A1991FA94000003
J	BURTON, FH; HASEL, KW; BLOOM, FE; SUTCLIFFE, JG				BURTON, FH; HASEL, KW; BLOOM, FE; SUTCLIFFE, JG			PITUITARY HYPERPLASIA AND GIGANTISM IN MICE CAUSED BY A CHOLERA-TOXIN TRANSGENE	NATURE			English	Article							HORMONE-RELEASING-FACTOR; ADENYLATE-CYCLASE ACTIVITY; GROWTH-HORMONE; GENE; EXPRESSION; CELLS; MECHANISMS; INJECTION; ABLATION; INVITRO	CYCLIC AMP 1 is thought to act as an intracellular second messenger, mediating the physiological response of many cell types to extracellular signals 2,3. In the pituitary, growth hormone (GH)-producing cells (somatotrophs) proliferate and produce GH in response to hypothalamic GH-releasing factor 4-8, which binds a receptor that stimulates G(s) protein activation of adenylyl cyclase 3,9-12. We have now determined whether somatotroph proliferation and GH production are stimulated by cAMP alone 5,7,11,13-15, or require concurrent, non-G(s)-mediated induction of other regulatory molecules by designing a transgene to induce chronic supraphysiological concentrations of cAMP in somatotrophs. The rat GH promoter 16,17 was used to express an intracellular form of cholera toxin 18, a non-cytotoxic and irreversible activator of G(s) (ref. 19). Introduction of this transgene into mice caused gigantism, elevated serum GH levels, somatotroph proliferation and pituitary hyperplasia. These results support the direct triggering of these events by cAMP, and illustrate the utility of cholera toxin transgene as a tool for physiological engineering.	SCRIPPS RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	BURTON, FH (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							ASA SL, 1984, J CLIN ENDOCR METAB, V58, P796, DOI 10.1210/jcem-58-5-796; ASA SL, 1990, P SOC EXP BIOL MED, V193, P232; BARINAGA M, 1985, NATURE, V314, P279, DOI 10.1038/314279a0; BARTA A, 1981, P NATL ACAD SCI-BIOL, V78, P4867, DOI 10.1073/pnas.78.8.4867; BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BOURNE HR, 1987, NATURE, V330, P517, DOI 10.1038/330517a0; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; GILL DM, 1978, P NATL ACAD SCI USA, V75, P3050, DOI 10.1073/pnas.75.7.3050; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; HAMMER RE, 1985, NATURE, V315, P413, DOI 10.1038/315413a0; HOEFFLER JP, 1985, ENDOCRINOLOGY, V117, P187, DOI 10.1210/endo-117-1-187; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; ROBISON GA, 1968, ANNU REV BIOCHEM, V37, P149, DOI 10.1146/annurev.bi.37.070168.001053; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHOFIELD JG, 1967, NATURE, V215, P1382, DOI 10.1038/2151382b0; SMIGEL M, 1984, ADV CYCLIC NUCL PROT, V17, P1; STEFANEANU L, 1989, ENDOCRINOLOGY, V125, P2710, DOI 10.1210/endo-125-5-2710; STRUTHERS RS, 1989, ENDOCRINOLOGY, V124, P24, DOI 10.1210/endo-124-1-24; SUTHERLAND EW, 1957, J AM CHEM SOC, V79, P3608, DOI 10.1021/ja01570a087; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0	27	179	180	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1991	350	6313					74	77		10.1038/350074a0	http://dx.doi.org/10.1038/350074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1848356				2022-12-28	WOS:A1991FA69300069
J	READ, AE; DONEGAN, E; LAKE, J; FERRELL, L; GALBRAITH, C; KURAMOTO, IK; ZELDIS, JB; ASCHER, NL; ROBERTS, J; WRIGHT, TL				READ, AE; DONEGAN, E; LAKE, J; FERRELL, L; GALBRAITH, C; KURAMOTO, IK; ZELDIS, JB; ASCHER, NL; ROBERTS, J; WRIGHT, TL			HEPATITIS-C IN PATIENTS UNDERGOING LIVER-TRANSPLANTATION	ANNALS OF INTERNAL MEDICINE			English	Article							NON-B-HEPATITIS; HEPATOCELLULAR-CARCINOMA; NON-A; VIRUS; ANTIBODIES; RECIPIENTS; PREVALENCE; ASSAY	Objective: To determine the prevalence of antibodies to hepatitis C virus (anti-HCV) among patients undergoing liver transplantation and the relation between anti-HCV and post-transplant hepatitis. Design: Retrospective cohort. Patients: Serum samples from 128 patients who underwent liver transplantation. Sixty-six patients who had 6 months of follow-up and for whom both pretransplant and post-transplant serum samples were available were included in a study to assess the relation between anti-HCV and post-transplant hepatitis. Measurements: Sera were tested for anti-HCV using an enzyme-linked immunosorbent assay (ELISA) and, if positive, two confirmatory tests were done. Patients had a biopsy every week until two specimens showed no abnormal findings. Main Results: Only patients with chronic non-A, non-B hepatitis (15 of 30; 50%), alcoholic cirrhosis (7 of 19; 37%), and chronic hepatitis B infection (3 of 11; 27%) were anti-HCV positive. No patient with another form of chronic liver disease or with acute liver failure due to non-A, non-B hepatitis was anti-HCV positive. After transplantation, loss of anti-HCV was frequent and acquisition rare. Hepatitis developed in the graft in 17% of patients, but the incidence was similar among anti-HCV negative and anti-HCV-positive patients. Conclusions: Hepatitis C virus is a common cause of chronic liver disease in patients requiring liver transplantation, but anti-HCV is rarely found in patients with acute liver failure. Previous HCV infection, based on detection of anti-HCV, is not an independent risk factor for post-transplant hepatitis.	VET AFFAIRS MED CTR, SAN FRANCISCO, CA USA; UNIV CALIF DAVIS, DAVIS, CA 95616 USA; SACRAMENTO MED FDN, CTR BLOOD, SACRAMENTO, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Davis	READ, AE (corresponding author), UNIV CALIF SAN FRANCISCO, GASTROENTEROL UNIT 1120 HSW, SAN FRANCISCO, CA 94143 USA.			Lake, John/0000-0002-4332-0528	NIDDK NIH HHS [DK-26743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRUIX J, 1989, LANCET, V2, P1004; COLOMBO M, 1989, LANCET, V2, P1006; DEMETRIS AJ, 1986, AM J PATHOL, V125, P161; ESTEBAN JI, 1989, LANCET, V2, P294; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; PAYA CV, 1987, J CLIN MICROBIOL, V25, P755, DOI 10.1128/JCM.25.5.755-757.1987; ZELDIS JB, 1990, ANN INTERN MED, V112, P958, DOI 10.7326/0003-4819-112-12-958	8	93	93	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1991	114	4					282	284		10.7326/0003-4819-114-4-282	http://dx.doi.org/10.7326/0003-4819-114-4-282			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX521	1846278				2022-12-28	WOS:A1991EX52100005
J	LUSSO, P; DEMARIA, A; MALNATI, M; LORI, F; DEROCCO, SE; BASELER, M; GALLO, RC				LUSSO, P; DEMARIA, A; MALNATI, M; LORI, F; DEROCCO, SE; BASELER, M; GALLO, RC			INDUCTION OF CD4 AND SUSCEPTIBILITY TO HIV-1 INFECTION IN HUMAN CD8+ LYMPHOCYTES-T BY HUMAN HERPESVIRUS-6	NATURE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; CELLS; VIRUS; EXPRESSION; ANTIGEN; GENE; DIFFERENTIATION; CYTOMEGALOVIRUS; INDIVIDUALS; RETROVIRUS	DURING intrathymic T-cell ontogenesis, functionally competent CD3+CD4+CD8- and CD3+CD4-CD8+ T lymphocytes develop from immature CD4-CD8- thymocytes after transiently acquiring a double-positive CD4+CD8+ phenotype 1-3. The partition between CD4+CD8- and CD4-CD8+ T cells is generally considered to be irreversible, although a small percentage of circulating CD3+ T lymphocytes coexpressing CD4 and CD8 molecules has been identified 4. It has been suggested that in CD8+ T cells the CD4 genes may be methylated and thus highly repressed 5, whereas in CD4+ T cells the CD8 genes are unmethylated 6 and their transcription can be induced by physiological stimuli such as interleukin-4 (ref. 7). Here, we demonstrate that infection with human herpesvirus 6 (HHV-6) (ref. 8), a virus proposed as a potential cofactor in AIDS (ref. 9), dramatically upregulates the expression of CD4-the receptor for human immunodeficiency virus type-1 (HIV-1) (refs 10-12)-in a human neoplastic T-cell line. More importantly, HHV-6 induces de novo expression of CD4 messenger RNA and protein in normal mature CDE8+ T lymphocytes, rendering them susceptible to infection with HIV-1. These findings demonstrate that human CD3+CD4-CD8+ T lymphocytes can reacquire CD4 in the post-thymic life and elucidate a novel mechanism-receptor regulation-through which HHV-6 may positively interact with HIV-1 in coinfected patients.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; NCI,FREDERICK CANC RES FACIL,PROGRAM RESOURCES INC,FREDERICK,MD 21701; NIAID,IMMUNOGENET LAB,BETHESDA,MD 20892; ADV BIOSCI LABS,DEPT CELL BIOL,KENSINGTON,MD 20895	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	LUSSO, P (corresponding author), NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892, USA.		de maria, andrea/F-7116-2016; Malnati, Mauro/AAN-4207-2020	de maria, andrea/0000-0001-5782-333X; Malnati, mauro/0000-0001-5355-1680				BACH MA, 1984, J IMMUNOL, V132, P735; BALACHANDRAN N, 1989, J VIROL, V63, P2835, DOI 10.1128/JVI.63.6.2835-2840.1989; BIASSONI R, 1988, J IMMUNOL, V140, P1685; BLUE ML, 1986, J IMMUNOL, V137, P1202; BLUE ML, 1985, J IMMUNOL, V134, P2281; CARBONE AM, 1988, SCIENCE, V242, P1174, DOI 10.1126/science.2460926; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERSTOFT J, 1985, SCAND J IMMUNOL, V22, P463, DOI 10.1111/j.1365-3083.1985.tb01904.x; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MORETTA A, 1983, J EXP MED, V157, P743, DOI 10.1084/jem.157.2.743; PAGANO JS, 1988, J VIROL METHODS, V21, P229, DOI 10.1016/0166-0934(88)90069-9; PALIARD X, 1988, NATURE, V335, P642, DOI 10.1038/335642a0; PSALLIDOPOULOS MC, 1989, J VIROL, V63, P4626, DOI 10.1128/JVI.63.11.4626-4631.1989; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; RICE GPA, 1984, P NATL ACAD SCI-BIOL, V81, P6134, DOI 10.1073/pnas.81.19.6134; RICHARDSON B, 1986, J IMMUNOL, V137, P35; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SHARMA B, 1985, CLIN EXP IMMUNOL, V62, P296; SHEARER GM, 1985, J CLIN INVEST, V76, P1699, DOI 10.1172/JCI112158; SOLBACH W, 1982, J EXP MED, V156, P1250, DOI 10.1084/jem.156.4.1250; STINSKI MF, 1977, J VIROL, V23, P751, DOI 10.1128/JVI.23.3.751-767.1977; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933	30	244	246	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					533	535		10.1038/349533a0	http://dx.doi.org/10.1038/349533a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846951				2022-12-28	WOS:A1991EW57100070
J	MARRACK, P; KUSHNIR, E; KAPPLER, J				MARRACK, P; KUSHNIR, E; KAPPLER, J			A MATERNALLY INHERITED SUPERANTIGEN ENCODED BY A MAMMARY-TUMOR VIRUS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; NUCLEOTIDE-SEQUENCE; EXPRESSION; GENE; REACTIVITY; TOLERANCE; PRODUCTS; REGION; MLS	A COLLECTION of superantigens, molecules which in combination with class II major histocompatibility complex (MHC) engage T cells bearing particular V-beta chains as part of their alpha-beta receptors, have recently been described 1,2. The mouse self superantigen, Mls-1a, for example, in conjunction with many MHC class II proteins, engages mouse T cells bearing V-beta-6, 7, 8.1 and 9, almost regardless of the sequences of the other variable components of the receptors on the T cells 3-5. Two types of superantigen have been identified so far: first, superantigens encoded in the mouse genome, such as mls-1a; second, superantigens produced by bacteria, such as the staphylococcal enterotoxins 1,2. Although the latter type of super-antigens are in many cases known to be proteins of about 220 amino acids 6,7, nothing is known about the structures of any of the superantigens encoded in mouse. Here we describe the properties of a new mouse superantigen. The antigen is maternally transmitted in milk and is probably encoded by a mammary tumour virus (MTV). Given the known genetic linkage between at least one of the mouse genomic superantigens and endogenous MTV integration sites 8, it is tempting to speculate that the superantigen described here and some of the endogenous mouse superantigens are encoded by MTVs.			MARRACK, P (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,HOWARD HUGHES MED INST,DENVER,CO 80206, USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687				ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; Andervont HB, 1940, J NATL CANCER I, V1, P147; BETLEY MJ, 1988, J BACTERIOL, V170, P34, DOI 10.1128/jb.170.1.34-41.1988; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; HAPP MP, 1989, P NATL ACAD SCI USA, V86, P6293, DOI 10.1073/pnas.86.16.6293; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JONES CL, 1986, J BACTERIOL, V166, P29, DOI 10.1128/jb.166.1.29-33.1986; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAPPLER JW, 1989, J EXP MED, V169, P1533, DOI 10.1084/jem.169.5.1533; KING LB, 1990, J IMMUNOL, V144, P3218; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; OLTER AD, 1988, MOL ENDOCRINOL, V2, P143; ONEILL HC, 1987, CELL, V49, P143, DOI 10.1016/0092-8674(87)90764-1; PARKS WP, 1974, SCIENCE, V184, P158, DOI 10.1126/science.184.4133.158; RINGOLD GM, 1983, CURR TOP MICROBIOL, V106, P79; SOLTER D, 1988, ANNU REV GENET, V22, P127; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; 1987, JAX430 NOT	20	345	354	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					524	526		10.1038/349524a0	http://dx.doi.org/10.1038/349524a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846947				2022-12-28	WOS:A1991EW57100066
J	EDIDIN, M; KUO, SC; SHEETZ, MP				EDIDIN, M; KUO, SC; SHEETZ, MP			LATERAL MOVEMENTS OF MEMBRANE-GLYCOPROTEINS RESTRICTED BY DYNAMIC CYTOPLASMIC BARRIERS	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEINS; DIFFUSION; MOBILITY; PARTICLES; ANTIGENS; SURFACE	Cell membranes often are patchy, composed of lateral domains. These domains may be formed by barriers within or on either side of the membrane bilayer. Major histocompatibility complex (MHC) class 1 molecules that were either transmembrane- (H-2D(b)) or glycosylphosphatidylinositol (GPI)-anchored (Qa2) were labeled with antibody-coated gold particles and moved across the cell surface with a laser optical tweezers until they encountered a barrier, the barrier-free path length (BFP). At room temperature, the BFPs of Qa2 and H-2D(b) were 1.7 +/- 0.2 and 0.6 +/- 0.1 (micrometers +/- SEM), respectively. Barriers persisted at 34-degrees-C, although the BFP for both MHC molecules was fivefold greater at 34-degrees-C than at 23-degrees-C. This indicates that barriers to lateral movement are primarily on the cytoplasmic half of the membrane and are dynamic.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Duke University; Johns Hopkins University					NIGMS NIH HHS [GM 36277] Funding Source: Medline; PHS HHS [AL14584] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036277] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; BENNETT GV, 1990, CURR OPIN CELL BIOL, V2, P51; Block S, 1990, NONINVASIVE TECHNIQU, V9, P375; DEBRABANDER M, 1991, J CELL BIOL, V112, P111, DOI 10.1083/jcb.112.1.111; EDIDIN M, 1991, J CELL BIOL, V112, P1143, DOI 10.1083/jcb.112.6.1143; EDIDIN M, IN PRESS STRUCTURE C; GHOSH RN, 1990, BIOPHYS J, V57, pA286; JACOBSON K, 1987, ANNU REV PHYSIOL, V49, P163, DOI 10.1146/annurev.ph.49.030187.001115; KUCIK DF, 1991, J CELL BIOL, V114, P1029, DOI 10.1083/jcb.114.5.1029; NIGG EA, 1980, P NATL ACAD SCI-BIOL, V77, P4702, DOI 10.1073/pnas.77.8.4702; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1980, J IMMUNOL, V125, P2473; PETERS R, 1988, FEBS LETT, V234, P1, DOI 10.1016/0014-5793(88)81290-0; SAXTON MJ, 1990, BIOPHYS J, V58, P1303, DOI 10.1016/S0006-3495(90)82470-X; SHEETZ MP, 1983, SEMIN HEMATOL, V20, P175; SHEETZ MP, 1980, NATURE, V285, P510, DOI 10.1038/285510a0; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; STROYNOWSKI I, 1987, CELL, V50, P759, DOI 10.1016/0092-8674(87)90334-5; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441	19	222	222	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1991	254	5036					1379	1382		10.1126/science.1835798	http://dx.doi.org/10.1126/science.1835798			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1835798				2022-12-28	WOS:A1991GR77700057
J	GABRIEL, SE; JAAKKIMAINEN, L; BOMBARDIER, C				GABRIEL, SE; JAAKKIMAINEN, L; BOMBARDIER, C			RISK FOR SERIOUS GASTROINTESTINAL COMPLICATIONS RELATED TO USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS - A METAANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review							AUTOMATED RECORD LINKAGE; PEPTIC-ULCER; POSTMARKETING SURVEILLANCE; ANTIINFLAMMATORY DRUGS; GASTRIC-ULCER; ASPIRIN; TRACT; HOSPITALIZATION; GASTROPATHY; ASSOCIATION	Objective: To describe the relative risk for serious gastrointestinal complications due to nonaspirin nonsteroidal anti-inflammatory drug (NSAID) exposure among NSAID users as well as in selected subgroups. Design: Overview and meta-analysis. Data identification: A literature search of English-language studies examining the association between NSAIDs and adverse gastrointestinal events for the period 1975 to 1990 identified using MEDLINE and communicating with three internationally recognized experts. Data Analysis: A qualitative summary of study characteristics and a critical appraisal of study quality were done. The results of 16 primary studies were selected and combined statistically. Summary estimates were weighted by sample size and quality score. Main Results: The overall odds ratio of the risk for adverse gastrointestinal events related to NSAID use, summarized from 16 studies (9 case-control and 7 cohort) was 2.74 (95% Cl, 2.54 to 2.97). The summary odds ratios were as follows: elderly patients, (aged greater-than-or-equal-to 60 years), 5.52 (Cl, 4.63 to 6.60); patients under 65 years of age, 1.65 (Cl, 1.08 to 2.53); women, 2.32 (Cl, 1.91 to 2.82); and men, 2.40 (Cl, 1.85 to 3.11). The odds ratio for NSAID users receiving concomitant corticosteroids compared with NSAID users not receiving corticosteroids was 1.83 (Cl, 1.20 to 2.78). The odds ratio for the first gastrointestinal event was 2.39 (Cl, 2.16 to 2.65). The relative risk for a subsequent or unspecified gastrointestinal event was 4.76 (Cl, 4.05 to 5.59). The summary odds ratio for less than 1 month of NSAID exposure was 8.00 (Cl, 6.37 to 10.06); for more than 1 month but less than 3 months of exposure, the summary odds ratio was 3.31 (Cl, 2.27 to 4.82); and for more than 3 months of exposure, the odds ratio was 1.92 (Cl, 1.19 to 3.13). Conclusions: Users of NSAIDs are at approximately three times greater relative risk for developing serious adverse gastrointestinal events than are nonusers. Additional risk factors include age greater than 60 years, previous history of gastrointestinal events, and concomitant corticosteroid use. Another possible risk factor is the first 3 months of NSAID therapy. The risk for serious gastrointestinal events appears to be equal among men and women. These data represent summary statistics from 16 studies and cannot be considered generalizable to all NSAID users.	WELLESLEY COLL HOSP, TORONTO M4Y 1J3, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	GABRIEL, SE (corresponding author), MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, 200 1ST ST, ROCHESTER, MN 55905 USA.							ALEXANDER AM, 1985, J CLIN HOSP PHARM, V10, P89; ARMSTRONG CP, 1987, GUT, V28, P527, DOI 10.1136/gut.28.5.527; BARRIER CH, 1989, ARTHRITIS RHEUM, V32, P926; BARTLE WR, 1986, ARCH INTERN MED, V146, P2365, DOI 10.1001/archinte.146.12.2365; BAUM C, 1985, ARTHRITIS RHEUM, V28, P686, DOI 10.1002/art.1780280613; BEARD K, 1987, ARCH INTERN MED, V147, P1621, DOI 10.1001/archinte.147.9.1621; BEARDON PHG, 1989, Q J MED, V71, P497; BLOOM BS, 1989, ARCH INTERN MED, V149, P1019, DOI 10.1001/archinte.149.5.1019; Breslow N, 1980, STATISTICAL METHODS, V32; BUTT J H, 1988, American Journal of Medicine, V84, P5, DOI 10.1016/0002-9343(88)90248-3; CARSON J L, 1988, Journal of Clinical Pharmacology, V28, P554; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; CHALMERS TC, 1988, ALIMENT PHARM THERAP, V2, P9; CLINCH D, 1987, J ROY COLL PHYS LOND, V21, P183; COLLIER DS, 1985, GUT, V26, P359, DOI 10.1136/gut.26.4.359; DICKERSON K, 1990, 11TH SOC CLIN TRIALS, P24; DUGGAN JM, 1986, GUT, V27, P929, DOI 10.1136/gut.27.8.929; FAICH GA, 1989, CLIN PHARMACOL THER, V46, P387, DOI 10.1038/clpt.1989.155; FLEISS JL, 1973, STATISTICAL METHODS, P143; FRIES JF, 1989, GASTROENTEROLOGY, V96, P647, DOI 10.1016/S0016-5085(89)80061-7; GABRIEL SE, 1990, J RHEUMATOL, V17, P1; GIBSON T, 1988, BRIT J RHEUMATOL, V27, P87; GRAHAM DY, 1988, GASTROENTEROLOGY, V95, P327, DOI 10.1016/0016-5085(88)90487-8; GRAHAM DY, 1986, ANN INTERN MED, V104, P390, DOI 10.7326/0003-4819-104-3-390; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GUESS HA, 1988, J CLIN EPIDEMIOL, V41, P35, DOI 10.1016/0895-4356(88)90007-8; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; Hedges LV, 1985, STAT METHODS METAANA, P122; Henry D A, 1985, Agents Actions Suppl, V17, P105; HENRY DA, 1987, BRIT MED J, V295, P1227, DOI 10.1136/bmj.295.6608.1227; JICK H, 1985, PHARMACOTHERAPY, V5, P280; JICK SS, 1987, LANCET, V2, P380; LANGMAN M J S, 1988, American Journal of Medicine, V84, P15, DOI 10.1016/0002-9343(88)90249-5; LANGMAN MJS, 1989, GASTROENTEROLOGY, V96, P640, DOI 10.1016/S0016-5085(89)80060-5; LEVY M, 1988, ARCH INTERN MED, V148, P281, DOI 10.1001/archinte.148.2.281; LEVY M, 1974, NEW ENGL J MED, V290, P1158, DOI 10.1056/NEJM197405232902102; MANN C, 1990, SCIENCE, V249, P476, DOI 10.1126/science.2382129; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARTIO J, 1980, SCAND J RHEUMATOL, V9, P55; MCINTOSH JH, 1988, AM J EPIDEMIOL, V128, P761, DOI 10.1093/oxfordjournals.aje.a115029; MCINTOSH JH, 1985, GUT, V26, P789, DOI 10.1136/gut.26.8.789; ROTH SH, 1987, ARCH INTERN MED, V147, P2093, DOI 10.1001/archinte.147.12.2093; SHAPIRO S, 1989, CLIN PHARMACOL THER, V46, P371, DOI 10.1038/clpt.1989.154; SLAVIN HS, 1987, NEW ENGL J MED, V316, P450; SOMERVILLE K, 1986, LANCET, V1, P462; SPITZER WO, 1991, J CLIN EPIDEMIOL, V44, P103, DOI 10.1016/0895-4356(91)90258-B; STROM BL, 1990, AGENT ACTION SUPPL, V29, P27; STROM BL, 1989, CLIN PHARMACOL THER, V46, P390, DOI 10.1038/clpt.1989.156; TENENBAUM J, 1987, CLIN INVEST MED, V10, P246; 1989, REFERENCE MANAGER VE; 1987, ORACLE VERSION 5 1 2	53	1032	1052	4	38	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					787	796		10.7326/0003-4819-115-10-787	http://dx.doi.org/10.7326/0003-4819-115-10-787			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1834002				2022-12-28	WOS:A1991GP80000009
J	LAUPACIS, A; CONNOLLY, SJ; GENT, M; ROBERTS, RS; CAIRNS, J; JOYNER, C				LAUPACIS, A; CONNOLLY, SJ; GENT, M; ROBERTS, RS; CAIRNS, J; JOYNER, C			HOW SHOULD RESULTS FROM COMPLETED STUDIES INFLUENCE ONGOING CLINICAL-TRIALS - THE CAFA STUDY EXPERIENCE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ATRIAL-FIBRILLATION; META-ANALYSIS	Seven randomized studies during the past 5 years have evaluated or are evaluating the efficacy of warfarin or aspirin or both in decreasing the risk of embolic events in patients with nonrheumatic atrial fibrillation. By March 1990, two of the studies had been published, both of which showed a statistically significant decrease in embolic events in patients treated with warfarin and a low rate of major bleeding events. The investigators associated with the other ongoing studies were forced to consider how these results should affect the decision to recruit and continue follow-up of patients in their own studies. The Steering Committee of the Canadian Atrial Fibrillation Anticoagulation (CAFA) study thought the newly Published results from other studies were valid, clinically important, and generalizable. The committee considered the following options for the CAFA study: continue patient recruitment as planned, provide the data available in CAFA to its External Safety and Efficacy Monitoring Committee for analysis to determine whether the CAFA data already showed a benefit of warfarin, stop patient recruitment but continue to follow Patients in the group to which they were assigned, stop the trial immediately and perform a final analysis, and attempt to perform a meta-analysis of all data available from all trials. The Steering Committee of CAFA decided that the evidence of benefit with warfarin, from the two published studies, was sufficiently compelling as to stop recruitment into CAFA without any preliminary examination of the CAFA data.			LAUPACIS, A (corresponding author), OTTAWA CIVIC HOSP, LOEB RES INST, CLIN EPIDEMIOL UNIT, 1053 CARLING AVE, OTTAWA K1Y 4E9, ONTARIO, CANADA.		Cairns, John/AAI-8744-2021					[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; MCBRIDE R, 1990, NEW ENGL J MED, V322, P863; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PETERSEN P, 1989, LANCET, V1, P175; PHILLIPS SJ, 1990, MAYO CLIN PROC, V65, P344, DOI 10.1016/S0025-6196(12)62535-X; POCOCK SJ, 1989, CONTROL CLIN TRIALS, V10, pS209; WALKER MD, 1989, LANCET, V1, P325	15	20	20	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					818	822		10.7326/0003-4819-115-10-818	http://dx.doi.org/10.7326/0003-4819-115-10-818			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1834003				2022-12-28	WOS:A1991GP80000012
J	ELASHOFF, JD; JACKNOW, AD; SHAIN, SG; BRAUNSTEIN, GD				ELASHOFF, JD; JACKNOW, AD; SHAIN, SG; BRAUNSTEIN, GD			EFFECTS OF ANABOLIC-ANDROGENIC STEROIDS ON MUSCULAR STRENGTH	ANNALS OF INTERNAL MEDICINE			English	Article						ANABOLIC STEROIDS; EXERCISE THERAPY; MUSCLE STRENGTH; ANDROGENS; METAANALYSIS	BODY-COMPOSITION; METHANDIENONE; PERFORMANCE; WEIGHT; MEN	Objective: To assess the effects of anabolic-androgenic steroids on human muscle strength. Data Sources: A MEDLINE search for the period from January 1966 to April 1990, supplemented by manual searches of previous reviews, produced 30 studies in which subjects received more than one dose of the study steroid and in which changes in muscular strength were measured. Study Selection: Of the 30 studies, 14 were not included in the detailed data summary because they did not use a placebo control, did not randomize subjects to groups, or did not make objective strenght measurements, or because percent change in strength data could not be abstracted. Data Extraction: Details of study design, reporting of results, and the adequacy and correctness of statistical methods were tabulated. Percent improvement in strength for the largest muscle group studied was computed, using the difference between results for the placebo and for the steroid-treated groups. Data Synthesis: Previously trained athletes show slightly greater improvements in strength in the anabolic-androgenic steroid-treated group than in the placebo group, with a median difference of 5% across the nine studies (range, 1.2% to 18.7%). A meta-analysis of the three studies with enough information to compute effect size showed a mean difference of 1.0 standard deviations (95% Cl, 0.49 to 1.5). However, the poor overall quality of the studies in terms of design, sample size, and analysis; the lack of a dose-response effect across the narrow range of dosages tested; and the tendency for differences to be smaller in the larger studies throw these results into question. No evidence was found to support enhanced muscle strength with steroid use in eight studies in untrained normal volunteers. Conclusions: Anabolic steroids may slightly enhance muscle strength in previously trained athletes. No firm conclusion is possible concerning the efficacy of anabolic steroids in enhancing overall athletic performance. Results for the low steroid dosages studied in the published reports cannot be generalized to steroid-using athletes taking megadose regimens.	UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR,SCH MED,DEPT MED,ROOM B118, 8700 BEVERLY BLVD, LOS ANGELES, CA 90048 USA; SO CALIF PERMANENTE MED GRP, PANORAMA CITY, CA 91402 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups								ARIEL G, 1972, J APPL PHYSIOL, V32, P795, DOI 10.1152/jappl.1972.32.6.795; ARIEL G, 1974, J SPORT MED PHYS FIT, V14, P103; ARIEL G, 1973, J SPORT MED PHYS FIT, V13, P187; ARIEL G, 1972, MED SCI SPORT EXER, V4, P124; Beckett A H, 1978, Br J Sports Med, V12, P185; BERGMAN R, 1985, CLIN ORTHOP RELAT R, V198, P169; BOWERS RW, 1972, MED SCI SPORT EXER, V4, P54; Casner S W Jr, 1971, J Sports Med Phys Fitness, V11, P98; CRIST DM, 1983, J APPL PHYSIOL, V54, P366, DOI 10.1152/jappl.1983.54.2.366; FAHEY TD, 1973, MED SCI SPORT EXER, V5, P272; FORBES GB, 1985, METABOLISM, V34, P571, DOI 10.1016/0026-0495(85)90196-9; FOWLER WM, 1965, J APPL PHYSIOL, V20, P1038, DOI 10.1152/jappl.1965.20.5.1038; FREED DLJ, 1975, BRIT MED J, V2, P471, DOI 10.1136/bmj.2.5969.471; FREINHAR JP, 1985, J CLIN PSYCHIAT, V46, P354; Golding L, 1974, PHYSICIAN SPORTSMED, V2, P39; GOTZSCHE PC, 1990, DAN MED BULL, V37, P329; HAUPT HA, 1984, AM J SPORT MED, V12, P469, DOI 10.1177/036354658401200613; Hedges L, 1985, STATISTICAL METHODS; Hervey G R, 1975, Br J Sports Med, V9, P74; HERVEY GR, 1976, LANCET, V2, P699; HERVEY GR, 1981, CLIN SCI, V60, P457, DOI 10.1042/cs0600457; JOHNSON LC, 1975, MED SCI SPORT EXER, V7, P287; JOHNSON LC, 1972, MED SCI SPORT EXER, V4, P43; JOHNSON LC, 1969, SCIENCE, V164, P957, DOI 10.1126/science.164.3882.957; KEUL J, 1976, MED KLIN, V71, P497; Kochakian CD, 1936, AM J PHYSIOL, V117, P642, DOI 10.1152/ajplegacy.1936.117.4.642; Kochakian CD, 1935, J NUTR, V10, P437, DOI 10.1093/jn/10.4.437; LAMB DR, 1984, AM J SPORT MED, V12, P31, DOI 10.1177/036354658401200105; MUNSON AR, 1970, THESIS U SO CALIFORN; O'Shea J., 1970, NUTR REP INT, V2, P351; O'SHEA J P, 1971, Nutrition Reports International, V4, P363; O'SHEA J. P., 1970, Nutrition Reports International, V1, P337; OSHEA JP, 1974, NUTR REP INT, V10, P381; POPE HG, 1987, LANCET, V1, P863; Potts G.O., 1976, ANABOLIC ANDROGENIC, P361; RYAN AJ, 1981, FED PROC, V40, P2682; Samuels LT, 1942, J CLIN ENDOCRINOL, V2, P649, DOI 10.1210/jcem-2-11-649; STAMFORD BA, 1974, J SPORT MED PHYS FIT, V14, P191; STROMME SB, 1974, MED SCI SPORT EXER, V6, P203; TAHMINDJIS AJ, 1976, MED J AUSTRALIA, V1, P991, DOI 10.5694/j.1326-5377.1976.tb128921.x; WARD P, 1973, MED SCI SPORT EXER, V5, P277; Weiss U, 1968, Schweiz Z Sportmed, V16, P79; WELLER O, 1966, ARZNEI-FORSCHUNG, V16, P465; WILSON JD, 1988, ENDOCR REV, V9, P181, DOI 10.1210/edrv-9-2-181; Win-May M, 1975, J Sports Med Phys Fitness, V15, P266; 1977, MED SCI SPORTS, V9, pR11; 1984, AM J SPORTS MED, V12, P13	47	99	102	1	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					387	393		10.7326/0003-4819-115-5-387	http://dx.doi.org/10.7326/0003-4819-115-5-387			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1830732				2022-12-28	WOS:A1991GC06500010
J	OGAWA, K				OGAWA, K			4 ATP-BINDING SITES IN THE MIDREGION OF THE BETA-HEAVY CHAIN OF DYNEIN	NATURE			English	Article							URCHIN SPERM FLAGELLA; PHOTOSENSITIZED CLEAVAGE; TAU-PROTEIN; FRAGMENT-A; OUTER ARM; SEQUENCE; IRRADIATION; SUBUNITS; ENZYMES; MOTOR	THE 'motor' proteins of eukaryotic cells contain specialized domains that hydrolyse ATP to produce force and movement along a cytoskeletal polymer (actin in the case of the myosin family; microtubules in the case of the kinesin family and dyneins). There are motor-protein superfamilies in which each member has a conserved force-generating domain joined to a different 'tail' which conveys specific attachment properties (see ref. 1 for a review). The minus-end-directed microtubule motors, the dyneins 2, may also constitute a superfamily of force-generating proteins with distinct attachment domains 3. Axonemal outer-arm dynein from sea urchin spermatozoa is a multimeric protein consisting of two heavy chains (alpha and beta) with ATPase activity. three intermediate chains and several light chains 4. Here I report the sequence of cloned complementary DNA encoding the beta-heavy chain of a dynein motor molecule. The predicted amino-acid sequence reveals four ATP-binding consensus sequences in the central domain. The dynein beta-heavy chain is thought to associate transiently with a microtubule during ATP hydrolysis 5, but the ATP-dependent microtubule-binding sequence common to the kinesin superfamily is not found in the dynein beta-heavy chain. These unique features distinguish the dynein beta-heavy chain from other motor protein superfamilies and may be characteristic of the dynein superfamily.			OGAWA, K (corresponding author), NATL INST BASIC BIOL, DEPT CELL BIOL, OKAZAKI, AICHI 444, JAPAN.							GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GIBBONS IR, 1981, J CELL BIOL, V91, pS107, DOI 10.1083/jcb.91.3.107s; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NISHIKAWA K, 1986, J BIOCHEM-TOKYO, V100, P1043, DOI 10.1093/oxfordjournals.jbchem.a121783; NISHIKAWA K, 1991, METHOD ENZYMOL, V202, P31; OGAWA K, 1975, J BIOL CHEM, V250, P6476; OGAWA K, 1987, EUR J CELL BIOL, V43, P3; OGAWA K, 1990, CELL MOTIL CYTOSKEL, V16, P58, DOI 10.1002/cm.970160108; OGAWA K, 1991, P JPN ACAD B-PHYS, V67, P27, DOI 10.2183/pjab.67.27; OW RA, 1987, J BIOL CHEM, V262, P3409; PFISTER KK, 1984, J BIOL CHEM, V259, P8499; SALE WS, 1988, J CELL BIOL, V107, P1793, DOI 10.1083/jcb.107.5.1793; SALE WS, 1985, J CELL BIOL, V101, P1400, DOI 10.1083/jcb.101.4.1400; TANG WJY, 1982, J BIOL CHEM, V257, P508; TANG WJY, 1987, J BIOL CHEM, V262, P17728; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	21	173	176	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					643	645		10.1038/352643a0	http://dx.doi.org/10.1038/352643a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1830928				2022-12-28	WOS:A1991GB21100063
J	THOMSON, BJ; EFSTATHIOU, S; HONESS, RW				THOMSON, BJ; EFSTATHIOU, S; HONESS, RW			ACQUISITION OF THE HUMAN ADENOASSOCIATED VIRUS TYPE-2 REP GENE BY HUMAN HERPESVIRUS TYPE-6	NATURE			English	Article							INHIBITS CELLULAR-TRANSFORMATION; HUMAN PARVOVIRUS B19; NUCLEOTIDE-SEQUENCE; GENOME ORGANIZATION; EXPRESSION; CELLS; DNA; INFECTION; BINDING; TROPISM	HUMAN herpesvirus type-6 (HHV-6) is a recently isolated herpesvirus which is highly prevalent in adult populations around the world 1-3. HHV-6 was first isolated from the peripheral blood of six individuals with lymphoproliferative disorders, two of whom were also infected with human immunodeficiency virus 1. HHV-6, in common with other herpesviruses, transactivates the HIV long terminal repeat linked to reporter genes 4,5 and has in addition been shown to accelerate HIV gene expression and CD4 cell death in cultures co-infected with both viruses 6. The virus is tropic for CD4+ lymphocytes 7,8 and persists in the peripheral blood of most seropositive individuals 9. We have now identified a gene in HHV-6 encoding a 490-amino-acid polypeptide homologous to the human adeno-associated virus type-2 (AAV-2) rep gene 10. This gene has an essential role in AAV-2 DNA replication 11,12, can trans-regulate homologous and heterologous gene expression 13-17, and inhibits cellular transformation 18. The acquisition of rep by HHV-6 could be due to natural transfer of genetic information between DNA viruses of eukaryotes and is likely to have important consequences for the life-cycle of HHV-6 and for host CD4 cell.	UNIV CAMBRIDGE,DEPT PATHOL,DIV VIROL,CAMBRIDGE CB2 1QP,ENGLAND	University of Cambridge	THOMSON, BJ (corresponding author), NATL INST MED RES,DIV VIROL,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.			Thomson, Brian/0000-0001-8490-2332				ANTONI BA, 1991, J VIROL, V65, P396, DOI 10.1128/JVI.65.1.396-404.1991; ASTELL CR, 1987, J GEN VIROL, V68, P885, DOI 10.1099/0022-1317-68-3-885; ASTELL CR, 1983, NUCLEIC ACIDS RES, V11, P999, DOI 10.1093/nar/11.4.999; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BECK S, 1988, NATURE, V331, P269, DOI 10.1038/331269a0; BRIGGS M, 1988, LANCET, V1, P40; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; CHEN KC, 1986, J VIROL, V60, P1085, DOI 10.1128/JVI.60.3.1085-1097.1986; CHEUNG AKM, 1980, J VIROL, V33, P739, DOI 10.1128/JVI.33.2.739-748.1980; ENSOLI B, 1989, EMBO J, V8, P3019, DOI 10.1002/j.1460-2075.1989.tb08452.x; GOPAL MR, 1990, LANCET, V335, P1598, DOI 10.1016/0140-6736(90)91433-B; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; HERMONAT PL, 1989, VIROLOGY, V172, P253, DOI 10.1016/0042-6822(89)90127-X; HERMONAT PL, 1984, J VIROL, V51, P329, DOI 10.1128/JVI.51.2.329-339.1984; HIELBRONN R, 1990, J VIROL, V64, P3012; HOGGAN MD, 1966, P NATL ACAD SCI USA, V55, P1467, DOI 10.1073/pnas.55.6.1467; HORVAT RT, 1989, J VIROL, V63, P970, DOI 10.1128/JVI.63.2.970-973.1989; IM DS, 1990, CELL, V61, P447, DOI 10.1016/0092-8674(90)90526-K; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LABOW MA, 1987, MOL CELL BIOL, V7, P1320, DOI 10.1128/MCB.7.4.1320; LABOW MA, 1986, J VIROL, V60, P250; LAWRENCE GL, 1990, J VIROL, V64, P287, DOI 10.1128/JVI.64.1.287-299.1990; LI X, 1990, J VIROL, V64, P4654, DOI 10.1128/JVI.64.10.4654-4660.1990; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; MARTIN MED, 1991, J GEN VIROL, V72, P157, DOI 10.1099/0022-1317-72-1-157; MENDELSON E, 1986, J VIROL, V62, P68; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; OKUNO T, 1989, J CLIN MICROBIOL, V27, P651, DOI 10.1128/JCM.27.4.651-653.1989; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REED AP, 1988, J VIROL, V62, P266, DOI 10.1128/JVI.62.1.266-276.1988; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SHADE RO, 1986, J VIROL, V58, P921, DOI 10.1128/JVI.58.3.921-936.1986; SRIVASTAVA A, 1983, J VIROL, V45, P555, DOI 10.1128/JVI.45.2.555-564.1983; SRIVASTAVA CH, 1989, P NATL ACAD SCI USA, V86, P8078, DOI 10.1073/pnas.86.20.8078; STADEN R, 1990, COMPUT APPL BIOSCI, V6, P387; STADEN R, 1986, NUCLEIC ACIDS RES, V14, P217, DOI 10.1093/nar/14.1.217; TAKAHASHI K, 1989, J VIROL, V63, P3161, DOI 10.1128/JVI.63.7.3161-3163.1989; TRATSCHIN JD, 1986, MOL CELL BIOL, V6, P2884, DOI 10.1128/MCB.6.8.2884; TREMPE JP, 1988, J VIROL, V62, P68, DOI 10.1128/JVI.62.1.68-74.1988	40	107	114	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					78	80		10.1038/351078a0	http://dx.doi.org/10.1038/351078a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	1851252				2022-12-28	WOS:A1991FK19300065
J	SUNAHARA, RK; GUAN, HC; ODOWD, BF; SEEMAN, P; LAURIER, LG; NG, G; GEORGE, SR; TORCHIA, J; VANTOL, HHM; NIZNIK, HB				SUNAHARA, RK; GUAN, HC; ODOWD, BF; SEEMAN, P; LAURIER, LG; NG, G; GEORGE, SR; TORCHIA, J; VANTOL, HHM; NIZNIK, HB			CLONING OF THE GENE FOR A HUMAN DOPAMINE D5-RECEPTOR WITH HIGHER AFFINITY FOR DOPAMINE THAN D1	NATURE			English	Article							HUMAN-BRAIN; RECEPTORS; SCHIZOPHRENIA; EXPRESSION	DOPAMINE receptors belong to a superfamily of receptors that exert their biological effects through guanine nucleotide-binding (G) proteins. Two main dopamine receptor subtypes have been identified, D1 and D2, which differ in their pharmacological and biochemical characteristics. D1 stimulates adenylyl cyclase activity, whereas D2 inhibits it 1-3. Both receptors are primary targets for drugs used to treat many psychomotor diseases, including Parkinson's disease and schizophrenia 4,5. Whereas the dopamine D1 receptor has been cloned 6-9, biochemical and behavioural data indicate that dopamine D1-like receptors exist which either are not linked to adenylyl cyclase or display different pharmacological activities 10, 11. We report here the cloning of a gene encoding a 477-amino-acid protein with strong homology to the cloned D1 receptor. The receptor, called D5, binds drugs with a pharmacological profile similar to that of the cloned D1 receptor, but displays a 10-fold higher affinity for the endogenous agonist, dopamine. As with D1, the dopamine D5 receptor stimulates adenylyl cyclase activity. Northern blot and in situ hybridization analyses reveal that the receptor is neuron-specific, localized primarily within limbic regions of the brain; no messenger RNA was detected in kidney, liver, heart or parathyroid gland. The existence of a dopamine D1-like receptor with these characteristics had not been predicted and may represent an alternative pathway for dopamine-mediated events and regulation of D2 receptor activity 12-14.	UNIV TORONTO, DEPT PSYCHIAT, TORONTO M5S 1A8, ONTARIO, CANADA; UNIV TORONTO, DEPT PHARMACOL, TORONTO M5S 1A8, ONTARIO, CANADA; ADDICT RES FDN, TORONTO M5S 2S1, ONTARIO, CANADA; CLARKE INST PSYCHIAT, MOLEC NEUROBIOL LAB, TORONTO M5T 1R8, ONTARIO, CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada			George, Susan R/P-9669-2018; George, Susan/W-7494-2019; Sunahara, Roger/AAJ-8667-2020					ALBERT PR, 1990, J BIOL CHEM, V265, P2098; ANDERSEN PH, 1990, TRENDS PHARMACOL SCI, V11, P231, DOI 10.1016/0165-6147(90)90249-8; BESSON MJ, 1988, NEUROSCIENCE, V26, P101, DOI 10.1016/0306-4522(88)90130-3; Bjorklund A., 1984, HDB CHEM NEUROANAT 1, V2, P55; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; CORTES R, 1989, NEUROSCIENCE, V28, P263, DOI 10.1016/0306-4522(89)90178-4; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DIOP L, 1988, SYNAPSE, V2, P395, DOI 10.1002/syn.890020406; EHRLICH ME, 1990, J MOL NEUROSCI, V2, P1, DOI 10.1007/BF02896920; FELDER RA, 1989, AM J PHYSIOL, V257, pF315, DOI 10.1152/ajprenal.1989.257.3.F315; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1988, J CELL BIOL, V107, P1, DOI 10.1083/jcb.107.1.1; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; NIZNIK HB, 1988, BIOCHEMISTRY-US, V27, P7594, DOI 10.1021/bi00420a004; NIZNIK HB, 1987, MOL CELL ENDOCRINOL, V54, P1, DOI 10.1016/0303-7207(87)90134-1; NIZNIK HB, 1989, BIOCHEMISTRY-US, V28, P6925, DOI 10.1021/bi00443a022; ODOWD BF, 1990, FEBS LETT, V262, P8, DOI 10.1016/0014-5793(90)80140-E; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; ONGINI E, 1989, INT REV NEUROBIOL, V31, P239; SALOMON Y, 1979, ADV CYCLIC NUCLEOTID, V10; SAVASTA M, 1986, BRAIN RES, V375, P291, DOI 10.1016/0006-8993(86)90749-3; SEEMAN P, 1989, P NATL ACAD SCI USA, V86, P10156, DOI 10.1073/pnas.86.24.10156; SEEMAN P, 1987, SYNAPSE, V1, P133, DOI 10.1002/syn.890010203; SEEMAN P, 1980, PHARMACOL REV, V32, P229; SEEMAN P, 1990, FASEB J, V4, P2737, DOI 10.1096/fasebj.4.10.2197154; SEEMAN P, 1987, NEUROPSYCHOPHARMACOL, V1, P5, DOI 10.1016/0893-133X(87)90004-2; SELBIE LA, 1989, DNA-J MOLEC CELL BIO, V8, P683, DOI 10.1089/dna.1.1989.8.683; Shivers B D, 1986, Methods Enzymol, V124, P497; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WADDINGTON JL, 1989, PHARMACOL THERAPEUT, V43, P1, DOI 10.1016/0163-7258(89)90046-6; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	40	1017	1067	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	1991	350	6319					614	619		10.1038/350614a0	http://dx.doi.org/10.1038/350614a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	1826762				2022-12-28	WOS:A1991FH11200061
J	PATTEE, G; RINGEL, SP				PATTEE, G; RINGEL, SP			ELEVATED CREATINE-KINASE LEVELS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							MYOGLOBINURIA				PATTEE, G (corresponding author), UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262, USA.							BERLIN BS, 1974, JAMA-J AM MED ASSOC, V227, P1414; GABOW PA, 1982, MEDICINE, V61, P141, DOI 10.1097/00005792-198205000-00002; SCHLESINGER JJ, 1978, ARCH INTERN MED, V138, P422, DOI 10.1001/archinte.138.3.422; Schooley R, 1987, HARRISONS PRINCIPLES, P699	4	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					2004	2004						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	1848909				2022-12-28	WOS:A1991FF76800031
J	LECHLEITER, J; GIRARD, S; CLAPHAM, D; PERALTA, E				LECHLEITER, J; GIRARD, S; CLAPHAM, D; PERALTA, E			SUBCELLULAR PATTERNS OF CALCIUM RELEASE DETERMINED BY G-PROTEIN-SPECIFIC RESIDUES OF MUSCARINIC RECEPTORS	NATURE			English	Article							SUBTYPES; CELL; HYDROLYSIS	CALCIUM release from intracellular stores is a point of convergence for a variety of receptors involved in cell signalling 1. Consequently, the mechanism(s) by which cells differentiate between individual receptor signals is central to transmembrane communication 2-5. There are significant differences in timing and magnitude of Ca2+ release stimulated by the m2 and m3 muscarinic acetylcholine receptors 6-11. The m2 receptors couple to a pertussis toxin-sensitive G protein to activate phosphatidyl inositol hydrolysis weakly and to stimulate small, delayed and oscillatory chloride currents. In contrast, m3 receptors potently activate phosphatidyl inositol hydrolysis and stimulate large, rapid and transient chloride currents by a pertussis toxin-insensitive G protein pathway. Using confocal microscopy, we now show that the m2- and m3-coupled Ca2+ release pathways can also be spatially distinguished. At submaximal acetylcholine concentrations, both receptors stimulated pulses of Ca2+ release from discrete foci in random, periodic and frequently bursting patterns of activity. But maximal stimulation of m2 receptors increased the number of focal release sites, whereas m3 receptors invariably evoked a Ca2+ wave propagating rapidly just beneath the plasma membrane surface. Analysis of pertussis toxin sensitivity and hybrid m2-m3 muscarinic acetylcholine receptors confirmed that these Ca2+ release patterns represent distinct cell signalling pathways.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University	LECHLEITER, J (corresponding author), MAYO CLIN & MAYO FDN,DEPT PHARMACOL,200 1ST ST SW,ROCHESTER,MN 55905, USA.		Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; FUKUDA K, 1987, NATURE, V327, P623, DOI 10.1038/327623a0; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LECHLEITER J, 1989, TRENDS PHARM SCI S4, V10, P34; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; ROONEY TA, 1990, J BIOL CHEM, V265, P10792	15	153	155	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					505	508		10.1038/350505a0	http://dx.doi.org/10.1038/350505a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	1849616				2022-12-28	WOS:A1991FG14300053
J	SKOLNIK, EY; MARGOLIS, B; MOHAMMADI, M; LOWENSTEIN, E; FISCHER, R; DREPPS, A; ULLRICH, A; SCHLESSINGER, J				SKOLNIK, EY; MARGOLIS, B; MOHAMMADI, M; LOWENSTEIN, E; FISCHER, R; DREPPS, A; ULLRICH, A; SCHLESSINGER, J			CLONING OF PI3 KINASE ASSOCIATED P85 UTILIZING A NOVEL METHOD FOR EXPRESSION CLONING OF TARGET PROTEINS FOR RECEPTOR TYROSINE KINASES	CELL			English	Article							PHOSPHOLIPASE C-II; PHOSPHATIDYLINOSITOL KINASE; SIGNAL TRANSDUCTION; PDGF RECEPTOR; CATALYTIC DOMAINS; PHOSPHORYLATION; TRANSFORMATION; ELEMENTS	A novel method has been developed to allow cloning of protein targets for receptors with tyrosine kinase activity. By utilizing the carboxy-terminal tail of EGF receptor (EGFR) as a probe to screen lambda-gt11 expression libraries, several EGFR-binding proteins have been cloned; two have been analyzed and contain unique SH2 and SH3 domains. One gene (GRB-1) has been fully sequenced, is expressed in various tissues and cell lines, and has a molecular mass of 85 kd. Interestingly, GRB-1 encodes the human counterpart of the PI3 kinase-associated protein p85. Advantages of this technique include the ease of cloning tyrosine kinase receptor targets present at low levels and the ability to identify proteins that are related in their capacity to bind activated receptors but contain no significant DNA sequence homology. This method, termed CORT (for cloning of receptor targets), offers a general approach for the identification and cloning of various receptor targets.	MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Max Planck Society	SKOLNIK, EY (corresponding author), NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016, USA.		Mohammadi, Moosa/ABA-6745-2020; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001927] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK01927] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MACGREGOR PF, 1990, ONCOGENE, V5, P451; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARGOLIS G, 1990, EMBO J, V9, P4375; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; OTSU M, 1991, CELL; PAWSON T, 1988, ONCOGENE, V3, P491; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1989, NATURE, V335, P90; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; [No title captured]	42	596	646	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					83	90		10.1016/0092-8674(91)90410-Z	http://dx.doi.org/10.1016/0092-8674(91)90410-Z			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1849461	hybrid			2022-12-28	WOS:A1991FF77300011
J	VARKI, A; HOOSHMAND, F; DIAZ, S; VARKI, NM; HEDRICK, SM				VARKI, A; HOOSHMAND, F; DIAZ, S; VARKI, NM; HEDRICK, SM			DEVELOPMENTAL ABNORMALITIES IN TRANSGENIC MICE EXPRESSING A SIALIC-ACID SPECIFIC 9-O-ACETYLESTERASE	CELL			English	Article							INFLUENZA-C VIRUS; MELANOMA-ASSOCIATED GANGLIOSIDE; DE-ORTHO-ACETYLATION; CELL-SURFACE; O-ACETYLATION; MEMBRANE-FUSION; GERMINAL CELLS; RAT RETINA; LOW-PH; HEMAGGLUTININ	9-O-acetylation of sialic acids is tissue specific and developmentally regulated. We have selectively destroyed these O-acetyl groups during murine embryogenesis by expressing the 9-O-acetyl-sialic acid-specific esterase of influenza C. DNA constructs driven by the metallothionein promoter arrested development at the 2-cell stage and gave a markedly decreased yield of live mice. A similar construct driven by the phenylethanolamine-N-methyltransferase promoter did not cause this block, but gave transgenic mice with selective expression of esterase in the retina and the adrenal gland. These organs showed variable abnormalities in organization, while all other tissues examined appeared normal. The ganglioside 9-O-acetyl-G(D3) was selectively destroyed in target tissues. Thus, 9-O-acetylated sialic acids may play an role in murine development at the 2-cell stage and in certain differentiated tissues.	UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	VARKI, A (corresponding author), UNIV CALIF SAN DIEGO, SAN DIEGO CANC CTR, LA JOLLA, CA 92093 USA.		Hedrick, Stephen M/E-9171-2010	Hedrick, Stephen/0000-0002-6345-8751	NATIONAL CANCER INSTITUTE [P30CA023100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032373, R01GM035880, R01GM032373] Funding Source: NIH RePORTER; NCI NIH HHS [CA23100] Funding Source: Medline; NIGMS NIH HHS [GM35880, GM32373] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BECH K, 1969, ACTA PATHOL MIC SC, V76, P391; BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; BOUHOURS D, 1983, J BIOL CHEM, V258, P299; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BRINSTER RL, 1982, NATURE, V296, P39, DOI 10.1038/296039a0; CHANEY W, 1986, J BIOL CHEM, V261, P551; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CHERESH DA, 1984, J BIOL CHEM, V259, P7453; CHOU DKH, 1990, J NEUROCHEM, V54, P1598, DOI 10.1111/j.1471-4159.1990.tb01210.x; CHOU DKH, 1989, J BIOL CHEM, V264, P3409; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; CORFIELD AP, 1986, BIOL CHEM H-S, V367, P433, DOI 10.1515/bchm3.1986.367.1.433; DEKAN G, 1990, AM J PATHOL, V137, P913; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; DRZENIEK R, 1973, HISTOCHEM J, V5, P271, DOI 10.1007/BF01004994; EISENLOHR LC, 1988, J IMMUNOL, V141, P1870; ELS MC, 1989, VIROLOGY, V170, P346, DOI 10.1016/0042-6822(89)90394-2; FARQUHAR MG, 1991, IN PRESS INTRACELLUL; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FORMANOWSKI F, 1990, J GEN VIROL, V71, P1181, DOI 10.1099/0022-1317-71-5-1181; FUKUDA MN, 1990, P NATL ACAD SCI USA, V87, P7443, DOI 10.1073/pnas.87.19.7443; FUKUDA MN, 1987, J BIOL CHEM, V262, P7195; GENDEL S, 1983, J BACTERIOL, V156, P148, DOI 10.1128/JB.156.1.148-154.1983; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1986, CHEM PHYS LIPIDS, V42, P209, DOI 10.1016/0009-3084(86)90054-X; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HAYES BK, 1989, J BIOL CHEM, V264, P19443; HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x; HIGA HH, 1989, J BIOL CHEM, V264, P19427; HOFMANN SL, 1988, SCIENCE, V239, P1277, DOI 10.1126/science.3344433; HOGAN B, 1986, MANIPULATING MOUSE E; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; IWAKURA Y, 1988, EMBO J, V7, P3757, DOI 10.1002/j.1460-2075.1988.tb03259.x; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1982, CIBA F SYMP, V92, P138; LEVINE JM, 1984, J NEUROSCI, V4, P820; LEVINE JM, 1986, DEV BRAIN RES, V27, P211, DOI 10.1016/0165-3806(86)90247-6; LINDAHL U, 1989, ANN NY ACAD SCI, V556, P36; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MENDEZOTERO R, 1988, J NEUROSCI, V8, P564; MONK M, 1987, MAMMALIAN DEV; MORAHAN G, 1989, P NATL ACAD SCI USA, V86, P3782, DOI 10.1073/pnas.86.10.3782; MORRISON TG, 1989, VIROLOGY, V171, P10, DOI 10.1016/0042-6822(89)90505-9; MUCHMORE EA, 1987, FASEB J, V1, P229, DOI 10.1096/fasebj.1.3.3623000; MUCHMORE EA, 1987, SCIENCE, V236, P1293, DOI 10.1126/science.3589663; NAKADA S, 1984, J VIROL, V50, P118, DOI 10.1128/JVI.50.1.118-124.1984; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; NISHIMURA H, 1988, J GEN VIROL, V69, P2545, DOI 10.1099/0022-1317-69-10-2545; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PFEIFER JB, 1984, VIRUS RES, V1, P281, DOI 10.1016/0168-1702(84)90017-0; REID PE, 1984, HISTOCHEM J, V16, P235, DOI 10.1007/BF01003608; REITMAN ML, 1982, J BIOL CHEM, V257, P357; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; Rosenberg Abraham, 1976, BIOL ROLES SIALIC AC; Rutishauser U, 1990, Adv Exp Med Biol, V265, P179; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; SCHACHTER H, 1988, BIOCHIMIE, V70, P1701, DOI 10.1016/0300-9084(88)90309-4; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SCHLOSSHAUER B, 1988, J NEUROSCI, V8, P580; SERONFERRE M, 1981, ANNU REV PHYSIOL, V43, P141, DOI 10.1146/annurev.ph.43.030181.001041; SPARROW JR, 1988, J NEUROSCI RES, V21, P398, DOI 10.1002/jnr.490210231; STALLCUP WB, 1989, DEV BIOL, V132, P212, DOI 10.1016/0012-1606(89)90218-2; STEGMANN T, 1987, J BIOL CHEM, V262, P17744; STEVENS ME, 1989, EXP CELL RES, V183, P319, DOI 10.1016/0014-4827(89)90392-3; THEILER K, 1974, Z ANAT ENTWICKLUNGS, V144, P195, DOI 10.1007/BF00519775; THURIN J, 1985, J BIOL CHEM, V260, P4556; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; VAN MEER G, 1985, BIOCHEMISTRY-US, V24, P3593, DOI 10.1021/bi00335a030; VARKI A, 1983, J BIOL CHEM, V258, P2465; VLASAK R, 1989, J VIROL, V63, P2056, DOI 10.1128/JVI.63.5.2056-2062.1989; VLASAK R, 1987, VIROLOGY, V160, P419, DOI 10.1016/0042-6822(87)90013-4; WARING H, 1936, J MICROSC SCI, V78, P329; WHARTON SA, 1986, VIROLOGY, V149, P27, DOI 10.1016/0042-6822(86)90083-8; WHARTON SA, 1988, J BIOL CHEM, V263, P4474; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0	82	124	124	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1991	65	1					65	74		10.1016/0092-8674(91)90408-Q	http://dx.doi.org/10.1016/0092-8674(91)90408-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1826463	Bronze			2022-12-28	WOS:A1991FF77300009
J	DECOCK, KM; GNAORE, E; ADJORLOLO, G; BRAUN, MM; LAFONTAINE, MF; YESSO, G; BRETTON, G; COULIBALY, IM; GERSHYDAMET, GM; BRETTON, R; HEYWARD, WL				DECOCK, KM; GNAORE, E; ADJORLOLO, G; BRAUN, MM; LAFONTAINE, MF; YESSO, G; BRETTON, G; COULIBALY, IM; GERSHYDAMET, GM; BRETTON, R; HEYWARD, WL			RISK OF TUBERCULOSIS IN PATIENTS WITH HIV-I AND HIV-II INFECTIONS IN ABIDJAN, IVORY-COAST	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; WEST-AFRICA; AIDS; TYPE-2	Objective - To examine the association between HIV-II infection and tuberculosis. Design - Cross sectional study comparing the prevalence of HIV-I and HIV-II infections in patients with tuberculosis and in blood donors. Setting - Abidjan, Ivory Coast, west Africa. Patients - 2043 consecutive ambulant patients with tuberculosis (confirmed pulmonary, presumed pulmonary, or extrapulmonary) and 2127 volunteer blood donors. Main outcome measure - Prevalence of HIV-I and HIV-II infections as assessed by presence of serum antibodies. Results - Overall rates of HIV infection were 40.2% in patients with tuberculosis (26.4% positive for HIV-I, 4.7% for HIV-II, and 9.0% for both); and 10.4% in blood donors (7.2% positive for HIV-I, 1.9% for HIV-II, and 1.3% for both). HIV-II infection was significantly more common in patients with all types of tuberculosis than in blood donors (97/2043, 4.7% v 40/2127, 1.9%; odds ratio 3.8%, 95% confidence interval 2.6 to 5.6). Conclusion - Both HIV-I and HIV-II infection are associated with tuberculosis in Abidjan. 35% of adult tuberculosis in Abidjan is attributable to HIV infection and 4% specifically to HIV-II.	CTR DIS CONTROL, CTR INFECT DIS, DIV HIV & AIDS, ATLANTA, GA 30333 USA; CTR ANTITB, ABIDJAN, COTE IVOIRE; INST PASTEUR COTE IVOIRE, ABIDJAN, COTE IVOIRE	Centers for Disease Control & Prevention - USA	DECOCK, KM (corresponding author), PROJET RETRO CI, ABIDJAN, COTE IVOIRE.							BRAUN MM, 1990, IN PRESS AM REV RESP; CHAISSON RE, 1989, J INFECT DIS, V159, P96, DOI 10.1093/infdis/159.1.96; CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903; COLEBUNDERS R, 1987, LANCET, V1, P492; DECOCK KM, 1990, AIDS, V4, P443, DOI 10.1097/00002030-199005000-00010; DECOCK KM, 1989, LANCET, V2, P408; HARRIES AD, 1990, LANCET, V335, P387, DOI 10.1016/0140-6736(90)90216-R; Hennekens CH., 1987, EPIDEMIOLOGY MED, P87; KANKI PJ, 1987, AIDS, V1, P141; KANKI PJ, 1987, SCIENCE, V236, P827, DOI 10.1126/science.3033826; MURRAY JF, 1989, AM REV RESPIR DIS, V140, P1788, DOI 10.1164/ajrccm/140.6.1788; NAUCLER A, 1989, J ACQ IMMUN DEF SYND, V2, P88; ODEHOURI K, 1989, AIDS, V3, P509, DOI 10.1097/00002030-198908000-00004; POULSEN AG, 1989, LANCET, V1, P827, DOI 10.1016/S0140-6736(89)92281-2; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; ROMIEU I, 1990, J ACQ IMMUN DEF SYND, V3, P220; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; 1985, SPSSX ADV STATISTICS	18	110	110	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	1991	302	6775					496	499		10.1136/bmj.302.6775.496	http://dx.doi.org/10.1136/bmj.302.6775.496			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB055	1849431	Green Published, Bronze			2022-12-28	WOS:A1991FB05500017
J	WHITE, E				WHITE, E			EVERYDAY AIDS AND APPLIANCES - LEISURE AND RECREATION	BRITISH MEDICAL JOURNAL			English	Article											WHITE, E (corresponding author), ST LUKES HOSP,BRADFORD BD5 0NA,ENGLAND.							CHAMBERLAIN MA, 1989, EVERYDAY AIDS APPLIA, P96; COCHRANE GM, 1987, GARDENING; CORRAD OJ, 1989, EVERYDAY AIDS APPLIA, P1; DARNBOROUGH A, 1989, DIRECTORY DISABLED P; JAY P, 1984, COPING DISABILITY; Thomson N., 1984, SPORTS RECREATION PR; 1979, BSI BS5810 BRIT STAN	7	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					461	463		10.1136/bmj.302.6774.461	http://dx.doi.org/10.1136/bmj.302.6774.461			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	1825932	Bronze, Green Published			2022-12-28	WOS:A1991EZ03300028
J	HIGASHIYAMA, S; ABRAHAM, JA; MILLER, J; FIDDES, JC; KLAGSBRUN, M				HIGASHIYAMA, S; ABRAHAM, JA; MILLER, J; FIDDES, JC; KLAGSBRUN, M			A HEPARIN-BINDING GROWTH-FACTOR SECRETED BY MACROPHAGE-LIKE CELLS THAT IS RELATED TO EGF	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; FACTOR FAMILY; FACTOR-ALPHA; EXPRESSION; AFFINITY; DNA; ATHEROSCLEROSIS; PURIFICATION; AMPHIREGULIN	Macrophage-like U-937 cells secrete a 22-kilodalton heparin-binding growth factor that is mitogenic for BALB-3T3 fibroblasts and smooth muscle cells, but not endothelial cells. The amino acid sequence predicted from complementary DNA clones indicates that the mitogen is a new member of the epidermal growth factor (EGF) family. This heparin-binding EGF-like growth factor (HB-EGF) binds to EGF receptors on A-431 epidermoid carcinoma cells and smooth muscle cells, but is a far more potent mitogen for smooth muscle cells than is EGF. HB-EGF is also expressed in cultured human macrophages and may be involved in macrophage-mediated cellular proliferation.	CHILDRENS HOSP MED CTR,DEPT SURG RES,BOSTON,MA 02115; CALIF BIOTECHNOL INC,MT VIEW,CA 94043; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA037392, P01CA045548, R37CA037392, R56CA037392] Funding Source: NIH RePORTER; NCI NIH HHS [CA45548, CA37392] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AQEL NM, 1985, J PATHOL, V146, P197, DOI 10.1002/path.1711460306; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BAIRD A, 1985, BIOCHEM BIOPH RES CO, V126, P358, DOI 10.1016/0006-291X(85)90614-X; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GREGORY H, 1975, NATURE, V257, P235; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HIGASHIYAMA S, UNPUB; IBERG N, 1989, J BIOL CHEM, V264, P19951; KIMBALL ES, 1984, BIOCHIM BIOPHYS ACTA, V771, P82, DOI 10.1016/0005-2736(84)90113-5; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MINTA JO, 1985, AM J PATHOL, V119, P111; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SINGH JP, 1987, METHOD ENZYMOL, V147, P13; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	39	1075	1142	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					936	939		10.1126/science.1840698	http://dx.doi.org/10.1126/science.1840698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	1840698				2022-12-28	WOS:A1991EY62900044
J	EZEKOWITZ, RAB				EZEKOWITZ, RAB			A CONTROLLED TRIAL OF INTERFERON-GAMMA TO PREVENT INFECTION IN CHRONIC GRANULOMATOUS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY BURST OXIDASE; SUPEROXIDE PRODUCTION; CYTOCHROME-B; GRANULOCYTES; NEUTROPHILS; DEFECT; MACROPHAGES; COMPONENTS; SECRETION; DEFENSE	Background. Chronic granulomatous disease is an uncommon inherited disorder of phagocytes in which defective production of the reactive intermediates of oxygen predisposes patients to recurrent and severe pyogenic infections. Evidence from in vitro and in vivo studies indicates that interferon gamma can partially correct the metabolic defect in phagocytes. We assessed the efficacy of interferon gamma in decreasing the frequency of serious infections in patients with this disease. Methods. We conducted a randomized, double-blind, placebo-controlled study in 128 patients with chronic granulomatous disease (median age, 15 years). Patients received interferon gamma (50-mu-g per square meter of body-surface area) or placebo subcutaneously, three times a week for up to a year. The primary end point of the study was the time to the first serious infection, defined as an event requiring hospitalization and parenteral antibiotics. Measures of phagocyte function were also monitored. Results. In terms of the time to the first serious infection, there was a clear benefit from interferon as compared with placebo (P = 0.0006). Of the 63 patients assigned to interferon, 14 had serious infections, as compared with 30 of the 65 patients assigned to placebo (P = 0.002). There was also a reduction in the total number of serious infections-20 with interferon as compared with 56 with placebo (P < 0.0001). Interferon was beneficial regardless of age, the use or nonuse of prophylactic antibiotics, and the mode of inheritance (X-linked or autosomal recessive). However, there were no significant changes in the measures of superoxide production by phagocytes. Interferon therapy was well tolerated, and there was no evidence of serious toxicity. Conclusions. For patients with chronic granulomatous disease, interferon gamma therapy is an effective and well-tolerated treatment that reduces the frequency of serious infections.			EZEKOWITZ, RAB (corresponding author), CHILDRENS HOSP MED CTR, DEPT PEDIAT, ENDERS BLDG, 7TH FL, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.							ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; BABIOR BM, 1988, HEMATOL ONCOL CLIN N, V2, P201, DOI 10.1016/S0889-8588(18)30615-4; BABIOR BM, 1981, LEUKOCYTE FUNCTION, P1; BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104; BAEHNER RL, 1967, SCIENCE, V155, P835, DOI 10.1126/science.155.3764.835; BERTON G, 1986, BIOCHEM BIOPH RES CO, V138, P1276, DOI 10.1016/S0006-291X(86)80421-1; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; COX DR, 1972, J R STAT SOC B, V34, P187; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1974, NEW ENGL J MED, V290, P593, DOI 10.1056/NEJM197403142901104; CURNUTTE JT, 1974, J CLIN INVEST, V53, P1662, DOI 10.1172/JCI107717; CURNUTTE JT, 1988, J CLIN INVEST, V81, P606, DOI 10.1172/JCI113360; CURNUTTE JT, 1975, NEW ENGL J MED, V293, P628, DOI 10.1056/NEJM197509252931303; CURNUTTE JT, 1987, ADV HUM GENET, V16, P229; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; Dixon W.J., 1981, BMDP BIOMEDICAL COMP; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.2307/2334377; EZEKOWITZ RAB, 1985, J CLIN INVEST, V76, P2368, DOI 10.1172/JCI112249; EZEKOWITZ RAB, 1987, J CLIN INVEST, V80, P1009, DOI 10.1172/JCI113153; EZEKOWITZ RAB, 1988, NEW ENGL J MED, V319, P146, DOI 10.1056/NEJM198807213190305; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; FLEMING TR, IN PRESS COUNTING PR; FORREST CB, 1988, HEMATOL ONCOL CLIN N, V2, P253, DOI 10.1016/S0889-8588(18)30619-1; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; HANNIGAN JR, 1982, 74 STANF U DIV BIOST; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MILLS EL, 1983, ADV HOST DEFENSE MEC, V3, P25; MURRAY HW, 1988, ANN INTERN MED, V108, P595, DOI 10.7326/0003-4819-108-4-595; NATHAN CF, 1986, CIBA F SYMP, V118, P211, DOI 10.1002/9780470720998.ch14; NATHAN CF, 1986, NEW ENGL J MED, V315, P6, DOI 10.1056/NEJM198607033150102; NATHAN CF, 1985, P NATL ACAD SCI USA, V82, P8686, DOI 10.1073/pnas.82.24.8686; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SECHLER JMG, 1988, P NATL ACAD SCI USA, V85, P4874, DOI 10.1073/pnas.85.13.4874; SECHLER JMG, 1988, P NATL ACAD SCI USA, V319, P146; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; TAUBER AI, 1983, MEDICINE, V62, P286, DOI 10.1097/00005792-198309000-00003; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; 1985, SAS USERS GUIDE STAT	46	466	475	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 21	1991	324	8					509	516		10.1056/NEJM199102213240801	http://dx.doi.org/10.1056/NEJM199102213240801			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX918	1846940	Bronze			2022-12-28	WOS:A1991EX91800001
J	WEINTRAUB, H; DAVIS, R; TAPSCOTT, S; THAYER, M; KRAUSE, M; BENEZRA, R; BLACKWELL, TK; TURNER, D; RUPP, R; HOLLENBERG, S; ZHUANG, Y; LASSAR, A				WEINTRAUB, H; DAVIS, R; TAPSCOTT, S; THAYER, M; KRAUSE, M; BENEZRA, R; BLACKWELL, TK; TURNER, D; RUPP, R; HOLLENBERG, S; ZHUANG, Y; LASSAR, A			THE MYOD GENE FAMILY - NODAL POINT DURING SPECIFICATION OF THE MUSCLE-CELL LINEAGE	SCIENCE			English	Article							CREATINE-KINASE GENE; ACHAETE-SCUTE COMPLEX; MYOGENIC DIFFERENTIATION; REGULATED EXPRESSION; 10T1/2 FIBROBLASTS; MYC HOMOLOGY; DNA-BINDING; MYOBLASTS; ENHANCER; DAUGHTERLESS	The myoD gene converts many differentiated cell types into muscle. MyoD is a member of the basic-helix-loop-helix family of proteins; this 68-amino acid domain in MyoD is necessary and sufficient for myogenesis. MyoD binds cooperatively to muscle-specific enhancers and activates transcription. The helix-loop-helix motif is responsible for dimerization, and, depending on its dimerization partner, MyoD activity can be controlled. MyoD senses and integrates many facets of cell state. MyoD is expressed only in skeletal muscle and its precursors; in nonmuscle cells myoD is repressed by specific genes. MyoD activates its own transcription; this may stabilize commitment to myogenesis.			WEINTRAUB, H (corresponding author), FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Krause, Michael/0000-0001-6127-3940; zhuang, yuan/0000-0002-2964-3654				ALONSO LG, 1986, ROUX ARCH DEV BIOL, V195, P259, DOI 10.1007/BF02438959; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENEZRA R, UNPUB; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BISCHOFF R, 1970, J CELL BIOL, V44, P134, DOI 10.1083/jcb.44.1.134; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CAMPOSORTEGA J, 1990, FEBS LETT, V190, P1; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; COHEN R, 1977, NATURE, V266, P538, DOI 10.1038/266538a0; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RE, UNPUB; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIENSTMAN SR, 1975, RESULTS PROBLEMS CEL, V7, P1; DIUGOSZ AA, 1983, CANCER RES, V43, P2780; DWARKI V, UNPUB; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ELLIS HM, 1990, CELL, V61, P39; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; FALLONE G, 1985, P NATL ACAD SCI USA, V82, P426; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; HOLTZER H, 1975, Q REV BIOPHYS, V8, P523, DOI 10.1017/S0033583500001980; HOPWOOD ND, 1990, NATURE, V347, P197, DOI 10.1038/347197a0; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; Jacob F., 1982, POSSIBLE ACTUAL; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; KIM K, 1989, NATURE, V341, P200; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LASSAR AB, UNPUB; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; OLSON E, IN PRESS P NATL ACAD; ONEILL MC, 1974, DEV BIOL, V37, P117, DOI 10.1016/0012-1606(74)90173-0; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RICHARDS CA, 1990, CANCER RES, V50, P1521; RUPP RA, UNPUB; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; SCRABLE HJ, 1990, P NATL ACAD SCI USA, V87, P2182, DOI 10.1073/pnas.87.6.2182; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; STOCKDALE F, 1964, SCIENCE, V146, P533, DOI 10.1126/science.146.3643.533; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; TAPSCOTT SJ, 1989, SCIENCE, V245, P532, DOI 10.1126/science.2547249; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	86	1481	1578	6	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					761	766		10.1126/science.1846704	http://dx.doi.org/10.1126/science.1846704			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1846704				2022-12-28	WOS:A1991EX57500035
J	KLEIJNEN, J; KNIPSCHILD, P; TERRIET, G				KLEIJNEN, J; KNIPSCHILD, P; TERRIET, G			CLINICAL-TRIALS OF HOMEOPATHY	BRITISH MEDICAL JOURNAL			English	Review							RHEUMATOID-ARTHRITIS; HOMEOPATHY	Objective-To establish whether there is evidence of the efficacy of homoeopathy from controlled trials in humans. Design-Criteria based meta-analysis. Assessment of the methodological quality of 107 controlled trials in 96 published reports found after an extensive search. Trials were scored using a list of predefined criteria of good methodology, and the outcome of the trials was interpreted in relation to their quality. Setting-Controlled trials published world wide. Main outcome measures-Results of the trials with the best methodological quality. Trials of classical homoeopathy and several modern varieties were considered separately. Results-In 14 trials some form of classical homoeopathy was tested and in 58 trials the same single homoeopathic treatment was given to patients with comparable conventional diagnoses. Combinations of several homoeopathic treatments were tested in 26 trials; isopathy was tested in nine trials. Most trials seemed to be of very low quality, but there were many exceptions. The results showed a positive trend regardless of the quality of the trial or the variety of homoeopathy used. Overall, of the 105 trials with interpretable results, 81 trials indicated positive results whereas in 24 trials no positive effects of homoeopathy were found. The results of the review may be complicated by publication bias, especially in such a controversial subject as homoeopathy. Conclusions-At the moment the evidence of clinical trials is positive but not sufficient to draw definitive conclusions because most trials are of low methodological quality and because of the unknown role of publication bias. This indicates that there is a legitimate case for further evaluation of homoeopathy, but only by means of well performed trials.			KLEIJNEN, J (corresponding author), UNIV LIMBURG,DEPT EPIDEMIOL & HLTH CARE RES,POB 616,6200 MD MAASTRICHT,NETHERLANDS.		Riet, Gerben ter/A-6943-2011	Riet, Gerben ter/0000-0002-2231-7637				ALBERTINI H, 1984, HOMEOPATHIE FRANCAIS, V71, P47; ALIBEU JP, 1990, PEDIATRIE, V45, P465; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; ARNALLASERRE MN, 1986, THESIS U R DESCARTES; AUDRADE LEC, 1988, RANDOMISED DOUBLE BL; AULAGNIER G, 1985, HOMEOPATHIE, P42; AULAS JJ, 1985, HOMEOPATHIE; BASU TK, 1980, HAHNEMANNIAN GLEANIN, V47, P224; BERTIER P, 1985, 40TH P C LIG MED HOM, P79; Bordes L., 1986, CAH OTORHINOLARINGOL, V21, P731; BOURGEOIS JC, 1984, THESIS U PARIS N BOB; BRIGO B, 1987, J LIGA MED HOMEOPATH, P18; BUNGETZIANU G, 1988, 43RD P C LIG MED HOM, P143; Campbell A., 1976, BR HOMOEOPATH J, V65, P154; CAREY H, 1986, COMM BR HOMEOPATH RE, V15, P12; Carlini EA, 1987, REV ASSOC MED BRAS, V33, P83; CASANOVA PA, 1981, ESSAI CLIN UN PRODUI; Casper J, 1967, THERAPIEWOCHE, V17, P892; CASTELIN T, 1979, THESIS U BORDEAUX 2; CASTRO D, 1975, J AM I HOMEOPATHY, P211; CHAKRAVARTY BN, 1977, 32ND P C LIG MED H S, P41; CHEVREL JP, 1984, PRESSE MED, V13, P833; Consoli AM., 1987, BRIT HOM J, V76, P114; COUDERTDEGUILLA.M, 1981, THESIS U LIMOGES LIM; DAVIES AE, 1971, BRIT HOMOEOPATHIC J, V60, P36; DAVIES AE, 1988, MIDLANDS HOMEOPATHIC, P42; DELANGEDEKLERK ESM, 1986, SIMILIA SIMILIBUS CU, V16, P78; DELAUNAY M, 1985, MED DOUCES       SEP, P35; DEXPERT M, 1987, HOMEOPATHIE FRANCAIS, V75, P353; DORFMAN P, 1988, CAHIERS BIOTHERAPIE, P77; ESTRANGIN M, 1979, THESIS U SCI MED GRE; FERLEY JP, 1989, BRIT J CLIN PHARMACO, V27, P329, DOI 10.1111/j.1365-2125.1989.tb05373.x; FERLEY JP, 1987, IMMUNOLOGIE MED, P22; FISHER P, 1989, BRIT MED J, V299, P365, DOI 10.1136/bmj.299.6695.365; Fisher P, 1986, BR HOM J, V75, P142; GASSINGER CA, 1981, ARZNEIMITTEL-FORSCH, V31-1, P732; GAUTHIER JE, 1983, THESIS U BORDEAUX 2; GEIGER G, 1968, Medizinische Welt, P1203; GIBSON RG, 1978, BRIT J CLIN PHARMACO, V6, P391, DOI 10.1111/j.1365-2125.1978.tb04602.x; GIBSON RG, 1980, BRIT J CLIN PHARMACO, V9, P453, DOI 10.1111/j.1365-2125.1980.tb05840.x; HADJICOSTAS C, 1988, 43RD P C LIG MED HOM, P536; HARIVEAU E, 1987, HOMEOPATHIE, P55; HEULLUY B, 1985, ESSAI RANDOMISE OUVE; HILDEBRANDT G, 1983, HUFELANDGESELLSCHAFT, V1; HITZENBERGER G, 1982, WIEN KLIN WOCHENSCHR, V94, P665; HOURST P, 1982, THESIS U P M CURIE P; KENNEDY CO, 1971, BRIT HOM J, V60, P120; KHAN MT, 1976, 31ST P C LIG MED HOM, P265; KHAN MT, 1985, 40 C LIG MED HOM INT, P232; KIENLE G, 1973, ARZNEIMITTEL-FORSCH, V23, P840; KIRCHHOFF HW, 1982, PRAKTISCHE ARZT, V21, P621; KNIPSCHILD P, 1989, BRIT MED J, V299, P491, DOI 10.1136/bmj.299.6697.491; KNIPSCHILD P, 1990, SOC SCI MED, V31, P625, DOI 10.1016/0277-9536(90)90099-E; KNIPSCHILD P, 1990, TIJDSCHR SOC GEZONDH, V68, P31; KUBISTA E, 1986, Gynaekologische Rundschau, V26, P65; LEAMAN AM, 1989, ARCH EMERG MED, V6, P259; LECOCQ PL, 1985, CAHIERS BIOTHERAPIE, P65; LEWIS D, 1984, MIDLANDS HOMEOPATHIC, P49; LEWITH G, 1989, COMPLEMENT MED RES, V3, P22; MAIWALD L, 1988, ARZNEIMITTEL-FORSCH, V38-1, P578; MASCIELLO E, 1985, 40TH P C LIG MED HOM, P271; MASTER FJ, 1987, 42ND P C LIG MED HOM, P330; Master FJ., 1987, BRIT HOM J, V76, P120; MAYAUX MJ, 1988, LANCET, V1, P528; MEINERT CL, 1986, MONOGRAPHS EPIDEMIOL, V8; MERGEN H, 1969, Muenchener Medizinische Wochenschrift, V111, P298; MICHAUD J, 1981, THESIS U NANTES NANT; MOSSINGER P, 1982, ALLGEMEINE HOMOOPATH, V227, P89; MOSSINGER P, 1973, ALLGEMEINE HOMOOPATH, V218, P111; MOSSINGER P, 1976, ALLG HOMOOPATH ZTG, V221, P177; MOSSINGER P, 1976, ALLG HOMOOPATH ZTG, V221, P26; MOSSINGER P, 1985, KINDERARZT, V16, P581; MOSSINGER P, 1980, ALLGEMEINE HOMOOPATH, V225, P22; MOSSINGER P, 1974, PRAKTISCHE ARZT ALS, P99; OWEN D, 1990, INVESTIGATION HOMOEO; PATERSON J, 1943, BRIT HOMEOPATHIC J, V23, P131; PINSENT RJF, 1986, COMMUNICATIONS BRIT, P3; Poitevin B, 1987, DEVENIR HOMEOPATHIE; PONTI M, 1986, RECHERCHES HOMEOPATH, P7; RAHLFS VW, 1979, DEUT MED WOCHENSCHR, V104, P140, DOI 10.1055/s-0028-1103859; RAHLFS WV, 1976, ARZNEIMITTEL-FORSCH, V26, P2230; REILLY DT, 1986, LANCET, V2, P881; REILLY DT, 1990, 45TH P C LIG MED HOM; Reily D, 1985, BRIT HOMOEOPATHIC J, V74, P65; Righetti M, 1988, FORSCHUNG HOMOOPATHI; RITTER H, 1966, HIPPOCRATES, P472; Savage R.H., 1977, BRIT HOMOEOPATHIC J, V66, P207; Savage R.H., 1978, BR HOM J, V67, P210; SCHMIDT W, 1987, THERAPIEWOCHC, V37, P2803; SCHWAB G, 1990, ALLGEMEINE HOMOOPATH, V235, P135; SCOFIELD A M, 1984, Biological Agriculture and Horticulture, V2, P1; SHIPLEY M, 1983, LANCET, V1, P97; SKALIODAS S, 1988, 43RD P C LIG MED HOM, P549; Subramanyam V. R., 1990, BRIT HOMOEOPATHIC J, V79, P157; TSIAKOPOULOS I, 1988, 43RD P C LIG MED HOM, P94; USTIANOWSKI PA, 1974, BRIT HOMOEOPATHIC J, V63, P276; VALERO EM, 1981, THESIS U SCI MED GRE; VENTOSKOVSKIY BM, 1990, BRIT HOMEOPATHY J, V79, P201; VUDINSAO, 1983, HOMEOPATHIE FRANCAIS, V71, P147; WIESENAUER M, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1745; WIESENAUER M, 1983, FORTSCHR MED, V101, P811; WIESENAUER M, 1989, ARZNEIMITTEL-FORSCH, V39-1, P620; WIESENAUER M, 1986, DTSCH APOTHEKER ZEIT, V126, P2179; WIESENAUER M, 1987, Z ALLGEMEINMED, V63, P18; Zell J, 1988, Fortschr Med, V106, P96; 1980, MIDLANDS HOMOEOPATHI, P19; 1989, PRESSE MED, V18, P59	107	351	360	1	62	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 9	1991	302	6772					316	323		10.1136/bmj.302.6772.316	http://dx.doi.org/10.1136/bmj.302.6772.316			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX569	1825800	Bronze, Green Published			2022-12-28	WOS:A1991EX56900021
J	MAHENDRAN, R; SPOTTSWOOD, MR; MILLER, DL				MAHENDRAN, R; SPOTTSWOOD, MR; MILLER, DL			RNA EDITING BY CYTIDINE INSERTION IN MITOCHONDRIA OF PHYSARUM-POLYCEPHALUM	NATURE			English	Article							NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; TRYPANOSOME MITOCHONDRIA; PLANT-MITOCHONDRIA; ALPHA-SUBUNIT; ATP-SYNTHASE; STOP CODON; PROTEIN; OPERON; GENE	A COROLLARY of the central dogma of molecular biology is that genetic information passes from DNA to RNA by the continuous synthesis of RNA on a DNA template. The demonstration of RNA editing 1 (the specific insertion, deletion or substitution of residues in RNA to create an RNA with a sequence different from its owen template) raised the possibility that is some cases not all of the genetic information for a trait resides in the DNA template. Two different types of RNA editing have been identified in mitochondria: insertional editing represented by the extensive insertion (and occasional deletion) of uridine residues in mitochondrial RNAs of the kinetoplastid protozoa 2-4 and the substitutional editing represented by the cytidine to uridine substitutions in some plant mitochondria 5-7. these editing types have not been shown to be present in the same organism of may have very different mechanisms. RNA editing of both types has been observed in nonmitochondrial systems 8-17 but it is not as extensive and may involve still different mechanisms. Here we report the discovery of extensive insertional RNA editing in mitochondria from an organism other than a kinetoplastid protozoan. The mitochondrial RNA apparently encoding the alpha-subunit of ATP synthetase in the acellular slime mould, Physarum polycephalum, is edited at 54 sites by cytidine insertion.			MAHENDRAN, R (corresponding author), UNIV TEXAS,CELL & MOLEC BIOL PROGRAM,BOX 830688,RICHARDSON,TX 75083, USA.		Mahendran, Ratha/B-3827-2012					BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRAUN CJ, 1985, PLANT PHYSIOL, V79, P571, DOI 10.1104/pp.79.2.571; CATTANEO R, 1988, CELL, V55, P255, DOI 10.1016/0092-8674(88)90048-7; CATTANEO R, 1989, CELL, V56, P759, DOI 10.1016/0092-8674(89)90679-X; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; DENO H, 1983, NUCLEIC ACIDS RES, V11, P2185, DOI 10.1093/nar/11.7.2185; ELLIOTT MS, 1984, J BIOL CHEM, V259, P2407; FARKAS WR, 1973, J BIOL CHEM, V248, P7780; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HOSPATTANKAR AV, 1987, BIOCHEM BIOPH RES CO, V148, P279, DOI 10.1016/0006-291X(87)91107-7; HOWES NK, 1978, J BIOL CHEM, V253, P9082; JONES EP, 1990, CURR GENET, V17, P331, DOI 10.1007/BF00314881; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; LAMB RA, 1989, NATURE, V337, P19, DOI 10.1038/337019a0; MCCARN DF, 1988, J BACTERIOL, V170, P3448, DOI 10.1128/jb.170.8.3448-3458.1988; MOHBERG J, 1971, EXP CELL RES, V66, P305, DOI 10.1016/0014-4827(71)90682-3; OKADA N, 1979, J BIOL CHEM, V254, P3067; OKADA N, 1979, J BIOL CHEM, V254, P3061; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHWER B, 1988, EMBO J, V7, P1183, DOI 10.1002/j.1460-2075.1988.tb02929.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; STUART K, 1989, PARASITOL TODAY, V5, P5, DOI 10.1016/0169-4758(89)90211-1; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; THOMAS SM, 1988, CELL, V54, P891, DOI 10.1016/S0092-8674(88)91285-8; TYBULEWICZ VLJ, 1984, J MOL BIOL, V179, P185, DOI 10.1016/0022-2836(84)90465-0; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4	34	122	125	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					434	438		10.1038/349434a0	http://dx.doi.org/10.1038/349434a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1825131				2022-12-28	WOS:A1991EV51400058
J	SILVA, LR; AMITAI, Y; CONNORS, BW				SILVA, LR; AMITAI, Y; CONNORS, BW			INTRINSIC OSCILLATIONS OF NEOCORTEX GENERATED BY LAYER-5 PYRAMIDAL NEURONS	SCIENCE			English	Article							RAT CEREBRAL-CORTEX; CAT VISUAL-CORTEX; HIPPOCAMPAL SLICE; N-METHYLASPARTATE; INVITRO; RESPONSES; RECEPTOR; TRANSMITTERS; POTENTIALS; CELLS	Rhythmic activity in the neocortex varies with different behavioral and pathological states and in some cases may encode sensory information. However, the neural mechanisms of these oscillations are largely unknown. Many pyramidal neurons in layer 5 of the neocortex showed prolonged, 5- to 12-hertz rhythmic firing patterns at threshold. Rhythmic firing was due to intrinsic membrane properties, sodium conductances were essential for rhythmicity, and calcium-dependent conductances strongly modified rhythmicity. Isolated slices of neocortex generated epochs of 4- to 10-hertz synchronized activity when N-methyl-D-aspartate receptor-mediated channels were facilitated. Layer 5 was both necessary and sufficient to produce these synchronized oscillations. Thus, synaptic networks of intrinsically rhythmic neurons in layer 5 may generate or promote certain synchronized oscillations of the neocortex.	BROWN UNIV,DIV BIOL & MED,NEUROBIOL SECT,PROVIDENCE,RI 02912	Brown University			Connors, Barry/AAX-1975-2020; Amitai, Yael/G-2791-2013	Connors, Barry/0000-0002-3739-3157; Amitai, Yael/0000-0001-6664-8705				AGMON A, 1989, NEUROSCI LETT, V99, P137, DOI 10.1016/0304-3940(89)90278-4; ALONSO A, 1989, NATURE, V342, P175, DOI 10.1038/342175a0; ALVING BO, 1968, J GEN PHYSIOL, V51, P29, DOI 10.1085/jgp.51.1.29; ANDERSON WW, 1986, BRAIN RES, V398, P215, DOI 10.1016/0006-8993(86)91274-6; ARMSTRONGJAMES M, 1988, BRAIN RES, V451, P189, DOI 10.1016/0006-8993(88)90763-9; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V62, P1149, DOI 10.1152/jn.1989.62.5.1149; CHAGNACAMITAL Y, 1990, J COMP NEUROL, V296, P598, DOI 10.1002/cne.902960407; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; CONNORS BW, 1984, NATURE, V310, P685, DOI 10.1038/310685a0; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; FREEMAN WJ, 1985, BRAIN RES REV, V10, P147, DOI 10.1016/0165-0173(85)90022-0; FREEMAN WJ, 1988, BRAIN RES, V422, P627; GETTING PA, 1989, METHODS NEURONAL MOD, P171; GORMAN ALF, 1982, J PHYSIOL-LONDON, V333, P681, DOI 10.1113/jphysiol.1982.sp014475; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GRILLNER S, 1987, TRENDS NEUROSCI, V10, P34, DOI 10.1016/0166-2236(87)90123-8; GUTNICK MJ, 1982, J NEUROPHYSIOL, V48, P1321, DOI 10.1152/jn.1982.48.6.1321; HAGIWARA S, 1983, TRENDS NEUROSCI, V6, P189, DOI 10.1016/0166-2236(83)90084-X; HEGSTAD E, 1989, EPILEPSY RES, V3, P174, DOI 10.1016/0920-1211(89)90046-6; HORIKAWA K, 1988, J NEUROSCI METH, V25, P1, DOI 10.1016/0165-0270(88)90114-8; JONES KA, 1988, J NEUROSCI, V8, P3522; Kooi K., 1978, FUNDAMENTALS ELECTRO; KRISTIANSEN K, 1949, ELECTROEN CLIN NEURO, V1, P265, DOI 10.1016/0013-4694(49)90191-1; LLINAS R, 1989, Society for Neuroscience Abstracts, V15, P660; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; Lopes da Silva F.H., 1978, ARCHITECTONICS CEREB, P319; LOTURCO JJ, 1990, NEUROSCI LETT, V114, P265, DOI 10.1016/0304-3940(90)90574-S; MASON A, 1990, J NEUROSCI, V10, P1415; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; SCHWINDT PC, 1989, J NEUROPHYSIOL, V61, P233, DOI 10.1152/jn.1989.61.2.233; SCHWINDT PC, 1988, J NEUROPHYSIOL, V59, P424, DOI 10.1152/jn.1988.59.2.424; STANTON PK, 1987, EPILEPSY RES, V1, P53, DOI 10.1016/0920-1211(87)90051-9; STERIADE M, 1988, PHYSIOL REV, V68, P649, DOI 10.1152/physrev.1988.68.3.649; SUTOR B, 1987, PFLUG ARCH EUR J PHY, V410, P102, DOI 10.1007/BF00581902; SUTOR B, 1989, J NEUROPHYSIOL, V61, P621, DOI 10.1152/jn.1989.61.3.621; THOMSON AM, 1986, J PHYSIOL-LONDON, V370, P531, DOI 10.1113/jphysiol.1986.sp015949; THOMSON AM, 1985, NATURE, V313, P479, DOI 10.1038/313479a0; TRAUB RD, 1989, SCIENCE, V243, P1319, DOI 10.1126/science.2646715; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; YAROM Y, 1989, EXPT BRAIN RES SERIE, V17, P209	43	535	540	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					432	435		10.1126/science.1824881	http://dx.doi.org/10.1126/science.1824881			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1824881				2022-12-28	WOS:A1991EU50400042
J	FARNETT, L; MULROW, CD; LINN, WD; LUCEY, CR; TULEY, MR				FARNETT, L; MULROW, CD; LINN, WD; LUCEY, CR; TULEY, MR			THE J-CURVE PHENOMENON AND THE TREATMENT OF HYPERTENSION - IS THERE A POINT BEYOND WHICH PRESSURE REDUCTION IS DANGEROUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY HEART-DISEASE; DIASTOLIC BLOOD-PRESSURE; MYOCARDIAL-INFARCTION; ELDERLY PATIENTS; FOLLOW-UP; MORTALITY; RISK; TRIAL; FRAMINGHAM; CARE	We critically appraised the medical literature to evaluate whether there is a point beyond which blood pressure reduction in hypertensive subjects is no longer beneficial and possibly even deleterious. Thirteen studies that stratified cardiovascular outcomes by level of achieved blood pressure in treated hypertensive subjects who had been followed up for at least 1 year were critiqued by four independent reviewers. Data addressing population, protocol, and methodological characteristics were evaluated. Studies did not show a consistent J-shaped relationship between treated blood pressure and stroke, but they did demonstrate a consistent J-shaped relationship for cardiac events and diastolic blood pressure. The beneficial therapeutic threshold point was 85 mm Hg. We conclude that low treated diastolic blood pressure levels, ie, below 85 mm Hg, are associated with increased risk of cardiac events.	AUDIE L MURPHY MEM VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,7400 MERTON MINTER BLVD,SAN ANTONIO,TX 78248; UNIV TEXAS,COLL PHARM,AUSTIN,TX 78712; UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV GEN INTERNAL MED,SAN ANTONIO,TX 78284	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Health San Antonio								ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ALDERMAN MJ, 1990, LANCET, V235, P1092; ANDERSON TW, 1978, LANCET, V2, P1139; [Anonymous], 1982, Lancet, V1, P185; AROMAA A, 1981, ACTA MED SCAND, V646, P43; ASHCROFT MT, 1978, LANCET, V2, P1167; BERGLUND G, 1989, AM J HYPERTENS, V2, P586, DOI 10.1093/ajh/2.7.586; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; COOPE J, 1990, J HUM HYPERTENS, V4, P1; COOPER SP, 1988, AM J EPIDEMIOL, V127, P387, DOI 10.1093/oxfordjournals.aje.a114812; CRUICKSHANK JM, 1987, LANCET, V1, P581; CRUICKSHANK JM, 1987, J HYPERTENS, V5, P489; CRUICKSHANK JM, 1990, LANCET, V235, P1092; FLETCHER AE, 1988, J HUM HYPERTENS, V2, P11; HOLME I, 1976, ACTA MED SCAND, V200, P229; KANNEL WB, 1971, AM J CARDIOL, V27, P335, DOI 10.1016/0002-9149(71)90428-0; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; KAPLAN NM, 1990, LANCET, V335, P1093; KAPLAN NM, 1989, AM J HYPERTENS, V2, P75, DOI 10.1093/ajh/2.2.75; Le Heuzey J Y, 1988, Am J Med, V84, P65; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MATTILA K, 1988, BRIT MED J, V296, P887, DOI 10.1136/bmj.296.6626.887; MIALL WE, 1982, CLIN EXP HYPERTENS A, V4, P1121, DOI 10.3109/10641968209060779; NETER J, 1985, APPLIED LINEAR STATI; NOBREGA FT, 1977, NEW ENGL J MED, V296, P145, DOI 10.1056/NEJM197701202960305; PAUL O, 1971, BRITISH HEART J    S, V33, P116; PERERA GA, 1960, JAMA-J AM MED ASSOC, V173, P11, DOI 10.1001/jama.1960.03020190013003; RABKIN SW, 1978, ANN INTERN MED, V88, P342, DOI 10.7326/0003-4819-88-3-342; SAMUELSSON O, 1987, JAMA-J AM MED ASSOC, V258, P1768; STAESSEN J, 1989, BMJ-BRIT MED J, V298, P1552, DOI 10.1136/bmj.298.6687.1552; STEWART IMG, 1979, LANCET, V1, P861; SVENSSON GI, 1982, J CHRON DIS, V35, P165, DOI 10.1016/0021-9681(82)90136-9; TAGUCHI J, 1975, CIRC RES S1, V37, P1257; TRAFFORD JAP, 1981, BMJ-BRIT MED J, V282, P1111, DOI 10.1136/bmj.282.6270.1111; WALLER PC, 1988, J HUM HYPERTENS, V2, P7; WILHELMSEN L, 1987, J HYPERTENS, V5, P561, DOI 10.1097/00004872-198710000-00009; 1988, J HYPERTENS, V6, P693; 1984, J AM COLL CARDIOL, V4, P1135; 1988, BMJ, V296, P1565; 1985, J HYPERTENS, V3, P379; 1979, BUILD BLOOD PRESSURE	41	351	355	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	1991	265	4					489	495		10.1001/jama.265.4.489	http://dx.doi.org/10.1001/jama.265.4.489			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET377	1824642				2022-12-28	WOS:A1991ET37700029
J	FASANO, L; RODER, L; CORE, N; ALEXANDRE, E; VOLA, C; JACQ, B; KERRIDGE, S				FASANO, L; RODER, L; CORE, N; ALEXANDRE, E; VOLA, C; JACQ, B; KERRIDGE, S			THE GENE TEASHIRT IS REQUIRED FOR THE DEVELOPMENT OF DROSOPHILA EMBRYONIC TRUNK SEGMENTS AND ENCODES A PROTEIN WITH WIDELY SPACED ZINC FINGER MOTIFS	CELL			English	Review							DORSAL-VENTRAL POLARITY; BLASTODERM FATE MAP; COMBS-REDUCED GENE; PAIR-RULE GENES; FUSHI-TARAZU; LARVAL CUTICLE; ZYGOTIC LOCI; REGULATORY INTERACTIONS; MOLECULAR ANALYSIS; PATTERN-FORMATION	We have discovered a reporter gene insertion that is expressed in the trunk region of Drosophila embryos. Genetic and molecular details of a new regulatory gene neighboring the reporter gene insertion, which we call teashirt (tsh), are described. In situ hybridization of a tsh probe to embryos shows that this gene is expressed in a way similar to the reporter gene. Mutations of tsh show that the gene is required for normal development of the ventral trunk region of embryos, which correlates with the spatial expression of the gene in the anteroposterior axis but not in the dorsoventral axis. Sequencing of a tsh cDNA shows that the putative protein possesses three distantly spaced CX2CX12HX5H zinc finger motifs.	CTR UNIV MARSEILLE LUMINY,CNRS,LGBC,F-13288 MARSEILLE 9,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite			Röder, Laurence/M-1260-2016; Fasano, Laurent/AFL-9580-2022; Fasano, Laurent/AAH-1688-2022	Fasano, Laurent/0000-0003-2307-8428; Fasano, Laurent/0000-0003-2307-8428; Roder, Laurence/0000-0002-6193-4531				AGNEL M, 1989, GENE DEV, V3, P85, DOI 10.1101/gad.3.1.85; AKAM M, 1987, DEVELOPMENT, V101, P1; ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BELLON B, 1988, NUCLEIC ACIDS RES, V16, P1837, DOI 10.1093/nar/16.5.1837; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CANAL I, 1986, J NEUROGENET, V3, P293, DOI 10.3109/01677068609106856; CARROLL SB, 1986, CELL, V45, P113, DOI 10.1016/0092-8674(86)90543-X; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DURA JM, 1987, CELL, V51, P829, DOI 10.1016/0092-8674(87)90106-1; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; ENGELS WR, 1988, MOBILE DNA, P437; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FASANO L, 1988, ROUX ARCH DEV BIOL, V197, P507, DOI 10.1007/BF00385685; FASANO L, 1988, DEVELOPMENT, V104, P245; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOE VE, 1983, J CELL SCI, V61, P31; FONTECILLACAMPS JC, 1981, TRENDS BIOCHEM SCI, V6, P291, DOI 10.1016/0968-0004(81)90105-5; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; FRIDELL RA, 1990, GENE DEV, V4, P559, DOI 10.1101/gad.4.4.559; GAUL U, 1987, TRENDS GENET, V3, P127, DOI 10.1016/0168-9525(87)90202-2; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; GIBSON TJ, 1988, PROTEIN ENG, V2, P209, DOI 10.1093/protein/2.3.209; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; HARDING K, 1986, SCIENCE, V233, P953, DOI 10.1126/science.3755551; HARTENSTEIN V, 1988, DEVELOPMENT, V102, P869; HARTENSTEIN V, 1987, ROUX ARCH DEV BIOL, V196, P101, DOI 10.1007/BF00402031; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; INGHAM PW, 1986, EMBO J, V5, P1659, DOI 10.1002/j.1460-2075.1986.tb04409.x; IRISH VF, 1989, EMBO J, V8, P1527, DOI 10.1002/j.1460-2075.1989.tb03537.x; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JACK T, 1990, EMBO J, V9, P1187, DOI 10.1002/j.1460-2075.1990.tb08226.x; JURGENS G, 1987, ROUX ARCH DEV BIOL, V196, P141, DOI 10.1007/BF00376308; JURGENS G, 1986, ROUX ARCH DEV BIOL, V195, P359, DOI 10.1007/BF00402870; JURGENS G, 1988, EMBO J, V7, P189, DOI 10.1002/j.1460-2075.1988.tb02799.x; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KERRIDGE S, 1982, J EMBRYOL EXP MORPH, V68, P211; KUROIWA A, 1985, EMBO J, V4, P3757, DOI 10.1002/j.1460-2075.1985.tb04145.x; LAUGHON A, 1985, COLD SPRING HARB SYM, V50, P253, DOI 10.1101/SQB.1985.050.01.032; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LEFEVRE G, 1976, GENETICS BIOL DROS A, V1, P32; LEVINE M, 1988, CELL, V52, P785, DOI 10.1016/0092-8674(88)90418-7; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LOHSSCHARDIN M, 1979, DEV BIOL, V73, P239, DOI 10.1016/0012-1606(79)90065-4; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MAHAFFEY JW, 1987, GENETICS, V117, P51; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MARTINEZARIAS A, 1985, NATURE, V313, P639, DOI 10.1038/313639a0; MARTINEZARIAS A, 1987, DEVELOPMENT, V100, P673; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MERRILL VKL, 1989, DEV BIOL, V135, P376, DOI 10.1016/0012-1606(89)90187-5; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; NOLAN JM, 1986, P NATL ACAD SCI USA, V83, P3664, DOI 10.1073/pnas.83.11.3664; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAYS E, 1987, J MOL BIOL, V197, P147, DOI 10.1016/0022-2836(87)90617-6; REUTER G, 1990, NATURE, V344, P219, DOI 10.1038/344219a0; RHODES D, 1988, NUCLEIC ACIDS MOL BI, V2, P149; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RILEY PD, 1987, GENE DEV, V1, P716, DOI 10.1101/gad.1.7.716; ROBERTSON HM, 1988, GENETICS, V118, P461; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCOTT MP, 1986, ANNU REV CELL BIOL, V2, P49; SIMPSON P, 1983, GENETICS, V105, P615; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9; WAKIMOTO BT, 1981, DEV BIOL, V81, P51, DOI 10.1016/0012-1606(81)90347-X; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; WRIGHT TRF, 1976, GENETICS, V84, P267; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	99	188	190	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					63	79		10.1016/0092-8674(91)90209-H	http://dx.doi.org/10.1016/0092-8674(91)90209-H			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846092				2022-12-28	WOS:A1991ET17500009
J	OLNEY, JW; LABRUYERE, J; WANG, G; WOZNIAK, DF; PRICE, MT; SESMA, MA				OLNEY, JW; LABRUYERE, J; WANG, G; WOZNIAK, DF; PRICE, MT; SESMA, MA			NMDA ANTAGONIST NEUROTOXICITY - MECHANISM AND PREVENTION	SCIENCE			English	Article							CEREBROCORTICAL NEURONS; KETAMINE; PHENCYCLIDINE; DIAZEPAM	Antagonists of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor, including phencyclidine (PCP) and ketamine, protect against brain damage in neurological disorders such as stroke. However, these agents have psychotomimetic properties in humans and morphologically damage neurons in the cerebral cortex of rats. It is now shown that the morphological damage can be prevented by certain anticholinergic drugs or by diazepam and barbiturates, which act at the gamma-aminobutyric acid (GABA) receptor-channel complex and are known to suppress the psychotomimetic symptoms caused by ketamine. Thus, it may be possible to prevent the unwanted side effects of NMDA antagonists, thereby enhancing their utility as neuroprotective drugs.	UNIV MISSOURI,SCH OPTOMETRY,ST LOUIS,MO 63110	University of Missouri System; University of Missouri Saint Louis	OLNEY, JW (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110, USA.				NIA NIH HHS [AG 05681] Funding Source: Medline; NIDA NIH HHS [DA 53568] Funding Source: Medline; NIMH NIH HHS [MH 38894] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005681] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKAIKE N, 1987, J PHYSIOL-LONDON, V394, P85, DOI 10.1113/jphysiol.1987.sp016861; ALLEN HL, 1990, SCIENCE, V247, P221, DOI 10.1126/science.2403696; AYIM EN, 1976, E AFR MED J, V53, P377; Burke R E, 1986, Mov Disord, V1, P135, DOI 10.1002/mds.870010208; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COPPEL DL, 1973, ANAESTHESIA, V28, P293, DOI 10.1111/j.1365-2044.1973.tb00449.x; FREEDMAN SB, 1988, EUR J PHARMACOL, V156, P133, DOI 10.1016/0014-2999(88)90155-0; KORTTILA K, 1978, ACTA ANAESTH SCAND, V22, P640, DOI 10.1111/j.1399-6576.1978.tb01348.x; LABRUYERE J, 1989, Society for Neuroscience Abstracts, V15, P761; LEVITAN ES, 1988, NEURON, V1, P773, DOI 10.1016/0896-6273(88)90125-0; MACDONALD RL, 1978, SCIENCE, V200, P775, DOI 10.1126/science.205953; MAGBAGBEOLA JA, 1974, CAN ANAESTH SOC J, V21, P321, DOI 10.1007/BF03005737; MARSHALL BE, 1990, GOODMAN GILMANS PHAR, P307; OLNEY J, UNPUB; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; OLNEY JW, 1986, NEUROSCI LETT, V68, P29, DOI 10.1016/0304-3940(86)90224-7; OLNEY JW, 1988, EXCITATORY AMINO ACI, P337; Paxinos G., 2004, J CHEM INF MODEL, V5th; REICH DL, 1989, CAN J ANAESTH, V36, P186, DOI 10.1007/BF03011442; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; SESMA MA, IN PRESS SOC NEUR AB; SHARP J W, 1990, Society for Neuroscience Abstracts, V16, P1122; STUDY RE, 1981, P NATL ACAD SCI-BIOL, V78, P7180, DOI 10.1073/pnas.78.11.7180; ZORUMSKI CF, 1991, AM J PSYCHIAT, V148, P162	25	759	795	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1515	1518		10.1126/science.1835799	http://dx.doi.org/10.1126/science.1835799			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1835799				2022-12-28	WOS:A1991GT90300043
J	CORNALL, RJ; PRINS, JB; TODD, JA; PRESSEY, A; DELARATO, NH; WICKER, LS; PETERSON, LB				CORNALL, RJ; PRINS, JB; TODD, JA; PRESSEY, A; DELARATO, NH; WICKER, LS; PETERSON, LB			TYPE-1 DIABETES IN MICE IS LINKED TO THE INTERLEUKIN-1 RECEPTOR AND LSH/ITY/BCG GENES ON CHROMOSOME-1	NATURE			English	Article							NOD MOUSE; NONOBESE; RESISTANCE; PREVENTION; DISEASE; CYCLOPHOSPHAMIDE; INSULITIS; MELLITUS; ALPHA; MAP	HUMAN type 1 (insulin-dependent) diabetes is a common autoimmune disease of the insulin-producing beta-cells of the pancreas which is caused by both genetic and environmental factors 1,2. Several features or the genetics and immunopathology of diabetes in nonobese diabetic (NOD) mice are shared with the human disease 1,3,4. Of the three diabetes-susceptibility genes, Idd-1 (refs 5-7), -3 and -4 (ref. 4) that have been mapped in mice to date, only in the case of Idd-1 is there any evidence for the identity of the gene product: allelic variation within the murine immune response I-A-beta gene and its human homologue HLA-DQB1 correlates with susceptibility, implying that I-A-beta is a component of Idd-1 (refs 5-11). We report here the mapping of Idd-5 to the proximal region of mouse chromosome 1. This region contains at least two candidate susceptibility genes, the interleukin-1 receptor gene (Il-1r1; ref. 12) and Lsh/Ity/Bcg (refs 13-19), which encodes resistance to bacterial and parasitic infections and affects the function of macrophages.	MERCK SHARP & DOHME LTD, DEPT CELLULAR & MOLEC PHARMACOL, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, AUTOIMMUNE DIS RES, RAHWAY, NJ 07065 USA	Merck & Company; Merck & Company	CORNALL, RJ (corresponding author), JOHN RADCLIFFE HOSP, NUFFIELD DEPT SURG, OXFORD OX3 9DU, ENGLAND.		Wicker, Linda S/F-7384-2010; Todd, John A/A-3542-2010	Todd, John A/0000-0003-2740-8148; Prins, Jan-Bas/0000-0002-1831-8522	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLACKWELL JM, IN PRESS IMMUN LETT; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; COPELAND NG, 1991, GENOMICS, V9, P44, DOI 10.1016/0888-7543(91)90219-5; CORNALL RJ, 1991, GENOMICS, V10, P874, DOI 10.1016/0888-7543(91)90175-E; HARADA M, 1984, DIABETOLOGIA, V27, P604, DOI 10.1007/BF00276978; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HEARNE CM, 1991, MAMM GENOME, V1, P273, DOI 10.1007/BF00352339; HILLYARD AL, 1991, LOCUS MAP MOUSE COMP; HOGARTH PM, 1991, J IMMUNOL, V146, P369; HUTCHINGS P, 1990, NATURE, V348, P639, DOI 10.1038/348639a0; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P968, DOI 10.1073/pnas.87.3.968; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; LUND T, 1990, NATURE, V345, P727, DOI 10.1038/345727a0; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; MALO D, 1991, ENOMICS, V10, P356; MANDRUPPOULSEN T, 1990, CURR TOP MICROBIOL, V164, P169; MIYAZAKI T, 1990, NATURE, V345, P722, DOI 10.1038/345722a0; MOCK B, 1990, GENOMICS, V7, P57, DOI 10.1016/0888-7543(90)90518-Y; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; RISCH N, 1987, AM J HUM GENET, V40, P1; SCHURR E, 1991, IMMUNOL TODAY, V12, P42; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SKAMENE E, 1982, NATURE, V297, P506, DOI 10.1038/297506a0; SLATTERY RM, 1990, NATURE, V345, P724, DOI 10.1038/345724a0; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; WICKER LS, 1987, J EXP MED, V165, P1639, DOI 10.1084/jem.165.6.1639; WICKER LS, 1991, FRONTIERS DIABETES R, V2, P67; WICKER LS, IN PRESS P P S BIOME; YASUNAMI R, 1988, EUR J IMMUNOL, V18, P481, DOI 10.1002/eji.1830180325	30	186	187	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 19	1991	353	6341					262	265		10.1038/353262a0	http://dx.doi.org/10.1038/353262a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1832743				2022-12-28	WOS:A1991GF67400061
J	DRIFE, JO				DRIFE, JO			ONE IN 3	BRITISH MEDICAL JOURNAL			English	Editorial Material											DRIFE, JO (corresponding author), UNIV LEEDS,OBSTET & GYNAECOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					653	653						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1813099				2022-12-28	WOS:A1991GF67500078
J	GIBBONS, IR; GIBBONS, BH; MOCZ, G; ASAI, DJ				GIBBONS, IR; GIBBONS, BH; MOCZ, G; ASAI, DJ			MULTIPLE NUCLEOTIDE-BINDING SITES IN THE SEQUENCE OF DYNEIN BETA-HEAVY CHAIN	NATURE			English	Article							SEA-URCHIN SPERM; OUTER ARM DYNEIN; PHOTOSENSITIZED CLEAVAGE; MOLECULAR-CLONING; FLAGELLA; MYOSIN; ALPHA; PROTEINS; KINESIN; ATP	AXONEMAL dyneins have two or three globular heads joined by flexible tails to a common base, with each head/tail unit consisting of a single heavy-chain polypeptide of relative molecular mass > 400,000. The sizes of the components have been deduced by electron microscopy 1-3 . The isolated-beta heavy chain of sea urchin sperm flagella, which is immunologically identical to that of the embryo cilia (data not shown; ref. 4), is of particular interest as it retains the capability for microtubule translocation in vitro 5,6. Limited proteolysis of the beta-heavy chain divides it into two fragments, A and B, which sediment separately at 12S and 6S, and possibly correspond to the head and tail domains of the molecule 7. Dynein ATPase is the energy-transducing enzyme that generates the sliding movement between tubules that underlies the beating of cilia and flagella of eukaryotes, and possibly also other large intracellular movements 8,9. Here we report that the deduced amino-acid sequence of the beta-heavy chain of axonemal dynein from embryos of the sea urchin Tripneustes gratilla has 4,466 residues and contains the consensus motifs for five nucleotide-binding sites. The probable hydrolytic ATP-binding site can be identified by its location close to or at the V1 site of vanadate-mediated photocleavage 10. The general features of the map of photocleavage and proteolytic peptides reported earlier have been confirmed, except that the map's polarity is reversed. The predicted secondary structure of the beta-heavy chain consists of an alpha/beta-type pattern along its whole length. The two longest regions of potential alpha helix, with unbroken heptad hydrophobic repeats 120 and 50 amino acids long, may be of functional importance. But dynein does not seem to contain an extended coiled-coil tail domain.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	GIBBONS, IR (corresponding author), UNIV HAWAII,PACIFIC BIOMED RES CTR,HONOLULU,HI 96822, USA.		Gibbons, Ian/B-5842-2013; Mocz, Gabor/A-7308-2009	Mocz, Gabor/0000-0001-9855-2206				CREMO CR, 1990, BIOCHEMISTRY-US, V29, P7982, DOI 10.1021/bi00486a029; CREMO CR, 1991, BIOPHYS J, V59, P513; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; FOLTZ KR, 1990, CELL MOTIL CYTOSKEL, V16, P33, DOI 10.1002/cm.970160106; GARBER AT, 1989, EMBO J, V8, P1727, DOI 10.1002/j.1460-2075.1989.tb03565.x; GASCUEL O, 1988, COMPUT APPL BIOSCI, V4, P357; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GIBBONS IR, 1988, J BIOL CHEM, V263, P15837; GIBBONS IR, IN PRESS P NATN ACAD; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; HAYASHI M, 1972, BIOCHEMISTRY-US, V11, P2977, DOI 10.1021/bi00766a008; KING SM, 1989, J BIOL CHEM, V264, P10210; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MOCZ G, 1990, J BIOL CHEM, V265, P2917; MOCZ G, 1988, J CELL BIOL, V106, P1607, DOI 10.1083/jcb.106.5.1607; MOCZ G, 1990, BIOCHEMISTRY-US, V29, P48; MOCZ G, IN PRESS BIOCHEMISTR; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OGAWA K, 1990, CELL MOTIL CYTOSKEL, V16, P58, DOI 10.1002/cm.970160108; OGAWA K, 1991, P JPN ACAD B-PHYS, V67, P27, DOI 10.2183/pjab.67.27; OGAWA K, IN PRESS P INT ECHIN; OW RA, 1987, J BIOL CHEM, V262, P3409; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SALE WS, 1988, J CELL BIOL, V107, P1793, DOI 10.1083/jcb.107.5.1793; SALE WS, 1985, J CELL BIOL, V101, P1400, DOI 10.1083/jcb.101.4.1400; SMITH EF, 1991, CELL MOTIL CYTOSKEL, V18, P258, DOI 10.1002/cm.970180403; TANG WJY, 1987, J BIOL CHEM, V262, P17728; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	34	222	225	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					640	643		10.1038/352640a0	http://dx.doi.org/10.1038/352640a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1830927				2022-12-28	WOS:A1991GB21100062
J	YONISHROUACH, E; RESNITZKY, D; LOTEM, J; SACHS, L; KIMCHI, A; OREN, M				YONISHROUACH, E; RESNITZKY, D; LOTEM, J; SACHS, L; KIMCHI, A; OREN, M			WILD-TYPE P53 INDUCES APOPTOSIS OF MYELOID LEUKEMIC-CELLS THAT IS INHIBITED BY INTERLEUKIN-6	NATURE			English	Article							TUMOR SUPPRESSION; C-MYC; GROWTH; DIFFERENTIATION; EXPRESSION; GENE; PROTEIN; ONCOGENE; SURVIVAL; BCL-2	WILD-TYPE p53 protein has many properties consistent with its being the product of a tumour suppressor gene 1-3. Although the normal roles of tumour suppressor genes are still largely unknown, it seems that they could be involved in promoting cell differentiation 4-6 as well as in mediating growth arrest by growth-inhibitory cytokines 7-9. Hence, the abrogation of wild-type p53 expression, which is a common feature of many tumours, could eliminate these activities. We have now tested this notion by restoring the expression of p53 in a murine myeloid leukaemic cell line that normally lacks p53. The use of a temperature-sensitive p53 mutant 10 allowed us to analyse cells in which the introduced p53 had either wild-type or mutant properties. Although there seemed to be no effect on differentiation, the introduction of wild-type p53 resulted in rapid loss of cell viability in a way characteristic of apoptosis (programmed cell death). The effect of wild-type p53 was counteracted by interleukin-6. Thus products of tumour suppressor genes could be involved in restricting precursor cell populations by mediating apoptosis.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT MOLEC GENET & VIROL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIBACH E, 1973, P NATL ACAD SCI USA, V70, P343, DOI 10.1073/pnas.70.2.343; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARRIS H, 1989, CIBA F SYMP, V142, P199; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LOTEM J, IN PRESS BLOOD; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINHASI O, 1984, MOL CELL BIOL, V4, P2180, DOI 10.1128/MCB.4.10.2180; PROKOCIMER M, 1986, BLOOD, V68, P113; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SACHS L, 1989, CIBA F SYMP, V142, P217; SACHS L, 1990, CANCER-AM CANCER SOC, V65, P2196, DOI 10.1002/1097-0142(19900515)65:10<2196::AID-CNCR2820651006>3.0.CO;2-Y; SHABO Y, 1988, BLOOD, V72, P2070; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STANBRIDGE EJ, 1990, REV GENET, V24, P615; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790	41	2157	2202	2	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 25	1991	352	6333					345	347		10.1038/352345a0	http://dx.doi.org/10.1038/352345a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852210				2022-12-28	WOS:A1991FY28900074
J	DELISA, JA; JAIN, SS				DELISA, JA; JAIN, SS			PHYSICAL MEDICINE AND REHABILITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									KESSLER INST REHABIL,W ORANGE,NJ	Kessler Institute for Rehabilitation	DELISA, JA (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,NEWARK,NJ 07103, USA.							AYERS JWT, 1988, FERTIL STERIL, V49, P1089; BACH JR, 1990, CHEST, V98, P613, DOI 10.1378/chest.98.3.613; BACH JR, IN PRESS B NY ACAD M; BEJJANI FJ, 1989, J BIOMECH, V22, P439, DOI 10.1016/0021-9290(89)90204-2; CAREY RG, 1988, ARCH PHYS MED REHAB, V69, P337; CHANG MS, 1987, ERGONOMICS, V30, P331; COHEN LG, 1991, BRAIN, V114, P615, DOI 10.1093/brain/114.1.615; Figoni S F, 1990, J Am Paraplegia Soc, V13, P33; GRESHAM GE, 1990, STROKE, V21, P1; JOHNSTON MV, IN PRESS BRAIN INJ; LINSENMEYER TA, 1991, NEUROREHABILITATION, V1, P22; PATTERSON RP, 1990, ARCH PHYS MED REHAB, V71, P340; ROBINSON LR, 1990, AM J PHYS MED REHAB, V69, P307, DOI 10.1097/00002060-199012000-00006; TRAVERS PH, 1988, OCCUP MED, V3, P271; VERVILLE RE, 1990, ARCH PHYS MED REHAB, V71, P1010	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3158	3160						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	1828273				2022-12-28	WOS:A1991FQ77000035
J	HOLZBAUR, ELF; HAMMARBACK, JA; PASCHAL, BM; KRAVIT, NG; PFISTER, KK; VALLEE, RB				HOLZBAUR, ELF; HAMMARBACK, JA; PASCHAL, BM; KRAVIT, NG; PFISTER, KK; VALLEE, RB			HOMOLOGY OF A 150K CYTOPLASMIC DYNEIN-ASSOCIATED POLYPEPTIDE WITH THE DROSOPHILA GENE GLUED	NATURE			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; RETROGRADE AXONAL-TRANSPORT; MEMBRANOUS ORGANELLES; SEQUENCE-ANALYSIS; MELANOGASTER; LOCUS; KINETOCHORES; LOCALIZATION; MUTATIONS; MOTOR	CYTOPLASMIC dynein is a microtubule-activated ATPase which produces force towards the minus ends of microtubules 1,2. It is thought to be responsible for retrograde axonal transport and other aspects of organelle motility 2-6 and may have a role in the poleward movement of mitotic chromosomes 7,8. Cytoplasmic dynein is an oligomeric complex of two catalytic heavy chains and a number of accessory subunits 1,9,10. We now report the cloning and sequencing of a complementary DNA for one of these species, a cytoplasmic dynein-associated polypeptide of relative molecular mass 150,000 (M(r) 150K). A full-length cDNA was found to contain an open reading frame of 4.0 kilobases, which is predicted to encode a polypeptide of M(r) 145K. It has extensive homology with the product of the Drosophila gene Glued, which encodes a polypeptide of M(r) 148K 11. The Glued mutation is dominant, with pleiotropic developmental defects in heterozygotes and an embryonic lethal phenotype in homozygotes. As dominant mutations may involve disruption of normal protein-protein interactions, the Glued mutation should provide insight into the mode of action of cytoplasmic dynein in vivo.	UNIV VIRGINIA, HLTH SCI CTR, DEPT ANAT & CELL BIOL, CHARLOTTESVILLE, VA 22903 USA	University of Virginia	HOLZBAUR, ELF (corresponding author), WORCESTER FDN EXPTL BIOL INC, SHREWSBURY, MA 01545 USA.							CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FORMAN DS, 1983, BRAIN RES, V272, P194, DOI 10.1016/0006-8993(83)90381-5; GAREN SH, 1983, DEV BIOL, V96, P445, DOI 10.1016/0012-1606(83)90182-3; HARTE PJ, 1982, GENETICS, V101, P477; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; HOLZBAUR ELF, 1988, J CELL BIOL, V109, pA157; KING SM, 1990, J BIOL CHEM, V265, P19807; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MEYEROWITZ EM, 1978, DEV BIOL, V62, P112, DOI 10.1016/0012-1606(78)90096-9; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; Plough HH, 1935, GENETICS, V20, P0042; Sambrook J, 1989, MOL CLONING; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHROER T A, 1990, Journal of Cell Biology, V111, p294A; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; SWAROOP A, 1985, P NATL ACAD SCI USA, V82, P1751, DOI 10.1073/pnas.82.6.1751; SWAROOP A, 1987, P NATL ACAD SCI USA, V84, P6501, DOI 10.1073/pnas.84.18.6501; SWAROOP A, 1986, MOL CELL BIOL, V6, P833, DOI 10.1128/MCB.6.3.833; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; VALLEE RB, 1988, NATURE, V332, P561, DOI 10.1038/332561a0	25	173	176	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1991	351	6327					579	583		10.1038/351579a0	http://dx.doi.org/10.1038/351579a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1828535				2022-12-28	WOS:A1991FR03400063
J	EVAVOLD, BD; ALLEN, PM				EVAVOLD, BD; ALLEN, PM			SEPARATION OF IL-4 PRODUCTION FROM TH-CELL PROLIFERATION BY AN ALTERED T-CELL RECEPTOR LIGAND	SCIENCE			English	Article							ANTIGEN-PRESENTATION; B-CELLS; ACTIVATION; EXPRESSION; INVIVO; IDENTIFICATION; HYDROLYSIS; MOLECULES; RESPONSES; PATHWAYS	In the presence of antigen presenting cells, a murine T helper (Th) cell specific for murine hemoglobin (Hb) responded to its immunogenic peptide by both cytokine (interleukin-4) secretion and proliferation. An altered Hb peptide with a single amino acid substitution induced only cytokine secretion and did not induce proliferation. Interleukin-1 costimulated and restored the Th proliferative response to normal levels. The altered peptide also supported cognate T cell-B cell interactions indicative of T cell helper function. Thus, this result suggests that the T cell receptor has the capacity of differential signaling.	WASHINGTON UNIV,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Evavold, Brian/0000-0002-3561-3494	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024157, R37AI024157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007066] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24157] Funding Source: Medline; NIEHS NIH HHS [ESO7066] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; ASHWELL JD, 1984, J EXP MED, V159, P881, DOI 10.1084/jem.159.3.881; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BRIAN AA, 1988, P NATL ACAD SCI USA, V85, P564, DOI 10.1073/pnas.85.2.564; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; EVAVOLD BD, UNPUB; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KRZYCH U, 1982, J IMMUNOL, V128, P1529; KURTJONES EA, 1987, J EXP MED, V166, P1774, DOI 10.1084/jem.166.6.1774; LORENZ RG, 1989, J EXP MED, V170, P203, DOI 10.1084/jem.170.1.203; LORENZ RG, 1988, P NATL ACAD SCI USA, V85, P5220, DOI 10.1073/pnas.85.14.5220; LORENZ RG, 1989, NATURE, V337, P560, DOI 10.1038/337560a0; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NOELLE RJ, 1990, IMMUNOL TODAY, V11, P361, DOI 10.1016/0167-5699(90)90142-V; OROURKE AM, 1990, SCIENCE, V249, P171, DOI 10.1126/science.2164711; ROJO JM, 1989, EUR J IMMUNOL, V19, P2061, DOI 10.1002/eji.1830191114; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHIGETA M, 1986, J IMMUNOL, V136, P34; SUSSMAN JJ, 1988, NATURE, V334, P625, DOI 10.1038/334625a0; TITE JP, 1987, J IMMUNOL, V139, P2892; WEAVER CT, 1988, P NATL ACAD SCI USA, V85, P8181, DOI 10.1073/pnas.85.21.8181	22	539	566	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1308	1310		10.1126/science.1833816	http://dx.doi.org/10.1126/science.1833816			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1833816				2022-12-28	WOS:A1991FN85700040
J	KELLUM, R; SCHEDL, P				KELLUM, R; SCHEDL, P			A POSITION-EFFECT ASSAY FOR BOUNDARIES OF HIGHER-ORDER CHROMOSOMAL DOMAINS	CELL			English	Article							BETA-GLOBIN GENE; WHITE GENE; DROSOPHILA-MELANOGASTER; TRANSGENIC MICE; CHROMATIN; DNA; EXPRESSION; ORGANIZATION; ELEMENTS; SITES	Eukaryotic chromosomes are thought to be organized into a series of discrete higher order chromatin domains. This organization is believed to be important not only in the compaction of the chromatin fiber, but also in the utilization of genetic information. Each domain would define an independent unit of gene activity, insulated from the regulatory influences of adjacent domains. Critical to this model of chromosome organization and function are the domain boundaries: the special nucleoprotein structures that delimit each higher order domain and segregate the chromosome into units of independent gene activity. In the work reported here we have tested whether two putative domain boundaries, scs and scs', from the Drosophila 87A7 heat shock locus can establish a domain of independent gene activity in vivo and insulate against chromosomal position effects.			KELLUM, R (corresponding author), PRINCETON UNIV,DEPT BIOL,PRINCETON,NJ 08544, USA.							ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; ADOLPH KW, 1980, EXP CELL RES, V125, P95, DOI 10.1016/0014-4827(80)90193-7; BASLER J, 1981, BIOCHEMISTRY-US, V20, P6921, DOI 10.1021/bi00527a027; BELMONT AS, 1989, CHROMOSOMA, V98, P129, DOI 10.1007/BF00291049; BENYAJATI C, 1976, CELL, V9, P393, DOI 10.1016/0092-8674(76)90084-2; BOWEN BC, 1981, NUCLEIC ACIDS RES, V9, P5093, DOI 10.1093/nar/9.19.5093; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COOK PR, 1976, J CELL SCI, V22, P303; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; JUDD BH, 1976, GENETICS BIOL DROS B, V1, P767; LEBKOWSKI JS, 1982, J MOL BIOL, V156, P325, DOI 10.1016/0022-2836(82)90332-1; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; LEVIS R, 1985, EMBO J, V4, P3489, DOI 10.1002/j.1460-2075.1985.tb04108.x; MARSDEN MPF, 1979, CELL, V17, P849, DOI 10.1016/0092-8674(79)90325-8; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; PIRROTTA V, 1985, EMBO J, V4, P3501, DOI 10.1002/j.1460-2075.1985.tb04109.x; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RATTNER JB, 1985, CELL, V42, P291, DOI 10.1016/S0092-8674(85)80124-0; ROBERTSON HM, 1988, GENETICS, V118, P461; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SCHOLNICK SB, 1983, CELL, V34, P37, DOI 10.1016/0092-8674(83)90134-4; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; WIDOM J, 1985, CELL, V43, P207, DOI 10.1016/0092-8674(85)90025-X; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42	32	543	568	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					941	950		10.1016/0092-8674(91)90318-S	http://dx.doi.org/10.1016/0092-8674(91)90318-S			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1848159				2022-12-28	WOS:A1991FA94000011
J	KAUFMAN, RH				KAUFMAN, RH			HUMAN PAPILLOMAVIRUS AND CERVICAL-CANCER - RISK TO MALE PARTNER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KAUFMAN, RH (corresponding author), BAYLOR UNIV,HOUSTON,TX 77030, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1179	1180						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1847486				2022-12-28	WOS:A1991EZ47400038
J	WEISS, S; BOGEN, B				WEISS, S; BOGEN, B			MHC CLASS-II-RESTRICTED PRESENTATION OF INTRACELLULAR ANTIGEN	CELL			English	Article							TOXIC LYMPHOCYTES-T; B-LYMPHOMA CELLS; SOLUBLE-PROTEIN; LIGHT-CHAINS; INFLUENZA HEMAGGLUTININ; ENDOPLASMIC-RETICULUM; PRESENTING CELLS; IMMUNOGLOBULIN; RECOGNITION; SEQUENCE	An endogenously produced immunoglobulin light chain (lambda-2(315)) is processed and presented to T cells in association with major histocompatibility complex (MHC) class II molecules. Using transfectants producing variant forms of lambda-2(315) that are neither expressed on the cell surface nor secreted, we demonstrate that intracellular lambda-2(315), which has never been exported outside of the cell, is the source of processed lambda-2(315) idiotype. This challenges the currently accepted paradigm that endogenous antigens are only presented by MHC class I molecules. Variants of lambda-2(315) protein that are retained in the endoplasmic recticulum (ER) are also presented. Variants that are expressed in the cytosol as well as those that are transported into the nucleus rather than the ER are not presented. Thus, the ER is likely to be the processing compartment.	INST IMMUNOL & RHEUMATOL,N-0172 OSLO,NORWAY		WEISS, S (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.							BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BARNABA V, 1990, NATURE, V345, P258, DOI 10.1038/345258a0; BEVAN MJ, 1987, NATURE, V325, P192, DOI 10.1038/325192b0; BIKOFF EK, 1989, EUR J IMMUNOL, V19, P1903, DOI 10.1002/eji.1830191022; BOGEN B, 1989, EMBO J, V8, P1947, DOI 10.1002/j.1460-2075.1989.tb03599.x; BOGEN B, 1990, EUR J IMMUNOL, V20, P2359, DOI 10.1002/eji.1830201030; BOGEN B, 1986, EUR J IMMUNOL, V16, P1373, DOI 10.1002/eji.1830161110; BOGEN B, 1989, SCAND J IMMUNOL, V29, P273, DOI 10.1111/j.1365-3083.1989.tb01125.x; BOGEN B, 1986, EUR J IMMUNOL, V16, P1379, DOI 10.1002/eji.1830161111; BOGEN B, 1983, EUR J IMMUNOL, V13, P353, DOI 10.1002/eji.1830130502; BOGEN B, 1984, THESIS U TROMSO TROM; BOGEN B, 1988, HISTOPHYSIOLOGY IMMU, P877; BOTHWELL ALM, 1982, NATURE, V298, P380, DOI 10.1038/298380a0; BRACIALE TJ, 1987, J EXP MED, V166, P678, DOI 10.1084/jem.166.3.678; BROWNING MJ, 1990, J IMMUNOL, V145, P985; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DICK T, 1989, P NATL ACAD SCI USA, V86, P2316, DOI 10.1073/pnas.86.7.2316; DONERMEYER DL, 1989, J IMMUNOL, V142, P1063; EAGER KB, 1989, J IMMUNOL, V143, P2328; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JIN Y, 1988, J EXP MED, V168, P293, DOI 10.1084/jem.168.1.293; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEE P, 1988, J IMMUNOL, V140, P1063; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LORENZ RG, 1988, P NATL ACAD SCI USA, V85, P5220, DOI 10.1073/pnas.85.14.5220; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; ROCHE PA, 1990, NATURE, V345, P618; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAERZ UD, 1987, NATURE, V329, P449, DOI 10.1038/329449a0; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TAKAHASHI H, 1990, NATURE, V344, P873, DOI 10.1038/344873a0; THOMAS DB, 1990, J IMMUNOL, V144, P2789; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0; WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0; WEISS S, 1984, EUR J IMMUNOL, V14, P744, DOI 10.1002/eji.1830140814; WEISS S, 1989, P NATL ACAD SCI USA, V86, P282, DOI 10.1073/pnas.86.1.282; WINBERRY L, 1980, J IMMUNOL, V124, P1174; WINCHESTER G, 1984, IMMUNOGENETICS, V19, P487, DOI 10.1007/BF00403439; WU GE, 1982, NUCLEIC ACIDS RES, V10, P3831, DOI 10.1093/nar/10.13.3831; WU GE, 1983, CELL, V33, P77, DOI 10.1016/0092-8674(83)90336-7; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; YURIN VL, 1989, EUR J IMMUNOL, V79, P1685	62	273	278	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					767	776		10.1016/0092-8674(91)90506-T	http://dx.doi.org/10.1016/0092-8674(91)90506-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1847667				2022-12-28	WOS:A1991EZ47800012
J	HIRATA, M; HAYASHI, Y; USHIKUBI, F; YOKOTA, Y; KAGEYAMA, R; NAKANISHI, S; NARUMIYA, S				HIRATA, M; HAYASHI, Y; USHIKUBI, F; YOKOTA, Y; KAGEYAMA, R; NAKANISHI, S; NARUMIYA, S			CLONING AND EXPRESSION OF CDNA FOR A HUMAN THROMBOXANE-A2 RECEPTOR	NATURE			English	Article							HUMAN-PLATELETS; ACTIVATION; PROTEIN; DISTINCT; BINDING; U44069; GTPASE; CELLS	THROMBOXANE A2 is a very unstable arachidonate metabolite, yet a potent stimulator of platelet aggregation and a constrictor of vascular and respiratory smooth muscles 1. It has been implicated as a mediator in diseases such as myocardial infarction, stroke and bronchial asthma 2. Using a stable analogue of this compound we recently purified the human platelet thromboxane A2 receptor to apparent homogeneity 3. Using an oligonucleotide probe corresponding to its partial amino-acid sequence, we have obtained a complementary DNA clone encoding this receptor from human placenta and a partial clone from cultured human megakaryocytic leukaemia cells. The placenta cDNA encodes a protein of 343 amino acids with seven putative transmembrane domains. The protein expressed in COS-7 cells binds drugs with affinities identical to those of the platelet receptor, and that in Xenopus oocytes opens Ca2+-activated Cl- channel on agonist stimulation. Northern blot analysis and nucleotide sequences of the two clones suggest that an identical species of the thromboxane A2 receptor is present in platelets and vascular tissues. This first report on the molecular structure of an eicosanoid receptor will promote the molecular pharmacology and pathophysiology of these bioactive compounds.	KYOTO UNIV,FAC MED,DEPT IMMUNOL,KYOTO 606,JAPAN	Kyoto University	HIRATA, M (corresponding author), KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN.		Hayashi, Yasunori/C-2249-2008; Hayashi, Yasunori/AAF-1408-2019	Hayashi, Yasunori/0000-0002-7560-3004; Hayashi, Yasunori/0000-0002-7560-3004				ARITA H, 1989, PROG LIPID RES, V28, P27; Ausubel FM, 1988, MOL REPROD DEV; AVDONIN PV, 1985, THROMB RES, V40, P101, DOI 10.1016/0049-3848(85)90354-8; BRASS LF, 1987, J CLIN INVEST, V79, P1269, DOI 10.1172/JCI112947; COLEMAN RA, 1989, COMPREHENSIVE MED CH, V3, P643; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; HANASAKI K, 1988, BIOCHEM BIOPH RES CO, V150, P1170, DOI 10.1016/0006-291X(88)90752-8; HOUSLAY MD, 1986, BIOCHEM J, V234, P737, DOI 10.1042/bj2340737; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEFER AM, 1980, P NATL ACAD SCI-BIOL, V77, P1706, DOI 10.1073/pnas.77.3.1706; MAIS DE, 1985, J PHARMACOL EXP THER, V233, P418; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MURRAY R, 1989, P NATL ACAD SCI USA, V86, P124, DOI 10.1073/pnas.86.1.124; NAKAJIMA M, 1989, BIOCHEM BIOPH RES CO, V158, P958, DOI 10.1016/0006-291X(89)92815-5; NARUMIYA S, 1986, BRIT J PHARMACOL, V88, P323, DOI 10.1111/j.1476-5381.1986.tb10208.x; OGLETREE ML, 1987, FED PROC, V46, P133; OGURA M, 1985, BLOOD, V66, P1384; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; STRADER CD, 1988, J BIOL CHEM, V263, P10267; SWAYNE GTG, 1988, EUR J PHARMACOL, V152, P311, DOI 10.1016/0014-2999(88)90726-1; USHIKUBI F, 1989, J BIOL CHEM, V264, P16496; Ushikubi F, 1989, Eicosanoids, V2, P21; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	29	672	694	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 14	1991	349	6310					617	620		10.1038/349617a0	http://dx.doi.org/10.1038/349617a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	1825698				2022-12-28	WOS:A1991EX57000062
J	DUDEN, R; GRIFFITHS, G; FRANK, R; ARGOS, P; KREIS, TE				DUDEN, R; GRIFFITHS, G; FRANK, R; ARGOS, P; KREIS, TE			BETA-COP, A 110 KD PROTEIN ASSOCIATED WITH NON-CLATHRIN-COATED VESICLES AND THE GOLGI-COMPLEX, SHOWS HOMOLOGY TO BETA-ADAPTIN	CELL			English	Article							ENDOPLASMIC-RETICULUM; CELL-SURFACE; BREFELDIN-A; SECRETORY PROTEINS; VESICULAR TRANSPORT; PLASMA-MEMBRANE; BINDING; SEQUENCE; STACK; IDENTIFICATION	We have cloned and sequenced beta-COP, a peripheral 110 kd Golgi membrane protein. Beta-COP shows significant homology to beta-adaptin. It is present in a membrane-bound form and in a cytosolic complex of 13-14S, with a Stokes radius of approximately 10 nm and an estimated M(r) of approximately 550,000. By immunofluorescence labeling, beta-COP is associated with the structures of the Golgi complex. Immunoelectron microscopy has localized beta-COP to non-clathrin-coated vesicles and cisternae of the Golgi complex. These coated vesicles accumulate in rat liver Golgi fractions treated with GTP-gamma-S and strongly label for beta-COP. Our data suggest that beta-COP is a component of a coat associated with vesicles and cisternae of the Golgi complex.			DUDEN, R (corresponding author), EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY.		Duden, Rainer/GXH-3206-2022; Duden, Rainer/C-8917-2011					AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; AIZAWA H, 1990, J BIOL CHEM, V265, P13849; ALLAN V J, 1988, Journal of Cell Biology, V107, p759A; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; ARGOS P, 1987, J MOL BIOL, V193, P385, DOI 10.1016/0022-2836(87)90226-9; BAIROACH A, 1989, PROSITE DICT PROTEIN; BRESSAN GM, 1987, NUCLEIC ACIDS RES, V15, P10056, DOI 10.1093/nar/15.23.10056; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, IN PRESS J CELL BIOL; DUDEN R, 1988, J CELL BIOL, V107, P1049, DOI 10.1083/jcb.107.3.1049; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GAUSEPOHL H, 1986, ADV METHODS PROTEIN, P149; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GRIFFITHS G, 1989, J CELL BIOL, V108, P277, DOI 10.1083/jcb.108.2.277; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HO WC, 1990, EUR J CELL BIOL, V52, P315; HO WC, 1989, EUR J CELL BIOL, V48, P250; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KEEN JH, 1987, J BIOL CHEM, V262, P3864; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KIRCHHAUSEN T, 1990, MOL CELL BIOL, V10, P6089, DOI 10.1128/MCB.10.11.6089; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREIS TE, 1990, CELL MOTIL CYTOSKEL, V15, P67, DOI 10.1002/cm.970150202; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LINDSEY JD, 1985, J NEUROSCI, V5, P3124; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; ORCI L, 1985, P NATL ACAD SCI USA, V82, P5385, DOI 10.1073/pnas.82.16.5385; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEARSE BMF, 1981, ANNU REV BIOCHEM, V50, P85, DOI 10.1146/annurev.bi.50.070181.000505; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; RECHID R, 1989, COMPUT APPL BIOSCI, V5, P107; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; ROSSMANN MG, 1987, BIOESSAYS, V7, P99, DOI 10.1002/bies.950070302; ROSSMANN MG, 1981, ANNU REV BIOCHEM, V50, P497, DOI 10.1146/annurev.bi.50.070181.002433; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHEEL J, 1990, J CELL SCI, V96, P711; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SERAFINI T, 1991, IN PRESS NATURE; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Tanford C., 1961, PHYS CHEM MACROMOLEC, P356; TOOZE J, 1986, J CELL BIOL, V103, P839, DOI 10.1083/jcb.103.3.839; VINGRON M, 1989, COMPUT APPL BIOSCI, V5, P115; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	84	454	460	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					649	665		10.1016/0092-8674(91)90248-W	http://dx.doi.org/10.1016/0092-8674(91)90248-W			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1840503				2022-12-28	WOS:A1991EX36100020
J	HOU, JZ; KAN, M; MCKEEHAN, K; MCBRIDE, G; ADAMS, P; MCKEEHAN, WL				HOU, JZ; KAN, M; MCKEEHAN, K; MCBRIDE, G; ADAMS, P; MCKEEHAN, WL			FIBROBLAST GROWTH-FACTOR RECEPTORS FROM LIVER VARY IN 3 STRUCTURAL DOMAINS	SCIENCE			English	Article							COMPLEMENTARY-DNA; BINDING; CELL; PURIFICATION; PROTEINS; CLONING; GENE	Changes in heparin-binding fibroblast growth factor gene expression and receptor phenotype occur during liver regeneration and in hepatoma cells. The nucleotide sequence of complementary DNA predicts that three amino-terminal domain motifs, two juxtamembrane motifs, and two intracellular carboxyl-terminal domain motifs combine to form a minimum of 6 and potentially 12 homologous polypeptides that constitute the growth factor receptor family in a single human liver cell population. Amino-terminal variants consisted of two transmembrane molecules that contained three and two immunoglobulin-like disulfide loops, as well as a potential intracellular form of the receptor. The two intracellular juxtamembrane motifs differed in a potential serine-threonine kinase phosphorylation site. One carboxyl-terminal motif was a putative tyrosine kinase that contained potential tyrosine phosphorylation sites. The second carboxyl-terminal motif was probably not a tyrosine kinase and did not exhibit the same candidate carboxyl-terminal tyrosine phosphorylation sites.	W ALTON JONES CELL SCI CTR,10 OLD BARN RD,LAKE PLACID,NY 12946									BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; HOSHI H, 1988, FASEB J, V2, P2797, DOI 10.1096/fasebj.2.12.2457532; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KAN M, 1988, J BIOL CHEM, V263, P11306; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	10	223	231	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					665	668		10.1126/science.1846977	http://dx.doi.org/10.1126/science.1846977			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1846977				2022-12-28	WOS:A1991EW39900043
J	VONSCHEIDT, W; ENG, CM; FITZMAURICE, TF; ERDMANN, E; HUBNER, G; OLSEN, EGJ; CHRISTOMANOU, H; KANDOLF, R; BISHOP, DF; DESNICK, RJ				VONSCHEIDT, W; ENG, CM; FITZMAURICE, TF; ERDMANN, E; HUBNER, G; OLSEN, EGJ; CHRISTOMANOU, H; KANDOLF, R; BISHOP, DF; DESNICK, RJ			AN ATYPICAL VARIANT OF FABRYS-DISEASE WITH MANIFESTATIONS CONFINED TO THE MYOCARDIUM	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							ALPHA-GALACTOSIDASE-A; AMINO-ACID-SEQUENCE; NUCLEOTIDE-SEQUENCE; DIAGNOSIS; CARDIOMYOPATHY; SEDIMENT; PLASMA; ENZYME; URINE; GENE		CUNY MT SINAI SCH MED, DIV MED & MOLEC GENET, 5TH AVE & 100TH ST, NEW YORK, NY 10029 USA; NATL HEART HOSP, DEPT MORBID ANAT & HISTOPATHOL, LONDON W1M 8BA, ENGLAND; UNIV MUNICH, KLINIKUM GROSSHADERN, MED KLIN 1, W-8000 MUNICH 70, GERMANY; UNIV MUNICH, KLINIKUM GROSSHADERN, INST PATHOL, W-8000 MUNICH 70, GERMANY; CUNY MT SINAI SCH MED, DIV MED & MOLEC GENET, NEW YORK, NY 10029 USA; MAX PLANCK INST PSYCHIAT, W-8000 MUNICH 40, GERMANY	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Imperial College London; University of Munich; University of Munich; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Max Planck Society			Bishop, David F./X-4102-2019		NCRR NIH HHS [5-MO1-RR-00071] Funding Source: Medline; NIADDK NIH HHS [5-RO1-AM-34045] Funding Source: Medline; NICHD NIH HHS [5-T32-HD-07105] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007105] Funding Source: NIH RePORTER; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM034045] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BACH G, 1982, CLIN GENET, V21, P59; BECKER AE, 1975, AM J CARDIOL, V36, P829, DOI 10.1016/0002-9149(75)90468-3; BERNSTEIN HS, 1989, J CLIN INVEST, V83, P1390, DOI 10.1172/JCI114027; BISHOP DF, 1981, AM J HUM GENET, V33, pA71; BISHOP DF, 1981, J BIOL CHEM, V256, P1307; BISHOP DF, 1986, P NATL ACAD SCI USA, V83, P4859, DOI 10.1073/pnas.83.13.4859; BISHOP DF, 1981, LYSOSOMES LYSOSOMAL, P381; BRADY RO, 1967, NEW ENGL J MED, V276, P1163, DOI 10.1056/NEJM196705252762101; CHATTERJEE S, 1986, J BIOL CHEM, V261, P3474; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLARKE JTR, 1971, NEW ENGL J MED, V284, P233, DOI 10.1056/NEJM197102042840503; COLUCCI WS, 1982, NEW ENGL J MED, V307, P926, DOI 10.1056/NEJM198210073071505; DESNICK RJ, 1971, NEW ENGL J MED, V284, P739, DOI 10.1056/NEJM197104082841401; DESNICK RJ, 1970, J LIPID RES, V11, P31; DESNICK RJ, 1973, J LAB CLIN MED, V81, P157; DESNICK RJ, 1976, CIRCULATION, V54, P818, DOI 10.1161/01.CIR.54.5.818; DESNICK RJ, 1972, ANTENATAL DIAGNOSIS, P185; Desnick RJBD., 1989, METABOLIC BASIS INHE, V6, P1751; ELLEDER M, 1990, VIRCHOWS ARCH A, V417, P449, DOI 10.1007/BF01606034; ERDMANN E, 1980, DEUT MED WOCHENSCHR, V105, P1618, DOI 10.1055/s-2008-1070924; ERDMANN E, 1980, INTERNIST, V21, P165; FERRANS VJ, 1969, AM J CARDIOL, V24, P95, DOI 10.1016/0002-9149(69)90055-1; FRITZ P, 1978, MED WELT, V29, P1851; GOLDMAN ME, 1986, J AM COLL CARDIOL, V7, P1157, DOI 10.1016/S0735-1097(86)80238-8; HAMBURGER J, 1964, SCHWEIZ MED WSCHR, V94, P871; KOBAYASHI T, 1985, J NEUROL SCI, V67, P179, DOI 10.1016/0022-510X(85)90114-5; KOIDE T, 1990, FEBS LETT, V259, P353, DOI 10.1016/0014-5793(90)80046-L; KORNREICH R, 1990, J BIOL CHEM, V265, P9319; KORNREICH R, 1989, NUCLEIC ACIDS RES, V17, P3301, DOI 10.1093/nar/17.8.3301; MEHTA J, 1977, AM HEART J, V93, P699, DOI 10.1016/S0002-8703(77)80064-1; MOSSARD JM, 1972, ARCH MAL COEUR VAISS, V65, P495; OGAWA K, 1990, HUM PATHOL, V21, P1067, DOI 10.1016/0046-8177(90)90258-7; ROMEO G, 1975, BIOCHEM GENET, V13, P615, DOI 10.1007/BF00484919; ROUDEBUSH CP, 1973, NEW ENGL J MED, V289, P357, DOI 10.1056/NEJM197308162890709; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAKURABA H, 1990, AM J HUM GENET, V47, P784; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; STRASBERG PM, 1983, CLIN CHIM ACTA, V132, P29, DOI 10.1016/0009-8981(83)90230-9; URBAIN G, 1967, LANCET, V1, P1111; WOLF H, 1988, COMPUT APPL BIOSCI, V4, P187; WONG C, 1987, NATURE, V330, P384, DOI 10.1038/330384a0	43	297	309	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 7	1991	324	6					395	399		10.1056/NEJM199102073240607	http://dx.doi.org/10.1056/NEJM199102073240607			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW296	1846223				2022-12-28	WOS:A1991EW29600007
J	WOODLAND, DL; HAPP, MP; GOLLOB, KJ; PALMER, E				WOODLAND, DL; HAPP, MP; GOLLOB, KJ; PALMER, E			AN ENDOGENOUS RETROVIRUS MEDIATING DELETION OF ALPHA-BETA T-CELLS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCLONAL-ANTIBODIES; IMPARTS REACTIVITY; I-E; TOLERANCE; DIFFERENTIATION; EXPRESSION; ANTIGENS; TRANSCRIPTS; MOLECULE	A SPECIAL class of self-antigens (endogenous superantigens) is capable of deleting many murine T cells on the basis of their expression of particular T-cell receptor V-beta gene segments. In mice that endogenously express these antigens, tolerance is mediated in part by the clonal deletion of the relevant V-beta-bearing T cells 1-17. The deletion of I-E-reactive V-beta-5.2-bearing T cells is dependent on the coexpression of an I-E tolerogenic coligand (Etc) 14 and the gene for one of these coligands, Etc-1, maps to chromosome 12, near the mouse mammary tumour viral integrant, Mtv-9. Here we report a perfect genetic linkage between Etc-1 and Mtv-9 and show that Etc-1 is also involved in the I-E-dependent deletion of T cells bearing V-beta-5.1 and V-beta-11 domains. We also demonstrate that Mtv-9 transcripts are present in B cells expressing Etc-1 and suggest that the coligand recognized by roughly 15% of all T lymphocytes is encoded by the Mtv-9 genome.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT MICROBIOL & IMMUNOL, DENVER, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	WOODLAND, DL (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA.		Gollob, Kenneth J/GPX-8434-2022; Gollob, Kenneth J/C-1341-2008	Gollob, Kenneth J/0000-0003-4184-3867				BILL J, 1988, P NATL ACAD SCI USA, V85, P9184, DOI 10.1073/pnas.85.23.9184; BILL J, 1989, J EXP MED, V169, P115, DOI 10.1084/jem.169.1.115; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BILL J, 1990, J MOL CELL IMMUNOL, V4, P269; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; EICHER EM, 1990, GENETICS, V125, P431; HAPP MP, 1989, P NATL ACAD SCI USA, V86, P6293, DOI 10.1073/pnas.86.16.6293; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KING LB, 1989, P NATL ACAD SCI USA, V86, P2814, DOI 10.1073/pnas.86.8.2814; KING LB, 1990, J IMMUNOL, V144, P3218; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; KUMAGAI N, 1987, J IMMUNOL, V139, P1393; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEE BK, 1990, J VIROL, V64, P4568, DOI 10.1128/JVI.64.9.4568-4572.1990; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; OKADA CY, 1990, J IMMUNOL, V144, P3473; OKADA CY, 1989, J EXP MED, V169, P1703, DOI 10.1084/jem.169.5.1703; PALMER E, 1989, COLD SPRING HARB SYM, V54, P135; PENNELL CA, 1985, P NATL ACAD SCI USA, V82, P3799, DOI 10.1073/pnas.82.11.3799; PETERS G, 1986, J VIROL, V59, P535, DOI 10.1128/JVI.59.3.535-544.1986; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; SHARMA S, 1988, J IMMUNOL, V141, P2510; TAYLOR BA, 1987, ORIGIN INBRED MICE, P423; TOMONARI K, 1990, IMMUNOL REV, V116, P139, DOI 10.1111/j.1600-065X.1990.tb00808.x; TOMONARI K, 1988, IMMUNOGENETICS, V28, P445, DOI 10.1007/BF00355377; VACCHIO MS, 1990, J EXP MED, V172, P802; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289	30	318	323	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					529	530		10.1038/349529a0	http://dx.doi.org/10.1038/349529a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846949				2022-12-28	WOS:A1991EW57100068
J	KAWAMURA, S; MURAKAMI, M				KAWAMURA, S; MURAKAMI, M			CALCIUM-DEPENDENT REGULATION OF CYCLIC-GMP PHOSPHODIESTERASE BY A PROTEIN FROM FROG RETINAL RODS	NATURE			English	Article							OUTER SEGMENT; PHOTORECEPTOR-MEMBRANES; CGMP PHOSPHODIESTERASE; GUANYLATE-CYCLASE; PLASMA-MEMBRANE; SALAMANDER RODS; BINDING PROTEIN; ACTIVATION; CONDUCTANCE; SEQUENCE	IN vertebrate photoreceptors, light reduces cyclic GMP concentration and closes cGMP-activated channels to induce a hyperpolarizing response 1. As Ca2+ can permeate the channels and the Na+ - CA2+ exchanger continuously extrudes Ca2+, closure of the channel results in a reduction of the inter-rod Ca2+ concentration 2-4. This is believed to be one of the mechanisms of light adaptation produced by activation of guanylate cyclase 5-9. Effects of Ca2+ on the cGMP phosphodiesterase (PDE) have been reported 10-15, but their physiological significance has remained unclear. We have perfused the inside-out preparation of a frog rod outer segment (I/O ROS (ref. 16), originally termed truncated ROS (ref. 17)), and find that Ca2+ in a physiological range regulates the light-activation of PDE. Therefore, PDE regulation by Ca2+ must be involved in light-adaptation in rods. The effect is mediated by a newly found protein which binds to disk membranes at high Ca2+ concentrations and prolongs PDE activation.			KAWAMURA, S (corresponding author), KEIO UNIV,SCH MED,DEPT PHYSIOL,SHINANOMACHI 35,SHINJUKU KU,TOKYO 160,JAPAN.							BARKDOLL AE, 1989, J GEN PHYSIOL, V93, P1091, DOI 10.1085/jgp.93.6.1091; BUZDYGON BE, 1984, J BIOL CHEM, V259, P4567; DELPRIORE LV, 1983, BIOCHEM BIOPH RES CO, V113, P317, DOI 10.1016/0006-291X(83)90468-0; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; HODGKIN AL, 1988, J PHYSIOL-LONDON, V403, P439, DOI 10.1113/jphysiol.1988.sp017258; KAWAMURA S, 1986, BIOCHIM BIOPHYS ACTA, V870, P256, DOI 10.1016/0167-4838(86)90230-X; KAWAMURA S, 1981, J GEN PHYSIOL, V77, P571, DOI 10.1085/jgp.77.5.571; KAWAMURA S, 1989, J GEN PHYSIOL, V94, P649, DOI 10.1085/jgp.94.4.649; KAWAMURA S, 1989, NEUROSCI RES       S, V10, pS15; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; RATTO GM, 1988, J NEUROSCI, V8, P3240; ROBINSON PR, 1980, J GEN PHYSIOL, V76, P631, DOI 10.1085/jgp.76.5.631; TORRE V, 1986, P NATL ACAD SCI USA, V83, P7109, DOI 10.1073/pnas.83.18.7109; WAGNER R, 1989, FEBS LETT, V242, P249, DOI 10.1016/0014-5793(89)80479-X; WILSON PW, 1985, NUCLEIC ACIDS RES, V13, P8867, DOI 10.1093/nar/13.24.8867; YAMAGATA K, 1990, NEURON, V2, P469; YAMAKUNI T, 1986, NUCLEIC ACIDS RES, V14, P6768, DOI 10.1093/nar/14.16.6768; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0	22	210	212	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					420	423		10.1038/349420a0	http://dx.doi.org/10.1038/349420a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1846944				2022-12-28	WOS:A1991EV51400053
